Flap modulators

ABSTRACT

The present invention relates to compounds of Formula (I), or a form thereof wherein ring A 1 , R 1 , R 2 , R 3 , R 3 ′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 61/760,627, filed Feb. 4, 2013, and U.S. Provisional Application No. 61/800,353, filed Mar. 15, 2013, each of which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to substituted compounds useful as 5-lipoxygenase-activating protein (FLAP) modulators, pharmaceutical compositions of such compounds, methods of preparation and use thereof. More particularly, FLAP modulators are useful for preventing, treating or ameliorating FLAP-mediated diseases and/or disorders, including those inflammation diseases and/or disorders associated with dermatological and respiratory disorders, allergic disorders, autoimmunity, cancer, cardiovascular and metabolic disorders.

BACKGROUND OF THE INVENTION

FLAP is a key initiator of the leukotriene synthesis pathway that binds and then transfers arachidonic acid to 5-lipoxygenase (M. Abramovitz et al., “5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase,” Eur. J. Biochem., 1993, 215, 105-11). FLAP has been demonstrated to interact with LTC₄ synthase, and could putatively modulate the production of LTC₄ (T. Strid et al., “Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein,” Biochem. Biophys. Res. Comm., 2009, 381(4), 518-22). Modulation (including without limitation inhibition) or genetic deletion of FLAP blocks leukotriene production, specifically LTB₄, the cysteinyl leukotrienes (LTC₄, LTD₄ and LTE₄) as well as 5-oxo-ETE (J. Z. Haeggström et al., “Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease,” Chem Rev., 2011, 111(10), 5866-98).

Leukotrienes are immune-modulating lipids formed from arachidonic acid (reviewed in Samuelsson, “Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation,” Science, 1983, 220, 568-75). They are synthesized primarily by eosinophils, neutrophils, mast cells, basophils, dendritic cells, macrophages and monocytes. Leukotrienes mediate multiple biological effects including, by way of example only, smooth muscle contraction, leukocyte recruitment and activation, cytokine secretion, fibrosis, mucous secretion, and vascular function (J. Z. Haeggström, at 5866-98).

FLAP-deficient mice are healthy and reproduce normally. They do not produce leukotrienes and have decreased susceptibility in mouse models of arthritis (R. J. Griffiths et al., “Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice,” J. Exp. Med., 1997, 185, 1123-29). In humans, FLAP itself has been linked by genetic studies to respiratory disorders and cardiovascular disease, including myocardial infarction, atherosclerosis, cerebral infarctions, coronary artery disease and stroke (A. Helgadottir et al., “The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction, atherosclerosis and stroke,” Nat. Genet., 2004, 36, 233-39; A. S. Tulah et al., “The role of ALOX5AP, LTA4H and LTB4R polymorphisms in determining baseline lung function and COPD susceptibility in UK smokers,” BMC Med. Genet., 2011, 29(12), 173; R. Ji et al., “Genetic variants in the promoter region of the ALOX5AP gene and susceptibility of ischemic stroke,” Cerebrovasc. Dis., 2011, 32(3), 261-68; J. W. Holloway et al., “The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility,” Allergy. 2008, 63(8), 1046-53; J. Nair et al., “Expression analysis of leukotriene-inflammatory gene interaction network in patients with coronary artery disease,” J Atheroscler. Thromb., 2013; L. F. Chi et al., “Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese,” Neuroreport., 2013). In addition, studies using animal models support a causative role for leukotrienes in aortic aneurisms, atherosclerosis, pulmonary arterial hypertension, myocardial infarction, atherosclerosis, and stroke (reviewed in J. Z. Haeggström, at 5866-98).

Leukotrienes also play a role in autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease and multiple sclerosis (S. Chwieśko-Minarowska et al., “The role of leukotrienes in the pathogenesis of systemic sclerosis,” Folia Histochem. Cytobiol., 2012, 50(2), 180-85; M. Rosnowska et al., “Leukotrienes C4 and B4 in cerebrospinal fluid of patients with multiple sclerosis,” Pol. Merkuriusz Lek., 1997, 2, 254-55; and reviewed in J. Z. Haeggström, at 5866-98; I. Loell et al., “Activated LTB4 pathway in muscle tissue of patients with polymyositis or dermatomyositis,” Ann. Rheum. Dis., 2013, 72(2), 293-99; J. Chu et al., “Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model,” J. Neuroinflammation, 2012, 9, 127). Leukotrienes have also been implicated in several aspects of carcinogenesis including tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells (D. Wang and R. N. Dubois, “Eicosanoids and cancer,” Nat. Rev. Cancer, 2010, 10(3), 181-93).

Leukotrienes play a key role in allergic disorders such as allergic rhinitis, allergic dermatitis and asthma, as well as respiratory disorders such as exacerbations, non-allergic asthma, aspirin exacerbated respiratory disease, fibrotic lung diseases, acute respiratory distress syndrome and chronic obstructive pulmonary disease (reviewed in J. Z. Haeggström at 5866-98). Approved antagonists of the LTC₄ receptor and leukotriene synthesis modulators such as zileuton have shown clinical efficacy in a variety of respiratory disorders (reviewed in M. E. Krawiec and S. E. Wenzel, “Leukotriene modulators and non-steroidal therapies in the treatment of asthma,” Expert. Opin. Pharmacotherapy, 2001, 2(1), 47-65).

All the above evidence supports a key role of leukotrienes in a variety of human diseases and/or disorders, and FLAP modulation would be effective for the prevention, treatment, or amelioration of these immune-mediated inflammatory diseases and/or disorders. Furthermore, there still remains a need for FLAP modulator compounds that have pharmacokinetic and pharmacodynamic properties suitable for use as human pharmaceuticals.

SUMMARY OF THE INVENTION

In its many embodiments, the present invention provides novel compounds useful as, for example, FLAP modulators (including without limitation novel compounds that inhibit FLAP), methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical compositions comprising one or more such compounds, and methods of prophylaxis, treatment, amelioration, including without limitation inhibition, of one or more diseases and/or disorders associated with FLAP using such compounds or pharmaceutical compositions.

One aspect of the present invention is directed to compounds, methods, and compositions for the treatment or prophylaxis or amelioration of a variety of diseases and/or disorders that are mediated or sustained through the activity of leukotrienes, including pulmonary, allergic, fibrotic, neurological, inflammatory, autoimmune and cardiovascular diseases and cancer or associated symptoms or complications thereof. More specifically, this invention is directed to a method of treating exacerbations, non-allergic asthma, fibrotic lung diseases, acute respiratory distress syndrome and chronic obstructive pulmonary disease, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering a FLAP modulator.

Another aspect of the present invention is directed to compounds, methods, and compositions for the treatment or prophylaxis or amelioration of cardiac and cardiovascular diseases and/or disorders, or associated symptoms or complications thereof, that include but are not limited to myocardial infarction, atherosclerosis and stroke aortic aneurisms, atherosclerosis, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering a FLAP modulator.

Yet another aspect of the present invention is directed to compounds, methods, and compositions for the prophylaxis, treatment, or amelioration of autoimmune diseases and/or disorders, or associated symptoms or complications thereof, that include but are not limited to rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis or allergic disorders that include but are not limited to allergic rhinitis, allergic dermatitis and asthma, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering a FLAP modulator.

Finally, one aspect of the present invention is directed to compounds, methods, and compositions for the prophylaxis, treatment, or amelioration of carcinogenesis including but not limited to tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering a FLAP modulator.

Another aspect of the present invention features a compound of Formula (I)

wherein

-   -   L is a bond, —CH₂—, —SO₂—, —CH₂—SO₂—, —SO₂—CH₂—, —SO₂—NR—,

—SO₂—NR—CH₂—, —CH₂—SO₂—NR—, —NR—, —NR—SO₂—, —NR—SO₂—NR—, —S—, —S—CH₂—, —CH₂—S—,

—C(═O)—, —C(═O)—O—, —O—, —O—CH₂—, —NR—C(═O)—, —NR—C(═O)—NR—, or —C(═O)—NR—, wherein R is H,

C₁₋₂alkyl, C₁₋₂alkyl-OH or cyclopropyl;

-   -   R₁ is H, halo, methyl, CF₃, —O—CF₃, or —O— CH₃;     -   R₂ is H, cyano, halo, —SO₂—CH₃, 2-(trimethylsilyl)ethoxy,         phenyl, C₁₋₆alkyl, heteroaryl, heterocyclyl, C₃₋₉cycloalkyl,         provided R₂ is not H if L is a bond, and wherein said phenyl,         C₁₋₆alkyl, heteroaryl, heterocycyl or C₃₋₉cycloalkyl is         optionally and independently substituted with 1-4 substituents         selected from the group consisting of:     -   methyl, ethyl, oxo, fluoro, hydroxyl, cyano, amino, methoxy,         tert-butoxy, acetyl, cyclopropyl, cyclobutyl, cyclohexyl,         phenyl, azetidin-1-yl, azetidin-3-yl, pyrrolidin-1-yl,         2,4-dihydro-3H-1,2,4-triazol-3-one-4-yl, 1H-imidazol-4-yl,         pyrazin-2-yl, pyrimidin-2-yl, 1,3-oxazolidin-2-one-5-yl,         N-benzamide, benzo[d]imidazol-2(3H)-one, 4-methylpiperazin-1-yl,         morpholin-4-yl, CF₃, —SO₂—CH₃, —C(═O)-cyclopropyl,         —SO₂-cyclohexyl, —NHCH₃, —N(CH₃)₂, —NHAc, —NHCO₂t-Bu, —CH₂—NH₂,         —C(═O)—NH₂, —C(═O)—N(ethyl)₂, —NH—C(═O)—NH₂, —NH—C(═O)—CH₃,         —C(═O)—(C₁-C₄alkyl), —C(═O—OH, —C(═O)—NH(C₁-C₄alkyl)         —(CH₂)_(n)—OH, and —(CH₂)_(n)—CN, wherein n is 1 or 2;     -   V is CH, CR′, or N, wherein R is methyl or F;     -   W is CR″ or N, wherein R″ is H, F, hydroxyl, amino, CH₃ or         —O—CH₃;     -   ring A is selected from the group consisting of:

-   -   R₃ is H, F, methyl, or —O—CH₃;     -   R₃′ is H or F;     -   R₄ is H, methyl, cyano, amino, halo, —COOH, or —O—CH₃;     -   R₅ is H, methyl, cyano, or —CF₃;     -   R₆ is H, cyano, amino, halo, or —CF₃; and     -   R₇ is halo, amino, —CONH₂, cyano, —O—CH₃, —CF₃, or —COO-ethyl;

or an optical isomer, hydrate, metabolite, enantiomer, diastereomer, cis-trans isomer, racemate, prodrug or pharmaceutically acceptable salt thereof.

Another aspect of the present invention features a pharmaceutical composition comprising at least one compound of Formula (I) and at least one pharmaceutically acceptable carrier. The invention is also directed towards providing a process for formulating a pharmaceutical composition, comprising formulating a pharmaceutical composition of at least one compound of Formula (I) and at lease one pharmaceutically acceptable carrier. The present invention further relates to a process for making a pharmaceutical composition comprising mixing any of the compounds according to Formula (I) and a pharmaceutically acceptable carrier.

The present invention also features a method of treating a subject suffering from or diagnosed with a disease and/or disorder mediated by FLAP activity, comprising administering to the subject a therapeutically effective amount of at least one compound of Formula (I). Such a disease and/or disorder can include, but is not limited to respiratory disorders, cardiac and cardiovascular diseases, autoimmune disorders, carcinogenesis or associated symptoms or complications. More specifically, this invention is directed to a method of treating exacerbations, non-allergic asthma, fibrotic lung diseases, acute respiratory distress syndrome, chronic obstructive pulmonary disease myocardial infarction, atherosclerosis and stroke aortic aneurisms, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis, allergic rhinitis, allergic dermatitis and asthma, tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, or associated symptoms or complications thereof, wherein the method comprises administering a FLAP modulator to a subject in need thereof, a therapeutically effective amount of at least one compound of Formula (I), preferably in a pharmaceutical composition comprising at least one compound of Formula (I).

Additional embodiments and advantages of the invention will become apparent from the detailed discussion, schemes, examples, and claims below.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to novel FLAP modulators and compositions thereof for the prophylaxis, treatment, or amelioration of numerous diseases and/or disorders, including but not limited to respiratory diseases and/or disorders, cardiac and cardiovascular diseases and/or disorders, autoimmune diseases and/or disorders, carcinogenesis, and associated symptoms or complications thereof. One aspect of the present invention features a compound of Formula (I)

wherein

-   -   L is a bond, —CH₂—, —SO₂—, —CH₂—SO₂—, —SO₂—CH₂—, —SO₂—NR—,

—SO₂—NR—CH₂—, —CH₂—SO₂—NR—, —NR—, —NR—SO₂—, —NR—SO₂—NR—, —S—, —S—CH₂—, —CH₂—S—,

—C(═O)—, —C(═O)—O—, —O—, —O—CH₂—, —NR—C(═O)—, —NR—C(═O)—NR—, or —C(═O)—NR—, wherein R is H,

C₁₋₂alkyl, C₁₋₂alkyl-OH or cyclopropyl;

-   -   R₁ is H, halo, methyl, CF₃, —O—CF₃, or —O— CH₃;     -   R₂ is H, cyano, halo, —SO₂—CH₃, 2-(trimethylsilyl)ethoxy,         phenyl, C₁₋₆alkyl, heteroaryl, heterocyclyl, C₃₋₉cycloalkyl,         provided R₂ is not H if L is a bond, and wherein said phenyl,         C₁₋₆alkyl, heteroaryl, heterocyclyl or C₃₋₉cycloalkyl is         optionally and independently substituted with 1-4 substituents         selected from the group consisting of:     -   methyl, ethyl, oxo, fluoro, hydroxyl, cyano, amino, methoxy,         tert-butoxy, acetyl, cyclopropyl, cyclobutyl, cyclohexyl,         phenyl, azetidin-1-yl, azetidin-3-yl, pyrrolidin-1-yl,         2,4-dihydro-3H-1,2,4-triazol-3-one-4-yl, 1H-imidazol-4-yl,         pyrazin-2-yl, pyrimidin-2-yl, 1,3-oxazolidin-2-one-5-yl,         N-benzamide, benzo[d]imidazol-2(3H)-one, 4-methylpiperazin-1-yl,         morpholin-4-yl, CF₃, —SO₂—CH₃, —C(═O)-cyclopropyl,         —SO₂-cyclohexyl, —NHCH₃, —N(CH₃)₂, —NHAc, —NHCO₂t-Bu, —CH₂—NH₂,         —C(═O)—NH₂, —C(═O)—N(ethyl)₂, —NH—C(═O)—NH₂, —NH—C(═O)—CH₃,         —C(═O)—(C₁-C₄alkyl), —C(═O)—OH, —C(═O)—NH(C₁-C₄alkyl)         —(CH₂)_(n)—OH, and —(CH₂)_(n)—CN, wherein n is 1 or 2;     -   V is CH, CR′, or N, wherein R is methyl or F;     -   W is CR″ or N, wherein R″ is H, F, hydroxyl, amino, CH₃ or         —O—CH₃;     -   ring A is selected from the group consisting of:

-   -   R₃ is H, F, methyl, or —O—CH₃;     -   R₃′ is H or F;     -   R₄ is H, methyl, cyano, amino, halo, —COOH, or —O—CH;     -   R₅ is H, methyl, cyano, or —CF₃;     -   R₆ is H, cyano, amino, halo, or —CF₃; and     -   R₇ is halo, amino, —CONH₂, cyano, —O—CH₃, —CF₃, or —COO-ethyl.

Some embodiments are given by compounds of Formula (I), wherein ring A is

In some of these embodiments, wherein ring A is

R₄ is H or cyano.

In some of these embodiments, wherein ring A is

R₅ is H or —CF₃.

In some of these embodiments, wherein ring A is

R₆ is H, fluoro, chloro, or cyano.

Some embodiments are given by compounds of Formula (I), wherein ring A is

Some embodiments are given by compounds of Formula (I), wherein V is CH and R₁ is H, halo, methyl, or CF₃.

Some embodiments are given by compounds of Formula (I), wherein R₃′ is H.

In some of these embodiments, wherein V is CH and R₁ is H, halo, methyl, or CF₃, the attachment point of R₁ to the phenyl ring is in the ortho position with regard to V.

Some embodiments are given by compounds of Formula (I), wherein W is CF, R₃ is H, and R₃′ is H.

Some embodiments are given by compounds of Formula (I), wherein L is a bond, —CH₂—, —SO₂—, —SO₂—NH—, —SO₂—NR—CH₂—, —CH₂—SO₂—NR—, —S—, —CH₂—S—, —O—, or

—O—CH₂—.

In another embodiment, the present invention includes a compound of Formula (I) wherein

L is a bond, —O—, —SO₂—NH—, —NH—SO₂—, —SO₂—, —S—, —C(═O)—, fluoro or —C(═O)—NH—;

R₁ is H, bromo or CF₃;

R₂ is H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclohexyl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, tetrahydro-2H-thiopyran-4-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, pyrazin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl, provided R₂ is not H if L is a bond, and wherein R₂ is optionally substituted with hydroxyl, fluoro, amino, oxo, methyl, or —CH₂—NH₂;

V is CH or N;

W is CR″ or N, wherein R″ is H or F;

ring A is

R₃′ is H;

R₄ is H or cyano; and

R₅ is H or cyano.

In yet another embodiment, the present invention includes a compound of Formula (I) wherein

L is a bond, —O—, —SO₂—NH—, —NH—SO₂—, —SO₂—, —S—, or —C(═O)—;

R₁ is H or CF₃;

R₂ is H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclohexyl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, tetrahydro-2H-thiopyran-4-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, pyrazin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl, provided R₂ is not H if L is a bond, and wherein R₂ is optionally substituted with hydroxyl, fluoro, amino, oxo, methyl, or —CH₂—NH₂;

V is CH or N;

W is CR″ or N, wherein R″ is H or F;

ring A is

R₃ is H, and R₃′ is H.

The embodiments of the present invention also include the optical isomers, hydrates, metabolites, enantiomers, diastereomers, cis-trans isomers, racemates, prodrugs or pharmaceutically acceptable salts thereof.

It is an embodiment of the present invention to provide a compound selected from the compounds listed in Table 1.

TABLE 1 5-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]methanesulfonamide, 6-Amino-3-[3-fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazine-2- carbonitrile, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-methylpropyl)biphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1- methylethyl)biphenyl-2-sulfonamide (racemic), 4′-(5-Aminopyrazin-2-yl)-N-(cyclobutylmethyl)-3′-fluorobiphenyl-2- sulfonamide, (endo)-4′-(5-Aminopyrazin-2-yl)-N-bicyclo[2.2.1]hept-2-yl-3′- fluorobiphenyl-2-sulfonamide (racemic), 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-methylcyclobutyl)biphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(1,1-dimethylpropyl)-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1- dimethylethyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-cyclopentyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-phenylethyl)biphenyl-2- sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1- phenylethyl]biphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1- phenylethyl]biphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(2,3-dihydro-1H-inden-2-yl)-3′- fluorobiphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-3′- fluorobiphenyl-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-3′- fluorobiphenyl-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1-phenylethyl]biphenyl- 2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-N-[(3S)-1-ethyl-2-oxoazepan-3-yl]-3′- fluorobiphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-2-oxoazepan-3- yl]biphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-1-methyl-2-oxoazepan- 3-yl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1,2,2,6,6-pentamethylpiperidin-4- yl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-pyridin-3-ylbiphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfamide, N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)propane-2- sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]propane-1- sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-2-methylpropane-1- sulfonamide, N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)cyclopropanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]hexane-1- sulfonamide, N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)cyclobutanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1,1,1- trifluoromethanesulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N,N-dimethylbiphenyl-2- sulfonamide, 5-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, 5-[3-Fluoro-2′-(piperazin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide, 5-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(4,4-Difluoropiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, 5-{2′-[(3,3-Difluoropiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, 5-{2′-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, 5-{2′-[(3,3-Difluoroazetidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine, 5-[2′-(Azepan-1-ylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin- 2-amine, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4- (trifluoromethyl)piperidin-4-ol, 5-(3-Fluoro-2′-{[4-(methylsulfonyl)piperazin-1-yl]sulfonyl}biphenyl-4- yl)pyrazin-2-amine, 5-{2′-[(4-Acetylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2- amine, 5-(2′-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]sulfonyl}-3- fluorobiphenyl-4-yl)pyrazin-2-amine, 2-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperazin-1-yl)ethanol, 5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, racemic 5-[3-Fluoro-2′-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)- ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(3,5-Dimethylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidine-3-carbonitrile, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine- 4-carbonitrile, 5-{2′-[(4-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2- amine, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin- 2-one, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4- ol, (1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-yl)methanol, 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-4-yl)ethanol, racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-ol, racemic 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-yl)ethanol, 5-(3-Fluoro-2′-{[4-(methylamino)piperidin-1-yl]sulfonyl}biphenyl-4- yl)pyrazin-2-amine, 5-(2′-{[4-(Dimethylamino)piperidin-1-yl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrazin-2-amine, racemic 5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, N-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-4-yl)acetamide, racemic (1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-yl)methanol, racemic tert-Butyl (1-{[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-yl)carbamate, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1- (hydroxymethyl)-2-phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-3- methylbutyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxypropyl)biphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2R)-2-hydroxy-1-methyl-2- phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-1-(hydroxymethyl)-2- methylbutyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2R)-2- hydroxycyclohexyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1- (hydroxymethyl)propyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2S)-2- hydroxycyclohexyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2- sulfonamide, (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrrolidin-2-yl)methanol, (R)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine, (S)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine, (R) 5-(2′-{[2-(Aminomethyl)pyrrolidin-1-yl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrazin-2-amine, (S)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrrolidin-2-yl)methanol, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(methylsulfonyl)biphenyl-2- sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′- biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′- biphenyl]-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1- hydroxycyclohexyl)methyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-1,1- dimethylethyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2- methylpropyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-1,1- dimethylpropyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2- dimethylpropyl)biphenyl-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide, (trans)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidine-3,4-diol, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopyrrolidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1-(hydroxymethyl)-2- methylpropyl]biphenyl-2-sulfonamide, trans 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4- hydroxycyclohexyl)biphenyl-2-sulfonamide, (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrrolidin-3-yl)methanol, (S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidin-3-yl)methanol, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)biphenyl- 2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3- ylbiphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3- ylbiphenyl-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-phenylpropan-2- yl)-[1,1′-biphenyl]-2-sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-phenylethyl)- [1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1- phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin-3- ol, racemic (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2- hydroxycyclohexyl)biphenyl-2-sulfonamide, racemic (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2- (hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide, racemic (cis)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2- (hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-piperidin-4-ylbiphenyl-2- sulfonamide, 5-(2′-{[3-(Aminomethyl)azetidin-1-yl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-(azetidin-3-ylmethyl)-3′-fluorobiphenyl-2- sulfonamide, (R)-5-(3-Fluoro-2′-{[3-(methylamino)pyrrolidin-1-yl]sulfonyl}biphenyl-4- yl)pyrazin-2-amine, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1- methylethyl)biphenyl-2-sulfonamide, 5-[3-Fluoro-2′-(1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5- ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-4-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, 5-(2′-((1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)-3-fluoro- [1,1′-biphenyl]-4-yl)pyrazin-2-amine, 5-(2′-((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)-3-fluoro- [1,1′-biphenyl]-4-yl)pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-hydroxypentyl)biphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(6-hydroxyhexyl)biphenyl-2- sulfonamide, N-(4-Aminocyclohexyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2- sulfonamide, (S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2,3- dihydro-1H-indol-2-yl)methanol, 4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluoro-N-(2- hydroxyethyl)biphenyl-2-sulfonamide, (S)-5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N,N-bis(2-hydroxyethyl)biphenyl-2- sulfonamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidine-2- carboxamide, 4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluoro-N-(tetrahydro-2H- pyran-4-yl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1- methylethyl)biphenyl-2-sulfonamide, racemic (4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}morpholin-2-yl)methanol, (1R,5S)-3-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)-3-azabicyclo[3.1.0]hexan-6-amine, (S)-5-(3-fluoro-2′-((2-methylpiperazin-1-yl)sulfonyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine, (R)-5-(3-fluoro-2′-((2-methylpiperazin-1-yl)sulfonyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine, (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperazin-2-yl)methanol, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1- methylethyl]biphenyl-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-methylbutan-2- yl)-[1,1′-biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan- 2-yl)-[1,1′-biphenyl]-2-sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan- 2-yl)-[1,1′-biphenyl]-2-sulfonamide, tert-Butyl [2-({[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}amino)ethyl]carbamate, N-(2-Aminoethyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2- sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxybutan-2-yl)-[1,1′- biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(pyrrolidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide, N-[2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}amino)ethyl]acetamide, (S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- ylsulfonamido)propanoic acid, 4′-(5-Aminopyrazin-2-yl)-N-[2-(carbamoylamino)ethyl]-3′- fluorobiphenyl-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxy-2,3-dihydro- 1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2R)-2-hydroxy-2,3-dihydro- 1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2R)-2-hydroxy-2,3-dihydro- 1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2S)-2-hydroxy-2,3-dihydro- 1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxycyclohexyl)- [1,1′-biphenyl]-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[6-(trifluoromethyl)pyridin-3- yl]biphenyl-2-sulfonamide, 5-(3-Fluoro-2′-{[4-(1H-imidazol-4-yl)piperidin-1-yl]sulfonyl}biphenyl-4- yl)pyrazin-2-amine, N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4′-(5-aminopyrazin-2-yl)- 3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(2,6-dimethoxypyrimidin-4-yl)-3′- fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-methylpyrazin-2-yl)biphenyl-2- sulfonamide, (S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- ylsulfonamido)-4-methylpentanamide, 4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2- sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′- fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-methyloxetan-3-yl)biphenyl-2- sulfonamide, 3-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperazin-1-yl)propanenitrile, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-methoxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide, 5-{3-Fluoro-2′-[(4-pyrazin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(4-pyrimidin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazin-2-amine, 5-(2′-Amino-3-fluorobiphenyl-4-yl)pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1- (hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3- phenylpyrrolidin-3-ol, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1- sulfonamide, N′-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,N- dimethylsulfamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]morpholine-4- sulfonamide, (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidin-3-ol, (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidin-3-ol, (3′S,4′S)-1′-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}- 1,3′-bipyrrolidin-4′-ol, (3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4- morpholin-4-ylpyrrolidin-3-ol, (3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4- (4-methylpiperazin-1-yl)pyrrolidin-3-ol, 5-{3-Fluoro-2′-[(trifluoromethyl)-sulfanyl]biphenyl-4-yl}pyrazin-2- amine, 5-[2′-(tert-Butylsulfanyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(Ethylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(propylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{3,-Fluoro-2′-[(2-methylpropyl)sulfonyl]biphenyl-4-yl}pyrazin-2- amine, 5-[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(Cyclopentylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(Cyclobutylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-{3-Fluoro-2′-[(1-methylethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(trifluoromethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}acetamide, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}-N,N- diethylacetamide, 5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfanyl]biphenyl-4- yl}pyrazin-2-amine, (racemic) 5-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfanyl}methyl)-1,3-oxazolidin-2-one, N-(2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfanyl}ethyl)benzamide, 5-(3-Fluoro-2′-{[4-(methylsulfonyl)benzyl]sulfanyl}biphenyl-4- yl)pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- sulfonamide, 5-[3-Fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-4- (trifluoromethyl)biphenyl-2-sulfonamide, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- yl]sulfonyl}piperazin-2-one, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl- 2-sulfonamide, 5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine hydrochloride, 5-[3-Fluoro-2′-(pyrimidin-4-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine formate salt, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4- amine hydrochloride, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4- amine hydrochloride, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5- amine hydrochloride, 5-[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine hydrochloride, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5- amine hydrochloride, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N- methylmethanesulfonamide formic acid salt, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-(2- hydroxyethyl)methanesulfonamide formic acid salt, 1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]methyl}sulfonyl)azetidin-3-ol formic acid salt, 4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]methyl}sulfonyl)piperazin-2-one formic acid salt, (S)-1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1- hydroxypropan-2-yl)methanesulfonamide, (R)-1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1- hydroxypropan-2-yl)methanesulfonamide hydrochloride, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-(trans-4- hydroxycyclohexyl)methanesulfonamide, (S)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2- hydroxypropyl]methanesulfonamide hydrochloride, (R)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2- hydroxypropyl]methanesulfonamide, 5-(2′-{[(4-Aminopiperidin-1-yl)sulfonyl]methyl}-3-fluorobiphenyl-4- yl)pyrazin-2-amine hydrochloride, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide hydrochloride, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N- ethylmethanesulfonamide formate salt, 1-[1-({[4′-(5-Aminopyrazin-2-yl)-3-fluorobiphenyl-2- yl]methyl}sulfonyl)piperidin-4-yl]urea hydrochloride, N-[1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]methyl}sulfonyl)piperidin-4-yl]acetamide formate salt, 5-{2′-[(Ethylsulfanyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine formate salt, 5-{3-Fluoro-2′-[(methylsulfanyl)methyl]biphenyl-4-yl}pyrazin-2-amine hydrochloride, 5-(3-Fluoro-2′-{[(1-methylethyl)sulfanyl]methyl}biphenyl-4-yl)pyrazin- 2-amine hydrochloride, 2-(((4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)methyl)thio)pyrimidin-4-amine hydrochloride, 6-(((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)methyl)thio)pyrimidin-4-amine hydrochloride, 5-(3-fluoro-2′-((pyridazin-3-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin- 2-amine hydrochloride, 6-(((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)methyl)thio)pyridazin-3-amine hydrochloride, 5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrazin-2-amine, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2- amine hydrochloride, 5-(3-fluoro-2′-((pyrimidin-4-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin- 2-amine hydrochloride, 5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl)biphenyl-4- yl]pyrazin-2-amine, 5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfonyl)biphenyl-4- yl]pyrazin-2-amine hydrochloride, 5-(3-Fluoro-2′-{[3-(methylsulfonyl)propyl]sulfonyl}biphenyl-4- yl)pyrazin-2-amine hydrochloride, 5-(3-Fluoro-2′-{[(2R)-2-methylpiperazin-1-yl]sulfonyl}biphenyl-4- yl)pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1- (hydroxymethyl)propyl]biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′- fluorobiphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2- sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(3-hydroxy-2,2- dimethylpropyl)biphenyl-2-sulfonamide, racemic (4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}morpholin-2-yl)methanol, 5-(3-Fluoro-2′-{[(2S)-2-methylpiperazin-1-yl]sulfonyl}biphenyl-4- yl)pyrimidin-2-amine, 5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1- methylethyl]biphenyl-2-sulfonamide, 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3S)-piperidin-3- yl]biphenyl-2-sulfonamide, 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3R)-piperidin-3- yl]biphenyl-2-sulfonamide, [(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperazin-2-yl]methanol, racemic cis 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(cis)-2- hydroxycyclohexyl]biphenyl-2-sulfonamide, racemic trans 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(trans)-2- hydroxycyclohexyl]biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1- methylethyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(trans-4- hydroxycyclohexyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopyrrolidin-3- yl]biphenyl-2-sulfonamide, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl- 2-sulfonamide, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin- 3-ol trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3R)-2-oxopiperidin-3- yl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopiperidin-3- yl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)-2,2- dimethylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2,2- dimethylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2- methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-2- methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)-2- methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-[(2S)-2,3-dihydroxypropyl]-3′- fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2- sulfonamide trifluoroacetic acid salt, [(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt, [(2S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl- 2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-1,1- dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, 5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine trifluoroacetic acid salt, 2-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperazin-1-yl)ethanol trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid, 4′-(2-Aminopyrimidin-5-yl)-N-cyclopropyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-tert-butyl-3′-fluoro-3-methylbiphenyl-2- sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[3-Fluoro-2′-(piperazin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1- phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1- phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-methylpropyl)biphenyl-2- sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1- dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N,N-dimethylbiphenyl-2- sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 5-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-aminopyrimidin-5-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2- sulfonamide trifluoroacetic acid salt, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin- 2-one trifluoroacetic acid salt, tert-Butyl N-{[4′-(2-aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}-L-alaninate, N-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L- alanine, N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1- sulfonamide, N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]morpholine-4- sulfonamide, N′-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N,N- dimethylsulfamide, 5-(2′-(2-oxa-6-azaspiro[3.3]heptan-6-ylsulfonyl)-3-fluoro-[1,1′- biphenyl]-4-yl)pyrimidin-2-amine, 6-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-2- thia-6-azaspiro[3.3]heptane 2,2-dioxide, 1-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)azetidine-3-carbonitrile, 1-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3- (trifluoromethyl)azetidin-3-ol, 5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrimidin-2-amine hydrochloride, 2-(((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)methyl)quinazolin-4(3H)-one, 1-(3-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)propyl)-1H-benzo[d]imidazol-2(3H)-one, 5-(2′-{[3-(Cyclohexylsulfonyl)propyl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrimidin-2-amine, 5-{3-Fluoro-2′-[(1-methyl-1H-benzimidazol-2-yl)sulfonyl]biphenyl-4- yl}pyrimidin-2-amine, 5-(2′-{[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]sulfonyl}-3- fluorobiphenyl-4-yl)pyrimidin-2-amine, 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- sulfonamide, 5-[3-fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine, 4-{[4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- yl]sulfonyl}piperazin-2-one, 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-4- (trifluoromethyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluoro-4- (trifluoromethyl)biphenyl-2-sulfonamide, 5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(5-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine formate salt, 5-{2′-[(4-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine formate salt, 5-{2′-[(5-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine formate salt, 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine hydrochloride, 5-[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine hydrochloride, 5-{2′-[(6-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine formate salt, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrimidin-2-amine formate salt, 5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine formate salt, 5-{2′-[(5-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine hydrochloride, 5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfonyl)biphenyl-4- yl]pyrimidin-2-amine formate salt, 5-{2′-[(5-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine hydrochloride, 5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl)biphenyl-4- yl]pyrimidin-2-amine, 5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine, 4′-(6-aminopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2- sulfonamide, 4′-(6-aminopyridin-3-yl)-N,N-diethyl-3′-fluoro-[1,1′-biphenyl]-2- sulfonamide, 5-(3-fluoro-2′-(pyrrolidin-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2- amine, 5-(3-fluoro-2′-(piperidin-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2- amine, 4′-(6-aminopyridin-3-yl)-N-cyclohexyl-3′-fluoro-[1,1′-biphenyl]-2- sulfonamide, (S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-isobutyl-[1,1′-biphenyl]-2- sulfonamide, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(tert-pentyl)-[1,1′-biphenyl]-2- sulfonamide, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1,1,1-trifluoro-2-methylpropan-2- yl)-[1,1′-biphenyl]-2-sulfonamide, (S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-phenylethyl)- [1,1′-biphenyl]-2-sulfonamide, (R)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-methylcyclobutyl)-[1,1′- biphenyl]-2-sulfonamide, 4-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)thiomorpholine 1,1-dioxide, (S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1,1,1-trifluoropropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide, 5-(2′-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ylsulfonyl)-3-fluoro- [1,1′-biphenyl]-4-yl)pyridin-2-amine, tert-butyl 3-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2- ylsulfonamido)methyl)-3-hydroxyazetidine-1-carboxylate, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)- [1,1′-biphenyl]-2-sulfonamide, 2-(1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidin-4-yl)ethanol, 1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidin-4-ol, (1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidin-4-yl)methanol, 3′-Fluoro-N-[(1S)-2-hydroxy-1-methylethyl]-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2-sulfonamide, 3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2-sulfonamide, 3′-Fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]-4′-(1H-pyrrolo[2,3-b]pyridin-5- yl)biphenyl-2-sulfonamide, 5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]-1H-pyrrolo[2,3- b]pyridine, 3′-Fluoro-N-(2-hydroxyethyl)-4′-(1H-pyrrolo[2,3-b]pyridin-5- yl)biphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- sulfonamide, 3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide, N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- yl]methanesulfonamide, 3′-Fluoro-N,N-dimethyl-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide, N-tert-Butyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide, 2-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3- b]pyrazine, N,N-Diethyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide, 2-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3- b]pyrazine, 2-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3- b]pyrazine, 3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-N-(2,2,2-trifluoro-1- methylethyl)biphenyl-2-sulfonamide, 2-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3- b]pyrazine, 3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2-sulfonamide, 3′-Fluoro-N-methyl-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide, 3′-Fluoro-N-[(1S)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2-sulfonamide, 1-{[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- yl]sulfonyl}piperidin-4-amine, 2-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}- 5H-pyrrolo[2,3-b]pyrazine, 2-[3,5′-Difluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3- b]pyrazine, 2-[2′-(Ethylsulfanyl)-3-fluorobiphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, 7-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H- pyrido[3,2-b][1,4]oxazine, 7-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H- pyrido[3,2-b][1,4]oxazine, 4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-2- sulfonamide, 4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1S)-2- hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 1-{[4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl- 2-yl]sulfonyl}piperidin-4-amine, 4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1R)-2- hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-N,N-diethyl-3′- fluorobiphenyl-2-sulfonamide, 7-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}- 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine, N-tert-Butyl-4′-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′- fluorobiphenyl-2-sulfonamide, 2-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]-5-(trifluoromethyl)pyridin-3- yl}phenyl)-5H-pyrrolo[2,3-b]pyrazine, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2- amine, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]pyridin-3-yl}phenyl)pyrazin-2- amine, 2-{2-Fluoro-4-[2-(2,2,2-trifluoroethoxy)pyridin-3-yl]phenyl}-5H- pyrrolo[2,3-b]pyrazine, 2-{2-Fluoro-4-[2-(2-methylpropoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3- b]pyrazine, 2-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3- b]pyrazine, 2-{4-[2-(Cyclopropylmethoxy)pyridin-3-yl]-2-fluorophenyl}-5H- pyrrolo[2,3-b]pyrazine, 5-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-{4-[2-(Cyclopentyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, 5-{4-[2-(Cyclohexyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, 5-[2-Fluoro-4-(2-methoxypyridin-3-yl)phenyl]pyrazin-2-amine, 5-{4-[2-(Cyclobutyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, tert-Butyl 3-[({3-[4-(5-aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2- yl}oxy)methyl]pyrrolidine-1-carboxylate, 5-{2-Fluoro-4-[2-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]phenyl}pyrazin-2- amine, 5-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrimidin-2- amine, 5-[4-(2-Aminopyridin-3-yl)-2-fluorophenyl]pyrimidin-2-amine, 4′-(5-amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide, 3-Amino-6-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2- carbonitrile, 4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide, 4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-(2- hydroxyethyl)biphenyl-2-sulfonamide, 3-Amino-6-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazine-2-carbonitrile, 4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2- hydroxypropyl]biphenyl-2-sulfonamide, 3-Amino-6-[3-fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazine- 2-carbonitrile, 4′-(6-Aminopyridazin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, N-tert-Butyl-3′-fluoro-4′-(7H-pyrrolo[2,3-d]pyrimidin-2-yl)biphenyl-2- sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1,8-naphthyridin-3-yl)biphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-quinoxalin-6-ylbiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1H-indol-5-yl)biphenyl-2-sulfonamide, 4′-(1H-Benzimidazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(1H-Benzimidazol-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide, 4′-(1,3-Benzothiazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1H-pyrrolo[3,2-b]pyridin-6-yl)biphenyl-2- sulfonamide, 3′-Fluoro-N-methyl-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- sulfonamide, 4′-(5-Aminopyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-4′-(5,6-diaminopyrazin-2-yl)-3′-fluorobiphenyl-2- sulfonamide, N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin- 5-yl)biphenyl-2-sulfonamide, 4′-(6-Amino-5-fluoropyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, N-tert-Butyl-4′-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-3′- fluorobiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(3H-imidazo[4,5-b]pyridin-6-yl)biphenyl-2- sulfonamide, 4′-(5-Amino-6-methoxypyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Amino-6-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(6-Amino-4-cyanopyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(6-amino-2-cyanopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]- 2-sulfonamide, 4′-(5-amino-1,3,4-thiadiazol-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide, (R)-4′-(5-amino-1,3,4-thiadiazol-2-yl)-3′-fluoro-N-(1-hydroxypropan-2- yl)-[1,1′-biphenyl]-2-sulfonamide, 4-((4′-(5-amino-1,3,4-thiadiazol-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)thiomorpholine 1,1-dioxide, 4′-(5-Amino-6-chloropyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Amino-6-bromopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 6-amino-3-(2′-(cyclopropylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)picolinonitrile, N-tert-Butyl-3′-fluoro-4′-[1,2,4]triazolo[4,3-a]pyridin-7-ylbiphenyl-2- sulfonamide, 4′-(5-Amino-6-methylpyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1H-imidazo[4,5-b]pyrazin-5-yl)biphenyl-2- sulfonamide, N-tert-Butyl-4′-(5,6-diaminopyridin-3-yl)-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2- sulfonamide, 4′-(6-Amino-5-cyanopyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt, 4′-(6-Amino-5-chloropyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt, 4′-[6-Amino-5-(trifluoromethyl)pyridin-3-yl]-N-tert-butyl-3′- fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-[2-Amino-4-(trifluoromethyl)pyrimidin-5-yl]-N-tert-butyl-3′- fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Amino-4-methylpyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt, N-tert-Butyl-3′-fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5- yl]biphenyl-2-sulfonamide, 4′-(7-Amino-1H-indol-5-yl)-3′-fluoro-N-[1- (hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide, 3′-Fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N- methylbiphenyl-2-sulfonamide, 4′-(7-Amino-1H-indol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]acetamide, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]urea, 5-[2,3-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2- sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methylbiphenyl-2- yl]methanesulfonamide, 4′-(5-Aminopyrazin-2-yl)-2′,3′-difluorobiphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-2′,3′-difluoro-N-methylbiphenyl-2- sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2- sulfonamide trifluoroacetic acid salt, 5-[2′,3-Difluoro-4′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine, 5-(2′,3-Difluorobiphenyl-4-yl)pyrazin-2-amine, 5-(2′-Chloro-3-fluorobiphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2′-methylbiphenyl-4-yl)pyrazin-2-amine, 5-[2′,3-Difluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-(3-Fluoro-2′-methoxybiphenyl-4-yl)pyrazin-2-amine, 5-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-ol, 5-[3-Fluoro-2′-(phenylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-(2′,3,6′-Trifluorobiphenyl-4-yl)pyrazin-2-amine, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]benzenesulfonamide, 5-(2′-Ethyl-3-fluorobiphenyl-4-yl)pyrazin-2-amine, {[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid, 5-[3-Fluoro-2′-(1-methylethyl)biphenyl-4-yl]pyrazin-2-amine, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanone, 5-[3-Fluoro-2′-(2,2,2-trifluoroethoxy)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxylic acid, 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxamide, 5-[3-Fluoro-2′-(1-methylethoxy)biphenyl-4-yl]pyrazin-2-amine, 5-{4-[2-(Cyclopropylmethoxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2- amine, 2-[3,4′-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3- b]pyrazine, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N- methylmethanesulfonmide, N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- yl]ethanesulfonamide, N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-N- methylmethanesulfonamide, N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-N- methylethanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N- methylethanesulfonamide, N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-2- methylpropane-1-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N- ethylmethanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,2- dimethylpropane-1-sulfonamide, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-1H-pyrrolo[2,3- b]pyridine, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrimidin-2- amine, 2-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-5H-pyrrolo[2,3- b]pyrazine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2- carboxamide, 4′-(5-Aminopyrazin-2-yl)-N,N-diethyl-3′-fluorobiphenyl-2-carboxamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-carboxamide, 5-[3-Fluoro-2′-(piperazin-1-ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(4-Acetylpiperazin-1-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine, 4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2- carboxamide, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-carboxamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin- 4-ol, 5-{2′-[(4-Aminopiperidin-1-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2- amine, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-carboxamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-carboxamide, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperazin- 2-one, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}piperazin-2-one, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine, 4-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- yl]oxy}pyrimidin-2-amine, 2-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- yl]oxy}pyrimidin-4-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1H-pyrrolo[2,3- b]pyridine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrimidin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4- amine, 5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine, 6-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]oxy}methyl)pyridine-2-carbonitrile, 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]oxy}methyl)pyridine-3-carbonitrile, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2- amine, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2- amine, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4- amine, 5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile, 5-{2′-[(6-Azetidin-1-ylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine, 5-{2′-[(6-Azetidin-1-ylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine, 5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrazin-2- amine, 5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrimidin-2- amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1H-benzimidazole, 6-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-3H-imidazo[4,5- b]pyridine, 5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2- amine, 5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2- amine, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}biphenyl-4- yl)pyrazin-2-amine, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}biphenyl-4- yl)pyrimidin-2-amine, 5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2- amine, 5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin- 2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine, 5-[3-Fluoro-2′-methoxy-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2- amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- yl]oxy}pyrimidin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- yl]oxy}pyrimidin-4-amine, 5-[3-Fluoro-4′-(trifluoromethyl)-2′-{[2- (trimethylsilyl)ethoxy]methoxy}biphenyl-4-yl]pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol, 5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl- 4-yl}pyrimidin-2-amine, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- yl]oxy}pyrimidin-2-amine, 5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl- 4-yl}pyrimidin-2-amine, 5-[3-Fluoro-2′,4′-bis(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- carbonitrile, 5-{5-[2-(Pyrimidin-2-yloxy)-4-(trifluoromethyl)phenyl]pyridin-2- yl}pyrimidin-2-amine, 4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-5- (trifluoromethyl)phenoxy}pyrimidin-2-amine, 5-{5-[2-(Pyrimidin-2-yloxy)phenyl]pyridin-2-yl}pyrimidin-2-amine, 4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenoxy}pyrimidin-2- amine, 5-(5-{2-[(4-Aminopyrimidin-2-yl)oxy]phenyl}pyridin-2-yl)pyrimidin-2- amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methylbiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methoxybiphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-tert-butylbiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N,N-dimethylbiphenyl-2-sulfonamide, 5-[2′-(Morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-2′-fluoro-N,N-dimethylbiphenyl-2- sulfonamide, 4′-(2-Amino-1,3-oxazol-4-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(2-Amino-1,3-thiazol-4-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(2-Amino-1,3-thiazol-4-yl)-N,N-diethyl-3′-fluorobiphenyl-2- sulfonamide, 4-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]-1,3-thiazol-2- amine, N-tert-Butyl-3′-fluoro-4′-(8-fluoroimidazo[1,2-a]pyridin-2-yl)biphenyl-2- sulfonamide, 4′-(5-Aminoimidazo[1,2-a]pyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine- 6-carboxamide, 2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine- 6-carboxamide, N-tert-Butyl-4′-(5-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2- sulfonamide, N-tert-Butyl-4′-(6-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2- sulfonamide, N-tert-Butyl-3′-fluoro-4′-[6-(trifluoromethyl)imidazo[1,2-a]pyridin-2- yl]biphenyl-2-sulfonamide, Ethyl 2-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2- a]pyridine-5-carboxylate, and N-tert-Butyl-3′-fluoro-4′-(5-methoxyimidazo[1,2-a]pyridin-2-yl)biphenyl- 2-sulfonamide. 5-[2′-(Methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine. 5-[3-Methyl-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine. 4′-(5-Aminopyrazin-2-yl)-N,N,3′-trimethylbiphenyl-2-sulfonamide. 4′-(5-Aminopyrazin-2-yl)-3′-hydroxybiphenyl-2-sulfonamide. N-[4′-(5-Aminopyrazin-2-yl)biphenyl-2-yl]methanesulfonamide. 4′-(5-Aminopyrazin-2-yl)biphenyl-2-sulfonamide. N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-indol-5-yl)biphenyl-2- sulfonamide. N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)-3′- fluorobiphenyl-2-sulfonamide. 4′-(3-Amino-1H-indazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide. 3-Amino-6-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]pyrazine-2- carboxylic acid. 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}acetamide. 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N,N- diethylacetamide. 5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfonyl]biphenyl-4- yl}pyrimidin-2-amine. 5,5′-(3,3″-Difluoro-1,1′:2′,1″-terphenyl-4,4″-diyl)dipyrazin-2-amine. 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- carboxylic acid. 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- carbaldehyde. 5-[3-Fluoro-2′-(morpholin-4-ylmethyl)-4′-(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine. 5-{2′-[(4-Aminopiperidin-1-yl)methyl]-3-fluoro-4′- (trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine. 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- yl]methyl}amino)ethanol. 5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine. 5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine. 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4- yl)pyrazin-2-amine. 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4- yl)pyrimidin-2-amine. 5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4- yl)pyrazin-2-amine. 5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4- yl)pyrimidin-2-amine. 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-5- amine. 5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine. 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-6- methylpyrimidin-4-amine. 5-{2′-[(4-Amino-6-methylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine. 6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile. 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile. 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine. 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine. 5-{2′-[(6-Amino-2-methylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine. 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-2- methylpyrimidin-4-amine. 5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4- yl)pyrimidin-2-amine. 5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4- yl)pyrazin-2-amine. 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile. 6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile. 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol. 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol. 5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrazin-2-amine. 5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrimidin-2-amine. 5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine. 5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine. 5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine. 5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine. 5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4- yl}pyrazin-2-amine. 5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine. 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine. 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine. 5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrazin-2-amine. 5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine. {[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile. {[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile. {[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid. 5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine. 5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrimidin- 2-amine. 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine. 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine. 2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2- yl}oxy)ethanol. 2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol. 5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine. 5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine formic acid salt. 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3- yl]phenyl}pyrazin-2-amine. 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3- yl]phenyl}pyrimidin-2-amine. (2R)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol. (2R)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol. (2S)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol. (2I)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol. N-(4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)methanesulfonamide 5-(3-Fluoro-2′-(morpholinosulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2- sulfonamide 4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide trifluoroacetate 5-(2′-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-ylsulfonyl)-3-fluoro- [1,1′-biphenyl]-4-yl)pyridin-2-amine 4′-(6-Aminopyrazin-2-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)- [1,1′-biphenyl]-2-sulfonamide 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-methylpropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1- phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2- methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide (racemic)-1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′- biphenyl]-2-yl)sulfonyl)piperidin-3-ol 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1- phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide N-(1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidin-4-yl)acetamide racemic 2-(1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′- biphenyl]-2-yl)suifonyl)piperidin-3-yl)ethanol. racemic 1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidin-3-yl)methanol. 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2R)-2- hydroxypropyl]benzenesulfonamide. 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-ethyl-5- (trifluoromethyl)benzenesulfonamide. 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-tert- butylbenzenesulfonamide. 5-{5-[2-(Morpholin-4-ylmethyl)-4-(trifluoromethyl)phenyl]pyridin-2- yl}pyrimidin-2-amine. 5-{5-[2-(Morpholin-4-ylcarbonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine. 5-[5-(2-Methoxyphenyl)pyridin-2-yl]pyrimidin-2-amine. 5-(5-{2-[(3,3-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine trifluoroacetic acid salt. 5-(5-{2-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine trifluoroacetic acid salt. 5-{5-[2-(Azepan-1-ylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine trifluoroacetic acid salt. 5-(5-{2-[(4,4-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine trifluoroacetic acid salt. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethylbenzenesulfonamide trifluoroacetic acid salt. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N- (dicyclopropylmethyl)benzenesulfonamide trifluoroacetic acid salt. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1- methylethyl]benzenesulfonamide trifluoroacetic acid salt. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1- methylethyl]benzenesulfonamide trifluoroacetic acid salt. 4-({2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenyl}sulfonyl)piperazin- 2-one. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2S)-2- hydroxypropyl]benzenesulfonamide. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2R)-2- hydroxypropyl]benzenesulfonamide. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(2-hydroxyethyl)-5- (trifluoromethyl)benzenesulfonamide. 5-{5-[2-(Cyclopropylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine trifluoroacetic acid salt. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethyl-5- (trifluoromethyl)benzenesulfonamide trifluoroacetic acid salt. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]N-tert- butylbenzenesulfonamide. 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2-hydroxy-1- methylethyl]benzenesulfonamide. 3-Amino-6-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4- yl}pyrazine-2-carbonitrile trifluoroacetic acid salt. 5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)pyrazin-2-amine. 5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)-1H-pyrrolo[2,3-b]pyridine. 5-(3-fluoro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)pyrazin- 2-amine. 5-(2′,3,4′-Trifluorobiphenyl-4-yl)pyrazin-2-amine racemic 5-[3-Fluoro-2′-(methylsulfinyl)biphenyl-4-yl]pyrazin-2-amine 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carbonitrile 1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)imidazolidin- 2-one 4′-(2-Amino-4-cyanopyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide 6-Amino-3-{2′-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrazine-2-carbonitrile 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N- methylazetidine-3-carboxamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl- 2-sulfonamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2S)-2- hydroxypropyl]biphenyl-2-sulfonamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2- hydroxypropyl]biphenyl-2-sulfonamide 1-((4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidine-4-carboxamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2-sulfonamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)- [1,1′-biphenyl]-2-sulfonamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2- dimethylpropyl)biphenyl-2-sulfonamide 6-Amino-3-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4-yl}pyrazine-2-carbonitrile N-(2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}ethyl)benzamide 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3,3- dimethylbutan-2-one 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine 5-[3-Fluoro-2′-(pyrazin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine 5-[3-Fluoro-2′-(pyrimidin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine 5-{2′-[(6-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine 5-{2′-[(4-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine 5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrimidin-2-amine 5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin- 4-amine 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin- 4-amine 5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 6-Amino-3-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2- carbonitrile 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarbonitrile 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarboxamide 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanenitrile 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanamide 5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanenitrile 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanamide 5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarbonitrile 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarboxamide 5-(2′-{[1-(Aminomethyl)cyclopentyl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrimidin-2-amine 5-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrazin-2-amine 5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2- amine 5-(3-Fluoro-2′-(pyrimidin-4-ylthio)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine 5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 6-Amino-3-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4- yl}pyrazine-2-carbonitrile 8-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazine-2-carbonitrile 6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazine-2- carbonitrile N-(tert-Butyl)-3′-fluoro-4′-(5-(methylsulfonamido)pyrazin-2-yl)-[1,1′- biphenyl]-2-sulfonamide 5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine hydrogen chloride salt 5-{3-Fluoro-2′-[(methylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine 5-(3-Fluoro-2′-{[(1-methylethyl)sulfonyl]methyl}biphenyl-4-yl)pyrazin- 2-amine 5-{3-Fluoro-2′-[(pyrimidin-2-ylsulfonyl)methyl]biphenyl-4-yl}pyrazin- 2-amine 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]methyl}sulfonyl)pyrimidin-4-amine racemic 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4- yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}azetidin-3-ol 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(tetrahydro-2H-pyran-4- yl)biphenyl-2-carboxamide 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluoro-4′- (trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine 1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture). 1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture). 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl- 2-carboxamide 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2- carboxamide (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol (cis/trans) 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4- hydroxycyclohexyl)biphenyl-2-carboxamide (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol (cis/trans) 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(4- hydroxycyclohexyl)biphenyl-2-carboxamide racemic 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4- yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol 5-{2′-[(2,8-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine (diastereoisomeric mixture). 5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrazin-2-amine 5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrazin-2-amine 5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrazin-2-amine 5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrimidin-2-amine 5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrimidin-2-amine 5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrimidin-2-amine 5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine (diastereoisomeric mixture) 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}-1H- pyrrolo[2,3-b]pyridine 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3- yl]phenyl}pyrimidin-2-amine 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrazin- 2-amine 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-tert-butyl-5- (trifluoromethyl)benzamide 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1R)-2-hydroxy-1- methyl-ethyl]-5-(trifluoromethyl)benzamide 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1S)-2-hydroxy-1- methyl-ethyl]-5-(trifluoromethyl)benzamide 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1R)- 2,2,2-trifluoro-1-methyl-ethyl]benzamide 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N- [(1S)-2,2,2-trifluoro-1-methyl-ethyl]benzamide 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N- [(1R)-2,2,2-trifluoro-1-methyl-ethyl]benzamide 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1S)- 2,2,2-trifluoro-1-methyl-ethyl]benzamide [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-(3- hydroxyazetidin-1-yl)methanone [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-[4- (methylamino)-1-piperidyl]methanone [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5- (trifluoromethyl)phenyl]-(1,1-dioxo-1,4-thiazinan-4-yl)methanone 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tert-butyl-5- (trifluoromethyl)benzamide [2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5- (trifluoromethyl)phenyl]-(4-hydroxy-1-piperidyl)methanone [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5- (trifluoromethyl)phenyl]-(4-hydroxy-1-piperidyl)methanone 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tetrahydropyran-4-yl- benzamide racemic [2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]phenyl]-[2- (hydroxymethyl)morpholin-4-yl]methanone racemic [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-[2- (hydroxymethyl)morpholin-4-yl]methanone N-{3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}-2,2- dimethylpropanamide N-{3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}-2,2- dimethylpropanamide N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]pyridin-2- yl}-2,2-dimethylpropanamide racemic 5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3- yl)phenyl)pyrazin-2-amine hydrochloride 5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrimidin- 2-amine formic acid salt. 5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin- 2-amine hydrochloride. 5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin- 2-amine hydrochloride 5-(4-(2-(Cyclohexlsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin- 2-amine hydrochloride 5-(4-(2-(Cyclohexylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine hydrochloride 5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidine- 2-amine hydrochloride 5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin- 2-amine hydrochloride 5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine formic acid salt. 5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin- 2-amine formic acid salt. racemic 5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrimidin-2-amine formate racemic 5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2- amine formate 1-((3-(4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)piperidin-1-yl)ethanone 1-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)piperidin-1-yl)ethanone hydrogen chloride salt 5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3- yl)phenyl)pyrimidin-2-amine hydrogen chloride salt. 5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3- yl)phenyl)pyrazin-2-amine hydrogen chloride salt. 4-((3-(4-(2-aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide 4-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide 5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3- yl)phenyl)pyrimidin-2-amine formic acid salt. 5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3- yl)phenyl)pyrazin-2-amine 5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3- yl)pyrimidin-2-amine formic acid salt. 5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3- yl)pyrazin-2-amine formic acid salt. 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3- yl}phenyl)pyrimidin-2-amine 5-(2-Fluoro-4-(2-(isopropylsulfonyl)pyridine-3-yl)phenyl)-1H-pyrrolo[2,3- b]pyridine 5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin- 2-amine formic acid salt. 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin- 2-amine formic acid salt. 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin- 2-amine formic acid salt. 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3- yl]phenyl}pyrazin-2-amine hydrochloride 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3- yl]phenyl}pyrimidin-2-amine formic acid salt. 5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin- 2-amine hydrochloride 5-(2,3-Difluorobiphenyl-4-yl)pyrazin-2-amine. 5-(3-Fluoro-2-methoxybiphenyl-4-yl)pyrazin-2-amine. 5-[3-Fluoro-2-methoxy-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine. 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-2′-methoxybiphenyl-2- sulfonamide. N-[4′-(5-Aminopyrazin-2-y)-3′-fluoro-2′-methoxybiphenyl-2- yl]methanesulfonamide. 5-(3-Fluoro-2′-(pyrazin-2-yl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine 5-(3-Fluoro-2′-pyrazin-2-ylbiphenyl-4-yl)pyrimidin-2-amine. 5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrazin-2-amine. 5-[2′-(5-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine. 5-[2′-(6-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine. 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine. 5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrimidin-2-amine. 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-5-(trifluoromethyl)biphenyl-2- yl]pyrimidin-2-amine. 5-[3-Fluoro-2′-(2-methoxypyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine. 5-[3-Fluoro-2′-(1-methyl-1H-pyrazol-4-yl)bipheny-4-yl]pyrazin-2-amine. 5-(3-Fluoro-2′-pyrimidin-5-ylbiphenyl-4-yl)pyrazin-2-amine. 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidine-2- carbonitrile. 5-[3-Fluoro-2′-(2-morpholin-4-ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin- 2-amine. 1-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol- 1-yl}-2-methylpropan-2-ol. 5-[3-Fluoro-2′-(1,2,3,6-tetrahydropyridin-4-yl)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine. 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- yl]pyrimidin-2-amine. 5-{2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]phenyl}pyrmidin-2- amine. 5-{5-[2-(2-Aminopyrimidin-5-yl)phenyl]pyridin-2-yl}pyrimidin-2-amine. 5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4- yl]pyrazin-2-amine 5-[2′-(1,1-Dioxido-1,2-thiazinan-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2- amine 5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2- amine 5-[2-Fluoro-4-(2-pyrrolidin-1-ylpyridin-3-y)phenyl]pyrazin-2-amine 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidin-2-one 5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)-1H-pyrrolo[2,3-b]pyridine 5-(2′3,4′-Trifluorobiphenyl-4-yl)pyrazin-2-amine 5-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine 5-[2′-(Methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine 5-[3-Methyl-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine 4′-(5-Aminopyrazin-2-yl)-3′-hydroxybiphenyl-2-sulfonamide N-[4′-(5-Aminopyrazin-2-yl)biphenyl-2-yl]methanesulfonamide 4′-(5-Aminopyrazin-2-yl)biphenyl-2-sulfonamide 4′-(6-Aminopyridazin-3-yl)-3′-fluorobiphenyl-2-sulfonamide N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)-3′- fluorobiphenyl-2-sulfonamide 3-Amino-6-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]pyrazine-2- carboxylic acid 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5- (trifluoromethyl)biphenyl-2-sulfonamide 5-{5-[2-(Cyclopropylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}acetamide 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N,N- diethylacetamide 5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfonyl]biphenyl-4- yl}pyrimidin-2-amine 5-[5-(2-Methoxyphenyl)pyridin-2-yl]pyrimidin-2-amine 5-{5-[2-(Morpholin-4-ylcarbonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine 4′-(2-Amino-4-cyanopyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine 5-[3-Fluoro-2′-(pyrazin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine N-(2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}ethyl)benzamide 5-[3-Fluoro-2′-(pyrimidin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine 5-{2′-[(6-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine 5-{2′-[(4-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine 5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 5-(2-Fluoro-4-{2-[(2-morpholin-4-ylethyl)sulfonyl]pyridin-3- yl}phenyl)pyrimidin-2-amine 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-5-(trifluoromethyl)biphenyl-2- yl]pyrimidin-2-amine 5-{5-[2-(2-Aminopyrimidin-5-yl)phenyl]pyridin-2-yl}pyrimidin-2-amine 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrimidin-2-amine 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrazin- 2-amine 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrimidin- 2-amine 5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrimidin-2-amine 5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2- amine (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol 2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2- yl}oxy)ethanol 5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol 5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrimidin-2-amine 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanamide 5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine 5-(2′-{[1-(Aminomethyl)cyclopentyl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrimidin-2-amine 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl- 2-carboxamide (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol. {[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid. 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2- carboxamid 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2- carboxamide 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(tetrahydro-2H-pyran-4- yl)biphenyl-2-carboxamide 5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrazin-2-amine 5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine 2-[3,5′-Difluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3- b]pyrazine N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]methanesulfonamide 4′-(5-Aminopyrazin-2-yl)-N,N,3′-trimethylbiphenyl-2-sulfonamide 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-indol-5-yl)biphenyl-2- sulfonamide 4′-(3-Amino-1H-indazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide 5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrimidin-2-amine 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4- yl)pyrimidin-2-amine 5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrazin-2-amine N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methoxybiphenyl-2- yl]methanesulfonamide 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}azetidin-3- ol (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carbonitrile (2R)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol 5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2- amine 5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 4′-(6-Aminopyridin-3-yl)-3′-fluorobiphenyl-2-sulfonamide 5-{3-Fluoro-2′-[(methylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine 5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2- carboxamide 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3,3- dimethylbutan-2-one 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin- 4-amine 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol 2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol 5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine N-[4′-(6-Aminopyridin-3-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide 4-({2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenyl}sulfonyl)piperazin- 2-one 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}-1H- pyrrolo[2,3-b]pyridine 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2S)-2- hydroxypropyl]benzenesulfonamide 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2-hydroxy-1- methylethyl]benzenesulfonamide 5-{2-Fluoro-4-[2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin- 2-amine 5-(5-{2-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethylbenzenesulfonamide (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol. (2S)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanenitrile (2R)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2R)-2- hydroxypropyl]benzenesulfonamide 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin- 4-amine 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5-methoxybiphenyl-2- sulfonamide 5-(2-Fluoro-4-{2-[(3-methoxypropyl)sulfonyl]pyridin-3- yl}phenyl)pyrimidin-2-amine 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarboxamide 5-[3-Fluoro-2-methoxy-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2- amine 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1- methylethyl]benzenesulfonamide 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanamide {[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile 5-{4-[2-(tert-Butylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2- amine 5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine 5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine 5-(2-Fluoro-4-{2-[(2-morpholin-4-ylethyl)sulfonyl]pyridin-3- yl}phenyl)pyrazin-2-amine 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin- 2-amine 5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine 5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)pyrazin-2-amine 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4- yl)pyrimidin-2-amine 5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin- 2-amine 5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarbonitrile (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidine-3-carboxamide 5-{5-[2-(Morpholin-4-ylmethyl)-4-(trifluoromethyl)phenyl]pyridin-2- yl}pyrimidin-2-amine 5-(5-{2-[(4,4-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine 5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine 5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4- yl)pyrimidin-2-amine (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidine-3-carboxamide 5-(2-Fluoro-4-{2-[(tetrahydro-2H-pyran-4-ylmethyl)sulfonyl]pyridin-3- yl}phenyl)pyrimidin-2-amine 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(2-hydroxyethyl)-5- (trifluoromethyl)benzenesulfonamide (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- yl]methyl}amino)ethanol 5-{3-Fluoro-2′-[(pyrimidin-2-ylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2- amine 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2R)-2- hydroxypropyl]benzenesulfonamide 5-(5-{2-[(3,3-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3- yl]phenyl}pyrimidin-2-amine 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3- yl]phenyl}pyrimidin-2-amine 5-[3-Fluoro-2′-(1,2,3,6-tetrahydropyridin-4-yl)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2- amine 5-{2-Fluoro-4-[2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2- amine 6-Amino-3-{2′-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrazine-2-carbonitrile N-(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-4-yl)acetamide 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N- methylazetidine-3-carboxamide 5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyridin-2-amine 5-(3-Fluoro-2′-{[(1-methylethyl)sulfonyl]methyl}biphenyl-4-yl)pyrazin- 2-amine 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2- hydroxyethyl)biphenyl-2-sulfonamide {[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile (2S)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol 6-Amino-3-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2- carbonitrile 5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethyl-5- (trifluoromethyl)benzenesulfonamide 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1- methylethyl]benzenesulfonamide 5-{5-[2-(Azepan-1-ylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-tert- butylbenzenesulfonamide 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N- (dicyclopropylmethyl)benzenesulfonamide 5-{2′-[(4-Aminopiperidin-1-yl)methyl]-3-fluoro-4′- (trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine 5-{2′-[(6-Amino-2-methylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine 6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]pyridin-3- yl}-2-fluorophenyl)pyrimidin-2-amine 5-(2-Fluoro-4-{2-[(1-methylpropyl)sulfonyl]pyridin-3- yl}phenyl)pyrimidin-2-amine 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2S)-2- hydroxypropyl]biphenyl-2-sulfonamide 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanenitrile 5-{4-[2-(Cyclobutylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2- amine 5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2- amine 5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2- amine 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- carboxylic acid 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4- yl)pyrazin-2-amine 5-(2-Fluoro-4-{2-[(3-methoxypropyl)sulfonyl]pyridin-3- yl}phenyl)pyrazin-2-amine 6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazine-2- carbonitrile 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-2′-methoxybiphenyl-2- sulfonamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2- hydroxypropyl]biphenyl-2-sulfonamide 1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-ol 5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine 5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3- yl]phenyl}pyrazin-2-amine 2-(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-yl)ethanol 5-{2′-[(5-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarboxamide 6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile 5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4- yl)pyrazin-2-amine 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide (1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-yl)methanol 6-Amino-3-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4- yl}pyrazine-2-carbonitrile 5-[3-Fluoro-2′-(2-methoxypyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine 5-(2-Fluoro-4-{2-[(tetrahydro-2H-pyran-4-ylmethyl)sulfonyl]pyridin-3- yl}phenyl)pyrazin-2-amine 5-{4-[2-(tert-Butylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine 3-Amino-6-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4- yl}pyrazine-2-carbonitrile 6-Amino-3-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4-yl}pyrazine-2-carbonitrile 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-4- (trifluoromethyl)biphenyl-2-carboxamide 5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4- yl)pyrazin-2-amine 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarbonitrile 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(2-hydroxy-1,1- dimethylethyl)biphenyl-2-sulfonamide 5-{4-[2-(Cyclohexylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2- amine 5-{3-Fluoro-2′-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5- ylsulfonyl]biphenyl-4-yl}pyrazin-2-amine 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidine-4-carboxamide 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- carbaldehyde 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3-hydroxyazetidin-3- yl)methyl]biphenyl-2-sulfonamide 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 5-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrazin-2- amine 5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]methyl}sulfanyl)pyrimidin-4-amine 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1- methyl-2-phenylethyl]-N-methylbiphenyl-2-sulfonamide 5-{4-[2-(Cyclopentylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2- amine 2-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]pyridin-3- yl}-2-fluorophenyl)pyrazin-2-amine 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2- amine 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-methyl-2- phenylethyl]-N-methylbiphenyl-2-sulfonamide 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluoro-4′- (trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine N,N-Diethyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- sulfonamide 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3- yl]phenyl}pyrazin-2-amine 5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrazin-2- amine 5-(2-Fluoro-4-{2-[(1-methylpropyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin- 2-amine 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(2-hydroxy-1,1- dimethylethyl)biphenyl-2-sulfonamide 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-ethyl-5- (trifluoromethyl)benzenesulfonamide 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2- dimethylpropyl)biphenyl-2-sulfonamide 6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl- 4-yl]pyrazine-2-carbonitrile 5-[3-Fluoro-2′-(morpholin-4-ylmethyl)-4′-(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2-sulfonamide 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine 5-{4-[2-(Cyclobutylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2- amine 4′-(5-Amino-3-cyanopyrazin-2-yl)-N-ethyl-3′-fluoro-4- (trifluoromethyl)biphenyl-2-sulfonamide 5-[3-Fluoro-2′-(pyrimidin-4-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4- (pentafluoroethyl)piperidin-4-ol 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)-1H- pyrrolo[2,3-b]pyridine 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-tert- butylbenzenesulfonamide tert-Butyl (1-{[3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- yl]sulfonyl}piperidin-4-yl)carbamate 5-{4-[2-(Cyclopentylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2- amine 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3,3′-difluorobiphenyl-2- sulfonamide 5-{4-[2-(Cyclohexylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2- amine 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2- sulfonamide 5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrimidin-2-amine 5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrazin-2-amine 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-5- amine 5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine 5-(2-fluoro-4-(2-(piperidin-4-yloxy)pyridin-3-yl)phenyl)pyrazin-2-amine 5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2- amine 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-6- methylpyrimidin-4-amine 5-{2′-[(4-Amino-6-methylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine 5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrazin-2-amine 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine 5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4- yl)pyrazin-2-amine 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine 5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4- yl)pyrimidin-2-amine 5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine 1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]carbonyl}morpholin-2-yl)ethanol 1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]carbonyl}morpholin-2-yl)ethanol 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4- yl)pyrazin-2-amine N-{3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}-2,2- dimethylpropanamide N-{3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}-2,2- dimethylpropanamide 5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine 5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]pyridin-2-yl}- 2,2-dimethylpropanamide

Particularly, an embodiment of the present invention comprises a compound selected from the compounds listed in Table 2.

TABLE 2 N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide, 5-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butylbiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide, 4′-(2-aminopyrimidin-5-yl)-N-(tert-butyl)-3′-fluoro- [1,1′-biphenyl]-2-sulfonamide trifluoroacetic acid salt, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1- dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt, 5-{2′-[(4-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2- amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-2′,3′-difluoro-N-methylbiphenyl- 2-sulfonamide trifluoroacetic acid salt, 4′-(5-Amino-6-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2- one, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin- 2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide triflucroacetic acid salt, 4′-(5-Amino-3-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide, 5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2,3-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin- 4-amine, 5-{4-[2-(Cyclopentyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, (R)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-methylcyclobutyl)-[1,1′-biphenyl]- 2-sulfonamide, 4-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)thiomorpholine 1,1-dioxide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 5-{3-Fluoro-2′-[(trifluoromethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1,1,1- trifluoromethanesulfonamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-4-ol, (1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4- yl)methanol, 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-4-yl)ethanol, racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-ol, racemic 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-yl)ethanol, racemic 5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, N-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-4-yl)acetamide, (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrrolidin-2-yl)methanol, (S)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro[1,1′-biphenyl]-4- yl)pyrazin-2-amine, (S)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrroidin-2-yl)methanol, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxypropyl)biphenyl-2- sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′- biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′- biphenyl]-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-1,1- dimethylethyl)biphenyl-2-sulfonamide, (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrrolidin-3-yl)methanol, N-tert-Butyl-3′-fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5- yl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1- (hydroxymethyl)-2-phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2R)-2-hydroxy-1-methyl-2- phenylethyl]biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl- 2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2- sulfonamide trifluoroacetic acid salt, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)biphenyl-2- sulfonamide, trans 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4 -hydroxycyclohexyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2- methylpropyl)biphenyl-2-sulfonamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}azetidin-3-ol, (R) 5-(2′-{[2-(Aminomethyl)pyrrolidin-1-yl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrazin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-2- methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, N-(2-Aminoethyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2- sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(pyrrolidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide, 3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-b]pyrazin- 2-yl)biphenyl-2-sulfonamide, (cis)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N[2- (hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopiperidin-3- yl]biphenyl-2-sulfonamide trifluoroacetic acid salt, (S)-5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, 4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1S)-2- hydroxy-1-methylethyl]biphenyl-2-sulfonamide, (1R,5S)-3-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)-3-azabicyclo[3.1.0]hexan-6-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1- (hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopyrrolidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2- amine, 2-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4- yl}-5H-pyrrolo[2,3-b]pyrazine, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2R)-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxycyclohexyl)-[1,1′- biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2S)-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, (S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-ylsulfonamido)- 4-methylpentanamide, 2-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-5H-pyrrolo[2,3- b]pyrazine, 4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2- sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopyrrolidin-3- yl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- sulfonamide, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-methyloxetan-3-yl)biphenyl-2- sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-carboxamide, 5-[3-Fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrimidin-2-amine, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- yl]sulfonyl}piperazin-2-one, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-4- (trifluoromethyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(trans-4- hydroxycyclohexyl)biphenyl-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluoro-4- (trifluoromethyl)biphenyl-2-Sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2- sulfonamide, 5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrazin-2- amine, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin- 4-amine, 5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine, 4′-(5-amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide, 4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2- hydroxypropyl]biphenyl-2-sulfonamide, N′-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,N- dimethylsulfamide, 5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2- amine, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2- amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2R)-2- hydroxypropyl]biphenyl-2-sulfonamide, 5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrazin-2-amine, 5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluoro-4′- (trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine, 5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2- amine, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine, 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine, 5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(4-pyrimidin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazin-2-amine, 5-{2′-[(5-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine formate salt, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]sulfanyl}pyrimidin-2-amine formate salt, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2- amine hydrochloride, 4′-(5-amino-1,3,4-thiadiazol-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5- amine hydrochloride, 4-((4′-(5-amino-1,3,4-thiadiazol-2-yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)thiomorpholine 1,1-dioxide, 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2- sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, and 4′-(5-Amino-6-chloropyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide.

Further, an embodiment of the present invention comprises a compound selected from the compounds listed in Table 1A.

TABLE 1A 5-[2′-Amino-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2- amine 5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)methoxy]-3- fluorobiphenyl-4-yl}pyrazin-2-amine 5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]-3- fluorobiphenyl-4-yl}pyrazin-2-amine 4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2- yl]oxy}methyl)benzoic acid 4-({[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]oxy}methyl)benzoic acid 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic acid 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic acid 2-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2- yl}sulfonyl)piperidin-1-yl]ethanol 4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2- amine 1-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2- yl}sulfonyl)piperidin-1-yl]propan-2-ol 5-[3-Fluoro-2′-(1H-pyrazol-4-yl)biphenyl-4-yl]pyrazin-2-amine 5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine 5-{3-Fluoro-2′-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]biphenyl-4- yl}pyrazin-2-amine 5-{5-[2-(Cyclopropylsulfonyl)phenyl]-3-fluoropyridin-2- yl}pyrimidin-2-amine 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2- yl]oxy}benzamide 5-{2′-[(trans-4-Aminocyclohexyl)oxy]-3-fluorobiphenyl-4- yl}pyrazin-2-amine 5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2- amine 6-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyridazin-3- amine {4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1- yl}acetonitrile 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N- methylpyrimidin-2-amine 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2,2,2- trifluoro-1-methylethyl]benzenesulfonamide 5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2- amine 5-[3-Fluoro-2′-(2-piperazin-1-ylpyrimidin-5-yl)biphenyl-4- yl]pyrazin-2-amine 5-{2′-[1-(2-Aminoethyl)-1H-pyrazol-4-yl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2S)-2- hydroxypropyl]benzenesulfonamide 5-(3-Fluoro-2′-isothiazol-4-ylbiphenyl-4-yl)pyrazin-2-amine 5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrazin-2-amine 5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrimidin-2-amine 2-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol- 1-yl}ethanol 5-(4-{2-[(1-Acetylpiperidin-3-yl)sulfonyl]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine 5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2- hydroxy-1-methylethyl]benzenesulfonamide 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1R)-2- hydroxy-1-methylethyl]benzenesulfonamide 5-[2-Fluoro-4-(2-phenylpyridin-3-yl)phenyl]pyrazin-2-amine 5-(2-Fluoro-4-{2-[(1-methylpyrrolidin-3-yl)sulfonyl]pyridin-3- yl}phenyl)pyrazin-2-amine 5-{2-Fluoro-4-[2-(pyridin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin- 2-amine 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}phenyl)pyrazin-2-amine 5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine 5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2- amine 5-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N- methylpyrimidin-2-amine 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}phenyl)pyrimidin-2-amine {4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol- 1-yl}acetonitrile 5-[3-Fluoro-2′-(1H-pyrazol-4-yl)biphenyl-4-yl]pyrimidin-2-amine 4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2- amine 5-{2-Fluoro-4-[2-(pyridin-3-yloxy)pyridin-3-yl]phenyl}pyrazin-2- amine 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine 5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4- yl]sulfonyl}pyridin-3-yl)phenyl]pyrazin-2-amine 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6- (trifluoromethyl)pyridin-3-yl]phenyl}pyrazin-2-amine 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6- (trifluoromethyl)pyridin-3-yl]phenyl}pyrimidin-2-amine 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-(2- hydroxyethyl)benzenesulfonamide 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1R)-2,2,2- trifluoro-1-methylethyl]benzenesulfonamide 5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4- yl]sulfonyl}pyridin-3-yl)phenyl]pyrimidin-2-amine

Additionally, an embodiment of the present invention comprises a compound selected from the compounds listed in Table 1, Table 2 and Table 1A.

The invention is also directed to a pharmaceutical composition which include, without limitation, one or more of the disclosed compounds, and pharmaceutically acceptable carriers or excipients.

Another embodiment of the present invention is a pharmaceutical composition of the present invention that comprises at least a compound selected from the compounds listed in Table 1. Another embodiment of the present invention is a pharmaceutical composition of the present invention that comprises at least a compound selected from the compounds listed in Table 3.

Particularly, an embodiment of the present invention is a pharmaceutical composition of the present invention that comprises at least a compound selected from the compounds listed in Table 2.

The present invention also features a method of treating a subject suffering from or diagnosed with a disease and/or disorder mediated by FLAP activity, comprising administering to the subject a therapeutically effective amount of at least one compound of Formula (I).

The present invention also features a method for preventing, treating, ameliorating, including without limitation inhibiting, the progression of an FLAP-mediated disease and/or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of at least one compound of Formula (I). Such a disease and/or disorder includes, but is not limited to diabetes, respiratory disorders, and associated symptoms or complications thereof. More specifically, this invention is directed to a method of treating, but not limited to, exacerbations, non-allergic asthma, fibrotic lung diseases, acute respiratory distress syndrome and chronic obstructive pulmonary disease, and their associated symptoms or complications, in a subject afflicted with such a disease and/or disorder.

In another embodiment, the compounds of the present invention are useful for the amelioration of symptoms associated with and/or the treatment of the following cardiac and cardiovascular diseases and/or disorders: myocardial infarction, atherosclerosis and stroke aortic aneurisms, atherosclerosis, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder.

In another embodiment, the compounds of the present invention are useful for the amelioration of symptoms associated with and/or the treatment of autoimmune or allergic diseases and/or disorders, wherein said autoimmune or allergic diseases and/or disorders include, but are not limited to, rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis, allergic rhinitis, allergic dermatitis and asthma, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder. In a further embodiment, the compounds of the present invention are useful for the amelioration of symptoms associated with and/or the prophylaxis or treatment of carcinogenesis, wherein said carcinogenesis include, but is not limited to, tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells.

It is a further embodiment of the invention to provide a process for making a pharmaceutical composition comprising admixing any of the compounds according to Formula (I) and a pharmaceutically acceptable carrier.

In a further embodiment of the invention, a method for treating or ameliorating an FLAP-mediated disease and/or disorder in a subject in need thereof comprises administering to the subject a therapeutically effective amount of at least one compound of Formula (I), wherein the therapeutically effective amount of the compound of Formula (I) is from about 0.1 mg/dose to about 5 g/dose. In particular, the therapeutically effective amount of the compound of Formula (I) is from about 0.5 mg/dose to about 1000 mg/dose.

More particularly, the therapeutically effective amount of the compound of Formula (I) is from about 1 mg/dose to about 100 mg/dose. In a further embodiment of the invention, the number of doses per day of a compound of Formula (I) is from 1 to 3 doses. In a further embodiment of the invention, the therapeutically effective amount of the compound of Formula (I) is from about 0.001 mg/kg/day to about 30 mg/kg/day. More particularly, the therapeutically effective amount of the compound of Formula (I) is from about 0.01 mg/kg/day to about 2 mg/kg/day.

The invention is further described below.

A) Terms

Some terms are defined below and by their usage throughout this disclosure.

It should also be noted that any atom with unsatisfied valences in the text, schemes, examples, structural formulae and any tables herein is assumed to have the hydrogen atom or atoms to satisfy the valences.

As used herein, the following terms are intended to have the following definitions. The definitions herein may specify that a chemical term has an indicated formula. The particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term. The scope of the per se definition of the term is intended to include the plurality of variations expected to be included by one of ordinary skill in the art.

The term “C₁₋₆alkyl” means a saturated branched or straight-chain hydrocarbon radical having from 1 up to 6 carbon atoms in a linear or branched arrangement, selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, and hexyl. Examples include isopropyl, isobutyl, tert-butyl, sec-butyl, n-butyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1,2-dimethylpropyl, butan-2-yl, 2-methylbutyl, 2-methylbutan-2-yl, 1-methyl-3-methylbutyl, 3,3-dimethylbutan-2-yl, and the like, and all that are exemplified in the below examples. An alkyl radical may be attached to a core molecule by any atom where allowed by available valences. The term “C₁₋₄alkyl” means a saturated branched or straight-chain hydrocarbon radical having from 1 up to 4 carbon atoms in a linear or branched arrangement,

The term “C₃₋₉cycloalkyl” means a saturated or partially unsaturated, monocyclic, polycyclic or benzofused hydrocarbon ring system radical. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptan-2-yl, 2,3-dihydro-1H-inden-2-yl, and the like, and all that are exemplified in the below examples. A C₃₋₉cycloalkyl radical may be attached to a core molecule by any ring atom where allowed by available valences.

The term “aryl” means an unsaturated, aromatic monocyclic or polycyclic hydrocarbon ring system radical. Examples include phenyl and the like, and all that are exemplified in the below examples. An aryl radical may be attached to a core molecule by any ring atom where allowed by available valences.

The term “hetero”, when used as a prefix for a ring system, refers to the replacement of at least one carbon atom member in the ring system with a heteroatom selected from N, O, S, S(O), or SO₂. A hetero ring may have 1, 2, 3 or 4 carbon atom members replaced by a nitrogen atom. Alternatively, a ring may have 1, 2 or 3 nitrogen atom members and 1 oxygen or sulfur atom member. Alternatively, a ring may have 1 oxygen or sulfur atom member. Alternatively, up to two adjacent ring members may be heteroatoms, wherein one heteroatom is nitrogen and the other heteroatom is selected from N. S or O.

The term “heteroaryl” means an unsaturated monocyclic, polycyclic aromatic “hetero” ring system radical, selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, and tetrazolyl. Examples include pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-4-yl, pyrazin-2-yl, pyrazin-4-yl, pyrimidin-2-yl, pyridazin-3-yl, 1H-benzimidazol-2-yl, 2H-tetrazol-5-yl, and the like, and all that are exemplied in the below examples. A heteroaryl radical may be attached to a core molecule by any ring atom where allowed by available valences.

The term “heterocycyl” means a saturated monocyclic or polycyclic “hetero” ring system radical, selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrazoyl, thiomorpholinyl, azepanyl, hexahydropyrrolo[1,2-a]pyrazinyl, tetrahydropyrazolo[4,3-c]pyridinyl, diazabicyclo[2.2.1]-heptanyl, dihydro-indolyl, tetrahydropyranyl, azabicyclo[3.1.0]hexanyl, oxetanyl, isothiazolidinyl, thiazinanyl, thiopyranyl, thia-azaspiro[3.3]heptanyl, oxa-azaspiro[3.3]heptanyl, tetrahydro-thiopyranyl, dihydroquinazolinyl, oxadiazolyl, oxa-azabicylco[2.2.1]heptanyl, piperazin-2-one-yl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, pyrrolidin-2-one-yl, imidazolidin-2-one-yl, 1,2-thiazinane 1,1-dioxide-yl, isothiazolidine 1,1-dioxide-yl, 1,2,3,6-tetrahydropyridinyl, and imidazolidinyl. Examples include azetidin-1-yl, azetidin-3-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, azepan-1-yl, azepan-3-yl, hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl, 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 2,3-dihydro-1H-indol-2-yl, tetrahydro-2H-pyran-4-yl, 3-azabicyclo[3.1.0]hexan-3-yl, oxetan-3-yl, isothiazolidin-2-yl, 1,2-thiazinan-2-yl, 2H-thiopyran-4-yl, 2-thia-6-azaspiro[3.3]heptan-6-yl, 2-oxa-6-azaspiro[3.3]heptan-6-yl, tetrahydro-2H-thiopyran-4-yl, 3,4-dihydroquinazolin-2-yl, 1,2,3-oxadiazol-5-yl, 2-oxa-5-azabicylco[2.2.1]heptan-5-yl, imidazolidin-1-yl, thiomorpholine 1,1-dioxide-yl, 4-amino-tetrahydro-2H-pyran-yl, tetrahydro-2H-thiopyran 1,1-dioxide-yl, and the like, and all that are exemplied in the below examples. A heterocyclyl radical may be attached to a core molecule by any ring atom where allowed by available valences.

The term “carboxy” means a radical of the formula: —C(O)OH.

The term “halogen” or “halo” means a radical selected from the group consisting of chloro, bromo, fluoro or iodo.

The term “oxo” means a radical of the formula: ═O.

The term “substituted” refers to a radical in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s). In a preferred embodiment, up to three hydrogen atoms are each independently replaced.

With reference to substituents, the term “independently” means that when more than one of such substituent is possible, such substituents may be the same or different from each other.

It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.

In general, unless otherwise specified, IUPAC nomenclature rules are used herein.

The term “about,” whether used explicitly or not in reference to a quantitative expression given herein, means that every quantity given herein qualified with the term or otherwise is meant to refer both to the actual given value and the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to experimental and/or measurement conditions for such given value.

The term “form” means, in reference to compounds of the present invention, such may exist as, without limitation in the following states, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof.

The term “isolated form” means, in reference to compounds of the present invention, such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or trans stereoisomer), a mixture of geometric isomers, and the like. The present invention encompasses all such compound forms and mixtures thereof.

The term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

The term “subject” as used herein, refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing an FLAP-mediated disorder.

The term “administering” further means that the individual ingredients to be combined may be administered at the same time or at different times during the treatment period, either as one preparation or as different preparations. Accordingly, the invention should be so interpreted that it encompasses any and every administration mode at the same time or at different times. The range of the combination of the compound of the invention and the other therapeutic agent useful for the above-mentioned disorders encompasses, in principle, all combinations of the compound of the invention and any and every pharmaceutical agent useful for the above-mentioned disorders.

The term “treating” refers, without limitation, to facilitating the eradication of, preventing, ameliorating or otherwise inhibiting the progression of or promoting stasis of an FLAP-mediated disease and/or disorder, or associated symptoms or complications thereof.

The term “prodrug” means a compound of Formula (I) or a form thereof that is converted in vivo into a functional derivative form that may contribute to therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such in vivo conversions. Prodrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.

The term “metabolite” means a prodrug form of a compound of Formula (I) or a form thereof converted by in vivo metabolism or a metabolic process to a relatively less active functional derivative of said compound.

The term “medicament” or “medicine” refers to a product containing a compound of Formula (I) or a form thereof. The present invention includes use of such a medicament for treating an FLAP-mediated disorder.

The term “combination form” refers to the use of a combination product comprising a compound of Formula (I) or a form, pharmaceutical composition, medicine or medicament thereof and at least one therapeutic agent for treating an FLAP-mediated disorder.

Methods are known in the art for determining effective doses for therapeutic and prophylactic purposes for the disclosed pharmaceutical compositions or the disclosed drug combinations, whether or not formulated in the same composition.

For therapeutic purposes, the term “therapeutically effective amount” or “effective amount” as used herein, means that amount of each active compound or pharmaceutical agent, alone or in combination, that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease and/or disorder being treated. For prophylactic purposes (i.e., inhibiting the progression of a disorder), the term “therapeutically effective amount” refers to that amount of each active compound or pharmaceutical agent, alone or in combination, that treats or inhibits in a subject the progression of a disorder as being sought by a researcher, veterinarian, medical doctor or other clinician. Thus, the present invention provides combinations of two or more drugs wherein, for example, (a) each drug is administered in an independently therapeutically or prophylactically effective amount; (b) at least one drug in the combination is administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but is therapeutic or prophylactic when administered in combination with the second or additional drugs according to the invention; or (c) both (or more) drugs are administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but are therapeutic or prophylactic when administered together. The effective amount of said compound is from about 0.001 mg/kg/day to about 300 mg/kg/day.

Advantageously, the effective amount of a combination product for treating an FLAP-mediated disease and/or disorder, or associated symptoms or complications thereof, may be a reduced amount of either or both, the compound or therapeutic agent, compared to the effective amount of the compound or therapeutic agent otherwise recommended for treating the disease and/or disorder, or associated symptoms or complications thereof. Therefore, it is contemplated that the compound is administered to the subject before, during or after the time the agent is administered.

The term “pharmaceutically acceptable salt” refers to non-toxic pharmaceutically acceptable salts (Ref. Int'l J. Pharm., 1986, 33: 201-217; J. Pharm. Sci., 1997 (January), 66(1): 1). Other salts well known to those in the art may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. Representative organic or inorganic bases include, but are not limited to, basic or cationic salts such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.

The compounds of the invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the “pharmaceutically acceptable salts” of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms.

Suitable salt forms include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of an acid such as acetic acid, adipic acid, benzoic acid, carbonic acid, citric acid, fumaric acid, glycolic acid, hydrochloric acid, maleic acid, malonic acid, phosphoric acid, saccharinic acid, succinic acid, sulphuric acid, tartaric acid, trifluoroacetic acid and the like.

Furthermore when the compounds of the present invention carry an acidic moiety, suitable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis. 3^(rd) Edition, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known in the art. The scope of the present invention encompasses all such protected compound forms and mixtures thereof.

The invention includes compounds of various isomers and mixtures thereof. The term “isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (optical isomers).

The term “stereoisomer” refers to isomers that have the same molecular formula and the same sequence of covalently bonded atoms but a different spatial orientation.

The term “optical isomer” means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions. The term “optical activity” means the degree to which an optical isomer rotates the plane of polarized light.

The term “racemate” or “racemic” means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.

The term “enantiomer” means an isomer having a nonsuperimposable mirror image. The term “diastereomer” means stereoisomers that are not enantiomers.

The term “chiral” means a molecule that, in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules that can be superimposed on their mirror images.

The two distinct mirror image versions of the chiral molecule are also known as levo (left-handed), abbreviated L, or dextro (right-handed), abbreviated D, depending on which way they rotate polarized light. The symbols “R” and “S” represent the configuration of groups around a stereogenic carbon atom(s).

The term “geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration according to the Cahn-Ingold-Prelog priority rules. In the “E” configuration, the substituents having the highest priorities are on opposite sides in relationship to the carbon-carbon double bond. In the “Z” configuration, the substituents having the highest priorities are oriented on the same side in relationship to the carbon-carbon double bond.

Substituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration. In the “cis” configuration, the substituents are on the same side in relationship to the plane of the ring; in the “trans” configuration, the substituents are on opposite sides in relationship to the plane of the ring. Compounds having a mixture of “cis” and “trans” species are designated “cis/trans”.

The isomeric descriptors (“R,” “S,” “E,” and “Z”) indicate atom configurations and are intended to be used as defined in the literature.

The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include combining the free base (or free acid) of each isomer of an isomeric pair using an optically active acid (or base) to form an optically active salt (followed by fractional crystallization and regeneration of the free base), forming an ester or amide of each of the isomers of an isomeric pair by reaction with an appropriate chiral auxiliary (followed by fractional crystallization or chromatographic separation and removal of the chiral auxiliary), or separating an isomeric mixture of either an intermediate or a final product using various well known chromatographic methods.

Furthermore, compounds of the present invention may have one or more polymorph or amorphous crystalline forms and, as such, are intended to be included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like) and, as such, are also intended to be encompassed within the scope of this invention.

B) Compounds

Representative compounds of the present invention are listed in Table 3 below:

TABLE 3 COM- POUND STRUCTURE # NAME

1 5-(3-fluoro-2′-(methylsulfonyl)-[1,1′- biphenyl]-4-yl)pyrazin-2-amine

2 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methanesulfonamide

3 6-Amino-3-[3.-fluoro-2′- (methylsulfonyl)biphenyl-4- yl]pyrazine-2-carbonitrile

4 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-fluorobiphenyl-2-sulfonamide

5 4′-(5-aminopyrazin-2-yl)-3′-fluoro- [1.1′-biphenyl]-2-sulfonamide

6 4′-(5-Aminopyrazin-2-yl)-N- cyclohexyl-3′-fluorobiphenyl-2- sulfonamide

7 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-methylpropyl)biphenyl-2- sulfonamide

8 (racemic)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-(2,2,2-trifluoro-1- methylethyl)biphenyl-2-sulfonamide racemic

9 4′-(5-Aminopyrazin-2-yl)-N- (cyclobutylmethyl)-3′-fluorobiphenyl- 2-sulfonamide

10 (racemic)-(endo)-4′-(5- Aminopyrazin-2-yl)-N- bicyclo[2.2.1]hept-2-yl-3′- fluorobiphenyl-2-sulfonamide racemic

11 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (1-methylcyclobutyl)biphenyl-2- sulfonamide

12 4′-(5-Aminopyrazin-2-yl)-N-(1,1- dimethylpropyl)-3′-fluorobiphenyl-2- sulfonamide

13 4′-(5-4minopyrazin-2-yl)-3′-fluoro-N- (2,2,2-trifluoro-1,1- dimethylethyl)biphenyl-2-sulfonamide

14 4′-(5-Aminopyrazin-2-yl)-N- cyclopentyl-3′-fluorobiphenyl-2- sulfonamide

15 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- methylbiphenyl-2-sulfonamide

16 4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′- fluorobiphenyl-2-sulfonamide

17 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-phenylethyl)biphenyl-2- sulfonamide

18 (R)-4′-5-Aminopyrazin-2-yl)-3′- fluoro-N-[(1R)-2,2,2-trifluoro-1- phenylethyl]biphenyl-2-sulfonamide

19 (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-[(1S)-2,2,2-trifluoro-1- phenylethyliblphenyl-2-sulfonamide

20 (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-[(S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide

21 4′-(5-Aminopyrazin-2-yl)-N-(2,3- dihydro-1H-inden-2-yl)-3′- fluorobiphenyl-2-sulfonamide

22 (S)-4′-(5-Aminopyrazin-2-yl)-N-[(1S)- 2,3-dihydro-1H-inden-1-yl]-3′- fluorobiphenyl-2-sulfonamide

23 (R)-4′-(5-Aminopyrazin-2-yl|)-N-[(1R)- 2,3-dihydro-1H-inden-1-yl]-3′- fluorobiphenyl-2-sulfonamide

24 (R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-[(1R)-1- phenylethyl]biphenyl-2-sulfonamide

25 (R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-[(1R)-2-hydroxy-1- methylethyl]piphenyl-2-sulfonamicie

26 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- phenylbiphenyl-2-sulfonamide

27 (S)-4′-(5-Aminopyrazin-2-yl)-N-[((3S)- 1-ethyl-2-oxoazepan-a-y]-3′- fluorobiphenyl-2-sulfonamide

28 (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-[(3S)-2-oxoazepan-3-yl]biphenyl-2- sulfonamide

29 (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-[(3S)-1-methyl-2-oxoazepan-3- yl]biphenyl-2-sulfonamide

30 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (1,2,2,6,6-pentamethylpiperidin-4- yl)biphenyl-2-sulfonamide

31 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- pyridin-3-ylbiphenyl-2-sulfonamide

32 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-2-hydroxy-1- methylethyl]piphenyl-2-sulfonamide

33 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfamide

34 N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro- [1,1′-biphenyl]-2-yl)propane-2- sulfonamide

35 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]ethanesulfonamide

36 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]propane-1- sulfonamide

37 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-2- methylpropane-1-sulfonamide

38 N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro- [1,1′-biphenyl]-2- yl)cyclopropanesulfonamide

39 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]hexane-1- sulfonamide

40 N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro- [1,1′-biphenyl]-2- yl)cyclobutanesulfonamide

41 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-1,1,1- trifluoromethanesulfonamide

42 4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N,N-dimethylbiphenyl-2-sulfonamide

43 5-[3-fluoro-2′-(piperidin-1- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine

44 5-[3-Fluoro-2′-(morpholin-4- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine

45 5-{2′-[(1,1-Dioxidothiomorpholin-4- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

46 5-[3-Fluoro-2′-(piperazin-1- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine

47 4′-(5-Aminopyrazin-2-yl)-N,N-diethyl- 3′-fluorobiphenyl-2-sulfonamide

48 5-[3-Fluoro-2′-(pyrrolidin-1- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine

49 5-{2′-[(4,4-Difluoropiperidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

50 5-{2′-[(3,3-Difluoropiperidin-1- yl)sulfonyl)-3-fluorobiphenyl-4- yl}pyrazin-2-amine

51 5-{2′-[(3,3-Difluoropyrrolidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

52 5-{2′-[(3,3-Difluoroazetidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

53 5-[2′-(Azepan-1-ylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine

54 5-{3-Fluoro-2′-[(4-methylpiperazin-1- yl)sulfonyl]biphenyl4-yl}pyrazin-2- amine

55 1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-4- (trifluoromethyl)piperidin-4-ol

56 5-(3-Fluoro-2′-{[4- (methylsulfonyl)piperazin-1- yl]sulfonyl}biphenyl-4-yl)pyrazin-2- amine

57 5-{2′-[(4-Acetylpiperazin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

58 5-(2′-{[4- (Cyclopropylcarbonyl)piperazin-1- yl]sulfonyl}-3-fluoroblphenyl-4- yl)pyrazin-2-amine

59 2-(4-{[4′-[5-Aminopymzin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperazin- 1-yl)ethanol

60 5-{2′-[(4-Cyclopropylpiperazin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

61 racemic 5-[3-Fluoro-2′- (hexahydropyrrolo[1,2-a]pyrazin- 2(1H)-ylsulfonyl)biphenyl-4- yl]pyrazin-2-amine

62 5-{2′-[(3,5-Dimethylpiperazin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

63 racemic 1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}piperidine-3-carbonitrile

64 1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]sulfonyl}piperidine-4-carbonitrile

65 5-{2′-[(4-Aminopiperidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

66 4-{1,4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-ylisulfonyl}piperazin- 2-one

67 1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-ol

68 (1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-yl)methanol

69 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-yl)ethanol

70 racemic 1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-ol

71 racemic 2-(1-{[4′-(5-Aminopyrazin-2- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-yl)ethanol

72 5-{3-Fluoro-2′-{[4- (methylamino)piperidin-1- yl]sulfonyl}biphenyl-4-yl)pyrazin.-2- amine

73 5-(2′-{[4-(Dimethylamino)piperidin-1- yl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrazin-2-amine

74 racemic 5-{2′-[(3-Aminopiperidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

75 N-(1-{[4′-(5-Aminopyrazin-2′yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-yl)acetamide

76 racemic (1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}piperldin-3-yl)methanol

77 racemic tert-Butyl (1-{[4′-(5- aminopyrazin-2-yl)-3′-fluorobiphenyl- 2-yl]sulfonyl}piperidin-3-yl)carbamate

78 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S,2S)-2-hydroxy-1- (hydroxymethyl)-2- phenylethyl]biphenyl-2-sulfonamide

79 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-1-(hydroxymethyl)-3- methylbutyl]biphenyl-2-sulfonamide

80 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (3-hydroxypropyl)biphenyl-2- sulfonamide

81 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-2-hydroxy-1- phenylethyl]biphenyl-2-sulfonamide

82 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R)-2-hydroxy-1- phenylethyl]biphenyl-2-sulfonamide

83 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S,2R)-2-hydroxy-1-methyl-2- phenylethyl]biphenyl-2-sulfonamide

84 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S,2S)-1-(hydroxymethyl)-2- methylbutyl]blphenyl-2-sulfonamide

85 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R,2R)-2- hydroxycyclohexyl]biphenyl-2- sulfonamide

86 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R)-1- (hydroxymethyl)propyl]biphenyl-2- sulfonamide

87 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R,2S)-2- hydroxycyclohexyl]biphenyl-2- sulfonamide

88 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxyethyl)biphenyl-2- sulfonamide

89 4′-(5-Aminopyrazin-2-yl)-N- cyclopropyl-3′-fluoroblphenyl-2- sulfonamide

90 4′-(5-Aminopyrazin-2-yl)-N- (cyclopropylmethyl)-3′-fluorobiphenyl- 2-sulfonamide

91 (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrrolidin-2-yl)methanol

92 (R)-5-(2′-((3-aminopyrrolidin-1- yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine

93 (S)-5-(2′-((3-aminopyrrolidin-1- yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine

94 (R) 5-(2′-{[2-(Aminomethyl)pyrrolidin- 1-yl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrazin-2-amine

95 (S)-(1-((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2′- yl)sulfonyl)pyrrolidin-2-yl)methanol

96 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (methylsulfonyl)biphenyl-2- sulfonamide

97 (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-hydroxypropyl)-[1,1′-biphenyl]-2- sulfonamide

98 (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-hydroxypropyl)-[1,1′-biphenyl]-2- sulfonamide

99 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1- hydroxycyclohexyl)methyl]biphenyl- 2-sulfonamide

100 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxy-1,1- dimethylethyl)biphenyl-2-sulfonamide

101 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxy-2-methylpropyl)biphenyl- 2-sulfonamide

102 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (3-hydroxy-1,1- dimethylpropyl)biphenyl-2- sulfonamide

103 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (3-hydroxy-2,2- dimethylpropyl)biphenyl-2- sulfonamide

104 (S)-4′-(5-aminopyrazin-2-yl)-N-(2,3- dihydroxypropyl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide

105 (R)-4′-(5-aminopyrazin-2-yl|)-N-(2,3- dihydroxypropyl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide

106 (trans)-1-{[4′-(5-Aminopyrazin-2-yl|)- 3′-fluorobiphenyl-2- yl]suifonyl}pyrrolidine-3,4-diol

107 (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-oxopyrrolidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide

108 (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-oxopiperidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide

109 (R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-[1-(hydroxymethyl)-2′- methylpropypiphenyl-2-sulfonamide

110 trans 4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-(4- hydroxycyclohexyl)biphenyl-2- sulfonamide

111 (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrrolidin-3-yl)methanol

112 (S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}pyrrolidin- 3-yl)methanol

113 (R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-(2-oxopipendin-3- yl)biphenyl-2-sulfonamide

114 (R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-methyl-N-piperidin-3- ylbiphenyl-2-sulfonamide

115 (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-methyl-N-piperidin-3-ylbiphenyl-2′- sulfonamide

116 (3),4-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxy-3-phenylpropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide

117 (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-hydroxy-2-phenylethyl)-[1,1′- biphenyl]-2-sulfonamide

118 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1S,2S)-1-hydroxy-1-phenylpropan- 2-yl)-N-methyl-[1,1′-biphenyl)-2- sulfonamide

119 1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}azetidin- 3-ol

120 racemic (trans)-4′-(5-Aminopyrazin-2- yl)-3′-fluoro-N-(2- hydroxycyclohexyl)biphenyl-2- sulfonamide

121 racemic (trans)-4′-(5-Aminopyrazin-2- yl)-3′-fluoro-N-[2- (hydroxymethyl)cyclohexyl]biphenyl- 2-sulfonamide

122 racemic (cis)-4′-(5-Aminopyrazin-2- yl)-3′-fluoro-N-[2- (hydroxymethyl)cyclohexyl]biphenyl- 2-sulfonamide

123 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- piperidin-4-ylbiphenyl-2-sulfonamide

124 5-(2′-{[3-(Aminomethyl)azetidin-1- yl]sulfonyl}-fluorobiphenyl-4- yl)pyrazin-2-amine

125 4′-(5-Aminopyrazin-2-yl)-N-(azetidin- 3-ylmethyl)-3′-fluorobiphenyl-2- sulfonamide

126 (R)-5-(3-Fluoro-2′-{[3- (methylamino)pyrrolidin-1- yl]sulfonyl}biphenyl-4-yl)pyrazin-2- amine

127 (R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-(2,2,2-trifluoro-1- methylethyl)biphenyl-2-sulfonamide

128 5-[3-Fluoro-2′-(1,4,6,7-tetrahydro-5H- pyrazolo[4,3-c]pyridin-5- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine

129 4-(1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-yl)-2,4-dihydro-3H-1,2,4-triazol-3- one

130 5-(2′-((1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2- ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine

131 5-(2′-((1S,4S)-2,5- diazabicyclo[2.2.1]heptan-2- ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine

132 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (5-hydroxypentyl)biphenyl-2- sulfonamide

133 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (6-hydroxyhexyl)biphenyl-2′- sulfonamide

134 N-(4-Aminocyclohexyl)-4′-(5- aminopyrazin-2-yl)-3′-fluorobiphenyl- 2-sulfonamide

135 (S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-2,3- dihydro-1H-indol-2-yl)methanol

136 4′-(5-Aminopyrazin-2-yl)-N- cyclohexyl-3′-fluoro-N-(2- hydroxyethyl)biphenyl-2-sulfonamide

137 (S)-5-{2′-[(3-Aminopiperidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

138 4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N,N-bis(2-hydroxyethyl)biphenyl-2- sulfonamide

139 1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl)sulfonyl}azetidine- 2-carboxamide

140 4′-(5-Aminopyrazin-2-yl)-N- cyclopropyl-3′-fluoro-N-(tetrahydro- 2H-pyran-4-yl)biphenyl-2- sulfonamide

141 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxyethyl)-N-(1- methylethyl)biphenyl-2-sulfonamide

142 racemic (4-{[4′-(5.-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}morpholin-2-yl)methanol

143 (1R,5S)-3-((4′-(5-aminopyrazin-2-yl)- 3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)- 3-azabicyclo[3.1.0]hexan-6-amine

144 (S)-5-(3-fluoro-2′-((2-methylpiperazin- 1-yl)sulfonyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine

145 (R)-5-(3-fluoro-2′-((2- methylpiperazin-1-yl)sulfonyl)-[1,1′- biphenyl]-4-yl)pyrazin-2-amine

146 (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperazin-2-yl)methanol

147 4′-(5-Aminopyrazin-2-yl)-3′-fluora-N- [2-hydroxy-1-(hydroxymethyl)-1- methylethyl]piphenyl-2-sulfonamide

148 (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxy-3-methylbutan-2-yl)- [1,1′-biphenyl]-2-sulfonamide

149 (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxy-3,3-dimethylbutan-2- yl)-[1,1′-biphenyl]-2-sulfonamide

150 (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxy-3,3-dimethylbutan-2- yl)-[1,1′-biphenyl]-2-sulfonamide

151 tert-Butyl [2-({4′-(5-aminopyrazin-2- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}amino)ethyl]carbamate

152 N-(2-Aminoethyl)-4′-(5-aminopyrazin- 2-yl)-3′-fluorobiphenyl-2-sulfonamide

153 (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxybutan-2-yl)-[1,1′- biphenyl]-2-suifonamide

154 (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(pyrrolidin-3-yl)-[1,1′-biphenyl]-2- sulfonamide

155 N-[2-({(4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]sulfonyl}amino)ethyl]acetamide

156 (S)-2-(4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- ylsulfonamido)propanoic acid

157 4′-(5-Aminopyrazin-2-yl)-N-[2- (carbamoylamino)ethyl]-3′- fluorobiphenyl-2-sulfonamide

158 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1S,2S-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2- sulfonamide

159 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1R,2R)-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2- sulfonamide

160 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1S,2R)-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2- sulfonamide

161 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1R,2S)-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2- sulfonamide

162 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1S,2S)-2-hydroxycyclohexyl)-[1,1′- biphenyl]-2-sulfonamide

163 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [6-(trifluoromethyl)pyridin-3- yl]biphenyl-2-sulfonamide

164 5-(3-Fluoro-2′-{[4-(1H-imidazol-4′- yl)piperidin-1-yl]sulfonyl}biphenyl-4- yl)pyrazin-2-amine

165 N-[(4-Amino-2-methylpyrimidin-5- yl)methyl]-4′-(5-aminopyrazin-2-yl)-3′- fluorobiphenyl-2-sulfonamide

166 4′-(5-Aminopyrazin-2-yl)-N-(2,6- dimethoxypyrimidin-4-yl)-3′- fluorobiphenyl-2-sulfonamide

167 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (5-methylpyrazin-2-yl)biphenyl-2- sulfonamide

168 (S)-2-(4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- ylsulfonamido)-4-methylpentanamide

169 4′-(5-Aminopyrazin-2-yl)-N-(2- cyanoethyl)-3′-fluorobiphenyl-2- sulfanamide

170 (R)-4′-(5-aminopyrazin-2-yl)-N-(1- cyanopropan-2-yl)-3′-fluoro-[1,1′- biphenyl)-2-sulfonamide

171 (S)-4′-(5-aminopyrazin-2-yl)-N-(1- cyanopropan-2-yl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide

172 4′-(5-Aminopyrazin-2-yl)-N-(2- cyanoethyl)-N-cyclopropyl-3′- fluorobiphenyl-2-suifonamide

173 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (3-methyloxetan-3-yl)biphenyl-2- sulfonamide

174 3-(4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluoroblphenyl-2-yl]sulfonyl}piperazin- 1-yl)propanenitrile

175 (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-methoxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide

176 5-{3-Fluoro-2′-[(4-pyrazin-2- ylpiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazin-2-amine

177 5-{3-Fluoro-2′-(4-pyrimidin-2- ylpiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazin-2-amine

178 5-(2′-Amino-3-fluorobiphenyl-4- yl)pyrazin-2-amine

179 4′-(5-Aminepyrazin-2-yl)-3′-fluoro-N- [1- hydroxymethyl)cyclopentyl]biphenyl- 2-sulfonamide

180 1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-3- phenylpyrrolidin-3-ol

181 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrroildine-1- sulfonamide

182 N′-[4′-(5-Aminopyrazin-2-yl)-3′- fluoroblphenyl-2-yl]-N,N- dimethylsulfamide

183 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]morpholine-4- sulfonamide

184 (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}pyrrolidin- 3-ol

185 (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluoroblphenyl-2-yl]sulfonyl}pyrrolidin- 3-ol

186 (3′S,4′S)-1′-{[4′-(5-Aminopyrazin-2- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}- 1,3′-bipyrrolidin-4′-ol

187 (3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2-yl]sulfonyl}-4- morpholin-4-ylpyrrolidin-3-ol

188 (3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2-yl]sulfonyl}-4-(4- methylpiperazin-1-yl)pyrrolidin-3-ol

189 5-{3-Fluoro-2′-[(trifluoromethyl)- sulfanyl]biphenyl-4-yl}pyrazin-2- amine

190 5-[2′-(tert-Butylsulfanyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine

191 5-[2′-(Ethylsulfonyl)-3-fluorobiphenyl- 4-yl]pyrazin-2-amine

192 5-[3-Fluoro-2′- (propylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine

193 5-{3-Fluoro-2′-[(2- methylpropyl)sulfonyyl]iphenyl-4- yl}pyrazin-2-amine

194 5-[2′-(tert-Butylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine

195 5-[2′-(Cyclopentylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine

196 5-[2′-(Cyclobutylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine

197 5-[2′-(Cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine

198 5-[3-Fluoro-2′- (hexylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine

199 5{3Fluoro-2′-[(1- methylethyl)sulfonyl]biphenyl-4- yl}pyrazin-2-amine

200 2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]sulfanyl}acetamide

201 2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}-N,N- diethylacetemide

202 5-{3-Fluoro-2′-[(2-morpholin-4-yl-2- oxoethyl)sulfanyl]biphenyl-4- yl}pyrazin-2-amine

203 (racemic) 5-({[4′-(5-Aminopyrazin-2- yl)-3′-fluorobiphenyl-2- yl]sulfanyl}methyly)-1,3-oxazolidin-2- one

204 N-(2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]sulfanyl}ethyl)benzamide

205 5-(3-Fluoro-2′-{[4- (methylsulfonyl)benzyl]sulfanyl}biphenyl- 4-yl)pyrazin-2-amine

206 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2- sulfonamide

207 5-[3-Fluoro-2′-(methylsulfonyl)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine

208 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- methyl-4-(trifluoromethyl)biphenyl-2- sulfonamide

209 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 4-(trifluoromethyl)biphenyl-2- yl]sulfonyl}piperazin-2-one

210 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2- sulfonamide

211 4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′- fluoro-4-(trifluoromethyl)biphenyl-2- sulfonamide

212 5-{3-Fluoro-2′-[(4-methylpiperazin-1- yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4-yl}pyrazin- 2-amine

213 5-[3-Fluoro-2′-(pyrimidin-2- ylsulfanyl)biphenyl-4-yl]pyrazin-2- amine hydrochloride

214 5-[3-Fluoro-2′-(pyrimidin-4- ylsulfanyl)biphenyl-4-yl]pyrimidin-2- amine formate salt

215 6-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 4-amine hydrochloride

216 2-{1,4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 4-amine hydrochloride

217 4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 5-amine hydrochloride

218 5-[3-Fluoro-2′-(pyrazin-2- ylsulfanyl)biphenyl-4-yl]pyrazin-2′ amine hydrochloride

219 2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 5-amine hydrochloride

220 1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorotiphenyl-2-yl]-N- methylmethanesulfonamide formic acid salt

221 1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N-(2- hydroxyethyl)methanesulfonamide formic acid salt

222 1-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methyl}sulfonyl)azetidin-3-ol formic acid salt

223 4-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methyl}sulfonyl)piperazin-2-one formic acid salt

224 (S)-1-(4′-(5-Aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2-yl)-N-(1- hydroxypropan-2- yl)methanesulfonamide

225 (R)-1-(4′-(5-Aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2-yl)-N-(1- hydroxypropan-2- yl)methanesulfonamide hydrochloride

226 1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N-(trans-4- hydroxycyclohexyl)methanesulfon- amide

227 (S)-1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N-[(2S)-2- hydroxypropyl]methanesulfonamide hydrochloride

228 (R)-1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N-[(2S)-2- hydroxypropyl]methanesulfonamide

229 5-(2′-{[(4-Aminopiperidin.-1- yl)sulfonyl]methyl}-3-fluorobiphenyl- 4-yl)pyrazin-2-amine hydrochloride

230 1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methanesulfonamide hydrochloride

231 1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- ethylmethanesulfonamide formate salt

232 1-[1-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methyl}sulfonyl)piperidin4-yl]urea hydrochloride

233 N-[1-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methyl}sulfonyl)piperidin-4- yl]acetamide formate salt

234 5-{2′-[(Ethylsulfanyl)methyl-3- fluorobiphenyl-4-yl}pyrazin-2-amine formate salt

235 5-{3-Fluoro-2′- [(methylsulfanyl)methylibiphenyl-4- yl}pyrazin-2-amine hydrochloride

236 5-(3-Fluoro-2-{[(1- methylethyl)sulfanyl]methyl}biphenyl- 4-yl)pyrazin-2-amine hydrochloride

237 2-(((4′-(5-Aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)methyl)thio)pyrimidin-4-amine hydrochloride

238 6-(((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)methyl)thio)pyrimidin-4-amine hydrochloride

239 5-(3-fluoro-2′-((pyridazin-3- ylthio)methyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine hydrochloride

240 6-(((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)methyl)thio)pyridazin-3-amine hydrochloride

241 5-{2′-[(1,1-Dioxidotatrahydro-2H- thiopyran-4-yl)sulfonyl)-3- fluorobiphenyl-4-yl}pyrazin-2-amine

242 4-{[4′(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 2-amine hydrochloride

243 5-(3-fluoro-2′-((pyrimidin-4- ylthio)methyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine hydrochloride

244 5-[3-Fluoro-2′-({[2- (trimethylsilyl)ethoxy]methyl}sulfanyl) biphenyl-4-yl]pyrazin-2-amine

245 5-[3-Fluoro-2′-({[2- (trimethylsilyl)ethoxy]methyl}sulfonyl) biphenyl-4-yl]pyrazin-2-amine hydrochloridee

246 5-(3-Fluoro-2′-{[3- (methylsulfonyl)propyl]sulfonyl}bi- phenyl-4yl)pyrazin-2-amine hydrochloride

247 5-(3-Fluoro-2′-{[(2R)-2- methylpiperazn-1- yl)sulfonyl)biphenyl-4-yl)pyrimidin-2- amine

248 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-1- (hydroxymethyl)propyl]biphenyl-2- sulfonamide

249 4′-(2-Aminopyrimidin-5-yl)-N-(2- cyanoethyl)-N-cyclopropyl-3′- fluorobiphenyl-2-sulfonamide

250 4′-(2-Aminopyrimidin-5-yl)-N-(2- cyanoethyl)-3′-fluorobiphenyl-2- sulfonamide

251 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(3-hydroxy-2,2- dimethylpropyl)biphenyl-2- sulfonamide

252 racemic (4-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}morpholin-2-yl)methanol

253 5-(3-Fluoro-2′-{[(2S)-2- methylpiperazin-1- yl)sulfonyl}biphenyl-4-yl)pyrimidin-2′- amine

254 5-[2′-(Cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]pyrimidin-2-amine

255 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[2-hydroxy-1-(hydroxymethyl)-1- methylethyl]biphenyl-2-sulfonamide

256 4′-(2-aminopyrimidin-5-yl)-3′-fluoro- N-methyl-N-[(3S)-piperidin-3- yl]biphenyl-2-sulfomamide

257 4′-(2-aminopyrimidin-5-yl)-3′-fluoro- N-methyl-N-[(3R)-piperidin-3- yl]biphenyl-2-suifonamide

258 [(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}piperazin-2-yl]methanol

259 racemic (cis) 4′-(2-Aminopyrimidin-5- yl)-3′-fluoro-N-[(cis)-2- hydroxycyclohexyl]biphenyl-2- sulfonamide

260 racemic (trans) 4′-(2-Aminopyrimidin- 5-yl)-3′-fluoro-N-[(trans)-2- hydroxycyclohexyl]biphenyl-2- sulfonamide

261 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxyethyl)-N-(1- methylethyl)biphenyl-2-sulfonamide

262 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(trans-4- hydroxycyclohexyl)biphenyl-2- sulfonamide

263 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(3S)-2-oxopyrrolidin-3-yl]biphenyl- 2-sulfonamide

264 5-{2′-[(1,1-Dioxidothiomorpholin-4- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine

265 1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}azetidin- 3-ol trifluoroacetic acid salt

266 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(3R)-2-oxopiperidin-3-yl]biphenyl- 2-sulfonamide trifluoroacetic acid salt

267 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(3S)-2-oxopiperidin-3-yl]biphenyl- 2-sulfonamide trifluoroacetic acid salt

268 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1R)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt

269 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N[(R)-1-(hydroxymethyl)-2,2- dimethylpropyl]biphenyl-2- sulfonamide trifluoroacetic acid salt

270 4′-2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-1-(hydroxymethyl)-2,2- dimethylpropyl]biphenyl-2- sulfonamide trifiuoroacetic acid salt

271 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-1-(hydroxymethyl)-2- methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt

272 4′-(2-Aminopyrimidin-5-y)-3′-fluoro- N-(2-hydroxy-2- methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt

273 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1R)-1-(hydroxymethyl)-2- methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt

274 4′-(2-Aminopyrimidin-5-yl)-N-[(2S)- 2,3-dihydroxypropyl]-3′- fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt

275 4′-(2-.Aminopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxyethyl)biphenyl-2′ sulfonamide trifluoroacetic acid salt

276 [(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt

277 [(2S)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- ylisulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt

278 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(2R)-2-hydroxypropyl]biphenyl-2- sulfonamide

279 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(2S)-2-hydroxypropyl]biphenyl-2- sulfonamide trifluoroacetic acid salt

280 4′-(2-.Aminopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxy-1,1- dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt

281 5-{2′-[(4-Cyclopropylpiperazin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine trifluoroacetic acid salt

282 2-(4-{(4′-[2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperazin- 1-yl)ethanol trifluoroacetic acid salt

283 4′-(2-Aminopyrimidin-5-yl)-N- (cyclopropylmethyl)-3′-fluorobiphenyl- 2-sulfonamide trifiuoroacetic acid

284 4′-(2-Aminopyrimidin-5-yl)-N- cyclopropyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt

285 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-phenylbiphenyl-2-sulfonamide trifluoroacetic acid salt

286 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt

287 4′-(2-Aminopyrimidin-5-yl)-N-tert- butyl-3′-fluoro-3-methylbiphenyl-2- sulfonamide trifluoroacetic acid salt

288 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt

289 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt

290 5-[3-Fluoro-2′-(piperazin-1- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine trifluoroacetic acid salt

291 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1R)-2,2,2-trifluoro-1- phanylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt

292 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-2,2,2-trifluoro-1- phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt

293 5-[2′-(tert-Butylsulfonyl)-3- fluorobiphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt

294 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(2-methylpropyl)biphenyl-2- sulfonamide trifiuoroacetic acid salt

295 4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′- fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt

296 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(2,2,2-trifluoro-1,1- dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt

297 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt

298 5-[3-Fluoro-2′-(pyrrolidin-1- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine trifluoroacetic acid salt

299 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N,N-dimethylbiphenyl-2-sulfonamide trifluoroacetic acid salt

300 4′-(2-Aminopyrimidin-5-yl)-N,N- diethyl-3′-fluorobiphenyl-2- sulfonamide trifiuoroacetic acid salt

301 5-[3-Fluoro-2′-(piperidin-1- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine trifluoroacetic acid salt

302 4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt

303 5-[3-Fluoro-2′-(morpholin-4- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine trifluoroacetic acid salt

304 5-[3-Fluoro-2′- (methylsulfonyl)biphenyl-4- yl]pyrimidin-2-amine trifluoroacetic acid salt

305 4′-(2-aminopyrimidin-5-yl)-N-(tert- butyl)-3′-fluoro[1,1′-biphenyl]-2- sulfonamide trifluoroacetic acid salt

306 4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperazin- 2-one trifluoroacetic acid salt

307 tert-Butyl N-{[4′-(2-aminopyrimidin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L- alaninate

308 N-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-L- alanine

309 N-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]pyrrolidine-1- sulfonamide

310 N-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]morpholine-4- sulfonamide

311 N′-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]-N,N- dimethylsulfamide

312 5-(2′-(2-oxa-6-azaspiro[3.3]heptan-6- ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrimidin-2-amine

313 6-((4′-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-2- thia-6-azaspiro[3.3]heptane 2,2- dioxide

314 1-((4′-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)azetidine-3-carbonitrile

315 1-((4-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3- (trifluoromethyl)azetidin-3-ol

316 5-{2′-[(1,1-Dioxidotetrahydro-2H- thiopyran-4-yl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrimidin.-2-amine hydrochloride

317 2-(((4′-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)methyl)quinazolin-4(3H)- one

318 1-(3-((4′-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)propyl)-1H- benzo[d]imidazol-2(3H)-one

319 5-(2′-{[3- (Cyclohexylsulfonyl)propyl]sulfonyl}- 3-fluorobiphenyl-4-yl)pyrimidin-2- amine

320 5-{3-Fluoro-2′-[(1-methyl-1H- benzimidazol-2-yl)sulfonyl]biphenyl- 4-yl}pyrimidin-2-amine

321 5-(2′-{[(3-Cyclopropyl-1,2,4- oxadiazol-5-yl)methyl]sulfonyl}-3- fluorobiphenyl-4-yl)pyrimidin-2-amine

322 4′-(2-aminopyrimidin-5-yl)-3′-fuoro-4- (trifluoromethyl)biphenyl-2- sulfonamide

323 5-[3-fluoro-2′-(methylsulfonyl)-4′- (trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine

324 4-{[4′-(2-aminopyrimidin-5-yl)-3′- fluoro-4-(trifluoromethyl)biphenyl-2- yl]sulfonyl}piperazin-2-one

325 4′-(2-aminopyrimidin-5-yl)-3′-fluoro- N-methyl-4-(trifluoromethyl)biphenyl- 2-sulfonamide

326 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2- sulfonamide

327 4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′- fluoro-4-(trifluoromethyl)biphenyl-2′- sulfonamide

328 5-{3-Fluoro-2′-[(4-methylpiperazin-1- yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4- yl}pyrimidin-2-amine

329 5-{2′-[(5-Aminopyrimidin-2- yl)sulfanyl)-3-fluorobiphenyl-4- yl)pyrimidin-2-amine formate salt

330 5-{2′-[(4-Aminopyrimidin-2- yl)sulfanyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine formate salt

331 5-{2′-[(5-Aminopyrimidin-4- yl)sulfanyl]-3-fluorobiphenyl-4- yl)pyrimidin-2-amine formate salt

332 5-[3-Fluoro-2′-(pyrimidin-2- ylsulfanyl)biphenyl-4-yl]pyrimidin-2- amine hydrochloride

333 5-[3-Fluoro-2′-(pyrazin-2- ylsulfanyl)biphenyl-4-yl]pyrimidin-2- amine hydrochloride

334 5-{2′-[(6-Aminopyrimidin-4- yl)sulfanyl)-3-fluorobiphenyl-4- yl}pyrimidin-2-amine formate salt

335 4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 2-amine formate salt

336 5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]- 3-fluorobiphenyl-4-yl}pyrimidin-2- amine formate salt

337 5-{2′-[(5-Aminopyrimidin-4- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine hydrochloride

338 5-[3-Fluoro-2′-({[2- trimethylsilyl)ethoxy]methyl}sulfonyl) biphenyl-4-yl]pyrimidin-2-amine formate salt

339 5-{2′-[(5-Aminopyrimidin-2- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine hydrochloride

340 5-[3-Fluoro-2′-({[2- (trimethylsilyl)ethoxy]methyl}sulfanyl) biphanyl-4-yl]pyrimidin-2-amine

341 5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′- biphenyl]-4-yl)pyridin-2-amine

342 4′-(6-aminopyridin-3-yl)-N-((tert-butyl)- 3′-fluoro-[1,1′-biphenyl]-2- sulfonamide

343 4′-(6-aminopyridin-3-yl)-N,N-diethyl- 3′-fluoro-[1,1′-biphenyl]-2- sulfonamide

344 5-(3-fluoro-2′-(pyrrolidin-1-ylsulfonyl)- [1,1′-biphenyl]-4-yl)pyridin-2-amine

345 5-(3-fluoro-2′-(piperidin-1-ylsulfonyl)- [1,1′-biphenyl]-4-yl)pyridin-2-amine

346 4′-(6-aminopyridin-3-yl)-N-cyclohexyl- 3′-fluoro-[1,1′-biphenyl]-2- sulfonamide

347 (S)-4′-(6-aminopyridin-3-yl)-3′-fluoro- N-(1-hydroxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide

348 4′-(6-aminopyridin-3-yl)-3′-fluoro-N- isobutyl-[1,1′-biphenyl]-2-sulfonamide

349 4′-(6-aminopyridin-3-yl)-3′-fluoro-N- (tert-pentyl)-[1,1′-biphenyl]-2- sulfonamide

350 4′-(6-aminopyridin-3-yl)-3′-fluoro-N- (1,1,1-trifluoro-2-methylpropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide

351 (S)-4′-(6-aminopyridin-3-yl)-3′-fluoro- N-(2,2,2-trifluoro-1-phenylethyl)-[1,1′- biphenyl]-2-sulfonamide

352 (R)-4′-(6-aminopyridin-3-yl)-3-fluoro- N-(1-hydroxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide

353 4′-(6-aminopyridin-3-yl)-3′-fluoro-N- (1-methylcyclobutyl)-[1,1′-biphenyl]- 2-sulfonamide

354 4-((4′-(6-aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2- yl)sulfonyl)thiomorpholine 1,1-dioxide

355 (S)-4′-(6-aminopyridin-3-yl)-3′-fluoro- N-(1,1,1-trifluoropropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide

356 5-(2′-((1S,4S)-2-oxa-5- azabicyclo[2.2.1]heptan-5-ylsulfonyl)- 3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2- amine

357 tert-butyl 3-((4′-(6-aminopyridin-3-yl)- 3′-fluoro-[1,1′-biphenyl]-2- ylsulfonamido)methyl)-3- hydroxyazetidine-1-carboxylate

358 4′-(6-aminopyridin-3-yl)-3′-fluoro-N- ((3-hydroxyazetidin-3-yl)methyl)-[1,1′- biphenyl]-2-sulfonamide

359 2-(1-(4′-(6-aminopyridin-3-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidin-4-yl)ethanol

360 1-((4′-(6-aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2-yl)sulfonyl)piperidin- 4-ol

361 (1-((4′-(6-aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2-yl)sulfonyl)piperidin- 4-yl)methanol

362 3′-Fluoro-N-[(1S)-2-hydroxy-1- methylethyl]-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2-sulfonamide

363 3′-Fluoro-N-[(1R)-2-hydroxy-1- methylethyl]-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2-sulfonamide

364 3′-Fluoro-N-[(3S)-2-oxopyrrolidin-3- yl]-4′-(1H-pyrrolo[2,3-b]pyridin-5- yl)biphenyl-2-sulfonamide

365 5-[2′-(Cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]-1H-pyrrolo[2,3- b]pyridine

366 3′-Fluoro-N-(2-hydroxyethyl)-4′-(1H- pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- sulfonamide

367 N-tert-Butyl-3′-fluoro-4′-(1H- pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- sulfonamide

368 3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin 5-yl)biphenyl-2-sulfonamide

369 N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- yl]methanesulfonamide

370 3′-Fluoro-N,N-dimethyl-4′-(5H- pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide

371 N-tert-Butyl-3′-fluoro-4′-(5H- pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide

372 2-[3-Fluoro-2′-(pyrrolidin-1- ylsulfonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine

373 N-Diethyl-3′-fluoro-4′-(5H- pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide

374 2-[3-Fluoro-2′-(piperidin-1- ylsulfonyl)biphenyl-4-yl)-5H- pyrrolo[2,3-b]pyrazine

375 2-[3.-Fluoro-2′-(morpholin-4- ylsulfonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine

376 3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)N-N-(2,2,2-trifluoro-1- methylethyl)biphenyl-2-sulfonamide

377 2-[3-Fluoro-2′- (methylsulfonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine

378 3′-Fluoro-N-[(1R)-2-hydroxy-1- methylethyl]-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- sulfonamide

379 3′-Fluoro-N-methyl-4′-(5H- pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide

380 3′-Fluoro-N-[(1S)-2-hydroxy-1- methylethyl]4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- sulfonamide

381 1-{[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- yl]sulfonyl}piperidin-4-amine

382 2-{2′-[(1,1-Dioxidothiomorpholin-4- yl)sulfonyl]-3-fluorobiphenyl-4-yl}-5H- pyrrolo[2,3-b]pyrazine

383 2-[3,5-Difiuoro-2′- (methylsulfanyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine

384 2-[2′-(Ethylsulfanyl)-3-fluorobiphenyl- 4-yl]-5H-pyrrolo[2,3-b]pyrazine

385 7-[3-Fluoro-2′- (methylsulfonyl)biphenyl-4-yl]-3,4- dihydro-2H-pyrido[3,2-b][1,4]oxazine

386 7-[3-Fluoro-2′-(piperidin-1- ylsulfonyl)biphenyl-4-yl]-3,4-dihydro- 2H-pyrido[3,2-b][1,4]oxazine

387 4′-(3,4-Dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)-3′-fluorobiphenyl- 2-sulfonamide

388 4′-(3,4-Dihydro-2H-pyrido[3,2- b]l[1,4]oxazin-7-yl)-3′-fluoro-N-[(1S)- 2-hydroxy-1-methylethyl]biphenyl-2- sulfonamide

389 1-{[4′-(3,4-Dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)-3′-fluorobiphenyl- 2-yl]sulfonyl}piperidin-4-amine

390 4′-(3,4-Dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1R)- 2-hydroxy-1-methylethyl]biphenyl-2- sulfonamide

391 4′-(3,4-Dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)-N,N-diethyl-3′- fluorobiphenyl-2-sulfonamide

392 7-{2′-[(1,1-Dioxidothiomorpholin-4- yl)sulfonyl]-3-fluorobiphenyl-4-yl]-3,4- dihydro-2H-pyrido[3,2-b][1,4]oxazine

393 N-tert-Butyl-4′-(3,4-dihydro-2H- pyrido[3,2-b][1,4]oxazin-7-yl)-3′- fluorobiphenyl-2-sulfonamide

394 2-(2-Fluoro-4-{2-[(1- methylethyl)sulfanyl]-5- (trifluoromethyl)pyridin-3-yl}phenyl)- 5H-pyrrolo[2,3-b]pyrazine

395 5-(2-Fluoro-4-{2-[(1- methylethyl)sulfonyl]pyridin-3- yl}phenyl)pyrazin-2-amine

396 5-(2-Fluoro-4-{2-[(1- methylethyl)sulfanyl]pyridin-3- yl}phenyl)pyrazin-2-amine

397 2-{2-Fluoro-4-[2-(2,2,2- trifluoroethoxy)pyridin-3-yl]phenyl}- 5H-pyrrolo[2,3-b]pyrazine

398 2-{2-Fluoro-4-[2-(2- methylpropoxy)pyridin-3-yl]phenyl)- 5H-pyrrolo[2,3-b]pyrazine

399 2-{2-Fluoro-4-[2-(1- methylethoxy)pyridin-3-yl]phenyl}- 5H-pyrrolo[2,3-b]pyrazine

400 2-{4-[2-(Cyclopropylmethoxy)pyridin- 3-yl]-2-fluorophenyl}-5H-pyrrolo[2,3- b]pyrazine

401 5-{2-Fluoro-4-[2-(1- methylethoxy)pyridin-3- yl]phenyl}pyrazin-2-amine

402 5-{4-[2-(Cyclopentyloxy)pyridin-3-yl]- 2-fluorophenyl}pyrazin-2-amine

403 5-{4-[2-(Cyclohexyloxy)pyridin-3-yl]- 2-fluorophenyl}pyrazin-2-amine

404 5-[2-Fluoro-4-(2-methoxypyridin-3- yl)phenyl]pyrazin-2-amine

405 5-{4-[2-(Cyclobutyloxy)pyridin-3-yl]-2- fluorophenyl}pyrazin-2-amine

406 tert-Butyl 3-[({3-[4-(5-aminopyrazin-2- yl)-3-fluorophenyl]pyridin-2- yl}oxy)methyl]pyrrolidine-1- carboxylate

407 5-{2-Fluoro-4-[2-(pyrrolidin-3′- ylmethoxy)pyridin-3- yl]phenyl}pyrazin-2-amine

408 5-{2-Fluoro-4-[2-(1- methylethoxy)pyridin-3- yl]phenyl}pyrimidin-2-amine

409 5-[4-(2-Aminopyridin-3-yl)-2- fluorophenyl]pyrimidin-2-amine

410 4′-(5-amino-6-cyanopyrazin-2-yl)-3′- fluoro-N-[(1R)-2-hydroxy-1- methylethypiphenyl-2-sulfonamide

411 3-Amino-6-[2′-(cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazine-2- carbonitrile

412 4′-(5-Amino-6-cyanopyrazin-2-yl)-3′- fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide

413 4′-(5-Amino-6-cyanopyrazin-2-yl)-3′- fluoro-N-(2-hydroxyethyl)biphenyl-2- sulfonamide

414 3-Amino-6-{3-fluoro-2′-[(3- oxopiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazine-2-carbontrile

415 4′-(5-Amine-6-cyanopyrazin-2-yl)-3′- fluoro-N-[(R)-2- hydroxypropyl]biphenyl-2- sulfonamide

416 3-Amino-6-[3-fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]pyrazine-2- carbonitrile

417 4′-(6-Aminopyridazin-3-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide

418 N-tert-Butyl-3′-fluoro-4′-(7H- pyrrolo[2,3-d]pyrimidin-2-yl)biphenyl- 2-sulfonamide

419 N-tert-Butyl-3′-fluoro-4′-(1,8- naphthyridin-3-yl)biphenyl-2- sulfonamide

420 N-tert-Butyl-3′-fluoro-4′-quinoxalin-6- ylbiphenyl-2-sulfonamide

421 N-tert-Butyl-3′-fluoro-4′-(1H-indol-5- yl)biphenyl-2-sulfonamide

422 4′-(1H-Benzimidazol-5-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide

423 4′-1H-Benzimidazol-5-yl)-3′-fluoro-N- methylbiphenyl-2-sulfonamide

424 4′-(1,3-Benzothiazol-5-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide

425 N-tert-Butyl-3′-fluoro-4′-(1H- pyrrolo[3,2-b]pyridin-6-yl)biphenyl-2- sulfonamide

426 3′-Fluoro-N-methyl-4′-(1H- pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- sulfonamide

427 4′-(5-Aminepyridin-2-yl)-N-tert-butyl- 3′-fluoro-biphenyl-2-sulfonamide

428 N-tert-Butyl-4′-(5,6-diaminopyrazin-2- yl)-3′-fluorobiphenyl-2-sulfonamide

429 N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3- dihydro-1H-imidazo[4,5-b]pyrazin-5- yl)biphenyl-2-sulfonamide

430 4′-(6-Amino-5-fluoropyridin-3-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide

431 N-tert-Butyl-4′-(2,3-dihydro-1H- pyrrolo[2,3-b]pyridin-5-yl)-3′- fluorobiphenyl-2-sulfonamide

432 N-tert-Butyl-3′-fluoro-4′-(3H- imidazo[4,5-b]pyridin-6-yl)biphenyl-2- sulfonamide

433 4′-(5-Amino-6-methoxypyrazin-2-yl)- N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide

434 4′-(5-Amino-6-cyanopyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide

435 4′-(5-Amino-3-cyanopyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide

436 4′-(6-Amino-4-cyanopyridin-3-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide

437 4′-(6-amino-2-cyanopyridin-3-yl)-N- (tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2- sulfonamide

438 4′-(5-amino-1,3,4-thiadiazol-2-yl)-N- (tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2- sulfonamide

439 (R)-4′-(5-amino-1,3,4-thiadiazol-2-yl)- 3-fluoro-N-(1-hydroxypropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide

440 4-((4′-(5-amino-1,3,4-thiadiazol-2-yl)- 3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)thiomorpholine 1,1-dioxide

441 4′-(5-Amino-6-chloropyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide

442 4′-(5-Amino-6-bromopyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide

443 6-amino-3-(2′-(cyclopropylsulfonyl)-3- fluoro-[1,1′-biphenyl]-4- yl)picolinonitrile

444 N-tert-Butyl-3′-fluoro-4′- [1,2,4]triazolo[4,3-a]pyridin-7- ylbiphenyl-2-sulfonamide

445 4′-(5-Amino-6-methylpyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide

446 4′-(5-Amino-6-methylpyrazin-2-yl)-3′- fluorobiphenyl-2-sulfonamide

447 N-tert-Butyl-3′-fluoro-4′-(1H- imidazo[4,5-b]pyrazin-5-yl)biphenyl- 2-sulfonamide

448 N-tert-Butyl-4′-(5,6-diaminopyridin-3- yl)-3′-fluorobiphenyl-2-sulfonamide

449 4′-(5-Amino-6-methylpyrazin-2-yl)-3′- fluoro-N-methylbiphenyl-2- sulfonamide

450 4′-(6-Amino-5-cyanopyridin-3-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt

451 4′-(6-Amino-5-chloropyridin-3-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt

452 4′-[6-Amino-5-(trifluoromethyl)pyridin- 3-yl]-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifiuoroacetic acid salt

453 4′-[2-Amino-4- (trifluoromethyl)pyrimidin-5-yl]-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt

454 4′-(2-Amino-4-methylpyrimidin-5-yl)- N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt

455 N-tert-Butyl-3′-fluoro-4′-[3- (hydroxymethyl)-1H-pyrrolo[2,3- b]pyridin-5-yl]biphenyl-2-sulfonamide

456 4′-(7-Amino-1H-indol-5-yl)-3′-fluoro- N-[1- (hydroxymethyl)cyclopentyl]biphenyl- 2-sulfonamide

457 3′-Fluoro-4′-[3-(hydroxymethyl)-1H- pyrrolo[2,3-b]pyridin-5-yl]-N- methylbiphenyl-2-sulfonamide

458 4′-(7-Amino-1H-indol-5-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide

459 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]acetamide

460 1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]urea

461 5-[2,3-Difluoro-2′- (methylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine

462 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 2′,3′-difluorobipnenyl-2-sulfonamide

463 N-[4′-(5-Aminopyrazin-2-y)-3′-fluoro- 2′-methylbiphenyl-2- yl]methanesulfonamide

464 4′-(5-Aminopyrazin-2-yl)-2′,3′- difluorobiphenyl-2-sulfonamide

465 4′-(2-Aminopyrimidin-5-yl)-2′,3′- difluoro-N-methylbiphenyl-2- sulfonamide trifluoroacetic acid salt

466 4′-(2-Aminopyrimidin-5-yl)-N-tert- butyl-2′,3′-difluorobipenyl-2- sulfonamide trifluoroacetic acid salt

467 5-[2′,3-Difluoro-4′- (trifluoromethoxy)biphenyl-4- yl]pyrazin-2-amine

468 5-(2′,3-Difluorobiphenyl-4-yl)pyrazin- 2-amine

469 5-(2′-Chloro-3-fluorobiphenyl-4- yl)pyrazin-2-amine

470 5-(3-Fluoro-2′-methylbiphenyl-4- yl)pyrazin-2-amine

471 5-[2′,3-Difiuoro-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine

472 5-[3-Fluoro-2′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine

473 5-(3-Fluoro-2′-methoxybiphenyl-4- yl)pyrazin-2-amine

474 5-[3-Fluoro-2′- (methylsulfanyl)biphenyl-4-yl]pyrazin- 2-amine

475 5-[3-Fluoro-2′- (trifluoromethoxy)biphenyl-4- yl]pyrazin-2-amine

476 4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-ol

477 5-[3-Fluoro-2′- (phenylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine

478 5-(2′,3,6′-Trifluorobiphenyl-4- yl)pyrazin-2-amine

479 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]benzenesulfonamide

480 5-(2′-Ethyl-3-fluorobiphenyl-4- yl)pyrazin-2-amine

481 {[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}acetic acid

482 5-[3-Fluoro-2′-(1- methylethyl)biphenyl-4-yl]pyrazin-2- amine

483 1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]ethanone

484 5-[3-Fluoro-2′-(2,2,2- trifluoroethoxy)biphenyl-4-yl]pyrazin- 2-amine

485 4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-carboxylic acid

486 4′-(5-Aminopyrazin-2′-yl)-3′- fluorobiphenyl-2-carboxamide

487 5-[3-Fluoro-2′-(1- methylethoxy)biphenyl-4-yl]pyrazin- 2-amine

488 5-{4-[2-(Cyclopropylmethoxy)pyridin- 3-yl]-2-fluorophenyl}pyrazin-2-amine

489 2-[3,4′-Difluoro-2′- (methylsulfonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine

490 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- methylmethanesulfonmide

491 N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- yl]ethanesulfonamide

492 N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2-yl]-N-N- methylmethanesulfonamide

493 N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2-yl]-N- methylethanesulfonamide

494 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- methylethanesulfonamide

495 N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2-yl]-2- methylpropane-1-sulfonamide

496 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- ethylmethanesulfonamide

497 N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N,2- dimethylpropane-1-sulfonamide

498 5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]-1H- pyrrolo[2,3-b]pyridine

499 5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]pyrimidin-2- amine

500 2-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine

501 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-fluorobiphenyl-2-carboxamide

502 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′,4-difluorobiphenyl-2-carboxamide

503 4′-(5-Aminopyrazin-2-yl)-N,N-diethyl- 3′-fluorobiphenyl-2-carboxamide

504 4′-(2-Aminopyrimidin-5-yl)-3-fluoro- N-[(1S)-2,2,2-trifluoro-1- methylethyl]piphenyl-2-carboxamide

505 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-carboxamide

506 5-[3-Fluoro-2′-(piperazin-1- ylcarbonyl)biphenyl-4-yl]pyrazin-2- amine

507 5-{2′-[(4-Acetylpiperazin-1- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

508 4′-(5-Aminopyrazin-2-yl)-N- cyclohexyl-3′-fluorobiphenyl-2- carboxamide

509 5-{2′-[(1,1-Dioxidathiomorpholin-4- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

510 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- methylbiphenyl-2-carboxamide

511 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-carboxamide

512 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R)-2-hydroxy-1- methylethyl]biphenyl-2-carboxamide

513 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-2-hydroxy-1- methylethyl]biphenyl-2-carboxamide

514 1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl)piperidin-4-ol

515 5-{2′-[(4-Aminopiperidin-1- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine

516 5-{2′-[(1,1-Dioxidothiomorpholin-4- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine

517 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-carboxamide

518 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N[(1R)-2,2,2-trifluoro-1- methylethypiphenyl-2-carboxamide

519 4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperazin-2-one

520 4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperazin-2-one

521 5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine

522 5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)-4′- (trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine

523 4-{[3′-Fluoro-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2- yl]oxy}pyrimidin-2-amine

524 2-{[3′-Fluoro-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2- yl]oxy}pyrimidin-4-amine

525 5-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]-1H-pyrrolo[2,3- b]pyridine

526 5-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]pyrazin-2-amine

527 5-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]pyrimidin-2-amine

528 2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-4- amine

529 5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3- fluorobiphenyl-4-yllpyrimidin-2-amine

530 6-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]oxy}methyl)pyridine-2-carbonitrile

531 2-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]oxy}methyl)pyridine-3-carbonitrile

532 2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile

533 4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-2- amine

534 4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-2- amine

535 6-{[4′-(5-Aminopyrazin-2′yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-4′- amine

536 5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3- fluorobiphenyl-4-yl}pyrimidin-2-amine

537 4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile

538 4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile

539 5-{2′-[(6-Azetidin-1-ylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine

540 5-{2′-[(6-Azetidin-1-ylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine

541 5-{3-Fluoro-2′-[(2-methylpyrimidin-4- yl)oxy]biphenyl-4-yl}pyrazin-2-amine

542 5-{3-Fluoro-2′-[(2-methylpyrimidin-4- yl)oxy]biphenyl-4-yl}pyrimidin-2- amine

543 5-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]-1H- benzimidazole

544 6-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]-3H-imidazo[4,5- b]pyridine

545 5-{3-Fluoro-2′-[(4-methylpyrimidin-2- yl)oxy]biphenyl-4-yl}pyrazin-2-amine

546 5-{3-Fluoro-2′-[(4-methylpyrimidin-2- yl)oxy]biphenyl-4-yl}pyrimidin-2- amine

547 5-(3-Fluoro-2′-{(2- (trifluoromethyl)pyrimidin-4- yl]oxy}biphenyl-4-yl)pyrazin-2-amine

548 5-(3-Fluoro-2′-{(2- (trifluoromethyl)pyrimidin-4- yl]oxylbiphenyl-4-yl)pyrimidin-2- amine

549 5-{3-Fluoro-2′-[(5-methoxypyrimidin- 2-yl)oxy]biphenyl-4-yl}pyrazin-2- amine

550 5-{3-Fluoro-2′-[(5-methoxypyrimidin- 2-yl)oxy]biphenyl-4-yl}pyrimidin-2- amine

551 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine

552 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′- (trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine

553 5-[3-Fluoro-2′-methoxy-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine

554 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2-ol

555 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 4-(trifluoromethyl)biphenyl-2- yl]oxy}pyrimidin-2-amine

556 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 4-(trifluoromethyl)biphenyl-2- yl]oxy}pyrimidin-4-amine

557 5-[3-Fluoro-4′-(trifluoromethyl)-2′-{[2- (trimethylsilyl)ethoxy]methoxy}biphenyl- yl-4-yl]pyrimidin-2-amine

558 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2-ol

559 5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3- fluoro-4′-(trifluoromethyl)biphenyl-4- yl}pyrimidin-2-amine

560 4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluoro-4-(trifluoromethyl)biphenyl-2- yl]oxy}pyrimidin-2-amine

561 5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3- fluoro-4′-(trifluoromethyl)biphenyl-4- yl}pyrimidin-2-amine

562 5-[3-Fluoro-2′,4′- bis(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine

563 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2- carbonitrile

564 5-{5-[2-(Pyrimidin-2-yloxy)-4- (trifluoromethyl)phenyl]pyridin-2- yl}pyrimidin-2-amine

565 4-{2-[6-(2-Aminopyrimidin-5- yl)pyridin-3-yl]-5- (trifluoromethyl)phenoxy}pyrimidin-2- amine

566 5-{5-[2-(Pyrimidin-2- yloxy)phenyl]pyridin-2-yl}pyrimidin-2- amine

567 4-{2-[6-(2-Aminopyrimidin-5- yl)pyridin-3-yl]phenoxy}pyrimidin-2- amine

568 5-(5-{2-[(4-Aminopyrimidin-2- yl)oxy]phenyl}pyridin-2-yl)pyrimidin- 2-amine

569 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-methylbiphenyl-2-sulfonamide

570 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-methoxybiphenyl-2-sulfonamide

571 4′-(5-Aminopyrazin-2-yl)-N-tert- butylbiphenyl-2-sulfonamide

572 4′-(5-Aminopyrazin-2-yl)-N,N- dimethylbiphenyl-2-sulfonamide

573 5-[2′-(Morpholin-4- ylsulfonyl)biphenyl-4-yl]pyrazin-2′- amine

574 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 2′-fluorobiphenyl-sultonamide

575 4′-(5-Aminopyrazin-2-yl)-2′-fluoro- N,N-dimethylbiphenyl-2-sulfonamide

576 4′-(2-Amino-1,3-oxazol-4-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide

577 4′-(2-Amino-1,3-thiazol-4-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide

578 4′-(2-Amino-1,3-thiazol-4-yl)-N,N- diethyl-3′-fluorobiphenyl-2- sulfonamide

579 4-[3-Fluoro-2′-(pyrrolidin-1- ylsulfonyl)biphenyl-4-yl]-1,3-thiazol-2- amine

580 N-tert-Butyl-3′-fluoro-4′-(8- fluoroimidazo[1,2-a]pyridin-2- yl)biphenyl-2-sulfonamide

581 4′-(5-Aminoimidazo[1,2-a]pyridin-2- yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide

582 2-[2′-(tert-Butylsulfamoyl)-3- fluorobiphenyl-4-yl]imidazo[1,2- a]pyridine-6-carboxamide

583 2-[2′-(tert-Butylsulfamoyl)-3- fluorobiphenyl-4-yl]imidazo[1,2- a]pyridine-6-carboxamide

584 N-tert-Butyl-4′-(5-cyanoimidazo[1,2- a]pyridin-2-yl)-3′-fluorobiphenyl-2- sulfonamide

585 N-tert-Butyl-4′-(6-cyanoimidazo[1,2- a]pyridin-2-yl)-3′-fluorobiphenyl-2- sulfonamide

586 N-tert-Butyl-3′-fluoro-4′-[6- (trifluoromethyl)imidazo[1,2-a]pyridin- 2-yl]biphenyl-2-sulfonamide

587 Ethyl 2-[2′-(tert-butylsulfamoyl)-3- fluorobiphenyl-4-yl]imidazo[1,2- a]pyridine-5-carboxylate

588 N-tert-Butyl-3-fluoro-4′-(5- methoxyimidazo[1,2-a]pyridin-2- yl)biphenyl-2-sulfonamide

589 5-[2′-(Methylsulfonyl)biphenyl-4- yl]pyrazin-2-amine.

590 5-[3-Methyl-2′- (methylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine.

591 4′-(5-Aminopyrazin-2-yl)-N,N,3′- trimethylbiphenyl-2-sulfonamide.

592 4′-(5-Aminopyrazin-2-yl)-3′- hydroxybiphenyl-2-sulfonamide.

593 n-[4′-(5-Aminopyrazin-2-yl)biphenyl- 2-yl]methanesulfonamide.

594 4′-(5-Aminopyrazin-2-yl)biphenyl-2- sulfonamide.

595 N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3- dihydro-1H-indol-5-yl)biphenyl-2- sulfonamide.

596 N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl)-3′- fluorobiphenyl-2-sulfonamide.

597 4′-(3-Amino-1H-indazol-5-yl)-N-tert- butyl-3′-fluorobiphenyl-2- sulfonamide.

598 3-Amino-6-[2′-(tert-butylsulfamoyl)-3- fluorobiphenyl-4-yl]pyrazine-2- carboxylic acid.

599 2-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]sulfonyl}acetamide.

600 2-{4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-N,N- diethylacetamide.

601 5-{3-Fluoro-2′-[(2-morpholin-4-yl-2- oxoethyl)sulfonyl]biphenyl-4- yl}pyrimidin-2-amine.

602 5,5′-(3,3′-Difluoro-1,1′:2′,1″- terphenyl-4,4″-diyl)dipyrazin-2- amine.

603 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2-carboxylic acid.

604 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2- carbaldehyde.

605 5-[3-Fluoro-2′-(morpholin-4-ylmethyl)- 4′-(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine.

606 5-{2′-[(4-Aminopiperidin-1-yl)methyl]- 3-fluoro-4′-(trifluoromethyl)biphenyl- 4-yl}pyrazin-2-amine.

607 2-({[4′-(5-Aminopyrazin-2-yl)-3′- fluoro-4-(trifluoromethyl)biphenyl-2- yl]methyl}amino)ethanol.

608 5-{2′-[(4,6-Dimethylpyrimidin-2- yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine.

609 5-{2′-[(4,6-Dimethylpyrimidin-2- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine.

610 5-(3-Fluoro-2′-{(2- (trifluoromethyl)pyridin-4- yl]oxy}biphenyl-4-yl)pyrazin-2-amine.

611 5-(3-Fluore-2′-{[2- (trifluoromethyl)pyridin-4- yl)oxy}biphenyl-4-yl)pyrimidin-2- amine.

612 5-(3-Fluoro-2′-{[4- (trifluoromethyl)pyrimidin-2- yl]oxy}biphenyl-4-yl)pyrazin-2-amine.

613 5-(3-Fluoro-2′-{[4- (trifluoromethyl)pyrimidin-2- yl]oxy}biphenyl-4-yl)pyrimidin-2- amine.

614 2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-5- amine.

615 5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3- fluorobiphenyl-4-yl}pyrimidin-2- amine.

616 2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}-6- methylpyrimidin-4-amine.

617 5-{2′-[(4-Amino-6-methylpyrimidin-2- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine.

618 6-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile.

619 6-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile.

620 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3- fluorobiphenyl-4-yl}pyrazin-2-amine.

621 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3- fluorobiphenyl-4-yl}pyrimidin-2- amine.

622 5-{2′-[(6-Amino-2-methylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine.

623 6-{[4′-(5-Aminopyrazin-2-yl)-(3′ fluorobiphenyl-2-yl]oxy}-2- methylpyrimidin4-amine.

624 5-(3-Fluoro-2′-{[6- (trifluoromethyl)pyridin-2- yl]oxy}biphenyl-4-yl)pyrimidin-2- amine.

625 5-(3-Fluoro-2′-{[6- (trifluoromethyl)pyridin-2- yl]oxy}biphenyl-4-yl)pyrazin-2-amine.

626 6-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile.

627 6-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile.

628 2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}ethanol.

629 2-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}ethanol.

630 5-[3-Fluoro-2′-(piperidin-4- yloxy)biphenyl-4-yl]pyrazin-2-amine.

631 5-[3-fluoro-2′-(piperidin-4- yloxy)biphenyl-4-yl]pyrimidin-2- amine.

632 5-{3-Fluoro-2′-[(3R)-piperidin-3- yloxy]biphenyl-4-yl}pyrazin-2-amine

633 5-{3-Fluoro-2′-[(3R)-piperidin-3- yloxy]biphenyl-4-yl}pyrimidin-2- amine.

634 5-{3-Fluoro-2′-[(3S)-piperidin-3- yloxy]biphenyl-4-yl}pyrazin-2-amine.

635 5-{3-Fluoro-2′-[(3S)-piperidin-3- yloxy]biphenyl-4-yl}pyrimidin-2- amine.

636 5-{2′-[(6-Cyclopropylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine.

637 5-{2′-[(6-Cyclopropylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine.

638 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3- fluorobiphenyl-4-yl}pyrazin-2-amine.

639 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3- fluorobiphenyl-4-yl}pyrimidin-2- amine.

640 5-[2′-(2-Aminoethoxy)-3- fluorobiphenyl-4-yl]pyrazin-2-amine.

641 5-[2′-(2-Aminoethoxy)-3- fluorobiphenyl-4-yl]pyrimidin-2- amine.

642 {[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}acetonitrile.

643 {[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}acetonitrile.

644 {[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}acetic acid.

645 5-{2-Fluoro-4-[2-(piperidin-4- yloxy)pyridin-3-ylphenyl}pyrazin-2- amine.

646 5-{2-Fluoro-4-[2-(piperidin-4- yloxy)pyridin-3-yl]phenyl}pyrimidin-2- amine.

647 5-(4-{2-[(1,1-Dioxidotetrahydro-2H- thiopyran4-yl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine.

648 5-(4-{2-[(1,1-Dioxidotetranydro-2H- thiopyran-4-yl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine.

649 2-({3-[4-(2-Aminopyrimidin-5-yl)-3- fluorophenyl]pyridin-2-yl}oxy)ethanol.

650 2-({3-[4-(5-Aminopyrazin-2-yl)-3- fluorophenyl]pyridin-2-yl}oxy)ethanol.

651 5-(4-{2-[(trans-4- Aminocyclohexyl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine.

652 5-(4-{2-[(trans-4- Aminocyclohexyl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine formic acid salt

653 5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-yloxy)pyridin-3- yl]phenyl}pyrazin-2-amine.

654 5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-yloxy)pyridin-3- yl]phenyl}pyrimidin-2-amine

655 (2R)-2-({3-[4-(5-Aminopyrazin-2-yl)- 3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol.

656 (2R)-2-({3-[4-(2-Aminopyrimidin-5-yl- 3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol.

657 (2S)-2-({3-[4-(5-Aminopyrazin-2-yl)- 3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol.

658 (2I)-2-({3-[4-(2-Aminopyrimidin-5-yl)- 3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol

659 N-(4′-(6-Aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2- yl)methanesulfonamide

660 5-(3-Fluoro-2′-(morpholinosulfonyl)- [1,1′-biphenyl]-4-yl)pyridin-2-amine

661 4′-(6.-Aminopyridin-3-yl)-3′-fluoro-N- methyl-[1,1′-biphenyl]-2-sulfonamide

662 4′-(6-Aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2-sulforiamide trifluoroacetate

663 5-(2′-((1S,4S)-2-Oxa-5- azabicyclo[2.2.1]heptan-5-ylsulfonyl)- 3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2- amine

664 4′-(6-Aminopyrazin-2-yl)-3′-fluoro-N- ((3-hydroxyazetidin-3-yl)methyl)-[1,1′- biphenyl]-2-sulfonamide

665 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N- (1-hydroxy-2-methylpropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide

666 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N- ((1S,2S)-1-hydroxy-1-phenylpropan- 2-yl)-N-methyl-[1,1′-biphenyl]-2- sulfonamide

667 4′-(6-Amino-5-fluoropyridin-3-yl)-3′- fluoro-N-(1-hydroxy-2-methylpropan- 2-yl)-[1,1′-biphenyl]-2-sulfonamide

668 (racemic)-1-((4′-(6-Amino-5- fluoropyridin-3-yl)-3′-fluoro-[1,1′- biphenyl]-2-yl)sulfonyl)piperidin-3-ol

669 4′-(6-Amino-5-fluoropyridin-3-yl)-3′- fluoro-N-((1S,2S)-1-hydroxy-1- phenylpropan-2-yl)-N-methyl-[1,1′- biphenyl]-2-sulfonamide

670 N-(1-((4′-(6-Amino-5-fluoropyridin-3- yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidin-4-yl)acetamide

671 racemic 2-(1-((4′-(6-Amino-5- fluoropyridin-3-yl)-3′-fluoro-[1,1′- biphenyl]-2-yl)sulfonyl)piperidin-3- yl)ethanol.

672 racemic 1-(4′-(6-Amino-5- fluoropyridin-3-yl)-3′-fluoro-[1,1′- biphenyl]-2-yl)sulfonyl)piperidin-3- yl)methanol.

673 2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-[(2R)-2- hydroxypropyl]benzenesulfonamide.

674 2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-ethyl-5- (trifluoromethyl)benzenesulfonamide.

675 2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-tert- butylbenzenesulfonamide.

676 5-{5-[2-(Morpholin-4-ylmethyl)-4- (trifluoromethyl)phenyl]pyridin-2- yl}pyrimidin-2-amine.

677 5-{5-[2-(Morpholin-4- ylcarbonyl)phenyl]pyridin-2- yl}pyrimidin-2-amine.

678 5-[5-(2-Methoxyphenyl)pyridin-2- yl]pyrimidin-2-amine.

679 5-(5-{2-[(3,3Difluoropiperidin-1- yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine trifluoroacetic acid salt.

680 5-(5-{2-[(3,3-Difluoropyrrolidin-1- yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine trifluoroacetic acid salt.

681 5-{5-[2-(Azepan-1- ylsulfonyl)phenyl]pyridin-2- yl}pyrimidin-2-amine trifluoroacetic acid salt.

682 5-(5-{2-[(4,4-Difluoropiperidin-1- yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine trifluoroacetic acid salt.

683 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-ethylbenzenesulfonamide trifluoroacetic acid salt.

684 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N- (dicyclopropylmethyl)benzene- sulfonamide trifluoroacetic acid salt.

685 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(1S)-2,2,2-trifluoro-1- methylethyl]benzenesulfonamide trifluoroacetic acid salt.

686 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(1R)-2,2,2-trifluoro-1- methylethyl]benzenesulfonamide trifluoroacetic acid salt.

687 4-({2-[6-(2-Aminopyrimidin-5- yl)pyridin-3- yl]phenyl}sulfonyl)piperazin-2-one.

688 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(2S)-2- hydroxypropyl]benzenesulfonamide.

689 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(2R)-2- hydroxypropyl]benzenesulfonamide.

690 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-(2-hydroxyethyl)-5- (trifluoromethyl)benzenesulfonamide.

691 5-{5-[2- (Cyclopropylsulfonyl)phenyl]pyridin- 2yl}pyrimidin-2-amine trifluoroacetic acid salt.

692 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-ethyl-5- (trifluoromethyl)benzenesulfonamide trifluoroacetic acid salt.

693 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-tert-butylbenzenesulfonamide.

694 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(1R)-2-hydroxy-1- methylethyl]benzenesulfonamide.

695 3-Amino-6-{2′-[(4-aminopyrimidin-2- yl)oxy]-3-fluorobiphenyl-4- yl}pyrazine-2-carbonitrile trifluoroacetic acid salt.

696 5-(4′-Bromo-2′,3-difluoroblphenyl-4- yl)pyrazin-2-amine.

697 5-(4′-Bromo-2′,3-difluorobiphenyl-4- yl)-1H-pyrrolo[2,3-b]pyridine.

698 5-(3-fluoro-2-methoxy-4′- (trifluoromethyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine.

699 5-(2′,3,4′-Trifluorobiphenyl-4- yl)pyrazin-2-amine

700 racemic 5-[3-Fluoro-2′- (methylsulfinyl)biphenyl-4-yl]pyrazin- 2-amine

701 4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-carbonitrile

702 1-(4′-(5-Aminopyrazin-2-yl)- 3′-fluoro-[1,1′-biphenyl]-2- yl)imidazolidin-2-one

703 4′-(2-Amino-4- cyanopyrimidin-5-yl)-N-tert-butyl-3′- fluorobiphanyl-2-sulfonamide

704 6-Amino-3-{2′-[(1,1- dioxidothiomorpholin-4-yl)sulfonyl]-3- fluorobiphenyl4-yl}pyrazine-2- carbonitrile

705 1-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N- methylazetidine-3-carboxamide

706 4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-(2- hydroxyethyl)biphenyl-2-sulfonamide

707 4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-[(2S)-2- hydroxypropyl]biphenyl-2- sulfonamide

708 4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-[(2R)-2- hydroxypropyl]biphenyl-2- sulfonamide

709 1-((4′-(2-Aminopyrimidin-5- yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidine-4-carboxamide

710 4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluora-N-[(1R)-2-hydroxy-1- methylethyl]piphenyl-2-sulfonamide

711 4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethypiphenyl-2-sulfonamide

712 4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2- sulfonamide

713 4′-(5-Amino-3-cyanopyrazin- 2-yl)-N-ethyl-3′-fluoro-4- (trifluoromethyl)-[1,1′-biphenyl]-2- sulfonamide

714 4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-(3-hydroxy-2,2- dimethylpropyl)biphenyl-2- sulfonamide

715 6-Amino-3-{3-fluoro-2′-[(3- oxopiperazin-1-yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4- yl}pyrazine-2-carbonitrile

716 N-(2-{[4′-(2-Aminopyrimidin- 5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}ethyl)benzamide

717 1-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl)- 3,3-dimethylbutan-2-one

718 5-[3-Fluoro-2′-(pyrimidin-2- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine

719 5-[3-Fluoro-2′-(pyrazin-2- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine

720 5-[3-Fluoro-2′-(pyrimidin-4- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine

721 5-{2′-[(6-Aminopyrimidin-4- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine

722 5-{2′-[(4-Aminopyrimidin-2- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine

723 5-{2′-[(5-Aminopyrazin-2- yl)sulfonyl]-3-fluorobiphenyl-4′- yl}pyrimidin-2-amine

724 4-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrimidin-2-amine

725 5-{2′-[(6-Aminopyrazin-2- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine

726 6-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}pyrimidin-4-amine

727 2.-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}pyrimidin-4-amine

728 5-{2′- [(Cyclopropylmethyl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrimidin-2-amine

729 6-Amino-3-[2′- (cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazine-2- carbonitrile

730 1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarbonitrile

731 1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarboxamide

732 2-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanenitrile

733 2-{[4′-(2-Aminopyridin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanamide

734 5--{2′-[(2-Amino-1,1- dimethylethyl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrimidin-2-amine

735 2-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanenitrile

736 2-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanamide

737 5-{2′-[(2-Amino-1,1- dimethylethyl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrazin-2-amine

738 1-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarbonitrile

739 1-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarboxamide

740 5-(2′-{[1- (Aminomethyl)cyclopentyl]sulfonyl}- 3-fluorobiphenyl-4-yl)pyrimidin-2- amine

741 5-{[4′-(5-Aminopyrazin-2′-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrazin- 2-amine

742 5-{2′-[(6-Aminopyrazin-2- yl)sulfanyl]-fluorobiphenyl-4- yl}pyrazin-2-amine

743 5-(3-Fluoro-2′-(pyrimidin-4- ylthio)-[1,1′-biphenyl]-4-yl)pyrazin-2- amine

744 5-{2′-[(5-Aminopyrazin-2- yl)sulfanyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine

745 6-Amino-3-{2′-[(4-aminopyrimidin-2- yl)oxy]-3-fluorobiphenyl-4- yl}pyrazine-2-carbanitrile

746 6-Amino-3-[3-fluoro-2′-(pyrimidin-2- yloxy)-4′-(trifluoramethyl)biphenyl-4- yl]pyrazine-2-carbonitrile

747 6-Amino-3-[3-fluoro-2′- (pyrimidin-2-yloxy)biphenyl-4- yl]pyrazine-2-carbonitrile

748 N-(tert-Butyl)-3′-fluoro-4′-(5- (methylsulfonamido)pyrazin-2-yl)- [1,1′-biphenyl]-2-sulfonamide

749 5-{2′-[(Ethylsulfonyl)methyl]-3- fluorobiphenyl-4-yl}pyrazin-2-amine hydrogen chloride salt

750 5-{3-Fluoro-2′- [(methylsulfonyl)methyl]biphenyl-4- yl}pyrazin-2-amine

751 5-(3-Fluoro-2′-{[(1- methylethyl)sulfonyl]methyl}biphenyl- 4-yl)pyrazin-2-amine

752 5-{3-Fluoro-2′-(pyrimidin-2- ylsulfonyl)methyl]biphenyl-4- yl}pyrazin-2-amine

753 2-({(4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]methyl}sulfanyl)pyrimidin-4-amine

754 racemic 5-(3-Fluoro-2′-{[2- {trifluoromethyl)morpholin-4- yl]carbonyl}biphenyl-4-yl)pyrazin-2- amine

755 1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]carbonyl}azetidin- 3-ol

756 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (tetrahydro-2H-pyran-4-yl)biphenyl-2- carboxamide

757 5-{2′-[(1,1-Dioxidothiomorpholin-4- yl)carbonyl]-3-fluoro-4′- (trifluoromethyl)biphenyl-4-yl}pyrazin- 2-amine

758 1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl)morpholin-2-yl)ethanol (diastereomeric mixture).

759 1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture).

760 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxyethyl)biphenyl-2- carboxamide

761 4′-(2-4minopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxyethyl)biphenyl-2- carboxamide

762 (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol

763 (cis/trans) 4′-(5-Aminopyrazin-2-yl)- 3′-fluoro-N-(4- hydroxycyclohexyl)biphenyl-2- carboxamide

764 (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol

765 (cis/trans) 4′-(2-Aminopyrimidin-5-yl)- 3′-fluoro-N-(4- hydroxycyclohexyl)biphenyl-2- carboxamide

766 racemic 5-(3-Fluoro-2′-{[2- (trifluoromethyl)morpholin-4- yl]carbonyl}biphenyl-4-yl)pyrimidin-2- amine

767 (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol

768 (3S)-1-{[4-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol

769 (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol

770 (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol

771 (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol

772 (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol

773 5-{2′-[(2,6-Dimethylmorpholin-4- yl)carbonyl]-3-fluorobiphenyl-4- yl)pyrazin-2-amine (diastereoisomeric mixture).

774 5-(3-Fluoro-2′-{[(3S)-3- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrazin-2- amine

775 5-(3-Fluoro-2′-{[(3R)-3- methylmorpholin-4- yl]carbonyl}biphenyyl-4-yl)pyrazin-2- amine

776 5-(3-Fluoro-2′-{[(2S)-2- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrazin-2- amine

777 5-(3-Fluoro-2′-{[(2S)-2- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrimidin-2- amine

778 5-(3-Fluoro-2′-{[(3S)-3- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrimidin-2′- amine

779 5-(3-Fluoro-2′-{[(3R)-3- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrimidin-2- amine

780 5-{2′-[(2,6-Dimethylmorpholin-4- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine (diastereoisomeric mixture)

781 5-{2-Fluoro-4-[2-(morpholin-4- ylcarbonyl)pyridin-3-yl]phenyl]-1H- pyrrolo[2,3-b]pyridine

782 5-{2-Fluoro-4-[2-(morpholin-4- ylcarbonyl)pyridin-3- yl]phenyl}pyrimidin-2-amine

783 5-{2-Fluoro-4-[2-(morpholin-4- ylcarbonyl)pyridin-3- yl]phenyl}pyrazin-2-amine

784 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-N-tert-butyl-5- (trifluoromethyl)benzamide

785 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-N-[(1R)-2-hydroxy-1-methyl- ethyl]-5-(trifluoromethyl)benzamide

786 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-N-[(1S)-2-hydroxy-1-methyl- ethyl]-5-(trifluoromethyl)benzamide

787 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-5-(trifluoromethyl)-N-[(1R)- 2,2,2-trifluoro-1-methyl- ethyl]enzamide

788 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro- phenyl]-5-(trifuoromethyl)-N-[(1S)- 2,2,2-trifluoro-1-methyl- ethyl]enzamide

789 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro- phenyl]-5-(trifluoromethyl)-N-(1R)- 2,2,2-trifluoro-1-methyl- ethyl)benzamide

790 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-5-(trifiuoromethyl)-N-[(1S)- 2,2,2-trifluoro-1-methyl- ethyl]benzamide

791 [2-[4-(2-Aminopyrimidin-5-yl)-3- fluoro-phenyl]phenyl]-(3- hydroxyazetidin-1-yl)methanone

792 [2-[4-(2-Aminopyrimidin-5-yl)-3- fluoro-phenyl]phenyl]-[4- (methylamino)-1-piperidyl]methanone

793 [2-[4-(2-Aminopyrimidin-5-yl)-3- fluoro-phenyl]-5- (trifluoromethyl)phenyl]-(1,1-dioxo- 1,4-thiazinan-4-yl)methanone

794 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro- phenyl]-N-tert-butyl-5- (trifluoromethyl)benzamide

795 [2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-5-(trifluoromethyl)phenyl]-(4- hydroxy-1-piperidyl)methanone

796 [2-[4-(2-Aminopyrimidin-5-yl)-3- fluoro-phenyl]-5- (trifluoromethyl)phenyl]-(4-hydroxy-1- piperidyl)methanone

797 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro- phenyl]-N-tetrahydropyran-4-yl- benzamide

798 racemic [2-]4-(5-Aminopyrazin-2-yl)- 3-fluoro-phenyl]phenyl]-[2- (hydroxymethyl)morpholin-4- yl]methanone

799 racemic [2-[4-(2-Aminopyrimidin-5- yl)-3-fluoro-phenyl]phenyl]-2- (hydroxymethyl)morpholin-4- yl]methanone

800 N-[3-[4-(2-Aminopyrimidin-5-yl)-3- fluorophenyl]pyridin-2-yl}-2,2- dimethylpropanamide

801 N-{3-[4-(5-Aminopyrazin-2-yl)-3- fluorophenyl]pyridin-2-yl}-2,2- dimethylpropanamide

802 N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3- b]pyridin-5-yl)phenyl]pyridin-2-yl}-2,2- dimethylpropanamide

803 racemic 5-(2-Fluoro-4-(2- (pyrrolidin-3-ylsulfonyl)pyridin-3- yl)phenyl)pyrazin-2-amine hydrochloride

804 5-(2-Fluoro-4-(2- (pyrrolidin-3- ylsulfonyl)pyridin-3- yl)phenyl)pyrimidin-2-amine formic acid salt.

805 5-(4-(2- (Cyclobutylsulfonyl)pyridin-3- yl)-2-fluorophenyl)pyrimidin- 2-amine hydrochloride.

806 5-(4-(2- (Cyclobutylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine hydrochloride

807 5-(4-(2- (Cyclohexylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrimidin-2-amine hydrochloride

808 5-(4-(2- (Cyclohexylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine hydrochloride

809 5-(4-2- (Cyclopentylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrimidine-2-amine hydrochloride

810 5-(4-(2- (Cyclopentylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine hydrochloride

811 5-(4-(2-(tert- Butylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrimidin-2-amine formic acid salt.

812 5-(4-(2-(tert- Butylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine formic acid salt.

813 racemic 5-(4-(2-(sec- Butylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrimidin-2-amine formate

814 racemic 5-(4-(2-(sec- Butylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine formate

815 1-((3-(4-(2-Aminopyrimidin-5- yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)piperidin-1-yl)ethanone

816 1-((3-(4-(2-Aminopyrazin-5- yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)piperidin-1-yl)ethanone hydrogen chloride salt

817 5-(2-Fluoro-4-(2-((3- methoxypropyl)sulfonyl)pyridine-3- yl)phenyl)pyrimidin-2-amine hydrogen chloride salt.

818 5-(2-Fluoro-4-(2-((3- methoxypropyl)sulfonyl)pyridine-3- yl)phenyl)pyrazin-2-amine hydrogen chloride salt.

819 4-((3-(4-(2-aminopyrimidin-5- yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide

820 4-((3-(4-(2-Aminopyrazin-5- yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide

821 5-(2-Fluoro-4-(2-((2- morpholinoethyl)sulfonyl)pyridine- 3-yl)phenyl)pyrimidin-2- amine formic acid salt.

822 5-(2-Fluoro-4-(2-((2- morpholinoethyl)sulfonyl)pyridine-3- yl)phenyl)pyrazin-2-amine

823 5-(2-Fluoro-4-(2- (((tetrahydro-2H-pyran-4- yl)methyl)sulfonyl)pyridine-3- yl)pyrimidin-2-amine formic acid salt.

824 5-(2-Fluoro-4-(2- (((tetrahydro-2H-pyran-4- yl)methyl)sulfonyl)pyridine-3- yl)pyrazin-2-amine formic acid salt.

825 5-(2-Fluoro-4-{2-[(1- methylethyl)sulfonyl]pyridin-3- yl}phenyl)pyrimidin-2-amine

826 5-(2-Fluoro-4-(2- (isopropylsulfonyl)pyridine-3- yl)phenyl)-1H-pyrrolo[2,3-b]pyridine

827 5-{2-Fluoro-4-[2-(piperidin-4- ylsulfonyl)pyridin-3- yl]phenyl)pyrimidin-2-amine formic acid salt.

828 5-{4-[2-(Cyclopropylsulfonyl)pyridin- 3-yl]-2-fluorophenyl}pyrimidin-2- amine formic acid salt.

829 5-{4-[2-(Cyclopropylsulfonyl)pyridin- 3-yl]-2-fluorophenyl}pyrazin-2-amine formic acid salt.

830 5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-ylsulfonyl)pyridin-3- yl]phenyl}pyrazin-2-amine hydrochloride

831 5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-ylsulfonyl)pyridin-3- yl]phenyl}pyrimidin-2-amine formic acid salt.

832 5-{2-Fluoro-4-[2-(piperidin-4- ylsulfonyl)pyridin-3-yl]phenyl}pyrazin- 2-amine hydrochloride

833 5-(2,3-Difluorobiphenyl-4-yl)pyrazin- 2-amine.

834 5-(3-Fluoro-2-methoxybiphenyl-4- yl)pyrazin-2-amine.

835 5-[3-Fluoro-2-methoxy-2′- (methylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine.

836 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-fluoro-2′-methoxybiphenyl-2- sulfonamide.

837 N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 2′-methoxybiphenyl-2- yl]methanesulfonamide.

838 5-(3-fluoro-2′-(pyrazin-2-yl-[1,1′- biphenyl]-4-yl)pyrazin-2-amine

839 5-(3-Fluoro-2′-pyrazin-2-ylbiphenyl-4- yl)pyrimidin-2-amine.

840 5,5′-(3′-Fluorobiphenyl-2,4′- diyl)dipyrazin-2-amine.

841 5-[2′-(5-Aminopyrazin-2-yl)-3- fluorobiphenyl-4-yl]pyrimidin-2- amine.

842 5-[2′-(6-Aminopyrazin-2-yl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine.

843 5-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrimidin-2- amine.

844 5-5′-(3′-Fluorobiphenyl-2,4′- diyl)dipyrimidin-2-amine.

845 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 5-(trifluoromethyl)biphenyl-2- yl]pyrimidin-2-amine.

846 5-[3-Fluoro-2′-(2-methoxypyrimidin-5- yl)biphenyl-4-yl]pyrazin-2-amine.

847 5-[3-Fluoro-2′-(1-methyl-1H-pyrazol- 4,yl)biphenyl-4-yl]pyrazin-2-amine.

848 5-(3-Fluoro-2′-pyrimidin-5-ylbiphenyl- 4-yl)pyrazin-2-amine.

849 5-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrimidine-2- carbonitrile.

850 5-[3-Fluoro-2′-(2-morpholin-4- ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin- 2-amine.

851 1-{4-[4-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl)-1H-pyrazol-1-yl}- 2-methylpropan-2-ol.

852 5-[3-Fluoro-2′-(1,2,3,6- tetrahydropyridin-4-yl)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine.

853 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 4-(trifluoromethyl)biphenyl-2- yl]pyrimidin-2-amine.

854 5-{2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]phenyl}pyrimidin-2- amine.

855 5-{5-[2-(2-Aminopyrimidin-5- yl)phenyl]pyridin-2-yl}pyrimidin-2- amine.

856 5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)- 3-fluorobiphenyl-4-yl]pyrazin-2-amine

857 5-[2′-(1,1-Dioxido-1,2-thiazinan-2-yl)- 3-fluorobiphenyl-4-yl]pyrazin-2-amine

858 5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)- 3-fluorobiphenyl-4-yl]pyrimidin-2- amine

859 5-[2-Fluoro-4-(2-pyrrolidin-1- ylpyridin-3-yl)phenyl]pyrazin-2-amine

860 1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrrolidin-2-one

861 5-[2′-(6-Aminopyridin-3-yl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine

862 5-[3-Fluoro-2′-(2-piperazin-1- ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin- 2-amine

863 6-[4-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyridazin-3-amine

864 5-{2′-[1-(2-Aminoethyl)-1H-pyrazol-4- yl]-3-fluorobiphenyl-4-yl]pyrazin-2- amine

865 5-[2′-(6-Aminopyridin-3-yl)-3- fluorobiphenyl-4-yl]pyrimidin-2-amine

866 5-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]-N- methylpyrimidin-2-amine

867 4-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]pyrimidin-2-amine

868 4-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrimidin-2-amine

869 5-{3-Fluoro-2′-[1-(2-methoxyethyl)- 1H-pyrazol-4-yl]biphenyl-4- yl}pyrazin-2-amine

870 5-[3-Fluoro-2′-(1H-pyrazol-4- yl)biphenyl-4-yl]pyrazin-2-amine

871 {4-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-1H-pyrazol-1- yl}acetonitrile

872 5-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- methylpyrimidin-2-amine

873 5-(3-Fluoro-2′-isothiazol-4-ylbiphenyl- 4-yl)pyrazin-2-amine

874 2-{4-[4′-(5-Aminopyrazin-2-yl)-3′- flluoroblphenyl-2-yl-1H-pyrazol-1- yl}ethanol

875 {4-[4′-(2-Aminopyrimidin.-5-yl)-3′- fluorobiphenyl-2-yl]-1H-pyrazol- yl}acetonitrile

876 5-[3-Fluoro-2′-(1H-pyrazo-4- yl)biphenyl-4-yl]pyrimidin-2-amine

877 2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-[(1S)-2,2,2- trifluoro-1- methylethyl]penzenesulfonamide as the hydrochloride salt

878 5-{5-[2-(Cyclopropylsulfonyl)phenyl]- 3-fluoropyridin-2-yl}pyrimidin-2-amine

879 2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-[(2S)-2- hydroxypropyl]benzenesulfonamide

880 2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-[(1S)-2-hydroxy- 1-methylethyl]benzenesulfonamide

881 2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-a-yl]-N-[(1R)-2-hydroxy- 1-methylethyl]benzenesulfonamide

882 2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-(2- hydroxyethyl)benzenesulfonamide.

883 2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3yl]-N-[(1R)-2,2,2- trifluoro-1- methylethyl]benzenesulfonamide

884 5-{2′-[(1,1-Dioxidotetrahydro-2H- thiopyran-4-yl)methoxy]-3- fluorobiphenyl-4-yl}pyrazin-2-amine

885 5-{2′-[(1,1-Dioxidotetrahydro-2H- thiopyran-4-yl)oxy]-3-fluorobiphenyl- 4-yl}pyrazin-2-amine

886 4-(([4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]oxy}methyl)benzoic acid

887 4-({[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]oxy}methyl)benzoic acid

888 4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}benzoic acid

889 4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}benzoic acid

890 4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy)benzamide

891 5-{2′-1(trans-4-Aminocyclohexyl)oxy]- 3-fluorobiphenyl-4-yl}pyrazin-2-amine

892 5-[2′-Amino-3-fluoro-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine

893 5-[2-Fluoro-4-(2-phenylpyridin-3- yl)phenyl]pyrazin-2-amine

894 5-[2-Fluoro-4-(2-phenoxypyridin-3- yl)phenyl]pyrazin-2-amine

895 5-[2-Fluoro-4-(2-phenoxypyridin-3- yl)phenyl]pyrimidin-2-amine

896 5-{2-Fluoro-4-[2-(pyridin-3- yloxy)pyridin-3-yl]phenyl}pyrazin-2- amine

897 5-{2-Fluoro-4-[2- (phenylsulfonyl)pyridin-3- yl]phenyl}pyrazin-2-amine

898 5-{2-fluoro-4-[2- (phenylsulfonyl)pyridin-3- yl]phenyl}pyrimidin-2-amine

899 5-{2-Fluoro-4-[2-(pyridin-3- ylsulfonyl)pyridin-3-yl]phenyl}pyrazin- 2-amine

900 5-(2-Fluoro-4-{2-[(1-methylpyrrolidin- 3-yl)sulfonyl]pyridin-3- yl}phenyl)pyrazin-2-amine

901 5-(2-Fluoro-4-{2-[(1- methylethyl)sulfonyl]-6- (trifluoromethyl)pyridin-3- yl}phenyl)pyrazin-2-amine

902 5-(2-Fluoro-4-{2-[(1- methylethyl)sulfonyl]-6- (trifluoromethyl)pyridin-3- yl}phenyl)pyrimidin-2-amine

903 5-(4-{2-[(1-Acetylpiperidin-3- yl)sulfonyl]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine

904 2-[4-({3-[4-(5-Aminopyrazin-2-yl)-3- fluorophenyl]pyridin-2- yl}sulfonyl)pipendin-1-yl]ethanol

905 (racemic)-1-[4({3-[4-(5- Aminopyrazin-2-yl)-3- fluorophenyl]pyridin-2- yl}sulfonyl)piperidin-1-yl]propan-2-ol

906 5-{2-Fluoro-4-[2-tetrahydro-2H- pyran-4-ylsulfonyl)-6- (trifluoromethyl)pyridin-3- yl]phenyl}pyrazin-2-amine

907 5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-ylsulfonyl)-6- (trifluoromethyl)pyridin-3- yl]phenyl}pyrimidin-2-amine

908 5-(2-Fluoro-4-(2-{[1- (methylsulfonyl)piperidin-4- yl]sulfonyl}pyridin-3- yl)phenyl]pyrazin-2-amine

909 5-(2-Fluoro-4-(2-{[1- (methylsulfonyl)piperidin-4- yl]sulfonyl}pyridin-3- yl)phenyl]pyrimidin-2-amine

910 5-(4-{2-[(1-Acetylpiperidin-4- yl)sulfonyl]-6-(trifluoromethyl)pyridin- 3-yl}-2-fluorophenyl)pyrazin-2-amine

911 5-(4-{2-[(1-Acetylpiperidin-4- yl)sulfonyl]-6-(trifluoromethyl)pyridin- 3-yl}-2-fluorophenyl)pyrimidin-2- amine

912 5-(4-{2-[(1,1-Dioxidotetrahydra-2H- thiopyran-4-yl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine

913 5-(4-{2-[(1,1-Dioxidotetrahydro-2H- thiopyran-4-yl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine

C) Synthesis

The invention provides methods of making the disclosed compounds according to traditional organic synthetic methods as well as matrix or combinatorial synthetic methods. Scheme A described suggested synthetic routes. Using the schemes, the guidelines below, and the examples, a person of skill in the art may develop analogous or similar methods for a given compound that is within the invention. These methods are representative of the synthetic schemes, but are not to be construed as limiting the scope of the invention.

Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. Where the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form or as individual enantiomers or diasteromers by either stereospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers or diastereomers by standard techniques, such as the formation of stereoisomeric pairs by salt formation with an optically active base, followed by fractional crystallization and regeneration of the free acid. The compounds may also be resolved by formation of stereoisomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column. It is to be understood that all stereoisomers, racemic and scalemic mixtures, diastereomers, geometric isomers, and enantiomers thereof are encompassed within the scope of the present invention.

Representative compounds of the present invention can be synthesized in accordance with the general synthetic schemes described below and are illustrated more particularly in the specific synthetic examples that follow. The general schemes are offered by way of illustration; the invention should not be construed as being limited by the chemical reactions and conditions expressed. The methods for preparing the various starting materials used in the schemes and examples are well within the skill of persons versed in the art. No attempt has been made to optimize the yields obtained in any of the example reactions. One skilled in the art would know how to increase such yields through routine variations in reaction times, temperatures, solvents and/or reagents.

General: ¹H and ¹³C NMR spectra were measured on a Bruker AC-300 (300 MHz) spectrometer using tetramethylsilane and the deuterated solvent respectively as internal standards. Elemental analyses were obtained by Quantitative Technologies Inc. (Whitehouse, N.J.) and the results were within 0.4% of the calculated values unless otherwise mentioned. Melting points were determined in open capillary tubes with a Mel-Temp II apparatus (Laboratory Devices Inc.) and were uncorrected. Electrospray mass spectra (MS-ESI) were recorded in the positive mode on a Hewlett Packard 59987A spectrometer. High resolution mass spectra (HRMS) were obtained on a Micromass Autospec. E spectrometer by fast atom bombardment (FAB) technique.

Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

Examples of the described synthetic routes include Scheme A-G, Intermediates A-HZ. Examples 1-588 and prophetic Examples 1-247. Compounds analogous to the target compounds of these examples can be made according to similar routes. The disclosed compounds are useful as pharmaceutical agents as described herein.

Abbreviations or acronyms useful herein include:

Abbreviation Meaning BOC/boc tert-butyloxycarbonyl BOP benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate Cpd compound DCE dichloroethane DCM dichloromethane DIPEA diisopropyl ethyl amine DMA N,N-dimethylacetamide DMAP N,N-dimethylaminopyridine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide DPBS Dulbecco's phosphate buffered saline EDC 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride ESI electrospray ionization Et₃N or TEA triethylamine EtOAc ethyl acetate h/hr/hrs hour(s) HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate HOBT 1-hydroxybenzotriazole hydrate HBTU O-benzotriazol-1-yloxy-N,N,N′,N′-tetramethyluronium hexafluorophosphate I.D. interior diameter LG Leaving group LiOH lithium hydroxide m-CPBA meta-chloroperoxybenzoic acid min minute(s) MS mass spectroscopy NMR nuclear magnetic resonance spectroscopy OTf Triflate PG protecting group RT/rt room temperature TBME tert-butyl methyl ether THF tetrahydrofuran TLC thin layer chromatography Tos p-toluenesulfonyl dppf 1,1′-Bis(diphenylphosphino)ferrocene General Guidance Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated more particularly in the schemes that follow. Since the schemes are illustrations, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art. The substituents for compounds of Formula (I) or a form thereof, represented in the schemes below, are as previously defined herein.

Unless otherwise specified, reaction solutions were stirred at room temperature under a N_(2(g)) or Ar_((g)) atmosphere. When solutions were “concentrated to dryness”, they were concentrated using a rotary evaporator under reduced pressure, when solutions were dried, they are typically dried over a drying agent such as MgSO₄ or Na₂SO₄.

Normal phase flash column chromatography (FCC) was performed on silica gel with RediSep® silica gel columns using ethyl acetate (EtOAc)/hexanes, CH₂Cl₂/MeOH, CH₂Cl₂/10% 2 N NH₃ in MeOH, CH₂Cl₂/i-PrOH, and the like as eluent, unless otherwise indicated.

Reverse phase high performance liquid chromatography (HPLC) was performed under the following conditions: 1) Instrument, Shimadzu; Column, Waters XBridge C18 10 μm (250×50 mm), Phenomenex Gemini column 5 μm C18 (150×21.2 mm) or Waters Xterra RP18 OBD 5 μm (100×30 mm); Gradient, 95:5 to 0:100 water (0.05% trifluoroacetic acid (TFA))/CH₃CN (0.05% TFA); Flow rate, 30-80 mL/min; Detection, UV at λ=220-254 nM; 2) Instrument, Gilson; Column, Phenomenex LUNA column 5 μm C18 (250×50 mm) or Waters XBridge Prep C18 OBD 5 μm (30×150 mm); Gradient, 95:5 to 0:100 water (0.05% TFA)/CH₃CN (0.05% TFA); Flow rate, 30-80 mL/min; Detection, UV at λ=220-254 nM; 3) Instrument. Gilson/Shimadzu: Column, Inertsil ODS-3 column (30×100 mm) or Inertsil ODS-3 (30×50 mm, 5 μm); Gradient, water-acetonitrile with both phases with 0.05% by volume trifluoroacetic acid; 1 min hold at 5% ACN, then 6 min gradient to 99% ACN followed by a hold at that concentration for 3 min. Flow rate, 80 ml/min; heated column at 46° Celsius with detection of UV light at λ=254 nm; and 4) Instrument, Dionex: UVD 170U Diode array detector and ThermoFinnegan Surveyor MSQ plus mass spectrometer for data collection. Waters XBridge C18 5 μm OBD 50×100 mm prep column.

All runs on the Dionex utilized water acetonitrile with 20 mM NH₄OH added to the aqueous phase and a flow rate for all gradients was 80 mL/min using four possible gradients: 1) 5-60% MeCN over 12 min, then ramped to 100% MeCN and held for 6.3 min; 2) 30-70% MeCN over 12 min, then ramped to 100% MeCN and held for 6.3 min; 3) 50-80% MeCN over 12 min, then ramped to 100% MeCN and held for 6.3 min; and 4) 60-100% MeCN over 12 min, and then held for 6.3 min. The total run time for all gradient systems was 18.5 min.

Instances where solutions were filtered through a syringe filter, Pall 0.45 μM GHP membrane 13 mm and 25 mm diameter syringe filters were used

Thin-layer chromatography was performed using Merck silica gel 60 F₂₅₄ 2.5 cm×7.5 cm 250 μm or 5.0 cm×10.0 cm 250 m pre-coated silica gel plates. Preparative thin-layer chromatography was performed using EM Science silica gel 60 F₂₅₄ 20 cm×20 cm 0.5 mm pre-coated plates with a 20 cm×4 cm concentrating zone. Microwave reactions were carried out in either a CEM Discover™ or a Biotage Initiator™ or Optimizer™ Microwave at specified temperatures. Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated mass corresponds to the exact mass.

NMR spectra were obtained on either a Bruker model DPX400 (400 MHz), DPX500 (500 MHz), DRX600 (600 MHz) spectrometer. The format of the ¹H NMR data below is: chemical shift in ppm down field of the tetramethylsilane reference (multiplicity, coupling constant J in Hz, integration).

Hydrochloride salts were obtained by treating the corresponding free bases with HCl (4 N in dioxane, 2 M in Et₂O, or 1.25 N in MeOH) at room temperature with mixtures either concentrated to obtain the HCl salt, or the resulting solid being isolated by filtration. Trifluoroacetic acid salts were obtained by purification of the crude reaction product by preparative reverse phase HPLC, whereby the final products were isolated as either mono-, di- or tri-fluoro acetic acid salts.

Chemical names were generated using ChemDraw Ultra 12.0 (CambridgeSoft Corp., Cambridge, Mass.) or ACD/Name Version 10.01 (Advanced Chemistry).

The compounds of Formula (I), wherein ring A, L, V, W, R, R′, n, R₁, R₂, R₃, and R₄ are defined as in Formula (I), may be synthesized as outlined by the general synthetic route illustrated in Scheme A-G.

Referring to Scheme A, compounds of formulae (XI) can be obtained through a series of metal mediated cross coupling reactions starting from compound (XIII). Compounds of formulae (XIV) in which Ar¹ can be an amine substituted or des-amino 5-, 6-membered or 5/6- or 6/6-fused aromatic or heteroaromatic nitrogen containing ring system, can be prepared via Pd mediated cross coupling of either an aryl or heteroaryl boronic acid or ester, Ar¹—B(OP)₂, with intermediates of structure (XIII) in which W is bromo or chloro, Y is an alkyl, hetero-alkyl, aryl, or heteroaryl and Z is H, fluoro, alkyl or heteroalkyl. In instances where W is either bromo or chloro, the boronic acid or ester of compound (XIII) can be formed via palladium catalysis using bis(pinacolato)diboron and KOAc in the presence of [1,1′-bis(diphenylphosphino)ferrocene]-dichloro-palladium(II).CH₂Cl₂ (Pd(dppf)Cl₂.CH₂Cl₂) or the X-Phos pre-catalyst in solvents such as 1,4-dioxane or DMSO, at temperatures ranging from 0-100° Celsius. Alliteratively, compounds of Formulae (XIII) in which W is B(OP)₂ can be cross-coupled with an aryl or heteroaryl halide, Ar¹⁻X where X is either bromo or chloro to obtain compounds of formulae (XII). Preferably, in compounds of formulae (XII), Y is t-butyl, cyclobutyl, trifluoromethoxy, or SF₅, Z is H or -fluoro ortho to Ar¹, and Ar¹ iseither amino-pyrazine, amino-pyrimidine, or amino-pyridine alliteratively substituted with or without CN, CH₃, OCH₃, CF₃, Cl, F, OH, and NH₂. Preferred solvents for cross coupling reactions include DME, DMSO, 1,4-dioxane, THF, EtOH DMF, water, and toluene or mixtures thereof, in the presence of a base, such as Na₂CO₃, K₂CO₃, KOAc, KH₂PO₄, and K₃PO₄ using catalysts such as Pd(dppf)Cl₂.CH₂Cl₂, palladium trifluoroacetate and PhP₃, chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl)]-palladium(II), 1,1′-bis[di-t-butylphosphino)ferrocene]palladium chloride with temperatures ranging from rt to 100° Celsius.

Compounds of formulae (XI) can be prepared from compounds of formulae (XIII) via sequential (XIII→XIV→XI or XIII→XV→XI) Pd mediated cross-coupling using methods and intermediates, analogous to those described above compounds of formulae (XV) can be obtained via compounds of formulae (XIII), wherein Y is a boronic acid or ester and W is bromo or chloro, Compounds of formulae (XIII) in which Y is the boronic acid or ester can be obtained from the corresponding iodide wherein W is either bromo or chloro. Preferred methods for conversion of the iodo to the corresponding boronic acid or ester are analogous to the methods described above. In some cases, aryl and heteroaryl halides, boronic esters and acids are commercially available or can be prepared by known methods.

Compounds (XIV) in which Y is alkyl or cycloalykyl can be obtained from the corresponding bromide using alkylzinc bromides in solvents such as THF in the presence of palladium acetate and 2-dicyclohexylphosphine-2′,6′-dimethoxy-1,1′-biphenyl at temperatures ranging from rt to 100° Celsius.

In further embodiments, compounds of formulae (XI) containing a pyridine core, where Z is H or -fluoro ortho to Ar¹, can be prepared using analogous Pd mediated cross coupling reactions described herein.

Referring to Scheme B, substituted aryl and heteroaryl sulfonamides (XVI) possessing from 0 to 3 G groups, where a G group is alkyl, cycloalkyl, heteroalkyl, CF₃, F, Cl, Br, or combinations thereof, and where X is bromo or chloro, can be prepared by addition of various primary and secondary amines to the aryl or heteroaryl sulfonyl chloride in solvents such as CH₂Cl₂, CH₃CN, THF, and DMF in the presences of bases such as pyridine, Et₃N and i-Pr₂EtNH at temperatures ranging from −20° to 1000 Celsius.

Alliteratively, sulfones (XVI) can be obtained from the corresponding bromo or chloro aryl thiol (XVIII). S_(N)1 substitution in the presence of a strong acid, such as H₂SO₄, with an appropriately reactive alcohol, such as tert-butanol, provides the desired aryl sulfide. Additionally, one can obtain substituted aryl sulfides via S_(N)2 or S_(N)Ar displacement of alkyl or aryl bromide, chloride, and fluorides (aryl only) under basic conditions using bases such as NaH or i-Pr₂EtNH and the desired in solvents such as THF, DMSO, and DMF at temperatures ranging from rt to 1000 Celsius. Sulfone (XVI) can then be obtained via oxidation of the sulfide using an appropriate oxidant such as m-CPBA, oxone, or RuCl₃/NalO₄.

Referring to Scheme C, sulfonamides of formulae (XIX) can be prepared from an aniline (XX) possessing from 0 to 3 G groups G, where a G group can be a variety of alky, heteroalkyl, F, Cl, Br, CF₃, or combinations thereof, and X is bromo, chloro, B(OH)₂, or B(OP)₂, by treatment with an appropriate sulfonyl chloride on which R is alkyl, cycloalkyl, substituted aryl, substituted heteroaryl or CF₃, in a solvent, such as CH₂Cl₂, in the presence of a base, such as pyridine, at temperatures ranging from 0° to 100° Celsius.

Referring to Scheme D, methanesulfonamides of formulae (XXI) can be prepared by treatment of a substituted (halomethyl)benzene, where X is bromo or chloro and possessing 0 to 3 G groups, which can be a variety of alkyl, cycloalkyl, heteroalkyl, F, Cl, Br, CF₃, or combinations thereof, with sodium sulfite to provide the desired arylmethyl sulfonate which can be subsequently treated with phosphorous pentachloride to provide the desired arylmethylsulfonyl chloride (XXIII). Sulfonyl chlorides (XXIII) can then be transformed to the corresponding sulfonamide (XXI) using methods described herein.

Referring to Scheme E, variously substituted amides (XXIV) can be prepared using standard amide coupling reactions. Substituted carboxylic acid (XXV), where X is bromo or chloro, and possessing 0 to 3 G groups, which can be a variety of alkyl, cycloalkyl, heteroalkyl, F, Cl, Br, CF₃, or combinations thereof, can be treated with various primary and secondary amines using standard carbodiimide peptide coupling reagents, such as HATU or EDCl, in solvents such as DMF and CH₂Cl₂, at temperatures ranging from 0-60° Celsius, to provide amide (XXIV).

Referring to Scheme F, phenyl ethers of formulae (XXVI) can be prepared from the corresponding phenol (XXVII), where X is bromo or chloro, and possessing 0 to 3 G groups, which can be a variety of alkyl, cycloalkyl, heteroalkyl, F, Cl, Br, CF₃, or combinations thereof, and n=0, 1. Treatment of phenol (XXVII) with appropriately substituted halo aromatic heterocycles, where halo refers to F, Cl, and Br, or halomethyl aromatic heterocycles in which halo refers to Cl or Br, a base, such as Cs₂CO₃, K₂CO₃, or Na₂CO₃, In a polar solvent, such as DMSO, CH₃CN, or DMF at temperatures ranging from rt to 100° Celsius, provides ethers (XXVI).

Referring to Scheme G, instances where Ar¹ in Scheme A is a 5-, 6-membered, or 5/5-, 5/6-fused heterocyle, compounds of formulae (XXVIII) and (XXX) can be obtained starting from methyl ketone (XXIX). Treatment of the ketone with either urea or thiourea in the presence of I₂ in EtOH at temperatures ranging from rt to 80° Celsius results in the corresponding five-membered amino heterocycle (XXVIII). Whereas, treatment of the ketone under analogous conditions with substituted 2-amino pyridines, possessing 0 to 3 G groups, which can be a variety of alkyl, cycloalkyl, heteroalkyl. F, Cl, Br, CF₃, or combinations thereof, results in a substituted fused 5/6 heterocycle (XXX).

EXAMPLES

The following examples are offered by way of illustration: the invention should not be construed as being limited by the chemical reactions and conditions expressed.

Intermediate A

Method 1

To a 250 mL round-bottomed flask were added a stirbar, 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (3.07 g, 11.5 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (5.82 g, 22.9 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (512 mg, 0.623 mmol), and KOAc (2.30 g, 23.4 mmol). The flask was then thoroughly sparged with nitrogen and then charged with 1,4-dioxane (114 mL, sparged with N₂ for 30 min). The flask was then heated at 80° Celsius for 19.5 hours before cooling to rt, filtering the reaction mixture through Na₂SO₄ and concentrating the filtrate to dryness. The residue was purified by FCC to give the title compound. MS (ESI): mass calcd. for C₁₆H₁₉BFN₃O₂, 315.16; m/z found, 316.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.38 (dd, J=2.4, 1.5, 1H), 8.02 (d, J=1.5, 1H), 7.96-7.89 (m, 1H), 7.56 (dd, J=7.7, 1.1, 1H), 7.42 (dd, J=11.8, 1.1, 1H), 6.77 (s, 2H), 1.31 (s, 12H).

Method 2 Step A: 5-(4-Bromo-2-fluorophenyl)pyrazin-2-amine

To a solution of 5-bromopyrazin-2-amine (1.74 g, 10.0 mmol) in 1,4-dioxane (40 mL) were added 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.65 g, 10.5 mmol) and KOAc (1.96 g, 20.0 mmol). The mixture was sparged with N₂ several times before adding Pd(dppf)Cl₂.CH₂Cl₂ (0.41 g, 0.5 mmol). The resultant mixture was stirred at 90° Celsius for 60 hours under N₂. After cooling to rt, 4-bromo-2-fluoro-1-iodobenzene (4.5 g, 15.0 mmol), K₂CO₃ (2.76 g, 20.0 mmol) and another portion of Pd(dppf)Cl₂.CH₂Cl₂ (0.41 g, 0.5 mmol) were added. The resultant mixture was sparged with N₂ again, and stirred at 80° Celsius for 48 hours under N₂. The mixture was then cooled to rt, diluted with THF (30 mL) and filtered. The filtrate was concentrated to dryness and the residue purified by FCC to give 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (0.4 g, 15%). ¹H NMR (300 MHz, DMSO-d₆) δ 8.33 (s, 1H), 8.01 (s, 1H), 7.82 (m, 1H), 7.63 (dd, J=11.1, 2.1, 1H), 7.50 (dd, J=8.4, 2.1, 1H), 6.75 (s, 2H).

Step B

To a solution of 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (535 mg, 2.0 mmol) in 1,4-dioxane (20 mL) was added 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.1 g, 4.0 mmol) and KOAc (0.39 g, 4.0 mmol). The mixture was sparged by bubbling N₂ for 10 min. The mixture was treated with Pd(dppf)Cl₂.CH₂Cl₂ (82 mg, 0.1 mmol) and then stirred at 80° Celsius for 1 hour under N₂. After cooling to rt, the reaction mixture was filtered through Na₂SO₄ and the filtrate concentrated to dryness. The residue was purified by FCC to give the title compound (460 mg, 72%).

Intermediate B

Step A: 6-Amino-3-(4-chloro-2-fluorophenyl)pyrazine-2-carbonitrile

To a 200 mL round-bottomed flask were added a stirbar, 5-amino-3-cyano-2-bromopyrazine (4.09 g, 20.5 mmol), 4-chloro-2-fluorophenylboronic acid (3.90 g, 22.4 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (839 mg, 1.03 mmol) and K₂CO₃ (8.36 g, 60.5 mmol). The flask was flushed with nitrogen and then charged with toluene (17.5 mL), water (17.5 mL) and DMF (10.5 mL), all of which were sparged with N₂. The flask was heated at 80° Celsius for 19 hours before cooling to rt and adding MgSO₄ until the mixture was a thick paste. The reaction mixture was then stirred with EtOAc and filtered through a thick pad of celite. The pad was rinsed with EtOAc until the filtrate was colorless. The filtrate was concentrated to dryness and subjected to FCC to give 6-amino-3-(4-chloro-2-fluorophenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C₁₁H₆ClFN₄, 248.03; m/z found, 249.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d) δ 8.22 (s, 1H), 7.67-7.60 (m, 2H), 7.46 (dd, J=8.4, 2.0, 1H), 7.37 (s, 2H).

Step B

To a 200 mL round-bottomed flask were added a stirbar, 6-amino-3-(4-chloro-2-fluorophenyl)pyrazine-2-carbonitrile (1.175 g, 4.73 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.583 g, 6.23 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (194 mg, 0.247 mmol), and KOAc (1.43 g, 14.6 mmol). The flask was fitted with a septum and sparged with nitrogen for 30 min before adding 48 mL of thoroughly N₂ sparged THF via syringe. The mixture was then heated at 80° Celsius for 16.5 hours before cooling the mixture to rt and concentrating to dryness. The dark residue was taken up in DCM, filtered through a plug of celite, and concentrated to dryness. The residue was subjected to FCC to give the title compound. ¹H NMR (600 MHz, DMSO-d₆) δ 8.23 (s, 1H), 7.66-7.58 (m, 2H), 7.53-7.46 (d, J=10.2, 1H), 7.40 (s, 2H), 1.34 (s, 12H).

Intermediate C

Step A: 4-Bromo-2-fluorobenzoyl chloride

A solution of 4-bromo-2-fluorobenzoic acid (10.8 g, 50.0 mmol) in SOCl₂ (50 mL) was stirred at 70° Celsius for 1 hour. After cooling to rt, the resulting mixture was concentrated to give 4-bromo-2-fluorobenzoyl chloride as colorless oil, which was used directly in the next step without purification.

Step B: 2-(4-Bromo-2-fluorobenzoyl)-hydrazinecarbothioamide

Hydrazinecarbothioamide (6.8 g, 75 mmol) was added to a solution of 4-bromo-2-fluorobenzoyl chloride (11.8 g, 50.0 mmol) in THF (50 mL) at rt and stirred for 1 hour. The reaction mixture was concentrated to give 2-(4-bromo-2-fluorobenzoyl)-hydrazinecarbothioamide as a white solid, which was used directly in the next step without purification. MS (ESI): mass calcd. for C₈H₇BFN₃OS, 290.95, m/z found, 292.1 [M+H]⁺.

Step C: 5-(4-Bromo-2-fluorophenyl)-1,3,4-thiadiazol-2-amine

H₂SO₄ (2 mL) was added to a solution of 2-(4-bromo-2-fluorobenzoyl)-hydrazinecarbothioamide (2.9 g, 10.0 mmol) in pentanoic acid (5 mL) and the resulting mixture was stirred at 110° Celsius for 2 hours. After cooling to rt, the reaction mixture was poured into ice-water (20 mL) and treated with NH₃.H₂O (15 mL). 5-(4-Bromo-2-fluorophenyl)-1,3,4-thiadiazol-2-amine was then isolated via vacuum filtration and air dried. MS (ESI): mass calcd. for C₈H₅BFN₃OS, 272.94, m/z found, 274.1 [M+H]⁺.

Step D

To a solution of 5-(4-bromo-2-fluorophenyl)-1,3,4-thiadiazol-2-amine (2.73 g, 10.0 mmol) in 1,4-dioxane (20 mL) were added 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.54 g, 10.0 mmol) and KOAc (1.5 g, 20.0 mmol). The mixture was sparged with N₂ for 10 min. Pd(dppf)Cl₂.CH₂Cl₂ (82 mg, 0.1 mmol) was then added, and the mixture, stirred at 80° Celsius for 1 hour under N₂. After cooling to rt, the reaction mixture was filtered through a pad of anhydrous Na₂SO₄ and the filtrate concentrated to dryness. The residue was purified by FCC to give the title compound. MS (ESI): mass calcd. for C₁₄H₁₇N₃BO₂SBr 321.11, m/z found 322.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.28-8.19 (m, 1H), 7.65 (dd, J=7.8, 1.0, 1H), 7.57 (d, J=11.3, 1H), 5.39 (s, 2H), 1.36 (s, 12H).

Intermediate D

Step A: 4′-Bromo-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-sulfonamide

1-Bromo-2-fluoro-4-iodobenzene (6.30 g, 20.9 mmol) and (2-(N-methyl-sulfamoyl)-phenyl) boronic acid (4.50 g, 20.9 mmol) were added to a 250 mL flask equipped with a stir bar and reflux condenser. 1,4-Dioxane (50 mL) and Na₂CO₃ (2 M, 50 mL) were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 minutes before Pd(dppf)Cl₂.CH₂Cl₂ (766 mg, 1.05 mmol) was added and the reaction was stirred at 80° Celsius for 15 hours. The reaction was then diluted with 50 mL of water and extracted with ethyl acetate (1×50 mL, 3×100 mL). The combined organic extracts were dried with Na₂CO₃, filtered and concentrated to dryness. The crude product was purified by FCC to give 4′-bromo-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-sulfonamide. ¹H NMR (500 MHz, CDCl₃) δ 8.17-8.11 (m, 1H), 7.66-7.59 (m, 2H), 7.59-7.54 (m, 1H), 7.33-7.29 (m, 1H), 7.28-7.23 (m, 1H), 7.20-7.13 (m, 1H), 3.67-3.56 (dd, J=10.1, 4.5, 1H), 2.46-2.43 (d, J=5.3, 3H).

Step B: 3′-Fluoro-N-methyl-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide

4′-Bromo-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-sulfonamide (2.0 g, 5.8 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.95 g, 11.6 mmol) and anhydrous KOAc (1.71 g, 17.4 mmol) and 1,4-dioxane (50 mL) were added to a flask, equipped with a stir bar and reflux condenser. The reaction mixture was sparged with argon for 10 min, before adding Pd(dppf)Cl₂.CH₂Cl₂ (0.425 g, 0.58 mmol) was added. The flask was heated at 80° Celsius for 15 hours before cooling to rt, diluting with ethyl acetate (50 mL), filtering through Na₂SO₄ and concentrating to dryness. The crude product was purified by FCC to provide the title compound. ¹H NMR (400 MHz, CDCl₃) δ 8.19-8.12 (dd, J=7.8, 1.4, 1H), 7.87-7.78 (dd, J=7.6, 6.2, 1H), 7.64-7.59 (dd, J=7.5, 1.5, 1H), 7.58-7.51 (m, 1H), 7.35-7.27 (m, 2H), 7.19-7.11 (dd, J=9.6, 1.5, 1H), 3.57-3.45 (d, J=5.5, 1H), 2.41-2.37 (d, J=5.4, 3H), 1.39 (s, 12H).

Intermediate E

The title compound was prepared in a manner similar to that described for Intermediate D using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid in Step A. ¹H NMR (400 MHz, CDCl₃) δ 8.17 (dd, J=7.9, 1.4, 1H), 7.81 (dd, J=7.6, 6.2, 1H), 7.62-7.53 (m, 1H), 7.53-7.46 (m, 1H), 7.36-7.30 (m, 1H), 7.29-7.27 (m, 1H), 7.19 (dd, J=9.9, 1.5, 1H), 3.61 (s, 1H), 1.39 (s, 12H), 1.04 (s, 9H).

Intermediate F

The title compound was prepared in a manner similar to that described for Intermediate D using 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide in Step A. ¹H NMR (500 MHz, CD₃OD) δ 8.09-8.03 (dd, J=8.0, 1.3, 1H), 7.76-7.70 (dd, J=7.6, 6.2, 1H), 7.68-7.62 (m, 1H), 7.61-7.54 (dd, J=8.5, 7.1, 1H), 7.37-7.31 (dd, J=7.5, 1.4, 1H), 7.24-7.20 (dd, J=7.6, 1.5, 1H), 7.16-7.11 (dd, J=10.0, 1.5, 1H), 3.48-3.43 (t, J=5.9, 2H), 2.88-2.82 (t, J=5.9, 2H), 1.37 (s, 12H).

Intermediate G

The title compound was prepared using analogous methods described in Intermediate D using 7-amino-5-bromoindole in Step A. MS (ESI): mass calcd. for C₂₀H₂₂BFN₂O₂, 352.18; m/z found, 353.3 [M+H]⁺.

Intermediate H

To a solution of 3-amino-6-bromopyrazine-2-carbonitrile (2.00 g, 9.55 mmol) in 1,4-dioxane (48 mL), were added (4-chloro-2-fluorophenyl)boronic acid (1.66 g, 9.55 mmol) and aqueous Na₂CO₃ (2 M, 24 mL, 48 mmol) and the reaction mixture sparged with N₂ gas for 10 min. Pd(dppf)Cl₂.CH₂Cl₂ (0.349 g, 0.477 mmol) was then added and the reaction mixture sparged for an additional 10 min with N₂ gas. The reaction vessel was sealed and heated for 3 hours at 80° Celsius. The mixture was cooled to rt, filtered through celite, and the filter cake washed with EtOAc (300 mL). The filtrate was washed with a 1:1 mixture of brine/H₂O (2×100 mL). The organic phase was concentrated to dryness and subjected to FCC to give the title compound (1.99 g, 84%). MS (ESI): mass calcd. for C₁₁H₆ClFN₄, 248.03; m/z found 249.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, J=2.0, 1H), 7.83 (m, 1H), 7.25-7.08 (m, 2H), 5.36 (s, 2H).

Intermediate I

To a solution of 3-amino-6-(4-chloro-2-fluorophenyl)pyrazine-2-carbonitrile (0.290 g, 1.17 mmol) in 1,4-dioxane (12 mL), were added (4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.370 g, 1.46 mmol) and KOAc (0.343 g, 3.50 mmol). The reaction mixture sparged with N₂ gas for 10 min, before adding chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (18 mg, 0.023 mmol) and then sparged for an additional 10 min with N₂ gas. The reaction vessel was sealed, heated 3 hours at 80° Celsius and cooled to rt. The mixture was filtered through celite and the filter cake washed with EtOAc (30 mL). The filtrate was concentrated in vacuo onto silica gel and purified via FCC to give the product which was then triturated with hexanes to give 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile (0.25 g, 63%). MS (ESI): mass calcd. for C₁₇H₁₈BFN₄O₂, 340.15; m/z found 341.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.79 (d, J=1.8, 1H), 7.94 (m, 1H), 7.67 (dd, J=7.7, 1.1, 1H), 7.58 (dd, J=11.8, 1.1, 1H), 5.35 (s, 2H), 1.36 (s, 12H).

Intermediate K

To a 20 mL vial were added a stirbar, 2-bromobenzene-1-sulfonyl chloride (1.053 g, 4.12 mmol), cyclohexylamine (431 mg, 4.34 mmol) and dry pyridine (5 mL). The mixture was stirred for 3 hours before adding it to a separatory funnel containing 1 N HCl and EtOAc. The layers were mixed thoroughly and then separated. The organic layer was then washed with water followed by sat. NaHCO₃, dried over MgSO₄, filtered and evaporated to dryness to give the title compound. MS (ESI): mass calcd. for C₁₂H₁₆NO₂SBr 317.01, m/z found 318.0 [M+H]⁺; ¹H NMR (500 MHz, CDCl₃) δ 8.14 (dd, J=7.9, 1.7, 1H), 7.71 (dd, J=7.9, 1.2, 1H), 7.49-7.42 (m, 1H), 7.42-7.35 (m, 1H), 5.05 (d, J=7.7, 1H), 3.19-3.04 (m, 1H), 1.79-1.66 (m, 2H), 1.66-1.57 (m, 2H), 1.52-1.44 (m, 1H), 1.28-1.04 (m, 5H).

Intermediate L

The title compound was prepared using analogous conditions to those described in Intermediate K using cyclopropylamine. ¹H NMR (500 MHz, CDCl₃) 8.19 (dd, J=7.8, 1.8, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.51-7.45 (m, 1H), 7.44-7.39 (m, 1H), 5.46 (s, 1H), 2.21-2.08 (m, 1H), 0.69-0.60 (m, 2H), 0.60-0.51 (m, 2H).

Intermediate M

The title compound was prepared using analogous conditions to those described in Intermediate K using cyclopentylamine. ¹H NMR (500 MHz, DMSO-d₆) δ 8.02 (dd, J=7.7, 1.8, 1H), 7.84 (dd, J=7.8, 1.3, 2H), 7.61-7.55 (m, 1H), 7.55-7.50 (m, 1H), 3.51-3.40 (m, 1H), 1.64-1.49 (m, 4H), 1.45-1.30 (m, 4H).

Intermediate N

The title compound was prepared using analogous conditions to those described in Intermediate K using isobutylamine. ¹H NMR (500 MHz, CDCl₃) δ 8.12 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.9, 1.3, 1H), 7.48-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.18-5.03 (m, 1H), 2.67 (t, J=6.6, 2H), 1.78-1.64 (m, 1H), 0.87 (d, J=6.7, 6H).

Intermediate O

The title compound was prepared using analogous conditions to those described in Intermediate K using 2-phenethylamine. ¹H NMR (600 MHz, CDCl₃) δ 8.14-8.09 (dd, J=7.9, 1.7, 1H), 7.69-7.63 (dd, J=7.8, 1.2, 1H), 7.47-7.42 (m, 1H), 7.42-7.36 (m, 1H), 7.29-7.24 (m, 2H), 7.24-7.17 (m, 1H), 7.12-7.06 (m, 2H), 5.16-5.00 (t, J=6.1, 1H), 3.23-3.10 (m, 2H), 2.84-2.73 (t, J=7.0, 2H).

Intermediate P

The title compound was prepared using analogous conditions to those described in Intermediate K using cyclopropylmethylamine. ¹H NMR (500 MHz, CDCl₃) δ 8.18 (dd, J=7.8, 1.7, 1H), 7.70 (dd, J=7.9, 1.2, 1H), 7.50-7.43 (m, 1H), 7.42-7.36 (m, 1H), 5.52 (s, 1H), 1.17-1.09 (m, 3H), 0.89-0.76 (m, 2H), 0.50-0.41 (m, 2H).

Intermediate Q

The title compound was prepared using analogous conditions to those described in Intermediate K using 2,3-dihydro-1H-inden-2-amine. ¹H NMR (600 MHz, DMSO-d₆) δ 8.34-8.27 (d, J=7.0, 1H), 8.09-8.04 (dd, J=7.7, 1.8, 1H), 7.91-7.85 (dd, J=7.8, 1.3, 1H), 7.64-7.54 (m, 2H), 7.17-7.06 (m, 4H), 4.01-3.92 (m, 1H), 2.98-2.89 (m, 2H), 2.87-2.79 (m, 2H).

Intermediate R

The title compound was prepared using analogous conditions to those described in Intermediate K using racemic 2-amino-1,1,1-trifluoropropane. ¹H NMR (500 MHz, CDCl₃) 8.10 (dd, J=7.7, 1.9, 1H), 7.74 (dd, J=7.7, 1.4, 1H), 7.49-7.38 (m, 2H), 5.33 (d, J=9.8, 1H), 4.03-3.88 (m, 1H), 1.29 (d, J=7.0, 3H).

Intermediate S

The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-2-amino-1,1,1-trifluoropropane.

Intermediate T

The title compound was prepared using analogous conditions to those described in Intermediate K using racemic (endo)-bicyclo[2.2.1]heptan-2-amine ¹H NMR (500 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 1.8, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.49-7.42 (m, 1H), 7.42-7.37 (m, 1H), 4.98 (d, J=7.1, 1H), 3.17-3.04 (m, 1H), 2.27-2.14 (m, 1H), 2.05 (d, J=3.7, 1H), 1.62-1.50 (m, 1H), 1.45-1.28 (m, 3H), 1.28-1.17 (m, 1H), 1.17-1.08 (m, 1H), 1.05-0.91 (m, 2H).

Intermediate U

The title compound was prepared using analogous conditions to those described in Intermediate K using cyclobutylmethylamine. ¹H NMR (500 MHz, CDCl₃) δ 8.12 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.36 (m, 1H), 5.04 (d, J=6.0, 1H), 2.89 (dd, J=7.4, 6.1, 2H), 2.45-2.31 (m, 1H), 2.04-1.91 (m, 2H), 1.90-1.71 (m, 2H), 1.64-1.52 (m, 2H).

Intermediate V

The title compound was prepared using analogous conditions to those described in Intermediate K using 1-amino-1-methylcyclobutane. ¹H NMR (500 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.70 (dd, J=7.9, 1.3, 1H), 7.47-7.41 (m, 1H), 7.40-7.34 (m, 1H), 5.26 (s, 1H), 2.26-2.13 (m, 2H), 1.86-1.76 (m, 2H), 1.76-1.59 (m, 2H), 1.32 (t, J=0.8, 3H).

Intermediate W

The title compound was prepared using analogous conditions to those described in Intermediate K using 2-methylbutan-2-amine. ¹H NMR (500 MHz, DMSO-d₆) δ 7.81 (dd, J=7.8, 1.7, 1H), 7.58 (dd, J=7.8, 1.3, 1H), 7.35-7.29 (m, 1H), 7.29-7.24 (m, 1H), 1.24 (q, J=7.4, 2H), 0.80 (s, 6H), 0.52 (t, J=7.4, 3H).

Intermediate X

The title compound was prepared using analogous conditions to those described in Intermediate K using 1,1,1-trifluoro-2-methylpropan-2-amine. ¹H NMR (500 MHz, DMSO-d₆) δ 8.61 (s, 1H), 8.05 (dd, J=7.7, 1.8, 1H), 7.86 (dd, J=7.7, 1.4, 1H), 7.62-7.57 (m, 1H), 7.57-7.52 (m, 1H), 1.30 (s, 6H).

Intermediate Y

The title compound was prepared using analogous conditions to those described in Intermediate K using (R)-2,2,2-trifluoro-1-phenylethanamine. ¹H NMR (600 MHz, DMSO-d₆) δ 9.64-9.53 (d, J=10.2, 1H), 8.03-7.91 (dd, J=7.8, 1.7, 1H), 7.68-7.62 (dd, J=7.8, 1.2, 1H), 7.53-7.39 (m, 4H), 7.34-7.23 (m, 3H), 5.25-5.11 (m, 1H).

Intermediate Z

The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-2,2,2-trifluoro-1-phenylethanamine.

Intermediate AA

The title compound was prepared using analogous conditions to those described in Intermediate K using (R)-1-phenylethanamine ¹H NMR (600 MHz, DMSO-d₆) δ 8.46-8.34 (d, J=8.4, 1H), 7.94-7.83 (dd, J=7.7, 1.9, 1H), 7.74-7.65 (dd, J=7.7, 1.4, 1H), 7.50-7.37 (m, 2H), 7.27-7.07 (m, 5H), 4.42-4.29 (m, 1H), 1.37-1.27 (d, J=7.0, 3H).

Intermediate AB

The title compound was prepared using analogous conditions to those described in Intermediate K using (R)-2,3-dihydro-1H-inden-1-amine. ¹H NMR (600 MHz, DMSO-d₆) δ 8.47-8.39 (d, J=9.0, 1H), 8.14-8.06 (dd, J=7.7, 1.8, 1H), 7.93-7.87 (dd, J=7.8, 1.3, 1H), 7.64-7.53 (m, 2H), 7.23-7.10 (m, 4H), 4.77-4.64 (m, 1H), 2.91-2.78 (m, 1H), 2.72-2.61 (m, 1H), 2.21-2.10 (m, 1H), 1.91-1.77 (m, 1H).

Intermediate AC

The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-2,3-dihydro-1H-inden-1-amine. NMR spectra as for Intermediate AB.

Intermediate AD

The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-3-amino-1-ethylazepan-2-one. ¹H NMR (600 MHz, DMSO-d₆) δ 8.04-7.99 (dd, J=7.8, 1.7, 1H), 7.84-7.80 (dd, J=7.9, 1.3, 1H), 7.58-7.53 (m, 2H), 7.53-7.49 (m, 1H), 4.13-4.04 (m, 1H), 3.40-3.31 (m, 1H), 3.30-3.15 (m, 3H), 1.85-1.73 (m, 2H), 1.73-1.63 (m, 1H), 1.62-1.52 (m, 1H), 1.50-1.40 (m, 1H), 1.28-1.16 (m, 1H), 0.96-0.88 (t, J=7.1, 3H).

Intermediate AE

The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-3-aminoazepan-2-one. ¹H NMR (600 MHz, DMSO-d₆) δ 8.05-8.01 (dd, J=7.8, 1.7, 1H), 7.96-7.91 (m, 1H), 7.85-7.81 (dd, J=7.8, 1.3, 1H), 7.60-7.55 (m, 1H), 7.55-7.50 (m, 1H), 7.47-7.43 (d, J=6.0, 1H), 3.95-3.86 (m, 1H), 3.04-2.93 (m, 2H), 1.89-1.79 (m, 2H), 1.71-1.62 (m, 1H), 1.59-1.44 (m, 2H), 1.20-1.07 (m, 1H).

Intermediate AF

The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-3-amino-1-methylazepan-2-one. MS (ESI): mass calcd. for C₁₃H₁₇BrN₂O₃S 360.01, m/z found 361.0 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.03-8.00 (dd, J=7.8, 1.8, 1H), 7.84-7.81 (dd, J=7.8, 1.3, 1H), 7.59-7.50 (m, 3H), 4.17-4.07 (m, 1H), 3.48-3.38 (m, 1H), 3.20-3.09 (m, 1H), 2.87-2.79 (s, 3H), 1.92-1.81 (dd, J=14.4, 3.4, 1H), 1.81-1.70 (m, 1H), 1.67-1.52 (m, 2H), 1.52-1.41 (m, 1H), 1.34-1.21 (m, 1H).

Intermediate AG

The title compound was prepared using analogous conditions to those described in Intermediate K using 1,2,2,6,6-pentamethylpiperidin-4-amine. MS (ESI): mass calcd. for C₁₆H₂₅BrN₂O₂S 388.08, m/z found 389.1 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.07-8.03 (dd. J=7.8, 1.7, 1H), 7.87-7.81 (m, 2H), 7.61-7.56 (m, 1H), 7.56-7.51 (m, 1H), 3.32-3.21 (m, 1H), 2.11-2.02 (s, 3H), 1.46-1.37 (m, 2H), 1.35-1.26 (m, 2H), 1.01-0.92 (s, 6H), 0.83-0.74 (s, 6H).

Intermediate AH

The title compound was prepared using analogous conditions to those described in Intermediate K using aniline. ¹H NMR (600 MHz, DMSO-d₆) δ 10.68-10.56 (s, 1H), 8.13-8.02 (dd, J=7.9, 1.7, 1H), 7.85-7.75 (dd, J=7.8, 1.3, 1H), 7.62-7.46 (m, 2H), 7.25-7.16 (m, 2H), 7.12-7.04 (m, 2H), 7.02-6.93 (m, 1H).

Intermediate AI

The title compound was prepared using analogous conditions to those described in Intermediate K using 3-aminopyridine. MS (ESI): mass calcd. for C₁₁H₉BrN₂O₂S 311.96, m/z found 312.9 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 11.05-10.87 (s, 1H), 8.40-8.29 (m, 1H), 8.25-8.17 (dd, J=4.7, 1.4, 1H), 8.15-8.06 (dd, J=7.8, 1.8, 1H), 7.93-7.78 (dd, J=7.8, 1.3, 1H), 7.66-7.52 (m, 2H), 7.47-7.44 (dd, J=2.7, 1.4, 1H), 7.32-7.23 (m, 2H).

Intermediate AJ

The title compound was prepared using analogous conditions to those described in Intermediate K using (R)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C₉H₁₂NOSBr 292.97, m/z found 294.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.9, 1.3, 1H), 7.48-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.42 (d, J=7.4, 1H), 3.60-3.50 (m, 1H), 3.49-3.40 (m, 1H), 3.38-3.28 (m, 1H), 2.16 (t, J=5.4, 1H), 1.04 (d, J=6.8, 3H).

Intermediate AK

To a 20 mL vial were added a stirbar, 2-bromobenzene-1-sulfonyl chloride (0.995 g, 3.89 mmol), and THF (5 mL). The vial was then charged with EtNH₂ in THF (5 mL, 2.0 M). The mixture was stirred for 24 hours before adding it to a separatory funnel containing 1 N HCl and EtOAc. The layers were mixed thoroughly and then separated. The organic layer was then washed with water followed by sat. NaHCO₃, dried over MgSO₄, filtered and concentrated to dryness to give the crude product. Subjecting the oil to FCC yielded the title compound (580 mg, 56%). ¹H NMR (600 MHz, CDCl₃) 8.17-8.10 (dd, J=7.8, 1.7, 1H), 7.75-7.69 (dd, J=7.8, 1.2, 1H), 7.48-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.16-4.91 (t, J=6.7, 1H), 3.06-2.87 (m, 2H), 1.19-1.00 (t, J=7.3, 3H).

Intermediate AL

The title compound was prepared using analogous conditions to those described in Intermediate AK using 0.5 M methylamine in 1,4-dioxane. ¹H NMR (600 MHz, CDCl₃) δ 8.15-8.11 (dd, J=7.8, 1.7, 1H), 7.75-7.70 (dd, J=7.8, 1.3, 1H), 7.49-7.45 (m, 1H), 7.44-7.39 (m, 1H), 5.11-5.00 (d, J=6.6, 1H), 2.66-2.55 (d, J=5.4, 3H).

Intermediate AM

To a 500 mL round-bottomed flask were added a stirbar, (S)-2-aminopropan-1-ol (2.151 g, 28.65 mmol), dry DCM (100 mL), and DIPEA (14.0 mL, 81.2 mmol). The mixture was then treated with 2-bromobenzene-1-sulfonyl chloride (6.981 g, 27.32 mmol) and stirred for 66.5 hours before concentrating to dryness and subjecting the residue to FCC to give the title compound. (7.31 g, 91%).

Intermediate AN

The title compound was prepared using analogous conditions to those described in Intermediate AM using 2-amino-2-methylpropan-1-ol. MS (ESI): mass calcd. for C₁₀H₁₄BrNO₃S 306.99, m/z found 330.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.14 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.9, 1.2, 1H), 7.50-7.42 (m, 1H), 7.42-7.35 (m, 1H), 5.33 (s, 1H), 3.46 (d, J=6.3, 2H), 1.11 (s, 6H).

Intermediate AO

The title compound was prepared using analogous conditions to those described in Intermediate AM using (R)-2-amino-3-methylbutan-1-ol. MS (ESI): mass calcd. for C₁₁H₁₆BrNO₃S 321.00, m/z found 322.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.15-8.06 (m, 1H), 7.78-7.67 (m, 1H), 7.50-7.42 (m, 1H), 7.42-7.34 (m, 1H), 5.39 (s, 1H), 3.65-3.54 (m, 1H), 3.54-3.43 (m, 1H), 3.11-3.01 (m, 1H), 1.82 (d, J=5.7, 1H), 0.95-0.83 (m, 3H), 0.83-0.73 (m, 3H).

Intermediate AP

The title compound was prepared using analogous conditions to those described in Intermediate AM using (S)-3-aminopiperidin-2-one. MS (ESI): mass calcd. for C₁₁H₁₃BrN₂O₃S 331.98, m/z found 333.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.08 (dd, J=7.8, 1.8, 1H), 7.71 (dd, J=7.8, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.36 (m, 1H), 6.77 (s, 1H), 6.52-6.41 (m, 1H), 3.61-3.49 (m, 1H), 3.34-3.18 (m, 2H), 2.43-2.32 (m, 1H), 1.96-1.84 (m, 1H), 1.81-1.69 (m, 2H).

Intermediate AQ

To a 20 mL vial were added a stir-bar, trans-4-aminocyclohexanol (683 mg, 4.50 mmol), DMF (5 mL), and DIPEA (2.0 mL, 12 mmol). The mixture was then treated with 2-bromobenzene-1-sulfonyl chloride (1.00 g, 3.93 mmol) and the mixture stirred for 2 hours before subjecting the vial's content to FCC to give the title compound. (978 mg, 74%). MS (ESI): mass calcd. for C₁₂H₁₆BrNO₃S 333.00, m/z found 334.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.12 (dd, J=7.8, 1.7, 1H), 7.70 (dd, J=7.8, 1.2, 1H), 7.49-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.10 (d, J=7.5, 1H), 3.62-3.47 (m, 1H), 3.11-3.01 (m, 1H), 2.12 (s, 1H), 1.91-1.75 (m, 4H), 1.31-1.15 (m, 4H).

Intermediate AR

The title compound was prepared using analogous conditions to those described in Intermediate AQ using (S)-pyrrolidin-3-ylmethanol. ¹H NMR (600 MHz, CDCl₃) δ 8.06 (dd, J=7.9, 1.7, 1H), 7.70 (dd, J=7.9, 1.2, 1H), 7.44-7.38 (m, 1H), 7.38-7.32 (m, 1H), 3.61-3.54 (m, 1H), 3.54-3.45 (m, 3H), 3.39-3.33 (m, 1H), 3.17 (dd, J=9.8, 6.4, 1H), 2.53-2.39 (m, 2H), 2.04-1.94 (m, 1H), 1.74-1.65 (m, 1H).

Intermediate AS

The title compound was prepared using analogous conditions to those described in Intermediate AQ using (R)-pyrrolidin-3-ylmethanol.

Intermediate AT

The title compound was prepared using analogous conditions to those described in Intermediate AQ using (R)-3-aminopiperidin-2-one.

Intermediate AU

To a 20 mL vial were added a stirbar, 3-amino-3-methylbutan-1-ol (428 mg, 4.15 mmol), ACN (5 mL), and DIPEA (2.0 mL, 12 mmol). The mixture was then treated with 2-bromobenzene-1-sulfonyl chloride (994 mg, 3.89 mmol) and stirred for 12.5 hours before concentrating to dryness and subjecting the residue to FCC to give the title compound. (676 mg, 54%). MS (ESI): mass calcd. for C₁₁H₁₆BrNO₃S 321.00, m/z found 344.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.15 (dd, J=7.9, 1.7, 1H), 7.70 (dd, J=7.8, 1.2, 1H), 7.46-7.39 (m, 1H), 7.39-7.31 (m, 1H), 6.15 (s, 1H), 3.93-3.81 (m, 2H), 1.76 (t, J=6.0, 2H), 1.20 (s, 6H).

Intermediate AV

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3-(methylamino)piperidine-1-carboxylate. MS (ESI): mass calcd. for C₁₇H₂₅BrN₂O₄S 432.07, m/z found 455.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.14 (dd, J=7.9, 1.7, 1H), 7.72 (dd, J=7.9, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.06 (s, 2H), 3.67 (s, 1H), 2.85 (s, 3H), 2.72 (s, 1H), 2.47 (s, 1H), 1.86 (d, J=11.8, 1H), 1.75-1.65 (m, 1H), 1.65-1.55 (m, 1H), 1.54-1.46 (m, 1H), 1.38 (s, 9H).

Intermediate AW

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3-(methylamino)piperidine-1-carboxylate.

Intermediate AX

The title compound was prepared using analogous conditions to those described in Intermediate AU using (1S,2R)-1-amino-2,3-dihydro-1H-inden-2-ol. MS (ESI): mass calcd. for C₁₅H₁₄BrNO₃S 366.99, m/z found 389.9 [M+Na]⁴; ¹H NMR (600 MHz, CDCl₃) δ 8.20 (dd, J=7.7, 1.9, 1H), 7.79 (dd, J=7.8, 1.4, 1H), 7.50-7.42 (m, 2H), 7.24-7.16 (m, 4H), 5.85 (d, J=8.2, 1H), 4.70-4.63 (m, 1H), 4.38-4.31 (m, 1H), 3.09-2.97 (m, 1H), 2.95-2.86 (m, 1H), 2.12 (d, J=5.2, 1H).

Intermediate AY

The title compound was prepared using analogous conditions to those described in Intermediate AU using (1S,2R)-2-amino-1-phenylpropane-1,3-diol. MS (ESI): mass calcd. for C₁₅H₁₆BrNO₄S 384.00, m/z found 407.9 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 7.88 (dd, J=7.6, 1.9, 1H), 7.54 (dd, J=7.6, 1.5, 1H), 7.34-7.26 (m, 2H), 7.23-7.19 (m, 2H), 7.17-7.09 (m, 3H), 5.89 (d, J=6.4, 1H), 4.97 (dd, J=4.3, 2.4, 1H), 3.83-3.73 (m, 1H), 3.73-3.64 (m, 1H), 3.48-3.38 (m, 1H), 3.05 (d, J=2.6, 1H), 2.37-2.27 (m, 1H).

Intermediate AZ

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-3-phenylpropan-1-ol. MS (ESI): mass calcd. for C₁₅H₁₆BrNO₃S 369.00, m/z found 392.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.07 (dd, J=7.8, 1.7, 1H), 7.62 (dd, J=7.9, 1.2, 1H), 7.45-7.39 (m, 1H), 7.38-7.32 (m, 1H), 7.20-7.10 (m, 3H), 7.05-6.95 (m, 2H), 5.46 (d, J=6.8, 1H), 3.63-3.54 (m, 1H), 3.54-3.43 (m, 2H), 2.88-2.78 (m, 1H), 2.78-2.68 (m, 1H), 2.14-1.97 (m, 1H).

Intermediate BA

The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-2-amino-3-phenylpropan-1-ol. ¹H NMR (600 MHz, CDCl₃) δ 8.10 (dd, J=7.8, 1.8, 1H), 7.71 (dd, J=7.8, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.37 (m, 1H), 7.33-7.28 (m, 2H), 7.28-7.25 (m, 3H), 5.68-5.57 (m, 1H), 4.78 (dd, J=8.7, 3.7, 1H), 3.26-3.15 (m, 1H), 3.04-2.94 (m, 1H), 2.41 (s, 1H).

Intermediate BB

The title compound was prepared using analogous conditions to those described in Intermediate AU using (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol. MS (ESI): mass calcd. for C₁₆H₁₈BrNO₃S 383.02, m/z found 406.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.19 (dd, J=7.9, 1.7, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.41-7.36 (m, 1H), 7.34-7.29 (m, 2H), 7.29-7.25 (m, 3H), 4.45 (dd, J=9.4, 3.4, 1H), 3.95-3.85 (m, 1H), 3.05 (d, J=3.4, 1H), 2.98 (s, 3H), 0.97-0.86 (d, J=6.7, 3H).

Intermediate BC

The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-1-aminoethane-1,2-diol. MS (ESI): mass calcd. for C₉H₁₂BrNO₄S 308.97, m/z found 310.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.05 (dd, J=7.8, 1.7, 1H), 7.68 (dd, J=7.9, 1.3, 1H), 7.49-7.40 (m, 1H), 7.40-7.32 (m, 1H), 6.18 (t, J=6.3, 1H), 3.95-3.75 (m, 3H), 3.64 (dd, J=11.8, 3.6, 1H), 3.54 (dd, J 11.6, 6.0, 1H), 3.06-2.97 (m, 1H), 2.97-2.85 (m, 1H).

Intermediate BD

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-3-aminopyrrolidin-2-one. MS (ESI): mass calcd. for C₁₀H₁₁BrN₂O₃S 317.97, m/z found 318.9 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.14-8.05 (m, 1H), 7.71 (dd, J=7.8, 1.3, 1H), 7.49-7.36 (m, 2H), 7.06 (s, 1H), 6.22 (d, J=4.7, 1H), 3.81-3.68 (m, 1H), 3.41-3.29 (m, 1H), 3.29-3.18 (m, 1H), 2.47-2.34 (m, 1H), 2.12-2.00 (m, 1H).

Intermediate BE

The title compound was prepared using analogous conditions to those described in Intermediate AU using 1-amino-2-methylpropan-2-ol. MS (ESI): mass calcd. for C₁₀H₁₄BrNO₃S 306.99, m/z found 290.0 [M−OH]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.11 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.48-7.43 (m, 1H), 7.43-7.38 (m, 1H), 5.53 (t, J=6.0, 1H), 2.79 (d, J=6.6, 2H), 1.22 (s, 6H).

Intermediate BF

The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-2-amino-1,1,1-trifluoropropane.

Intermediate BG

The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-tert-butyl (pyrrolidin-2-ylmethyl)carbamate. MS (ESI): mass calcd. for C₁₆H₂₃BrN₂O₄S 418.06, m/z found 319.0 [M-Boc+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.10 (dd, J=7.9, 1.7, 1H), 7.73 (dd, J=7.9, 1.3, 1H), 7.46-7.41 (m, 1H), 7.41-7.36 (m, 1H), 4.99 (t, J=6.5, 1H), 4.05-3.95 (m, 1H), 3.50-3.40 (m, 1H), 3.40-3.34 (m, 1H), 3.32-3.17 (m, 2H), 1.98-1.86 (m, 2H), 1.86-1.71 (m, 2H), 1.40 (s, 9H).

Intermediate BH

The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl 4-aminopiperidine-1-carboxylate. MS (ESI): mass calcd. for C₁₆H₂₃BrN₂O₄S 418.06, m/z found 441.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.38 (m, 1H), 5.15 (d, J=7.5, 1H), 3.86 (s, 2H), 3.32-3.20 (m, 1H), 2.75 (s, 2H), 1.69 (d, J=12.2, 2H), 1.40 (s, 9H), 1.38-1.29 (m, 2H).

Intermediate BI

The title compound was prepared using analogous conditions to those described in Intermediate AU using azetidin-3-ol. MS (ESI): mass calcd. for C₉H₁₀BrNO₃S 290.96, m/z found 292.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.02 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.44-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.61-4.51 (m, 1H), 4.18-4.10 (m, 2H), 3.97-3.91 (m, 2H), 2.92 (d, J=6.3, 1H).

Intermediate BJ

The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-(1,2-trans)-1R-2-aminocyclohexanol. MS (ESI): mass calcd. for C₁₂H₁₆BrNO₃S 333.00, m/z found 334.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.15 (dd, J=7.8, 1.7, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.50-7.44 (m, 1H), 7.44-7.39 (m, 1H), 5.29 (d, J=7.4, 1H), 3.38-3.28 (m, 1H), 2.88-2.77 (m, 1H), 2.58 (d, J=3.0, 1H), 2.04-1.96 (m, 1H), 1.77-1.69 (m, 1H), 1.59-1.51 (m, 1H), 1.27-1.12 (m, 3H), 1.12-1.01 (m, 1H).

Intermediate BK

The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-(1,2-trans)-1R-2-aminocyclohexyl)methanol. MS (ESI): mass calcd. for C₁₃H₁₈BrNO₃S 347.02, m/z found 348.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.44-7.38 (m, 1H), 5.19-5.06 (m, 1H), 4.10-4.00 (m, 1H), 3.51-3.41 (m, 1H), 3.08-2.97 (m, 1H), 2.45-2.36 (m, 1H), 1.72-1.66 (m, 1H), 1.66-1.60 (m, 1H), 1.59-1.53 (m, 1H), 1.52-1.46 (m, 1H), 1.41-1.32 (m, 1H), 1.31-1.24 (m, 1H), 1.20-1.07 (m, 2H), 1.05-0.96 (m, 1H).

Intermediate BL

The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-(1,2-cis)-1R-2-aminocyclohexanol. MS (ESI): mass calcd. for C₁₂H₁₆BrNO₃S 333.00, m/z found 334.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.38 (m, 1H), 5.52 (d, J=7.7, 1H), 3.80-3.72 (m, 1H), 3.27-3.15 (m, 1H), 1.80 (d, J=4.8, 1H), 1.74-1.63 (m, 1H), 1.63-1.51 (m, 2H), 1.51-1.43 (m, 2H), 1.43-1.36 (m, 1H), 1.36-1.26 (m, 1H), 1.26-1.11 (m, 1H).

Intermediate BM

The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-(1,2-cis)-1R-2-aminocyclohexyl)methanol. MS (ESI): mass calcd. for C₁₃H₁₈BrNO₃S 347.02, m/z found 348.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 1.8, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.44-7.39 (m, 1H), 5.43 (d, J=9.3, 1H), 3.76-3.65 (m, 1H), 3.65-3.54 (m, 1H), 3.45-3.33 (m, 1H), 2.82 (dd, J=8.9, 5.2, 1H), 1.73-1.60 (m, 2H), 1.58-1.51 (m, 1H), 1.42-1.35 (m, 1H), 1.35-1.16 (m, 4H), 1.10-0.97 (m, 1H).

Intermediate BN

The title compound was prepared using analogous conditions to those described in Intermediate AU using 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. MS (ESI): mass calcd. for C₁₂H₁₂BrN₃O₂S 340.98, m/z found 341.9 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.15 (dd, J=7.8, 1.7, 1H), 7.71 (dd, J=7.9, 1.2, 1H), 7.47-7.42 (m, 1H), 7.41-7.36 (m, 1H), 7.33 (s, 1H), 4.45 (s, 2H), 3.66 (t, J=5.8, 2H), 2.83 (t, J=5.8, 2H).

Intermediate BO

The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl (azetidin-3-ylmethyl)carbamate. MS (ESI): mass calcd. for C₁₅H₂₁BrN₂O₄S 404.04, m/z found 349.0 [M-tBu+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.04 (dd. J=7.8, 1.8, 1H), 7.73 (dd, J=7.7, 1.3, 1H), 7.44-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.71 (s, 1H), 4.13-4.03 (m, 2H), 3.70 (dd, J=7.9, 5.4, 2H), 3.35-3.22 (m, 2H), 2.78-2.64 (m, 1H), 1.40 (s, 9H).

Intermediate BP

The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl 3-(aminomethyl)azetidine-1-carboxylate. ¹H NMR (600 MHz, CDCl₃) δ 8.12 (dd. J=7.8, 1.7, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.50-7.45 (m, 1H), 7.45-7.39 (m, 1H), 5.42-5.30 (m, 1H), 3.96-3.85 (m, 2H), 3.52 (d, J=9.3, 2H), 3.17-3.02 (m, 2H), 2.69-2.54 (m, 1H), 1.39 (s, 9H).

Intermediate BQ

The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-tert-butyl methyl(pyrrolidin-3-yl)carbamate. MS (ESI): mass calcd. for C₁₆H₂₃BrN₂O₄S 418.06, m/z found 441.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.08 (dd. J=7.9, 1.8, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.34 (m, 1H), 4.80 (s, 1H), 3.61 (s, 1H), 3.51 (s, 1H), 3.38-3.30 (m, 1H), 3.19 (dd, J=9.9, 7.4, 1H), 2.73 (s, 3H), 2.12-2.03 (m, 1H), 2.03-1.93 (m, 1H), 1.41 (s, 9H).

Intermediate BR

The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate. MS (ESI): mass calcd. for C₁₆H₂₁BrN₂O₄S 416.04, m/z found 439.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) 8.10 (dd, J=7.9, 1.8, 1H), 7.73 (dd, J=8.0, 1.2, 1H), 7.46-7.40 (m, 1H), 7.40-7.34 (m, 1H), 4.63-4.39 (m, 2H), 3.59-3.39 (m, 2H), 3.33-3.22 (m, 2H), 1.88-1.76 (m, 2H), 1.42 (d, J=5.0, 9H).

Intermediate BS

The title compound was prepared using analogous conditions to those described in Intermediate AU (1S,4S)-tert-butyl 2,5-diazabicyclo[2.2.]heptane-2-carboxylate.

Intermediate BT

The title compound was prepared using analogous conditions to those described in Intermediate AU using 4-(piperidin-4-yl)-1H-1,2,4-triazol-5(4H)-one. MS (ESI): mass calcd. for C₁₃H₁₅BrN₄O₃S 386.00, m/z found 387.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 9.63 (s, 1H), 8.10 (dd, J=7.8, 1.8, 1H), 7.75 (dd, J=7.9, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.37 (m, 2H), 4.05-3.97 (m, 3H), 2.97-2.89 (m, 2H), 2.09-2.03 (m, 2H), 1.89-1.79 (m, 2H).

Intermediate BU

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-3-aminopropane-1,2-diol.

Intermediate BV

The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl ((cis)-4-aminocyclohexyl)carbamate. MS (ESI): mass calcd. for C₁₇H₂₅BrN₂O₄S 432.07, m/z found 455.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.8, 1.2, 1H), 7.48-7.43 (m, 1H), 7.43-7.38 (m, 1H), 5.17 (s, 1H), 4.45 (s, 1H), 3.47 (s, 1H), 3.30-3.20 (m, 1H), 1.66 (s, 2H), 1.60-1.49 (m, 4H), 1.45 (d, J=7.3, 1H), 1.41 (s, 9H).

Intermediate BW

The title compound was prepared using analogous conditions to those described in Intermediate AU using 5-aminopentan-1-ol. MS (ESI): mass calcd. for C₁₁H₁₆BrNO₃S 321.00, m/z found 322.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) b 8.10 (dd. J=7.8, 1.7, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.48-7.42 (m, 1H), 7.42-7.35 (m, 1H), 5.23 (t, J=6.3, 1H), 3.62-3.50 (m, 2H), 2.93-2.83 (m, 2H), 1.55 (s, 1H), 1.52-1.42 (m, 4H), 1.39-1.29 (m, 2H).

Intermediate BX

The title compound was prepared using analogous conditions to those described in Intermediate AU using 6-aminohexan-1-ol. MS (ESI): mass calcd. for C₁₂H₁₈BrNO₃S 335.02, m/z found 336.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.11 (dd, J=7.8, 1.8, 1 H), 7.71 (dd, J=7.9, 1.3, 1H), 7.48-7.42 (m, 1H), 7.42-7.36 (m, 1H), 5.15 (t, J=6.2, 1H), 3.57 (t, J=6.6, 2H), 2.94-2.81 (m, 2H), 1.56-1.35 (m, 5H), 1.33-1.21 (m, 4H).

Intermediate BY

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-indolin-2-ylmethanol. MS (ESI): mass calcd. for C₁₅H₁₄BrNO₃S 366.99, m/z found 389.9 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.12 (dd, J=7.9, 1.7, 1H), 7.65 (dd, J=7.9, 1.3, 1H), 7.42-7.36 (m, 1H), 7.36-7.31 (m, 1H), 7.27 (d, J=8.1, 1H), 7.14-7.09 (m, 1H), 7.09-7.04 (m, 1H), 6.98-6.93 (m, 1H), 4.86-4.78 (m, 1H), 3.81-3.68 (m, 2H), 3.28 (dd, J=16.2, 9.6, 1H), 2.88-2.79 (m, 1H), 2.20 (s, 1H).

Intermediate BZ

The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-(cyclohexylamino)ethanol. MS (ESI): mass calcd. for C₁₄H₂₀BrNO₃S 361.03, m/z found 362.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.14 (dd. J=7.9, 1.7, 1H), 7.71 (dd, J=7.8, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.34 (m, 1H), 3.71 (m, 2H), 3.65-3.57 (m, 1H), 3.47 (t, J=6.1, 2H), 2.22 (t, J=5.9, 1H), 1.80-1.67 (m, 4H), 1.62-1.53 (m, 1H), 1.44-1.32 (m, 2H), 1.27-1.15 (m, 2H), 1.07-0.94 (m, 1H).

Intermediate CA

The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-azetidine-2-carboxamide. MS (ESI): mass calcd. for C₁₀H₁₁BrN₂O₃S 319.97, m/z found 319.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.11-8.07 (m, 1H), 7.83-7.79 (m, 1H), 7.53-7.46 (m, 2H), 6.91 (s, 1H), 5.53 (s, 1H), 4.75 (t, J=8.8, 1H), 4.02-3.94 (m, 1H), 3.75-3.67 (m, 1H), 2.49-2.39 (m, 2H).

Intermediate CB

Step A: 1-[(2-Bromophenyl)sulfonyl]-4-{1-[(2-bromophenyl)sulfonyl]-1H-imidazol-4-yl}piperidine

To a 20 mL vial were added a stirbar, 4-(1H-imidazol-4-yl)piperidine.HCl (696 mg, 3.71 mmol), ACN (5 mL), and DIPEA (2.0 mL, 12 mmol). The mixture was then treated with 2-bromobenzene-1-sulfonyl chloride (900 mg, 3.52 mmol) and the mixture was stirred for 15.5 hours before concentrating to dryness and subjecting the residue to FCC to give the title compound (950 mg, 92%). MS (ESI): mass calcd. for C₂₀H₁₉Br₂N₃O₄S₂ 586.92 m/z found 587.9 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.20 (dd, J=7.9, 1.8, 1H), 8.08 (dd, J=7.8, 1.7, 1H), 8.06 (d, J=1.3, 1H), 7.75 (dd, J=7.7, 1.3, 1H), 7.72 (dd, J=7.9, 1.2, 1H), 7.58-7.53 (m, 1H), 7.53-7.49 (m, 1H), 7.45-7.40 (m, 1H), 7.39-7.34 (m, 1H), 6.93-6.91 (m, 1H), 3.90-3.82 (m, 2H), 2.93-2.83 (m, 2H), 2.68-2.59 (m, 1H), 2.02 (dd, J=13.9, 3.0, 2H), 1.70-1.59 (m, 2H).

Step B

To a 20 mL vial containing 1-[(2-bromophenyl)sulfonyl]-4-{1-[(2-bromophenyl)-sulfonyl]-1H-imidazol-4-yl}piperidine (884 mg, 1.50 mmol) were added a stirbar and DMSO (10 mL). Once the DMSO solution was homogeneous, LiOH (3 mL, 1.0 M) was added slowly. After 30 min the reaction mixture was diluted with EtOAc, washed with water (×4) and brine (×1), dried over MgSO₄, filtered and concentrated to dryness to give the title compound (522 mg, 94%). MS (ESI): mass calcd. for C₁₄H₁₆BrN₃O₂S 369.01 m/z found 370.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.08 (dd, J=7.9, 1.7, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.62 (s, 1H), 7.45-7.41 (m, 1H), 7.40-7.35 (m, 1H), 6.76 (s, 1H), 3.88 (d, J=12.8, 1H), 2.90 (m, 2H), 2.76-2.69 (m, 1H), 2.09-2.01 (m, 2H), 1.77-1.67 (m, 2H).

Intermediate CC

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl piperidin-3-ylcarbamate. MS (ESI): mass calcd. for C₁₆H₂₃BrN₂O₄S 418.06 m/z found 441.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.10-8.06 (m, 1H), 7.73 (dd, J=7.7, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.88 (d, J=8.5, 1H), 3.77 (s, 1H), 3.44 (s, 1H), 3.28 (d, J=11.8, 1H), 3.23-3.03 (m, 2H), 1.85-1.55 (m, 4H), 1.39 (s, 9H).

Intermediate CD

The title compound was prepared using analogous conditions to those described in Intermediate AU using 2,2′-azanediyldiethanol. MS (ESI): mass calcd. for C₁₀H₁₄BrNO₄S 322.98 m/z found 324.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.10-8.05 (m, 1H), 7.74 (dd, J=7.8, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.37 (m, 1H), 3.83 (dd, J=7.3, 3.8, 4H), 3.48 (t, J=5.0, 4H), 3.38 (s, 2H).

Intermediate CE

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3-methylpiperazine-1-carboxylate. MS (ESI): mass calcd. for C₁₆H₂₃BrN₂O₄S 418.06 m/z found 319.0 [M-Boc+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.14 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.45-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.16-3.73 (m, 3H), 3.63-3.42 (m, 1H), 3.32-3.22 (m, 1H), 3.17-2.68 (m, 2H), 1.42 (s, 9H), 1.25-1.09 (m, 3H).

Intermediate CF

The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-tert-butyl 3-methylpiperazine-1-carboxylate.

Intermediate CG

The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-(isopropylamino)ethanol. MS (ESI): mass calcd. for C₁₁H₁₆BrNO₃S 321.00 m/z found 322.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.15 (dd. J=7.9, 1.7, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.46-7.41 (m, 1H), 7.39-7.34 (m, 1H), 4.01 (hept, J=6.7, 1H), 3.74 (m, 2H), 3.47 (t, J=6.1, 2H), 2.27 (t, J=5.8, 1H), 1.13 (d, J=6.8, 6H).

Intermediate CH

The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate. MS (ESI): mass calcd. for C₁₆H₂₃BrN₂O₅S 434.05 m/z found 335.0 [M-Boc+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.16 (dd, J=7.8, 1.8, 1H), 7.73 (dd, J=7.9, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.37 (m, 1H), 4.32-3.43 (m, 6H), 3.27-3.15 (m, 1H), 3.15-2.66 (m, 3H), 1.44 (s, 9H).

Intermediate CI

The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-amino-2-methylpropane-1,3-diol. ¹H NMR (600 MHz, CDCl₃) δ 8.14 (dd, J=7.8, 1.7, 1H), 7.73 (dd, J=7.9, 1.3, 1H), 7.48-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.93 (s, 1H), 3.72-3.56 (m, 4H), 2.53-2.44 (m, 2H), 0.93 (s, 3H).

Intermediate CJ

The title compound was prepared using analogous conditions to those described in Intermediate AU using endo-3-azabicyclo[3.1.0]hexan-6-amine. MS (ESI): mass calcd. for C₁₁H₁₃BrN₂O₂S 315.99 m/z found 317.0 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 7.97 (dd, J=7.7, 1.9, 1H), 7.88 (dd, J=7.7, 1.4, 1H), 7.62-7.58 (m, 1H), 7.58-7.54 (m, 1H), 3.42-3.38 (m, 2H), 3.37-3.29 (m, 4H), 2.02 (t, J=2.2, 1H), 1.46-1.41 (m, 2H).

Intermediate CK

The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl(2-aminoethyl)carbamate. ¹H NMR (600 MHz, CDCl₃) δ 8.10 (dd, J=7.7, 1.7, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.47-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.66 (t, J=5.8, 1H), 4.86 (s, 1H), 3.21 (t, J=5.8, 2H), 3.03-2.95 (m, 2H), 1.40 (s, 9H).

Intermediate CL

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-3-methylbutan-1-ol. ¹H NMR (600 MHz, CDCl₃) δ 8.11 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.9, 1.2, 1H), 7.47-7.42 (m, 1H), 7.41-7.36 (m, 1H), 5.35 (d, J=8.6, 1H), 3.63-3.54 (m, 1H), 3.54-3.43 (m, 1H), 3.11-3.01 (m, 1H), 1.88-1.75 (m, 2H), 0.86 (d, J=6.9, 3H), 0.80 (d, J=6.8, 3H).

Intermediate CM

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-3,3-dimethylbutan-1-ol. MS (ESI): mass calcd. for C₁₂H₁₈BrNO₃S 335.02 m/z found 336.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.09 (dd, J=7.9, 1.7, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.46-7.41 (m, 1H), 7.40-7.35 (m, 1H), 5.40 (d, J=9.4, 1H), 3.66-3.55 (m, 2H), 3.11-3.01 (m, 1H), 1.81 (t, J=5.6, 1H), 0.85 (s, 9H).

Intermediate CN

The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-2-amino-3,3-dimethylbutan-1-ol.

Intermediate CO

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-aminobutan-1-ol. MS (ESI): mass calcd. for C₁₀H₁₄BrNO₃S 306.99 m/z found 308.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.11 (dd. J=7.8, 1.7, 1H), 7.72 (dd, J=7.9, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.37 (m, 1H), 5.41 (d, J=7.9, 1H), 3.59-3.46 (m, 2H), 3.19-3.10 (m, 1H), 2.15-1.99 (m, 1H), 1.56-1.38 (m, 2H), 0.78 (t, J=7.5, 3H).

Intermediate CP

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3-aminopyrrolidine-1-carboxylate. MS (ESI): mass calcd. for C₁₅H₂₁BrN₂O₄S 404.04 m/z found 427.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.17-8.11 (m, 1H), 7.77-7.69 (m, 1H), 7.51-7.45 (m, 1H), 7.45-7.39 (m, 1H), 5.38-5.29 (m, 1H), 3.87-3.75 (m, 1H), 3.46-3.32 (m, 2H), 3.32-3.21 (m, 1H), 3.16-3.05 (m, 1H), 2.05-1.68 (m, 2H), 1.39 (s, 9H).

Intermediate CQ

The title compound was prepared using analogous conditions to those described in Intermediate AU using (1S,2S)-1-amino-2,3-dihydro-1H-inden-2-ol. MS (ESI): mass calcd. for C₁₅H₁₄BrNO₃S 366.99 m/z found 390.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.21 (dd, J=7.7, 1.8, 1H), 7.80 (dd, J=7.8, 1.3, 1H), 7.52-7.47 (m, 1H), 7.47-7.43 (m, 1H), 7.25-7.21 (m, 1H), 7.21-7.13 (m, 3H), 5.61 (d, J=6.8, 1H), 4.58-4.47 (m, 1H), 4.44-4.37 (m, 1H), 3.26 (dd, J=15.9, 7.7, 1H), 3.13 (d. J=2.7, 1H), 2.84-2.73 (m, 1H).

Intermediate CR

The title compound was prepared using analogous conditions to those described in Intermediate AU using (1R,2R)-1-amino-2,3-dihydro-1H-inden-2-ol.

Intermediate CS

The title compound was prepared using analogous conditions to those described in Intermediate AU using (1R,2S)-1-amino-2,3-dihydro-1H-inden-2-ol.

Intermediate CT

The title compound was prepared using analogous conditions to those described in Intermediate AU using N-cyclopropyltetrahydro-2H-pyran-4-amine. MS (ESI): mass calcd. for C₁₄H₁₈BrNO₃S 359.02 m/z found 392.0 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.16 (dd, J=7.9, 1.7, 1H), 7.69 (dd, J=7.9, 1.2, 1H), 7.47-7.40 (m, 1H), 7.40-7.34 (m, 1H), 4.40-4.30 (m, 1H), 4.05-3.96 (m, 2H), 3.52-3.39 (m, 2H), 2.34-2.25 (m, 1H), 2.16-2.06 (m, 2H), 1.85-1.75 (m, 2H), 0.64-0.56 (m, 2H), 0.54-0.46 (m, 2H).

Intermediate CU

The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic morpholin-2-ylmethanol. MS (ESI): mass calcd. for C₁₁H₁₄BrNO₄S 334.98 m/z found 357.9 [M+Na]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.06 (dd, J=7.8, 1.8, 1H), 7.74 (dd, J=7.8, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.36 (m, 1H), 3.93 (m, 1H), 3.70-3.58 (m, 5H), 3.58-3.51 (m, 1H), 2.94 (m, 1H), 2.77 (m, 1H), 1.96-1.83 (m, 1H).

Intermediate CV

The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-aminopyrazine. MS (ESI): mass calcd. for C₁₀H₈BrN₃O₂S 312.95 m/z found 313.9 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 11.94 (s, 1H), 8.34 (s, 1H), 8.25-8.16 (m, 2H), 8.11 (dd, J=2.7, 1.5, 1H), 7.81 (dd, J=7.9, 1.2, 1H), 7.68-7.59 (m, 1H), 7.59-7.51 (m, 1H).

Intermediate CW

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-4-methylpentanamide. MS (ESI): mass calcd. for C₁₂H₁₇BrN₂O₃S 348.01 m/z found 349.0 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.01 (dd, J=7.7, 1.8, 1H), 7.92 (d, J=8.3, 1H), 7.82 (dd, J=7.8, 1.3, 1H), 7.58-7.49 (m, 2H), 7.24 (d, J=2.3, 1H), 6.97 (d, J=2.2, 1H), 3.67-3.56 (m, 1H), 1.65-1.53 (m, 1H), 1.51-1.40 (m, 1H), 1.35-1.25 (m, 1H), 0.79 (d, J=6.6, 3H), 0.61 (d, J=6.5, 3H).

Intermediate CX

The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-aminoacetamide. MS (ESI): mass calcd. for C₈H₉BrN₂O₃S 291.95 m/z found 293.0 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.00 (dd, J=7.7, 1.8, 1H), 7.88 (s, 1H), 7.84 (dd, J=7.8, 1.3, 1H), 7.59-7.54 (m, 1H), 7.54-7.50 (m, 1H), 7.27 (s, 1H), 7.13 (s, 1H), 3.51 (s, 2H).

Intermediate CY

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-3-phenylpropanamide. MS (ESI): mass calcd. for C₁₅H₁₅BrN₂O₃S 382.00 m/z found 382.9 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 7.95 (d, J=8.8, 1H), 7.71-7.65 (m, 2H), 7.44-7.35 (m, 3H), 7.20-7.12 (m, 5H), 7.06 (d, J=2.2, 1H), 3.93 (m, 1H), 2.91 (dd, J=13.7, 4.9, 1H), 2.77 (dd, J=13.7, 9.4, 1H).

Intermediate CZ

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-aminopropanamide. MS (ESI): mass calcd. for C₉H₁₁BrN₂O₃S 305.97 m/z found 307.0 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.01 (dd, J=7.7, 1.8, 1H), 7.86 (d, J=5.2, 1H), 7.84 (dd, J=7.7, 1.3, 1H), 7.60-7.55 (m, 1H), 7.55-7.50 (m, 1H), 7.24 (s, 1H), 7.07 (s, 1H), 3.78-3.69 (m, 1H), 1.17 (d, J=7.1, 3H).

Intermediate DA

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3,4-diamino-4-oxobutanoate. MS (ESI): mass calcd. for C₁₄H₁₉BrN₂O₅S 406.02 m/z found 429.0 [M+Na]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.04-7.99 (m, 2H), 7.80 (dd, J=7.7, 1.3, 1H), 7.58-7.53 (m, 1H), 7.53-7.49 (m, 1H), 7.24 (s, 1H), 7.16 (s, 1H), 4.00 (m, 1H), 2.56-2.51 (m, 1H), 2.45-2.39 (m, 1H), 1.32 (s, 9H).

Intermediate DB

The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-2-amino-2-phenylacetamide. MS (ESI): mass calcd. for C₁₄H₁₃BrN₂O₃S 367.98 m/z found 369.0 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.20 (d, J=8.8, 1H), 7.91-7.86 (m, 1H), 7.76-7.71 (m, 1H), 7.58 (d, J=2.0, 1H), 7.49-7.43 (m, 2H), 7.35-7.29 (m, 2H), 7.26-7.20 (m, 4H), 4.94 (d, J=8.8, 1H).

Intermediate DC

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl-2-amino-3-methylbutanoate. ¹H NMR (600 MHz, DMSO-d₆) δ 8.24 (d, J=9.6, 1H), 8.00 (dd, J=7.8, 1.7, 1H), 7.82 (dd, J=7.9, 1.3, 1H), 7.58-7.54 (m, 1H), 7.54-7.48 (m, 1H), 3.45 (dd, J=9.5, 7.1, 1H), 1.97 (h, J=6.8, 1H), 1.22 (s, 9H), 0.87 (d, J=6.7, 3H), 0.82 (d, J=6.8, 3H).

Intermediate DD

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 2-aminopropanoate. MS (ESI): mass calcd. for C₁₃H₁₈BrNO₄S 363.01 m/z found 386.0 [M+Na]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.36 (d, J=8.6, 1H), 7.99 (dd, J=7.8, 1.8, 1H), 7.83 (dd, J=7.8, 1.3, 1H), 7.58-7.53 (m, 1H), 7.53-7.49 (m, 1H), 3.87-3.78 (m, 1H), 1.30-1.21 (m, 12H).

Intermediate DE

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-pyrrolidine-3-carboxamide. MS (ESI): mass calcd. for C₁₁H₁₃BrN₂O₃S 331.98, m/z found 333.0 [M+H]+; ¹H NMR (500 MHz, DMSO-d₆) δ 8.05-7.97 (dd, J=7.7, 1.9, 1H), 7.92-7.85 (dd, J=7.7, 1.5, 1H), 7.64-7.53 (m, 2H), 7.43 (s, 1H), 6.96 (s, 1H), 3.57-3.50 (dd, J=9.5, 8.0, 1H), 3.46-3.39 (m, 1H), 3.37-3.27 (m, 2H), 3.02-2.94 (p, J=7.8, 1H), 2.12-2.02 (m, 1H), 2.02-1.91 (m, 1H).

Intermediate DF

The title compound was prepared using analogous conditions to those described in Intermediate AU using piperidine-4-carboxamide. MS (ESI): mass calcd. for C₁₂H₁₅BrN₂O₃S 346.00, m/z found 347.0 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.03-7.97 (dd, J=7.8, 1.8, 1H), 7.91-7.86 (dd, J=7.8, 1.3, 1H), 7.63-7.53 (m, 2H), 7.28 (s, 1H), 6.82 (s, 1H), 3.72-3.62 (m, 2H), 2.83-2.73 (m, 2H), 2.27-2.17 (m, 1H), 1.79-1.70 (m, 2H), 1.57-1.44 (m, 2H).

Intermediate DG

The title compound was prepared using analogous conditions to those described in Intermediate AU using 3-(trifluoromethyl)azetidin-3-ol. MS (ESI): mass calcd. for C₁₀H₉BrF₃NO₃S 358.94; m/z found 359.9 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.03-8.00 (m, 1H), 7.94-7.91 (dd, J=7.4, 1.7, 1H), 7.65-7.58 (m, 3H), 4.20-4.15 (m, 2H), 4.09-4.04 (m, 2H).

Intermediate DH

The title compound was prepared using analogous conditions to those described in Intermediate AU using N-methylazetidine-3-carboxamide. MS (ESI): mass calcd. for C₁₁H₁₃BrN₂O₃S 331.98; m/z found 333.0 [M+H]⁺; ¹H NMR (600 MHz, CDCl₃) δ 8.09-8.04 (dd, J=7.8, 1.8, 1H), 7.79-7.74 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.44-7.37 (m, 1H), 5.72 (s, 1H), 4.25-4.13 (m, 4H), 3.29-3.16 (m, 1H), 2.89-2.77 (d, J=4.8, 3H).

Intermediate DI

The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-oxa-6-azaspiro[3.3]heptane. MS (ESI): mass calcd. for C₁₁H₁₂BrNO₃S 316.97; m/z found 317.9 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.00-7.96 (m, 1H), 7.91-7.88 (m, 1H), 7.63-7.56 (m, 2H), 4.62 (s, 4H), 4.11 (s, 4H).

Intermediate DJ

The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide. MS (ESI): mass calcd. for C₁₁H₁₂BrNO₄S₂ 364.94; m/z found 365.9 [M+H]⁺; ¹H NMR (600 MHz, DMSO-d₆) δ 8.02-7.98 (m, 1H), 7.93-7.89 (m, 1H), 7.64-7.58 (m, 2H), 4.46 (s, 4H), 4.17 (s, 4H).

Intermediate DL

To a solution of 2-bromoaniline (344 mg, 2.0 mmol) in pyridine (5 mL) was slowly added ethyl-sulfonyl chloride (257 mg, 2.0 mmol) at rt and the mixture was stirred at rt for 16 hours. The pyridine was removed under reduced pressure and resulting residue diluted with water (30 mL) and extracted with DCM (10 mL×2). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by FCC to give the title compound (240 mg, 45%). MS (ESI): mass calcd. for C₈H₁₀BrNO₂S 262.96 m/z found 264.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) 7.71 (dd, J=4.8, 1.5, 1H), 7.59 (dd, J=4.8, 1.5, 1H), 7.32-7.28 (m, 1H), 7.08-7.05 (m, 1H), 6.77 (bs, 1H), 3.14 (q, J=7.2, 2H), 1.41 (t, J=7.5, 3H).

Intermediate DM

The title compound was prepared using analogous conditions described for Intermediate DL utilizing n-propylsulfonyl chloride. MS (ESI): mass calcd. for C₉H₁₂BrNO₂S, 276.98; m/z found, 278.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 7.70 (dd, J=4.8, 1.5, 1H), 7.59 (dd, J=4.8, 1.5, 1H), 7.32-7.28 (m, 1H), 7.08-7.05 (m, 1H), 6.72 (br s, 1H), 3.15-2.94 (m, 2H), 1.93-1.73 (m, 2H), 1.00 (t, J=7.4, 3H).

Intermediate DN

The title compound was prepared using analogous conditions described for Intermediate DL utilizing iso-butylsulfonyl chloride. MS (ESI): mass calcd. for C₁₀H₁₄BrNO₂S, 290.99; m/z found, 292.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (dd, J=4.8, 1.5, 1H), 7.59 (dd, J=4.8, 1.5, 1H), 7.32-7.28 (m, 1H), 7.08-7.05 (m, 1H), 6.77 (br s, 1H), 2.99 (d, J=4.2, 2H), 2.38-2.25 (m, 1H), 1.07 (d, J=6.9, 6H).

Intermediate DO

Step A: Sodium (2-bromophenyl)methanesulfonate

A mixture of 1-bromo-2-(bromomethyl)benzene (20 g, 0.08 mol) and Na₂SO₃ (15 g, 0.12 mol) in methanol/H₂O (100 mL/100 mL) was stirred at 85° Celsius for 2.5 hours, concentrated to dryness and dried to give sodium (2-bromophenyl)methanesulfonate (34 g, crude). ¹H NMR (300 MHz, DMSO-d₆) δ 7.54 (m, 2H), 7.27 (m, 1H), 7.12 (m, 1H), 3.91 (s, 2H).

Step B: (2-Bromophenyl)methanesulfonyl chloride

To a suspension of crude sodium (2-bromophenyl)methanesulfonate (34 g) in toluene (500 mL) was added PCl₅ (34 g, 0.16 mol). The resulting mixture was stirred at 100° Celsius for 4 hours before concentrating to dryness and pouring the residue onto crushed ice (150 g), stirring for 5 min, and extracting with DCM (3×50 mL). The combined organic extracts were dried over MgSO₄, filtered and concentrated to dryness to give (2-bromophenyl)methanesulfonyl chloride (16.8 g, 77%). ¹H NMR (300 MHz, DMSO-d₆) δ 7.62-7.45 (m, 2H), 7.29 (m, 1H), 7.18-7.01 (m, 1H), 3.97 (s, 2H).

Step C

To a solution of (2-bromophenyl)methanesulfonyl chloride (2 g, 7 mmol) in THF (15 mL) was added CH₃NH₂/H₂O (25%, 2 g, 20 mmol) at 0° Celsius. The resulting mixture was warmed up to rt, stirred for 16 hours, concentrated to dryness and purified by HPLC to give the title compound (0.8 g, 41%). MS (ESI): mass calcd. for C₈H₈BrO₂S, 262.96; m/z found, 264.0 [M+H]⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.65-7.54 (m, 2H), 7.35 (m, 1H), 7.22 (dd, J=7.6, 1.7, 1H), 4.53 (s, 2H), 4.10 (s, 1H), 2.72 (s, 3H).

Intermediate DP

The title compound was prepared using analogous conditions described for Intermediate DO utilizing ethylamine. MS (ESI): mass calcd. for C₉H₁₂BrNO₂S, 276.98; m/z found, 277.9 [M+H]⁺; ¹H NMR (300 MHz, CD₃OD) δ 7.64 (dd, J=8.0, 1.0, 1H), 7.57 (dd, J=7.6, 1.6, 1H), 7.37 (m, 1H), 7.25 (m, 1H), 4.54 (s, 2H), 3.03 (q, J=7.2, 2H), 1.12 (t, J=7.2, 3H).

Intermediate DQ

The title compound was prepared using analogous conditions described for Intermediate DO utilizing ethanolamine. MS (ESI): mass calcd. for C₉H₁₂BrNO₃S, 292.97; m/z found, 294.0 [M+H]⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.69-7.52 (m, 2H), 7.35 (m, 1H), 7.26-7.19 (m, 1H), 4.77 (t, J=6, 1H), 4.56 (s, 2H), 3.65 (t, J=6, 2H), 3.12 (t, J=6, 2H), 2.13 (br s, 1H).

Intermediate DR

The title compound was prepared using analogous conditions described for Intermediate DO utilizing (S)-3-amino-2-propanol. The product was isolated as a x. MS (ESI): mass calcd. for C₇H₄BrF₃O₂S, 306.99; m/z found, 307.9 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 7.69-7.52 (m, 2H), 7.35 (m, 1H), 7.29-7.20 (m, 1H), 4.67 (s, 1H), 3.96-3.76 (m, 1H), 3.17-2.96 (m, 1H), 2.95-2.74 (m, 1H), 1.90-1.63 (m, 2H), 1.15 (d, J=6.3, 3H).

Intermediate DS

The title compound was prepared using analogous conditions described for Intermediate DO utilizing (R)-3-amino-2-propanol.

Intermediate DT

The title compound was prepared using analogous conditions described for Intermediate DO using ammonia. ¹H NMR (300 MHz, DMSO-d₆) δ 7.65 (d, J=7.9, 1H), 7.52 (dd, J=7.6, 1.6, 1H), 7.41 (m, 1H), 7.28 (m, 1H), 7.04 (s, 2H), 4.46 (s, 2H).

Intermediate DU

The title compound was prepared using analogous conditions described for Intermediate DO utilizing piperazin-2-one. The product was isolated as a white solid. MS (ESI): mass calcd. for C₁₁H₁₃BrN₂O₃S, 331.98; m/z found, 333.0 [M+H]+; ¹H NMR (300 MHz, CDCl₃) δ 7.68-7.57 (m, 2H), 7.37 (m, 1H), 7.29-7.21 (m, 1H), 6.93 (s, 1H), 4.55 (s, 2H), 3.90 (s, J=18.1, 2H), 3.43-3.17 (m, 4H).

Intermediate DV

The title compound was prepared using analogous conditions described for Intermediate DO utilizing trans-4-aminocyclohexanol. The product was isolated as a white solid. MS (ESI): mass calcd. for C₇H₄BrF₃O₂S, 347.02; m/z found, 348.0 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 7.70-7.56 (m, 2H), 7.37 (m, 1H), 7.26 (m, 1H), 4.55 (s, 2H), 3.54-3.42 (m, 1H), 3.10-2.93 (m, 1H), 2.05-1.82 (m, 4H), 1.40-1.16 (m, 4H).

Intermediate DW

The title compound was prepared using analogous conditions described for Intermediate DO utilizing tert-butyl piperazine-1-carboxylate. The product was isolated as a white solid. MS (ESI): mass calcd. for C₁₇H₂₅BrN₂O₄S, 432.07; m/z found, 454.9 [M+Na]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 7.67 (dd, J=7.9, 1.2, 1H), 7.52 (dd, J=7.7, 1.7, 1H), 7.41 (m, 1H), 7.36-7.26 (m, 1H), 6.92 (d, J=7.8, 1H), 4.51 (s, 2H), 3.50 (d, J=12.2, 2H), 3.45-3.35 (m, 1H), 2.92 (t, J=11.3, 2H), 1.77 (d, J=12.5, 2H), 1.45-1.30 (m, 11H).

Intermediate DX

Step A: 1-(2-Bromobenzylsulfonyl)piperidin-4-amine.HCl

A mixture of tert-butyl (1-((2-bromobenzyl)sulfonyl)piperidin-4-yl)carbamate (500 mg, 1.15 mmol) in HCl methanol (6 N, 20 mL) was stirred at rt for 24 hours, and then concentrated to dryness to give 1-(2-bromobenzylsulfonyl)piperidin-4-amine.HCl (400 mg, 94%), which was directly used for next step without any further purification. MS (ESI): mass calcd. for C₁₄H₁₉BrN₂O₃S, 332.02; m/z found, 332.9 [M+H]⁺.

Step B

To a mixture of 1-(2-bromobenzylsulfonyl)piperidin-4-amine.HCl (200 mg, 0.54 mmol) and Et₃N (164 mg, 1.62 mmol) in dry DCM (20 mL) was added acetyl chloride (85 mg, 1.1 mmol) drop-wise at rt. The reaction mixture was stirred at rt for 2 hours before concentrating to dryness and purifying the residue by HPLC to give the title compound (180 mg, 89%). MS (ESI): mass calcd. for C₁₄H₁₉BrN₂O₃S, 374.03; m/z found, 374.8 [M+H]⁺.

Intermediate DY

To a mixture of 1-(2-bromobenzylsulfonyl)piperidin-4-amine.HCl (200 mg, 0.54 mmol) and Et₃N (164 mg, 1.62 mmol) in dry THF (20 mL) was added (COCl₂)₃ (160 mg, 0.54 mmol) at rt. The reaction mixture was stirred at rt for 1 hour, and then a solution of NH₃ in THF (4 N, 10 mL) was added drop-wise. The resulting mixture was stirred at rt for 5 hours, concentrated to dryness and purified by HPLC to give the title compound (140 mg, 69%). MS (ESI): mass calcd. for C₁₃H₁₈BrN₃O₃S, 375.03; m/z found, 376.0 [M+H]⁺.

Intermediate DZ

The title compound was prepared using analogous conditions described for Intermediate DO utilizing 3-hydroxyazetidine. The product was isolated as a white solid. MS (ESI): mass calcd. for C₇H₄BrF₃O₂S, 304.97; m/z found 306.0 [M+H]⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.59 (dd, J=17.3, 7.8, 2H), 7.33 (m, 1H), 7.24-7.17 (m, 1H), 4.61-4.37 (m, 3H), 4.04-3.90 (m, 2H), 3.87-3.75 (m, 2H), 2.13 (br s, 1H).

Intermediate EA

To a 50 mL round-bottomed flask were added a stirbar, water (3.5 mL) and H₂SO₄ (5.0 mL, 18 M). The flask was then cooled to approximately −10° Celsius and treated with t-BuOH (0.70 mL, 7.5 mmol) followed by 2-bromo-thiophenol (0.60 mL, 5.0 mmol) (drop-wise over three minutes). The resulting mixture was stirred for 24 hours with gradual warming to rt. The reaction mixture was then added to a separatory funnel containing Et₂O and sat. NaHCO₃. The layers were mixed thoroughly and then separated. The organic layer was washed with 1 N NaOH, dried over MgSO₄, filtered and concentrated to dryness. The resulting residue was subjected to FCC gave the title compound (686 mg, 56%). ¹H NMR (500 MHz, DMSO-d₆) δ 7.75 (dd, J=7.8, 1.4, 1H), 7.68 (dd, J=7.6, 1.6, 1H), 7.43-7.37 (m, 1H), 7.36-7.29 (m, 1H), 1.28 (s, 9H).

Intermediate EB

To a 20 mL vial containing 411 mg (1.43 mmol) 2-bromophenyl)(tert-butyl)sulfane were added DCM (6.0 mL) and a stirbar. The vial was cooled to 0° Celsius and then charged with m-CPBA (77%, 922 mg, 4.43 mmol). The resultant mixture was stirred for 22 hours with gradual warming to rt. The mixture was diluted with EtOAc, washed with aq Na₂S₂O₃ followed by 1 N NaOH, dried over MgSO₄, filtered and concentrated to dryness. The residue was subjected to FCC to give the title compound (304 mg, 77%). ¹H NMR (500 MHz, CDCl₃) δ 8.09-8.02 (dd, J=7.9, 1.8, 1 H), 7.79-7.74 (dd, J=7.9, 1.3, 1H), 7.50-7.45 (m, 1H), 7.45-7.39 (m, 1H), 1.42-1.37 (s, 9H).

Intermediate EC

Step A: (2-Bromophenyl)(3-(methylthio)propyl)sulfane

To a solution of 1-bromo-3-chloropropane (1.2 mL, 12.0 mmol), DIPEA (2.1 mL, 12.0 mmol) in DCM (50 mL) was added 2-bromobenzenethiol (1.08 mL, 6.0 mmol) at 5° Celsius. The reaction mixture was warmed to rt and stirred for 4 hours. The reaction mixture was concentrated to dryness and the residue dissolved in ethanol (50 mL) and treated with NaSCH₃ (1.26 g, 18.0 mmol). The resulting mixture was stirred at rt for 18 h. The ethanol was then removed under reduced pressure and the residue taken up in DCM (100 mL) and washed with water (3×20 mL). The organic phase was dried over Na₂SO₄, filtered and concentrated to dryness to give (2-bromophenyl)(3-(methylthio)propyl)sulfane (2.3 g, crude).

Step B

The procedure to make 1-bromo-2-(3-(methylsulfonyl)propylsulfonyl)benzene is analogous to the one used to make Intermediate EB utilizing (2-bromophenyl)(3-(methylthio)propyl)sulfane. MS (ESI): mass calcd. for C₁₀H₁₃BrO₄S₂, 339.94; m/z found, 340.9 [M+H]⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.19-8.12 (m, 1H), 7.83-7.75 (m, 1H), 7.59-7.46 (m, 2H), 3.65 (t, J=7.1, 2H), 3.34-3.23 (m, 2H), 2.94 (s, 3H), 2.43-2.30 (m, 2H).

Intermediate ED

To a suspension of NaH (135 mg, 3.40 mmol, 60% in mineral oil) in anhydrous DMF (5 mL) was added 2-bromobenzenethiol (580 mg, 3.10 mmol) drop-wise at rt. After the resultant mixture was stirred at 20° Celsius for 10 min, bromoethane (670 mg, 6.10 mmol) was slowly added into the mixture. The reaction mixture was stirred at 30° Celsius for 14 hours in an oil bath. The reaction was diluted with water (60 mL) and extracted with petroleum ether (20 mL×2). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was dissolved in a mixture of methanol (10 mL) and water (15 mL) then treated with oxone (10 g, 15 mmol) portion-wise. The reaction mixture was stirred at 80° Celsius for 16 hours. The mixture was cooled to rt and the methanol removed. The remaining aqueous mixture was further diluted with water (50 mL) and extracted with DCM (20 mL×2). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, concentrated to dryness and purified by FCC to give the title compound (570 mg, 75%). ¹H NMR (300 MHz, CDCl₃) δ 8.18-8.12 (m, 1H), 7.76 (dd, J=7.8, 1.5, 1H), 7.52-7.43 (m, 2H), 3.46 (q, J=7.5, 2H), 1.26 (t, J=7.5, 3H).

Intermediate EE

The title compound was prepared using analogous conditions described for Intermediate ED utilizing 1-bromopropane. MS (ESI): mass calcd. for C₉H₁₁BrO₂S, 261.97; m/z found, 263.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) 68.15 (dd, J=7.8, 2.1, 1H), 7.78-7.74 (m, 1H), 7.54-7.42 (m, 2H), 3.45-3.37 (m, 2H), 1.80-1.67 (m, 2H), 1.02 (t. J=7.5, 3H).

Intermediate EF

The title compound was prepared using analogous conditions described for Intermediate ED utilizing 1-bromohexane. MS (ESI): mass calcd. for C₁₂H₁₇BrO₂S, 304.01; m/z found, 305.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.20-8.12 (m, 1H), 7.82-7.73 (m, 1H), 7.58-7.44 (m, 2H), 3.49-3.38 (m, 2H), 1.77-1.63 (m, 2H), 1.43-1.24 (m, 6H), 0.86 (t, J=6.6, 3H).

Intermediate EG

The title compound was prepared using analogous conditions described for Intermediate ED utilizing isopropyl bromide. MS (ESI): mass calcd. for C₉H₁₁BrO₂S, 261.97; m/z found, 263.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.14-8.10 (m, 1H), 7.77-7.72 (m, 1H), 7.50-7.43 (m, 2H), 3.93-3.83 (m, 1H), 1.30 (d, J=6.9, 6H).

Intermediate EH

The title compound was prepared using analogous conditions described for Intermediate ED utilizing isobutyl bromide. MS (ESI): mass calcd. for C₁₀H₁₃BrO₂S, 275.98; m/z found, 277.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.19-8.14 (m, 1H), 7.78-7.73 (m, 1H), 7.55-7.42 (m, 2H), 3.34 (d, J=6.6, 2H), 2.30-2.19 (m, 1H), 1.07 (d, J=6.6, 6H).

Intermediate EI

The title compound was prepared using analogous conditions described for Intermediate ED utilizing bromocyclopropane. MS (ESI): mass calcd. for C₉H₉BrO₂S, 259.95; m/z found, 261.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.11-8.04 (m, 1H), 7.76 (dd, J=7.8, 1.5, 1H), 7.52-7.43 (m, 2H), 3.22-3.14 (m, 1H), 1.36-1.31 (m, 2H), 1.08-1.03 (m, 2H).

Intermediate EJ

The title compound was prepared using analogous conditions described for Intermediate ED utilizing bromocyclobutane. MS (ESI): mass calcd. for C₁₀H₁₁BrO₂S, 273.97; m/z found, 275.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 2.1, 1H), 7.73 (dd, J=7.8, 1.5, 1H), 7.53-7.38 (m, 2H), 4.46 (p, J=8.1, 1H), 2.65-2.46 (m, 2H), 2.25-2.12 (m, 2H), 2.08-1.98 (m, 2H).

Intermediate EK

The title compound was prepared using analogous conditions described for Intermediate ED utilizing bromocyclopentane. MS (ESI): mass calcd. for C₁₁H₁₃BrO₂S, 287.98; m/z found, 289.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.20-8.10 (m, 1H), 7.80-7.72 (m, 1H), 7.58-7.39 (m, 2H), 4.27-4.12 (m, 1H), 2.12-1.97 (m, 2H), 1.93-1.75 (m, 4H), 1.70-1.57 (m, 2H).

Intermediate EL

The title compound was prepared using analogous conditions described for Intermediate ED utilizing trifluoroiodomethane. MS (ESI): mass calcd. for C₇H₄BrF₃O₂S, 287.91; m/z found, 289.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.15-8.07 (m, 1H), 7.80-7.72 (m, 1H), 7.52-7.43 (m, 2H).

Intermediate EM

To a solution of 2-aminophenylboronic acid hydrochloride (347 mg, 2.0 mmol) in pyridine (5 mL) was slowly added chlorosulfonylisopropane (300 mg, 2.1 mmol). The mixture was stirred below 20° Celsius for 14 hours, concentrated to dryness and the residue purified by FCC to give the title compound (280 mg, 57% yield). ¹H NMR (300 MHz, D₂O+DMSO-d₆) δ 8.57-8.55 (m, 1H), 7.82-7.79 (m, 1H), 7.49-7.46 (m, 1H), 7.40-7.37 (m, 2H), 7.08-7.05 (m, 1H), 3.31-3.27 (m, 1H), 1.26 (d, J=6.9, 6H).

Intermediate EN

A solution of 2-bromobenzene-1-sulfonyl chloride (0.300 g, 1.17 mmol) and 3,3-difluoropyrrolidine hydrochloride (0.169 g, 1.17 mmol) in pyridine (5 mL) was stirred for 16 hours at 60° Celsius. The reaction was then cooled to rt, diluted with EtOAc (25 mL), washed with 1 N HCl (2×25 mL), and brine (50 mL). The organic layer was isolated, dried over MgSO₄, filtered and concentrated to dryness to yield the title compound (0.335 g, 86%), The product was used without further purification. ¹H NMR (500 MHz, CDCl₃) δ 8.13-8.09 (m, 1H), 7.80-7.76 (m, 1H), 7.50-7.41 (m, 2H), 3.74 (t, J=12.8, 2H), 3.67 (t, J=7.2, 2H), 2.44-2.35 (m, 2H).

Intermediate EO

The title compound was prepared in a manner similar to that described in Intermediate EN using 4,4-difluoropiperidine. ¹H NMR (500 MHz, CDCl₃) δ 8.13-8.11 (m, 1H), 7.78-7.75 (m, 1H), 7.50-7.45 (m, 1H), 7.44-7.39 (m, 1H), 3.53-3.44 (m, 4H), 2.12-2.03 (m, 4H).

Intermediate EP

The title compound was prepared in a manner similar to that described in Intermediate EN using piperazine.

Intermediate EQ

The title compound was prepared in a manner similar to that described in Intermediate EN using 3,3-difluoropiperidine. ¹H NMR (500 MHz, CDCl₃) δ 8.14-8.11 (m, 1H), 7.77-7.74 (m, 1H), 7.49-7.44 (m, 1H), 7.44-7.39 (m, 1H), 3.54 (t, J=11.2, 2H), 3.32 (t, J=5.5, 2H), 2.04-1.94 (m, 2H), 1.91-1.85 (m, 2H).

Intermediate ER

The title compound was prepared in a manner similar to that described in Intermediate EN using 3,3-difluoroazetidine. ¹H NMR (500 MHz, CDCl₃) 8.11-8.06 (m, 1H), 7.80-7.76 (m, 1H), 7.50-7.42 (m, 2H), 4.42 (t, J=12.1, 4H).

Intermediate ES

The title compound was prepared in a manner similar to that described in Intermediate EN using azepane.

Intermediate ET

The title compound was prepared in a manner similar to that described in Intermediate EN using 4-(trifluoromethyl)piperidin-4-ol.

Intermediate EU

A solution of 2-bromobenzene-1-sulfonyl chloride (50 mg, 0.20 mmol), tert-butyl piperidin-4-ylcarbamate (49 mg, 0.25 mmol), and diisopropylethyl amine (0.101 mL, 0.59 mmol) in CH₂Cl₂ was stirred for 90 min at rt. The reaction mixture was then concentrated to dryness to give the title compound in quantitative yield. The product was used without further purification.

Intermediate EV

The title compound was prepared in a manner similar to that described in Intermediate EU using racemic tert-butyl piperidin-3-ylcarbamate. ¹H NMR (400 MHz, CDCl₃) δ 8.12-8.09 (m, 1H), 7.77-7.74 (m, 1H), 7.48-7.38 (m, 2H), 4.91 (d, J=8.0, 1H), 3.79 (s, 1H), 3.45 (s, 1H), 3.32 (d, J=12.4, 1H), 3.23-3.07 (m, 2H), 1.86-1.59 (m, 4H), 1.45 (s, 9H).

Intermediate EW

A solution of racemic tert-butyl (1-((2-bromophenyl)sulfonyl)piperidin-3-yl)carbamate (82 mg, 0.20 mmol) in CH₂Cl₂ (5 mL) was treated with 2 N HCl/Et₂O (1 mL, 2 mmol) and stirred 16 hours at rt. The reaction mixture was then concentrated to dryness to give the title compound in quantitative yield. The product was used without further purification.

Intermediate EX

The title compound was prepared in a manner similar to that described in Intermediate EW using tert-butyl (1-((2-bromophenyl)sulfonyl)piperidin-4-yl)carbamate.

Intermediate EY

The title compound was prepared in a manner similar to that described in Intermediate EU using 1-(methylsulfonyl)piperazine.

Intermediate EZ

The title compound was prepared in a manner similar to that described in Intermediate EU using 1-(piperazin-1-yl)ethanone.

Intermediate FA

The title compound was prepared in a manner similar to that described in Intermediate EU using cyclopropyl(piperazin-1-yl)methanone.

Intermediate FB

The title compound was prepared in a manner similar to that described in Intermediate EU using 2-(piperazin-1-yl)ethanol.

Intermediate FC

The title compound was prepared in a manner similar to that described in Intermediate EU using 1-cyclopropylpiperazine.

Intermediate FD

The title compound was prepared in a manner similar to that described in Intermediate EU using racemic-octahydropyrrolo[1,2-a]pyrazine.

Intermediate FE

The title compound was prepared in a manner similar to that described in Intermediate EU using piperazin-2-one.

Intermediate FF

The title compound was prepared in a manner similar to that described in Intermediate EU using racemic-piperidine-3-carbonitrile.

Intermediate FG

The title compound was prepared in a manner similar to that described in Intermediate EU using piperidine-4-carbonitrile.

Intermediate FH

The title compound was prepared in a manner similar to that described in Intermediate EU using 1-methylpiperazine.

Intermediate FI

A solution of 2-bromobenzene-1-sulfonyl chloride (0.500 g, 1.96 mmol), 4-acetamidopiperidine (0.335 g, 2.45 mmol), and diisopropylethyl amine (1.0 mL, 5.8 mmol) in CH₂Cl₂ (5 mL) was stirred for 15 min at rt. The reaction mixture was then washed with 1 N HCl (2×5 mL) followed by brine (10 mL). The organic layer was isolated, dried over MgSO₄, filtered, and concentrated to dryness to give the title compound (0.672 g, 95%). The product was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 8.09-8.05 (m, 1H), 7.77-7.74 (m, 1H), 7.49-7.38 (m, 2H), 6.08 (d, J=8.0, 1H), 3.87-3.79 (m, 2H), 2.93-2.85 (m, 2H), 2.00-1.93 (m, 5H), 1.59-1.51 (m, 3H).

Intermediate FJ

The title compound was prepared in a manner similar to that described in Intermediate FI using piperidin-4-ol. ¹H NMR (400 MHz, CDCl₃) δ 8.11-8.07 (m, 1H), 7.77-7.73 (m, 1H), 7.48-7.36 (m, 2H), 3.92-3.84 (m, 1H), 3.65-3.55 (m, 2H), 3.18-3.11 (m, 2H), 1.99-1.88 (m, 2H), 1.69-1.59 (m, 2H).

Intermediate FK

The title compound was prepared in a manner similar to that described in Intermediate FI using piperidin-4-ylmethanol. ¹H NMR (400 MHz, CDCl₃) δ 8.11-8.07 (m, 1H), 7.76-7.73 (m, 1H), 7.47-7.36 (m, 2H), 3.90-3.84 (m, 2H), 3.50 (d, J=6.4, 2H), 2.82-2.73 (m, 2H), 1.79-1.84 (m, 2H), 1.67-1.56 (m, 1H), 1.37-1.24 (m, 2H).

Intermediate FL

The title compound was prepared in a manner similar to that described in Intermediate FI using 2-(piperidin-4-yl)ethanol. ¹H NMR (400 MHz, CDCl₃) δ 8.10-8.06 (m, 1H), 7.76-7.72 (m, 1H), 7.47-7.36 (m, 2H), 3.86-3.79 (m, 2H), 3.68 (t, J=6.3, 2H), 2.80-2.72 (m, 2H), 1.78-1.71 (m, 2H), 1.56-1.51 (m, 3H), 1.37-1.23 (m, 2H).

Intermediate FM

The title compound was prepared in a manner similar to that described in Intermediate FI using racemic piperidin-3-ol. ¹H NMR (400 MHz, CDCl₃) δ 8.13-8.09 (m, 1H), 7.77-7.73 (m, 1H), 7.50-7.37 (m, 2H), 3.89-3.82 (m, 1H), 3.57-3.51 (m, 1H), 3.40-3.32 (m, 1H), 3.24-3.16 (m, 1H), 3.06-3.00 (m, 1H), 2.16 (s, 1H), 1.94-1.80 (m, 2H), 1.70-1.50 (m, 2H).

Intermediate FN

The title compound was prepared in a manner similar to that described in Intermediate FI using racemic piperidin-3-ylmethanol. ¹H NMR (400 MHz, CDCl₃) δ 8.11-8.07 (m, 1H), 7.76-7.72 (m, 1H), 7.47-7.36 (m, 2H), 3.76-3.51 (m, 4H), 3.02-2.94 (m, 1H), 2.83-2.75 (m, 1H), 1.94-1.84 (m, 1H), 1.82-1.71 (m, 3H), 1.67-1.57 (m, 1H), 1.29-1.17 (m, 1H).

Intermediate FO

The title compound was prepared in a manner similar to that described in Intermediate FI using racemic 2-(piperidin-3-yl)ethanol. ¹H NMR (400 MHz, CDCl₃) δ 8.10-8.06 (m, 1H), 7.76-7.72 (m, 1H), 7.47-7.36 (m, 2H), 3.72-3.62 (m, 4H), 2.88-2.80 (m, 1H), 2.60-2.53 (m, 1H), 1.89-1.39 (m, 7H), 1.16-1.03 (m, 1H).

Intermediate FP

The title compound was prepared in a manner similar to that described in Intermediate FI using thiomorpholine 1,1-dioxide. ¹H NMR (400 MHz, CDCl₃) δ 8.17-8.11 (m, 1H), 7.81-7.76 (m, 1H), 7.53-7.43 (m, 2H), 3.92-3.86 (m, 4H), 3.24-3.13 (m, 4H).

Intermediate FQ

The title compound was prepared in a manner similar to that described in Intermediate FI using (1S,2S)-2-amino-1-phenylpropane-1,3-diol.

Intermediate FR

The title compound was prepared in a manner similar to that described in Intermediate FI using (S)-2-amino-4-methylpentan-1-ol.

Intermediate FS

The title compound was prepared in a manner similar to that described in Intermediate FI using 3-aminopropan-1-ol

Intermediate FT

The title compound was prepared in a manner similar to that described in Intermediate FI using (S)-2-amino-2-phenylethanol.

Intermediate FU

The title compound was prepared in a manner similar to that described in Intermediate FI using (R)-2-amino-2-phenylethanol

Intermediate FV

The title compound was prepared in a manner similar to that described in Intermediate FI using (1R,2S)-2-amino-1-phenylpropan-1-ol.

Intermediate FW

The title compound was prepared in a manner similar to that described in Intermediate FI using (2S,3S)-2-amino-3-methylpentan-1-ol.

Intermediate FX

The title compound was prepared in a manner similar to that described in Intermediate FI using (1R,2R)-2-aminocyclohexanol.

Intermediate FY

The title compound was prepared in a manner similar to that described in Intermediate FI using (1S,2R)-2-aminocyclohexanol

Intermediate FZ

The title compound was prepared in a manner similar to that described in Intermediate FI using (R)-2-aminobutan-1-ol.

Intermediate GA

A solution of 2-bromobenzene-1-sulfonyl chloride (100 mg, 0.39 mmol), 2,6-dimethylpiperazine (56 mg, 0.49 mmol), and diisopropylethyl amine (0.202 mL, 1.17 mmol) in CH₂Cl₂ (2.5 mL) was allowed to stir for 15 min at rt. The reaction mixture was then directly subjected to FCC purification to give the title compound (0.105 g, 81%). ¹H NMR (600 MHz, CDCl₃) δ 8.09-8.07 (m, 1H), 7.76-7.73 (m, 1H), 7.47-7.44 (m, 1H), 7.43-7.37 (m, 1H), 3.70-3.66 (m, 2H), 2.97-2.91 (m, 2H), 2.38-2.33 (m, 2H), 1.06-1.04 (m, 6H).

Intermediate GB

The title compound was prepared in a manner similar to that described in Intermediate EU using N-methylpiperidin-4-amine.

Intermediate GC

The title compound was prepared in a manner similar to that described in Intermediate EU using N,N-dimethylpiperidin-4-amine.

Intermediate GD

The title compound was prepared using analogous conditions to those described in Intermediate AM using cycloleucinol. ¹H NMR (500 MHz, CDCl₃) δ 8.16 (dd, J=7.8, 1.8, 1H), 7.75 (dd, J=7.9, 1.3, 1H), 7.51-7.45 (m, 1H), 7.44-7.39 (m, 1H), 5.25 (s, 1H), 4.23 (s, 1H), 3.59 (d. J=6.4, 2H), 2.36 (t, J=6.5, 1H), 1.90-1.78 (m, 1H), 1.77-1.60 (m, 4H), 1.56-1.49 (m, 2H).

Intermediate GE

The title compound was prepared using analogous conditions to those described in Intermediate AM using 3-phenyl-3-pyrrolidinol. ¹H NMR (500 MHz, CDCl₃) δ 8.17 (dd, J=7.8, 1.8, 1H), 7.77 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 3H), 7.43-7.34 (m, 3H), 7.34-7.27 (m, 1H), 3.82-3.75 (m, 3H), 3.71 (d, J=10.8, 1H), 2.46-2.37 (m, 1H), 2.29-2.23 (m, 1H), 2.15 (s, 1H).

Intermediate GF

The title compound was prepared using analogous conditions to those described in Intermediate AM using (R)-3-hydroxypyrrolidine. ¹H NMR (500 MHz, CDCl₃) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.75 (dd, J=7.8, 1.3, 1H), 7.48-7.42 (m, 1H), 7.39 (m, 1H), 4.57-4.47 (m, 1H), 3.63-3.51 (m, 3H), 3.48-3.40 (m, 1H), 2.14-2.04 (m, 1H), 2.04-1.94 (m, 1H), 1.94-1.84 (m, 1H).

Intermediate GG

The title compound was prepared using analogous conditions to those described in Intermediate AM using (S)-3-hydroxypyrrolidine. ¹H NMR (500 MHz, CDCl₃) δ 8.12 (dd, J=7.8, 1.7, 1H), 7.75 (dd, J=7.8, 1.3, 1H), 7.45 (m, 1H), 7.39 (m, 1H), 4.56-4.46 (m, 1H), 3.65-3.50 (m, 3H), 3.44 (m, 1H), 2.13-2.03 (m, 1H), 2.03-1.87 (m, 2H).

Intermediate GH

The title compound was prepared using analogous conditions to those described in Intermediate AM using (racemic)-[1,3′-bipyrrolidin]-4′-ol. ¹H NMR (500 MHz, CDCl₃) δ 8.12 (dd, J=7.8, 1.8, 1H), 7.75 (dd, J=7.8, 1.3, 1H), 7.48-7.34 (m, 2H), 4.42-4.29 (m, 1H), 3.74 (m, 2H), 3.36 (m, 2H), 2.83 (dd, J=10.9, 6.3, 1H), 2.70-2.43 (m, 4H), 1.83-1.66 (m, 4H).

Intermediate GI

The title compound was prepared using analogous conditions to those described in Intermediate AM using Racemic-4-morpholinopyrrolidin-3-ol. ¹H NMR (500 MHz, CDCl₃) δ 8.11 (dd, J=7.8, 1.8, 1H), 7.76 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.44-7.38 (m, 1H), 4.35 (t, J=7.4, 1H), 3.78-3.70 (m, 2H), 3.70-3.67 (m, 4H), 3.35-3.26 (m, 2H), 2.89 (m, 1H), 2.65-2.56 (m, 2H), 2.52-2.44 (m, 2H).

Intermediate GJ

The title compound was prepared using analogous conditions to those described in Intermediate AM using Racemic-4-(4-methylpiperazin-1-yl)pyrrolidin-3-ol. ¹H NMR (500 MHz, CDCl₃) δ 8.10 (dd, J=7.8, 1.8, 1H), 7.76 (dd, J=7.8, 1.3, 1H), 7.51-7.37 (m, 2H), 4.37 (dd, J=12.1, 5.8, 1H), 3.81-3.65 (m, 2H), 3.29 (m, 2H), 2.99 (dd, J=13.1, 7.3, 1H), 2.91-2.57 (m, 8H), 2.45 (s, 3H).

Intermediate GK

The title compound was prepared using analogous conditions to those described in Intermediate EU using 2-bromobenzene-1-sulfonyl chloride and piperazin-2-one. MS (ESI): mass calcd. for C₁₀H₁₁BrN₂O₃S, 317.96; m/z found, 319.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.12 (s, 1H), 8.09-8.00 (m, 1H), 7.93-7.89 (m, 1H), 7.62 (m, 2H), 3.79 (s, 2H), 3.50-3.43 (m, 2H), 3.18 (m, 2H).

Intermediate GL

The title compound was prepared in a manner similar to that described for Intermediate EU using 2-aminoethanol. ¹H NMR (500 MHz, CDCl₃) δ 8.17-8.11 (dd, J=7.8, 1.8, 1H), 7.79-7.72 (dd. J=7.8, 1.3, 1H), 7.52-7.46 (m, 1H), 7.46-7.40 (m, 1H), 5.79-5.66 (t, J=5.7, 1H), 3.73-3.65 (dd, J=5.6, 4.6, 2H), 3.13-3.03 (m, 2H), 2.14 (s, 1H).

Intermediate GM

The title compound was prepared in a manner similar to that described for Intermediate EU using (R)-pyrrolidin-2-ylmethanol. ¹H NMR (500 MHz, CDCl₃) δ 8.25-8.04 (m, 1H), 7.86-7.70 (m, 1H), 7.54-7.45 (m, 1H), 7.45-7.39 (m, 1H), 4.11-3.96 (m, 1H), 3.75-3.57 (m, 2H), 3.58-3.46 (dd, J=10.8, 4.5, 1H), 3.46-3.36 (m, 1H), 2.91-2.39 (m, 1H), 2.14-1.85 (m, 3H), 1.85-1.74 (dd, J=10.7, 5.3, 1H).

Intermediate GN

The title compound was prepared in a manner similar to that described for Intermediate EU using (S)-pyrrolidin-2-ylmethanol. ¹H NMR (500 MHz, CDCl₃) δ 8.18-8.07 (dd, J=7.9, 1.8, 1H), 7.81-7.70 (dd, J=7.9, 1.3, 1H), 7.52-7.45 (m, 1H), 7.45-7.38 (m, 1H), 4.08-3.92 (m, 1H), 3.70-3.56 (m, 2H), 3.55-3.45 (m, 1H), 3.45-3.35 (m, 1H), 2.76-2.67 (t. J=6.1, 1H), 2.03-1.87 (m, 3H), 1.84-1.74 (m, 1H).

Intermediate GO

The title compound was prepared in a manner similar to that described for Intermediate EU using (R)-1-aminopropan-2-ol. ¹H NMR (500 MHz, CDCl₃) δ 8.17-8.09 (dd, J=7.8, 1.8, 1H), 7.81-7.71 (dd, J=7.8, 1.3, 1H), 7.51-7.46 (m, 1H), 7.46-7.40 (m, 1H), 5.65-5.60 (t, J=6.1, 1H), 3.98-3.81 (m, 1H), 3.08-2.96 (m, 1H), 2.85-2.58 (m, 1H), 2.04-2.02 (d, J=4.3, 1H), 1.18-1.14 (d, J=6.3, 3H).

Intermediate GP

The title compound was prepared in a manner similar to that described for Intermediate EU using (S)-1-aminopropan-2-ol. ¹H NMR (500 MHz, CDCl₃) δ 8.21-8.04 (dd, J=7.8, 1.8, 1H), 7.78-7.72 (dd, J=7.8, 1.3, 1H), 7.53-7.46 (m, 1H), 7.46-7.38 (m, 1H), 5.71-5.54 (d, J=5.9, 1H), 3.97-3.84 (m, 1H), 3.07-2.96 (m, 1H), 2.80-2.69 (m, 1H), 2.03-1.95 (d, J=4.4, 1H), 1.19-1.07 (d, J=6.3, 3H).

Intermediate GQ

The title compound was prepared in a manner similar to that described for Intermediate EU using 1-(aminomethyl)cyclohexanol. ¹H NMR (500 MHz, CDCl₃) δ 8.17-8.09 (dd. J=7.8, 1.8, 1H), 7.78-7.70 (dd, J=7.8, 1.3, 1H), 7.51-7.45 (m, 1H), 7.45-7.39 (m, 1H), 5.56-5.45 (t, J=6.3, 1H), 3.71 (s, 1H), 2.89-2.77 (d, J=6.4, 2H), 1.60-1.28 (m, 10H).

Intermediate GR

The title compound was prepared in a manner similar to that described for Intermediate EU using (S)-tert-butyl pyrrolidin-3-ylcarbamate. ¹H NMR (500 MHz, CDCl₃) δ 8.17-8.06 (dd, J=7.8, 1.8, 1H), 7.81-7.67 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.37 (m, 1H), 4.73 (s, 1H), 4.25 (s, 1H), 3.65-3.51 (d, J=8.8, 2H), 3.51-3.43 (m, 1H), 3.37-3.20 (dd, J=10.0, 3.8, 1H), 2.33-2.12 (m, 1H), 1.98-1.81 (dd, J=12.8, 6.9, 1H), 1.43 (s, 9H).

Intermediate GS

The title compound was prepared in a manner similar to that described for Intermediate EU using (R)-tert-butyl pyrrolidin-3-ylcarbamate. ¹H NMR (500 MHz, CDCl₃) δ 8.15-8.10 (dd, J=7.8, 1.8, 1H), 7.79-7.73 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.37 (m, 1H), 4.73 (s, 1H), 4.25 (s, 1H), 3.65-3.52 (m, 2H), 3.51-3.43 (m, 1H), 3.34-3.22 (m, 1H), 2.25-2.13 (m, 1H), 1.95-1.82 (dd, J=12.6, 7.0, 1H), 1.43 (s, 9H).

Intermediate GT

The title compound was prepared in a manner similar to that described for Intermediate EU using 2-(piperazin-1-yl)pyrazine. ¹H NMR (500 MHz, CDCl₃) δ 8.16-8.09 (m, 2H), 8.07-8.02 (dd, J=2.6, 1.5, 1H), 7.90-7.87 (d, J=2.6, 1H), 7.78-7.74 (dd, J=7.9, 1.3, 1H), 7.51-7.45 (m, 1H), 7.44-7.37 (m, 1H), 3.74-3.58 (m, 4H), 3.48-3.38 (m, 4H).

Intermediate GU

The title compound was prepared in a manner similar to that described for Intermediate EU using 2-(piperazin-1-yl)pyrimidine. ¹H NMR (500 MHz, CDCl₃) δ 8.33-8.27 (d, J=4.7, 2H), 8.15-8.06 (dd, J=7.9, 1.7, 1H), 7.78-7.71 (dd, J=7.9, 1.3, 1H), 7.50-7.43 (m, 1H), 7.43-7.36 (m, 1H), 6.57-6.43 (t, J=4.7, 1H), 3.98-3.78 (m, 4H), 3.42-3.31 (m, 4H).

Intermediate GV

The title compound was prepared in a manner similar to that described for Intermediate EU using methylamine and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500 MHz, CDCl₃) δ 8.46-8.29 (d, J=2.4, 1H), 7.99-7.79 (d, J=8.3, 1H), 7.79-7.59 (dd. J=8.3, 2.3, 1H), 5.20-5.01 (d, J=6.4, 1H), 2.80-2.56 (d, J=5.3, 3H).

Intermediate GW

The title compound was prepared in a manner similar to that described for Intermediate EU using ethylamine and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500 MHz, CDCl₃) δ 8.43-8.38 (m, 1H), 7.93-7.86 (dd, J=8.3, 0.9, 1H), 7.70-7.62 (m, 1H), 5.08 (s, 1H), 3.11-2.96 (m, 2H), 1.19-1.09 (t, J=7.2, 3H).

Intermediate GX

The title compound was prepared in a manner similar to that described for Intermediate EU using 2-aminoethanol and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500 MHz, CD₃OD) δ 8.35-8.30 (m, 1H), 8.07-7.98 (dd, J=8.2, 0.9, 1H), 7.82-7.76 (m, 1H), 3.59-3.50 (t, J=5.9, 2H), 3.10-3.02 (t, J=5.9, 2H).

Intermediate GY

The title compound was prepared in a manner similar to that described for Intermediate EU using 1-methylpiperazine and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500 MHz, CDCl₃) δ 8.37-8.28 (d, J=2.2, 1H), 7.98-7.86 (d, J=8.2, 1H), 7.73-7.59 (d, J=8.2, 1H), 3.45-3.31 (t, J=5.0, 4H), 2.60-2.42 (t, J=4.9, 4H), 2.40-2.20 (d, J=1.5, 3H).

Intermediate GZ

The title compound was prepared in a manner similar to that described for Intermediate EU using piperazin-2-one and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (400 MHz, CDCl₃) δ 8.43-8.35 (d, J=2.3, 1H), 7.99-7.89 (d, J=8.2, 1H), 7.77-7.65 (dd, J=8.3, 2.3, 2H), 6.95 (s, 2H), 3.99 (s, 3H), 3.73-3.58 (t, J=5.3, 3H), 3.51-3.42 (m, 3H), 1.36-1.04 (m, 1H).

Intermediate HA

To a 500 mL round-bottomed flask were added 5-bromo-2-aminopyrimidine (4.0 g, 23 mmol), 4-chloro-2-fluorophenylboronic acid (3.9 g, 23 mmol), palladium(II)trifluoroacetate (240 mg, 0.72 mmol), and triphenylphoshine (373 mg, 1.40 mmol). The reaction vessel was fitted with a rubber septum, sparged with nitrogen and then charged with sparged toluene (75 mL), ethanol (75 mL), and a 2M solution of sodium carbonate (42 mL, 84 mmol) (solvents were sparged individually nitrogen gas for 30 minutes). The resulting mixture was stirred vigorously and heated at 50° Celsius. After 12 hours, the mixture was cooled to rt and treated with 100 mL of water. The precipitate was isolated via vacuum filtration, and the filtrate extracted with EtOAC. The EtOAc solution was dried, filtered and concentrated to dryness. The resultant solids were recrystallized from IPA (80 mL) to afford title compound (3.8 g, 74%). MS (ESI): mass calcd. for C₁₀H₇ClFN₃, 223.03; m/z found, 224.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.44 (d, J=1.4, 2H), 7.59 (m, 1H), 7.54 (dd, J=10.7, 2.1, 1H), 7.37 (dd, J=8.3, 2.1, 1H), 6.94 (s, 2H).

Intermediate HB

Nitrogen sparged 1,4-dioxane (80 mL) was added to a 250 mL round-bottomed flask containing 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.1 g, 8.4 mmol), 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine (1.5 g, 6.7 mmol), chloro(2-dicyclohexyl-phosphino-2′,4′,6′-triisopropyl-1-1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (X-Phos pre-catalyst) (0.1 g, 0.13 mmol), and potassium acetate (1.9 g, 20 mmol). The reaction mixture was heated at 80° Celsius for 4 hours before cooling to rt, concentrating to dryness, and the residue subjected to FCC to provide the title compound (1.8 g, 83%). MS (ESI): mass calcd. for C₁₆H₁₉BFN₃O₂, 315.15; m/z found, 316.4 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.53 (d, J=1.3 Hz, 2H), 7.64 (dd. J=7.6, 1.0 Hz, 1H), 7.58 (dd, J=11.0, 0.9 Hz, 1H), 7.38 (m, 1H), 5.23 (s, 2H), 1.36 (s, 12H).

Example 1

Method 1

To a 100 mL round-bottomed flask were added a stirbar, 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine, (3.639 g, 13.57 mmol) (2-(methylsulfonyl)-phenyl)boronic acid (4.076 g, 20.38 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (1.136 g, 1.391 mmol) and K₂CO₃ (5.663 g, 40.97 mmol). The flask was flushed with nitrogen and then charged with 56.0 mL thoroughly sparged (1 hour of bubbling N₂) DMSO. The flask was heated at 80° Celsius for 5.25 hours before cooling to room temperature, diluting the reaction mixture with EtOAc and filtering the mixture through a pad of celite. The filtrate was washed twice with 1 N NaOH and the organic layer dried over MgSO₄. Filtering and concentrating the filtrate to dryness gave the crude product. The soluble portion of the residue was then subjected to FCC to give the title compound. (3.80 g, 81%).

Method 2 Step A: 5-(4-Chloro-2-fluorophenyl)pyrazin-2-amine

To a nitrogen flushed flask containing 4-chloro-2-fluorobenzene boronic acid (40.0 g, 229 mmol), 2-amino-5-bromopyrazine (39.9 g, 229 mmol), palladium(II) trifluoroacetate (1.5 g, 4.6 mmol), and triphenylphosphine (2.4 g, 9.2 mmol) were added sparged toluene (750 mL), ethanol (750 mL), and 2 M Na₂CO_(3(aq)) (418 mL, 836 mmol). The mixture was stirred and heated at 50° Celsius for 15 hours and then cooled to rt. Water (750 mL) was added and the layers were separated. The aqueous layer was washed with ethyl acetate (750 mL). The combined organic layers were washed with brine (500 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give 55.4 g of crude product. The crude solid was crystallized from toluene (450 mL) to provide the title compound (40.0 g, 78%). MS (ESI): mass calcd. for C₁₀H₇ClFN₃, 223.03; m/z found, 224.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.34 (dd, J=2.6, 1.5, 1H), 8.03 (d, J=1.6, 1H), 7.89 (m, 1H), 7.52 (dd, J=11.3, 2.1, 1H), 7.38 (dd, J=8.5, 2.1, 1H), 6.79 (s, 2H).

Step B: 5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine

To a nitrogen sparged flask containing 5-(4-chloro-2-fluorophenyl)pyrazin-2-amine (34.0 g, 152 mmol), 2-methylsulfonylphenylboronic acid (38.0 g, 190 mmol), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (2.39 g, 3.0 mmol) were added sparged THF (300 mL) and K₃PO_(4(aq)) (608 mL, 0.5 M). The mixture was stirred for 15 hours at rt and then concentrated under reduced pressure to remove the THF. The remaining portion was treated with toluene (325 mL) and THF (25 mL). The biphasic slurry was stirred for 20 h at rt and then filtered and the isolated solid washed with water (150 mL) and toluene (150 mL). The filter cake was dried to provide the title compound (47.1 g, 90%). MS (ESI): mass calcd. for C₁₇H₁₄FN₃O₂S, 343.08; m/z found, 344.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.41 (dd, J=2.4, 1.5, 1H), 8.12 (dd, J=7.9, 1.4, 1H), 8.04 (d, J=1.5, 1H), 7.93 (m, 1H), 7.80 (m, 1H), 7.72 (m, 1H), 7.48 (dd, J=7.6, 1.4, 1H), 7.37 (dd, J=12.3, 1.7, 1H), 7.32 (dd, J=8.1, 1.7, 1H), 6.76 (s, 2H), 2.95 (s, 3H).

Example 2

The title compound was prepared using analogous conditions to those described in Example 1 using (2-(methylsulfonamido)phenyl)boronic acid. MS (ESI): mass calcd. for C₁₇H₁₅FN₄O₂S, 358.09; m/z found, 359.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 9.11 (s, 1H), 8.40 (dd, J=2.3, 1.4, 1H), 8.04 (d, J=1.5, 1H), 7.97-7.89 (m, 1H), 7.50-7.34 (m, 6H), 6.71 (s, 2H), 2.84 (s, 3H).

Example 3

The title compound was prepared using analogous conditions to those described in Example 1 using 2-(methylsulfonyl)phenylboronic acid and 5-(4-bromo-2-fluorophenyl)-6-cyanopyrazin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₃FN₄O₂S, 368.07; m/z found, 369.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.26 (s, 1H), 8.13 (dd, J=8.0, 1.4, 1H), 7.84-7.77 (m, 1H), 7.76-7.70 (m, 1H), 7.69-7.62 (m, 1H), 7.51 (dd, J=7.6, 1.4, 1H), 7.46 (dd, J=11.0, 1.6, 1H), 7.42-7.35 (m, 3H), 2.97 (s, 3H).

Example 4

The title compound was prepared using analogous conditions to those described in Example 1 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-de) δ 8.39 (dd. J=2.2, 1.4, 1H), 8.09-8.02 (m, 2H), 7.93-7.87 (m, 1H), 7.68-7.63 (m, 1H), 7.63-7.57 (m, 1H), 7.38 (dd, J=7.5, 1.4, 1H), 7.33-7.26 (m, 2H), 6.94 (s, 1H), 6.71 (s, 2H), 1.02 (s, 9H).

Example 5

Method 1

To a 50 mL round-bottomed flask were added 1.071 g (2.67 mmol) 4′-(5-aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, a stirbar and 20 mL TFA. The mixture was heated at 50° Celsius for 2 hours and then carefully and slowly added to 300 mL rapidly stirring sat. NaHCO₃. The resulting mixture was stirred for 30 min and then the solid was isolated via vacuum filtration. The solid was washed with 200 mL deionized water, air dried and then further dried under high vacuum with gentle heating to give the title compound (751 mg, 82%).

Method 2 Step A: 4′-(5-Aminopyrazin-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide

To a nitrogen flushed flask containing 5-(4-chloro-2-fluorophenyl)pyrazin-2-amine (82.8 g, 370 mmol), (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid (100.0 g, 388.9 mmol), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (5.83 g, 7.41 mmol) were added N₂ sparged THF (926 mL) and sparged 0.5 M K₃PO_(4(aq)) (1.65 L, 825 mmol). The mixture was stirred for 15 hours at room temperature. The layers were separated and the organic layer was washed with 600 mL brine, dried over MgSO₄, filtered, and concentrated to dryness to give a solid residue. The solid was dissolved in 900 mL DMA, stirred with 60 g activated charcoal at 80° Celsius for 2 hours, and then stirred at room temperature for an additional 16 hours. The charcoal was removed by filtration and then washed with 150 mL DMA. The combined filtrates were treated three times with fresh Silicycle brand SiliaMetS Thiol Pd Scavenger (30 g, 15 g, 7.5 g) in DMA at 80° Celsius for 8 hours to 16 hours. Upon cooling to rt the scavenger was filtered off and the filtrate was concentrated to dryness. The resulting solid was triturated in toluene (1.2 L) at 90° Celsius for 2 hours. Upon cooling to rt the solid was collected by filtration and washed twice with toluene (700 mL) and twice with hexanes (700 mL) yielding the title compound (120.0 g, 80.9%). MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.42-8.37 (m, 1H), 8.10-8.02 (m, 2H), 7.95-7.86 (m, 1H), 7.70-7.63 (m, 1H), 7.63-7.58 (m, 1H), 7.41-7.35 (m, 1H), 7.35-7.26 (m, 2H), 7.00-6.92 (s, 1H), 6.79-6.66 (s, 2H), 1.10-0.95 (s, 9H).

Step B: 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide

A solution of 4′-(5-aminopyrazin-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (130.0 g, 298.0 mmol), anisole (97.4 mL, 894.0 mmol), and TFA (228.0 mL, 2.98 mol) was stirred at 60° Celsius for 16 hours. The reaction was cooled to rt, concentrated to dryness, and partitioned between 600 mL H₂O and 600 mL acetone. 750 mL sat. NaHCO_(3(aq)), was added over 30 min. The resulting precipitate was isolated via filtration and rinsed with 300 mL H₂O then 300 mL acetone. The precipitate was triturated with 1.5 L acetone at 50° Celsius for 16 hours. After cooling to room temperature the solid was collected by filtration and rinsed twice with 250 mL acetone then dried in a vacuum oven at 50° Celsius for 16 hours yielding the title compound (74.3 g, 72.4%). MS (ESI): mass calcd. for C₁₆H₁₃FN₄O₂S, 344.07; m/z found, 345.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.44-8.36 (s, 1H), 8.10-8.02 (m, 2H), 7.92-7.85 (m, 1H), 7.69-7.59 (m, 2H), 7.43-7.35 (m, 3H), 7.35-7.27 (m, 2H), 6.77-6.69 (s, 2H). Elemental analysis: calcd. for C₁₆H₁₃FN₄O₂S, C, 55.80; H, 3.81; N, 16.27; measured: C, 55.43; H, 3.54; N, 16.22.

Example 6

To a 5 mL microwave vial were added a stirbar, 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (54 mg, 0.17 mmol), 2-bromo-N-cyclohexylbenzenesulfonamide (58 mg, 0.18 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (10 mg, 0.013 mmol), and K₂CO₃(80 mg, 0.58 mmol). The vial was capped and flushed with nitrogen before adding 1 mL N₂ sparged DMSO and heating at 80° Celsius for 20 hours. The vial was cooled to rt and the reaction mixture subjected to FCC purification to give the title compound (45 mg, 62%). MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₂S, 426.15; m/z found, 427.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.43-8.35 (m, 1H), 8.05-8.03 (d, J=1.4, 1H), 8.03-7.99 (dd, J=7.9, 1.4, 1H), 7.92-7.84 (m, 1H), 7.70-7.64 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.37 (m, 2H), 7.32-7.24 (m, 2H), 6.72 (s, 2H), 2.85-2.72 (m, 1H), 1.69-1.52 (m, 5H), 1.48-1.39 (m, 1H), 1.19-0.93 (m, 5H).

Example 7

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(2-methylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.42-8.37 (m, 1H), 8.05-8.01 (d, J=1.5, 1H), 7.95-7.91 (dd, J=7.9, 1.3, 1H), 7.91-7.86 (m, 1H), 7.70-7.65 (m, 1H), 7.64-7.59 (m, 1H), 7.55-7.49 (m, 1H), 7.44-7.40 (dd, J=7.5, 1.4, 1H), 7.33-7.26 (m, 2H), 6.73 (s, 2H), 2.55-2.51 (m, 2H), 1.65-1.54 (m, 1H), 0.81-0.75 (d, J=6.7, 6H).

Example 8

The title compound was prepared using analogous conditions to those described in Example 6 utilizing racemic 2-bromo-N-(2,2,2-trifluoro-1-methylethyl)-benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₂S, 440.09; m/z found, 441.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.54-8.47 (d, J=8.9, 1H), 8.43-8.36 (m, 1H), 8.09-8.00 (m, 2H), 7.93-7.86 (m, 1H), 7.73-7.68 (m, 1H), 7.68-7.61 (m, 1H), 7.44-7.39 (dd, J=7.5, 1.4, 1H), 7.30-7.21 (m, 2H), 6.73 (s, 2H), 3.96-3.83 (m, 1H), 1.19-1.10 (d, J=6.9, 3H).

Example 9

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(cyclobutylmethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₂S, 412.14; m/z found, 413.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.41-8.36 (dd, J=2.2, 1.4, 1H), 8.06-8.01 (d, J=1.5, 1H), 7.97-7.91 (dd, J=7.9, 1.4, 1H), 7.91-7.85 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.59 (m, 1H), 7.52-7.47 (m, 1H), 7.44-7.39 (dd. J=7.5, 1.4, 1H), 7.33-7.24 (m, 2H), 6.73 (s, 2H), 2.79-2.69 (dd, J=7.2, 5.8, 2H), 2.35-2.24 (m, 1H), 1.93-1.82 (m, 2H), 1.81-1.67 (m, 2H), 1.59-1.50 (m, 2H).

Example 10

The title compound was prepared using analogous conditions to those described in Example 6 utilizing racemic (endo)-N-Bicyclo[2.2.1]hept-2-yl-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O₂S, 438.15; m/z found, 439.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.42-8.36 (m, 1H), 8.06-8.01 (d, J=1.5, 1 H), 7.99-7.94 (dd, J=7.9, 1.3, 1H), 7.91-7.85 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.60 (m, 1H), 7.43-7.39 (dd, J=7.5, 1.4, 1H), 7.39-7.34 (d, J=6.9, 1H), 7.30-7.22 (m, 2H), 6.73 (s, 2H), 2.83-2.74 (m, 1H), 2.12-2.06 (m, 1H), 1.97-1.92 (m, 1H), 1.47-1.37 (m, 2H), 1.34-1.21 (m, 3H), 1.01-0.77 (m, 4H).

Example 11

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(1-methylcyclobutyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₂S, 412.14; m/z found, 413.1 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.52 (s, 1H), 8.26 (s, 1H), 8.16-8.11 (dd, J=7.9, 1.3, 1H), 8.11-8.05 (m, 1H), 7.62-7.58 (m, 1H), 7.56-7.51 (m, 1H), 7.40-7.37 (dd, J=8.1, 1.7, 1H), 7.34-7.28 (m, 2H), 4.37 (s, 1H), 2.13-2.00 (m, 2H), 1.82-1.73 (m, 2H), 1.69-1.59 (m, 2H), 1.24 (s, 3H).

Example 12

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(1,1-dimethylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₂S, 414.15; m/z found, 415.1 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.56 (s, 1H), 8.28 (s, 1H), 8.18-8.13 (dd, J=7.9, 1.3, 1H), 8.12-8.06 (m, 1H), 7.62-7.56 (m, 1H), 7.55-7.49 (m, 1H), 7.44-7.39 (dd, J=8.1, 1.7, 1H), 7.35-7.28 (m, 2H), 3.90 (s, 1H), 1.50-1.39 (q, J=7.4, 2H), 1.01 (s, 6H), 0.78-0.68 (t, J=7.4, 3H).

Example 13

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(2,2,2-trifluoro-1,1-dimethylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₈F₄N₄O₂S, 454.11; m/z found, 455.1 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.54 (s, 1H), 8.27 (s, 1H), 8.15-8.10 (dd, J=8.0, 1.3, 1H), 8.10-8.04 (m, 1H), 7.66-7.59 (m, 1H), 7.57-7.52 (m, 1H), 7.40-7.27 (m, 3H), 4.49 (s, 1H), 1.33 (s, 6H).

Example 14

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-cyclopentylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₂S, 412.14; m/z found, 413.1 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.46 (s, 1H), 8.21 (s, 1H), 8.14-8.10 (dd, J=8.0, 1.4, 1H), 8.10-8.04 (m, 1H), 7.64-7.59 (m, 1H), 7.57-7.51 (m, 1H), 7.38-7.25 (m, 3H), 4.42-4.25 (d, J=6.6, 1 H), 3.49-3.35 (m, 1H), 1.80-1.66 (m, 2H), 1.63-1.48 (m, 2H), 1.48-1.38 (m, 2H), 1.35-1.19 (m, 2H).

Example 15

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-methylbenzenesulfonamide. MS (ESI): mass calcd. for C₁₇H₁₅FN₄O₂S, 358.09; m/z found, 359.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.32 (s, 2H), 8.07-8.01 (dd, J=7.9, 1.4, 1H), 7.99-7.94 (m, 1H), 7.71-7.64 (m, 1H), 7.63-7.57 (m, 1H), 7.43-7.37 (dd, J=7.5, 1.4, 1H), 7.35-7.26 (m, 2H), 2.45 (s, 3H).

Example 16

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-ethylbenzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.11; m/z found, 373.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.37 (s, 1H), 8.30 (s, 1H), 8.10-8.01 (dd, J=8.0, 1.5, 1H), 8.01-7.93 (m, 1H), 7.70-7.62 (m, 1H), 7.62-7.54 (m, 1H), 7.42-7.36 (dd, J=7.6, 1.5, 1H), 7.35-7.25 (m, 2H), 2.91-2.74 (q, J=7.2, 2H), 1.08-0.93 (t, J=7.2, 3H).

Example 17

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(2-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₂₁FN₄O₂S, 448.14; m/z found, 449.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.35 (s, 1H), 8.14 (s, 1H), 8.10-8.05 (dd, J=7.9, 1.3, 1H), 7.99-7.91 (m, 1H), 7.63-7.57 (m, 1H), 7.57-7.49 (m, 1H), 7.31-7.26 (dd, J=7.5, 1.4, 1H), 7.23-7.17 (m, 2H), 7.17-7.09 (m, 3H), 7.05-6.98 (m, 2H), 4.82-4.67 (m, 1H), 3.15-3.00 (m, 2H), 2.75-2.65 (t, J=7.1, 2H).

Example 18

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1R)-2,2,2-trifluoro-1-phenylethyl]-benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₁₈F₄N₄O₂S, 502.08; m/z found, 503.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.37-8.31 (s, 1H), 8.23-8.18 (dd, J=8.0, 1.4, 1 H), 7.99-7.93 (d, J=1.6, 1H), 7.87-7.80 (m, 1H), 7.63-7.57 (m, 1H), 7.55-7.49 (m, 1H), 7.36-7.31 (d, J=7.4, 1H), 7.30-7.25 (m, 2H), 7.23-7.18 (d, J=7.6, 1H), 7.20-7.10 (m, 2H), 7.11-7.02 (m, 2H), 5.04-4.93 (s, 2H), 4.84-4.72 (m, 1H).

Example 19

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1S)-2,2,2-trifluoro-1-phenylethyl]-benzenesulfonamide.

Example 20

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₂S, 440.09; m/z found, 441.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.21-8.12 (m, 2H), 7.92-7.85 (s, 1H), 7.85-7.79 (m, 1H), 7.62-7.55 (m, 1H), 7.54-7.47 (m, 1H), 7.43-7.36 (d, J=8.0, 1H), 7.33-7.27 (dd, J=7.5, 1.4, 1H), 7.19-7.07 (d, J=12.6, 1H), 5.45-5.13 (s, 2H), 4.04-3.90 (m, 1H), 1.31-1.22 (d, J=7.0, 3H).

Example 21

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(2,3-dihydro-1H-inden-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₅H₂₁FN₄O₂S, 460.14; m/z found, 461.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.44-8.39 (m, 1H), 8.24-8.18 (dd, J=8.0, 1.4, 1H), 8.05-8.00 (d, J=1.5, 1H), 7.91-7.84 (m, 1H), 7.65-7.58 (m, 1H), 7.58-7.51 (m, 1H), 7.34-7.29 (dd, J=7.5, 1.4, 1H), 7.27-7.21 (m, 1H), 7.15-7.04 (m, 5H), 4.89-4.74 (s, 2H), 4.74-4.61 (d, J=6.6, 1H), 4.00-3.89 (m, 1H), 3.06-2.92 (dd, J=15.9, 6.9, 2H), 2.70-2.58 (dd, J=15.9, 5.6, 2H).

Example 22

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1S)-2,3-dihydro-1H-inden-1-yl]benzenesulfonamide. MS (ESI): mass calcd. for C₂₅H₂₁FN₄O₂S, 460.14; m/z found, 461.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.30-8.24 (dd, J=7.9, 1.4, 1H), 8.24-8.19 (m, 1H), 8.00-7.95 (d, J=1.5, 1H), 7.85-7.78 (m, 1H), 7.65-7.58 (m, 1H), 7.58-7.52 (m, 1H), 7.34-7.27 (dd, J=7.5, 1.4, 1H), 7.23-7.18 (d, J=7.7, 1H), 7.18-7.12 (dd, J=4.9, 1.1, 2H), 7.07-6.98 (m, 2H), 6.96-6.88 (d, J=7.6, 1H), 5.05-4.90 (d, J=8.7, 1H), 4.87-4.79 (s, 2H), 4.79-4.71 (m, 1H), 2.86-2.74 (m, 1H), 2.74-2.60 (m, 1H), 2.28-2.16 (m, 1H), 1.79-1.64 (m, 1H).

Example 23

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1R)-2,3-dihydro-1H-inden-1-yl]benzenesulfonamide.

Example 24

The title compound was prepared using analogous conditions to those described in Example 6 using 2-bromo-N-[(1R)-1-phenylethyl]benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₂₁FN₄O₂S, 448.14; m/z found, 449.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.44-8.37 (d, J=1.4, 1H), 8.19-8.12 (m, 1H), 8.10-8.03 (dd, J=8.0, 1.3, 1H), 7.97-7.89 (m, 1H), 7.61-7.53 (m, 1H), 7.52-7.45 (m, 1H), 7.22-7.15 (m, 4H), 7.12-7.00 (s, 1H), 6.97-6.91 (m, 2H), 6.89-6.78 (s, 1H), 4.68-4.51 (d, J=7.0, 1H), 4.39-4.25 (m, 1H), 1.45-1.33 (d, J=6.9, 3H).

Example 25

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.28 (m, 2H), 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.01-7.93 (m, 1H), 7.71-7.63 (m, 1H), 7.62-7.55 (m, 1H), 7.43-7.37 (dd, J=7.6, 1.4, 1H), 7.37-7.30 (m, 2H), 3.42-3.37 (m, 1H), 3.30-3.25 (dd, J=10.9, 6.3, 1H), 3.24-3.16 (m, 1H), 1.04-0.98 (d, J=6.6, 3H).

Example 26

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-phenylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₁₇FN₄O₂S, 420.11; m/z found, 421.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 10.12 (s, 1H), 8.45-8.37 (m, 1H), 8.13-8.06 (d, J=1.5, 1H), 8.06-8.00 (dd, J=8.0, 1.4, 1H), 7.92-7.84 (t, J=8.3, 1H), 7.70-7.63 (m, 1H), 7.63-7.57 (m, 1H), 7.39-7.32 (dd, J=7.6, 1.4, 1H), 7.24-7.16 (dd, J=8.5, 7.3, 2H), 7.12 (s, 1H), 7.11-7.08 (dd, J=4.1, 1.6, 1H), 7.01-6.96 (m, 1H), 6.95-6.89 (m, 2H).

Example 27

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(3S)-1-ethyl-2-oxoazepan-3-yl]benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₂₆FN₅O₃S, 483.17; m/z found, 484.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.39-8.33 (d, J=1.4, 1H), 8.25-8.20 (d, J=1.4, 1H), 8.10-8.05 (m, 1H), 8.05-8.00 (dd, J=8.0, 1.3, 1H), 7.61-7.55 (m, 1H), 7.53-7.47 (m, 1H), 7.43-7.38 (dd, J=8.1, 1.7, 1H), 7.34-7.30 (dd, J=7.5, 1.4, 1H), 7.30-7.25 (dd, J=12.3, 1.7, 1H), 6.02-5.93 (d, J=5.5, 1H), 3.91-3.83 (m, 1H), 3.45-3.20 (m, 3H), 3.18-3.10 (m, 1H), 2.04-1.94 (m, 1H), 1.92-1.81 (m, 1H), 1.81-1.70 (m, 1H), 1.66-1.53 (m, 1H), 1.52-1.42 (m, 1H), 1.34-1.21 (m, 1H), 1.09-0.99 (t, J=7.2, 3H).

Example 28

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(3S)-2-oxoazepan-3-yl]benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₂FN₅O₃S, 455.14; m/z found, 456.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.46-8.33 (s, 1H), 8.24-8.14 (s, 1H), 8.10-8.00 (m, 2H), 7.63-7.56 (m, 1H), 7.56-7.48 (m, 1H), 7.41-7.35 (dd, J=8.0, 1.7, 1 H), 7.35-7.29 (dd, J=7.4, 1.4, 1H), 7.29-7.25 (d, J=1.8, 1H), 7.00-6.82 (s, 1H), 5.88-5.71 (d, J=6.0, 1H), 3.89-3.73 (d, J=9.4, 1H), 3.24-3.11 (m, 1H), 3.11-2.97 (m, 1H), 2.09-1.98 (d, J=12.5, 1H), 1.98-1.85 (d, J=13.2, 1H), 1.81-1.67 (m, 1H), 1.64-1.44 (m, 2H), 1.37-1.21 (m, 1H).

Example 29

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(3S)-1-methyl-2-oxoazepan-3-yl]benzenesulfonamide. MS (ESI): mass calcd. for C₂₃H₂₄FN₅O₃S, 469.16; m/z found, 470.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.44-8.38 (d, J=1.3, 1H), 8.22 (s, 1H), 8.10-8.05 (m, 1H), 8.05-8.00 (dd, J=7.9, 1.3, 1H), 7.63-7.56 (m, 1H), 7.54-7.47 (m, 1H), 7.43-7.37 (dd, J=8.1, 1.5, 1H), 7.34-7.29 (dd, J=7.6, 1.4, 1H), 7.28-7.24 (m, 1H), 6.00-5.85 (d, J=5.6, 1H), 3.98-3.86 (d, J=11.4, 1H), 3.39-3.28 (dd, J=15.2, 11.4, 1H), 3.16-3.05 (dd, J=15.3, 5.1, 1H), 2.95 (s, 3H), 2.04-1.93 (dd, J=17.1, 4.1, 1H), 1.91-1.81 (m, 1H), 1.77-1.66 (m, 1H), 1.65-1.53 (m, 1H), 1.53-1.42 (m, 1H), 1.38-1.26 (m, 1H).

Example 30

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₆H₃₂FN₅O₂S, 497.23; m/z found, 498.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39-8.35 (d, J=1.4, 1H), 8.35-8.30 (m, 1H), 8.18-8.13 (dd, J=8.0, 1.3, 1H), 8.05-7.99 (m, 1H), 7.73-7.67 (m, 1H), 7.65-7.59 (m, 1H), 7.45-7.40 (dd, J=7.6, 1.3, 1H), 7.39-7.36 (m, 1H), 7.36-7.32 (dd, J=2.9, 1.5, 1H), 3.49-3.39 (m, 1H), 2.75 (s, 3H), 1.95-1.87 (m, 2H), 1.75-1.64 (m, 2H), 1.38 (s, 6H), 1.30 (s, 6H).

Example 31

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-pyridin-3-ylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O₂S, 421.10; m/z found, 422.1 [M+H]⁺. ¹H NMR (600 MHz. CD₃OD) δ 8.38-8.34 (d, J=1.5, 1H), 8.34-8.30 (m, 2H), 8.29-8.23 (m, 2H), 7.91-7.85 (m, 1H), 7.83-7.79 (m, 1H), 7.75-7.71 (m, 1H), 7.71-7.68 (dd, J=8.6, 5.4, 1H), 7.68-7.64 (m, 1H), 7.41-7.37 (dd, J=7.6, 1.3, 1H), 7.20-7.15 (dd, J=12.1, 1.7, 1H), 7.15-7.12 (dd, J=8.0, 1.7, 1H).

Example 32

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1S)-2-hydroxy-1-methylethyl]benzenesulfonamide.

Example 33

To a solution of tert-butanol (13 mg, 0.18 mmol) in DCM (5 mL) was added chlorosulfonylisocyanate (25 mg, 0.18 mmol) at 0° Celsius. The resulting solution containing N-(tert-butoxycarbonyl)sulfamoyl chloride was added to a reaction flask containing 5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazin-2-amine (50 mg, 0.18 mmol) and triethylamine (36 mg, 0.36 mmol) in anhydrous DCM (10 mL) at 0° Celsius. The mixture was warmed to rt, stirred 2 hours, then concentrated to dryness, re-dissolved in TFA/DCM (5 mL/5 mL), stirred at rt for 1 hour, and concentrated to dryness. The residue was diluted with water (10 mL) and saturated NaHCO_(3(aq)) (10 mL), extracted with DCM (10 mL×3) and the combined organic extracts washed with brine, dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by HPLC to give the title compound (10 mg, 16%). MS (ESI): mass calcd. for C₁₆H₁₄FN₅O₂S, 359.09; m/z found, 360.0 [M+H]⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.33 (s, 1H), 8.04 (d, J=1.3, 1H), 7.91 (m, 1H), 7.63 (d, J=7.8, 1H), 7.44-7.22 (m, 4H), 7.24 (m, 1H), 7.05 (s, 2H), 6.70 (s, 2H).

Example 34

To a solution of 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (309 mg, 1.15 mmol) in DMSO (5 mL) was added K₂CO₃ (317 mg, 2.3 mmol). The mixture was sparged with N₂ several times. Pd(PPh₃)₄ (66 mg, 0.058 mmol) and (2-(1-methylethylsulfonamido)-phenyl)boronic acid (280 mg, 1.15 mmol) were added and the resultant mixture sparged with N₂. The mixture was heated at 80° Celsius for 14 hours before cooling to rt and diluting with water (70 mL). The precipitate was collected, rinsed with water, air dried, and then purified by HPLC to give the title compound (40 mg, 9%). MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₂S, 386.12; m/z found, 387.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.72 (s, 1H), 8.25 (d, J=1.2, 1H), 8.16 (m, 1H), 7.50 (d, J=7.8, 1H), 7.47-7.34 (m, 5H), 3.15-3.03 (m, 1H), 1.23 (d, J=6.8, 6H).

Example 35

The title compound was prepared using analogous conditions to those described in Example 34 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(2-bromophenyl)ethanesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.11; m/z found, 372.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.08 (s, 1H), 8.43-8.36 (m, 1H), 8.04 (d, J=1.0, 1H), 7.93 (m, 1H), 7.46-7.28 (m, 6H), 6.72 (s, 2H), 2.91 (q, J=7.4, 2H), 1.07 (t, J=7.3, 3H).

Example 36

The title compound was prepared using analogous conditions to those described in Example 34 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-bromo-2-(propylsulfonyl)benzene. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₂S, 386.12; m/z found, 387.3 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.09 (s, 1H), 8.38 (s, 1H), 8.04 (d, J=1.3, 1H), 7.93 (m, 1H), 7.42-7.35 (m, 6H), 6.71 (s, 2H), 2.87-2.74 (m, 2H), 1.59-1.44 (m, 2H), 0.81 (t, J=7.4, 3H).

Example 37

The title compound was prepared using analogous conditions to those described in Example 34 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(2-bromophenyl)isobutylsulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.38 (s, 1H), 8.14 (s, 1H), 7.96 (m, 1H), 7.49 (d, J=7.0, 1H), 7.45-7.30 (m, 5H), 2.77 (d, J=6.5, 2H), 2.15-2.02 (m, 1H), 0.97 (d, J=6.7, 6H).

Example 38

Step A: 2-(di-tert-Butyloxycarbonyl)amino-5-(4-bromo-2-fluorophenyl)pyrazine

2-Amino-5-(4-bromo-2-fluorophenyl)pyrazine (3.0 g, 11 mmol) was dissolved in pyridine (40 mL), and then slowly treated with (Boc)₂O (6.8 g, 34 mmol) at rt. The mixture was stirred at rt for 18 hours, concentrated to dryness and purified by FCC to give 2-(di-tert-butyloxycarbonyl)amino-5-(4-bromo-2-fluorophenyl)pyrazine (3.6 g, 68%) as a white solid. MS (ESI): mass calcd. for C₂₀H₂₃FBrN₃O₄S, 467.09; m/z found, 468.0 [M+H]⁺.

Step B: 2-(di-tert-Butyloxycarbonyl)amino-5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazine

To a solution of 2-(di-tert-butyloxycarbonyl)amino-5-(4-bromo-2-fluorophenyl)-pyrazine (232 mg, 0.5 mmol) and 2-aminophenylboronic acid hydrochloride (174 mg, 1.0 mmol) in 1,4-dioxane/H₂O (10 mL/0.5 mL) was added Na₂CO₃ (232 mg, 2.0 mmol). The mixture was sparged with N₂ several times. Pd(PPh₃)₄ (29 mg, 0.025 mmol) was added and the resulted mixture was stirred at 80° Celsius for 14 hours under N₂. After cooling to rt, the mixture was diluted with water (50 mL) and extracted with DCM (15 mL×3). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated to dryness to give 2-(di-tert-butyloxycarbonyl)amino-5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazine, which was directly used in next step without any further purification. MS (ESI): mass calcd. for C₂₆H₂₉FN₄O₄S, 480.22; m/z found, 481.0 [M+H]⁺.

Step C

To a solution of 2-(di-tert-butyloxycarbonyl)amino-5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazine (280 mg crude, 0.5 mmol) in pyridine (5 mL) was slowly added cyclopropane-sulfonyl chloride (105 mg, 0.75 mmol) at rt. The resultant mixture was stirred at 60° Celsius for 16 hours. The mixture was concentrated to dryness, the residue diluted with 40 mL of water and extracted with DCM (10 mL×2). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by FCC to give 230 mg of impure product. The solid was dissolved in HCl (4 N) in EtOH (5 mL) and stirred at rt for 1 hour, then concentrated to dryness. The residue was purified by HPLC to give the title compound (55 mg, 37% yield). MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₄S, 384.11; m/z found, 385.1 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 9.14 (s, 1H), 8.39 (s, 1H), 8.05 (d, J=1.3, 1H), 7.92 (m, 1H), 7.51 (d, J=7.8, 1H), 7.48-7.34 (m, 5H), 6.81 (s, 2H), 2.48-2.42 (m, 1H), 0.89-0.75 (m, 4H).

Example 39

The title compound was prepared using analogous conditions to those described in Example 38 utilizing hexane-1-sulfonyl chloride. MS (ESI): mass calcd. for C₂₂H₂₅FN₄O₂S, 428.17; m/z found, 429.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 1H), 8.40 (s, 1H), 8.04 (d, J=1.1, 1H), 7.96 (m, 1H), 7.48-7.34 (m, 6H), 6.73 (s, 2H), 2.77-2.63 (m, 2H), 1.41-1.33 (m, 2H), 1.16-0.95 (m, 6H), 0.72 (t, J=6.9, 3H).

Example 40

The title compound was prepared using analogous conditions to those described in Example 38 utilizing cyclobutanesulfonyl chloride. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂S, 398.12; m/z found, 399.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 9.07 (s, 1H), 8.38 (s, 1H), 8.04 (s, 1H), 7.92 (m, 1H), 7.47-7.31 (m, 6H), 6.71 (s, 2H), 3.66 (p, J=7.7, 1H), 2.21-2.08 (m, 2H), 2.03-1.92 (m, 2H), 1.86-1.70 (m, 2H).

Example 41

Trifluoromethanesulfonic anhydride (263 mg, 0.95 mmol) was added drop-wise to a solution consisting of 2-(di-tert-butyloxycarbonyl)amino-5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazine (300 mg, 0.62 mmol) and Et₃N (190 mg, 1.86 mmol) and DCM (10 mL), at rt. The resulting mixture was stirred at rt for 16 hours, then quenched with sat. NaHCO₃ (20 mL), diluted with water (40 mL), and extracted with DCM (15 mL×3). The combined organic fractions were washed with brine, dried over Na₂SO₄ and concentrated to dryness. The solid was dissolved in 4 N HCl in EtOH (10 mL) and stirred at rt for 1 hour, concentrated to dryness and purified by HPLC to give the title compound. MS (ESI): mass calcd. for C₁H₁₂F₄N₄O₂S, 412.06; m/z found, 413.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.41 (s, 1H), 8.06 (s, 1H), 7.96 (m, 1H), 7.56-7.45 (m, 3H), 7.44-7.32 (m, 3H), 6.77 (s, 2H).

Example 42

To a 20 mL vial were 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (50 mg, 0.19 mmol), (2-(N,N-dimethylsulfamoyl)phenyl)boronic acid, K₂CO₃ (43 mg, 0.19 mmol), and Pd(dppf)Cl₂.CH₂Cl₂ (8 mg, 0.009 mmol), and a stir-bar. The vial was sealed with a teflon lined cap and sparged with N₂. The vial was then charged with freshly sparged DMSO (2 mL) and then stirred 16 hours at 80° Celsius. The reaction mixture was then cooled to rt, filtered, and purified by HPLC to give the title compound (36 mg, 40%). MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.11; m/z found, 373.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.33 (s, 2H), 8.06-7.96 (m, 2H), 7.72-7.67 (m, 1H), 7.64-7.59 (m, 1H), 7.43-7.39 (m, 1H), 7.32-7.26 (m, 2H), 2.49 (s, 6H).

Example 43

The title compound was prepared in a manner similar to that described in Example 42 using 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2-(piperidin-1-ylsulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₂S, 412.14; m/z found, 413.3 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.40-8.30 (m, 2H), 8.10-8.06 (m, 1H), 7.98 (m, 1H), 7.79-7.73 (m, 1H), 7.71-7.64 (m, 1H), 7.62-7.56 (m, 1H), 7.43-7.39 (m, 1H), 7.34-7.28 (m, 1H), 2.86 (d, J=5.3, 4H), 1.50-1.38 (m, 6H).

Example 44

The title compound was prepared in a manner similar to that described in Example 42 using 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2-(morpholinosulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.38 (s, 1H), 8.31 (s, 1H), 8.13-8.09 (m, 1H), 7.99 (m, 1H), 7.75-7.69 (m, 1H), 7.65-7.60 (m, 1H), 7.46-7.43 (m, 1H), 7.37-7.31 (m, 2H), 3.54-3.46 (m, 4H), 2.91-2.84 (m, 4H).

Example 45

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₄S₂, 462.08: m/z found, 463.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.62-8.60 (m, 1H), 8.16-8.14 (m, 1H), 8.13-8.12 (m, 1H), 8.05 (t, J=8.1 Hz, 1H), 7.69-7.65 (m, 1H), 7.59-7.54 (m, 1H), 7.39-7.36 (m, 1H), 7.25-7.21 (m, 2H), 4.81 (s, 2H), 3.36-3.30 (m, 4H), 3.02-2.98 (m, 4H).

Example 46

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)piperazine. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.39 (m, 1H), 8.21-8.13 (m, 2H), 8.01-7.95 (m, 1H), 7.79-7.74 (m, 1H), 7.69-7.63 (m, 1H), 7.50-7.46 (m, 1H), 7.37-7.30 (m, 2H), 3.14-3.08 (m, 4H), 3.06-2.99 (m, 4H).

Example 47

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N,N-diethylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.29 (d, J=1.4, 1H), 8.08-8.04 (m, 1H), 8.0-7.94 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.55 (m, 1H), 7.41-7.36 (m, 1H), 7.32-7.25 (m, 2H), 2.96 (q, J=7.1, 4H), 1.00 (t, J=7.1, 6H).

Example 48

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)pyrrolidine. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂S, 398.12; m/z found, 399.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.38 (s, 1H), 8.28 (d, J=1.4, 1H), 8.12-8.08 (m, 1H), 8.0-7.94 (m, 1H), 7.71-7.65 (m, 2H), 7.62-7.56 (m, 1H), 7.42-7.39 (m, 1H), 7.34-7.27 (m, 2H), 2.94 (t, J=6.7, 4H), 1.81-1.69 (m, 4H).

Example 49

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4,4-difluoropiperidine. MS (ESI): mass calcd. for C₂₁H₁₉F₃N₄O₂S, 448.12: m/z found, 449.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.35 (s, 1H), 8.27 (d, J=1.4, 1H), 8.12 (d, J=8.0, 1H), 7.98 (m, 1H), 7.75-7.67 (m, 1H), 7.63 (m, 1H), 7.43 (d, J=7.6, 1H), 7.32 (d, J=10.6, 2H), 3.02-2.93 (m, 4H), 1.90-1.73 (m, 4H).

Example 50

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoropiperidine. MS (ESI): mass calcd. for C₂₁H₁₉F₃N₄O₂S, 448.12; m/z found, 449.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.35-8.27 (m, 2H), 8.12-8.05 (m, 1H), 8.01-7.94 (m, 1H), 7.74-7.67 (m, 1H), 7.65-7.58 (m, 1H), 7.44-7.38 (m, 1H), 7.32-7.24 (m, 2H), 3.04-2.96 (m, 2H), 2.95-2.88 (m, 2H), 1.96-1.82 (m, 2H), 1.69-1.61 (m, 2H).

Example 51

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoropyrrolidine. MS (ESI): mass calcd. for C₂₀H₁₇F₃N₄O₂S, 434.10; m/z found, 435.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.35 (d, J=1.3, 1H), 8.27 (d, J=1.4, 1H), 8.11 (d, J=7.9, 1H), 7.99 (m, 1H), 7.77-7.69 (m, 1H), 7.67-7.59 (m, 1H), 7.47-7.40 (m, 1H), 7.34-7.25 (m, 2H), 3.23 (t, J=12.9, 2H), 3.14 (t, J=7.3, 2H), 2.28-2.14 (m, 2H).

Example 52

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoroazetidine. MS (ESI): mass calcd. for C₁₉H₁₅F₃N₄O₂S, 420.09; m/z found, 421.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37-8.26 (m, 2H), 8.14-8.07 (m, 1H), 8.02-7.95 (m, 1H), 7.77-7.69 (m, 1H), 7.66-7.57 (m, 1H), 7.48-7.40 (m, 1H), 7.35-7.24 (m, 2H), 4.02-3.92 (m, 4H).

Example 53

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)azepane. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₂S, 426.15; m/z found, 427.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.21 (s, 1H), 8.02 (d, J=7.9, 1H), 7.96 (t, J=8.2, 1H), 7.66 (m, 1H), 7.60-7.55 (m, 1H), 7.38 (d, J=6.5, 1H), 7.31-7.24 (m, 2H), 1.63-1.52 (m, 12H).

Example 54

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-methylpiperazine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.2 [M+H]⁺. ¹H NMR (400 MHz. CD₃OD) δ 8.37 (m, 1H), 8.23 (d, J=1.4, 1H), 8.16-8.12 (m, 1H), 8.02-7.96 (m, 1H), 7.78-7.73 (m, 1H), 7.68-7.62 (m, 1H), 7.48-7.45 (m, 1H), 7.34 (s, 1H), 7.32-7.30 (m, 1H), 3.61-3.33 (m, 4H), 3.01-2.70 (m, 7H).

Example 55

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-(trifluoromethyl)piperidin-4-d. MS (ESI): mass calcd. for C₂₂H₂₀F₄N₄O₃S, 496.12; m/z found, 497.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.38 (s, 1H), 8.23 (d, J=1.1, 1H), 8.15-8.11 (m, 1H), 7.94 (m, 1H), 7.75-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.45-7.41 (m, 1H), 7.35-7.27 (m, 2H), 3.29-3.22 (m, 2H), 2.79-2.64 (m, 2H), 1.65-1.48 (m, 4H).

Example 56

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-(methylsulfonyl)piperazine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₄S₂, 491.11; m/z found, 492.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.23 (s, 1H), 8.13 (d, J=7.0, 1H), 7.97 (m, 1H), 7.77-7.71 (m, 1H), 7.67-7.61 (m, 1H), 7.46 (d, J=6.4, 1H), 7.39-7.32 (m, 2H), 3.03-2.94 (m, 8H), 2.78 (s, 3H).

Example 57

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluor-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)ethanone. MS (ESI): mass calcd. for C₂₂H₂₂FN₅O₃S, 455.14; m/z found, 456.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.34 (d, J=6.0, 2H), 8.11-8.08 (m, 1H), 8.00 (m, 1H), 7.75-7.70 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.41 (m, 1H), 7.37-7.29 (m, 2H), 3.43-3.34 (m, 4H), 2.96-2.81 (m, 4H), 2.02 (s, 3H).

Example 58

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (4-((2-bromophenyl)sulfonyl)piperazin-1-yl)(cyclopropyl)-methanone. MS (ESI): mass calcd. for C₂₄H₂₄FN₅O₃S, 481.16: m/z found, 482.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.63-8.59 (m, 1H), 8.16-8.10 (m, 2H), 8.00 (m, 1H), 7.67-7.62 (m, 1H), 7.58-7.53 (m, 1H), 7.39-7.36 (m, 1H), 7.32-7.30 (m, 1H), 7.28 (s, 1H), 4.76 (s, 2H), 3.48 (s, 4H), 2.94-2.82 (m, 4H), 1.63-1.54 (m, 1H), 0.97-0.89 (m, 2H), 0.79-0.70 (m, 2H).

Example 59

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)ethanol. MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₃S, 457.16; m/z found, 458.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.38 (m, 1H), 8.21 (d, J=1.5, 1H), 8.16-8.13 (m, 1H), 7.98 (m, 1H), 7.79-7.73 (m, 1H), 7.68-7.63 (m, 1H), 7.49-7.45 (m, 1H), 7.36-7.30 (m, 2H), 3.86-3.78 (m, 2H), 3.66-3.32 (m, 4H), 3.24-3.20 (m, 2H), 3.15-2.72 (m, 4H).

Example 60

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-cyclopropylpiperazine. MS (ESI): mass calcd. for C₂₃H₂₄FN₅O₂S, 453.16; m/z found, 454.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 8.18-8.12 (m, 2H), 7.97 (m, 1H), 7.79-7.74 (m, 1H), 7.68-7.63 (m, 1H), 7.49-7.46 (m, 1H), 7.34-7.30 (m, 2H), 3.28-2.98 (d, J=1.6, 8H), 2.82-2.75 (m, 1H), 0.96-0.85 (m, 4H).

Example 61

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic 2-((2-bromophenyl)sulfonyl)octahydropyrrolo[1,2-a]pyrazine. MS (ESI): mass calcd. for C₂₃H₂₄FN₅O₂S, 453.16; m/z found, 454.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (d, J=1.4, 1H), 8.24 (d, J=1.4, 1H), 8.17-8.13 (m, 1H), 7.99 (m, 1H), 7.78-7.73 (m, 1H), 7.68-7.63 (m, 1H), 7.48-7.45 (m, 1H), 7.36-7.30 (m, 2H), 3.89-3.35 (m, 4H), 3.26-2.53 (m, 6H), 2.18-1.97 (m, 3H).

Example 62

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and Racemic-1-((2-bromophenyl)sulfonyl)-3,5-dimethylpiperazine. MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₂S, 441.16; m/z found, 442.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.24 (d, J=1.4, 1H), 8.17-8.14 (m, 1H), 7.99 (m, 1H), 7.79-7.73 (m, 1H), 7.68-7.63 (m, 1H), 7.49-7.46 (m, 1H), 7.37-7.32 (m, 2H), 3.49-3.42 (m, 2H), 3.14-3.01 (m, 2H), 2.47-2.39 (m, 2H), 1.17 (d, J=6.6, 6H).

Example 63

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic 1-((2-bromophenyl)sulfonyl)piperidine-3-carbonitrile. MS (ESI): mass calcd. for C₂₂H₂₀FN₅O₂S, 437.13; m/z found, 438.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.35 (s, 1H), 8.29 (d, J=1.1, 1H), 8.11-8.07 (m, 1H), 7.98 (m, 1H), 7.74-7.68 (m, 1H), 7.65-7.60 (m, 1H), 7.44-7.40 (m, 1H), 7.36-7.30 (m, 2H), 3.06-3.02 (m, 2H), 2.90-2.86 (m, 2H), 2.80-2.74 (m, 1H), 1.89-1.80 (m, 1H), 1.77-1.61 (m, 2H), 1.53-1.42 (m, 1H).

Example 64

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)piperidine-4-carbonitrile. MS (ESI): mass calcd. for C₂₂H₂₀FN₅O₂S, 437.13; m/z found, 438.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.35 (s, 1H), 8.29 (d, J=1.1, 1H), 8.12-8.09 (m, 1H), 7.99 (m, 1H), 7.74-7.69 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.42 (m, 1H), 7.34 (s, 1H), 7.32-7.30 (m, 1H), 3.10-3.02 (m, 2H), 2.86-2.73 (m, 3H), 1.82-1.73 (m, 2H), 1.64-1.53 (m, 2H).

Example 65

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)piperidin-4-amine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.36 (s, 1H), 8.25-8.23 (d. J=1.4, 1H), 8.11-8.08 (m, 1H), 7.96 (m, 1H), 7.74-7.69 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.41 (m, 1H), 7.32-7.29 (m, 1H), 7.28 (s, 1H), 3.47-3.40 (m, 2H), 3.18-3.08 (m, 1H), 2.57-2.43 (m, 2H), 1.91-1.84 (m, 2H), 1.51-1.39 (m, 2H).

Example 66

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 4-((2-bromophenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 427.11; m/z found, 428.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.27 (d, J=1.4, 1H), 8.17-8.13 (m, 1H), 7.98 (m, 1H), 7.77-7.72 (m, 1H), 7.67-7.62 (m, 1H), 7.47-7.43 (m, 1H), 7.34-7.26 (m, 2H), 3.39 (s, 2H), 3.14 (s, 4H).

Example 67

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)piperidin-4-ol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.36-8.31 (m, 2H), 8.10-8.06 (m, 1H), 7.99 (m, 1H), 7.73-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (m, 1H), 7.34-7.28 (m, 2H), 3.66-3.55 (m, 1H), 3.20-3.08 (m, 2H), 2.71-2.61 (m, 2H), 1.72-1.63 (m, 2H), 1.39-1.26 (m, 2H).

Example 68

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (1-((2-bromophenyl)sulfonyl)piperidin-4-yl)methanol. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.36-8.29 (m, 2H), 8.11-8.07 (m, 1H), 7.98 (m, 1H), 7.74-7.67 (m, 1H), 7.64-7.59 (m, 1H), 7.44-7.41 (m, 1H), 7.36-7.29 (m, 2H), 3.40-3.32 (m, 4H), 2.46-2.36 (m, 2H), 1.59 (d, J=10.5, 2H), 1.48-1.36 (m, 1H), 1.01-0.89 (m, 2H).

Example 69

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)ethanol. MS (ESI): mass calcd. for C₂₃H₂₅FN₄O₃S, 456.16; m/z found, 457.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.34 (s, 1H), 8.31 (d, J=1.2, 1H), 8.10-8.07 (m, 1H), 7.98 (m, 1H), 7.73-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.41 (m, 1H), 7.34 (s, 1H), 7.32-7.30 (m, 1H), 3.56-3.48 (m, 2H), 3.32 (d, J=4.5, 2H), 2.45-2.36 (m, 2H), 1.61-1.54 (m, 2H), 1.46-1.34 (m, 3H), 1.01-0.87 (m, 2H).

Example 70

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic-1-((2-bromophenyl)sulfonyl)piperidin-3-ol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.34 (s, 1H), 8.31 (d, J=1.4, 1H), 8.11-8.06 (m, 1H), 8.01-7.96 (m, 1H), 7.73-7.68 (m, 1H), 7.64-7.59 (m, 1H), 7.44-7.40 (m, 1H), 7.34-7.32 (m, 1H), 7.31-7.29 (m, 1H), 3.44-3.35 (m, 1H), 3.27-3.21 (m, 1H), 3.15-3.06 (m, 1H), 2.48-2.38 (m, 1H), 2.27-2.21 (m, 1H), 1.88-1.79 (m, 1H), 1.68-1.59 (m, 1H), 1.41-1.28 (m, 1H), 1.26-1.15 (m, 1H).

Example 71

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic-2-(1-((2-bromophenyl)sulfonyl)piperidin-3-yl)ethanol. MS (ESI): mass calcd. for C₂₃H₂₅FN₄O₃S, 456.16; m/z found, 457.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.36-8.31 (m, 2H), 8.10-8.05 (m, 1H), 8.01-7.95 (m, 1H), 7.73-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (m, 1H), 7.36-7.29 (m, 2H), 3.52-3.40 (m, 2H), 3.26-3.16 (m, 2H), 2.48-2.36 (m, 1H), 2.14-2.08 (m, 1H), 1.77-1.67 (m, 1H), 1.62-1.53 (m, 1H), 1.49-1.37 (m, 1H), 1.36-1.25 (m, 3H), 1.02-0.89 (m, 1H).

Example 72

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-N-methylpiperidin-4-amine. MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₂S, 441.16; m/z found, 442.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.21 (d, J=1.4, 1H), 8.12-8.09 (m, 1H), 7.96 (m, 1H), 7.75-7.70 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.41 (m, 1H), 7.32-7.30 (m, 1H), 7.28 (s, 1H), 3.49-3.42 (m, 2H), 3.10-3.01 (m, 1H), 2.63 (s, 3H), 2.54-2.42 (m, 2H), 2.00-1.92 (m, 2H), 1.47-1.35 (m, 2H).

Example 73

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-N,N-dimethylpiperidin-4-amine. MS (ESI): mass calcd. for C₂₃H₂₆FN₅O₂S, 455.18; m/z found, 456.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.38 (m, 1H), 8.20 (d, J=1.5, 1H), 8.14-8.10 (m, 1H), 7.99-7.94 (m, 1H), 7.76-7.71 (m, 1H), 7.66-7.61 (m, 1H), 7.47-7.43 (m, 1H), 7.36-7.30 (m, 2H), 3.52-3.45 (m, 2H), 3.26-3.16 (m, 1H), 2.78 (s, 6H), 2.55-2.44 (m, 2H), 1.93 (d, J=11.6, 2H), 1.48-1.36 (m, 2H).

Example 74

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic-1-((2-bromophenyl)sulfonyl)piperidin-3-amine. MS (ESI): mass calcd. for C₂₆H₃₀FN₅O₄S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.45 (s, 1H), 8.33 (s, 1H), 8.11-8.07 (m, 1H), 8.03 (m, 1H), 7.76-7.70 (m, 1H), 7.67-7.62 (m, 1H), 7.46-7.42 (m, 1H), 7.36-7.29 (m, 2H), 3.40-3.41 (m, 1H), 3.13-3.02 (m, 2H), 2.66-2.60 (m, 2H), 2.01-1.92 (m, 1H), 1.78-1.67 (m, 1H), 1.55-1.42 (m, 2H).

Example 75

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)acetamide. MS (ESI): mass calcd. for C₂₃H₂₄FN₅O₃S, 469.16; m/z found, 470.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.41-8.38 (m, 1H), 8.08 (d, J=1.4, 1H), 8.01-7.97 (m, 1H), 7.90 (m, 1H), 7.80 (d, J=7.6, 1H), 7.77-7.72 (m, 1H), 7.68-7.63 (m, 1H), 7.46-7.42 (m, 1H), 7.33-7.24 (m, 2H), 3.61-3.50 (m, 1H), 3.26-3.18 (m, 2H), 2.59-2.52 (m, 2H), 1.76 (s, 3H), 1.67-1.59 (m, 2H), 1.27-1.15 (m, 2H).

Example 76

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic (1-((2-bromophenyl)sulfonyl)piperidin-3-yl)methanol. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.33 (d, J=8.7, 2H), 8.10-8.06 (m, 1H), 7.96 (m, 1H), 7.73-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (m, 1H), 7.36-7.29 (m, 2H), 3.43-3.32 (m, 2H), 3.27-3.16 (m, 2H), 2.43-2.34 (m, 1H), 2.22-2.14 (m, 1H), 1.68-1.54 (m, 2H), 1.53-1.42 (m, 1H), 1.35-1.21 (m, 1H), 1.03-0.91 (m, 1H).

Example 77

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic tert-butyl (1-((2-bromophenyl)sulfonyl)piperidin-3-yl)carbamate. MS (ESI): mass calcd. for C₂₆H₃₀FN₅O₄S, 527.20: m/z found, 528.3 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.34 (d, J=9.1, 2H), 8.10-8.07 (m, 1H), 8.00 (m, 1H), 7.73-7.68 (m, 1H), 7.64-7.59 (m, 1H), 7.44-7.40 (m, 1H), 7.35-7.29 (m, 2H), 3.30-3.20 (m, 2H), 3.15-3.06 (m, 1H), 2.51-2.40 (m, 1H), 2.30-2.21 (m, 1H), 1.79-1.70 (m, 1H), 1.65-1.56 (m, 1H), 1.39-1.28 (m, 10H), 1.26-1.14 (m, 1H).

Example 78

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((1S,2S)-1,3-dihydroxy-1-phenylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₅H₂₃FN₄O₄S, 494.14; m/z found, 495.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.45 (d. J=1.4, 1H), 8.10 (s, 1H), 7.87-7.80 (m, 2H), 7.55 (t, J=7.5, 1H), 7.43-7.36 (m, 2H), 7.30-7.14 (m, 8H), 4.89 (d, J=4.0, 1H), 3.65-3.57 (m, 1H), 3.36 (d, J=1.4, 2H).

Example 79

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (S)-2-bromo-N-(1-hydroxy-4-methylpentan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₅FN₄O₃S, 444.16; m/z found, 445.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.33 (s, 1H), 8.29 (d, J=1.4, 1H), 8.16-8.12 (m, 1H), 7.98-7.92 (m, 1H), 7.68-7.63 (m, 1H), 7.60-7.55 (m, 1H), 7.40-7.28 (m, 3H), 3.41-3.34 (m, 1H), 3.29-3.22 (m, 2H), 1.59-1.47 (m, 1H), 1.35-1.17 (m, 2H), 0.81 (d, J=6.7, 3H), 0.73 (d, J=6.5, 3H).

Example 80

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-(3-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (d, J=1.2, 1H), 8.30 (s, 1H), 8.08-8.03 (m, 1H), 8.01-7.96 (m, 1H), 7.70-7.63 (m, 1H), 7.62-7.56 (m, 1H), 7.42-7.32 (m, 1H), 7.36-7.28 (m, 2H), 3.51 (t, J=6.2, 2H), 2.88 (t, J=7.0, 2H), 1.65-1.54 (m, 2H).

Example 81

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (S)-2-bromo-N-(2-hydroxy-1-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₂₁FN₄O₃S, 464.13; m/z found, 465.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.30 (m, 2H), 8.05-8.01 (m, 1H), 7.85 (t, J=8.2, 1H), 7.61-7.56 (m, 1H), 7.50-7.44 (m, 1H), 7.26-7.19 (m, 4H), 7.10-6.97 (m, 4H), 4.20 (t, J=6.6, 1H), 3.69-3.58 (m, 2H).

Example 82

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (R)-2-bromo-N-(2-hydroxy-1-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₂₁FN₄O₃S, 464.13; m/z found, 465.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.36-8.32 (m, 1H), 8.07-8.01 (m, 2H), 7.75 (t, J=8.2, 1H), 7.60-7.54 (m, 1H), 7.49-7.44 (m, 1H), 7.25-7.18 (m, 4H), 7.07-7.00 (m, 3H), 6.98-6.92 (m, 1H), 4.19 (t, J=6.6, 1H), 3.69-3.58 (m, 2H).

Example 83

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₅H₂₃FN₄O₃S, 478.15; m/z found, 479.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.36 (s, 1H), 8.12-8.05 (m, 2H), 7.89-7.83 (m, 1H), 7.67-7.62 (m, 1H), 7.59-7.54 (m, 1H), 7.37-7.34 (m, 1H), 7.27-7.12 (m, 7H), 4.60 (t, J=4.4, 1H), 3.42-3.34 (m, 1H), 0.91-0.84 (m, 3H).

Example 84

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((2S,3S)-1-hydroxy-3-methylpentan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₅FN₄O₃S, 444.16; m/z found, 445.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.16-8.13 (m, 1H), 8.06 (d, J=1.4, 1H), 7.86 (m, 1H), 7.67-7.62 (m, 1H), 7.58-7.53 (m, 1H), 7.39-7.28 (m, 3H), 3.46-3.35 (m, 2H), 3.13 (q, J=5.4, 1H), 1.60-1.49 (m, 1H), 1.48-1.36 (m, 1H), 1.07-0.93 (m, 1H), 0.84-0.74 (m, 6H).

Example 85

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((1R,2R)-2-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37-8.30 (m, 2H), 8.21-8.16 (m, 1H), 7.97 (m, 1H), 7.68-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.40-7.32 (m, 3H), 3.26-3.18 (m, 1H), 2.87-2.79 (m, 1H), 1.94-1.77 (m, 2H), 1.67-1.50 (m, 2H), 1.26-1.09 (m, 4H).

Example 86

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (R)-2-bromo-N-(1-hydroxybutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 417.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.32 (m, 2H), 8.16-8.12 (m, 1H), 7.96 (m, 1H), 7.68-7.63 (m, 1H), 7.60-7.55 (m, 1H), 7.40-7.30 (m, 3H), 3.43-3.35 (m, 1H), 3.33 (d, J=5.9, 1H), 3.12-3.05 (m, 1H), 1.60-1.48 (m, 1H), 1.42-1.28 (m, 1H), 0.79 (t, J=7.4, 3H).

Example 87

The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((1R,2S)-2-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.33 (s, 2H), 8.15-8.11 (m, 1H), 7.98 (m, 1H), 7.69-7.64 (m, 1H), 7.61-7.56 (m, 1H), 7.42-7.32 (m, 3H), 3.70-3.63 (m, 1H), 3.09-3.03 (m, 1H), 1.70-1.61 (m, 1H), 1.60-1.44 (m, 3H), 1.42-1.24 (m, 3H), 1.22-1.10 (m, 1H).

Example 88

5-(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (40 mg, 0.13 mmol) and 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide (53 mg, 0.19 mmol) were added to a 5 mL sealable vial equipped with a stir bar. 1,4-Dioxane (0.7 mL) and Na₂CO₃ (0.3 mL, 2 M) were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 min before adding Pd(dppf)Cl₂.CH₂Cl₂ (5 mg, 0.006 mmol) and heating the mixture heated 15 hours at 80° Celsius. The reaction was cooled to rt, diluted with 2 mL of ethylacetate, 2 mL of water and extracted with of ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na₂SO₄ and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₃S, 388.10; m/z found, 389.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.37 (dd, J=2.2, 1.5, 1H), 8.11-8.06 (m, 2H), 7.93-7.86 (m, 1H), 7.70-7.64 (m, 1H), 7.62-7.56 (m, 1H), 7.44-7.38 (dd, J=7.6, 1.3, 1H), 7.35-7.27 (m, 2H), 3.49-3.44 (t, J=5.9, 2H), 2.90-2.84 (t, J=5.9, 2H).

Example 89

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-cyclopropylbenzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₂S, 384.11; m/z found, 385.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39-8.31 (d, J=1.6, 1H), 8.26-8.18 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.0, 1.3, 1 H), 7.97-7.89 (m, 1H), 7.73-7.66 (m, 1H), 7.65-7.57 (m, 1H), 7.46-7.37 (dd, J=7.6, 1.4, 1H), 7.33-7.23 (m, 3H), 2.22-2.13 (m, 1H), 0.50-0.43 (m, 2H), 0.41-0.34 (m, 2H).

Example 90

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(cyclopropylmethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂S, 398.12; m/z found, 399.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.33 (m, 1H), 8.15-8.10 (dd, J=8.0, 1.3, 1H), 8.09-8.06 (d, J=1.5, 1 H), 7.91-7.82 (m, 1H), 7.70-7.63 (m, 1H), 7.61-7.53 (m, 1H), 7.40-7.35 (dd, J=7.6, 1.4, 1H), 7.25 (s, 1H), 7.24-7.21 (m, 1H), 1.21 (m, 3H), 0.50-0.46 (m, 2H), 0.39-0.28 (m, 2H).

Example 91

The title compound was prepared in a manner similar to that described in Example 88 using (R)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)methanol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39-8.34 (m, 1H), 8.24-8.19 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.0, 1.3, 1 H), 7.98-7.91 (m, 1H), 7.73-7.66 (m, 1H), 7.65-7.57 (m, 1H), 7.46-7.39 (dd, J=7.6, 1.3, 1H), 7.33-7.32 (m, 1H), 7.32-7.27 (dd, J=6.0, 1.6, 1H), 3.52-3.45 (m, 1H), 3.41-3.34 (dd, J=11.0, 3.9, 1H), 3.24-3.13 (m, 1H), 3.02-2.89 (m, 2H), 1.88-1.73 (m, 3H), 1.71-1.62 (dd, J=6.9, 4.6, 1H).

Example 92

The title compound was prepared in a manner similar to that described in Example 88 using (R)-1-((2-bromophenyl)sulfonyl)pyrrolidin-3-amine, followed by removal of the Boc group with trifluoroacetic acid in dichloromethane at rt. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.44-8.29 (m, 1H), 8.17-8.13 (d, J=1.5, 1H), 8.13-8.09 (dd, J=8.0, 1.3, 1 H), 7.99-7.88 (m, 1H), 7.79-7.69 (m, 1H), 7.69-7.59 (m, 1H), 7.50-7.42 (dd, J=7.6, 1.4, 1H), 7.32 (s, 1H), 7.31-7.29 (dd, J=2.9, 1.5, 1H), 3.77-3.60 (m, 1H), 3.29-3.25 (m, 1H), 3.21-3.12 (dd. J=10.9, 6.7, 1H), 3.12-3.01 (dd, J=10.9, 5.0, 1H), 2.98-2.86 (m, 1H), 2.23-2.12 (m, 1H), 1.94-1.78 (m, 1H).

Example 93

The title compound was prepared in a manner similar to that described in Example 88 using (S)-1-((2-bromophenyl)sulfonyl)pyrrolidin-3-amine, followed by removal of the Boc group with trifluoroacetic acid in dichloromethane at rt. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.35 (m, 1H), 8.16-8.13 (d, J=1.4, 1H), 8.13-8.09 (dd, J=8.0, 1.3, 1H), 7.98-7.90 (m, 1H), 7.77-7.71 (m, 1H), 7.68-7.60 (m, 1H), 7.47-7.43 (dd, J=7.5, 1.3, 1H), 7.34-7.31 (m, 1H), 7.31-7.29 (q, J=1.5, 1H), 3.73-3.63 (p, J=6.1, 1H), 3.29-3.23 (m, 1H), 3.19-3.13 (dd, J=10.8, 6.7, 1H), 3.10-3.03 (dd, J=10.9, 5.0, 1H), 2.98-2.85 (m, 1H), 2.25-2.11 (m, 1H), 1.93-1.80 (m, 1H).

Example 94

The title compound was prepared in a manner similar to that described in Example 88 using (R)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)-methan-amine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.38 (m, 1H), 8.16-8.13 (dd, J=8.1, 1.3, 1H), 8.13-8.12 (d, J=1.5, 1H), 7.94-7.89 (m, 1H), 7.78-7.73 (m, 1H), 7.69-7.63 (m, 1H), 7.48-7.45 (dd, J=7.6, 1.3, 1H), 7.36-7.30 (m, 2H), 3.71-3.62 (m, 1H), 3.15-3.08 (m, 1H), 3.05-2.98 (m, 1H), 2.86-2.74 (m, 2H), 1.92-1.76 (m, 2H), 1.73-1.62 (m, 2H).

Example 95

The title compound was prepared in a manner similar to that described in Example 88 using (S)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)methanol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.37-8.34 (m, 1H), 8.24-8.22 (d, J=1.4, 1H), 8.13-8.09 (dd, J=8.0, 1.3, 1 H), 7.98-7.93 (m, 1H), 7.73-7.67 (m, 1H), 7.63-7.59 (m, 1H), 7.44-7.40 (dd, J=7.6, 1.3, 1H), 7.34-7.32 (m, 1H), 7.32-7.30 (dd, J=5.9, 1.6, 1H), 3.52-3.45 (dd, J=7.6, 4.0, 1H), 3.40-3.34 (m, 1H), 3.22-3.11 (dd, J=10.8, 7.9, 1H), 3.02-2.87 (m, 2H), 1.90-1.72 (m, 3H), 1.71-1.62 (dd, J=6.7, 4.5, 1H).

Example 96

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(methylsulfonyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₇H₁₅FN₄O₄S₂, 422.05; m/z found, 423.0 [M+H]⁺. ¹H NMR (500 MHz, acetone-d₆) δ 8.56 (s, 1H), 8.25-8.18 (dd, J=7.9, 1.4, 1H), 8.16 (s, 1H), 7.90-7.84 (m, 1H), 7.64-7.57 (m, 1H), 7.57-7.50 (m, 1H), 7.46-7.40 (dd, J=8.2, 1.6, 1H), 7.38-7.31 (d, J=13.3, 1H), 7.31-7.26 (dd, J=7.4, 1.4, 1H), 2.96 (s, 3H).

Example 97

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.37 (s, 1H), 8.27-8.19 (m, 1H), 8.11-8.03 (dd, J=8.0, 1.3, 1H), 7.99-7.91 (m, 1H), 7.72-7.64 (m, 1H), 7.64-7.55 (m, 1H), 7.45-7.38 (d, J=7.5, 1H), 7.37-7.27 (m, 2H), 3.74-3.61 (m, 1H), 2.80-2.72 (m, 1H), 2.72-2.64 (m, 1H), 1.10-0.99 (d, J=6.2, 3H).

Example 98

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.35 (m, 1H), 8.21-8.17 (d, J=1.5, 1H), 8.10-8.04 (dd, J=8.0, 1.3, 1 H), 7.96-7.91 (m, 1H), 7.71-7.65 (m, 1H), 7.62-7.57 (m, 1H), 7.44-7.39 (dd, J=7.5, 1.3, 1H), 7.36-7.29 (m, 2H), 3.73-3.60 (m, 1H), 2.77-2.72 (m, 1H), 2.71-2.65 (m, 1H), 1.08-1.03 (d, J=6.3, 3H).

Example 99

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1-hydroxycyclohexyl)methyl)-benzenesulfonamide. MS (ESI): mass calcd. for C₂₃H₂₅FN₄O₃S, 456.16; m/z found, 457.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.44-8.37 (dd, J=2.2, 1.5, 1H), 8.10-8.04 (m, 2H), 7.96-7.87 (m, 1H), 7.71-7.64 (m, 1H), 7.63-7.56 (m, 1H), 7.46-7.39 (dd, J=7.6, 1.4, 1H), 7.37-7.28 (m, 2H), 2.67 (s, 2H), 1.61-1.22 (m, 10H).

Example 100

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 417.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.35 (m, 1H), 8.18-8.13 (m, 2H), 7.97-7.90 (m, 1H), 7.69-7.63 (m, 1H), 7.60-7.54 (m, 1H), 7.41-7.38 (dd, J=7.7, 1.4, 1H), 7.38-7.33 (m, 2H), 3.27 (s, 2H), 1.01 (s, 6H).

Example 101

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 417.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.38 (dd, J=2.2, 1.4, 1H), 8.10-8.07 (d, J=1.5, 1H), 8.07-8.03 (dd, J=7.9, 1.0, 1 H), 7.93-7.88 (m, 1H), 7.70-7.64 (m, 1H), 7.62-7.57 (m, 1H), 7.44-7.40 (dd, J=7.5, 1.2, 1H), 7.36-7.28 (m, 2H), 2.67 (s, 2H), 1.09 (s, 6H).

Example 102

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(4-hydroxy-2-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.36 (m, 1H), 8.18-8.16 (d, J=1.5, 1H), 8.16-8.12 (dd, J=8.0, 1.3, 1H), 7.96-7.89 (m, 1H), 7.68-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.42-7.37 (dd, J=7.6, 1.4, 1H), 7.37-7.35 (m, 1H), 7.35-7.32 (dd. J=3.9, 1.6, 1H), 3.61-3.53 (t, J=6.7, 2H), 1.67-1.62 (t, J=6.7, 2H), 1.08 (s, 6H).

Example 103

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(3-hydroxy-2,2-dimethylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.35 (m, 1H), 8.10-8.06 (d, J=1.5, 1H), 8.05-8.02 (dd, J=8.0, 1.3, 1 H), 7.95-7.85 (m, 1H), 7.71-7.63 (m, 1H), 7.63-7.54 (m, 1H), 7.45-7.39 (dd, J=7.6, 1.3, 1H), 7.38-7.28 (m, 2H), 3.19 (s, 2H), 2.62 (s, 2H), 0.77 (s, 6H).

Example 104

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(2,3-dihydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₄S, 418.11; m/z found, 419.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.33 (m, 1H), 8.27-8.23 (d, J=1.4, 1H), 8.11-8.05 (dd, J=8.0, 1.3, 1 H), 7.99-7.93 (m, 1H), 7.72-7.64 (m, 1H), 7.63-7.57 (m, 1H), 7.44-7.39 (dd, J=7.6, 1.4, 1H), 7.38-7.29 (m, 2H), 3.62-3.53 (m, 1H), 3.43-3.39 (m, 2H), 2.97-2.90 (dd, J=13.2, 4.8, 1H), 2.79-2.71 (dd, J=13.2, 7.0, 1H).

Example 105

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2,3-dihydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₄S, 418.11; m/z found, 419.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.32 (m, 1H), 8.29-8.22 (d, J=1.4, 1H), 8.11-8.05 (dd, J=8.0, 1.3, 1 H), 8.00-7.91 (m, 1H), 7.72-7.64 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (dd, J=7.6, 1.3, 1H), 7.37-7.29 (m, 2H), 3.61-3.52 (m, 1H), 3.43-3.39 (m, 2H), 2.97-2.90 (dd, J=13.1, 4.8, 1H), 2.80-2.72 (dd, J=13.1, 7.0, 1H).

Example 106

The title compound was prepared in a manner similar to that described in Example 88 using (trans)-1-((2-bromophenyl)sulfonyl)pyrrolidine-3,4-diol. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₄S, 430.11; m/z found, 431.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39-8.34 (m, 1H), 8.24-8.20 (d, J=1.5 Hz, 1H), 8.15-8.08 (dd. J=8.0, 1.3 Hz, 1H), 7.97-7.88 (m, 1H), 7.70-7.64 (td, J=7.5, 1.4 Hz, 1H), 7.62-7.54 (td, J=7.7, 1.4 Hz, 1H), 7.47-7.38 (dd, J=7.6, 1.3 Hz, 1H), 7.34-7.31 (dd, J=8.0, 1.7 Hz, 1H), 7.31-7.27 (dd, J=12.3, 1.7 Hz, 1H), 4.00-3.97 (m, 2H), 3.29-3.27 (m, 2H), 3.07-3.03 (m, 2H).

Example 107

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(2-oxopyrrolidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.38 (dd, J=2.2, 1.4, 1H), 8.26-8.22 (dd, J=8.2, 1.3, 1H), 8.08-8.06 (d, J=1.5, 1H), 7.91-7.84 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.55 (m, 1H), 7.41-7.38 (dd, J=7.6, 1.3, 1H), 7.38-7.32 (m, 2H), 3.88-3.81 (dd, J=10.3, 8.3, 1H), 3.28-3.22 (m, 1H), 3.22-3.15 (m, 1H), 2.38-2.30 (m, 1H), 1.96-1.86 (m, 1H).

Example 108

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(2-oxopiperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₃S, 441.13; m/z found, 442.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.37 (s, 1H), 8.25-8.15 (m, 2H), 7.97-7.88 (m, 1H), 7.71-7.62 (m, 1H), 7.62-7.54 (m, 1H), 7.42-7.30 (m, 3H), 3.67-3.57 (dd, J=10.4, 5.8, 1H), 3.22-3.17 (m, 2H), 2.19-2.07 (d, J=10.6, 1H), 1.90-1.79 (m, 1H), 1.78-1.64 (m, 2H).

Example 109

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.37 (dd, J=2.2, 1.4, 1H), 8.16-8.11 (dd, J=8.0, 1.3, 1 H), 8.10-8.06 (d, J=1.5, 1H), 7.91-7.84 (m, 1H), 7.68-7.61 (m, 1H), 7.60-7.53 (m, 1H), 7.39-7.35 (dd, J=7.7, 1.4, 1H), 7.36-7.28 (m, 2H), 3.45-3.39 (m, 1H), 3.38-3.33 (m, 1H), 3.10-3.03 (m, 1H), 1.89-1.75 (m, 1H), 0.86-0.75 (dd, J=6.9, 4.4, 6H).

Example 110

The title compound was prepared in a manner similar to that described in Example 88 using trans-2-bromo-N-(4-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.34 (m, 1H), 8.22-8.17 (d, J=1.5, 1H), 8.14-8.08 (dd, J=7.9, 1.3, 1H), 7.96-7.90 (m, 1H), 7.69-7.64 (m, 1H), 7.62-7.56 (m, 1H), 7.43-7.38 (dd, J=7.7, 1.3, 1H), 7.35-7.28 (m, 2H), 3.43-3.36 (m, 1H), 2.89-2.77 (m, 1H), 1.87-1.77 (m, 2H), 1.77-1.68 (dd, J=8.3, 4.0, 2H), 1.27-1.05 (m, 4H).

Example 111

The title compound was prepared in a manner similar to that described in Example 88 using (R)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-3-yl)methanol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.37 (s, 1H), 8.22-8.19 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.1, 1.3, 1H), 7.97-7.93 (m, 1H), 7.75-7.66 (m, 1H), 7.65-7.57 (m, 1H), 7.45-7.39 (dd, J=7.6, 1.3, 1H), 7.37-7.25 (m, 2H), 3.42-3.36 (m, 1H), 3.09-3.03 (dd, J=9.5, 7.5, 1H), 3.03-2.97 (m, 1H), 2.95-2.85 (m, 1H), 2.75-2.64 (dd, J=9.6, 7.2, 1H), 2.29-2.17 (m, 1H), 1.86-1.76 (m, 1H), 1.54-1.41 (m, 1H).

Example 112

The title compound was prepared in a manner similar to that described in Example 88 using (S)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-3-yl)methanol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.32 (m, 1H), 8.24-8.17 (d, J=1.5, 1H), 8.12-8.07 (dd, J=8.0, 1.3, 1 H), 7.99-7.93 (m, 1H), 7.72-7.66 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (dd, J=7.5, 1.3, 1H), 7.35-7.26 (m, 2H), 3.43-3.36 (m, 1H), 3.33-3.28 (m, 1H), 3.08-3.03 (dd, J=9.6, 7.6, 1H), 3.03-2.98 (m, 1H), 2.94-2.86 (m, 1H), 2.74-2.65 (dd, J=9.6, 7.1, 1H), 2.30-2.13 (m, 1H), 1.87-1.74 (m, 1H), 1.56-1.41 (m, 1H).

Example 113

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2-oxopiperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₃S, 441.13; m/z found, 442.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.37-8.34 (m, 1H), 8.26-8.19 (m, 2H), 7.97-7.91 (m, 1H), 7.69-7.64 (m, 1H), 7.62-7.54 (m, 1H), 7.42-7.34 (m, 3H), 3.67-3.58 (dd, J=10.4, 5.9, 1H), 3.22-3.16 (m, 2H), 2.19-2.10 (m, 1H), 1.88-1.80 (m, 1H), 1.78-1.64 (m, 2H).

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-methyl-N-(piperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂H₂₄FN₅O₂S, 441.16; m/z found, 442.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.37 (m, 1H), 8.20-8.16 (dd, J=8.1, 1.3, 1H), 8.16-8.14 (d, J=1.5, 1H), 8.00-7.92 (m, 1H), 7.78-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.48-7.43 (dd, J=7.6, 1.3, 1H), 7.37-7.35 (m, 1H), 7.35-7.32 (dd, J=7.0, 1.7, 1H), 3.64-3.53 (m, 1H), 3.23-3.17 (d, J=12.8, 1H), 3.06-3.00 (t, J=5.9, 1H), 3.00-2.93 (m, 1H), 2.78-2.70 (m, 1H), 2.42 (s, 3H), 1.92-1.81 (dd, J=16.5, 3.2, 1H), 1.68-1.57 (m, 1H), 1.57-1.44 (m, 1H), 1.44-1.33 (d, J=12.3, 1H).

Example 115

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-methyl-N-(piperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₂S, 441.16; m/z found, 442.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.36 (m, 1H), 8.21-8.15 (dd, J=8.1, 1.3, 1H), 8.14-8.09 (d, J=1.5, 1H), 7.99-7.90 (m, 1H), 7.78-7.72 (m, 1H), 7.67-7.61 (m, 1H), 7.49-7.43 (dd, J=7.6, 1.3, 1H), 7.36-7.35 (m, 1H), 7.35-7.32 (dd, J=7.1, 1.7, 1H), 3.64-3.52 (m, 1H), 3.22-3.17 (d, J=13.2, 1H), 3.05-3.00 (m, 1H), 3.00-2.93 (m, 1H), 2.79-2.69 (m, 1H), 2.42 (s, 3H), 1.93-1.82 (m, 1H), 1.67-1.56 (m, 1H), 1.56-1.45 (m, 1H), 1.43-1.34 (m, 1H).

Example 116

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxy-3-phenylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₅H₂₃FN₄O₃S, 478.15; m/z found, 479.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.35 (m, 1H), 8.10-8.05 (d, J=1.5, 1 H), 7.99-7.95 (dd, J=8.0, 1.3, 1H), 7.86-7.79 (t, J=8.1, 1H), 7.63-7.57 (m, 1H), 7.51-7.45 (m, 1H), 7.31-7.26 (dd, J=7.6, 1.3, 1H), 7.19-7.07 (m, 5H), 7.08-7.02 (dd, J=8.0, 1.5, 2H), 3.49-3.41 (m, 2H), 3.41-3.34 (m, 1H), 2.92-2.82 (dd, J=13.9, 6.3, 1H), 2.68-2.59 (dd, J=13.9, 6.8, 1H).

Example 117

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2-hydroxy-2-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₂₁FN₄O₃S, 464.13; m/z found, 465.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.33 (m, 1H), 8.11-8.03 (m, 2H), 7.90-7.82 (t, J=8.2, 1H), 7.70-7.63 (m, 1H), 7.61-7.54 (m, 1H), 7.42-7.36 (dd, J=7.6, 1.3, 1H), 7.30-7.16 (m, 7H), 4.60-4.53 (dd, J=7.9, 4.8, 1H), 2.98-2.92 (m, 1H), 2.92-2.86 (m, 1H).

Example 118

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₆H₂₅FN₄O₃S, 492.16; m/z found, 493.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.35 (m, 1H), 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.10-8.07 (d, J=1.5, 1H), 7.92-7.84 (t, J=8.0, 1H), 7.68-7.61 (m, 1H), 7.60-7.54 (m, 1H), 7.40-7.35 (dd, J=7.6, 1.4, 1H), 7.33-7.20 (m, 7H), 4.57-4.43 (d, J=8.4, 1H), 3.91-3.79 (m, 1H), 2.49 (s, 3H), 0.75-0.62 (d, J=6.8, 3H).

Example 119

The title compound was prepared in a manner similar to that described in Example 88 using 1-((2-bromophenyl)sulfonyl)azetidin-3-ol. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₃S, 400.10; m/z found, 401.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.29 (m, 1H), 8.22-8.17 (d, J=1.4, 1H), 8.10-8.05 (dd, J=8.0, 1.3, 1H), 7.97-7.91 (m, 1H), 7.75-7.67 (m, 1H), 7.64-7.56 (m, 1H), 7.46-7.40 (dd, J=7.5, 1.3, 1H), 7.36-7.27 (m, 2H), 4.37-4.25 (m, 1H), 3.70-3.60 (m, 2H), 3.60-3.53 (m, 2H).

Example 120

The title compound was prepared in a manner similar to that described in Example 88 using racemic-(trans)-2-bromo-N-(2-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.37 (s, 1H), 8.21-8.16 (m, 2H), 7.95-7.90 (m, 1H), 7.68-7.62 (m, 1H), 7.60-7.55 (m, 1H), 7.40-7.36 (dd, J=7.6, 1.3, 1H), 7.36-7.35 (m, 1H), 7.35-7.32 (dd, J=6.2, 1.6, 1H), 3.25-3.19 (m, 1H), 2.86-2.79 (m, 1H), 1.94-1.86 (m, 1H), 1.85-1.77 (m, 1H), 1.66-1.58 (m, 1H), 1.58-1.51 (m, 1H), 1.26-1.09 (m, 4H).

Example 121

The title compound was prepared in a manner similar to that described in Example 88 using racemic (trans)-2-bromo-N-(2-(hydroxymethyl)cyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₃H₂₅FN₄O₃S, 456.16; m/z found, 457.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.34 (m, 1H), 8.20-8.14 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.1, 1.3, 1H), 7.97-7.88 (m, 1H), 7.70-7.63 (m, 1H), 7.63-7.55 (m, 1H), 7.43-7.36 (dd, J=7.7, 1.4, 1H), 7.35-7.25 (m, 2H), 3.61-3.52 (dd, J=11.1, 3.7, 1H), 3.43-3.36 (dd, J=11.0, 6.4, 1H), 2.92-2.79 (m, 1H), 1.86-1.80 (m, 1H), 1.66-1.53 (m, 3H), 1.34-1.26 (m, 1H), 1.18-1.03 (m, 4H).

Example 122

The title compound was prepared in a manner similar to that described in Example 88 using racemic cis-2-bromo-N-(2-(hydroxymethyl)cyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₃H₂₅FN₄O₃S, 456.16; m/z found, 457.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.37 (m, 1H), 8.16-8.10 (dd, J=8.0, 1.3, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.92-7.85 (m, 1H), 7.70-7.63 (m, 1H), 7.62-7.55 (m, 1H), 7.43-7.37 (dd, J=7.5, 1.4, 1H), 7.34-7.26 (m, 2H), 3.58-3.51 (dd, J=11.1, 7.1, 1H), 3.47-3.39 (m, 1H), 3.38-3.33 (m, 1H), 1.69-1.59 (m, 1H), 1.58-1.50 (m, 1H), 1.47-1.16 (m, 7H).

Example 123

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(piperidin-4-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.37 (m, 1H), 8.16-8.10 (m, 2H), 7.95-7.89 (m, 1H), 7.74-7.66 (m, 1H), 7.64-7.56 (m, 1H), 7.46-7.40 (dd, J=7.7, 1.3, 1H), 7.38-7.29 (m, 2H), 3.30-3.22 (m, 2H), 3.21-3.14 (m, 1H), 2.98-2.89 (m, 2H), 1.98-1.85 (dd, J=14.6, 3.9, 2H), 1.65-1.48 (m, 2H).

Example 124

The title compound was prepared in a manner similar to that described in Example 88 using (1-((2-bromophenyl)sulfonyl)azetidin-3-yl)methanamine. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.37 (m, 1H), 8.14-8.11 (d, J=1.5, 1H), 8.11-8.07 (dd, J=8.0, 1.3, 1H), 7.97-7.90 (m, 1H), 7.76-7.70 (m, 1H), 7.65-7.57 (m, 1H), 7.52-7.42 (dd, J=7.7, 1.3, 1H), 7.39-7.25 (m, 2H), 3.81-3.67 (t, J=8.1, 2H), 3.42-3.36 (dd, J=8.1, 5.5, 2H), 3.07-3.00 (d, J=7.5, 2H), 2.72-2.59 (m, 1H).

Example 125

The title compound was prepared in a manner similar to that described in Example 88 using N-(azetidin-3-ylmethyl)-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.37 (m, 1H), 8.17-8.12 (d, J=1.5, 1H), 8.09-8.05 (dd, J=8.0, 1.3, 1 H), 7.97-7.88 (m, 1H), 7.73-7.66 (m, 1H), 7.65-7.58 (m, 1H), 7.47-7.41 (dd, J=7.6, 1.4, 1H), 7.36-7.28 (m, 2H), 4.02-3.95 (dd, J=11.2, 7.7, 2H), 3.91-3.78 (dd, J=11.3, 6.1, 2H), 3.04-2.91 (m, 3H).

Example 126

The title compound was prepared in a manner similar to that described in Example 88 using (R)-1-((2-bromophenyl)sulfonyl)-N-methylpyrrolidin-3-amine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.44-8.35 (m, 1H), 8.15-8.08 (m, 2H), 7.98-7.91 (m, 1H), 7.78-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.48-7.43 (dd, J=7.7, 1.3, 1H), 7.34-7.27 (m, 2H), 3.69-3.57 (m, 1H), 3.29-3.23 (m, 1H), 3.22-3.16 (m, 1H), 3.16-3.11 (m, 1H), 2.99-2.85 (m, 1H), 2.65 (s, 3H), 2.28-2.14 (m, 1H), 1.99-1.87 (m, 1H).

Example 127

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₂S, 440.09; m/z found, 441.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.38 (dd, J=2.1, 1.5, 1H), 8.13-8.09 (dd, J=8.1, 1.3, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.90-7.85 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.55 (m, 1H), 7.41-7.36 (dd, J=7.7, 1.4, 1H), 7.30-7.27 (dd, J=8.0, 1.7, 1H), 7.27-7.22 (dd, J=12.3, 1.7, 1H), 3.91-3.79 (m, 1H), 1.24-1.16 (d, J=7.0, 3H).

Example 128

The title compound was prepared in a manner similar to that described in Example 88 using 5-((2-bromophenyl)sulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]-pyridine. MS (ESI): mass calcd. for C₂₂H₁₉FN₆O₂S, 450.13; m/z found, 451.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.35 (m, 1H), 8.21-8.14 (dd, J=8.1, 1.3, 1H), 8.11-8.07 (d, J=1.5, 1H), 7.85-7.79 (m, 1H), 7.76-7.68 (m, 1H), 7.65-7.59 (m, 1H), 7.45-7.37 (dd, J=7.5, 1.4, 1H), 7.31-7.14 (m, 3H), 4.02-3.88 (m, 2H), 3.28-3.22 (t, J=5.9, 2H), 2.59-2.48 (t, J=5.9, 2H).

Example 129

The title compound was prepared in a manner similar to that described in Example 88 using 4-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)-1H-1,2,4-triazol-5(4H)-one. MS (ESI): mass calcd. for C₂₃H₂₂FN₇O₃S, 495.15; m/z found, 496.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.35 (m, 1H), 8.24-8.22 (d, J=1.5, 1H), 8.15-8.11 (dd, J=8.1, 1.3, 1H), 8.01-7.96 (m, 1H), 7.78 (s, 1H), 7.76-7.70 (m, 1H), 7.66-7.60 (m, 1H), 7.48-7.43 (dd, J=7.6, 1.3, 1H), 7.41-7.33 (m, 2H), 3.88-3.76 (m, 1H), 3.51-3.42 (m, 2H), 2.64-2.53 (m, 2H), 1.88-1.79 (d, J=12.3, 2H), 1.68-1.50 (m, 2H).

Example 130

The title compound was prepared in a manner similar to that described in Example 88 using (1R,4R)-2-((2-bromophenyl)sulfonyl)-2,5-diazabicyclo[2.2.1]heptane. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₂S, 425.13; m/z found, 426.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.38 (m, 1H), 8.19-8.14 (dd, J=8.1, 1.3, 1H), 8.14-8.10 (d, J=1.5, 1H), 7.99-7.91 (m, 1H), 7.79-7.72 (m, 1H), 7.68-7.60 (m, 1H), 7.51-7.43 (dd, J=7.6, 1.3, 1H), 7.38-7.35 (m, 1H), 7.33 (s, 1H), 4.32 (s, 1H), 4.05 (s, 1H), 3.38-3.33 (m, 1H), 3.30-3.25 (m, 1H), 3.21-3.14 (dd, J=11.6, 2.2, 1H), 3.04-2.98 (dd, J=11.0, 2.6, 1H), 1.85-1.72 (m, 2H).

Example 131

The title compound was prepared in a manner similar to that described in Example 88 using (1S,4S)-2-((2-bromophenyl)sulfonyl)-2,5-diazabicyclo[2.2.1]heptane. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₂S, 425.13; m/z found, 426.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.36 (m, 1H), 8.17-8.14 (m, 2H), 8.00-7.92 (m, 1H), 7.79-7.72 (m, 1H), 7.68-7.61 (m, 1H), 7.49-7.45 (dd, J=7.6, 1.3, 1H), 7.39-7.35 (m, 1H), 7.34 (s, 1H), 4.38-4.28 (m1H), 4.05 (s, 1H), 3.38-3.32 (dd, J=11.6, 1.7, 1H), 3.30-3.26 (m, 1H), 3.23-3.12 (dd, J=11.6, 2.2, 1H), 3.08-2.95 (dd, J=11.0, 2.6, 1H), 1.85-1.74 (m, 2H).

Example 132

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(5-hydroxypentyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.44-8.38 (m, 1H), 8.10-8.07 (d, J=1.5, 1H), 8.07-8.04 (dd, J=8.0, 1.3, 1H), 7.92-7.87 (m, 1H), 7.68-7.64 (m, 1H), 7.62-7.55 (m, 1H), 7.43-7.38 (dd, J=7.6, 1.4, 1H), 7.33-7.27 (m, 2H), 3.49-3.45 (t, J=6.6, 2H), 2.78-2.73 (t, J=7.1, 2H), 1.48-1.41 (m, 2H), 1.41-1.34 (m, 2H), 1.31-1.21 (m, 2H).

Example 133

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(6-hydroxyhexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₅FN₄O₃S, 444.16; m/z found, 445.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.38 (m, 1H), 8.09-8.08 (d, J=1.5, 1H), 8.08-8.04 (dd, J=7.9, 1.3, 1H), 7.94-7.85 (m, 1H), 7.70-7.63 (m, 1H), 7.62-7.56 (m, 1H), 7.43-7.37 (dd, J=7.7, 1.4, 1H), 7.33-7.26 (m, 2H), 3.51-3.46 (t, J=6.6, 2H), 2.78-2.72 (t, J=7.1, 2H), 1.51-1.41 (m, 2H), 1.42-1.33 (p, J=7.2, 2H), 1.33-1.16 (m, 4H).

Example 134

The title compound was prepared in a manner similar to that described in Example 88 using (cis)-N-(4-aminocyclohexyl)-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₂S, 441.16; m/z found, 442.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.36 (m, 1H), 8.19-8.14 (m, 1H), 8.13-8.07 (dd, J=8.0, 1.3, 1H), 7.97-7.91 (m, 1H), 7.73-7.67 (m, 1H), 7.65-7.58 (m, 1H), 7.46-7.41 (dd, J=7.5, 1.3, 1H), 7.35-7.33 (m, 1H), 7.33-7.31 (dd, J=6.2, 1.6, 1H), 3.15-3.00 (m, 2H), 1.80-1.69 (m, 4H), 1.68-1.57 (m, 2H), 1.58-1.48 (m, 2H).

Example 135

The title compound was prepared in a manner similar to that described in Example 88 using (S)-(1-((2-bromophenyl)sulfonyl)indolin-2-yl)methanol. MS (ESI): mass calcd. for C₂₅H₂₁FN₄O₃S, 476.13; m/z found, 477.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.36-8.33 (m, 1H), 8.22-8.20 (d, J=1.5, 1H), 8.19-8.14 (dd, J=8.0, 1.3, 1 H), 7.85-7.79 (m, 1H), 7.69-7.63 (m, 1H), 7.61-7.56 (m, 1H), 7.32-7.28 (dd, J=7.5, 1.4, 1H), 7.11-7.06 (m, 2H), 7.01-6.95 (dd, J=12.2, 1.7, 1H), 6.91-6.80 (m, 3H), 3.85-3.74 (m, 1H), 3.67-3.58 (dd, J=10.9, 4.2, 1H), 3.40-3.33 (dd, J=11.0, 7.8, 1H), 2.89-2.72 (m, 2H).

Example 136

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-cyclohexyl-N-(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₂₇FN₄O₃S, 470.18; m/z found, 471.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.40-8.34 (m, 1H), 8.21-8.18 (d, J=1.5, 1H), 8.16-8.12 (dd, J=8.0, 1.4, 1 H), 7.99-7.92 (m, 1H), 7.72-7.65 (m, 1H), 7.63-7.56 (m, 1H), 7.42-7.38 (dd, J=7.6, 1.4, 1H), 7.35-7.32 (m, 1H), 7.32-7.28 (dd, J=5.5, 1.6, 1H), 3.43-3.34 (dd, J=8.0, 6.9, 2H), 3.19-3.09 (m, 1H), 2.95-2.87 (dd, J=8.0, 6.9, 2H), 1.73-1.58 (d, J=12.6, 2H), 1.58-1.40 (m, 3H), 1.38-1.23 (m, 2H), 1.17-0.93 (m, 3H).

Example 137

The title compound was prepared in a manner similar to that described in Example 88 using (S)-1-((2-bromophenyl)sulfonyl)piperidin-3-amine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.41-8.37 (m, 1H), 8.18-8.14 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.0, 1.3, 1H), 7.97-7.90 (m, 1H), 7.79-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.49-7.42 (dd, J=7.6, 1.4, 1 H), 7.33-7.31 (m, 1H), 7.31-7.28 (dd, J=5.2, 1.6, 1H), 3.37-3.32 (m, 1H), 3.10-2.98 (m, 2H), 2.73-2.62 (m, 1H), 2.62-2.50 (dd, J=12.7, 8.9, 1H), 2.00-1.88 (m, 1H), 1.81-1.66 (m, 1H), 1.59-1.33 (m, 2H).

Example 138

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N,N-bis(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₄S, 432.13; m/z found, 433.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37-8.33 (m, 1H), 8.30-8.25 (d, J=1.4, 1H), 8.10-8.05 (dd, J=7.9, 1.3, 1 H), 8.01-7.94 (m, 1H), 7.72-7.65 (m, 1H), 7.65-7.56 (m, 1H), 7.43-7.38 (dd, J=7.6, 1.4, 1 H), 7.34-7.33 (m, 1H), 7.32-7.29 (dd, J=5.2, 1.6, 1H), 3.57-3.49 (t, J=6.0, 4H), 3.09-3.01 (t, J=6.0, 4H).

Example 139

The title compound was prepared in a manner similar to that described in Example 88 using racemic 1-((2-bromophenyl)sulfonyl)azetidine-2-carboxamide. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.38 (m, 1H), 8.19-8.13 (m, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.93-7.87 (m, 1H), 7.79-7.73 (m, 1H), 7.68-7.61 (m, 1H), 7.49-7.43 (dd, J=7.6, 1.3, 1H), 7.38-7.31 (m, 2H), 4.57-4.49 (dd, J=9.5, 7.8, 1H), 3.80-3.68 (m, 1H), 2.39-2.28 (m, 1H), 2.26-2.15 (m, 1H). (one proton obscured under methanol signal)

Example 140

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-cyclopropyl-N-(tetrahydro-2H-pyran-4-yl)-benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₂₅FN₄O₃S, 468.16; m/z found, 469.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.33 (m, 1H), 8.20-8.17 (dd, J=8.0, 1.3, 1H), 8.16-8.15 (d, J=1.5, 1H), 7.95-7.90 (m, 1H), 7.74-7.68 (m, 1H), 7.66-7.59 (m, 1H), 7.44-7.39 (dd, J=7.6, 1.3, 1H), 7.35-7.27 (m, 2H), 3.83-3.75 (dd, J=11.4, 4.3, 2H), 3.52-3.43 (m, 1H), 3.20-3.11 (m, 2H), 2.25-2.17 (m, 1H), 1.93-1.81 (m, 2H), 1.26-1.19 (d, J=12.0, 2H), 0.54-0.47 (m, 2H), 0.31-0.26 (dd, J=4.0, 2.3, 2H).

Example 141

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxyethyl)-N-isopropylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.36 (m, 1H), 8.21-8.17 (d, J=1.5, 1H), 8.14-8.10 (dd, J=8.0, 1.3, 1H), 8.00-7.91 (m, 1H), 7.72-7.66 (m, 1H), 7.63-7.56 (m, 1H), 7.44-7.38 (dd, J=7.5, 1.3, 1H), 7.36-7.27 (m, 2H), 3.69-3.55 (m, 1H), 3.43-3.37 (dd, J=7.8, 6.9, 2H), 2.92-2.84 (t, J=7.3, 2H), 1.01-0.97 (d, J=6.7, 6H).

Example 142

The title compound was prepared in a manner similar to that described in Example 88 using racemic (4-((2-bromophenyl)sulfonyl)morpholin-2-yl)methanol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₄S, 444.13; m/z found, 445.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.34 (m, 1H), 8.24-8.18 (d, J=1.4, 1H), 8.14-8.07 (dd, J=8.0, 1.3, 1 H), 7.98-7.92 (m, 1H), 7.76-7.69 (m, 1H), 7.69-7.60 (m, 1H), 7.49-7.43 (dd, J=7.6, 1.3, 1H), 7.35 (s, 1H), 7.34-7.31 (dd, J=3.6, 1.5, 1H), 3.78-3.70 (dd, J=11.3, 3.0, 1H), 3.45-3.39 (m, 1H), 3.38-3.33 (m, 1H), 3.29-3.25 (m, 1H), 3.22-3.16 (m, 2H), 3.12-3.04 (d, J=12.3, 1H), 2.62-2.49 (m, 1H), 2.45-2.31 (m, 1H).

Example 143

The title compound was prepared in a manner similar to that described in Example 88 using endo-3-((2-bromophenyl)sulfonyl)-3-azabicyclo[3.1.0]hexan-6-amine. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₂S, 425.13: m/z found, 426.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.38 (m, 1H), 8.16-8.14 (d, J=1.5, 1H), 8.11-8.06 (dd, J=8.1, 1.3, 1H), 7.98-7.91 (m, 1H), 7.75-7.69 (m, 1H), 7.65-7.59 (m, 1H), 7.46-7.42 (dd, J=7.7, 1.3, 1H), 7.35-7.28 (m, 2H), 3.28 (s, 1H), 2.99-2.90 (m, 2H), 2.25-2.16 (t, J=2.3, 1H), 1.90-1.80 (m, 2H).

Example 144

The title compound was prepared in a manner similar to that described in Example 88 using (S)-1-((2-bromophenyl)sulfonyl)-2-methylpiperazine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz. CD₃OD) δ 8.43-8.37 (m, 1H), 8.23-8.17 (dd, J=8.0, 1.3, 1H), 8.15-8.10 (d, J=1.5, 1H), 8.01-7.91 (m, 1H), 7.80-7.73 (m, 1H), 7.69-7.60 (m, 1H), 7.53-7.46 (dd, J=7.7, 1.3, 1H), 7.44-7.35 (d, J=9.9, 2H), 3.93-3.80 (m 1H), 3.23-3.15 (m, 1H), 3.15-3.03 (m, 3H), 2.79-2.63 (m, 2H), 1.21-1.14 (d, J=7.1, 3H).

Example 145

The title compound was prepared in a manner similar to that described in Example 88 using (R)-1-((2-bromophenyl)sulfonyl)-2-methylpiperazine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.38 (m, 1H), 8.23-8.16 (dd, J=8.1, 1.3, 1H), 8.16-8.12 (d, J=1.5, 1H), 8.01-7.95 (m, 1H), 7.80-7.73 (m, 1H), 7.68-7.62 (m, 1H), 7.52-7.45 (dd, J=7.6, 1.3, 1H), 7.44-7.36 (m, 2H), 3.95-3.79 (dd, J=7.1, 4.4, 1H), 3.23-3.15 (m, 1H), 3.15-3.03 (m, 3H), 2.79-2.64 (m, 2H), 1.19-1.15 (d, J=7.1, 3H).

Example 146

The title compound was prepared in a manner similar to that described in Example 88 using (R)-(1-((2-bromophenyl)sulfonyl)piperazin-2-yl)methanol. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₃S, 443.14; m/z found, 444.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.37 (m, 1H), 8.24-8.17 (dd, J=8.0, 1.3, 1H), 8.16-8.11 (d, J=1.5, 1 H), 8.01-7.94 (m, 1H), 7.82-7.74 (m, 1H), 7.69-7.61 (m, 1H), 7.53-7.46 (dd, J=7.7, 1.3, 1H), 7.41 (s, 1H), 7.40-7.36 (dd, J=4.3, 1.6, 1H), 3.79-3.64 (m, 3H), 3.49-3.43 (m, 1H), 3.43-3.35 (m, 1H), 3.29-3.25 (d, J=3.7, 1H), 3.21-3.11 (m, 1H), 2.81-2.70 (m, 1H), 2.70-2.62 (dd, J=13.1, 4.7, 1H).

Example 147

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(1,3-dihydroxy-2-methylpropan-2-yl)-benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₄S, 432.13; m/z found, 433.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.37 (dd, J=2.2, 1.5, 1H), 8.20-8.14 (dd, J=8.0, 1.3, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.93-7.84 (m, 1H), 7.69-7.63 (m, 1H), 7.60-7.54 (m, 1H), 7.42-7.38 (dd, J=7.5, 1.3, 1H), 7.38-7.32 (m, 2H), 3.45-3.39 (m, 2H), 3.39-3.33 (m, 2H), 0.97 (s, 3H).

Example 148

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.38 (d, J=1.7, 1H), 8.15-8.12 (dd, J=8.0, 1.3, 1H), 8.09-8.06 (d, J=1.5, 1H), 7.90-7.84 (m, 1H), 7.67-7.61 (m, 1H), 7.60-7.54 (m, 1H), 7.39-7.35 (dd, J=7.6, 1.4, 1H), 7.35-7.29 (m, 2H), 3.46-3.39 (m, 1H), 3.39-3.33 (m, 1H), 3.09-3.02 (q, J=5.5, 1H), 1.90-1.75 (m, 1H), 0.83-0.76 (dd, J=6.9, 4.4, 6H).

Example 149

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₅FN₄O₃S, 444.16; m/z found, 445.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.35 (dd, J=2.2, 1.5, 1H), 8.16-8.11 (dd, J=8.1, 1.3, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.93-7.83 (m, 1H), 7.65-7.59 (m, 1H), 7.58-7.52 (m, 1H), 7.37-7.35 (dd, J=3.3, 1.6, 1H), 7.35-7.31 (m, 2H), 3.55-3.49 (m, 1H), 3.49-3.43 (m, 1H), 3.11-3.04 (dd, J=5.9, 4.2, 1H), 0.82 (s, 9H).

Example 150

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₅FN₄O₃S, 444.16; m/z found, 445.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.37 (m, 1H), 8.15-8.11 (dd, J=8.0, 1.3, 1H), 8.09-8.05 (d, J=1.5, 1H), 7.92-7.86 (m, 1H), 7.65-7.59 (m, 1H), 7.58-7.52 (m, 1H), 7.38-7.35 (dd, J=3.3, 1.5, 1H), 7.35-7.31 (m, 2H), 3.55-3.49 (m, 1H), 3.49-3.42 (m, 1H), 3.10-3.04 (dd, J=5.9, 4.2, 1H), 0.82 (s, 9H).

Example 151

The title compound was prepared in a manner similar to that described in Example 88 using tert-butyl-(2-(2-bromophenylsulfonamido)ethyl)carbamate. MS (ESI): mass calcd. for C₂₃H₂₆FN₅O₄S, 487.17; m/z found, 488.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.57-8.54 (m, 1H), 8.18-8.13 (dd, J=8.0, 1.4, 1H), 8.11-8.08 (d, J=1.5, 1H), 8.05-7.98 (m, 1H), 7.65-7.59 (m, 1H), 7.58-7.52 (m, 1H), 7.37-7.33 (m, 2H), 7.32-7.29 (dd, J=11.8, 1.7, 1H), 4.78 (s, 3H), 4.46 (s, 1H), 3.17-3.04 (d, J=5.9, 2H), 2.97-2.77 (m, 2H), 1.38 (s, 9H).

Example 152

The title compound was prepared in a manner similar to that described in Example 88 using N-(2-aminoethyl)-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₈FN₅O₂S, 387.12; m/z found, 388.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.38 (d, J=1.7, 1H), 8.15-8.11 (d, J=1.5, 1H), 8.10-8.06 (dd, J=8.0, 1.3, 1 H), 7.98-7.91 (m, 1H), 7.74-7.69 (m, 1H), 7.65-7.59 (m, 1H), 7.47-7.43 (dd, J=7.6, 1.3, 1H), 7.33-7.32 (dd, J=4.1, 1.8, 1H), 7.31-7.29 (dd, J=8.2, 1.6, 1H), 3.05-2.98 (t, J=5.9, 2H), 2.97-2.92 (m, 2H).

Example 153

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxybutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 417.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.35 (d, J=1.6, 1H), 8.23-8.17 (d, J=1.5, 1H), 8.17-8.10 (dd, J=8.0, 1.3, 1H), 7.97-7.88 (m, 1H), 7.69-7.61 (m, 1H), 7.61-7.55 (m, 1H), 7.41-7.36 (dd, J=7.5, 1.4, 1H), 7.36-7.28 (m, 2H), 3.43-3.36 (m, 1H), 3.34-3.31 (m, 1H), 3.12-3.05 (m, 1H), 1.60-1.46 (m, 1H), 1.42-1.28 (m, 1H), 0.85-0.72 (t, J=7.4, 3H).

Example 154

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(pyrrolidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.37 (m, 1H), 8.15-8.10 (m, 2H), 7.96-7.90 (m, 1H), 7.75-7.69 (m, 1H), 7.66-7.60 (m, 1H), 7.45 (dd, J=7.6, 1.3 Hz, 1H), 7.33 (s, 1H), 7.31 (dd, J=3.7, 1.6 Hz, 1H), 3.74-3.60 (m, 1H), 3.33-3.32 (m, 1H), 3.28-3.26 (m, 1H), 3.25-3.18 (m, 1H), 3.11 (dd, J=12.3, 5.4 Hz, 1H), 2.17-2.04 (m, 1H), 1.85-1.73 (m, 1H).

Example 155

The title compound was prepared in a manner similar to that described in Example 88 using N-(2-(2-bromophenylsulfonamido)ethyl)acetamide. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₃S, 429.13; m/z found, 430.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39-8.33 (m, 1H), 8.28-8.25 (d, J=1.4, 1H), 8.09-8.03 (dd, J=8.0, 1.3, 1H), 8.00-7.93 (m, 1H), 7.70-7.65 (dd, J=7.5, 1.4, 1 H), 7.63-7.56 (m, 1H), 7.43-7.39 (dd, J=7.5, 1.4, 1H), 7.36-7.28 (m, 2H), 3.19-3.12 (t, J=6.3, 2H), 2.89-2.83 (t, J=6.3, 2H), 1.86 (s, 3H).

Example 156

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-(2-bromophenylsulfonamido)propanoic acid. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₄S, 416.10; m/z found, 417.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39-8.34 (m, 1H), 8.23-8.20 (d, J=1.4, 1H), 8.13-8.08 (dd, J=8.0, 1.3, 1H), 7.96-7.89 (m, 1H), 7.69-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.39-7.36 (dd, J=7.6, 1.3, 1 H), 7.36-7.34 (dd, J=8.0, 1.7, 1H), 7.34-7.30 (dd, J=12.3, 1.7, 1H), 3.77-3.66 (q, J=7.2, 1H), 1.33-1.25 (d, J=7.2, 3H).

Example 157

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-ureidoethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₆O₃S, 430.12; m/z found, 431.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.32 (m, 1H), 8.29 (s, 1H), 8.09-8.03 (dd, J=8.0, 1.3, 1H), 8.01-7.93 (m, 1H), 7.73-7.64 (m, 1H), 7.64-7.55 (m, 1H), 7.45-7.38 (dd, J=7.6, 1.4, 1H), 7.37-7.28 (m, 2H), 3.15-3.04 (t, J=6.2, 2H), 2.87-2.78 (t, J=6.2, 2H).

Example 158

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₅H₂₁FN₄O₃S, 476.13; m/z found, 477.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.34 (m, 1H), 8.29-8.24 (dd, J=8.0, 1.3, 1H), 8.07-8.05 (d, J=1.5, 1H), 7.84-7.79 (m, 1H), 7.71-7.66 (m, 1H), 7.63-7.58 (m, 1H), 7.42-7.37 (dd, J=7.6, 1.3, 1H), 7.31-7.23 (m, 2H), 7.21-7.13 (m, 2H), 7.12-7.07 (m, 1H), 7.03-6.97 (m, 1H), 4.49-4.45 (d, J=5.3, 1H), 4.28-4.22 (m, 1H), 3.19-3.11 (dd, J=15.8, 6.7, 1H), 2.70-2.64 (dd, J=15.8, 5.9, 1H).

Example 159

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1R,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₅H₂₁FN₄O₃S, 476.13; m/z found, 477.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.34 (m, 1H), 8.29-8.25 (dd, J=8.1, 1.3, 1H), 8.07-8.04 (d, J=1.5, 1H), 7.86-7.78 (m, 1H), 7.73-7.65 (m, 1H), 7.65-7.57 (m, 1H), 7.44-7.36 (dd, J=7.6, 1.3, 1H), 7.32-7.23 (m, 2H), 7.22-7.12 (m, 2H), 7.12-7.06 (m, 1H), 7.02-6.95 (d, J=7.6, 1H), 4.51-4.43 (d, J=5.4, 1H), 4.30-4.21 (m, 1H), 3.20-3.10 (dd, J=15.9, 6.7, 1H), 2.72-2.58 (dd, J=15.8, 6.0, 1H).

Example 160

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₅H₂₁FN₄O₃S, 476.13; m/z found, 477.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39-8.33 (m, 1H), 8.27-8.22 (dd. J=8.0, 1.3, 1H), 8.08-8.04 (d, J=1.5, 1H), 7.88-7.80 (m, 1H), 7.72-7.67 (m, 1H), 7.65-7.58 (m, 1H), 7.42-7.37 (dd. J=7.7, 1.4, 1H), 7.31-7.26 (dd, J=8.0, 1.7, 1H), 7.26-7.21 (dd, J=12.2, 1.7, 1H), 7.20-7.16 (dd, J=4.7, 1.2, 2H), 7.12-7.05 (m, 1H), 7.06-7.01 (m, 1H), 4.64-4.56 (dd, J=5.1, 1.0, 1H), 4.30-4.24 (m, 1H), 3.01-2.93 (dd, J=16.2, 5.2, 1H), 2.80-2.72 (dd, J=16.2, 2.6, 1H).

Example 161

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₅H₂₁FN₄O₃S, 476.13; m/z found, 477.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.32 (m, 1H), 8.28-8.21 (dd, J=8.0, 1.3, 1H), 8.09-8.02 (d, J=1.5, 1H), 7.88-7.79 (m, 1H), 7.73-7.66 (m, 1H), 7.65-7.57 (m, 1H), 7.42-7.38 (dd, J=7.6, 1.4, 1H), 7.30-7.26 (dd, J=8.0, 1.7, 1H), 7.26-7.21 (dd, J=12.2, 1.7, 1H), 7.20-7.16 (dd, J=4.7, 1.2, 2H), 7.11-7.05 (m, 1H), 7.06-7.01 (m, 1H), 4.62-4.55 (d, J=5.3, 1H), 4.30-4.21 (m, 1H), 3.04-2.92 (dd, J=16.2, 5.2, 1H), 2.81-2.72 (dd, J=16.1, 2.6, 1H).

Example 162

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1S,2S)-2-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.1 [M+H]⁴. ¹H NMR (500 MHz, CD₃OD) δ 8.36 (s, 1H), 8.26-8.22 (d, J=1.5, 2H), 8.22-8.15 (dd, J=8.0, 1.3, 2H), 7.97-7.90 (m, 2H), 7.69-7.62 (m, 2H), 7.61-7.54 (m, 2H), 7.41-7.32 (m, 5H), 3.25-3.18 (m, 1H), 2.88-2.77 (m, 2H), 1.96-1.84 (m, 2H), 1.85-1.77 (m, 2H), 1.68-1.59 (m, 2H), 1.59-1.49 (m, 2H), 1.25-1.18 (m, 4H), 1.18-1.11 (m, 3H).

Example 163

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(6-(trifluoromethyl)pyridin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₁₅F₄N₅O₂S, 489.09; m/z found, 490.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.38 (m, 1H), 8.29-8.24 (dd, J=8.0, 1.4, 1H), 8.11-8.08 (d, J=1.5, 1H), 8.08-8.06 (d, J=2.6, 1H), 7.87-7.80 (m, 1H), 7.72-7.67 (m, 1H), 7.67-7.61 (m, 1H), 7.58-7.52 (d, J=8.7, 1H), 7.46-7.42 (dd, J=8.7, 2.5, 1H), 7.38-7.33 (dd, J=7.5, 1.4, 1H), 7.16-7.10 (dd, J=12.1, 1.7, 1H), 7.10-7.05 (dd, J=8.0, 1.7, 1H).

Example 164

The title compound was prepared in a manner similar to that described in Example 88 using 1-((2-bromophenyl)sulfonyl)-4-(1H-imidazol-4-yl)piperidine. MS (ESI): mass calcd. for C₂₄H₂₃FN₆O₂S, 478.16; m/z found, 479.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.83-8.76 (d, J=1.4, 1H), 8.39-8.33 (m, 1H), 8.16-8.08 (m, 2H), 7.98-7.85 (m, 1H), 7.75-7.68 (m, 1H), 7.65-7.60 (m, 1H), 7.48-7.41 (dd, J=7.5, 1.3, 1H), 7.34 (s, 1H), 7.32-7.31 (m, 1H), 7.30-7.26 (d, J=1.2, 1 H), 3.48-3.39 (d, J=13.3, 2H), 2.84-2.69 (m, 1H), 2.64-2.48 (m, 2H), 1.93-1.80 (d, J=12.9, 2H), 1.52-1.33 (m, 2H).

Example 165

The title compound was prepared in a manner similar to that described in Example 88 using N-((4-amino-2-methylpyrimidin-5-yl)methyl)-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₀FN₇O₂S, 465.14; m/z found, 466.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.36 (s, 1H), 8.26-8.18 (d, J=1.4, 1H), 8.12-8.06 (d, J=7.9, 1H), 7.98-7.92 (m, 1H), 7.90 (s, 1H), 7.76-7.69 (m, 1H), 7.68-7.59 (m, 1H), 7.48-7.41 (dd, J=7.6, 1.4, 1H), 7.39-7.29 (m, 2H), 3.88 (s, 2H), 2.50 (s, 3H).

Example 166

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₁₉FN₆O₄S, 482.12; m/z found, 483.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.36 (m, 1H), 8.28-8.20 (d, J=8.0, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.84-7.77 (m, 1H), 7.66-7.52 (m, 3H), 7.34-7.29 (d, J=7.3, 1H), 7.14-7.05 (m, 2H), 3.75 (s, 3H), 3.60 (s, 3H).

Example 167

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(5-methylpyrazin-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₁₇FN₆O₂S, 436.11; m/z found, 437.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.37 (m, 1H), 8.25-8.21 (dd, J=8.1, 1.0, 1H), 8.10-8.07 (d, J=1.5, 1H), 7.94-7.85 (m, 2H), 7.82-7.76 (m, 1H), 7.67-7.60 (m, 1H), 7.61-7.54 (m, 1H), 7.34-7.27 (m, 1H), 7.15-7.05 (m, 2H), 2.23 (s, 3H).

Example 168

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-(2-bromophenylsulfonamido)-4-methylpentanamide. MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₃S, 457.16; m/z found, 458.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.37 (m, 1H), 8.13-8.09 (dd, J=8.0, 1.3, 1H), 8.09-8.06 (d, J=1.5, 1 H), 7.90-7.85 (m, 1H), 7.69-7.62 (m, 1H), 7.59-7.53 (m, 1H), 7.40-7.36 (dd, J=7.6, 1.3, 1H), 7.36-7.29 (m, 2H), 3.79-3.73 (dd, J=9.1, 5.7, 1H), 1.72-1.54 (m, 1H), 1.51-1.34 (m, 2H), 0.88-0.84 (d, J=6.6, 3H), 0.81-0.78 (d, J=6.6, 3H).

Example 169

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-cyanoethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆FN₅O₂S, 397.10; m/z found, 398.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39-8.34 (m, 1H), 8.21-8.17 (d, J=1.5, 1H), 8.09-8.06 (dd, J=8.0, 1.3, 1H), 7.96-7.90 (m, 1H), 7.72-7.66 (m, 1H), 7.64-7.57 (m, 1H), 7.43-7.39 (dd, J=7.7, 1.4, 1H), 7.37-7.27 (m, 2H), 3.09-3.02 (t, J=6.6, 2H), 2.56-2.50 (t, J=6.6, 2H).

Example 170

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(1-cyanopropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₂S, 411.12; m/z found, 412.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.36 (m, 1H), 8.17-8.14 (d, J=1.4, 1H), 8.14-8.10 (dd, J=8.0, 1.3, 1 H), 7.96-7.87 (m, 1H), 7.72-7.65 (m, 1H), 7.63-7.56 (m, 1H), 7.44-7.38 (dd, J=7.7, 1.4, 1H), 7.37-7.29 (m, 2H), 3.47-3.39 (dd, J=12.3, 6.1, 1H), 2.61-2.46 (m, 2H), 1.18-1.11 (d, J=6.7, 3H).

Example 171

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-cyanopropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₂S, 411.12; m/z found, 412.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.38 (dd, J=2.2, 1.5, 1H), 8.16-8.09 (dd, J=8.0, 1.3, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.93-7.86 (m, 1H), 7.71-7.65 (m, 1H), 7.64-7.56 (m, 1H), 7.45-7.38 (dd, J=7.5, 1.3, 1H), 7.37-7.28 (m, 2H), 3.51-3.37 (m, 1H), 2.64-2.45 (m, 2H), 1.18-1.11 (d, J=6.7, 3H).

Example 172

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-cyanoethyl)-N-cyclopropylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₀FN₅O₂S, 437.13; m/z found, 438.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.34 (d, J=1.6, 1H), 8.23-8.18 (d, J=1.4, 1H), 8.18-8.13 (dd, J=8.0, 1.3, 1H), 8.00-7.92 (m, 1H), 7.76-7.71 (m, 1H), 7.68-7.60 (m, 1H), 7.43-7.38 (dd, J=7.6, 1.3, 1H), 7.22 (s, 1H), 7.21-7.19 (dd, J=4.4, 1.5, 1H), 3.02-2.95 (t, J=6.7, 2H), 2.62-2.55 (t, J=6.7, 2H), 2.52-2.35 (m, 1H), 0.63-0.52 (m, 2H), 0.42-0.34 (m, 2H).

Example 173

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(3-methyloxetan-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38 (s, 1H), 8.17 (s, 1H), 8.14-8.08 (d, J=8.0, 1H), 7.97-7.88 (m, 1H), 7.73-7.65 (m, 1H), 7.65-7.55 (m, 1H), 7.47-7.38 (d, J=7.6, 1H), 7.37-7.25 (m, 2H), 4.57-4.49 (d, J=6.3, 2H), 4.20-4.13 (d, J=6.2, 2H), 1.46 (s, 3H).

Example 174

The title compound was prepared in a manner similar to that described in Example 88 using 3-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)propanenitrile. MS (ESI): mass calcd. for C₂₃H₂₃FN₆O₂S, 466.16; m/z found, 467.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40-8.38 (m, 1H), 8.15-8.11 (m, 2H), 8.00-7.92 (m, 1H), 7.78-7.70 (m, 1H), 7.67-7.60 (m, 1H), 7.49-7.43 (dd, J=7.6, 1.3, 1H), 7.34-7.32 (d, J=0.9, 1H), 7.32-7.30 (dd. J=3.7, 1.6, 1H), 3.13-3.07 (t, J=7.1, 2H), 3.07-3.02 (t. J=4.7, 4H), 2.87-2.81 (d, J=4.8, 4H), 2.81-2.76 (t, J=7.0, 2H).

Example 175

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-methoxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 417.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.37 (m, 1H), 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.91-7.86 (m, 1H), 7.70-7.62 (m, 1H), 7.61-7.53 (m, 1H), 7.42-7.36 (dd, J=7.5, 1.4, 1H), 7.35-7.26 (m, 2H), 3.37-3.31 (m, 1H), 3.22-3.18 (m, 1H), 3.17 (s, 3H), 3.15-3.10 (m, 1H), 1.06-1.00 (d, J=6.7, 3H).

Example 176

The title compound was prepared in a manner similar to that described in Example 88 using 2-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)pyrazine. MS (ESI): mass calcd. for C₂₄H₂₂FN₇O₂S, 491.15; m/z found, 492.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.32 (m, 1H), 8.23-8.17 (d, J=1.4, 1H), 8.16-8.10 (m, 2H), 8.09-8.05 (m, 1H), 7.97-7.90 (m, 1H), 7.80-7.76 (d, J=2.7, 1H), 7.75-7.70 (m, 1H), 7.67-7.60 (m, 1H), 7.47-7.42 (dd. J=7.6, 1.3, 1H), 7.36-7.33 (dd, J=5.1, 1.6, 1H), 7.33 (s, 1H), 3.53-3.39 (t, J=5.1, 4H), 3.02-2.95 (t, J=5.1, 4H).

Example 177

The title compound was prepared in a manner similar to that described in Example 88 using 2-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)pyrimidine. MS (ESI): mass calcd. for C₂₄H₂₂FN₇O₂S, 491.15; m/z found, 492.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39 (s, 1H), 8.29-8.23 (d, J=4.7, 2H), 8.16-8.10 (d, J=8.0, 1H), 8.08 (s, 1H), 7.95-7.87 (m, 1H), 7.76-7.68 (m, 1H), 7.66-7.57 (m, 1H), 7.50-7.42 (d, J=7.5, 1H), 7.34-7.32 (d, J=3.6, 1H), 7.31 (s, 1H), 6.68-6.51 (t, J=4.8, 1H), 3.73-3.56 (t, J=5.0, 4H), 2.97-2.85 (t, J=4.9, 4H).

Example 178

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromoaniline. MS (ESI): mass calcd. for C₁₆H₁₃FN₄, 280.11; m/z found, 281.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36 (s, 1H), 8.02 (s, 1H), 7.91 (m, 1H), 7.31 (d, J=12.7, 2H), 7.04 (d, J=7.3, 2H), 6.82-6.58 (m, 4H), 4.94 (s, 2H).

Example 179

The title compound was prepared in a manner similar to that described in Example 584 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromo-N-(1-(hydroxymethyl)-cyclopentyl)benzenesulfonamide in Step B. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.42 (s, 1H), 8.39 (s, 1H), 8.18 (d, J=7.3, 1 H), 8.08 (m, 1H), 7.66-7.60 (m, 1H), 7.58-7.52 (m, 1H), 7.43 (dd, J=8.1, 1.8, 1H), 7.38-7.32 (m, 2H), 4.12 (s, 1H), 3.49 (s, 2H), 1.64-1.39 (m, 8H).

Example 180

The title compound was prepared in a manner similar to that described in Example 584 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic 1-((2-bromophenyl)sulfonyl)-3-phenylpyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C₂₆H₂₃FN₄O₃S, 490.15; m/z found, 491.2 [M+H]⁴. ¹H NMR (500 MHz, CDCl₃) δ 8.57 (s, 1H), 8.20 (d, J=9.2, 1H), 8.11 (d, J=1.5, 1H), 8.00 (t, J=8.1, 1H), 7.61 (dd, J=7.5, 6.2, 1H), 7.53 (m, 1H), 7.40-7.34 (m, 3H), 7.34-7.28 (m, 5H), 4.68 (s, 2H), 3.41-3.23 (m, 4H), 3.18 (d, J=10.8, 1H), 2.21-2.11 (m, 1H), 2.10-2.01 (m, 1H).

Example 181

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(2-bromophenyl)pyrrolidine-1-sulfonamide in Step B. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.40 (dd, J=5.4, 1.4, 2H), 8.14 (m, 1H), 7.61 (dd, J=8.3, 1.1, 1H), 7.42-7.35 (m, 1H), 7.32 (dd, J=8.0, 1.7, 1H), 7.23 (dd, J=3.6, 1.6, 1H), 7.22-7.15 (m, 1H), 6.44 (s, 1H), 3.33-3.25 (m, 4H), 1.87 (dd, J=7.0, 0.9, 4H).

Example 182

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl) N,N-dimethylsulfonamide in Step B. MS (ESI): mass calcd. for C₁₈H₁₈FN₅O₂S, 387.12; m/z found, 388.3 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.60 (dd, J=2.3, 1.4, 1H), 8.12 (d, J=1.5, 1H), 8.07 (m, 1H), 7.61 (dd, J=8.3, 1.1, 1H), 7.40-7.34 (m, 1H), 7.29-7.26 (m, 1H), 7.25-7.24 (m, 1H), 7.21-7.16 (m, 2H), 6.42 (s, 1H), 4.72 (s, 2H), 2.79 (s, 6H).

Example 183

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl)morpholine-4-sulfonamide. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₃S, 429.13; m/z found, 430.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.45 (s, 1H), 8.34 (d, J=1.4, 1H), 8.14 (m, 1H), 7.63 (d, J=8.0, 1H), 7.43-7.35 (m, 1H), 7.31 (dd, J=8.0, 1.7, 1H), 7.24-7.19 (m, 2H), 6.39 (s, 1H), 3.67 (dd, J=5.8, 3.7, 4H), 3.23-3.14 (m, 4H).

Example 184

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and (S)-1-((2-bromophenyl)sulfonyl)pyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.44 (d, J=1.3, 1H), 8.33 (d, J=1.5, 1H), 8.13 (dd, J=7.9, 1.3, 1 H), 8.07 (m, 1H), 7.62 (m, 1H), 7.58-7.52 (m, 1H), 7.41-7.29 (m, 3H), 4.44-4.36 (m, 1H), 3.23-3.15 (m, 3H), 3.07-2.99 (m, 1H), 1.98-1.88 (m, 1H), 1.88-1.78 (m, 1H).

Example 185

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and (R)-1-((2-bromophenyl)sulfonyl)pyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.43 (d, J=1.4, 1H), 8.33 (d, J=1.5, 1H), 8.13 (dd, J=7.7, 1.3, 1 H), 8.07 (m, 1H), 7.62 (m, 1H), 7.55 (m, 1H), 1.98-1.88 (m, 1H), 7.42-7.29 (m, 3H), 3.24-3.15 (m, 3H), 3.04 (t, J=1.5, 1H), 1.86 (s, 1H), 4.44-4.35 (m, 1H).

Example 186

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and Racemic-1′-((2-bromophenyl)sulfonyl)-[1,3′-bipyrrolidin]-4′-ol in Step B. MS (ESI): mass calcd. for C₂₄H₂₆FN₅O₃S, 483.17; m/z found, 484.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.60-8.57 (m, 1H), 8.15 (d, J=6.8, 1H), 8.11 (d, J=1.5, 1H), 7.97 (m, 1H), 7.61 (dd, J=7.5, 6.1, 1H), 7.55-7.49 (m, 1H), 7.38-7.28 (m, 3H), 4.68 (s, 2H), 4.18-4.12 (m, 1H), 3.30 (dd, J=10.5, 6.2, 1H), 3.23 (dd, J=10.1, 6.8, 1H), 2.95 (dd, J=10.0, 6.4, 1H), 2.88 (dd, J=10.4, 4.4, 1H), 2.63-2.57 (m, 1H), 2.52-2.38 (m, 5H), 1.74-1.67 (m, 4H).

Example 187

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and Racemic-1-((2-bromophenyl)sulfonyl)-4-morpholinopyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C₂₄H₂₆FN₅O₄S, 499.17; m/z found, 500.3 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.41 (s, 1H), 8.32 (s, 1H), 8.13-8.09 (m, 1H), 7.99 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.56 (m, 1H), 7.38 (dd, J=7.5, 1.3, 1H), 7.35-7.30 (m, 2H), 4.72-4.63 (m, 2H), 3.94-3.85 (m, 3H), 3.40-3.25 (m, 3H), 3.22-3.10 (m, 3H), 3.05-2.94 (m, 2H), 2.92-2.84 (m, 2H), 2.08-2.02 (m, 2H).

Example 188

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and Racemic-1-((2-bromophenyl)sulfonyl)-4-(4-methylpiperazin-1-yl)pyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C₂₅H₂₉FN₆O₃S, 512.20; m/z found, 513.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 6.90-6.87 (m, 1H), 6.63-6.57 (m, 2H), 6.45-6.40 (m, 1H), 6.23-6.17 (m, 1H), 6.12-6.07 (m, 1H), 5.95-5.89 (m, 1H), 5.83-5.76 (m, 2H), 2.58-2.50 (m, 1H), 2.46 (s, 2H), 1.84-1.81 (m, 2H), 1.77-1.72 (m, 2H), 1.63-1.58 (m, 1H), 1.32 (s, 3H), 1.31-1.26 (m, 1H), 1.23-1.13 (m, 3H),

Example 189

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-trifluorothiomethylbromobenzene. MS (ESI): mass calcd. for C₁₇H₁₁F₄N₃S, 365.06; m/z found, 366.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.46-8.37 (m, 1H), 8.09 (d, J=1.3, 1H), 7.93 (m, 1H), 7.87 (d, J=7.7, 1H), 7.69-7.60 (m, 1H), 7.55-7.50 (m, 2H), 7.28-7.17 (m, 2H).

Example 190

The title compound was prepared using analogous conditions to those described in The title compound was prepared using analogous conditions to those described in Example 6 utilizing (2-bromophenyl)(tert-butyl)sulfane. MS (ESI): mass calcd. for C₂₀H₂₀FN₃S, 353.14; m/z found, 354.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.44-8.36 (m, 1H), 8.10-8.03 (d, J=1.5, 1H), 7.93-7.86 (m, 1H), 7.73-7.65 (dd, J=7.8, 1.4, 1H), 7.56-7.49 (m, 1H), 7.49-7.41 (m, 2H), 7.34-7.25 (m, 2H), 1.99 (s, 1H), 1.02 (s, 9H).

Example 191

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl)ethane-1-sulfonamide. MS (ESI): mass calcd. for C₁₈H₁₆FN₃O₂S, 357.09; m/z found, 358.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.48-8.36 (m, 1H), 8.16 (dd, J=7.9, 1.3, 1H), 8.09 (d, J=1.4, 1H), 7.94 (m, 1H), 7.78 (m, 1H), 7.68 (m, 1H), 7.48 (dd, J=7.5, 1.3, 1H), 7.34 (s, 1H), 7.31 (d, J=2.4, 1H), 2.84 (q, J=7.4, 2H), 1.06 (t, J=7.4, 3H).

Example 192

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(propylsulfonyl)benzene. MS (ESI): mass calcd. for C₁₉H₁₈FN₃O₂S, 371.11; m/z found, 372.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (s, 1H), 8.14 (d, J=1.2, 1H), 8.08 (dd, J=7.8, 1.1, 1H), 7.95 (m, 1H), 7.81 (m, 1H), 7.72 (m, 1H), 7.48 (dd, J=7.4, 1.1, 1H), 7.38 (dd, J=12.4, 1.4, 1H), 7.32 (dd, J=8.0, 1.6, 1H), 2.94-2.81 (m, 2H), 1.49-1.32 (m, 2H), 0.79 (t, J=7.4, 3H).

Example 193

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(isobutylsulfonyl)benzene. MS (ESI): mass calcd. for C₂₀H₂₀FN₃O₂S, 385.13; m/z found, 386.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.42 (s, 1H), 8.12 (dd, J=7.9, 1.1, 1H), 8.05 (d, J=1.4, 1H), 7.96 (m, 1H), 7.81 (m, 1H), 7.73 (m, 1H), 7.49 (dd, J=7.5, 1.0, 1H), 7.37 (dd, J=12.4, 1.5, 1H), 7.32 (dd. J=8.0, 1.6, 1H), 6.76 (s, 2H), 2.81 (d, J=6.4, 2H), 1.85-1.75 (m, 1H), 0.82 (d, J=6.7, 6H).

Example 194

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 1-bromo-2-(tert-butylsulfonyl)benzene. MS (ESI): mass calcd. for C₂₀H₂₀FN₃O₂S, 385.13; m/z found, 386.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.51-8.44 (d, J=1.4, 1H), 8.27-8.20 (d, J=1.4, 1H), 8.10-8.04 (dd, J=8.0, 1.4, 1H), 8.04-7.98 (m, 1H), 7.70-7.63 (m, 1H), 7.62-7.55 (m, 1H), 7.36-7.30 (dd, J=7.6, 1.4, 1H), 7.29-7.25 (dd, J=8.1, 1.7, 1H), 7.22-7.17 (dd, J=12.3, 1.7, 1H), 1.23-1.11 (s, 9H).

Example 195

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(cyclopentylsulfonyl)benzene MS (ESI): mass calcd. for C₂₁H₂FN₃O₂S, 397.13; m/z found, 398.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.65 (d, J=1.3, 1H), 8.30 (d, J=1.3, 1H), 8.19 (dd, J=7.9, 1.2, 1H), 8.14 (m, 1H), 7.79 (m, 1H), 7.71 (m, 1H), 7.48 (dd, J=7.5, 1.2, 1H), 7.42 (s, 1H), 7.41-7.38 (m, 1H), 3.23-3.15 (m, 1H), 1.92-1.81 (m, 2H), 1.77-1.63 (m, 4H), 1.60-1.51 (m, 2H).

Example 196

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(cyclobutylsulfonyl)benzene. MS (ESI): mass calcd. for C₂₀H₁₈FN₃O₂S, 383.11; m/z found, 384.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1H), 8.17 (dd, J=7.9, 1.1, 1H), 8.13 (d, J=1.4, 1H), 7.96 (m, 1H), 7.77 (m, 1H), 7.68 (m, 1H), 7.46 (dd, J=7.6, 1.1, 1H), 7.34 (s, 1H), 7.31 (dd, J=6.4, 1.5, 1H), 3.65-3.53 (m, 1H), 2.39-2.26 (m, 2H), 2.08-1.98 (m, 2H), 1.98-1.87 (m, 2H).

Example 197

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C₁₉H₁₆FN₃O₂S, 369.09; m/z found, 370.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.55-8.49 (m, 1H), 8.33 (s, 1H), 8.13 (dd, J=8.0, 1.2, 1H), 8.11-8.05 (m, 1H), 7.77 (m, 1H), 7.68 (m, 1H), 7.48 (dd, J=7.6, 1.1, 1H), 7.43-7.36 (m, 2H), 2.35-2.26 (m, 1H), 1.04-0.91 (m, 4H).

Example 198

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(hexylsulfonyl)benzene MS (ESI): mass calcd. for C₂₂H₂₄FN₃O₂S, 413.16; m/z found, 414.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.66 (s, 1H), 8.31 (s, 1H), 8.21-8.13 (m, 2H), 7.81 (m, 1H), 7.72 (m, 1H), 7.49 (dd, J=7.6, 1.2, 1H), 7.43 (dd, J=3.6, 1.4, 1H), 7.40 (s, 1H), 2.89-2.80 (m, 2H), 1.50 (m, 2H), 1.31-1.11 (m, 6H), 0.85 (t, J=7.1, 3H).

Example 199

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(isopropylsulfonyl)benzene. MS (ESI): mass calcd. for C₁₉H₁₈FN₃O₂S, 371.11; m/z found, 372.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.42 (s, 1H), 8.15 (dd, J=8.0, 1.1, 1H), 8.09 (d, J=1.4, 1H), 7.93 (m, 1H), 7.78 (m, 1H), 7.68 (m, 1H), 7.51-7.44 (m, 1H), 7.37-7.28 (m, 2H), 2.90-2.77 (m, 1H), 1.09 (d, J=6.8, 6H).

Example 200

The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenyl)thio)acetamide. MS (ESI): mass calcd. for C₁₈H₁₅FN₄OS, 354.10; m/z found, 355.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.36 (dd, J=2.2, 1.4, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.93-7.87 (m, 1H), 7.53-7.48 (m, 1H), 7.39-7.34 (m, 1H), 7.33-7.25 (m, 4H), 3.52 (s, 2H).

Example 201

The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenyl)thio)-N,N-diethylacetamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄OS, 410.16; m/z found, 411.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.42-8.35 (d, J=1.9, 1H), 8.12-8.06 (d, J=1.5, 1H), 7.94-7.86 (m, 1H), 7.63-7.55 (dd, J=7.1, 2.1, 1H), 7.41-7.23 (m, 5H), 3.62 (s, 2H), 3.31-3.26 (m, 4H), 1.13-1.08 (t, J=7.1, 3H), 1.07-1.03 (t, J=7.1, 3H).

Example 202

The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenyl)thio)-1-morpholinoethanone. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 425.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.39 (m, 1H), 8.10-8.08 (d, J=1.5, 1H), 7.95-7.89 (m, 1H), 7.68-7.61 (m, 1H), 7.41-7.34 (m, 2H), 7.34-7.29 (m, 2H), 7.29-7.25 (dd, J=12.2, 1.7, 1H), 3.66 (s, 2H), 3.58-3.53 (t, J=4.9, 2H), 3.54-3.49 (t, J=4.8, 2H), 3.49-3.44 (m, 2H), 3.40-3.35 (t, J=4.8, 2H).

Example 203

The title compound was prepared in a manner similar to that described in Example 88 using racemic 5-(((2-bromophenyl)thio)methyl)oxazolidin-2-one. MS (ESI): mass calcd. for C₂₀H₁₇FN₄O₂S, 396.11; m/z found, 397.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.37 (m, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.94-7.88 (m, 1H), 7.65-7.59 (m, 1H), 7.43-7.37 (m, 1H), 7.37-7.29 (m, 3H), 7.28-7.23 (dd, J=12.2, 1.7, 1 H), 4.68-4.54 (m, 1H), 3.56-3.48 (t, J=8.8, 1H), 3.29-3.22 (dd, J=9.2, 6.4, 1H), 3.20-3.13 (m, 1H), 3.07-3.01 (m, 1H).

Example 204

The title compound was prepared in a manner similar to that described in Example 88 using N-(2-((2-bromophenyl)thio)ethyl)benzamide. MS (ESI): mass calcd. for C₂₅H₂₁FN₄OS, 444.14; m/z found, 445.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.32 (m, 1H), 8.09-8.03 (d, J=1.4, 1H), 7.89-7.83 (t, J=8.1, 1H), 7.73-7.67 (m, 2H), 7.67-7.63 (d, J=7.9, 1H), 7.52-7.45 (m, 1H), 7.44-7.34 (m, 3H), 7.30-7.26 (m, 3H), 7.26-7.21 (dd, J=12.4, 1.7, 1H), 3.53-3.46 (t. J=7.0, 2H), 3.11-3.03 (t, J=7.0, 2H).

Example 205

The title compound was prepared in a manner similar to that described in Example 88 using (2-bromophenyl)(4-(methylsulfonyl)benzyl)sulfane. MS (ESI): mass calcd. for C₂₄H₂₀FN₃O₂S₂, 465.10; m/z found, 466.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.35 (m, 1H), 8.12-8.04 (d, J=1.5, 1H), 7.87-7.81 (m, 1H), 7.79-7.73 (m, 2H), 7.59-7.48 (m, 1H), 7.39-7.30 (m, 4H), 7.29-7.24 (m, 1H), 7.18-7.12 (dd, J=8.0, 1.7, 1H), 7.11-7.03 (dd, J=12.3, 1.7, 1H), 4.04 (s, 2H), 3.08 (s, 3H).

Example 206

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₇H₁₂F₄N₄O₂S, 412.06; m/z found, 413.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41 (s, 1H), 8.38 (s, 1H), 8.22-8.16 (m, 1H), 8.01-7.92 (m, 2H), 7.63-7.58 (d, J=8.0, 1H), 7.40-7.30 (m, 2H).

Example 207

The title compound was prepared in a manner similar to that described in Example 88 using 1-bromo-2-(methylsulfonyl)-4-(trifluoromethyl)benzene and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₃F₄N₃O₂S, 411.07; m/z found, 412.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.45-8.44 (d, J=2.0, 1H), 8.43 (s, 1H), 8.10-8.09 (d, J=1.5, 1H), 8.09-8.06 (dd, J=7.8, 1.7, 1H), 8.02-7.97 (m, 1H), 7.71-7.68 (d, J=7.9, 1H), 7.41-7.39 (m, 1H), 7.39-7.37 (m, 1H), 2.88 (s, 3H).

Example 208

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-methyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₄F₄N₄O₂S, 426.08; m/z found, 427.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.36 (m, 1H), 8.34-8.27 (d, J=1.9, 1H), 8.21-8.14 (d, J=1.4, 1H), 8.02-7.92 (m, 2H), 7.66-7.61 (d, J=7.9, 1H), 7.35 (s, 1H), 7.34-7.32 (dd, J=4.3, 1.6, 1H), 2.46 (s, 3H).

Example 209

The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromo-5-(trifluoromethyl)phenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C₂₁H₁₇F₄N₅O₃S, 495.10; m/z found, 496.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.37 (m, 2H), 8.24-8.21 (d, J=1.4, 1H), 8.08-8.04 (dd, J=8.0, 1.8, 1H), 8.04-7.99 (m, 1H), 7.69-7.65 (d, J=7.9, 1H), 7.38-7.35 (m, 1H), 7.35-7.32 (dd, J=5.8, 1.6, 1H), 3.38 (s, 2H), 3.15 (s, 4H).

Example 210

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₃S, 456.09; m/z found, 457.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.39 (m, 1H), 8.36 (s, 1H), 8.16-8.13 (d, J=1.5, 1H), 7.99-7.93 (m, 2H), 7.64-7.61 (d, J=8.0, 1H), 7.38-7.36 (m, 1H), 7.36-7.33 (dd, J=5.0, 1.6, 1H), 3.49-3.45 (t, J=5.9, 2H), 2.93-2.86 (t, J=5.8, 2H).

Example 211

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₂S, 440.09; m/z found, 441.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.37 (m, 1H), 8.34-8.31 (m, 1H), 8.20-8.16 (d, J=1.5, 1H), 8.01-7.94 (m, 2H), 7.65-7.59 (d, J=7.9, 1H), 7.37-7.34 (m, 1H), 7.34-7.31 (dd, J=2.9, 1.5, 1H), 2.88-2.76 (q, J=7.2, 2H), 1.07-0.94 (t, J=7.2, 3H).

Example 212

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₁F₄N₅O₂S, 495.14; m/z found, 496.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.44-8.41 (m, 1H), 8.41-8.38 (d, J=2.0, 1H), 8.13-8.10 (d, J=1.5, 1H), 8.10-8.06 (m, 1H), 8.05-7.97 (m, 1H), 7.73-7.60 (d, J=8.0, 1H), 7.39-7.37 (dd, J=6.6, 1.6, 1H), 7.37-7.35 (dd, J=2.8, 1.7, 1H), 2.85 (s, 3H), 3.93-2.45 (br m, 8H).

Example 213

Step A: Ethyl 3-(2-bromophenylthio)propanoate

A mixture of 2-bromobenzenethiol (6 g, 30 mmol), ethyl 3-chloropropanoate (13 g, 96 mmol), K₂CO₃ (8.8 g, 64 mmol) and acetone (150 mL) was refluxed for 15 h. The reaction mixture was filtered and the filter cake washed with acetone (50 mL). The filtrate was concentrated to dryness and subjected to FCC to give ethyl 3-(2-bromophenylthio)propanoate (7 g, 78%). MS (ESI): mass calcd. for C₁₁H₁₃O₂S, 287.98; m/z found, 288.8 [M+H]⁺.

Step B: Ethyl 3-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylthio) propanoate

A mixture of ethyl 3-(2-bromophenylthio)propanoate (7 g, 24 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (7.6 g, 24 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (378 mg, 0.52 mmol) and Na₂CO₃ (5 g, 48 mmol) in dioxane/water (20 mL/5 mL) was stirred at 80° Celsius for 5 hours under N₂, then poured into water (60 mL) and extracted with EtOAc (50 mL×3). The combined organic extracts were dried over Na₂SO₄, filtered, concentrated to dryness and purified by FCC to give ethyl 3-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylthio) propanoate (7.7 g, 80%) as a white solid. MS (ESI): mass calcd. for C₂₁H₂₀FN₃O₂S, 397.13; m/z found, 397.9 [M+H]⁺.

Step C: 4′-(5-Aminopyrazin-2-yl)-5′-fluorobiphenyl-2-thiol

To a solution consisting of ethyl 3-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylthio) propanoate (7.7 g, 19.4 mmol) and THF (60 mL) was added t-BuOK (4.3 g, 38.8 mmol) and the mixture stirred for 1 hour at rt. The reaction mixture was poured into water (100 mL) and the system brought to a pH=5-6 with 1 M HCl. The mixture was, extracted with EtOAc (80 mL×3) and the combined extracts dried over Na₂SO₄, filtered and concentrated to dryness to give 4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-thiol (4.6 g, 80%). MS (ESI): mass calcd. for C₁₆H₁₂FN₃S, 297.07; m/z found, 298.0 [M+H]⁺.

Step D

To a solution of 4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-thiol (400 mg, 1.34 mmol) and 2-chloropyrimidine (167 mg, 1.47 mmol) in DMF (8 mL) were added DIPEA (345 mg, 2.68 mmol) and Ph₃P (351 mg, 1.34 mmol) and the resultant mixture heated at 80° Celsius for 1 hour under a N₂ atmosphere for 15 h. The mixture was cooled to rt, concentrated to dryness and the residue subjected to FCC to give the title compound (350 mg, 68%). MS (ESI): mass calcd. for C₂₀H₁₄FN₅S.HCl, 375.10; m/z found, 376.0 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.42 (d, J=4.9, 2H), 8.33-8.28 (m, 1H), 8.03 (d, J=1.4, 1H), 7.79-7.69 (m, 2H), 7.60-7.53 (m, 1H), 7.51-7.43 (m, 2H), 7.21 (dd, J=8.0, 1.7, 1H), 7.15 (dd, J=12.3, 1.6, 1H), 7.06 (m, 1H).

Example 214

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₄FN₅S, 375.10; m/z found, 375.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.84 (d, J=1.1, 1H), 8.46 (d, J=1.4, 2H), 8.44 (d, J=5.6, 1H), 7.81-7.75 (m, 1H), 7.73-7.65 (m, 1H), 7.62-7.51 (m, 3H), 7.30 (dd, J 20=11.8, 1.6, 1H), 7.24 (dd, J=7.9, 1.7, 1H), 6.96 (dd, J=5.6, 1.3, 1H), 6.90 (s, 2H).

Example 215

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-amino-6-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 391.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.29-8.25 (m, 3H), 7.94 (m 1H), 7.82 (d, J=7.4, 1H), 7.74 (m, 1H), 7.67-7.58 (m, 2H), 7.34-7.23 (m, 2H), 5.94 (s, 1H).

Example 216

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 390.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.31 (m, 1H), 8.16 (s, 1H), 7.88 (m, 1H), 7.83-7.75 (m, 2H), 7.71-7.63 (m, 1H), 7.58-7.52 (m, 2H), 7.32-7.21 (m, 2H), 6.37 (d, J=7.2, 1H).

Example 217

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 5-amino-4-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11: m/z found, 391.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.35-8.30 (m, 1H), 8.22 (s, 1H), 8.02 (d, J=1.4, 1H), 7.90 (s, 1H), 7.80 (m, 1H), 7.59-7.54 (m, 2H), 7.52-7.44 (m, 2H), 7.24 (dd, J=6.5, 1.6, 1H), 7.21 (m, 1H).

Example 218

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 2-chloropyrazine. MS (ESI): mass calcd. for C₂₀H₁₄FN₅S, 375.10; m/z found, 375.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.26-8.24 (m, 3H), 8.18 (d, J=2.6, 1H), 8.08 (d, J=1.4, 1H), 7.84 (m, 1H), 7.77-7.69 (m, 1H), 7.64-7.55 (m, 1H), 7.55-7.46 (m, 2H), 7.27-7.14 (m, 2H).

Example 219

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 5-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 391.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.36 (s, 1H), 8.24 (s, 1H), 7.95 (s, 2H), 7.88 (m, 1H), 7.65-7.59 (m, 1H), 7.53-7.38 (m, 3H), 7.27-7.16 (m, 2H).

Example 220

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)-N-methylmethanesulfonamide. MS (ESI): mass calcd. for C₁₆H₁₇FN₄O₂S, 372.11; m/z found, 373.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.34 (s, 1H), 8.25 (s, 1H), 7.99 (m, 1H), 7.68-7.60 (m, 1H), 7.50-7.40 (m, 2H), 7.39-7.31 (m, 3H), 4.36 (s, 2H), 2.49 (s, 3H).

Example 221

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)-N-(2-hydroxyethyl)methanesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.38 (d, J=1.2, 1H), 8.31 (s, 1H), 8.02 (m, 1H), 7.70-7.63 (m, 1H), 7.49-7.40 (m, 2H), 7.40-7.30 (m, 3H), 4.40 (s, 2H), 3.51 (t, J=5.9, 2H), 2.95 (t, J=5.9, 2H), 2.66 (s, 1H).

Example 222

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-((2-bromobenzyl)sulfonyl)azetidin-3-ol. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 414.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.43-8.38 (m, 1H), 8.08 (d, J=1.5, 1H), 7.95 (m, 1H), 7.68-7.60 (m, 1H), 7.49-7.41 (m, 2H), 7.39-7.28 (m, 3H), 4.45-4.36 (m, 3H), 3.79-3.70 (m, 2H), 3.67-3.59 (m, 2H).

Example 223

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 4-((2-bromobenzyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₃S, 441.13; m/z found, 441.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.08 (d, J=1.3, 1H), 7.96 (m, 1H), 7.70-7.62 (m, 1H), 7.52-7.28 (m, 5H), 4.48 (s, 2H), 3.63 (s, 2H), 3.25 (s, 4H).

Example 224

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and(S)-1-(2-bromophenyl)-N-(1-hydroxypropan-2-yl)methanesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 416.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) 8.43-8.36 (m, 1H), 8.03 (d, J=1.5, 1H), 7.92 (m, 1H), 7.70-7.59 (m, 1H), 7.47-7.28 (m, 5H), 7.12 (d, J=6.6, 1H), 6.71 (s, 2H), 4.75 (t, J=5.4, 1H), 4.35 (q, J=14.1, 2H), 3.31-3.11 (m, 3H), 1.01 (d, J=6.2, 3H).

Example 225

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and (R)-1-(2-bromophenyl)-N-(1-hydroxypropan-2-yl)methanesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.48; m/z found, 417.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.32 (d, J=3.7, 2H), 7.99 (m, 1H), 7.77-7.66 (m, 1H), 7.50-7.39 (m, 2H), 7.39-7.28 (m, 3H), 4.41 (q, J=13.9, 2H), 3.49-3.33 (m, 3H), 1.11 (d, J=6.3, 3H).

Example 226

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and trans-1-(2-bromophenyl)-N-((trans)-4-hydroxycyclohexyl)-methane-sulfonamide. MS (ESI): mass calcd. for C₂₃H₂₅FN₄O₃S.HCO₂H, 456.16; m/z found, 457.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 8.08 (d, J=1.3, 1H), 7.94 (m, 1H), 7.72-7.63 (m, 1H), 7.47-7.38 (m, 1H), 7.38-7.27 (m, 3H), 4.36 (s, 2H), 3.42 (s, 1H), 2.97 (s, 1H), 1.84 (d, J=9.0, 4H), 1.38-1.10 (m, 4H).

Example 227

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (S)-1-(2-bromophenyl)-N-(2-hydroxypropyl)-methane-sulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 417.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.67 (s, 1H), 8.28-8.23 (m, 1H), 8.13 (m, 1H), 7.70-7.62 (m, 1H), 7.49-7.30 (m, 5H), 4.40 (s, 2H), 3.77-3.65 (m, 1H), 2.80 (d. J=5.9, 2H), 1.09 (d, J=6.3, 3H).

Example 228

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (R)-1-(2-bromophenyl)-N-(2-hydroxypropyl)methane-sulfonamide.

Example 229

Step A: tert-Butyl 1-((4′-(5-aminopyrazin-2-yl-5′-fluorobiphenyl-2-yl)methylsulfonyl)-piperidin-4-ylcarbamate

A mixture of tert-butyl (1-((2-bromobenzyl)sulfonyl)piperidin-4-yl)carbamate (200 mg, 0.46 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (175 mg, 0.55 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (34 mg, 0.046 mmol) and Na₂CO₃ (150 mg, 1.36 mmol) in dry DMF (15 mL) was stirred at 130° Celsius under N₂. After 5 hours, the solvent was removed under vacuum and the residue was subjected to FCC purification to give tert-butyl 1-((4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methylsulfonyl)piperidin-4-ylcarbamate (190 mg, 76%). MS (ESI): mass calcd. for C₂₇H₃₂FN₅O₂S, 541.22; m/z found, 542.1 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.03 (s, 1H), 7.95 (s, 1H), 7.78-7.29 (m, 7H), 6.87 (d, J=5.2, 1H), 6.73 (s, 2H), 4.34 (s, 2H), 3.45-3.33 (m, 3H), 2.85-2.75 (m, 2H), 1.72 (d, J=12.4, 2H), 1.45-1.30 (m, 11H).

Step B

A mixture of tert-butyl 1-((4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methylsulfonyl)piperidin-4-ylcarbamate (190 mg, 0.35 mmol) in HCl (20 mL, 6 N in methanol) was stirred at rt for 24 hours. The solvent was removed under reduced pressure and the residue purified by HPLC to give the title compound (80 mg HCl salt, 61%). MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₂S, 441.16; m/z found, 442.1 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 8.38 (s, 1H), 8.10 (br, 4H), 7.95 (m, 1H), 7.64-7.55 (m, 1H), 7.52-7.32 (m, 4H), 4.80 (br, 4H), 4.37 (s, 2H), 3.50 (d, J=13.0, 2H), 3.10 (s, 1H), 2.76 (t. J=12.6, 2H), 1.91 (d. J=11.0, 3H), 1.58-1.41 (m, 2H).

Example 230

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and (2-bromophenyl)methanesulfonamide. MS (ESI): mass calcd. for C₁₇H₁₅FN₄O₂S, 358.09; m/z found, 359.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36 (s, 1H), 8.12 (s, 1H), 7.92 (m, 1H), 7.66-7.56 (m, 1H), 7.38 (m, 5H), 6.98 (s, 2H), 4.31 (s, 2H).

Example 231

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)-N-ethylmethanesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₂S, 386.12; m/z found, 387.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.39 (s, 1H), 8.08 (d, J=1.4, 1H), 7.93 (m, 1H), 7.71-7.61 (m, 1H), 7.49-7.27 (m, 5H), 4.36 (s, 2H), 2.85 (q, J=7.2, 2H), 1.06 (t, J=7.2, 3H).

Example 232

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(1-((2-bromobenzyl)sulfonyl)piperidin-4-yl)urea. MS (ESI): mass calcd. for C₂₃H₂₅FN₆O₃S, 484.17; m/z found, 485.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.16 (s, 1H), 7.96 (t, J=8.2, 1H), 7.66-7.28 (m, 6H), 4.35 (s, 2H), 3.41-3.32 (m, 2H), 2.85-2.70 (m, 2H), 1.83-1.70 (m, 2H), 1.33-1.19 (m, 2H).

Example 233

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(1-((2-bromobenzyl)sulfonyl)piperidin-4-yl)acetamide. MS (ESI): mass calcd. for C₂₄H₂₆FN₅O₃S, 483.17; m/z found, 484.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.03 (d, J=1.3, 1H), 7.95 (m, 1H), 7.81 (d, J=7.3, 1H), 7.64-7.55 (m, 1H), 7.50-7.31 (m, 5H), 6.73 (s, 2H), 4.35 (s, 2H), 3.71-3.56 (m, 1H), 3.39 (d, J=11.6, 2H), 2.79 (t, J=10.8, 2H), 1.82-1.67 (m, 5H), 1.41-1.24 (m, 3H).

Example 234

Step A: (4′-(5-Aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methanol

A mixture of 2-(hydroxymethyl)phenylboronic acid (1 g, 7 mmol), 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (1.76 g, 6.6 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (483 mg, 0.66 mmol) and Na₂CO₃ (2.1 g, 20 mmol) in DMF (50 mL) was stirred at 110° Celsius overnight under N₂. The solution was concentrated to dryness and the residue purified by FCC to give (4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methanol (1.2 g, 62%). ¹H NMR (300 MHz, DMSO-d₆) δ 8.38 (s, 1H), 8.02 (d, J=1.4, 1H), 7.90 (m, 1H), 7.57 (d, J=7.4, 1H), 7.49-7.26 (m, 5H), 6.69 (s, 2H), 5.20 (t, J=5.3, 1H), 4.44 (d, J=5.3, 2H).

Step B: 5-(6′-(Chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine

A mixture of (4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methanol (1.8 g, 6.1 mmol) and SOCl₂ (6 mL) in DCM (20 mL) was stirred at 70° Celsius for 4 hours. The reaction mixture was cooled to rt and concentrated to dryness to give 5-(6′-(chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine (1.86 g, 98%). ¹H NMR (300 MHz, DMSO-d₆) δ 8.40 (s, 1H), 8.04 (s, 1H), 7.96 (m, 1H), 7.66-7.57 (m, 1H), 7.51-7.42 (m, 2H), 7.40-7.30 (m, 3H), 6.89-6.62 (br s, 2H), 4.73 (s, 2H).

Step C: S-(4′-(5-Aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate

A mixture of 5-(6′-(chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine (1.86 g, 5.94 mmol) and KSAc (0.81 g, 7.1 mmol) in 1,4-dioxane/H₂O (30 mL/6 mL) was stirred at rt for 2 hours. Then the solvent was removed under vacuum and the residue purified by FCC to give S-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate (1.42 g, 68%). MS (ESI): mass calcd. for C₁₉H₁₈FN₃OS, 353.10; m/z found, 353.9 [M+H]⁺.

Step D

To a solution of S-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate (100 mg, 0.28 mmol) in CH₃OH (30 mL) were added Ph₃P (147 mg, 0.56 mmol) and K₂CO₃ (78 mg, 0.56 mmol) followed by drop-wise addition of bromoethane (60 mg, 0.56 mmol). After 16 hours, the mixture was concentrated to dryness and the residue was purified by prep-TLC and followed by HPLC to give the title compound (70 mg HCOOH salt, 73%). MS (ESI): mass calcd. for C₁₉H₁₈FN₃S, 339.12; m/z found, 340.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.38 (m, 1H), 8.07 (d, J=1.5, 1H), 7.89 (m, 1H), 7.48-7.40 (m, 1H), 7.37-7.21 (m, 5H), 3.71 (s, 2H), 2.42 (q, J=7.4, 2H), 1.13 (t, J=7.4, 3H).

Example 235

The title compound was prepared using analogous conditions to those described in Example 234 utilizing iodomethane. MS (ESI): mass calcd. for C₁₈H₁₆FN₃S, 325.10; m/z found, 326.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.45 (s, 1H), 8.30 (d, J=1.0, 1H), 8.04 (m, 1H), 7.49-7.24 (m, 6H), 3.68 (s, 2H).

The title

Example 236

The title compound was prepared using analogous conditions to those described in Example 234 utilizing 2-iodopropane. MS (ESI): mass calcd. for C₂₀H₂₀FN₃S, 353.14; m/z found, 354.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.66 (s, 1H), 8.23 (d, J=1.2, 1H), 8.12 (m, 1H), 7.48-7.23 (m, 6H), 3.73 (s, 2H), 2.84-2.71 (m, 1H), 1.16 (d, J=6.7, 6H).

Example 237

The title compound was prepared using analogous conditions to those described in Example 234 utilizing 4-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C₁₈H₁₆FN₃S, 404.12; m/z found, 404.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.77-8.68 (m, 1H), 8.21 (d, J=1.3, 1H), 8.10 (m, 1H), 7.79 (d, J=6.9, 1H), 7.63-7.55 (m, 1H), 7.45-7.22 (m, 5H), 6.73 (d, J=6.8, 1H), 4.57 (s, 2H).

Example 238

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 4-amino-6-chloropyrimidine. MS (ESI): mass calcd. for C₂₁H₁₇FN₆S, 404.12; m/z found, 405.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.78-8.68 (m, 1H), 8.38 (d, J=0.6, 1H), 8.26 (d, J=1.3, 1H), 8.16 (m, 1H), 7.66-7.57 (m, 1H), 7.50-7.44 (m, 2H), 7.42-7.31 (m, 3H), 6.58 (d, J=3.4, 1H), 4.51 (s, 2H).

Example 239

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 3-chloropyrazine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅S, 389.11; m/z found, 390.1 [M+H]⁴. ¹H NMR (400 MHz. CD₃OD) δ 9.33-9.24 (m, 1H), 8.74 (s, 1H), 8.31-8.20 (m, 2H), 8.14 (m, 2H), 7.72-7.64 (m, 1H), 7.50-7.33 (m, 5H), 4.63 (s, 2H).

Example 240

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 3-chloropyrazine. MS (ESI): mass calcd. for C₂₁H₁₇FN₆S, 404.12; m/z found, 405.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.70-8.63 (m, 1H), 8.28 (d, J=1.1, 1H), 8.12 (m, 1H), 7.65-7.57 (m, 2H), 7.46-7.41 (m, 2H), 7.39 (dd, J=8.1, 1.6, 1H), 7.36-7.30 (m, 3H), 4.43 (s, 2H).

Example 241

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 4-((2-bromophenyl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C₂₁H₂₀FN₃O₄S₂, 461.09; m/z found, 462.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.42 (s, 1H), 8.07-8.04 (m, 2H), 7.92 (m, 1H), 7.84 (m, 1H), 7.75 (m, 1H), 7.49 (dd, J=7.5, 1.0, 1H), 7.38-7.31 (m, 1H), 7.29 (dd, J=8.0, 1.6, 1H), 6.74 (s, 2H), 3.25-3.06 (m, 5H), 2.16-2.04 (m, 2H), 2.02-1.86 (m, 2H).

Example 242

The title compound was prepared using analogous conditions to those described in Example 234 utilizing 2-amino-4-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 391.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39-8.32 (m, 1H), 8.01 (d, J=1.5, 1H), 7.94 (d, J=6.1, 1H), 7.85 (m, 1H), 7.76 (d, J=7.8, 1H), 7.71-7.65 (m, 1H), 7.62-7.53 (m, 2H), 7.35-7.24 (m, 2H), 6.88 (s, 2H), 6.18 (d, J=6.4, 1H).

Example 243

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 4-chloropyrimidine. MS (ESI): mass calcd. for C₁₈H₁₆FN₃S, 389.11; m/z found, 390.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.70 (d, J=1.4, 1H), 8.53 (d, J=4.9, 2H), 8.20 (d, J=1.3, 1H), 8.10 (m, 1H), 7.65-7.55 (m, 1H), 7.39-7.25 (m, 5H), 7.13 (m, 1H), 4.46 (s, 2H).

Example 244

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl)-pyrazin-2-amine and (2-(((2-bromophenyl)thio)methoxy)ethyl)trimethylsilane. MS (ESI): mass calcd. for C₂₂H₂₆FN₃OSSi, 427.16; m/z found, 428.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.43-8.36 (m, 1H), 8.07 (d, J=1.5, 1H), 7.89 (m, 1H), 7.73 (dd, J=6.7, 1.4, 1H), 7.40-7.17 (m, 5H), 4.90 (s, 2H), 3.64-3.50 (m, 2H), 0.91-0.78 (m, 2H). 0.04 (s, 9H).

Example 245

The title compound was prepared using analogous conditions to those described in Example Example 244 utilizing 5-[3-fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl-biphenyl-4-yl]-pyrazin-2-amine. MS (ESI): mass calcd. for C₂₂H₂₆FN₃O₃SSi, 459.14; m/z found, 459.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.44-8.39 (m, 1H), 8.18 (dd, J=8.0, 1.3, 1H), 8.08 (d, J=1.4, 1H), 7.94 (m, 1H), 7.80-7.75 (m, 1H), 7.72-7.65 (m, 1H), 7.47 (dd, J=7.5, 1.4, 1H), 7.31 (dd, J=3.6, 1.7, 1H), 7.28 (dd, J=7.7, 1.5, 1H), 4.34 (s, 2H), 3.77-3.68 (m, 2H), 0.85-0.75 (m, 2H), 0.08 (s, 9H).

Example 246

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-bromo-2-((3-(methylsulfonyl)propyl)sulfonyl)benzene. MS (ESI): mass calcd. for C₂₀H₂₀FN₃O₄S₂, 449.53; m/z found, 450.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.69 (d, J=1.3, 1H), 8.25 (d, J=1.3, 1H), 8.18 (dd, J=7.9, 1.3, 1H), 8.12 (m, 1H), 7.81 (m, 1H), 7.71 (m, 1H), 7.48 (dd, J=7.4, 1.3, 1H), 7.44-7.34 (m, 2H), 3.20-3.09 (m, 4H), 2.89 (s, 3H), 2.12-1.96 (m, 2H).

Example 247

Step A: (R)-tert-Butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl-3-methylpiperazine-1-carboxylate

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (R)-tert-butyl 4-((2-bromophenyl)sulfonyl)-3-methypiperazine-1-carboxylate. MS (ESI): mass calcd. for C₂₆H₃₀FN₅O₄S, 527.20; m/z found, 528.2 [M+H]⁺.

Step B

The title compound was prepared by dissolving (R)-tert-butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-methylpiperazine-1-carboxylate (42 mg, 0.08 mmol) in a 50/50 mixture of DCM/TFA (1 mL) and allowing it to stir at rt for 2 h. The reaction mixture was concentrated to dryness and the residue subjected to HPLC purification to give the title compound (29 mg, 85%). MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, J=1.4, 2H), 8.16 (dd, J=8.0, 1.4, 1H), 7.65-7.58 (m, 1H), 7.56-7.49 (m, 1H), 7.48-7.39 (m, 1H), 7.38-7.31 (m, 3H), 5.18 (s, 2H), 3.64-3.52 (m, 1H), 2.99-2.87 (m, 2H), 2.81-2.69 (m, 1H), 2.61-2.41 (m, 4H), 1.18 (d, J=6.8, 3H).

Example 248

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-phenyl)pyrimidin-2-amine and (S)-2-bromo-N-(1-hydroxybutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 417.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.47 (d, J=1.3, 2H), 8.18 (dd, J=7.9, 1.4, 1H), 7.67-7.57 (m, 1H), 7.59-7.49 (m, 1H), 7.42-7.30 (m, 4H), 5.39 (s, 2H), 5.07 (d, J=8.0, 1H), 3.55-3.38 (m, 2H), 3.25-3.11 (m, 1H), 1.93 (s, 1H), 1.54-1.29 (m, 2H), 0.80 (t, J=7.4, 3H).

Example 249

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)phenyl)pyrimidin-2-amine and 2-bromo-N-(2-cyanoethyl)-N-cyclopropylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₀FN₅O₂S, 437.13; m/z found, 438.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, J=1.4, 2H), 8.17 (dd, J=7.9, 1.3, 1H), 7.71-7.62 (m, 1H), 7.62-7.52 (m, 1H), 7.49-7.40 (m, 1H), 7.33 (dd, J=7.5, 1.4, 1H), 7.20 (dd, J=8.0, 1.7, 1H), 7.14 (dd, J=11.1, 1.7, 1H), 5.20 (s, 2H), 3.02 (t, J=7.0, 2H), 2.59-2.41 (m, 3H), 0.65-0.55 (m, 2H), 0.39-0.28 (m, 2H).

Example 250

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)phenyl)pyrimidin-2-amine and 2-bromo-N-(2-cyanoethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆FN₅O₂S, 397.10; m/z found, 398.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) 8.50 (d, J=1.4, 2H), 8.18 (dd, J=7.9, 1.4, 1H), 7.70-7.64 (m, 1H), 7.62-7.55 (m, 1H), 7.49-7.42 (m, 1H), 7.40-7.32 (m, 3H), 5.36 (s, 2H), 5.24 (t, J=6.5, 1H), 3.07 (m, 2H), 2.50 (t, J=6.5, 2H).

Example 251

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)phenyl)pyrimidin-2-amine and 2-bromo-N-(3-hydroxy-2,2-dimethylpropyl)-benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, J=1.4, 2H), 8.12 (dd, J=7.8, 1.5, 1 H), 7.62-7.55 (m, 1H), 7.55-7.48 (m, 1H), 7.48-7.38 (m, 1H), 7.38-7.27 (m, 3H), 5.08 (s, 2H), 4.23 (t, J=6.6, 1H), 3.33-3.21 (m, 2H), 2.61 (d, J=6.8, 2H), 1.40 (s, 6H).

Example 252

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)phenyl)pyrimidin-2-amine and racemic (4-((2-bromophenyl)sulfonyl)morpholin-2-yl)methanol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₄S, 444.13; m/z found, 445.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, J=1.4, 2H), 8.10 (dd, J=7.9, 1.4, 1H), 7.70-7.60 (m, 1H), 7.60-7.52 (m, 1H), 7.47-7.35 (m, 2H), 7.33-7.26 (m, 2H), 5.22 (s, 2H), 3.86-3.76 (m, 1H), 3.63-3.51 (m, 1H), 3.51-3.29 (m, 3H), 3.24-3.09 (m, 2H), 2.64-2.52 (m, 1H), 2.45 (dd, J=12.4, 10.5, 1H), 1.95 (s, 1H).

Example 253

Step A: (S-tert-Butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl-3-methylpiperazine-1-carboxylate

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-tert-butyl 4-((2-bromophenyl)sulfonyl)-3-methypiperazine-1-carboxylate. MS (ESI): mass calcd. for C₂₆H₃₀FN₅O₄S, 527.20: m/z found, 528.2 [M+H]⁺.

Step B

The title compound was prepared as described in the preparation of Example 252 using (S)-tert-butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-methylpiperazine-1-carboxylate. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₂S, 427.15; m/z found, 428.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) b 8.56 (d, J=1.4, 2H), 8.16 (dd, J=7.9, 1.3, 1H), 7.65-7.58 (m, 1H), 7.56-7.49 (m, 1H), 7.48-7.39 (m, 1H), 7.38-7.31 (m, 3H), 5.16 (s, 2H), 3.64-3.51 (m, 1H), 3.02-2.86 (m, 2H), 2.81-2.70 (m, 1H), 2.63-2.41 (m, 4H), 1.18 (d, J=6.8, 3H).

Example 254

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C₁₉H₁₆FN₃O₂S, 369.10; m/z found, 370.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J=1.5, 2H), 8.14 (dd, J=7.9, 1.5, 1H), 7.70-7.63 (m, 1H), 7.62-7.54 (m, 1H), 7.45 (m, 1H), 7.41-7.28 (m, 3H), 5.23 (s, 2H), 2.19-2.06 (m, 1H), 1.16-1.07 (m, 2H), 0.93-0.81 (m, 2H).

Example 255

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-bromo-N-(1,3-dihydroxy-2-methylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₄S, 432.13; m/z found, 433.1 [M+H]⁺.

Example 256

Step A: (S)-tert-Butyl 3-(4′-2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-ylsulfonamido)piperidine-1-carboxylate

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-tert-butyl 3-(2-bromo-N-methylphenylsulfonamido)-piperidine-1-carboxylate yielding 41 mg (48%) of the title compound after HPLC purification. MS (ESI): mass calcd. for C₂₇H₃₂FN₅O₄S, 541.21; m/z found, 542.1 [M+H]⁺.

Step B

The title compound was prepared as described in the preparation of Example 247 using (S)-tert-butyl 3-(4′-2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-ylsulfonamido)piperidine-1-carboxylate. The crude product was purified by HPLC to give the title compound (35 mg, 91%). MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₂S, 441.16; m/z found, 442.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, J=1.4, 2H), 8.14 (dd, J=7.9, 1.4, 1H), 7.65-7.57 (m, 1H), 7.56-7.49 (m, 1H), 7.48-7.38 (m, 1H), 7.37-7.24 (m, 3H), 5.19 (s, 2H), 3.43-3.24 (m, 1H), 2.96-2.74 (m, 2H), 2.51 (t, J=11.3, 1H), 2.42 (s, 4H), 2.38-2.27 (m, 1H), 1.78-1.21 (m, 4H).

Example 257

Step A: R)-tert-Butyl 3-(4′-2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-ylsulfonamido)piperidine-1-carboxylate

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (R)-tert-butyl 3-(2-bromo-N-methylphenylsulfonamido)piperidine-1-carboxylate. MS (ESI): mass calcd. for C₂₇H₃₂FN₅O₄S, 541.21; m/z found, 542.2 [M+H]⁺.

Step B

The title compound was prepared as described in the preparation of Example 247 using (R)-tert-butyl 3-(4′-2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-ylsulfonamido)piperidine-1-carboxylate. MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₂S, 441.16; m/z found, 442.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, J=1.4, 2H), 8.14 (dd, J=8.0, 1.4, 1H), 7.65-7.57 (m, 1H), 7.56-7.49 (m, 1H), 7.47-7.36 (m, 1H), 7.37-7.25 (m, 3H), 5.18 (s, 2H), 3.42-3.26 (m, 1H), 2.93-2.73 (m, 2H), 2.57-2.46 (m, 1H), 2.42 (s, 3H), 2.38-2.27 (m, 2H), 1.73-1.23 (m, 4H).

Example 258

Step A: (R)-tert-Butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-(hydroxymethyl)piperazine-1-carboxylate

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (R)-tert-butyl 4-((2-bromophenyl)sulfonyl)-3-hydroxymethy)piperazine-1-carboxylate. MS (ESI): mass calcd. for C₂₆H₃₀FN₅O₅S, 543.20; m/z found, 544.2 [M+H]⁺.

Step B

The title compound was prepared as described in the preparation of Example 247 using (R)-tert-butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-(hydroxymethyl)piperazine-1-carboxylate. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₃S, 443.14; m/z found, 444.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, J=1.4, 2H), 8.18 (dd, J=8.0, 1.3, 1H), 7.66-7.59 (m, 1H), 7.57-7.49 (m, 1H), 7.47-7.40 (m, 1H), 7.39-7.31 (m, 3H), 5.19 (s, 2H), 3.94-3.77 (m, 2H), 3.52-3.39 (m, 1H), 3.34-3.18 (m, 1H), 3.17-2.99 (m, 2H), 2.88-2.77 (m, 1H), 2.65-2.46 (m, 2H), 1.65 (br s, 2H).

Example 259

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and racemic 2-bromo-N-((cis)-2-hydroxycyclohexyl)-benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.51 (d, J=1.3, 2H), 8.17 (dd, J=8.0, 1.4, 1H), 7.64-7.59 (m, 1H), 7.57-7.51 (m, 1H), 7.44-7.31 (m, 4H), 5.30 (s, 2H), 4.83 (d, J 20=7.7, 1H), 3.78 (s, 1H), 3.20-3.11 (m, 1H), 1.72-1.65 (m, 1H), 1.57-1.10 (m, 8H).

Example 260

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-bromo-N-((trans)-2-hydroxycylohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.51 (d, J=1.3, 2H), 8.17 (dd, J=8.0, 1.4, 1H), 7.64-7.59 (m, 1H), 7.57-7.51 (m, 1H), 7.44-7.31 (m, 4H), 5.30 (s, 2H), 4.83 (d, J=7.7, 1H), 3.78 (s, 1H), 3.20-3.11 (m, 1H), 1.72-1.65 (m, 1H), 1.57-1.10 (m, 8H).

Example 261

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-bromo-N-(2-hydroxyethyl)-N-isopropylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d. J=1.4, 2H), 8.10 (dd. J=8.0, 1.4, 1H), 7.65-7.57 (m, 1H), 7.58-7.49 (m, 1H), 7.49-7.38 (m, 1H), 7.37-7.28 (m, 3H), 5.22 (s, 2H), 3.72 (p, J=6.7, 1H), 3.65-3.50 (m, 2H), 2.99 (t, J=6.0, 2H), 2.19 (d, J=7.0, 1H), 1.04 (d, J=6.7, 6H).

Example 262

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and trans-2-bromo-N-4-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.15; m/z found, 443.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.53 (s, 1H), 8.22-8.15 (m, 1H), 7.67-7.60 (m, 1H), 7.59-7.51 (m, 1H), 7.48-7.39 (m, 1H), 7.39-7.31 (m, 3H), 5.26 (s, 2H), 4.11 (d, J=7.1, 1H), 3.60-3.43 (m, 1H), 3.10-2.94 (m, 1H), 1.93-1.73 (m, 4H), 1.38 (d, J=4.4, 1H), 1.34-1.00 (m, 5H).

Example 263

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-2-bromo-N-(2-oxopyrrolidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.51 (dd, J=2.2, 1.3, 2H), 8.18 (dd, J=7.9, 1.3, 1H), 7.67-7.60 (m, 1H), 7.58-7.51 (m, 1H), 7.45-7.31 (m, 4H), 6.05 (d, J=9.3, 1H), 5.51 (dd, J=9.8, 3.3, 1H), 5.35 (d, J=3.1, 2H), 3.67-3.55 (m, 1H), 3.39-3.19 (m, 2H), 2.65-2.50 (m, 1H), 2.16-1.99 (m, 1H).

Example 264

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₄S₂. 462.08; m/z found, 463.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.78 (d, J=0.9, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.75 (m, 1H), 7.71-7.62 (m, 2H), 7.44 (dd, J=7.6, 1.1, 1H), 7.40-7.31 (m, 2H), 3.34 (dd, J=7.8, 3.2, 4H), 3.04-2.99 (m, 4H).

Example 265

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)azetidin-3-ol. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₃S, 400.10; m/z found, 401.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.79 (d, J=0.7, 2H), 8.08 (dd, J=8.0, 1.1, 1H), 7.72 (m, 1H), 7.68-7.55 (m, 2H), 7.47-7.38 (m, 1H), 7.36 (dd, J=8.3, 1.5, 2H), 4.36 (m, 1H), 3.76-3.64 (m, 2H), 3.60-3.53 (m, 2H).

Example 266

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(2-oxopiperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₃S, 441.13; m/z found, 442.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.71 (d, J=0.7, 2H), 8.24 (dd, J=8.0, 1.2, 1H), 7.67 (m, 1H), 7.58 (m, 2H), 7.42 (s, 1H), 7.41-7.39 (m, 1H), 7.38 (dd, J=7.6, 1.2, 1H), 3.63 (dd, J=10.5, 5.8, 1H), 3.20 (dd, J=8.9, 5.1, 2H), 2.17 (m, 1H), 1.89-1.80 (m, 1H), 1.78-1.64 (m, 2H).

Example 267

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(2-oxopiperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₃S, 441.13; m/z found, 442.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.74 (d, J=0.8, 2H), 8.24 (dd, J=8.0, 1.1, 1H), 7.67 (m, 1H), 7.62-7.54 (m, 2H), 7.42 (s, 1H), 7.42-7.40 (m, 1H), 7.38 (dd, J=7.6, 1.2, 1H), 3.64 (dd, J=10.5, 5.8, 1H), 3.20 (dd, J=8.7, 5.0, 2H), 2.17 (m, 1H), 1.89-1.80 (m, 1H), 1.80-1.65 (m, 2H).

Example 268

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₂S, 440.09; m/z found, 441.0 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.64 (d, J=0.9, 2H), 8.10 (dd, J=8.0, 1.1, 1H), 7.67 (m, 1H), 7.59 (m, 1H), 7.55 (m, 1H), 7.37 (dd, J=7.6, 1.2, 1H), 7.33-7.24 (m, 2H), 3.86 (m, 1H), 1.22 (m, 3H).

Example 269

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₅FN₄O₃S, 444.16; m/z found, 445.2 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.68 (d, J=1.0, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.62 (m, 1H), 7.58-7.49 (m, 2H), 7.42-7.35 (m, 2H), 7.35-7.29 (m, 1H), 3.50 (m, 2H), 3.06 (dd, J=5.8, 4.3, 1H), 0.84 (s, 9H).

Example 270

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₅FN₄O₃S, 444.16; m/z found, 445.2 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.69 (d, J=1.0, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.63 (m, 1H), 7.59-7.47 (m, 2H), 7.41-7.36 (m, 2H), 7.33 (m, 1H), 3.50 (m, 2H), 3.06 (dd, J=5.9, 4.2, 1H), 0.84 (s, 9H).

Example 271

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.71 (d, J=0.9, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.66-7.61 (m, 1H), 7.60-7.54 (m, 2H), 7.36 (m, 3H), 3.47-3.38 (m, 1H), 3.38-3.32 (m, 1H), 3.06 (q, J=5.5, 1H), 1.84 (m, 1H), 0.83-0.78 (m, 6H).

Example 272

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 417.1 [M+H]⁴. ¹H NMR (600 MHz. CD₃OD) δ 8.75 (d, J=1.0 Hz, 2H), 8.04 (dd, J=8.0, 1.3 Hz, 1H), 7.70-7.65 (m, 1H), 7.64-7.58 (m, 2H), 7.41 (dd, J=7.6, 1.3 Hz, 1H), 7.39-7.35 (m, 2H), 2.71 (s, 2H), 1.11 (s, 6H).

Example 273

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.71 (d, J=0.9, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.66-7.61 (m, 1H), 7.60-7.54 (m, 2H), 7.36 (m, 3H), 3.47-3.38 (m, 1H), 3.38-3.32 (m, 1H), 3.06 (q, J=5.5, 1H), 1.84 (m, 1H), 0.83-0.78 (m, 6H).

Example 274

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(2,3-dihydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₄S, 418.11; m/z found, 419.1 [M+H]⁺.

Example 275

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₃S, 388.10; m/z found, 389.1 [M+H]⁴. ¹H NMR (600 MHz, CD₃OD) δ 8.75 (d, J=0.9, 2H), 8.07 (m, 1H), 7.71-7.66 (m, 1H), 7.63-7.59 (m, 2H), 7.40 (dd, J=7.6, 1.1, 1H), 7.37 (m, 2H), 3.49 (t, J=5.9, 2H), 2.90 (t, J=5.9, 2H).

Example 276

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)methanol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) G 8.70 (d, J=1.0, 2H), 8.10 (dd, J=8.0, 1.2, 1H), 7.70 (m, 1H), 7.64-7.61 (m, 1H), 7.59 (dd, J=10.9, 5.4, 1H), 7.41 (dd, J=7.6, 1.2, 1 H), 7.37-7.32 (m, 2H), 3.50 (m, 1H), 3.37 (dd, J=10.8, 3.9, 1H), 3.21-3.15 (m, 1H), 3.03-2.95 (m, 2H), 1.88-1.75 (m, 3H), 1.73-1.66 (m, 1H).

Example 277

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)methanol. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.70 (d, J=1.0, 2H), 8.10 (dd, J=8.0, 1.2, 1H), 7.70 (m, 1H), 7.64-7.61 (m, 1H), 7.59 (dd, J=10.9, 5.4, 1H), 7.41 (dd, J=7.6, 1.2, 1H), 7.37-7.32 (m, 2H), 3.50 (m, 1H), 3.37 (dd, J=10.8, 3.9, 1H), 3.21-3.15 (m, 1H), 3.03-2.95 (m, 2H), 1.88-1.75 (m, 3H), 1.73-1.66 (m, 1H).

Example 278

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.60 (d, J=1.2 Hz, 2H), 8.06 (dd, J=8.0, 1.3 Hz, 1H), 7.71-7.65 (m, 1H), 7.63-7.58 (m, 1H), 7.58-7.51 (m, 1H), 7.41 (dd, J=7.5, 1.4 Hz, 1H), 7.35 (s, 1H), 7.34-7.30 (m, 1H), 3.74-3.63 (m, 1H), 2.76 (dd, J=13.1, 5.0 Hz, 1H), 2.69 (dd, J=13.0, 6.8 Hz, 1H), 1.06 (d, J=6.3 Hz, 3H).

Example 279

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.60 (d, J=1.2 Hz, 2H), 8.06 (dd, J=8.0, 1.3 Hz, 1H), 7.71-7.65 (m, 1H), 7.63-7.58 (m, 1H), 7.58-7.51 (m, 1H), 7.41 (dd, J=7.5, 1.4 Hz, 1H), 7.35 (s, 1H), 7.34-7.30 (m, 1H), 3.74-3.63 (m, 1H), 2.76 (dd, J=13.1, 5.0 Hz, 1H), 2.69 (dd, J=13.0, 6.8 Hz, 1H), 1.06 (d, J=6.3 Hz, 3H)

Example 280

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₃S, 416.13; m/z found, 417.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.69 (s, 2H), 8.16 (dd, J=8.0, 1.2, 1H), 7.66 (m, 1H), 7.61-7.55 (m, 2H), 7.38 (dd, J=7.8, 1.3, 3H), 3.27 (s, 2H), 1.03 (s, 6H).

Example 281

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-cyclopropylpiperazine. MS (ESI): mass calcd. for C₂₃H₂₄FN₅O₂S, 453.16; m/z found, 454.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.75 (d, J=0.6, 2H), 8.13 (dd, J=8.0, 1.2, 1H), 7.79-7.74 (m, 1H), 7.69-7.59 (m, 2H), 7.45 (dd, J=7.6, 1.2, 1H), 7.37-7.32 (m, 2H), 3.59-3.33 (m, 4H), 3.28-3.00 (m, 4H), 2.82 (m, 1H), 1.00-0.86 (m, 4H).

Example 282

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)ethanol. MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₃S, 457.16; m/z found, 458.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.72 (s, 2H), 8.13 (dd, J=8.0, 1.2, 1H), 7.77 (m, 1H), 7.71-7.59 (m, 2H), 7.46 (dd, J=7.6, 1.2, 1H), 7.39-7.33 (m, 2H), 3.85-3.80 (m, 2H), 3.68-3.33 (m, 4H), 3.26-3.22 (m, 2H), 3.17-2.81 (m, 4H).

Example 283

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(cyclopropylmethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂S, 398.12; m/z found, 399.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.67 (s, 2H), 8.10 (dd, J=8.0, 1.4 Hz, 1H), 7.70-7.65 (m, 1H), 7.65-7.53 (m, 2H), 7.39-7.35 (m, 1H), 7.31-7.25 (m, 2H), 1.22 (s, 3H), 0.52-0.48 (m, 2H), 0.38-0.33 (m, 2H).

Example 284

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-cyclopropylbenzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₂S, 384.10; m/z found, 385.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.68 (d, J=1.0, 2H), 8.11 (dd, J=8.0, 1.2, 1H), 7.69 (m, 1H), 7.62 (m, 1H), 7.56 (m, 1H), 7.40 (dd, J=7.6, 1.2, 1H), 7.35-7.22 (m, 2H), 2.20 (m, 1H), 0.55-0.34 (m, 4H).

Example 285

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-phenylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₁₇FN₄O₂S, 420.10; m/z found, 421.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.66 (s, 1H), 8.14 (d, J=7.8, 1H), 7.57 (m, 3H), 7.33 (m, 2H), 7.12 (m, 4H), 7.02-6.75 (m, 3H).

Example 286

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.11; m/z found, 403.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.59 (d, J=1.3, 2H), 8.07 (dd, J=7.9, 1.4, 1H), 7.68 (td, J=7.5, 1.4, 1H), 7.65-7.58 (m, 2H), 7.39 (dd, J=7.5, 1.4, 1H), 7.35 (dd, J=11.8, 1.8, 1H), 7.29 (dd, J=7.9, 1.8, 1H), 7.25 (d, J=7.5, 1H), 3.30 (dd, J=10.3, 4.9, 1H), 3.14-3.09 (m, 1H), 3.09-3.01 (m, 1H), 0.96 (d. J=6.5, 3H).

Example 287

To a 6 mL microwave vial the following were added 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine (60 mg, 0.19 mmol), N-(tert-butyl)-2-chloro-6-methylbenzenesulfonamide (62 mg, 0.24 mmol), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1-1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (3 mg, 0.004 mmol). The vial was flushed with nitrogen and charged with N₂ sparged THF (0.3 mL) and N₂ sparged K₃PO₄ (0.8 mL, 0.5 M). The resulting biphasic mixture was stirred at rt for 1 h and at 45° C. for 1 h. The resulting mixture was concentrated to dryness and the resulting residue was purified by HPLC to provide the title compound. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₂S, 414.15: m/z found, 415.1 [M+H]⁺.

Example 288

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-methylbenzenesulfonamide. MS (ESI): mass calcd. for C₁₇H₁₅FN₄O₂S, 358.09; m/z found, 359.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.59 (s, 2H), 7.93 (dd, J=7.8, 1.4, 1H), 7.70 (td, J=7.5, 1.4, 1H), 7.67-7.58 (m, 2H), 7.42 (dd, J=7.5, 1.5, 1H), 7.34 (dd, J=11.8, 1.8, 1H), 7.31-7.26 (m, 4H), 2.41 (d, J=4.8, 3H).

Example 289

Method 1

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide.

Method 2

A mixture of 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine (30.0 g, 95.2 mmol), K₃PO₄ (70.7 g, 333 mmol), (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide (28.0 g, 95.2 mmol), PdCl₂(dppf).CH₂Cl₂ (0.70 g, 0.95 mmol), acetonitrile (476 mL), and water (190 mL) was sparged with N₂ and stirred at 75° Celsius for 26 hours. After filtration, water was added and the reaction mixture was cooled to rt. Solid precipitate was collected by vacuum filtration and dried in a vacuum oven at 70° Celsius (24.0 g, 63%). The solid was recrystallized from EtOH and treated successively with activated charcoal and silica-supported thiol to remove residual Pd and afford the title compound (21.6 g, 57%). MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.52 (d, J=1.4, 2H), 8.12-7.99 (m, 1H), 7.73-7.65 (m, 1H), 7.65-7.53 (m, 2H), 7.39 (dd, J=7.5, 1.4, 1H), 7.36-7.31 (m, 1H), 7.28 (dd, J=7.9, 1.8, 1H), 7.23 (d, J=7.5, 1H), 6.92 (s, 2H), 4.75-4.67 (m, 1H), 3.33-3.27 (m, 1H), 3.16-3.01 (m, 2H), 0.96 (d, J=6.4, 3H). Chiral HPLC: Chiralpak IC 4.6×250 mm column, 30% EtOH+0.2% TEA, 70% CO₂, 2 mL/min, retention time 22.4 min, ee>99%.

Example 290

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)piperazine. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.63 (s, 2H), 8.54 (d, J=1.0, 2H), 8.08-8.04 (m, 1H), 7.81 (m, 1H), 7.74-7.68 (m, 1H), 7.61 (m, 1H), 7.50 (d, J=7.6, 1H), 7.36 (dd, J=11.6, 1.5, 1H), 7.29 (dd, J=7.9, 1.7, 1H), 7.05 (s, 2H), 3.04-2.86 (m, 8H).

Example 291

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(2,2,2-trifluoro-1-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₁₈F₄N₄O₂S, 502.11; m/z found, 503.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 9.28 (d, J=10.1, 1H), 8.54 (d, J=1.2, 2H), 7.88 (dd, J=8.1, 1.1, 1H), 7.59 (m, 1H), 7.53 (t, J=8.3, 1H), 7.46-7.40 (m, 3H), 7.41-7.30 (m, 3H), 7.27 (dd, J=7.6, 1.2, 1H), 7.12-6.97 (m, 4H), 5.14-4.96 (m, 1H).

Example 292

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(2,2,2-trifluoro-1-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₄H₁₈F₄N₄O₂S, 502.11; m/z found, 503.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d) 8 9.29 (d, J=10.1, 1H), 8.59 (s, 2H), 7.88 (dd, J=8.0, 1.0, 1H), 7.60 (m, 1H), 7.54 (t, J=8.2, 1H), 7.47-7.42 (m, 3H), 7.38-7.31 (m, 3H), 7.27 (dd, J=7.6, 1.0, 1H), 7.11-7.04 (m, 2H), 5.11-5.03 (m, 1H).

Example 293

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) pyrimidin-2-amine and 1-bromo-2-(tert-butylsulfonyl)benzene. MS (ESI): mass calcd. for C₂₀H₂₀FN₃O₂S, 385.12; m/z found, 386.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.57 (d, J=0.8, 2H), 8.03 (dd, J=8.0, 1.2, 1H), 7.81 (m, 1H), 7.72 (m, 1H), 7.56 (m, 1H), 7.41 (dd, J=7.6, 1.2, 1H), 7.32 (dd, J=11.9, 1.6, 1H), 7.25 (dd, J=7.9, 1.7, 1H), 7.14 (s, 2H), 1.08 (s, 9H).

Example 294

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-isobutylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.53 (s, 2H), 7.94 (dd, J=7.9, 1.0, 1H), 7.68 (m, 1H), 7.65-7.57 (m, 2H), 7.52 (m, 1H), 7.41 (dd, J=7.5, 1.1, 1H), 7.33 (dd, J=11.8, 1.4, 1H), 7.29 (dd, J=7.9, 1.6, 1H), 7.03 (s, 2H), 2.53 (t, J=6.4, 2H), 1.60 (m, 1H), 0.79 (d, J=6.7, 6H).

Example 295

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-ethylbenzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.11; m/z found, 373.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.57 (d, J=1.3, 2H), 7.96 (dd, J=7.9, 1.4, 1H), 7.69 (td, J=7.5, 1.4, 1H), 7.66-7.58 (m, 2H), 7.44-7.40 (m, 2H), 7.34 (dd, J=11.8, 1.8, 1H), 7.29 (dd, J=7.9, 1.7, 1H), 7.18 (s, 2H), 2.77 (qd, J=7.2, 5.6, 2H), 0.97 (t. J=7.2, 3H).

Example 296

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(1,1,1-trifluoro-2-methylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₈F₄N₄O₂S, 454.11; m/z found, 455.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.65 (s, 2H), 8.12 (dd, J=8.0, 1.1, 1H), 7.67 (m, 1H), 7.60 (m, 1H), 7.55 (m, 1H), 7.39 (dd, J=7.5, 1.2, 1H), 7.32 (dd, J=6.0, 4.7, 2H), 1.29 (s, 6H).

Example 297

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₂S, 440.09; m/z found, 441.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.71 (s, 2H), 8.10 (d, J=7.9, 1H), 7.68 (m, 1H), 7.63-7.53 (m, 2H), 7.40-7.34 (m, 1H), 7.33-7.26 (m, 2H), 3.87 (m, 1H), 1.23 (d, J=7.0, 3H).

Example 298

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂S, 398.12; m/z found, 399.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.54 (d. J=1.2, 2H), 7.98 (dd. J=7.9, 1.1, 1H), 7.73 (m, 1H), 7.67-7.59 (m, 2H), 7.43 (dd, J=7.5, 1.1, 1H), 7.34 (dd, J=11.8, 1.6, 1H), 7.28 (dd. J=7.9, 1.7, 1H), 7.05 (s, 2H), 2.88 (t, J=6.7, 4H), 1.76-1.60 (m, 4H).

Example 299

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(N,N-dimethyl-sulfamoyl)phenyl)boronic acid MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.10; m/z found, 373.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.56 (d, J=1.1, 2H), 7.95 (dd, J=7.9, 1.2, 1H), 7.73 (m, 1H), 7.66 (m, 1H), 7.61 (m, 1H), 7.43 (dd, J=7.5, 1.2, 1H), 7.32 (dd, J=11.8, 1.6, 1H), 7.26 (dd, J=7.9, 1.7, 1H), 2.50 (s, 6H).

Example 300

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(N,N-diethyl-sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.54 (d, J=1.3, 2H), 7.96 (dd, J=8.0, 1.2, 1H), 7.71 (m, 1H), 7.63 (m, 2H), 7.41 (dd, J=7.5, 1.2, 1H), 7.30 (m, 1H), 7.26 (m, 1H), 7.04 (s, 2H), 2.93 (q, J=7.1, 4H), 0.94 (t, J=7.1, 6H).

Example 301

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(piperidin-1-ylsulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₂S, 412.14; m/z found, 413.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.54 (d, J=1.2, 2H), 7.99 (dd, J=8.0, 1.2, 1H), 7.73 (m, 1H), 7.69-7.57 (m, 2H), 7.44 (dd, J=7.6, 1.2, 1H), 7.33 (m, 1H), 7.27 (dd, J=7.9, 1.7, 1H), 7.05 (s, 2H), 2.84-2.74 (m, 4H), 1.43-1.25 (m, 6H).

Example 302

Trifluoroacetic acid (1 mL) was added to neat 4′-(2-aminopyrimidin-5-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (52 mg, 0.13 mmol). After 4 hours, the resulting solution was concentrated to dryness and purified by HPLC to provide the title compound (33 mg, 59%) as a clear glassy solid. MS (ESI): mass calcd. for C₁₆H₁₃FN₄O₂S, 344.07; m/z found, 345.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.54 (d, J=1.3, 2H), 8.05 (dd, J=7.8, 1.4, 1H), 7.70-7.56 (m, 3H), 7.40-7.28 (m, 5H), 7.03 (s, 2H).

Example 303

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(morpholino-sulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.56 (d, J=1.3, 2H), 8.02 (dd, J=8.0, 1.2, 1H), 7.77 (m, 1H), 7.68 (m, 1H), 7.62 (m, 1H), 7.46 (dd, J=7.6, 1.2, 1H), 7.38 (dd, J=11.8, 1.6, 1H), 7.31 (dd, J=7.9, 1.7, 1H), 3.46-3.37 (m, 4H), 2.83-2.73 (m, 4H).

Example 304

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(methyl-sulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₁₇H₁₄FN₃O₂S, 343.08; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.57 (d, J=1.3, 2H), 8.12 (dd, J=8.0, 1.2, 1H), 7.80 (m, 1H), 7.72 (m, 1H), 7.65 (m, 1H), 7.46 (dd, J=7.5, 1.2, 1H), 7.40 (dd, J=11.7, 1.7, 1H), 7.33 (dd, J=7.9, 1.7, 1H), 2.96 (s, 3H).

Example 305

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.55 (s, 2H), 8.06 (dd, J=7.9, 1.3, 1H), 7.66 (m, 1H), 7.63-7.57 (m, 2H), 7.38 (dd, J=7.5, 1.2, 1H), 7.33 (dd, J=11.9, 1.5, 1H), 7.28 (dd, J=7.9, 1.6, 1H), 6.99-6.88 (m, 1H), 1.03 (s, 9H).

Example 306

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 4-((2-bromophenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.22 (d, J=0.7, 2H), 6.61 (m, 1H), 6.22 (m, 1H), 6.12 (m, 1H), 6.07 (dd, J=11.3, 4.9, 1H), 5.92 (dd, J=7.6, 1.2, 1H), 5.82 (t, J=1.8, 1H), 5.80 (dd, J=5.4, 1.4, 1H), 1.81 (s, 2H), 1.63 (m, 4H).

Example 307

The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-tert-butyl 2-(2-bromophenylsulfonamido)propanoate. MS (ESI): mass calcd. for C₂₃H₂₅FN₄O₄S, 472.16; m/z found, 473.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.65 (d, J=1.1, 2H), 8.08 (dd, J=8.0, 1.2, 1H), 7.66 (m, 1H), 7.61-7.49 (m, 2H), 7.37 (m, 3H), 3.66 (q, J=7.2, 1H), 1.34 (s, 9H), 1.26 (d, J=7.2, 3H).

Example 308

Trifluoroacetic acid (0.5 mL) was added to a solution of tert-butyl N-{[4′-(2-aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L-alaninate (80 mg, 0.17 mmol) in DCM (1 mL) at rt. After 2 hours, the solution was concentrated to dryness and purified by HPLC to afford the title compound (70 mg, 89%). MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₄S, 416.10; m/z found, 417.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.72 (s, 2H), 8.10 (dd, J=8.0, 1.2, 1H), 7.66 (m, 1H), 7.61-7.53 (m, 2H), 7.37 (m, 3H), 3.73 (q, J=7.2, 1H), 1.31 (d, J=7.2, 3H).

Example 309

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and N-(2-bromophenyl)pyrrolidine-1-sulfonamide MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.4 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) 8.63 (s, 2H), 7.59 (d, J=8.4, 1H), 7.50 (m, 1H), 7.39 (m, 1H), 7.32-7.29 (m, 2H), 7.24-7.22 (m, 1H), 7.22-7.15 (m, 1H), 6.87-6.79 (m, 2H), 6.36 (s, 1H), 3.37-3.26 (m, 4H), 1.94-1.83 (m, 4H).

Example 310

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and N-(2-bromophenyl)morpholine-4-sulfonamide. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₃S, 429.13; m/z found, 430.4 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.63 (d, J=1.2, 2H), 7.70-7.54 (m, 2H), 7.48-7.25 (m, 5H), 3.70-3.55 (m, 4H), 3.05 (dd, J=5.7, 3.8, 4H).

Example 311

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and N-(2-bromophenyl)-N,N-dimethylsulfonamide. MS (ESI): mass calcd. for C₁₈H₁₈FN₅O₂S, 387.12; m/z found, 388.3 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.57 (d, J=1.4, 2H), 7.61-7.55 (m, 1H), 7.50 (m, 1H), 7.42-7.35 (m, 1H), 7.24-7.21 (m, 1H), 7.21-7.17 (m, 2H), 6.36 (s, 1H), 5.17 (s, 2H), 2.82 (s, 6H).

Example 312

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 6-((2-bromophenyl)sulfonyl)-2-oxa-6-azaspiro[3.3]heptanes and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O₃S, 426.12; m/z found, 426.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.53 (s, 2H), 8.05-7.96 (d, J=7.9, 1H), 7.78-7.71 (m, 1H), 7.68-7.58 (m, 2H), 7.47-7.41 (d, J=7.5, 1H), 7.35-7.28 (m, 1H), 7.28-7.23 (m, 1H), 6.90 (s, 2H), 4.51 (d, J=1.3, 4H), 3.71 (d, J=1.4, 4H).

Example 313

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 6-((2-bromophenyl)sulfonyl)-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O₄S₂, 474.08; m/z found, 474.8 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.56-8.50 (d, J=1.4, 2H), 8.05-7.99 (dd, J=8.0, 1.3, 1H), 7.80-7.73 (m, 1H), 7.69-7.60 (m, 2H), 7.48-7.43 (dd, J=7.6, 1.3, 1H), 7.38-7.32 (dd, J=11.8, 1.8, 1H), 7.31-7.26 (dd, J=7.9, 1.7, 1H), 6.90 (s, 2H), 4.32 (s, 4H), 3.76 (s, 4H).

Example 314

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 1-((2-bromophenyl)sulfonyl)azetidine-3-carbonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₆FN₅O₂S, 409.10; m/z found, 409.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d) δ 8.52 (s, 2H), 8.08-8.00 (d, J=8.0, 1H), 7.83-7.75 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.51-7.43 (d, J=7.5, 1H), 7.38-7.31 (d, J=11.7, 1H), 7.31-7.26 (m, 1H), 6.89 (s, 2H), 3.96-3.87 (m, 2H), 3.68-3.59 (m, 3H).

Example 315

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 1-((2-bromophenyl)sulfonyl)-3-(trifluoromethyl)azetidin-3-ol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₆F₄N₄O₃S, 468.09; m/z found, 469.0 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.53-8.47 (d, J=1.4, 2H), 8.06-8.01 (dd, J=8.0, 1.3, 1H), 7.81-7.76 (m, 1H), 7.70-7.65 (m, 1H), 7.64-7.58 (m, 1H), 7.51-7.45 (m, 2H), 7.35-7.29 (dd, J=11.7, 1.8, 1H), 7.28-7.24 (dd, J=7.8, 1.7, 1H), 6.94 (s, 2H), 3.81-3.76 (d, J=9.3, 2H), 3.71-3.66 (m, 2H)

Example 316

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 4-((2-bromophenyl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C₂₁H₂₀FN₃O₄S₂, 461.09; m/z found, 461.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.55 (s, 2H), 8.06 (d, J=7.9, 1H), 7.85 (m, 1H), 7.76 (m, 1H), 7.61 (m, 1H), 7.49 (d, J=7.5, 1H), 7.37 (d, J=11.6, 1H), 7.30 (d, J=8.0, 1H), 6.94 (s, 2H), 3.26-3.07 (m, 5H), 2.12-2.09 (m, 2H), 2.01-1.86 (m, 2H).

Example 317

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-(((2-bromophenyl)sulfonyl)methyl)quinazolin-4(3H)-one. MS (ESI): mass calcd. for C₂₅H₁₈FN₅O₃S, 487.11; m/z found, 487.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 12.36 (s, 1H), 8.60-8.43 (d, J=1.4, 2H), 8.12-8.02 (dd, J=8.0, 1.5, 1H), 7.96-7.89 (dd, J=8.0, 1.3, 1H), 7.84-7.71 (m, 2H), 7.66-7.42 (m, 4H), 7.42-7.22 (m, 3H), 6.91 (s, 2H), 4.37 (s, 2H).

Example 318

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 1-(3-((2-bromophenyl)sulfonyl)propyl)-1H-benzo[d]imidazol-2(3H)-one. MS (ESI): mass calcd. for C₂₆H₂₂FN₅O₃S, 503.14; m/z found, 503.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 10.85 (s, 1H), 8.45 (s, 2H), 8.12-8.03 (d, J=7.8, 1H), 7.83-7.75 (m, 1H), 7.75-7.66 (m, 1H), 7.45-7.30 (m, 2H), 7.27-7.19 (d, J=11.5, 1H), 7.09-6.88 (m, 6H), 3.79-3.72 (t, J=6.5, 2H), 2.97-2.88 (dd, J=9.7, 6.3, 2H), 1.79-1.68 (m, 2H).

Example 319

The title compound was prepared in a manner similar to that described in Example 88 using 1-bromo-2-((3-(cyclohexylsulfonyl)propyl)sulfonyl)benzene and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₅H₂₈FN₃O₄S₂, 517.15; m/z found, 518.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.59-8.51 (d, J=1.4, 2H), 8.20-8.14 (dd, J=8.0, 1.3, 1H), 7.82-7.76 (m, 1H), 7.72-7.67 (m, 1H), 7.59-7.52 (m, 1H), 7.51-7.46 (dd, J=7.7, 1.3, 1H), 7.38-7.31 (m, 2H), 3.16-3.08 (t, J=7.5, 2H), 3.08-3.01 (t, J=7.3, 2H), 2.94-2.82 (m, 1H), 2.07-1.97 (m, 4H), 1.91-1.80 (m, 2H), 1.79-1.62 (d, J=13.0, 1H), 1.48-1.35 (m, 2H), 1.35-1.25 (m, 2H), 1.24-1.12 (m, 1H).

Example 320

The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenyl)sulfonyl)-1-methyl-1H-benzo[d]imidazole and 5-(2-fluor-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₄H₁₈FN₅O₂S, 459.12; m/z found, 460.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.03-6.96 (dd, J=7.8, 1.5, 1H), 6.88-6.86 (d, J=1.4, 2H), 6.43-6.28 (m, 1.5, 2H), 6.15-6.09 (d, J=8.2, 1H), 6.08-5.99 (m, 2H), 5.97-5.86 (m, 2H), 5.64-5.53 (m, 1H), 5.34-5.30 (dd, J=7.8, 1.7, 1H), 5.30-5.23 (dd, J=11.3, 1.7, 1H), 2.22 (s, 3H).

Example 321

The title compound was prepared in a manner similar to that described in Example 88 using 5-(((2-bromophenyl)sulfonyl)methyl)-3-cyclopropyl-1,2,4-oxadiazole and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₁₈FN₅O₃S, 451.11: m/z found, 452.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.56 (s, 1H), 7.98-7.94 (m, 1H), 7.85-7.77 (dd, J=8.2, 6.9, 1H), 7.67-7.61 (m, 1H), 7.61-7.57 (m, 1H), 7.52-7.46 (d, J=7.6, 1H), 7.39-7.35 (dd, J=7.9, 1.6, 1H), 7.35-7.31 (m, 1H), 2.05-1.94 (m, 1H), 1.04-0.94 (m, 1H), 0.79-0.72 (m, 1H).

Example 322

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-5-(trifluoromethyl)benzenesulfonamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₇H₁₂F₄N₄O₂S, 412.06; m/z found, 413.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.56-8.53 (d, J=1.4, 2H), 8.43-8.40 (m, 1H), 7.98-7.92 (d, J=7.7, 1H), 7.63-7.58 (d, J=8.0, 1H), 7.58-7.52 (m, 1H), 7.37-7.35 (m, 1H), 7.35-7.32 (m, 1H).

Example 323

The title compound was prepared in a manner similar to that described in Example 88 using 1-bromo-2-(methylsulfonyl)-4-(trifluoromethyl)benzene and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₃F₄N₃O₂S, 411.07; m/z found, 412.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.61-8.51 (d, J=1.4, 2H), 8.44 (s, 1H), 8.11-8.05 (d, J=7.5, 1H), 7.72-7.66 (d, J=8.0, 1H), 7.66-7.59 (m, 1H), 7.45-7.35 (m, 2H), 2.89 (s, 3H).

Example 324

The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromo-5-(trifluoromethyl)phenyl)-sulfonyl)-piperazin-2-one and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₇F₄N₅O₃S, 495.10; m/z found, 496.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.70-8.61 (d, J=1.2, 2H), 8.40 (s, 1H), 8.10-8.03 (d, J=7.7, 1H), 7.71-7.64 (d, J=7.9, 1H), 7.64-7.58 (m, 1H), 7.39-7.37 (m, 1H), 7.36 (s, 1H), 3.34 (s, 2H), 3.22-3.17 (m, 2H), 3.17-3.12 (m, 2H).

Example 325

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-methyl-5-(trifluoromethyl)benzenesulfonamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₄F₄N₄O₂S, 426.08; m/z found, 427.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.57-8.52 (d, J=1.4, 2H), 8.33-8.27 (m, 1H), 8.02-7.94 (m, 1H), 7.66-7.60 (d, J=7.9, 1H), 7.60-7.52 (m, 1H), 7.38-7.31 (m, 2H), 2.46 (s, 3H).

Example 326

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₃S, 456.09; m/z found, 457.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.57-8.53 (d, J=1.4, 2H), 8.38-8.35 (m, 1H), 8.00-7.96 (dd, J=8.1, 1.5, 1H), 7.63-7.60 (d, J=8.0, 1H), 7.59-7.54 (m, 1H), 7.38-7.36 (dd, J=6.1, 1.6, 1H), 7.36-7.34 (m, 1H), 3.51-3.45 (t, J=5.9, 2H), 2.95-2.86 (t, J=5.9, 2H).

Example 327

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₂S, 440.09; m/z found, 441.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.56-8.53 (d, J=1.4, 2H), 8.34-8.31 (m, 1H), 7.99-7.95 (m, 1H), 7.63-7.59 (d, J=8.0, 1H), 7.59-7.53 (m, 1H), 7.36-7.34 (dd, J=7.1, 1.6, 1H), 7.34-7.32 (m, 1H), 2.97-2.71 (q, J=7.2, 2H), 1.15-0.84 (t, J=7.2, 3H).

Example 328

The title compound was prepared in a manner similar to that described in Example 88 using 1-((2-bromo-5-(trifluoromethyl)phenyl)sulfonyl)-4-methylpiperazine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₂₁F₄N₅O₂S, 495.14; m/z found, 496.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.63-8.61 (d, J=1.4, 2H), 8.40-8.37 (d, J=1.4, 1H), 8.10-8.05 (m, 1H), 7.70-7.67 (d, J=8.0, 1H), 7.67-7.63 (m, 1H), 7.46-7.30 (m, 2H), 2.86 (s, 3H), 3.83-2.53 (br m, 8H).

Example 329

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 5-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 391.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.4, 2H), 7.95 (s, 2H), 7.66-7.59 (m, 1H), 7.55-7.48 (m, 2H), 7.46-7.41 (m, 2H), 7.27-7.20 (m, 2H), 6.89 (s, 2H), 5.45 (s, 2H).

Example 330

The title compound was prepared using analogous conditions to those described in Example 213 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 390.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.4, 2H), 7.80 (d, J=5.8, 1H), 7.73-7.66 (m, 1H), 7.57-7.50 (m, 2H), 7.48-7.44 (m, 2H), 7.32-7.23 (m, 2H), 6.90-6.88 (m, 4H), 6.11 (d, J=5.8, 1H).

Example 331

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 5-amino-4-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₅FN₆S, 390.11; m/z found, 391.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, J=1.4, 2H), 8.16 (s, 1H), 7.92 (s, 1H), 7.59-7.49 (m, 3H), 7.49-7.44 (m, 2H), 7.30-7.20 (m, 2H), 6.89 (s, 2H), 5.44 (s, 2H).

Example 332

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and and 2-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₄FN₅S, 375.10; m/z found, 375.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.66 (s, 2H), 8.56 (d, J=4.9, 2H), 7.79-7.73 (m, 1H), 7.63-7.56 (m, 2H), 7.55-7.48 (m, 2H), 7.33-7.24 (m, 2H), 7.21 (m, 1H), 6.23 (s, 2H).

Example 333

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 2-chloropyrazine. MS (ESI): mass calcd. for C₂H₁₄FN₅S, 375.10; m/z found, 375.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.70-8.57 (m, 2H), 8.41 (dd, J=2.5, 1.6, 1H), 8.35 (d, J=2.6, 1H), 8.27 (d. J=1.5, 1H), 7.72 (dd. J=8.0, 1.2, 1H), 7.64-7.57 (m, 2H), 7.56-7.50 (m, 2H), 7.34 (d, J=11.8, 1H), 7.27 (d, J=8.0, 1H), 6.01 (s, 2H).

Example 334

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-amino-6-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 390.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.48 (d, J=1.4, 2H), 8.06 (s, 1H), 7.77-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.60-7.52 (m, 3H), 7.29 (dd, J=11.9, 1.5, 1H), 7.25 (dd, J=7.9, 1.7, 1H), 6.88 (s, 2H), 6.78 (s, 2H), 5.78 (d, J=0.9, 1H).

Example 335

The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 2-amino-4-chloropyrimidine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 390.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.3, 2H), 7.90 (d, J=5.3, 1 H), 7.78-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.59-7.51 (m, 3H), 7.30 (dd. J=11.8, 1.6, 1H), 7.25 (dd, J=7.9, 1.7, 1H), 6.89 (s, 2H), 6.64 (s, 2H), 5.86 (d, J=5.3, 1H).

Example 336

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 2-amino-6-chloropyrazine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 391.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.3, 2H), 7.67-7.60 (m, 1H), 7.59-7.51 (m, 3H), 7.49-7.46 (m, 2H), 7.31 (dd, J=11.9, 1.5, 1H), 7.26 (dd, J=7.9, 1.7, 1H), 7.18 (s, 1H), 6.90 (s, 2H), 6.57 (s, 2H).

Example 337

To a solution of 5-{2′-[(5-aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}-pyrimidin-2-amine (200 mg, 0.51 mmol) in MeCN/DCM/H₂O (5 mL/5 mL/5 mL) were added NalO₄ (326 mg, 1.50 mmol) and RuCl₃ (16 mg, 0.075 mmol). The reaction mixture was stirred at rt for 10 hours then poured into water (50 mL) and extracted with EtOAc (30 mL×3). The combined organic extracts were concentrated and purified by HPLC to give the title compound as a white solid. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O₂S, 422.10; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.57 (s, 2H), 8.30-8.25 (m, 2H), 8.22 (s, 1H), 7.83 (m, 1H), 7.77 (m, 1H), 7.44-7.33 (m, 2H), 6.88 (d, J=9.5, 2H), 6.29 (s, 2H).

Example 338

The title compound was prepared using analogous conditions to those described in Example 337 utilizing 5-[3-fluoro-2′-({[2-(trimethylsilyl)-ethoxy]methyl}-sulfanyl)-biphenyl-4-yl]pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₂₆FN₃O₃SSi, 459.14; m/z found, 460.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.63 (s, 2H), 8.19 (dd, J=7.9, 1.4, 1H), 7.79 (m, 1H), 7.70 (m, 1H), 7.59 (m, 1H), 7.46 (dd, J=7.5, 1.3, 1 H), 7.34-7.31 (m, 2H), 4.36 (s, 2H), 3.80-3.68 (m, 2H), 0.87-0.76 (m, 2H), 0.08 (s, 9H).

Example 339

The title compound was prepared using analogous conditions to those described in Example 337 utilizing 5-{2′-[(5-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt MS (ESI): mass calcd. for C₂₀H₁₅FN₆O₂S, 422.10; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.83 (s, 2H), 8.34 (dd, J=7.7, 1.5, 1H), 7.94 (s, 2H), 7.79-7.69 (m, 2H), 7.44 (m, 1H), 7.34 (dd, J=7.3, 1.4, 1H), 6.93 (dd, J=7.9, 1.6, 1H), 6.88 (dd, J=11.5, 1.5, 1H).

Example 340

The title compound was prepared using analogous conditions to those described in Example 6 utilizing utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (2-(((2-bromophenyl)thio)methoxy)ethyl)trimethylsilane. MS (ESI): mass calcd. for C₂₂H₂₆FN₃OSSi, 427.16; m/z found, 428.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.47 (d, J=1.4, 2H), 7.69 (dd, J=7.7, 1.1, 1H), 7.44 (m, 1H), 7.34-7.15 (m, 5H), 4.86 (s, 2H), 3.60-3.47 (m, 2H), 0.88-0.76 (m, 2H), 0.06 (s, 9H)

Example 341

Step A: 5-(4-Chloro-2-fluorophenyl)pyridin-2-amine

Solid 4-chloro-2-fluorobenzeneboronic acid (10.0 g, 57.4 mmol), 2-amino-5-bromopyridine (9.92 g, 57.4 mmol), palladium (II) trifluoroacetate (0.381 g, 1.15 mmol), and triphenylphosphine (0.602 g, 2.29 mmol) were combined in a 1 L flask under nitrogen, then toluene (150 mL), EtOH (150 mL), and 2 M Na₂CO₃ (100 mL) were added. The mixture was sparged with nitrogen for 30 min using a gas dispersion tube, then heated at 80° Celsius for 20 hours with vigorous stirring. The mixture was cooled to rt, diluted with EtOAc (200 mL), and transferred to a separatory funnel. The aqueous phase was removed, and the organic phase washed with brine. The combined aqueous phases were extracted with an equal volume of EtOAc, and the combined organic phases were dried and concentrated to dryness. The residue was subjected to FCC to provide 5-(4-chloro-2-fluorophenyl)pyridin-2-amine (9.10 g, 71%). MS (Cl): mass calcd. for C₁₁H₈CFN₂, 222.04; m/z found, 223.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.54-8.22 (s, 2H), 8.22-8.18 (d, J=2.1, 1H), 8.15-8.10 (m, 1H), 7.68-7.58 (m, 2H), 7.48-7.38 (m, 1H), 7.16-7.06 (d, J=9.3, 1H).

Step B: 5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine

5-(4-Chloro-2-fluorophenyl)pyridin-2-amine (100 mg, 0.449 mmol), 2-(methylsulfonyl)phenylboronic acid (112 mg, 0.561 mmol), and chloro(2-dicyclohexyl-phosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl)]palladium(II) (33 mg, 0.045 mmol) were placed in a sealable reaction tube under nitrogen. THF (2 mL, sparged with nitrogen) and K₃PO₄ (2 mL, 0.5 M sparged with nitrogen) were added, and the reaction vessel was sealed and heated at 60° Celsius for 16 hours with vigorous stirring. The mixture was cooled to rt, diluted with EtOAc, and washed with 2 M K₂CO₃, then dried and concentrated to dryness. The residue was subjected to FCC to provide the title compound (45 mg, 29%). MS (Cl): mass calcd. for C₁₈H₁₅FN₂O₂S, 342.08; m/z found, 343.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.38-8.31 (s, 1H), 8.29-8.22 (m, 1H), 7.77-7.71 (m, 1H), 7.71-7.65 (m, 1H), 7.64-7.57 (m, 1H), 7.52-7.45 (m, 1H). 7.42-7.37 (m, 1H), 7.36-7.27 (m, 2H), 6.64-6.59 (m, 1H), 4.66-4.51 (s, 2H), 2.81-2.69 (s, 2H).

Example 342

The title compound was prepared in a manner similar to that described in Example 341, using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C₂₁H₂₂FN₃O₂S, 399.14; m/z found, 400.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.22-8.13 (s, 1H), 8.10-8.03 (d, J=7.8, 1H), 7.67-7.57 (m, 3H), 7.53-7.48 (m, 1H), 7.40-7.36 (d, J=7.4, 1H), 7.31-7.22 (m, 2H), 6.94-6.89 (s, 1H), 6.60-6.52 (d, J=8.6, 1H), 6.24-6.11 (s, 2H), 1.07-0.99 (s, 9H).

Example 343

The title compound was prepared in a manner similar to that described in Example 341, using (2-(N,N-diethylsulfamoyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C₂₁H₂₂FN₃O₂S, 399.14; m/z found, 400.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.28-8.22 (d, J=1.9, 1H), 8.18-8.12 (d, J=9.3, 1H), 8.12-7.88 (m, 1H), 7.76-7.69 (m, 1H), 7.68-7.59 (m, 2H), 7.43-7.38 (dd, J=7.5, 1.1, 1H), 7.37-7.32 (m, 1H), 7.32-7.27 (m, 1H), 7.09-7.04 (d, J=9.2, 1H), 2.99-2.90 (m, 3H), 1.00-0.90 (m, 4H).

The title compound was prepared in a manner similar to that described in

Example 344

The title compound was prepared in a manner similar to that described in Example 341, using (2-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C₂₁H₂₀FN₃O₂S, 397.13; m/z found, 398.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.37-8.11 (m, 4H), 8.01-7.95 (m, 1H), 7.77-7.71 (m, 1H), 7.69-7.61 (m, 2H), 7.44-7.36 (m, 2H), 7.35-7.30 (m, 1H), 7.15-7.10 (d, J=9.3, 1H), 2.99-2.80 (m, 4H), 1.77-1.62 (m, 4H).

Example 345

The title compound was prepared in a manner similar to that described in Example 341, using (2-(piperidin-1-ylsulfonyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C₂₂H₂₂FN₃O₂S, 411.14; m/z found, 412.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d) δ 8.47-8.16 (m, 4H), 8.02-7.96 (m, 1H), 7.79-7.72 (m, 1H), 7.71-7.60 (m, 2H), 7.46-7.36 (m, 2H), 7.35-7.29 (m, 1H), 7.16-7.11 (d, J=9.3, 1H), 2.86-2.74 (m, 4H), 1.45-1.27 (m, 6H).

Example 346

Step A: (4-(6-Aminopyridin-3-yl)-3-fluorophenyl)boronic acid

5-(4-Chloro-2-fluorophenyl)pyridin-2-amine (2.0 g, 9.0 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.9 g, 11.0 mmol), chloro(2-dicyclohexyl-phosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.14 g, 0.18 mmol), and KOAc (2.7 g, 27 mmol) were combined in a sealable reaction vessel under nitrogen, and then treated with anhydrous 1,4-dioxane (100 mL, sparged with nitrogen). The vessel was sealed and then heated at 80° Celsius for 16 hours. The mixture was cooled to rt, HCl (1 m, 50 mL) was added and the mixture stirred for 20 min. The mixture was then diluted with EtOAc (200 mL) and the aqueous phase was collected. The organic phase was extracted with 1 M HCl (2×75 mL). The combined aqueous phases were cooled in an icebath and the pH was adjusted to ca. 7 using solid sodium bicarbonate. The resulting precipitate was collected by filtration, washed well with water, and dried to provide the title compound (2.1 g, 98%). MS (Cl): mass calcd. for C₁₁H₁₀BFN₂O₂, 232.08; m/z found, 233.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.29-8.20 (s, 2H), 8.18-8.13 (s, 1H), 7.80-7.72 (m, 1H), 7.69-7.63 (m, 1H), 7.63-7.57 (m, 1H), 7.51-7.44 (m, 1H), 6.84-6.57 (m, 3H).

Step B: 4′-(6-Aminopyridin-3-yl)-N-cyclohexyl-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide

A mixture of (4-(6-aminopyridin-3-yl)-3-fluorophenyl)boronic acid (75 mg, 0.32 mmol), 2-bromo-N-cyclohexylbenzenesulfonamide (0.11 g, 0.36 mmol), 1,1′-bis[di-tert-butylphosphino)ferrocene]palladium(II) chloride (11 mg, 0.016 mmol), K₂CO₃ (2 M, 1.6 mL, sparged with nitrogen) and THF (2 mL, sparged with nitrogen) were combined in a sealed vessel under nitrogen. The mixture was vigorously stirred at rt for 16 hours, then diluted with EtOAc. The aqueous phase was removed and the organic layer was dried and concentrated. The residue was subjected to FCC to provide the title compound (15 mg, 11%). MS (Cl): mass calcd. for C₂₃H₂₄FN₃O₂S, 425.16; m/z found, 426.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.20-8.14 (s, 1H), 8.05-7.96 (m, 1H), 7.70-7.57 (m, 3H), 7.55-7.47 (m, 1H), 7.44-7.35 (m, 2H), 7.30-7.20 (m, 2H), 6.59-6.52 (d, J=8.6, 1H), 6.23-6.11 (s, 2H), 2.83-2.69 (d, J=7.4, 1H), 1.68-1.52 (m, 4H), 1.49-1.38 (s, 1H), 1.19-0.92 (m, 6H).

Example 347

A mixture of (4-(6-aminopyridin-3-yl)-3-fluorophenyl)boronic acid (100 mg, 0.43 mmol), (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide (160 mg, 0.54 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (18 mg, 0.022 mmol), K₂CO₃ (340 mg, 2.4 mmol), and DMSO (3 mL) was sparged with nitrogen, then the reaction vessel was sealed and heated at 80° Celsius for 16 hours. The mixture was cooled to rt, then filtered, and subjected to HPLC purification to provide the title compound. MS (Cl): mass calcd. for C₂₀H₂₀FN₃O₃S, 401.12; m/z found, 402.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.31-7.93 (m, 5H), 7.72-7.57 (m, 3H), 7.42-7.25 (m, 4H), 7.11-7.04 (d, J=9.2, 1H), 3.34-3.25 (s, 1H), 3.18-3.00 (m, 2H), 1.00-0.91 (d, J=6.5, 3H).

Example 348

The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-iso-butylbenzenesulfonamide. MS (Cl): mass calcd. for C₂₁H₂₂FN₃O₂S, 399.14; m/z found, 400.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₅) δ 8.26-8.19 (d, J=2.1, 1H), 8.18-8.11 (d, J=9.2, 1H), 8.08-7.79 (m, 3H), 7.72-7.53 (m, 4H), 7.43-7.30 (m, 3H), 7.08-7.00 (d, J=9.2, 1H), 2.57-2.52 (m, 2H), 1.66-1.56 (m, 1H), 0.82-0.75 (d, J=6.7, 6H).

Example 349

The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-(tert-pentyl)benzenesulfonamide. MS (Cl): mass calcd. for C₂₂H₂₄FN₃O₂S, 413.16; m/z found, 414.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.23-8.19 (d, J=2.0, 1H), 8.19-8.11 (d, J=9.0, 1H), 8.10-8.05 (m, 1H), 8.05-7.79 (s, 2H), 7.69-7.57 (m, 3H), 7.40-7.29 (m, 3H), 7.09-7.02 (d, J=9.2, 1H), 6.98-6.91 (s, 1H), 1.48-1.36 (m, 2H), 1.04-0.91 (s, 6H), 0.79-0.67 (m, 3H).

Example 350

The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-(1,1,1-trifluoro-2-methylpropan-2-yl)benzenesulfonamide. MS (Cl): mass calcd. for C₂₁H₁₉F₄N₃O₂S, 453.11; m/z found, 454.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.28-8.19 (m, 2H), 8.17-8.11 (d, J=9.1, 1H), 8.07-8.02 (m, 1H), 8.03-7.80 (s, 2H), 7.74-7.65 (m, 2H), 7.64-7.58 (m, 1H), 7.43-7.39 (m, 1H), 7.38-7.32 (m, 1H), 7.32-7.28 (dd, J=7.9, 1.7, 1H), 7.07-7.00 (d, J=9.2, 1H), 1.29-1.17 (s, 6H).

Example 351

The title compound was prepared in a manner similar to that described in Example 347 using (S)-2-bromo-N-(2,2,2-trifluoro-1-phenylethyl)benzenesulfonamide. MS (Cl): mass calcd. for C₂₅H₁₉F₄N₃O₂S, 501.11; m/z found, 502.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 9.32-9.24 (d, J=10.1, 1H), 8.24-8.20 (d, J=2.1, 1H), 8.20-8.11 (d, J=9.2, 1H), 8.11-7.90 (s, 2H), 7.90-7.85 (m, 1H), 7.64-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.49-7.40 (m, 3H), 7.40-7.31 (m, 3H), 7.29-7.24 (dd, J=7.6, 1.2, 1H), 7.15-7.03 (m, 3H), 5.22-4.90 (m, 1H).

Example 352

The title compound was prepared in a manner similar to that described in Example 347 using (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (Cl): mass calcd. for C₂₀H₂₀FN₃O₃S, 401.12; m/z found, 402.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.26-8.20 (d, J=2.1, 1H), 8.19-8.11 (d, J=9.2, 1H), 8.09-8.05 (m, 1H), 8.05-7.84 (s, 2H), 7.72-7.58 (m, 3H), 7.41-7.35 (m, 2H), 7.35-7.27 (m, 2H), 7.08-7.02 (d, J=9.2, 1H), 5.05-4.29 (m, 1H), 3.34-3.27 (dd, J=10.3, 5.0, 1H), 3.14-3.02 (m, 2H), 1.00-0.93 (d, J=6.5, 3H).

Example 353

The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-(1-methylcyclobutyl)benzenesulfonamide. MS (Cl): mass calcd. for C₂₂H₂₂FN₃O₂S, 411.14; m/z found, 412.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.24-8.20 (s, 1H), 8.20-8.15 (d, J=9.5, 1H), 8.15-7.90 (m, 3H), 7.70-7.58 (m, 3H), 7.55-7.51 (s, 1H), 7.41-7.28 (m, 3H), 7.10-7.05 (d. J=9.2, 1H), 2.15-2.05 (m, 2H), 1.71-1.51 (m, 4H), 1.26-1.18 (s, 3H).

Example 354

The title compound was prepared in a manner similar to that described in Example 347 using 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (Cl): mass calcd. for C₂₁H₂₀FN₃O₄S₂, 461.09; m/z found, 462.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.27-8.21 (d, J=2.0, 1H), 8.20-8.14 (d, J=9.1, 1H), 8.13-7.88 (m, 3H), 7.82-7.76 (m, 1H), 7.72-7.62 (m, 2H), 7.48-7.39 (m, 2H), 7.37-7.31 (m, 1H), 7.10-7.02 (d, J=9.2, 1H), 3.12-3.04 (m, 4H), 3.34-3.26 (m, 4H).

Example 355

The title compound was prepared in a manner similar to that described in Example 347 using (S)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (Cl): mass calcd. for C₂₀H₁₇F₄N₃O₂S, 439.10; m/z found, 440.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.56-8.49 (d, J=8.9, 1H), 8.26-8.20 (s, 1H), 8.20-8.12 (d, J=9.5, 1H), 8.09-7.82 (m, 3H), 7.74-7.59 (m, 3H), 7.42-7.37 (m, 1H), 7.36-7.27 (m, 2H), 7.09-7.01 (d, J=9.1, 1H), 3.98-3.86 (m, 1H), 1.22-1.11 (d, J=7.0, 3H).

Example 356

The title compound was prepared in a manner similar to that described in Example 347 using (1S,4S)-5-((2-bromophenyl)sulfonyl)-2-oxa-5-azabicyclo[2.2.1]heptane. MS (Cl): mass calcd. for C₂₂H₂₀FN₃O₃S, 425.12; m/z found, 426.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.27-8.23 (d, J=2.0, 1H), 8.20-8.15 (d, J=9.2, 1H), 8.15-7.89 (m, 3H), 7.79-7.74 (m, 1H), 7.70-7.62 (m, 2H), 7.47-7.38 (m, 2H), 7.37-7.32 (m, 1H), 7.10-7.03 (d, J=9.2, 1H), 4.53-4.47 (s, 1H), 4.01-3.96 (s, 1H), 3.63-3.30 (m, 2H), 2.99-2.87 (m, 2H), 1.72-1.61 (d, J=10.0, 1H), 1.47-1.36 (m, 1H).

Example 357

The title compound was prepared in a manner similar to that described in Example 347 using tert-butyl 3-((2-bromophenylsulfonamido)methyl)-3-hydroxyazetidine-1-carboxylate. MS (Cl): mass calcd. for C₂₆H₂₉FN₄O₅S, 528.18; m/z found, 529.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.26-8.21 (d, J=2.0, 1H), 8.20-8.13 (d, J=9.4, 1H), 8.11-7.86 (m, 3H), 7.86-7.80 (m, 1H), 7.74-7.67 (m, 1H), 7.67-7.58 (m, 2H), 7.44-7.31 (m, 3H), 7.09-7.02 (d, J=9.1, 1H), 3.79-3.73 (m, 2H), 3.55-3.52 (m, 2H), 2.93-2.86 (d, J=6.5, 2H), 1.40-1.28 (s, 9H).

Example 358

A mixture of tert-butyl 3-((2-bromophenylsulfonamido)methyl)-3-hydroxyazetidine-1-carboxylate (15 mg, 0.028 mmol), TFA (1 mL), and MeOH (1 mL) was maintained at rt for 2 hours, then concentrated to dryness. The residue was purified by HPLC to provide the title compound (8.0 mg, 52%) MS (Cl): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.84-8.70 (s, 1H), 8.68-8.52 (s, 1H), 8.26-8.19 (d, J=2.1, 1H), 8.13-8.03 (d, J=7.4, 1H), 8.01-7.94 (m, 1H), 7.94-7.88 (m, 1H), 7.74-7.71 (m, 1H), 7.69-7.65 (m, 1H), 7.63-7.59 (m, 1H), 7.48-7.42 (m, 1H), 7.42-7.31 (m, 2H), 7.05-6.91 (d, J=8.8, 1H), 6.33-6.17 (s, 1H), 3.94-3.87 (m, 2H), 3.76-3.69 (m, 2H), 3.05-3.00 (d, J=6.5, 2H).

Example 359

The title compound was prepared in a manner similar to that described in Example 347 using 2-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)ethanol. MS (Cl): mass calcd. for C₂₄H₂₆FN₃O₃S, 455.17; m/z found, 456.3 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.24-8.20 (d, J=2.2, 1H), 8.17-8.09 (d, J=9.1, 1H), 8.02-7.98 (m, 1H), 3.37-3.36 (m, 5H), 7.97-7.78 (s, 2H), 7.77-7.73 (m, 1H), 7.69-7.64 (m, 1H), 7.64-7.59 (m, 1H), 7.44-7.41 (m, 1H), 7.41-7.35 (m, 1H), 7.34-7.30 (dd, J=7.9, 1.7, 1H), 7.07-6.99 (d, J=9.2, 1H), 3.40-3.34 (m, 3H), 3.25-3.21 (d, J=12.3, 2H), 2.43-2.34 (m, 2H), 1.59-1.50 (d, J=10.7, 2H), 1.45-1.31 (s, 1H), 1.31-1.20 (m, 2H), 0.89-0.78 (m, 2H).

Example 360

The title compound was prepared in a manner similar to that described in Example 347 using 1-((2-bromophenyl)sulfonyl)piperidin-4-ol. MS (Cl): mass calcd. for C₂₂H₂₂FN₃O₃S, 427.14; m/z found, 428.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.26-8.22 (d, J=2.0, 1H), 8.19-8.15 (d, J=9.4, 1H), 8.14-7.92 (m, 3H), 7.78-7.73 (m, 1H), 7.69-7.65 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.40 (dd, J=7.6, 1.2, 1H), 7.40-7.35 (m, 1H), 7.33-7.28 (m, 1H), 7.09-7.04 (d, J=9.2, 1H), 3.54-3.52 (m, 2H), 3.09-3.01 (m, 2H), 2.69-2.61 (m, 2H), 1.64-1.53 (m, 2H), 1.28-1.17 (m, 2H).

Example 361

The title compound was prepared in a manner similar to that described in Example 347 using (1-((2-bromophenyl)sulfonyl)piperidin-4-yl)methanol. MS (Cl): mass calcd. for C₂₃H₂₄FN₃O₃S, 441.15; m/z found, 442.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.26-7.94 (m, 5H), 7.78-7.72 (m, 1H), 7.70-7.60 (m, 2H), 7.45-7.36 (m, 2H), 7.34-7.30 (dd, J=8.0, 1.6, 1H), 7.10-7.04 (d, J=9.2, 1H), 3.29-3.24 (d, J=12.4, 2H), 3.19-3.14 (d, J=6.3, 2H), 2.45-2.36 (m, 2H), 1.60-1.52 (d, J=10.7, 2H), 1.41-1.29 (s, 1H), 0.94-0.78 (m, 2H).

Example 362

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₀FN₃O₃S, 425.12; m/z found, 426.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 9.57 (s, 1H), 8.29-8.22 (m, 2H), 7.95-7.85 (m, 1H), 7.69-7.61 (m, 1H), 7.61-7.53 (m, 1H), 7.42-7.33 (m, 4H), 7.29 (d, J=7.8, 1H), 6.54-6.49 (m, 1H), 5.92 (d, J=6.7, 1H), 3.64-3.51 (m, 1H), 3.47-3.34 (m, 2H), 2.34 (s, 1H), 1.03 (d, J=6.5, 3H).

Example 363

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₀FN₃O₃S, 425.12; m/z found, 426.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) 89.65 (s, 1H), 8.30-8.19 (m, 2H), 7.93-7.84 (m, 1H), 7.69-7.61 (m, 1H), 7.61-7.53 (m, 1H), 7.44-7.31 (m, 4H), 7.27 (d, J=7.8, 1H), 6.56-7.47 (m, 1H), 6.07 (d, J=6.5, 1H), 3.57 (t, J=7.0, 1 H), 3.49-3.32 (m, 2H), 2.41 (s, 1H), 1.04 (d, J=6.4, 3H).

Example 364

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₃H₁₉FN₄O₃S, 450.12; m/z found, 451.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: 6 9.35 (s), 9.23 (s), 8.51-8.42 (m), 8.41-8.31 (m), 8.24-8.17 (m), 8.13-8.00 (m), 7.68-7.61 (m), 7.59-7.49 (m), 7.46-7.38 (m), 7.38-7.29 (m), 6.57-6.51 (m), 6.38 (s), 6.13 (s), 6.05 (s), 5.68 (s), 3.69-3.57 (m), 3.40-3.18 (m), 2.61-2.48 (m), 2.25-1.96 (m).

Example 365

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C₂₂H₁₇FN₂O₂S, 392.10; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.26 (s, 1H), 8.62-8.52 (m, 1H), 8.24-8.12 (m, 2H), 7.71-7.63 (m, 1H), 7.62-7.53 (m, 2H), 7.45-7.31 (m, 4H), 6.64-6.55 (m, 1H), 2.19-2.08 (m, 1H), 1.18-1.08 (m, 2H), 0.93-0.82 (m, 2H).

Example 366

The title compound was prepared in a manner similar to that described in Example 88 using 5-bromo-1H-pyrrolo[2,3-b]pyridine and 3′-fluoro-N-(2-hydroxyethyl)-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C₂₁H₁₈FN₃O₃S, 411.11; m/z found, 412.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.44-8.41 (m, 1H), 8.24-8.21 (m, 1H), 8.14-8.05 (dd, J=8.0, 1.3, 1H), 7.71-7.64 (m, 1H), 7.63-7.55 (m, 2H), 7.46-7.44 (d, J=3.5, 1H), 7.44-7.41 (dd, J=7.6, 1.2, 1H), 7.36-7.34 (dd, J=3.8, 1.7, 1H), 7.34-7.31 (dd, J=7.3, 1.4, 1H), 6.59-6.55 (d, J=3.5, 1H), 3.52-3.47 (t, J=5.9, 2H), 2.92-2.87 (t. J=5.9, 2H).

Example 367

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-1H-pyrrolo[2,3-b]pyridine. MS (ESI): mass calcd. for C₂₃H₂₂FN₃O₂S, 423.14; m/z found, 424.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.56-8.45 (m, 2H), 8.18-8.11 (dd, J=8.0, 1.3, 1H), 7.70-7.61 (m, 2H), 7.61-7.55 (m, 3H), 7.44-7.35 (m, 3H), 6.76-6.69 (d, J=3.5, 1H), 1.09 (s, 9H).

Example 368

The title compound was prepared by forming N-tert-butyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide then removing the tert-butyl group by dissolving the crude N-tert-butyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide in 1 mL of trifluoroacetic acid and heating it at 60° Celsius for 2 hours, after which time the reaction was cooled, concentrated to dryness and purified using FCC. MS (ESI): mass calcd. for C₁₉H₁₄FN₃O₂S, 367.08; m/z found, 368.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43 (s, 1H), 8.26-8.22 (m, 1H), 8.17-8.12 (dd, J=8.0, 1.3, 1H), 7.69-7.62 (m, 1H), 7.62-7.55 (m, 2H), 7.47-7.44 (d, J=3.5, 1H), 7.44-7.40 (dd, J=7.6, 1.4, 1H), 7.38-7.30 (m, 2H), 6.60-6.56 (d, J=3.5, 1H).

Example 369

Step A: 2-(4-Bromo-2-fluorphenyl)-5H-pyrrolo[2,3-b]pyrazine

To a 150 mL screw-cap vessel under nitrogen was added 5-bromo-4,7-diazaindole (1.0 g, 5.05 mmol), 4-bromo-2-fluorophenyl boronic acid (1.33 g, 6.06 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (0.2 g, 0.24 mmol), K₂CO₃ (2.09 g, 15.2 mmol), 1,4-dioxane (35 mL) and water (13 mL). The mixture was sparged with nitrogen for 10 minutes, the vessel capped and the reaction heated at 95° Celsius for 24 hours. The reaction was then cooled to rt, diluted with ethyl acetate (200 mL) and washed with water (1×100 mL) and brine (1×100 mL). The organic layer was dried with Na₂SO₄ and evaporated to dryness. The crude product was purified by HPLC giving the title compound (515 mg, 35%). MS (ESI): mass calcd. for C₁₂H₇BrFN₂, 290.98; m/z found, 292.0 [M+H]⁺.

Step B

To a mixture of 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine (50 mg, 0.17 mmol), N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-methane-sulfonamide (61 mg, 0.21 mmol) and Pd(dppf)Cl₂.CH₂Cl₂ (6.7 mg, 0.009 mmol) in a microwave vial were added acetonitrile (2.0 mL) and sat. NaHCO₃ (2.0 mL). The vial was sparged with nitrogen for 5 min then heated at 110° Celsius for 90 min via microwave irradiation. After cooling to rt, the reaction mixture was diluted with ethyl acetate (50 mL), washed with water (25 mL) and brine (25 mL), dried (Na₂SO₄) and concentrated to dryness. The crude product was purified by HPLC giving the title compound (45 mg, 69%). MS (ESI): mass calcd. for C₁₉H₁₅FN₄O₂S, 382.09; m/z found, 383.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 10.38 (s, 1H), 8.78 (d, J=2.7, 1H), 8.20-8.12 (m, 1H), 7.71-7.64 (m, 2H), 7.48-7.39 (m, 1H), 7.37-7.31 (m, 2H), 7.28-7.21 (m, 2H), 6.91 (s, 1H), 6.81-6.75 (m, 1H), 2.93 (s, 3H).

Example 370

The title compound was prepared using methods analogous to those described in Example 369 using N,N-dimethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide in Step B. MS (ESI): mass calcd. for C₂₀H₁₇FN₄O₂S, 396.11; m/z found, 397.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 10.57 (s, 1H), 8.79 (d, J=2.6, 1H), 8.15-8.04 (m, 2H), 7.69-7.59 (m, 2H), 7.58-7.51 (m, 1H), 7.41-7.31 (m, 3H), 6.81-6.74 (m, 1H), 2.48 (s, 6H).

Example 371

The title compound was prepared using methods analogous to those described in Example 369 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 425.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.69 (d, J=2.6, 1H), 8.13-8.04 (m, 1H), 8.03-7.93 (m, 2H), 7.74-7.55 (m, 2H), 7.47-7.32 (m, 3H), 7.02 (s, 1H), 6.73 (d, J=3.6, 1H), 1.04 (s, 9H).

Example 372

The title compound was prepared using methods analogous to those described in Example 369 using (2-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₂H₁₉FN₄O₂S, 422.12; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.22 (br s, 1H), 8.83 (d, J=2.5, 1H), 8.24 (d, J=2.5, 1H), 8.19-8.13 (m, 1H), 8.14-8.07 (m, 1H), 7.96-7.90 (m, 1H), 7.72-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.57-7.49 (m, 1H), 7.49-7.30 (m, 1H), 6.88-6.79 (m, 1H), 3.02-2.90 (m, 3H), 1.77-1.66 (m, 3H), 1.59 (s, 2H).

Example 373

The title compound was prepared using methods analogous to those described in Example 369 using (2-(N,N-diethylsulfamoyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 425.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.23 (s, 1H), 8.83 (d, J=2.5, 1H), 8.15-8.05 (m, 2H), 7.71-7.66 (m, 1H), 7.63-7.56 (m, 1H), 7.55-7.48 (m, 1H), 7.39-7.30 (m, 3H), 6.86-6.82 (m, 1H), 3.03-2.88 (m, 4H), 1.00 (t, J=7.15, 6H).

Example 374

The title compound was prepared using methods analogous to those described in Example 369 using (2-(piperidin-1-ylsulfonyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₃H₂₁FN₄O₂S, 436.14; m/z found, 437.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.20 (s, 1H), 8.83 (d, J=2.5, 1H), 8.18-8.03 (m, 2H), 7.71-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.41-7.32 (m, 3H), 6.87-6.82 (m, 1H), 2.93-2.81 (m, 4H), 1.46-1.36 (m, 6H).

Example 375

The title compound was prepared using methods analogous to those described in Example 369 using (2-(morphilinosulfonyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₂H₁₉FN₄O₃S, 438.12; m/z found, 439.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 10.69 (s, 1H), 8.79 (d, J=2.6, 1H), 8.17-8.06 (m, 2H), 7.71-7.61 (m, 2H), 7.61-7.53 (m, 1H), 7.44-7.33 (m, 3H), 6.80-6.74 (m, 1H), 3.54-3.45 (m, 4H), 2.94-2.83 (m, 4H).

Example 376

To a mixture of 2-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5H-pyrrolo[2,3-b]pyrazine (32 mg, 0.09 mmol), racemic 2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide (38 mg, 0.11 mmol) and Pd(dppf)Cl₂.CH₂Cl₂ (6 mg, 0.007 mmol) in a microwave vial were added acetonitrile (2.0 mL) and sat. NaHCO₃ (2.0 mL). The mixture was sparged with nitrogen for 5 min and then the vial capped and heated at 110° Celsius for 90 min. After cooling, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with water (25 mL) and brine (25 mL). The organic layer was dried (Na₂SO₄) and concentrated to dryness. The crude product was purified by HPLC to give the title compound (28 mg, 64%). MS (ESI): mass calcd. C₂₁H₁₆F₄N₄O₂S, 464.09; m/z found, 465.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.81 (s, 1H), 8.47 (s, 1H), 8.27-8.17 (m, 1H), 7.75-7.41 (m, 5H), 7.40-7.32 (m, 2H), 7.20 (d, J=12.6, 1H), 6.74-6.67 (m, 1H), 4.12-3.94 (m, 1H), 1.39-1.19 (m, 3H).

Example 377

Step A: 2-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine

The title compound was prepared using methods analogous to those described in Example 369 using (2-(methylthio)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₁₉H₁₄FN₃S., 335.09; m/z found, 336.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.97 (s, 1H), 8.81 (d, J=2.5, 1H), 8.11-8.01 (m, 1H), 7.69-7.63 (m, 1H), 7.44-7.19 (m, 6H), 6.87-6.82 (m, 1H), 2.41 (s, 3H).

Step B

To a 10 mL round bottomed flask under nitrogen at rt were added 2-[3-fluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine (32 mg, 0.07 mmol), m-CPBA (0.33 mg, 0.19 mmol) and DCM (1 mL). The mixture was stirred at rt for 2 hours. An additional 0.5 equivalents of mCPBA was added at this time and the reaction stirred an additional 1 hour. The reaction was then poured into sat. NaHCO₃ and extracted with DCM (×2). The solvent was then removed and the crude product purified by HPLC to give the title compound (12 mg, 35%). MS (ESI): mass calcd. for C₁₉H₁₄FN₃O₂S, 481.08; m/z found, 368.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.48 (s, 1H), 8.82 (s, 1H), 8.27 (d, J=8.0, 1H), 8.18-8.09 (m, 1H), 7.77-7.67 (m, 2H), 7.66-7.57 (m, 1H), 7.48-7.36 (m, 3H), 6.89-6.83 (m, 1H), 2.76 (s, 3H).

Example 378

The title compound was prepared using methods analogous to those described in Example 376 using (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. C₂₁H₁₉FN₄O₃S, 426.12; m/z found, 427.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.40 (s, 1H), 8.74 (d, J=2.7, 1H), 8.60 (s, 1H), 8.29-8.20 (m, 1H), 7.83-7.74 (m, 1H), 7.71-7.62 (m, 2H), 7.61-7.50 (m, 1H), 7.47-7.36 (m, 2H), 7.35-7.16 (m, 1H), 5.50 (s, 1H), 3.65-3.49 (m, 1H), 3.48-3.28 (m, 2H), 2.16-1.94 (m, 1H), 1.04 (d, J=6.6, 3H).

Example 379

The title compound was prepared using methods analogous to those described in Example 376 using 2-bromo-N-methylbenzenesulfonamide. MS (ESI): mass calcd. C₁₉H₁₅FN₄O₂S, 382.09; m/z found, 383.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.35 (s, 1H), 8.67 (d, J=2.2, 1H), 8.29-8.18 (m, 1H), 8.03-7.83 (m, 1H), 7.71-7.55 (m, 3H), 7.47-7.29 (m, 3H), 6.83-6.73 (m, 1H), 4.85 (s, 1H), 2.56 (d, J=5.2, 3H).

Example 380

The title compound was prepared using methods analogous to those described in Example 376 using (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. C₂₁H₁₉FN₄O₃S, 426.12; m/z found, 427.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.40 (s, 1H), 8.74 (d, J=2.7, 1H), 8.60 (s, 1H), 8.29-8.20 (m, 1H), 7.83-7.74 (m, 1H), 7.71-7.62 (m, 2H), 7.61-7.50 (m, 1H), 7.47-7.36 (m, 2H), 7.35-7.16 (m, 1H), 5.50 (s, 1H), 3.65-3.49 (m, 1H), 3.48-3.28 (m, 2H), 2.16-1.94 (m, 1H), 1.04 (d, J=6.6, 3H).

Example 381

Step A: tert-Butyl (1-((3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)-[1,1′-biphenyl]-2-yl)-sulfonyl)piperidin-4-yl)carbamate

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and tert-butyl (1-((2-bromophenyl)sulfonyl)piperidin-4-yl)carbamate. MS (ESI): mass calcd. for C₂₈H₃₀FN5O4S, 551.20; m/z found, 552.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.04 (s, 1H), 8.81 (d. J=2.4, 1H), 8.18-8.04 (m, 2H), 7.69-7.59 (m, 2H), 7.60-7.48 (m, 1H), 7.48-7.30 (m, 4H), 6.85 (dd, J=3.7, 1.9, 1H), 4.44 (d, J=8.2, 1H), 3.79 (d, J=13.2, 1H), 3.49-3.27 (m, 3H), 2.91 (t, J=11.7, 1H), 2.47 (t, J=12.2, 2H), 1.98 (d, J=13.4, 1H), 1.79 (d, J=11.8, 2H), 1.42 (d, J=9.5, 12H), 1.31-1.10 (m, 3H).

Step B

The title compound was prepared as described in the preparation of Example 247 using tert-butyl (1-((3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-yl)carbamate. MS (ESI): mass calcd. for C₂₃H₂₂FN₅O₂S, 451.15; m/z found, 452.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.66 (s, 1H), 8.82 (d, J=2.5, 1 H), 8.20-8.04 (m, 2H), 7.69 (d, J=3.7, 1H), 7.66-7.59 (m, 1H), 7.58-7.51 (m, 1H), 7.42-7.32 (m, 3H), 6.83 (d, J=3.7, 1H), 3.43-3.30 (m, 2H), 2.70-2.59 (m, 1H), 2.55-2.40 (m, 2H), 1.75-1.65 (m, 2H), 1.56 (br s, 2H), 1.24-1.07 (m, 2H).

Example 382

The title compound was prepared using methods analogous to those described in Example 376 using 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₂₂H₁₉FN₄O₄S₂, 486.08; m/z found, 487.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.19 (s, 1H), 8.83 (d, J=2.5, 1H), 8.22-8.11 (m, 2H), 7.75-7.65 (m, 2H), 7.64-7.55 (m, 1H), 7.43-7.37 (m, 1H), 7.34-7.21 (m, 2H), 6.88-6.80 (m, 1H), 3.45-3.26 (m, 4H), 3.09-2.94 (m, 4H).

Example 383

The title compound was prepared using methods analogous to those described in Example 369 using (5-fluoro-2-(methylthio)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₁₉H₁₃F₂N₃S, 353.08; m/z found, 354.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.98 (s, 1H), 8.82 (d, J=2.6, 1H), 8.14-8.05 (m, 1H), 7.70-7.63 (m, 1H), 7.41-7.28 (m, 3H), 7.13-7.01 (m, 2H), 6.87-6.80 (m, 1H), 2.36 (s, 3H).

Example 384

The title compound was prepared using methods analogous to those described in Example 369 using (2-(ethylthio)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₀H₁₆FN₃S, 349.10: m/z found, 350.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.12 (s, 1H), 8.83 (d, J=2.6, 1H), 8.11-8.02 (m, 1H), 7.69-7.63 (m, 1H), 7.44-7.21 (m, 6H), 6.86-6.81 (m, 1H), 2.85 (q, J=7.4, 2H), 1.26 (t, J=7.4, 3H).

Example 385

The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 1-bromo-2-(methylsulfonyl)benzene. MS (ESI): mass calcd. for C₂₀H₁₇FN₂O₃S, 384.09; m/z found, 385.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.27-8.24 (m, 1H), 7.99-7.93 (m, 1H), 7.71-7.65 (m, 1H), 7.63-7.57 (m, 1H), 7.47 (m, 1H), 7.41-7.38 (m, 1H), 7.33-7.27 (m, 3H), 4.32-4.24 (m, 2H), 3.67-3.59 (m, 2H), 2.76 (s, 3H).

Example 386

The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 1-((2-bromophenyl)sulfonyl)piperidine. MS (ESI): mass calcd. for C₂₄H₂₄FN₃O₃S, 453.15; m/z found, 454.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.07-8.03 (m, 1H), 7.82 (d, J=1.0, 1H), 7.73-7.67 (m, 2H), 7.65-7.55 (m, 2H), 7.42-7.39 (m, 1H), 7.36-7.30 (m, 2H), 4.41-4.32 (m, 2H), 3.74-3.71 (m, 2H), 2.91-2.79 (m, 4H), 1.49-1.37 (m, 6H).

Example 387

The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆FN₃O₃S, 385.09; m/z found, 386.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.14-8.11 (m, 1H), 7.80 (d, J=1.0, 1H), 7.73-7.71 (m, 1H), 7.68-7.62 (m, 1H), 7.61-7.52 (m, 2H), 7.39-7.31 (m, 3H), 4.40-4.34 (m, 2H), 3.75-3.69 (m, 2H).

Example 388

The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₂FN₃O₄S, 443.13; m/z found, 444.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.15-8.12 (m, 1H), 7.80 (m, 1H), 7.72 (d, J=1.3, 1H), 7.69-7.64 (m, 1H), 7.62-7.52 (m, 2H), 7.40-7.33 (m, 3H), 4.37 (t, J=4.6, 2H), 3.76-3.69 (m, 2H), 3.43-3.36 (m, 1H), 3.30-3.26 (m, 1H), 3.24-3.16 (m, 1H), 1.04-1.01 (m, 3H).

Example 389

The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 1-((2-bromophenyl)sulfonyl)piperidin-4-amine. MS (ESI): mass calcd. for C₂₄H₂₅FN₄O₃S, 468.16; m/z found, 469.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.09-8.05 (m, 1H), 7.83 (d, J=1.1, 1H), 7.75-7.68 (m, 2H), 7.66-7.55 (m, 2H), 7.43-7.39 (m, 1H), 7.34-7.26 (m, 2H), 4.39-4.35 (m, 2H), 3.76-3.68 (m, 2H), 3.47 (d, J=13.4, 2H), 3.21-3.11 (m, 1H), 2.60-2.50 (m, 2H), 1.96-1.87 (m, 2H), 1.56-1.43 (m, 2H).

Example 390

The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₂FN₃O₄S, 443.13; m/z found, 444.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.16-8.10 (m, 1H), 7.82-7.79 (m, 1H), 7.74-7.71 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.57 (m, 1H), 7.54-7.46 (m, 1H), 7.40-7.33 (m, 3H), 4.40-4.36 (m, 2H), 3.75-3.69 (m, 2H), 3.48-3.33 (m, 2H), 3.24-3.16 (m, 1H), 1.05-1.01 (m, 3H).

Example 391

The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 2-bromo-N,N-diethylbenzenesulfonamide. MS (ESI): mass calcd. for C₂₃H₂₄FN₃O₃S, 441.15; m/z found, 442.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.03-8.00 (m, 1H), 7.82 (d, J=1.0, 1H), 7.73-7.65 (m, 2H), 7.62-7.55 (m, 2H), 7.40-7.36 (m, 1H), 7.31 (s, 1H), 7.30-7.28 (m, 1H), 4.39-4.35 (m, 2H), 3.74-3.70 (m, 2H), 2.99 (q, J=7.1, 4H), 1.01 (t. J=7.1, 6H).

Example 392

Step A: 7-(4-Chloro-2-fluorophenyl-3,4-dihydro-2H-pyrido[3,2-b][1.4]oxazine

Prepared in a manner similar to that found in Example 1 using of 7-bromo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine with (4-chloro-2-fluorophenyl)boronic acid. ¹H NMR (400 MHz, CDCl₃) δ 7.84 (m, 1H), 7.35-7.28 (m, 1H), 7.20-7.14 (m, 3H), 4.29-4.25 (m, 2H), 3.64-3.58 (m, 2H).

Step B: 7-(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine

Into a 100 mL flask were added 7-(4-chloro-2-fluorophenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (1.25 g, 4.72 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.5 g, 5.9 mmol), KOAc (1.39 g, 14.2 mmol). Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II), 186 g, 0.236 mmol), and a stir bar. The flask was sealed with a rubber septum and sparged with N₂.

The flask was charged with freshly sparged 1,4-dioxane (25 mL) and heated at 80° Celsius for 16 hours. The reaction was cooled to rt and concentrated to dryness. The crude product was purified by FCC to give 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (1.208 g, 71%). ¹H NMR (500 MHz, CDCl₃) δ 7.86-7.84 (m, 1H), 7.61-7.59 (m, 1H), 7.56-7.53 (m, 1H), 7.38 (m, 1H), 7.27-7.24 (m, 1H), 4.27-4.22 (m, 2H), 3.61-3.58 (m, 2H), 2.09 (s, 1H), 1.35 (s, 12H).

Step C

7-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-3,4-dihydro-2H-pyrido[3,2-b]-b][1,4]oxazine. Prepared in a manner similar to that found in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b]-b][1,4]oxazine with 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₂₃H₂₂FN₃O₅S₂, 503.10; m/z found, 504.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.16-8.13 (m, 1H), 7.85-7.83 (m, 1H), 7.78-7.72 (m, 2H), 7.69-7.60 (m, 2H), 7.45-7.41 (m, 1H), 7.37-7.30 (m, 2H), 4.41-4.35 (m, 2H), 3.76-3.68 (m, 2H), 3.38-3.33 (m, 4H), 3.06-2.98 (m, 4H).

Example 393

The title compound was prepared in a manner similar to that described in Example 444 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 7-bromo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine. MS (ESI): mass calcd. for C₂₃H₂₄FN₃O₃S, 441.15; m/z found, 442.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.15-8.12 (m, 1H), 7.80 (d, J=0.9, 1H), 7.72-7.69 (m, 1H), 7.68-7.62 (m, 1H), 7.60-7.54 (m, 2H), 7.39-7.33 (m, 3H), 4.42-4.33 (m, 2H), 3.75-3.69 (m, 2H), 1.09 (s, 9H).

Example 394

The title compound was prepared using methods analogous to those described in Example 369 using (2-(isopropylthio)-5-(trifluoromethyl)pyridine-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₁H₁₆F₄N₄S, 432.10; m/z found, 433.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.12 (s, 1H), 8.83 (d, J=2.6, 1H), 8.74-8.68 (m, 1H), 8.19-8.10 (m, 1H), 7.71-7.66 (m, 1H), 7.62 (d, J=1.9, 1H), 7.42-7.37 (m, 1H), 7.33 (dd, J=1.7, 11.52, 1H), 6.87-6.82 (m, 1H), 4.19-4.03 (m, 1H), 1.40 (d, J=6.8, 6H).

Example 395

Step A: 3-Bromo-2-(isopropylthio)pyridine

3-Bromopyridine-2-thiol (500 mg, 2.63 mmol) was added drop-wise to a suspension of sodium hydride in mineral oil (60%, 126 mg, 3.16 mmol) in DMF (5.0 mL) at 0° Celsius. The mixture was then stirred at 0° Celsius for 30 min followed by removal of the ice bath and stirring at rt for an additional 30 min. 2-Iodopropane (537 mg, 3.16 mmol) was then added and the reaction stirred at 60° Celsius for 18 hours. The reaction was cooled to rt, carefully diluted with water (100 mL), and extracted with ethyl acetate (2×100 mL). The combined organic extracts were dried with Na₂SO₄, filtered and concentrated to dryness. The crude product was purified by FCC giving 453 mg (74%) of the target thioether. MS (ESI): mass calcd. for C₈H₁₀BrNS, 230.97; m/z found, 232.1 [M+H]⁺.

Step B: 3-Bromo-2-(isopropylsulfonyl)pyridine

3-Bromo-2-(isopropylthio)pyridine (100 mg, 0.43 mmol) was dissolved in DCM (6.0 mL) and m-CPBA (198 mg, 1.15 mmol) added. The reaction was stirred for 1.5 hours, and then treated with additional m-CPBA (100 mg, 0.058 mmol). Once complete conversion was achieved, the mixture was poured into sat. NaHCO₃ (50 mL) and extracted with DCM (2×50 mL). The combined extracts were concentrated to dryness and the crude product (112 mg, 98%) was used in next step without further purification.

Step C

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 3-bromo-2-(isopropylsulfonyl)pyridine yielding 52 mg (88%) of the title compound. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.11; m/z found, 373.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.69 (dd, J=4.6, 1.7, 1H), 8.60 (dd, J=2.1, 1.5, 1H), 8.10 (d, J=1.5, 1H), 8.08-7.98 (m, 1H), 7.81 (dd, J=7.8, 1.6, 1H), 7.58 (dd, J=7.8, 4.6, 1H), 7.38 (dd, J=8.0, 1.8, 1H), 7.32 (dd, J=11.7, 1.7, 1H), 4.71 (s, 2H), 4.19 (hept, J=6.8, 1H), 1.31 (d, J=6.9, 6H).

Example 396

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 3-bromo-2-(isopropylthio)pyridine. MS (ESI): mass calcd. for C₁₈H₁₇FN₄S, 340.12; m/z found, 341.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) 3 8.62-8.57 (m, 1H), 8.49-8.43 (m, 1H), 8.12 (d, J=1.5, 1H), 8.04-7.93 (m, 1H), 7.45-7.39 (m, 1H), 7.34-7.30 (m, 1H), 7.29-7.22 (m, 1H), 7.11-7.03 (m, 1H), 4.69 (s, 2H), 4.17-4.00 (m, 1H), 1.37 (d, J=6.8, 6H).

Example 397

The title compound was prepared using methods analogous to those described in Example 369 using (2-((2,2,2-trifluoroethoxy)pyridine-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C₁₉H₁₂F₄N₄O, 388.09; m/z found, 389.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.10 (s, 1H), 8.83 (d, J=2.5, 1H), 8.21-8.16 (m, 1H), 8.16-8.07 (m, 1H), 7.82-7.76 (m, 1H), 7.71-7.64 (m, 1H), 7.57-7.52 (m, 1H), 7.51-7.44 (m, 1H), 7.16-7.09 (m, 1H), 6.87-6.82 (m, 1H), 4.95-4.79 (m, 2H).

Example 398

The title compound was prepared using methods analogous to those described in Example 369 using (2-isobutoxypyridin-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O, 362.15; m/z found, 363.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.26 (s, 1H), 8.84 (d, J=2.5, 1H), 8.23-8.15 (m, 1H), 8.14-8.04 (m, 1H), 7.74-7.65 (m, 2H), 7.59-7.48 (m, 2H), 7.03-6.96 (m, 1H), 6.88-6.81 (m, 1H), 4.17 (d, J=6.6, 2H), 2.33-1.99 (m, 1H), 1.02 (d, J=6.7, 6H).

Example 399

The title compound was prepared using methods analogous to those described in Example 369 using (2-isopropoxypyridin-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₀H₁₇FN₄O, 348.14; m/z found, 349.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.22 (s, 1H), 8.83 (d, J=2.5, 1H), 8.17 (dd, J=1.9, 4.9, 1H), 8.11-8.01 (m, 1H), 7.72-7.64 (m, 2H), 7.57-7.46 (m, 2H), 6.96 (dd, J=5.0, 7.3, 1H), 6.87-6.80 (m, 1H), 5.52-5.37 (m, 1H), 1.38 (d, J=6.2, 6H).

Example 400

The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclopropylmethoxy)pyridin-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C₂₁H₁₇FN₄O, 360.14; m/z found, 361.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) G 9.28 (s, 1H), 8.83 (d, J=2.5, 1H), 8.19-8.14 (m, 1H), 8.13-8.04 (m, 1H), 7.74-7.64 (m, 2H), 7.61-7.53 (m, 2H), 6.99 (dd, J=5.0, 7.4, 1H), 6.84 (dd, J=1.9, 3.7, 1H), 4.25 (d, J=7.0, 2H), 1.39-1.23 (m, 1H), 0.67-0.57 (m, 2H), 0.41-0.31 (m, 2H).

Example 401

The title compound was prepared using methods analogous to those described in Example 369 using (2-isopropoxypyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O, 324.14; m/z found, 325.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.63-8.57 (m, 1H), 8.18-8.13 (m, 1H), 8.12 (d, J=1.4, 1H), 7.99-7.90 (m, 1H), 7.69-7.62 (m, 1H), 7.58-7.41 (m, 2H), 6.98-6.91 (m, 1H), 5.49-5.35 (m, 1H), 4.68 (s, 2H), 1.37 (d, J=6.2, 6H).

Example 402

The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclopentyloxy)pyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O, 350.15; m/z found, 351.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.62-8.58 (m, 1H), 8.19-8.15 (m, 1H), 8.12 (d, J=1.5, 1H), 8.00-7.90 (m, 1H), 7.69-7.63 (m, 1H), 7.48-7.40 (m, 2H), 6.98-6.92 (m, 1H), 5.59-5.50 (m, 1H), 4.68 (s, 2H), 2.03-1.89 (m, 2H), 1.89-1.70 (m, 4H), 1.71-1.55 (m, 2H).

Example 403

The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclohexyloxy)pyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O, 364.17; m/z found, 365.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.64-8.57 (m, 1H), 8.18-8.10 (m, 2H), 8.00-7.92 (m, 1H), 7.70-7.63 (m, 1H), 7.52-7.43 (m, 2H), 6.94 (dd, J=5.0, 7.4, 1H), 5.26-5.16 (m, 1H), 4.66 (s, 2H), 2.05-1.91 (m, 2H), 1.82-1.68 (m, 2H), 1.66-1.24 (m, 6H).

Example 404

The title compound was prepared using methods analogous to those described in Example 369 using (2-(methoxy)pyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₁₆H₁₃FN₄O, 296.11; m/z found, 297.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.62-8.56 (m, 1H), 8.19 (dd, J=1.9, 5.0, 1H), 8.12 (d, J=1.5, 1H), 8.01-7.94 (m, 1H), 7.70-7.65 (m, 1H), 7.48-7.41 (m, 2H), 7.00 (dd, J=5.0, 7.31, 1H), 4.66 (s, 2H), 4.00 (s, 3H).

Example 405

The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclobutoxy)pyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O, 336.14; m/z found, 337.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.63-8.57 (m, 1H), 8.17-8.10 (m, 2H), 8.01-7.92 (m, 1H), 7.66 (dd, J=1.9, 7.4, 1H), 7.52-7.43 (m, 2H), 7.00-6.93 (m, 1H), 5.38-5.22 (m, 1H), 4.67 (s, 2H), 2.57-2.37 (m, 2H), 2.26-2.05 (m, 2H), 1.90-1.61 (m, 2H).

Example 406

The title compound was prepared using methods analogous to those described in Example 369 using tert-butyl 3-(((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-yl)oxy)methyl)pyrrolidine-1-carboxylate and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₂₅H₂₈FN₅O₃, 465.22; m/z found, 466.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.63-8.58 (m, 1H), 8.18-8.09 (m, 2H), 8.03-7.94 (m, 1H), 7.73-7.64 (m, 1H), 7.48-7.36 (m, 2H), 7.05-6.96 (m, 1H), 4.70 (s, 2H), 4.47-4.22 (m, 2H), 3.68-3.26 (m, 3H), 3.25-3.09 (m, 1H), 2.77-2.60 (m, 1H), 2.14-1.98 (m, 1H), 1.84-1.68 (m, 1H), 1.44 (s, 9H).

Example 407

Step A: Tert-butyl 3-(((3-(4-(5-aminopyrazin-2-yl)-3-fluorophenyl)pyridine-2-yl)oxy)methyl)pyrrolidine-1-carboxylate

The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and tert-butyl 3-(((3-bromopyridin-2-yl)oxy)methyl)pyrrolidine-1-carboxylate yielding the title compound (47 mg, 54%). MS (ESI): mass calcd. for C₂₅H₂₈FN₅O₃, 465.22; m/z found, 466.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.63-8.58 (m, 1H), 8.18-8.09 (m, 2H), 8.03-7.94 (m, 1H), 7.73-7.64 (m, 1H), 7.48-7.36 (m, 2H), 7.05-6.96 (m, 1H), 4.70 (s, 2H), 4.47-4.22 (m, 2H), 3.68-3.26 (m, 3H), 3.25-3.09 (m, 1H), 2.77-2.60 (m, 1H), 2.14-1.98 (m, 1H), 1.84-1.68 (m, 1H), 1.44 (s, 9H).

Step B

The title compound was prepared as described in the preparation of Example 249 using tert-butyl 3-(((3-(4-(5-aminopyrazin-2-yl)-3-fluorophenyl)pyridine-2-yl)oxy)methyl)pyrrolidine-1-carboxylate to give the title compound (15 mg, 41%). MS (ESI): mass calcd. for C₂₀H₂₀FN₅O, 365.17; m/z found, 366.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.63-8.57 (m, 1H), 8.20-8.13 (m, 1H), 8.12 (d, J=1.5, 1H), 8.02-7.93 (m, 1H), 7.72-7.65 (m, 1H), 7.49-7.38 (m, 2H), 7.03-6.96 (m, 1H), 4.69 (s, 2H), 4.40-4.20 (m, 2H), 3.09 (dd, J=11.2, 7.7, 1H), 3.04-2.83 (m, 2H), 2.76 (dd, J=11.2, 6.1, 1H), 2.66-2.49 (m, 1H), 2.06-1.89 (m, 1H), 1.61-1.49 (m, 2H).

Example 408

To a microwave vial the following were added 5-(4-chloro-2-fluorophenyl)-pyrimidin-2-amine (50 mg, 0.22 mmol), (2-isopropoxypyridin-3-yl)boronic acid (51 mg, 0.28 mmol) and X-Phos precatalyst (4 mg, 0.005 mmol). The vial was flushed with nitrogen and then THF (0.5 mL) and 0.5 M K₃PO₄ (0.9 mL) were added. Both THF and the K₃PO₄ solution were sparged separately for 30 min prior to use. The resulting biphasic mixture was stirred at rt overnight. The reaction mixture was then poured into sat. NaHCO₃ (50 mL) and extracted with ethyl acetate (2×50 mL). The combined organic extracts were washed with water (1×50 mL) and brine (1×50 mL), dried (Na₂SO₄) and concentrated to dryness. The crude product was purified by HPLC to give the title compound (35 mg, 48%). MS (ESI): mass calcd. for C₁₈H₁₇FN₄O, 324.14; m/z found, 325.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, J=1.4, 2H), 8.21-8.13 (m, 1H), 7.68-7.60 (m, 1H), 7.50-7.36 (m, 3H), 6.99-6.91 (m, 1H), 5.51-5.37 (m, 1H), 5.15 (s, 2H), 1.38 (d, J=6.2, 6H).

Example 409

The title compound was prepared in a manner similar to that described in Example 88 using 3-bromopyridin-2-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₅H₁₂FN₅, 281.11; m/z found, 282.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.64-8.54 (m, 1H), 8.00-7.89 (m, 1H), 7.74-7.64 (m, 1H), 7.46-7.36 (m, 1H), 7.09-7.03 (m, 1H).

Example 410

The title compound was prepared in manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (400 MHz. CD₃OD) δ8.73 (d, J=2.1, 1H), 8.16 (dd. J=7.9, 1.4, 1H), 7.93 (m, 1H), 7.69 (m, 1H), 7.60 (m, 1H), 7.45-7.28 (m, 3H), 3.47-3.36 (m, 1H), 3.34-3.18 (m, 2H), 1.03 (d. J=6.6, 3H).

Example 411

The title compound was prepared in manner similar to that described in Example 88 using 1-bromo-2-(cyclopropylsulfonyl)benzene and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C₂₀H₁₅FN₄O₂S, 394.09; m/z found, 395.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.84 (d, J=1.8, 1H), 8.14 (dd, J=8.0, 1.4, 1H), 8.01 (m, 1H), 7.66 (m, 1H), 7.58 (m, 1H), 7.39-7.35 (m, 3H), 5.34 (s, 2H), 2.13-2.05 (m, 1H), 1.13-1.06 (m, 2H), 0.88-0.82 (m, 2H).

Example 412

The title compound was prepared in manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.78 (d, J=1.6, 1H), 8.18 (dd, J=7.9, 1.4, 1H), 8.01 (m, 1H), 7.63 (m, 1H), 7.56 (m, 1H), 7.40-7.32 (m, 3H), 5.43 (s, 2H), 4.46-4.36 (m, 1H), 3.55-3.46 (m, 1H), 3.43-3.28 (m, 2H), 1.76 (t, J=5.7, 1H), 0.99 (d, J=6.6, 3H).

Example 413

The title compound was prepared in manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C₁₉H₁₆FN₅O₃S, 413.10; m/z found, 414.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.81 (d, J=1.8, 1H), 8.17 (dd, J=8.0, 1.4, 1H), 8.02 (m, 1H), 7.64 (m, 1H), 7.56 (m, 1H), 7.40-7.31 (m, 3H), 5.38 (s, 2H), 4.35 (s, 1H), 3.64-3.58 (m, 2H), 2.95-2.87 (m, 2H), 1.64 (t, J=5.2, 1H).

Example 414

The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromophenyl)sulfonyl)piperazin-2-one and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C₂₁H₁₇FN₆O₃S, 452.11; m/z found, 453.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.65 (d. J=2.1, 1H), 8.05 (dd. J=8.1, 1.3, 1H), 7.85 (m, 1H), 7.65 (m, 1H), 7.55 (m, 1H), 7.36 (dd, J=7.6, 1.3, 1H), 7.26-7.17 (m, 2H), 3.29 (s, 2H), 3.04 (s, 4H).

Example 415

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.75 (d, J=2.1, 1H), 8.09 (dd, J=8.0, 1.3, 1H), 7.95 (m, 1H), 7.70 (m, 1H), 7.62 (m, 1H), 7.43 (dd, J=7.6, 1.4, 1H), 7.39-7.31 (m, 2H), 3.74-3.62 (m, 1H), 2.80-2.67 (m, 2H), 1.07 (d, J=6.3, 3H).

Example 416

The title compound was prepared in a manner similar to that described in Example 88 using (2-bromophenyl)(morpholino)methanone and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C₂₂H₁₈FN₅O₂, 403.14; m/z found, 404.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.45 (d, J=2.1, 1H), 6.71 (m, 1H), 6.32-6.21 (m, 3H), 6.17-6.10 (m, 2H), 6.07 (dd, J=12.4, 1.8, 1H), 2.40-2.22 (m, 3H), 2.13-2.03 (m, 2H), 1.86-1.77 (m, 1H), 1.62-1.49 (m, 2H).

Example 417

The title compound was prepared in a manner similar to that described in Example 444 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 6-chloropyridazin-3-amine. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.26-8.22 (m, 1H), 8.16-8.13 (m, 1H), 7.91-7.85 (m, 1H), 7.69-7.64 (m, 1H), 7.63-7.56 (m, 2H), 7.44-7.37 (m, 3H), 1.09 (s, 9H).

Example 418

The title compound was prepared in a manner similar to that described in Example 444 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 2-bromo-7H-pyrrolo[2,3-d]pyrimidine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 425.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.31 (s, 1H), 8.82 (s, 1H), 8.15 (m, 1H), 7.90 (d, J=3.6, 1H), 7.68 (d, J=7.5, 1H), 7.63 (d, J=6.3, 1H), 7.50 (s, 1H), 7.42 (d, J=7.1, 1H), 7.02 (d, J=3.6, 1H), 6.66 (d, J=3.6, 1H), 1.12 (s, 9H).

Example 419

The title compound was prepared in a manner similar to that described in Example 444 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 3-bromo-1,8-naphthyridine. MS (ESI): mass calcd. for C₂₄H₂₂FN₃O₂S, 435.14; m/z found, 436.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.46 (s, 1H), 9.23 (s, 1H), 8.89 (s, 1H), 8.85 (d, J=7.2, 1H), 8.18-8.14 (m, 1H), 7.94-7.90 (m, 1H), 7.80 (m, 1H), 7.70-7.65 (m, 1H), 7.62-7.57 (m, 1H), 7.49-7.40 (m, 3H), 1.11 (s, 9H).

Example 420

Step A: 4′-Bromo-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide

1-Bromo-2-fluoro-4-iodobenzene (117 mg, 0.389 mmol) and (2-(N-(tert-butyl)sulfamoyl)phenyl) boronic acid (100 mg, 0.389 mmol) were added to a 5 mL sealable vial equipped with a stir bar. 1,4-Dioxane (1 mL) and 2 M Na₂CO₃ (1 mL) solution were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 min then Pd(dppf)Cl₂.CH₂Cl₂ (14 mg, 0.019 mmol) was added. The mixture was then stirred for 15 hours at 80° Celsius under an argon atmosphere. The reaction was diluted with 2 mL of ethyl acetate and 2 mL of water and the aqueous layer was extracted with ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na₂SO₄ and concentrated to dryness. The crude product was purified by FCC to give the title compound. ¹H NMR (500 MHz, CDCl₃) δ 8.20-8.15 (dd, J=7.9, 1.4, 1H), 7.64-7.59 (dd, J=8.2, 7.1, 1H), 7.60-7.55 (m, 1H), 7.54-7.49 (m, 1H), 7.31-7.27 (m, 2H), 7.21-7.16 (dd, J=8.5, 2.2, 1H), 3.65 (s, 1H), 1.07 (s, 9H).

Step B: N-tert-Butyl-3′-fluoro-4′-quinoxalin-6-ylbiphenyl-2-sulfonamide

4′-Bromo-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (30 mg, 0.078 mmol) and 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline (12 mg, 0.085 mmol) were added to a 5 mL sealable vial equipped with a stir bar. Dioxane (0.2 mL) and 2 M Na₂CO₃ (0.2 mL) were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 min then Pd(dppf)Cl₂.CH₂Cl₂ (3 mg, 0.004 mmol) was added, and the mixture heated for 15 hours at 80° Celsius under an argon atmosphere. The reaction was diluted with 2 mL of ethyl acetate and 2 mL of water and the aqueous layer was extracted with ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na₂SO₄ and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C₂₄H₂₂FN₃O₂S, 435.14; m/z found, 436.4 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.93-8.91 (d, J=1.8, 1 H), 8.91-8.89 (d, J=1.8, 1H), 8.37-8.34 (m, 1H), 8.24-8.22 (m, 1H), 8.22-8.20 (m, 1H), 8.09-8.04 (m, 1H), 7.71-7.66 (m, 1H), 7.65-7.59 (m, 1H), 7.58-7.52 (m, 1H), 7.51-7.44 (dd, J=7.9, 1.8, 1H), 7.44-7.40 (dd, J=11.3, 1.7, 1H), 7.40-7.36 (dd, J=7.5, 1.4, 1H), 3.74 (s, 1H), 1.10 (s, 9H).

Example 421

The title compound was prepared in a manner similar to that described in Example 420 using tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate in Step B. After work up, the Boc group was then removed by treatment with trifluoroacetic acid (0.3 mL) in dichloromethane (1 mL) at rt followed by concentration and purification by HPLC to give the title compound. MS (ESI): mass calcd. for C₂₄H₂₃FN₂O₂S, 422.15; m/z found, 423.3 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.27 (s, 1H), 8.23-8.17 (dd, J=8.0, 1.3, 1H), 7.91-7.85 (m, 1H), 7.63-7.56 (m, 2H), 7.55-7.49 (m, 2H), 7.48-7.43 (m, 1H), 7.42-7.36 (m, 2H), 7.36-7.31 (dd, J=11.3, 1.8, 1H), 7.31-7.27 (dd, J=3.2, 2.4, 1H), 6.67-6.61 (m, 1H), 3.72 (s, 1H), 1.06 (s, 9H).

Example 422

The title compound was prepared in a manner similar to that described in Example 420 using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole in Step B. MS (ESI): mass calcd. for C₂₃H₂₂FN₃O₂S, 423.14; m/z found, 424.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 9.32-9.21 (d, J=6.0, 1H), 8.18-8.12 (dd, J=8.0, 1.3, 1H), 8.04 (s, 1H), 7.96-7.89 (m, 1H), 7.89-7.82 (m, 1H), 7.69-7.55 (m, 3H), 7.45-7.33 (m, 3H), 1.11 (s, 9H).

Example 423

The title compound was prepared in a manner similar to that described in Example 420 using (2-(N-methylsulfamoyl)phenyl)boronic acid in Step A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole in Step B. MS (ESI): mass calcd. for C₂₀H₁₆FN₃O₂S, 381.09; m/z found, 382.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 9.35 (s, 1H), 8.06 (s, 1H), 8.05-8.03 (dd, J=8.0, 1.3, 1H), 7.96-7.92 (m, 1H), 7.91-7.86 (m, 1H), 7.72-7.67 (m, 1H), 7.65-7.60 (m, 2H), 7.46-7.43 (dd, J=7.5, 1.4, 1H), 7.38-7.32 (m, 2H), 2.50 (s, 3H).

Example 424

The title compound was prepared in a manner similar to that described in Example 420 using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzo[d]thiazole in Step B. MS (ESI): mass calcd. for C₂₃H₂₁FN₂O₂S₂, 440.10; m/z found, 441.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 9.07 (s, 1H), 8.39-8.35 (m, 1H), 8.24-8.19 (dd, J=8.0, 1.3, 1H), 8.10-8.05 (dd, J=8.4, 0.6, 1H), 7.75-7.69 (m, 1H), 7.65-7.62 (m, 1H), 7.62-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.45-7.42 (dd, J=7.8, 1.8, 1H), 7.41-7.38 (dd, J=4.1, 1.5, 1H), 7.38-7.36 (d, J=1.6, 1H), 3.73 (s, 1H), 1.08 (s, 9H).

Example 425

The title compound was prepared in a manner similar to that described in Example 420 using 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine in Step B. MS (ESI): mass calcd. for C₂₃H₂₂FN₃O₂S, 423.14; m/z found, 424.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.87-8.81 (m, 1H), 8.77-8.70 (d, J=1.5, 1H), 8.20-8.17 (d, J=3.3, 1H), 8.17-8.12 (dd, J=8.0, 1.3, 1H), 7.78-7.71 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.47-7.44 (dd, J=4.9, 1.5, 1H), 7.44 (s, 1H), 7.43-7.40 (dd, J=7.5, 1.4, 1H), 6.95-6.89 (dd, J=3.2, 0.9, 1H), 1.12 (s, 9H).

Example 426

The title compound was prepared in a manner similar to that described in Example 420 using (2-(N-methylsulfamoyl)phenyl)boronic acid in Step A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine in Step B. MS (ESI): mass calcd. for C₂₀H₁₆FN₃O₂S, 381.09; m/z found, 382.1 [M+H]⁴. ¹H NMR (500 MHz, CD₃OD) δ 8.49 (s, 1H), 8.46-8.37 (m, 1H), 8.13-7.97 (dd, J=7.9, 1.3, 1H), 7.74-7.66 (m, 1H), 7.66-7.57 (m, 2H), 7.57-7.52 (d, J=3.5, 1H), 7.46-7.40 (dd, J=7.7, 1.4, 1H), 7.38-7.30 (m, 2H), 6.72-6.63 (d, J=3.5, 1H), 2.48 (s, 3H).

Example 427

N-(tert-Butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide (37 mg, 0.085 mmol) and 6-bromopyridin-3-amine (22 mg, 0.13 mmol) were added to a 5 mL sealable vial equipped with a stir bar. 1,4-Dioxane (0.2 mL) and 2 M Na₂CO₃ (0.2 mL) were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 min then Pd(dppf)Cl₂.CH₂Cl₂ (3 mg, 0.004 mmol) was added, and the mixture stirred for 15 hours at 80° Celsius under an argon atmosphere. The reaction was diluted with 2 mL of ethyl acetate and 2 mL of water and the aqueous layer was extracted with ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na₂SO₄ and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C₂₁H₂₂FN₃O₂S, 399.14; m/z found, 400.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.66 (s, 1H), 8.25-8.16 (dd, J=8.0, 1.4, 1H), 7.83-7.76 (dd, J=8.8, 1.7, 1H), 7.77-7.68 (m, 1H), 7.66-7.58 (m, 1H), 7.58-7.48 (m, 2H), 7.46-7.39 (m, 2H), 7.37-7.30 (dd, J=7.4, 1.5, 1H), 4.31 (s, 1H), 1.09 (s, 9H).

Example 428

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromopyrazine-2,3-diamine. MS (ESI): mass calcd. for C₂₀H₂₂FN₅O₂S, 415.15; m/z found, 416.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.11-8.06 (m, 1H), 7.66 (s, 1H), 7.66-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.40-7.35 (dd, J=7.5, 1.4, 1H), 7.35-7.34 (m, 1H), 7.34-7.31 (dd, J=7.7, 1.6, 1H), 1.07 (s, 9H).

Example 429

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-1H-imidazo[4,5-b]pyrazin-2(3H)-one. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₃S, 441.13; m/z found, 442.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.45-8.39 (d, J=1.7, 1H), 8.17-8.10 (m, 1H), 8.06-7.98 (m, 1H), 7.70-7.60 (m, 1H), 7.60-7.52 (m, 1H), 7.42-7.38 (dd, J=7.4, 1.3, 1H), 7.38-7.33 (m, 2H), 1.07 (s, 9H).

Example 430

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-3-fluoropyridin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₁F₂N₃O₂S, 417.13; m/z found, 418.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.04-7.97 (m, 2H), 7.69-7.62 (m, 1H), 7.61-7.53 (m, 2H), 7.39-7.32 (m, 3H), 1.24-0.86 (s, 9H).

Example 431

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine. MS (ESI): mass calcd. for C₂₃H₂₄FN₃O₂S, 425.16; m/z found, 426.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.18-8.06 (dd, J=7.9, 1.3, 1H), 7.95-7.85 (m, 1H), 7.76 (s, 1H), 7.68-7.62 (m, 1H), 7.61-7.49 (m, 2H), 7.43-7.30 (m, 3H), 4.03-3.92 (dd, J=8.8, 7.8, 2H), 3.37-3.32 (m, 2H), 1.10 (s, 9H).

Example 432

The title compound was prepared in a manner similar to that described in Example 427 using 6-bromo-3H-imidazo[4,5-b]pyridine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 425.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.92 (s, 1H), 8.84-8.74 (m, 1H), 8.40 (s, 1H), 8.21-8.08 (dd, J=8.1, 1.3, 1H), 7.70-7.63 (m, 2H), 7.62-7.55 (m, 1H), 7.46-7.36 (m, 3H), 1.10 (s, 9H).

Example 433

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-3-methoxypyrazin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.18-8.10 (m, 2H), 7.95 (s, 1H), 7.68-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.40-7.35 (m, 2H), 7.35-7.32 (dd, J=12.9, 1.6, 1H), 4.19 (s, 3H), 1.07 (s, 9H).

Example 434

The title compound was prepared in a manner similar to that described in Example 427 using 3-amino-6-bromopyrazine-2-carbonitrile. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₂S, 425.13; m/z found, 426.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.76-8.69 (d, J=2.1, 1H), 8.18-8.10 (dd, J=8.0, 1.3, 1H), 7.96-7.89 (m, 1H), 7.68-7.62 (m, 1H), 7.61-7.53 (m, 1H), 7.40-7.37 (dd, J=7.6, 1.4, 1 H), 7.37-7.36 (m, 1H), 7.36-7.33 (dd, J=4.4, 1.6, 1H), 1.07 (s, 9H).

Example 435

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 6-amino-3-(4-bromo-2-fluorophenyl)pyrazine-2-carbonitrile and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₂S, 425.13; m/z found, 426.1 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.25 (s, 1H), 8.19 (dd, J=8.0, 1.4, 1H), 7.64-7.56 (m, 2H), 7.54-7.49 (m, 1H), 7.47 (dd, J=7.9, 1.7, 1H), 7.40-7.33 (m, 2H), 1.04 (s, 9H).

Example 436

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-amino-5-(4-bromo-2-fluorophenyl)pyridine-4-carbonitrile and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 425.1 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.18 (d, J=7.8, 1H), 8.01 (s, 1H), 7.64-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.46-7.28 (m, 4H), 3.91 (s, 1H), 1.04 (s, 9H).

Example 437

The title compound was prepared using analogous conditions to those described in Example 6 utilizing N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 6-amino-3-bromo-2-cyanopyridine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 424.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.11-8.04 (d, J=7.9, 1H), 7.71-7.64 (m, 1H), 7.64-7.58 (m, 2H), 7.54-7.48 (m, 1H), 7.45-7.36 (dd, J=19.2, 9.2, 2H), 7.36-7.30 (dd, J=7.9, 1.6, 1H), 6.89-6.83 (d, J=8.7, 1H), 6.83-6.75 (d, J=10.0, 3H), 1.03 (s, 9H).

Example 438

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-thiadiazol-2-amine and 2-bromo-N-(tert-butyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₉FN₄O₂S₂, 406.09; m/z found, 407.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.20-8.10 (m, 2H), 7.69-7.56 (m, 2H), 7.46-7.36 (m, 3H), 1.08 (s, 9H).

Example 439

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-thiadiazol-2-amine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₇H₁₇FN₄O₃S₂, 408.07; m/z found, 409.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.15-8.12 (m, 2H), 7.68 (m, 1H), 7.61 (m, 1H), 7.44-7.38 (m, 3H), 3.42-3.38 (m, 1H), 3.30-3.25 (m, 1H), 3.22-3.18 (m, 1H), 1.02 (d, J=6.6, 3H).

Example 440

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-thiadiazol-2-amine and 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₄S₂, 468.04; m/z found, 469.0 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.19 (m, 1H), 8.15 (dd, J=8.0, 1.1, 1H), 7.76 (m, 1H), 7.67 (m, 1H), 7.45 (dd, J=7.6, 1.2, 1H), 7.39 (dd, J=11.9, 1.4, 1H), 7.36 (dd, J=8.1, 1.6, 1H), 3.42-3.33 (m, 4H), 3.09-3.02 (m, 4H).

Example 441

To a 25 mL round-bottomed flask were added a stirbar, 52 mg (0.13 mmol) 4′-(5-aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 27 mg (0.20 mmol) N-chlorosuccinamide, and dry DMF (2.0 mL). The flask was sparged with nitrogen and heated at 60° Celsius for 18 hours before cooling to rt and subjecting the reaction mixture (after syringe filtration) to HPLC purification to give the title compound (29.6 mg, 52%). MS (ESI): mass calcd. for C₂₀H₂₀ClFN₄O₂S, 434.10; m/z found, 435.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.44 (d, J=2.0, 1H), 8.06 (dd, J=8.1, 1.5, 1 H), 7.85 (dd, J=9.4, 6.8, 1H), 7.70-7.64 (m, 1H), 7.64-7.57 (m, 1H), 7.43-7.27 (m, 3H), 7.13 (s, 2H), 6.98 (d, J=3.7, 1H), 1.02 (s, 9H).

Example 442

To a 25 mL round-bottomed flask were added a stirbar, (55 mg, 14 mmol) 4′-(5-aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide (32 mg, 0.18 mmol) NBS, and dry DMF (2.0 mL). The flask was sparged with nitrogen and stirred at rt for 18 hours before subjecting the reaction mixture (after syringe filtration) to HPLC purification to give the title compound (46 mg, 70%). MS (ESI): mass calcd. for C₂₀H₂₀BrFN₄O₂S, 479.05; m/z found, 479.0 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.45 (d, J=1.8, 1H), 8.06 (dd, J=7.9, 1.4, 1H), 7.88-7.81 (m, 1H), 7.69-7.64 (m, 1H), 7.64-7.58 (m, 1H), 7.37 (dd, J=7.6, 1.4, 1H), 7.35-7.29 (m, 2H), 7.05 (s, 2H), 6.98 (s, 1H), 1.02 (s, 9H).

Example 443

The title compound was prepared using analogous conditions to those described in Example 6 2-(2′-(cyclopropylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and 6-amino-3-bromo-2-cyanopyridine. MS (ESI): mass calcd. for C₂₁H₁₆FN₃O₂S, 393.09; m/z found, 393.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.07 (d, J=7.9, 1H), 7.71-7.64 (m, 1H), 7.64-7.58 (m, 2H), 7.54-7.48 (m, 1H), 7.40 (dd, J=19.2, 9.2, 2H), 7.33 (dd, J=7.9, 1.6, 1H), 6.86 (d, J=8.7, 1H), 6.79 (d, J=10.0, 3H), 1.03 (s, 9H).

Example 444

To a 20 mL vial were added N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide (45 mg, 0.10 mmol), 7-bromo-[1,2,4]triazolo[4,3-a]pyridine (21 mg, 0.10 mmol) K₂CO₃ (29 mg, 0.21 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (4 mg, 0.005 mmol), and a stir bar. The vial was sealed with a teflon lined cap and the vial sparged with N₂. The vial was then charged with freshly sparged DMSO (2 mL) and stirred for 16 hours at 80° Celsius. The reaction mixture was then cooled to rt, filtered, and purified by HPLC to give the title compound (30 mg, 53%). MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 425.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.40 (s, 1H), 8.79 (s, 1H), 8.20-8.11 (m, 2H), 7.77 (m, 1H), 7.70-7.57 (m, 3H), 7.47-7.38 (m, 3H), 1.10 (s, 9H).

Example 445

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-3-methylpyrazin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₂S, 414.15; m/z found, 415.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.31-8.24 (m, 1H), 8.17-8.12 (dd, J=8.2, 1.3, 1H), 7.97-7.91 (m, 1H), 7.68-7.61 (m, 1H), 7.59-7.53 (m, 1H), 7.43-7.36 (dd, J=7.5, 1.3, 1H), 7.36-7.28 (m, 2H), 2.59-2.35 (m, 3H), 1.06 (s, 9H).

Example 446

The title compound was prepared by forming 4′-(5-Amino-6-methylpyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide then removing the tert-butyl group by dissolving the crude 4′-(5-Amino-6-methylpyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide in 1 mL of trifluoroacetic acid and heating it to 60° Celsius for 2 hours, after which time the reaction was cooled to rt, concentrated to dryness and purified using FCC. MS (ESI): mass calcd. for C₁₇H₁₅FN₄O₂S, 358.09; m/z found, 359.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.22 (s, 1H), 8.16-8.10 (dd, J=7.7, 1.3, 1H), 8.03-7.97 (m, 1H), 7.68-7.62 (m, 1H), 7.61-7.54 (m, 1H), 7.41-7.37 (dd, J=7.7, 1.4, 1H), 7.36-7.33 (dd, J=8.0, 1.7, 1H), 7.33-7.29 (dd, J=12.3, 1.6, 1 H), 2.66-2.43 (m, 3H).

Example 447

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-1H-imidazo[4,5-b]pyrazine. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₂S, 425.13; m/z found, 426.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 9.06-8.88 (d, J=2.1, 1H), 8.80 (s, 1H), 8.18-8.11 (dd, J=8.1, 1.3, 1H), 8.13-8.04 (m, 1H), 7.71-7.64 (m, 1H), 7.63-7.54 (m, 1H), 7.48-7.39 (m, 3H), 1.09 (s, 9H).

Example 448

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromopyridine-2,3-diamine. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₂S, 414.15; m/z found, 415.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.18-8.06 (m, 1H), 7.69-7.62 (m, 1H), 7.61-7.56 (m, 1H), 7.56-7.50 (m, 2H), 7.47-7.42 (m, 1H), 7.40-7.30 (m, 3H), 1.104 (s, 9H).

Example 449

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-3-methylpyrazin-2-amine and 3′-fluoro-N-methyl-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.11; m/z found, 373.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.27 (s, 1H), 8.09-8.00 (d, J=7.9, 1H), 7.96-7.87 (m, 1H), 7.71-7.63 (m, 1H), 7.63-7.55 (m, 1H), 7.44-7.38 (d, J=7.5, 1H), 7.34-7.21 (m, 2H), 2.46 (s, 3H), 2.44 (s, 3H).

Example 450

The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 2-amino-5-bromonicotinonitrile. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 425.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.49-8.44 (m, 1H), 8.12 (d, J=1.8, 1H), 8.06 (dd, J=7.9, 1.3, 1H), 7.66 (m, 1H), 7.63-7.56 (m, 2H), 7.38 (dd, J=7.5, 1.3, 1H), 7.33 (dd, J=11.9, 1.6, 1H), 7.27 (dd, J=7.9, 1.7, 1H), 7.18 (s, 2H), 6.90 (s, 1H), 1.03 (s, 9H).

Example 451

The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 5-bromo-3-chloropyridin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₁ClFN₃O₂S, 433.10; m/z found, 434.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.20 (s, 1H), 8.06 (dd, J=7.9, 1.2, 1H), 7.85 (s, 1H), 7.66 (m, 1H), 7.62-7.54 (m, 2H), 7.37 (m, 1H), 7.31 (dd, J=11.9, 1.6, 1H), 7.26 (dd, J=7.9, 1.7, 1H), 6.89 (s, 1H), 6.62 (s, 2H), 1.03 (s, 9H).

Example 452

The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 5-bromo-3-(trifluoromethyl)pyridin-2-amine. MS (ESI): mass calcd. for C₂₂H₂₁F₄N₃O₂S, 467.13; m/z found, 468.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.47 (s, 1H), 8.07 (dd, J=7.9, 1.2, 1H), 7.96 (s, 1H), 7.66 (m, 1H), 7.63-7.55 (m, 2H), 7.38 (dd, J=7.5, 1.3, 1H), 7.33 (dd, J=11.9, 1.6, 1H), 7.27 (dd, J=7.9, 1.7, 1H), 6.88 (s, 1H), 6.76 (s, 2H), 1.02 (s, 9H).

Example 453

The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 5-bromo-4-(trifluoromethyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₀F₄N₄O₂S, 468.12; m/z found, 469.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.45 (s, 1H), 8.07 (dd, J=7.8, 1.4, 1H), 7.67 (m, 1H), 7.62 (m, 1H), 7.53 (s, 2H), 7.45-7.38 (m, 2H), 7.37-7.29 (m, 2H), 6.74 (s, 1H), 1.01 (s, 9H).

Example 454

The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 5-bromo-4-methylpyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₂S, 414.15; m/z found, 415.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.17 (s, 1H), 8.08 (dd, J=8.0, 1.2, 1H), 7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.43-7.38 (m, 2H), 7.36 (dd, J=10.9, 1.6, 1H), 7.30 (dd, J=7.8, 1.7, 1H), 7.13 (s, 2H), 6.86 (s, 1H), 2.25 (d, J=0.8, 3H), 1.00 (s, 9H).

Intermediate HC

Step A: 5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde

Hexamethylenetetramine (1.08 g, 7.61 mmol) was added to a solution of 5-bromo-1H-pyrrolo[2,3-b]pyridine (1 g, 5 mol) in HOAc (6.34 mL). The mixture was heated at 100° Celsius for 6 hours. The reaction mixture was then cooled to rt and diluted with water. The mixture was extracted with EtOAc, dried (Na₂SO₄), filtered and concentrated to dryness. The residue was purified by FCC to provide the title compound (379 mg, 33%). ¹H NMR (500 MHz, CDCl₃) δ 10.02 (s, 1H), 8.77 (d, J=2.2, 1 H), 8.48 (d, J=2.2, 1H), 7.99 (d, J=2.7, 1H).

Step B

The title compound was prepared using analogous conditions to those described in Example 88 using 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde and 3′-fluoro-N-methyl-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C₂₁H₁₆FN₃O₃S, 409.09; m/z found, 410.2 [M+H]⁺.

Intermediate HD

The title compound was prepared using analogous conditions to those described in Example 88 using 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde and N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C₂₄H₂₂FN₃O₃S, 451.14; m/z found, 452.2 [M+H]⁺.

Intermediate HE

The title compound was prepared using analogous conditions to those described in Example 88 using 5-bromo-7-nitroindole and N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. ¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H), 8.27-8.18 (m, 2H), 7.65-7.58 (m, 2H), 7.58-7.50 (m, 1H), 7.50-7.35 (m, 4H), 6.83-6.77 (m, 1H), 1.17-1.03 (m, 9H).

Example 455

The title compound was prepared using similar methods to those described in Example 457 using N-(tert-butyl)-3′-fluoro-4′-(3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C₂₄H₂₄FN₃O₃S, 453.15; m/z found, 454.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.50 (s, 1H), 8.26-8.20 (m, 2H), 7.63-7.58 (m, 1H), 7.56-7.48 (m, 3H), 7.44-7.39 (m, 1H), 7.39-7.34 (m, 3H), 4.92 (s, 2H), 1.11 (d, J=12.1, 9H).

Example 456

The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-indol-7-amine and 2-bromo-N-(1-(hydroxymethyl)-cyclopentyl)benzenesulfonamide in Step B. MS (ESI): mass calcd. for C₂₆H₂₆FN₃O₃S, 479.17; m/z found, 480.3 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.18 (dd, J=8.1, 1.4, 1H), 8.13 (s, 1H), 7.65-7.50 (m, 3H), 7.42 (s, 1H), 7.41-7.31 (m, 3H), 6.87 (m, 1H), 6.61 (dd, J=3.1, 2.0, 1H), 4.05 (s, 1H), 3.48 (s, 2H), 1.50-1.34 (m, 4H), 1.37-1.22 (m, 2H), 0.93-0.73 (m, 2H).

Example 457

NaBH₄ (4.45 mg, 0.13 mmol) was added to 3′-fluoro-4′-(3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide (18 mg, 0.044 mmol) in MeOH (0.52 mL). The mixture was stirred at rt for 1 h and then concentrated to dryness. The residue was subjected to FCC purification to give the title compound. MS (ESI): mass calcd. for C₂₁H₁₈FN₃O₃S, 411.11; m/z found, 412.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 9.36 (s, 1H), 8.34 (s, 1H), 8.23 (dd, J=7.9, 1.2, 1H), 8.12 (s, 1H), 7.68-7.61 (m, 1H), 7.61-7.54 (m, 1H), 7.42-7.30 (m, 5H), 5.21 (s, 1H), 4.88 (s, 2H), 2.52 (dd, J=13.9, 5.3, 3H).

Example 458

Zn dust (123 mg, 1.88 mmol) was added to a solution of N-(tert-butyl)-3′-fluoro-4′-(7-nitro-1H-indol-5-yl)-[1,1′-biphenyl]-2-sulfonamide (23 mg, 0.19 mmol) and NH₄Cl (101 mg, 1.88 mmol) in water (0.75 mL) and acetone (3.76 mL). The mixture was stirred at rt for 1 hour and then filtered through Celite. The resulting filtrate was concentrated to dryness and then taken up in water and extracted with EtOAc. The organic extract was dried (Na₂SO₄), filtered and concentrated to dryness to give the title compound (23 mg, 28%). MS (ESI): mass calcd. for C₂₄H₂₄FN₃O₂S, 437.16: m/z found, 438.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.20 (dd, J=8.0, 1.3, 1H), 8.17-8.10 (m, 1H), 7.63-7.56 (m, 2H), 7.54-7.48 (m, 1H), 7.42 (s, 1H), 7.38 (dd, J=7.8, 1.7, 2H), 7.32 (dd, J=11.4, 1.8, 1H), 6.86 (m, 1H), 6.62 (dd, J=3.2, 2.0, 1H), 3.78-3.68 (m, 2H), 1.05 (s, 9H).

Example 459

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl)acetamide. MS (ESI): mass calcd. for C₁₈H₁₅FN₄O, 322.12; m/z found, 322.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.40 (s, 1H), 8.38 (s, 1H), 8.02 (s, 1H), 7.91 (m, 1H), 7.53-7.21 (m, 6H), 6.73 (s, 2H), 1.92 (s, 3H).

Example 460

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)urea. MS (ESI): mass calcd. for C₁₇H₁₄FN₅O, 323.12; m/z found, 323.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (s, 1H), 8.02 (s, 1H), 7.95 (m, 1H), 7.86 (d, J=8.9, 1H), 7.56 (s, 1H), 7.36-7.19 (m, 4H), 7.08 (m, 1H), 6.73 (s, 2H), 6.01 (s, 2H).

Intermediate HF

A mixture of (4-bromo-2,3-difluorophenyl)boronic acid (400 mg, 1.69 mmol) and 5-bromopyrazin-2-amine (588 mg, 3.38 mmol was suspended in EtOH (5.6 ml) and toluene (5.7 mL) The resulting mixture was treated with aqueous Na₂CO₃ (2.0 N, 4.2 mL, 8.45 mmol). The resulting mixture was then sparged with nitrogen through the mixture for 10 min, and then Pd(PPh₃)₄ (98 mg, 0.085 mmol) was added. The reaction vessel was sealed and heated at 80° Celsius for 17 hours. The reaction mixture was cooled to rt and then partitioned between saturated aqueous NH₄Cl and EtOAc. The organic layer was dried over MgSO₄ and concentrated to dryness. The residue was suspended in DCM and the solid isolated by filtration to afford the title compound (160 mg, 33%), which was used without further purification. MS (ESI): mass calcd. for C₁₀H₆BrF₂N₃. 284.97; m/z found, 286.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36 (s, 1H), 8.01 (d, J=1.2, 1H), 7.68-7.56 (m, 2H), 6.87 (s, 2H).

Example 461

Nitrogen sparged DMSO (0.73 ml) was added to a mixture of 5-(4-bromo-2,3-difluorophenyl)pyrazin-2-amine (50 mg, 0.18 mmol), (2-(methylsulfonyl)phenyl)boronic acid (35 mg, 0.18 mmol), K₂CO₃ (73 mg, 0.532 mmol) and PdCl₂(dppf).CH₂Cl₂ (13 mg, 0.018 mmol) and heated at 80° Celsius for 2.5 hours. The mixture was cooled to rt and partitioned between sat. NaHCO₃ and EtOAc. The organic layer was isolated, dried over MgSO₄, and concentrated to dryness. Purification by FCC afforded the title compound (26 mg, 41%). MS (ESI): mass calcd. for C₁₇H₁₃F₂N₃O₂S, 361.07; m/z found, 362.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.44-8.41 (m, 1H), 8.14 (dd, J=7.9, 1.4, 1H), 8.04 (d, J=1.5, 1H), 7.84 (m, 1H), 7.78 (m, 1H), 7.75-7.66 (m, 1H), 7.53 (dd, J=7.5, 1.3, 1H), 7.30 (dd, J=11.6, 4.9, 1H), 6.85 (s, 2H), 3.06 (s, 3H).

Example 462

The title compound was prepared by methods analogous to Example 461 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₀H₂₀F₂N₄O₂S, 418.13; m/z found, 419.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.36 (s, 1H), 8.25 (dd, J=7.9, 1.3, 1H), 7.94 (d, J=1.4, 1H), 7.71-7.66 (m, 1H), 7.60 (m, 1H), 7.55 (m, 1H), 7.34 (dd, J=7.4, 1.1, 1H), 7.33-7.28 (m, 1H), 5.47 (s, 1H), 5.19 (s, 2H), 1.20 (s, 9H).

Example 463

Step A: 5-(4-chloro-2-fluoro-3-methylphenyl)pyrazin-2-amine

The title compound was prepared by methods analogous to Intermediate HF using (4-chloro-2-fluoro-3-methylphenyl)boronic acid. MS (ESI): mass calcd. for C₁₁H₉ClFN₃, 237.05; m/z found, 238.0 [M+H]⁺.

Step B

To a mixture of 5-(4-chloro-2-fluoro-3-methylphenyl)pyrazin-2-amine (75 mg, 0.32 mmol), (2-(methylsulfonamido)phenyl)boronic acid (85 mg, 0.39 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (5.0 mg, 0.006 mmol) in a sealed tube flushed with N₂ were added N₂ sparged K₃PO₄ (1.26 ml, 0.5 N) followed by N₂ sparged THF (0.63 ml). The reaction mixture was stirred at rt for 18 hours. The reaction mixture was then partitioned between EtOAc and brine. The organic layer was isolated, dried over MgSO₄, filtered and concentrated to dryness. Purification by FCC afforded the title compound (100 mg, 85%). MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.10; m/z found, 373.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.81 (s, 1H), 8.39-8.35 (m, 1H), 8.02 (d, J=1.5, 1H), 7.70 (m, 1H), 7.47 (dd, J=8.1, 1.0, 1H), 7.45-7.39 (m, 1H), 7.29 (m, 1H), 7.21 (dd, J=7.6, 1.5, 1H), 7.07 (d, J=8.0, 1H), 6.67 (s, 2H), 2.87 (s, 3H), 2.01 (d, J=2.5, 3H).

Example 464

A suspension of 4′-(5-aminopyrazin-2-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2-sulfonamide (168 mg, 0.40 mmol) in TFA (3 mL) was heated at 50° Celsius for 3 hours. The reaction was then cooled to rt and carefully partitioned between NaHCO₃ and EtOAc. The organic layer was isolated, dried over MgSO₄, and concentrated to dryness. Purification by FCC afforded the title compound (140 mg, 96%). MS (ESI): mass calcd. for C₁₆H₁₂F₂N₄O₂S, 362.06; m/z found, 363.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.40 (s, 1H), 8.12-8.01 (m, 2H), 7.72-7.61 (m, 3H), 7.45-7.36 (m, 3H), 7.19 (m, 1H), 6.81 (s, 2H).

Intermediate HG

The title compound was prepared using analogous conditions to those described in 5-(4-chloro-2-fluorophenyl)pyrazin-2-amine using (4-bromo-2,3-difluorophenyl)boronic acid and 5-bromopyrimidin-2-amine. MS (ESI): mass calcd. for C₁₀H₆BrF₂N₃, 284.97; m/z found, 286.0 [M+H]⁺.

Example 465

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(4-bromo-2,3-difluorophenyl)pyrimidin-2-amine and (2-(N-methylsulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₁₇H₁₄F₂N₄O₂S, 376.08; m/z found, 377.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.56 (s, 2H), 7.98 (dd, J=7.7, 1.6, 1H), 7.72 (m, 2H), 7.45 (dd, J=7.3, 1.6, 1H), 7.41 (m, 1H), 7.35 (m, 1H), 7.19 (m, 1H), 7.12 (s, 2H), 2.40 (d, J=4.9, 3H).

Example 466

The title compound was prepared using analogous conditions to those described in Example 1 using 5-(4-bromo-2,3-difluorophenyl)pyrimidin-2-amine and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₂₀H₂₀F₂N₄O₂S, 418.13; m/z found, 419.1 [M+H]⁺. ¹H NMR (600 MHz, CD₃OD) δ 8.63 (d, J=0.9, 2H), 8.15 (dd, J=7.9, 1.2, 1H), 7.67 (m, 1H), 7.63-7.58 (m, 1H), 7.38 (dd, J=7.5, 1.3, 1H), 7.35-7.29 (m, 1H), 7.27-7.18 (m, 1H), 1.13 (s, 9H).

Example 467

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-fluoro-4-(trifluoromethoxy)bromobenzene. MS (ESI): mass calcd. for C₁₇H₁₀F₅N₃O, 367.07; m/z found, 368.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (s, 1H), 8.03-7.96 (m, 2H), 7.78 (m, 1H), 7.56-7.49 (m, 3H), 7.37 (d, J=8.2, 1H), 6.75 (s, 2H).

Example 468

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromofluorobenzene. MS (ESI): mass calcd. for C₁₆H₁₁F₂N₃, 283.09; m/z found, 284.1 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.63-8.54 (m, 1H), 8.13 (d, J=1.4, 1H), 8.00 (m, 1H), 7.52-7.31 (m, 4H), 7.24-7.12 (m, 2H), 4.72 (s, 2H).

Example 469

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromochlorobenzene. MS (ESI): mass calcd. for C₁₆H₁₁ClFN₃, 299.06; m/z found, 300.1 [M+H]⁺. ¹H NMR (600 MHz, CDCl₃) δ 8.60 (s, 1H), 8.12 (s, 1H), 7.98 (m, 1H), 7.54-7.44 (m, 1H), 7.41-7.23 (m, 5H), 4.68 (s, 2H).

Example 470

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromotoluene. MS (ESI): mass calcd. for C₁₇H₁₄FN₃, 279.12; m/z found, 280.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) 8.59 (s, 1H), 8.12 (s, 1H), 7.95 (m, 1H), 7.28-7.12 (m, 6H), 4.66 (s, 2H), 2.32 (s, 3H).

Example 471

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-fluoro-4-(trifluoromethyl)bromobenzene. MS (ESI): mass calcd. for C₁₇H₁₀F₅N₃, 351.08; m/z found, 351.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.42 (s, 1H), 8.11-7.97 (m, 2H), 7.90-7.83 (m, 2H), 7.71 (d, J=8.1, 1H), 7.61-7.54 (m, 2H), 6.78 (s, 2H).

Example 472

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-trifluoromethylbromobenzene. MS (ESI): mass calcd. for C₁₇H₁₁F₄N₃, 333.09; m/z found, 334.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 8.09 (s, 1H), 7.91 (m, 1H), 7.81 (d, J=7.6, 1H), 7.69 (m, 1H), 7.59 (m, 1H), 7.44 (d, J=7.8, 1H), 7.23 (d, J=8.7, 1H), 7.17 (d, J=11.8, 1H).

Example 473

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-methoxybromobenzene. MS (ESI): mass calcd. for C₁₇H₁₄FN₃O, 295.11; m/z found, 296.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.38 (s, 1H), 8.08 (s, 1H), 7.85 (m, 1H), 7.45-7.29 (m, 4H), 7.14-7.00 (m, 2H), 3.84 (s, 3H).

Example 474

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-thiomethylbromobenzene. MS (ESI): mass calcd. for C₁₇H₁₄FN₃S, 311.09; m/z found, 312.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.37 (s, 1H), 8.02 (d, J=1.2, 1H), 7.90 (m, 1H), 7.44-7.32 (m, 2H), 7.30 (s, 1H), 7.27-7.18 (m, 3H), 6.71 (s, 2H), 2.40 (s, 3H).

Example 475

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(trifluoromethoxy)bromobenzene. MS (ESI): mass calcd. for C₁₇H₁₁F₄N₃O, 349.08; m/z found, 350.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.02 (s, 1H), 7.96 (m, 1H), 7.65-7.47 (m, 4H), 7.42 (d, J=5.1, 1H), 7.39 (s, 1H), 6.73 (s, 2H).

Example 476

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromophenol. MS (ESI): mass calcd. for C₁₆H₁₂FN₃O, 281.10; m/z found, 282.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 9.72 (s, 1H), 8.36 (s, 1H), 8.01 (d, J=1.4, 1H), 7.87 (m, 1H), 7.49 (dd, J=4.4, 1.3, 1H), 7.45 (s, 1H), 7.34 (dd, J=7.4, 1.3, 1H), 7.19 (m, 1H), 6.95 (d, J=7.3, 1H), 6.89 (m, 1H), 6.68 (s, 2H).

Example 477

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(phenylsulfonyl)benzene. MS (ESI): mass calcd. for C₂₂H₁₆FN₃O₂S, 405.09; m/z found, 406.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.35 (s, 1H), 8.29 (dd, J=6.7, 2.5, 1H), 8.03 (d, J=1.4, 1H), 7.80-7.66 (m, 3H), 7.58 (m, 1H), 7.41-7.28 (m, 5H), 6.84 (dd, J=8.0, 1.6, 1H), 6.78-6.66 (m, 3H).

Example 478

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2,6-difluorobromobenzene. MS (ESI): mass calcd. for C₁₆H₁₀F₃N₃, 301.08; m/z found, 302.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.02 (s, 1H), 7.97 (m, 1H), 7.56-7.47 (m, 1H), 7.43 (d, J=12.5, 1H), 7.37 (d, J=7.9, 1H), 7.25 (m, 2H), 6.76 (s, 2H).

Example 479

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₁₇FN₄O₂S, 420.11; m/z found, 421.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.73 (s, 1H), 8.38 (s, 1H), 8.04 (s, 1H), 7.85-7.75 (m, 1H), 7.59-7.46 (m, 5H), 7.29-7.10 (m, 6H), 6.71 (s, 2H).

Example 480

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-ethylbromobenzene. MS (ESI): mass calcd. for C₁₈H₁₆FN₃, 293.13; m/z found, 294.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.03 (d, J=1.3, 1H), 7.92 (m, 1H), 7.36 (d, J=3.9, 2H), 7.32-7.19 (m, 4H), 6.71 (s, 2H), 2.60 (q, J=7.5, 2H), 1.06 (t, J=7.5, 3H).

Example 481

Step A: Methyl 2-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)oxy)acetate

To a solution consisting of 4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ol Example 476 (50 mg, 0.18 mmol) and DMF (1 mL) was added Cs₂CO₃ (116 mg, 0.36 mmol). The mixture was stirred at rt for 30 min. Methyl 2-bromoacetate (30 mg, 0.19 mmol) was added and the resultant mixture stirred at rt for 1 hour and then poured into 15 mL of water. The precipitate was collected and washed with water and air dried to give methyl 2-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)oxy)acetate (50 mg, 72%). MS (ESI): mass calcd. for C₁₉H₁₆FN₃O₃, 353.12; m/z found, 354.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 8.38 (s, 1H), 8.03 (s, 1H), 7.93 (m, 1H), 7.57 (d, J=13.0, 1H), 7.54 (d, J=9.2, 1H), 7.50 (d, J=7.4, 1H), 7.34 (m, 1H), 7.10-7.02 (m, 2H), 6.70 (s, 2H), 4.89 (s, 2H), 3.71 (s, 3H).

Step B

To a solution of methyl 2-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yloxy)acetate (50 mg, 0.14 mmol) in THF (2 mL) were added LiOH.H₂O (63 mg, 1.5 mmol) and H₂O (2 mL). The mixture was stirred at rt for 14 hours. The THF was removed under reduced pressure, and the residue diluted with 15 mL of water, washed with DCM (5 mL×2), and then acidified with 1 N HCl to pH=7. The precipitate was collected and washed with water and dried under high vacuum to give the title compound (40 mg, 95% yield). MS (ESI): mass calcd. for C₁₈H₁₄FN₃O₃, 339.10; m/z found, 340.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 13.02 (s, 1H), 8.36 (s, 1H), 8.01 (s, 1H), 7.88 (m, 1H), 7.55 (d, J=13.0, 1H), 7.48 (d, J=9.2, 1H), 7.40 (d, J=7.4, 1H), 7.33 (m, 1H), 7.08-7.00 (m, 2H), 6.69 (s, 2H), 4.76 (s, 2H).

Example 482

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-isopropylbromobenzene. MS (ESI): mass calcd. for C₁₉H₁₈FN₃, 307.15; m/z found, 308.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.03 (s, 1H), 7.91 (m, 1H), 7.49-7.34 (m, 2H), 7.27-7.17 (m, 4H), 6.71 (s, 2H), 3.06-2.97 (m, 1H), 1.14 (d, J=6.8, 6H).

Example 483

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2-acetylphenyl)boronic acid. MS (ESI): mass calcd. for C₁₈H₁₄FN₃O, 307.11; m/z found, 307.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.03 (d. J=1.2, 1H), 7.91 (m, 1H), 7.69 (d, J=7.5, 1H), 7.61 (m, 1H), 7.53 (d, J=7.5, 1H), 7.48 (d, J=8.2, 1H), 7.26 (d, J=12.4, 1H), 7.19 (dd, J=8.0, 1.3, 1H), 6.75 (s, 2H), 2.31 (s, 3H).

Example 484

The title compound was prepared using analogous conditions to those described in Example 1 utilizing what 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(2,2,2-trifluoroethoxy)bromobenzene. MS (ESI): mass calcd. for C₁₈H₁₃F₄N₃O, 363.10; m/z found, 363.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.03 (s, 1H), 7.91 (m, 1H), 7.56-7.34 (m, 4H), 7.25 (d, J=8.0, 1H), 7.16 (m, 1H), 6.71 (s, 2H), 4.82 (q. J=8.8, 2H).

Example 485

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromobenzoic acid. MS (ESI): mass calcd. for C₁₇H₁₂FN₃O₂, 309.09; m/z found, 310.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 12.88 (s, 1H), 8.36 (s, 1H), 8.02 (s, 1H), 7.87 (m, 1H), 7.76 (d, J=7.5, 1H), 7.60 (m, 1H), 7.50 (d, J=7.2, 1H), 7.44 (d, J=8.2, 1H), 7.25 (d, J=5.1, 1H), 7.22 (s, 1H), 6.70 (s, 2H).

Example 486

The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromobenzamide. MS (ESI): mass calcd. for C₁₇H₁₃FN₄O, 308.11; m/z found, 309.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.35 (s, 1H), 8.01 (s, 1H), 7.86 (m, 1H), 7.75 (s, 1H), 7.55-7.26 (m, 7H), 6.70 (s, 2H).

Example 487

The title compound was prepared using methods analogous to those described in Example 369 3 using (2-isopropoxyphenyl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₁₉H₁₈FN₃O, 323.14; m/z found, 324.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.63-8.57 (m, 1H), 8.12 (d, J=1.4, 1H), 7.97-7.87 (m, 1H), 7.48-7.42 (m, 1.5H), 7.42-7.34 (m, 1.5H), 7.34-7.28 (m, 1H), 7.07-6.97 (m, 2H), 4.65 (s, 2H), 4.59-4.44 (m, 1H), 1.29 (d, J=6.1, 6H).

Example 488

The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclopropylmethoxy)pyridin-3-yl)boronic and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O, 336.14; m/z found, 337.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.64-8.59 (m, 1H), 8.17-8.09 (m, 2H), 8.02-7.93 (m, 1H), 7.72-7.66 (m, 1H), 7.54-7.48 (m, 2H), 7.01-6.95 (m, 1H), 4.67 (s, 2H), 4.24 (d, J=7.0, 2H), 1.37-1.22 (m, 1H), 0.66-0.54 (m, 2H), 0.42-0.31 (m, 2H).

Example 489

The title compound was prepared using methods analogous to those described in Step B of Example 377 using 2-[3,4′-difluoro-2′-(methylthio)-[1,1′-biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. for C₁₉H₁₃F₂N₃O₂S, 385.07; m/z found, 386.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.48 (s, 1H), 8.82 (s, 1H), 8.27 (d, J=8.0, 1H), 8.18-8.09 (m, 1H), 7.77-7.67 (m, 2H), 7.66-7.57 (m, 1H), 7.48-7.36 (m, 2H), 6.89-6.83 (m, 1H), 2.76 (s, 3H).

Example 490

Step A: N-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide

To a solution of 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1 g, 5 mmol) in pyridine (20 mL) was added methanesulfonyl chloride (627 mg, 5.5 mmol) and the mixture stirred at rt for 24 hours. The solvent was then removed under reduced pressure, and the resulting residue redissolved in DCM (200 mL), washed with 1 N HCl (1×100 mL) and 20% NaHCO₃ (1×100 mL). The organic layer was then isolated, dried (Na₂SO₄) and concentrated to dryness. The crude product was purified by crystallization from DCM/hexanes to give the title compound (700 mg, 52%). ¹H NMR (400 MHz, CDCl₃) δ 8.43 (s, 1H), 7.82-7.77 (m, 1H), 7.59 (d, J=8.2, 1H), 7.51-7.43 (m, 1H), 7.17-7.10 (m, 1H), 2.95 (s, 3H), 1.37 (s, 12H).

Step B:—N-Methyl-N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-methane-sulfonamide

To a round bottom flask under nitrogen were added N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide (250 mg, 0.84 mmol), K₂CO₃ (140 mg, 1.01 mmol) and acetone (5.0 mL). Iodomethane (0.06 mL, 1 mmol) was then added to the mixture dropwise and the reaction stirred for 18 hours at rt. The reaction was then diluted with ethyl acetate (100 mL), washed with water (2×) and brine (1×), dried (Na₂SO₄) and concentrated to dryness. The crude product was purified by FCC providing the title compound (230 mg, 88%). ¹H NMR (400 MHz, CDCl₃) δ 7.82 (dd, J=7.3, 1.8, 1H), 7.51-7.43 (m, 1H), 7.40-7.29 (m, 2H), 3.32 (s, 3H), 2.93 (s, 3H), 1.36 (s, 12H).

Step C

The title compound was prepared using methods analogous to those described in Example 369 using N-methyl-N-(2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.11; m/z found, 373.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) 8.61-8.58 (m, 1H), 8.12 (d, J=1.5, 1H), 7.47-7.39 (m, 5H), 7.37-7.31 (m, 1H), 7.30-7.23 (m, 1H), 4.75 (s, 2H), 3.17 (s, 3H), 2.76 (s, 3H).

Example 491

Step A: N-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanesulfonamide

The title compound was prepared using methods analogous to those described in Step A of Example 490 using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline for 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline and ethanesulfonyl chloride. ¹H NMR (400 MHz, CDCl₃) δ 8.52 (s, 1H), 7.82-7.74 (m, 1H), 7.64 (d, J=8.3, 1H), 7.49-7.41 (m, 1H), 7.14-7.06 (m, 1H), 3.12 (q, J=7.4, 2H), 1.37 (s, 12H), 1.32 (t, J=7.4, 3H).

Step B

The title compound was prepared using methods analogous to those described in Step C of Example 490 using N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanesulfonamide and 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. for C₂₀H₁₇FN₄O₂S, 396.11; m/z found, 397.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.16 (s, 1H), 8.78 (d, J=2.6, 1H), 8.20-8.11 (m, 2H), 7.75-7.66 (m, 2H), 7.47-7.37 (m, 1H), 7.36-7.28 (m, 2H), 7.27-7.20 (m, 1H), 6.87-6.79 (m, 1H), 6.59 (s, 1H), 3.11 (q, J=7.4, 2H), 1.33-1.18 (m, 3H).

Example 492

The title compound was prepared using methods analogous to those described in Step C of Example 490 using 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. C₂₀H₁₇FN₄O₂S, 396.11; m/z found, 397.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.69 (d, J=2.6, 1H), 8.05-7.99 (m, 1H), 7.97 (d, J=3.6, 1H), 7.67-7.61 (m, 1H), 7.57-7.48 (m, 3H), 7.46-7.39 (m, 2H), 6.72 (d, J=3.6, 1H), 4.75 (s, 1H), 3.14 (s, 3H), 2.99 (s, 3H).

Example 493

The title compound was prepared using methods analogous to those described in Step C of Example 490 using 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. C₂₁H₁₉FN₄O₂S, 410.12: m/z found, 411.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 11.04 (s, 1H), 8.77 (d, J=2.7, 1H), 8.13-8.05 (m, 1H), 7.70-7.63 (m, 1H), 7.53-7.42 (m, 4H), 7.40-7.30 (m, 2H), 6.78-6.71 (m, 1H), 3.17 (s, 3H), 2.99-2.88 (m, 2H), 1.27 (t, J=7.4, 3H).

Example 494

The title compound was prepared using methods analogous to those described in Example 369 using N-methyl-N-(2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanesulfonamide and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. C₁₉H₁₉FN₄O₂S, 386.12; m/z found, 387.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.63-8.57 (m, 1H), 8.13-8.09 (d, J=1.5, 1H), 8.04-7.95 (m, 1H), 7.72-7.62 (m, 0.75H), 7.59-7.51 (m, 0.25H), 7.50-7.39 (m, 3.75H), 7.37-7.32 (m, 1H), 7.31-7.28 (m, 0.25H), 4.69 (s, 2H), 3.16 (s, 3H), 2.89 (q, J=7.4, 2H), 1.25 (t, J=7.4, 3H).

Example 495

Step A: N-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-methylpropanesulfonamide

The title compound was prepared using methods analogous to those described in Step B of Example 490 using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline and isobutylsulfonyl chloride. ¹H NMR (400 MHz, CDCl₃) δ 8.48 (s, 1H), 7.81-7.75 (m, 1H), 7.63-7.58 (m, 1H), 7.49-7.41 (m, 1H), 7.14-7.06 (m, 1H), 2.96 (d, J=10.1, 2H), 2.39-2.19 (m, 1H), 1.37 (s, 12H), 1.11-0.99 (m, 6H).

Step B

The title compound was prepared using methods analogous to those described in Step C of Example 490 using N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isobutylsulfonamide and 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. C₂₂H₂₁FN₄O₂S, 424.14; m/z found, 425.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.09 (s, 1H), 8.78 (d, J=2.6, 1H), 8.20-8.11 (m, 1H), 7.73-7.65 (m, 2H), 7.46-7.37 (m, 1H), 7.34-7.29 (m, 2H), 7.26-7.19 (m, 2H), 6.87-6.79 (m, 1H), 6.59 (s, 1H), 2.97 (d, J=6.6, 2H), 2.31-2.13 (m, 1H), 1.05 (d, J=6.7, 6H).

Example 496

Step A:—N-Ethyl-N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methane-sulfonamide

The title compound was prepared using methods analogous to those described in Step B of Example 490 using iodoethane. ¹H NMR (400 MHz, CDCl₃) δ 7.87-7.82 (m, 1H), 7.50-7.44 (m, 1H), 7.40-7.31 (m, 2H), 3.72 (q, J=7.1, 2H), 2.93 (s, 3H), 1.35 (s, 12H), 1.21-1.10 (m, 3H).

Step B

The title compound was prepared using methods analogous to those described in Step B of Example 369 by using N-ethyl-N-(2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine. MS (ESI): mass calcd. C₁₉H₁₉FN₄O₂S.C₂HF₃O₂, 386.12; m/z found, 387.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, J=1.2, 1H), 8.33 (d, J=1.2, 1H), 8.14-8.04 (m, 1H), 7.51-7.33 (m, 6H), 3.46 (s, 2H), 2.95 (s, 3H), 1.05 (t, J=7.2, 3H).

Example 497

Step A:—N-Methyl-N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-methylpropanesulfonamide

The title compound was prepared using methods analogous to those described in Step B of Example 490 using N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-methylpropanesulfonamide. ¹H NMR (400 MHz, CDCl₃) δ 7.83-7.78 (m, 1H), 7.49-7.43 (m, 1H), 7.38-7.29 (m, 2H), 3.30 (s, 3H), 2.97-2.91 (m, 2H), 2.38-2.23 (m, 1H), 1.36 (s, 12H), 1.12-1.04 (m, 6H).

Step B

The title compound was prepared using methods analogous to those described in Step B of Example 369 using N-methyl-N-(2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-methylpropanesulfonamide and 5-(4-bromo-2-fluoro-phenyl)pyrazin-2-amine yielding the title compound after purification by HPLC (32 mg, 41%). MS (ESI): mass calcd. C₂₁H₂₃FN₄O₂S, 414.15; m/z found, 415.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.59 (s, 1H), 8.11 (d, J=1.3, 1H), 8.04-7.94 (m, 1H), 7.47-7.37 (m, 4H), 7.36-7.31 (m, 1H), 7.30-7.24 (m, 1H), 4.69 (s, 2H), 3.13 (s, 3H), 2.70 (d, J=6.6, 2H), 2.26-2.11 (m, 1H), 1.00 (d, J=6.7, 6H).

Example 498

The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and (2-bromophenyl)(morpholino)methanone. MS (ESI): mass calcd. for C₂₄H₂₀FN₃O₂, 401.15; m/z found, 402.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.16 (s, 1H), 8.58-8.48 (m, 1H), 8.21-8.13 (m, 1H), 7.61-7.30 (m, 8H), 6.63-6.57 (m, 1H), 3.78-3.56 (m, 3H), 3.48-3.33 (m, 2H), 3.14-3.00 (m, 1H), 2.94-2.75 (m, 2H).

Example 499

The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (2-bromophenyl)(morpholino)methanone. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O₂, 378.15; m/z found, 379.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, J=1.4, 2H), 7.54-7.41 (m, 5H), 7.36 (dd. J=8.0, 1.8, 1H), 7.32 (dd, J=11.5, 1.8, 1H), 5.20 (s, 2H), 3.74-3.58 (m, 3H), 3.49-3.30 (m, 2H), 3.15-3.01 (m, 1H), 2.94-2.77 (m, 2H).

Example 500

The title compound was prepared using methods analogous to those described in Example 369 using (2-bromophenyl)(morpholino)methanone. MS (ESI): mass calcd. for C₂₃H₁₉FN₄O₂, 402.15; m/z found, 403.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.12 (s, 1H), 8.82 (d, J=2.5, 1H), 8.19-8.09 (m, 1H), 7.71-7.65 (m, 1H), 7.55-7.34 (m, 6H), 6.87-6.80 (m, 1H), 3.74-3.57 (m, 3H), 3.51-3.30 (m, 2H), 3.15-3.01 (m, 1H), 2.97-2.77 (m, 2H).

Example 501

The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-(tert-butyl)benzamide. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O, 364.17; m/z found, 365.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.55-8.50 (m, 1H), 8.13 (d, J=1.4, 1H), 8.04-7.95 (m, 1H), 7.64-7.58 (m, 1H), 7.51-7.44 (m, 1H), 7.43-7.37 (m, 2H), 7.36-7.31 (m, 1H), 7.29-7.22 (m, 1H), 5.69 (s, 1H), 5.45 (s, 2H), 2.65-2.54 (m, 1H), 1.24 (m, 9H).

Example 502

The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromo-N-(tert-butyl)-5-fluorobenzamide. MS (ESI): mass calcd. for C₂₁H₂₀F₂N₄O, 382.16; m/z found, 383.2 [M+H]⁺.

Example 503

The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N,N-diethylbenzamide. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O, 364.17; m/z found, 365.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.59-8.54 (m, 1H), 8.11 (d, J=1.5, 1H), 8.00-7.90 (m, 1H), 7.50-7.36 (m, 5H), 7.36-7.29 (m, 1H), 4.69 (s, 2H), 3.87-3.69 (m, 1H), 3.17-2.92 (m, 2H), 2.85-2.66 (m, 1H), 0.99 (t, J=7.1, 3H), 0.81 (t, J=7.1, 3H).

Example 504

Step A: Methyl 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylate

A mixture of methyl 2-bromobenzoate (155 mg, 0.72 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (250 mg, 0.79 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (31 mg, 0.036 mmol) and K₂CO₃ (2 mL, 2 N) in 1,4-dioxane (10 mL) was stirred at 60° Celsius under N₂ for 3 hours. The solvent was removed and the crude product was purified by FCC to afford the desired product (218 mg, 93%). MS (ESI): mass calcd. for C₁₈H₁₄FN₃O₂, 323.11; m/z found, 323.9 [M+H]⁺.

Step B: 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid

A solution of methyl 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylate (218 mg, 0.67 mmol) in NaOH (8 mL, 2 N) and THF (8 mL) was stirred at 80° Celsius for 48 hours, and then concentrated to dryness. The residue was acidified with 2 N HCl. The precipitate was collected by filtration and washed with water several times, and dried in vacuo to afford the desired product (220 mg, 106%). The crude product was used without further purification. MS (ESI): mass calcd. for C₁₇H₁₂FN₃O₂, 309.09; m/z found, 309.9 [M+H]⁺.

Step C:

To a solution of DIPEA (47 mg, 0.36 mmol) in DMF (2 mL) were added 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid (75 mg, 0.24 mmol), (S)-1,1,1-trifluoropropan-2-amine (30 mg, 0.27 mmol) and HATU (110 mg, 0.290 mmol). The reaction mixture was stirred at rt overnight. The solvent was removed and the residue was purified by FCC to afford the title compound (41 mg, 41%). MS (ESI): mass calcd. for C₂₀H₁₆F₄N₄O, 404.13; m/z found, 404.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.87 (d, J=8.9, 1H), 8.44 (d, J=1.4, 2H), 7.58-7.50 (m, 2H), 7.49-7.40 (m, 3H), 7.26-7.19 (m, 2H), 6.86 (s, 2H), 4.60 (dd, J=15.7, 7.8, 1H), 1.15 (d, J=7.0, 3H).

Example 505

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid. MS (ESI): mass calcd. for C₂₀H₁₆F₄N₄O, 404.13; m/z found, 405.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.91 (d, J=8.9, 1H), 8.46-8.28 (m, 1H), 8.01 (d, J=1.4, 1H), 7.90-7.80 (m, 1H), 7.57-7.52 (m, 1H), 7.50-7.41 (m, 3H), 7.28-7.20 (m, 2H), 6.69 (s, 2H), 4.66-4.57 (m, 1H), 1.16 (d, J=7.0, 3H).

Example 506

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and piperazine. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O, 377.17; m/z found, 378.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.64-8.56 (m, 1H), 8.11 (d, J=1.5, 1H), 8.04-7.93 (m, 1H), 7.53-7.40 (m, 4H), 7.37 (dd, J=8.1, 1.8, 1H), 7.30 (dd, J=12.2, 1.7, 1H), 4.77 (s, 2H), 3.72 (d, J=25.1, 2H), 3.14 (s, 1H), 2.92 (s, 2H), 2.65 (s, 2H), 2.05 (s, 1H).

Example 507

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid for and 1-(piperazin-1-yl)ethanone. MS (ESI): mass calcd. for C₂₃H₂₂FN₅O₂, 419.18; m/z found, 420.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.65-8.56 (m, 1H), 8.11 (d, J=1.5, 1H), 8.02 (dd, J=10.4, 5.8, 1H), 7.55-7.41 (m, 4H), 7.42-7.32 (m, 1H), 7.34-7.28 (m, 1H), 4.71 (s, 2H), 3.65 (s, 2H), 3.51-2.93 (m, 4H), 2.79 (s, 2H), 1.99 (d, 3H).

Example 508

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and cyclohexanamine. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O, 390.19; m/z found, 391.4 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.60-8.53 (m, 1H), 8.11 (d, J=1.5, 1H), 8.03-7.93 (m, 1H), 7.74-7.62 (m, 1H), 7.54-7.37 (m, 3H), 7.32 (dd, J=8.0, 1.7, 1H), 7.30-7.20 (m, 1H), 5.24 (d, J=8.3, 1H), 4.72 (s, 2H), 3.93-3.73 (m, 1H), 1.78-1.67 (m, 2H), 1.61-1.44 (m, 3H), 1.39-1.27 (m, 2H), 1.14-0.98 (m, 1H), 0.97-0.81 (m, 2H).

Example 509

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O₃S, 426.12; m/z found, 427.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.60 (s, 1H), 8.11 (s, 1H), 8.11-8.02 (m, 1H), 7.58-7.47 (m, 3H), 7.43 (d, J=7.5, 1H), 7.37 (dd, J=8.1, 1.8, 1H), 7.32 (dd, J=12.1, 1.7, 1H), 4.74 (s, 2H), 4.23 (s, 1H), 4.05 (s, 1H), 3.57-3.48 (m, 1H), 3.38 (s, 1H), 3.01 (s, 1H), 2.85 (s, 1H), 2.62 (s, 1H), 2.05 (s, 1H).

Example 510

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and methylamine. MS (ESI): mass calcd. for C₁₈H₁₅FN₄O, 322.12; m/z found, 323.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.35 (dd, J=2.3, 1.6, 1H), 8.15 (d, J=4.7, 1H), 8.00 (d, J=1.5, 1H), 7.84 (d, J=8.1, 1H), 7.52-7.41 (m, 4H), 7.27 (s, 1H), 7.24 (dd, J=5.5, 1.7, 1H), 6.68 (s, 2H), 2.59 (d, J=4.6, 3H).

Example 511

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and (R)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C₂₀H₁₆F₄N₄O, 404.13: m/z found, 405.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.91 (d, J=8.8, 1H) 8.34 (s, 1H), 8.01 (d, J=1.2, 1H), 7.90-7.80 (m, 1H), 7.58-7.40 (m, 4H), 7.29-7.18 (m, 2H), 6.69 (s, 2H), 4.68-4.56 (m, 1H), 1.16 (d, J=7.0, 3H).

Example 512

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and (R)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂, 366.15; m/z found, 367.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.15-7.97 (m, 2H), 7.94-7.82 (m, 1H), 7.55-7.39 (m, 4H), 7.37-7.26 (m, 2H), 6.71 (s, 2H), 4.64 (s, 1H), 3.92-3.73 (m, 1H), 3.26-3.10 (m, 2H), 0.98 (d, J=6.1, 3H).

Example 513

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and (S)-2-aminopropan-1-ol for (S)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂, 366.15; m/z found, 367.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.05 (d, J=5.1, 2H), 7.93-7.83 (m, 1H), 7.54-7.43 (m, 3H), 7.37-7.28 (m, 2H), 6.72 (s, 2H), 4.66 (t, J=5.6, 1H), 3.82 (d, J=7.0, 1H), 3.35 (s, 1H), 3.16 (d, J=10.4, 2H), 0.98 (d, J=6.6, 3H).

Example 514

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and piperidin-4-ol. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.54 (d, J=13.9), 8.11-8.05 (m), 7.98-7.83 (m), 7.47-7.27 (m), 6.72 (s), 4.68 (s), 4.24-4.05 (m), 3.76-3.53 (m), 3.27-3.18 (m), 2.91-2.80 (m), 2.62-2.51 (m), 1.82 (m), 1.69 (m), 1.51-1.45 (m), 1.26-1.18 (m), 0.48-0.41 (m).

Example 515

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and piperidin-4-amine. MS (ESI): mass calcd. for C₂₂H₂₂FN₅O, 391.18; m/z found, 392.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.34 (s, 1H), 7.99 (s, 1H), 7.88 (s, 1H), 7.48 (d, J=14.8, 3H), 7.35-7.20 (m, 3H), 6.69 (s, 2H), 4.31 (s, 1H), 3.08-2.50 (m, 6H), 1.75 (t, J=80.9, 2H), 1.38-0.86 (m, 2H).

Example 516

The title compound was prepared using methods analogous to those described in Step C of Example 504 using thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O₃S, 426.12; m/z found, 426.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (s, 2H), 7.63 (s, 1H), 7.52 (d, J=20.5, 4H), 7.30 (dd, J=16.9, 9.9, 2H), 6.89 (s, 2H), 3.97 (s, 1H), 3.84 (s, 1H), 3.46 (s, 1H), 3.32 (s, 1H), 3.02 (s, 1H), 2.85 (s, 1H), 2.47 (s, 1H), 2.11 (s, 1H).

Example 517

The title compound was prepared using methods analogous to those described in Step C of Example 504 using (S)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂, 366.15; m/z found, 366.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (s, 2H), 8.00 (d, J=8.1, 1H), 7.62-7.50 (m, 1H), 7.48 (d, J=4.1, 1H), 7.43 (d, J=7.3, 3H), 7.34-7.23 (m, 2H), 6.88 (s, 2H), 4.61 (s, 1H), 3.87-3.75 (m, 1H), 3.38 (s, 1H), 3.14 (s, 1H), 0.96 (d, J=6.6, 3H).

Example 518

The title compound was prepared using methods analogous to those described in Step C of Example 504 using (R)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C₂₀H₁₆F₄N₄O, 404.13; m/z found, 404.9 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.52 (d, J=1.0, 2H), 7.68 (dd, J=7.6, 1.4, 1H), 7.60-7.49 (m, 1H), 7.48-7.38 (m, 3H), 7.28-7.25 (m, 1H), 7.22 (dd, J=11.1, 1.7, 1H), 5.39 (d, J=9.6, 1H), 5.18 (s, 2H), 4.73 (m, 1H), 1.12 (d, J=7.0, 3H).

Example 519

The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1, l-biphenyl]-2-carboxylic acid and piperazin-2-one. MS (ESI): mass calcd. for C₂₁H₁₈FN₅O₂, 391.14; m/z found, 392.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.58-8.55 (m), 8.50-8.40 (m), 8.10 (d, J=1.5), 8.04-7.98 (m), 7.56-7.41 (m), 7.37-7.27 (m), 6.75 (s), 6.43 (s), 5.06 (s), 4.83 (s), 4.45 (d, J=19.2), 4.05-3.95 (m), 3.72-3.46 (m), 3.27 (s), 3.14 (s), 2.97 (s), 2.67 (s).

Example 520

The title compound was prepared using methods analogous to those described in Step C of Example 504 using piperazin-2-one. MS (ESI): mass calcd. for C₂₁H₁₈FN₅O₂, 391.14; m/z found, 391.9 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.47 (d, J=1.2), 8.41 (d, J=1.2), 7.49-7.34 (m), 7.29-7.19 (m), 6.68 (s), 6.35 (s), 5.45 (s), 5.25 (s), 4.38 (d, J=18.7), 4.03 (s), 3.59-3.50 (m), 3.31-2.88 (m), 2.64 (s).

Intermediate HH

2-Bromo-5-(trifluoromethyl)benzoic acid (200 mg, 0.74 mmol) was dissolved in DMF (4.65 mL) and HATU (424 mg, 1.12 mmol) added to the resultant mixture at rt. The solution was stirred for 10 min then treated with N,N-diisopropylethylamine (0.51 mL, 3.0 mmol) and morpholine (0.096 mL, 1.1 mmol). The reaction was stirred for 15 hours then quenched by the addition of saturated NH₄Cl (5 mL) and EtOAc (5 mL). The aqueous phase was extracted with ethyl acetate (3×10 mL) and the combined organic extracts washed with brine, dried over Na₂SO₄ and concentrated to dryness. The crude product was purified by FCC to give the title compound. ¹H NMR (500 MHz, CDCl₃) δ 7.76-7.71 (m, 1H), 7.55-7.49 (m, 2H), 3.92-3.86 (m, 1H), 3.83-3.69 (m, 4H), 3.66-3.58 (m, 1H), 3.32-3.24 (m, 1H), 3.25-3.17 (m, 1H).

Example 521

The title compound was prepared in a manner similar to that described in Example 88 using (2-bromo-5-(trifluoromethyl)phenyl)(morpholino)-methanone. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₄O₂, 446.14; m/z found, 447.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40 (s, 1H), 8.18 (s, 1H), 8.10-8.01 (m, 1H), 7.90-7.82 (d, J=7.9, 1H), 7.78-7.69 (m, 2H), 7.47-7.35 (m, 2H), 3.72-3.60 (dd, J=10.0, 4.2, 2H), 3.58-3.49 (m, 1H), 3.44-3.36 (m, 1H), 3.15-3.04 (m, 1H), 2.90-2.80 (dd, J=13.4, 5.2, 1 H), 2.80-2.72 (m, 1H).

Example 522

The title compound was prepared in a manner similar to that described in Example 88 using (2-bromo-5-(trifluoromethyl)phenyl)(morpholino)methanone and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₄O₂, 446.14; m/z found, 447.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.65-8.58 (d, J=1.3, 2H), 7.91-7.85 (dd, J=8.3, 1.9, 1H), 7.78-7.76 (m, 1H), 7.76-7.73 (d, J=8.1, 1H), 7.71-7.63 (m, 1H), 7.46-7.43 (dd, J=2.7, 1.8, 1H), 7.43-7.41 (dd, J=6.2, 1.7, 1H), 3.72-3.60 (m, 2H), 3.60-3.52 (m, 1H), 3.46-3.39 (m, 1H), 3.37-3.33 (m, 1H), 3.16-3.09 (m, 1H), 2.92-2.77 (m, 2H).

Example 523

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 4-(2-bromophenoxy)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₃H₁₆FN₅O, 397.13; m/z found, 398.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.30 (s, 1H), 8.55-8.45 (m, 1H), 8.18-8.08 (m, 1H), 8.07 (d, J=5.7, 1H), 7.55-7.28 (m, 8H), 7.22 (dd, J=8.0, 1.4, 1H), 6.08 (d, J=5.7, 1H), 4.95 (s, 2H).

Example 524

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 2-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C₂₃H₁₆FN₅O, 397.13; m/z found, 398.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.94 (s, 1H), 8.47 (s, 1H), 8.11 (d, J=2.1, 1H), 7.96 (d, J=5.7, 1H), 7.54-7.30 (m, 9H), 6.07 (d, J=5.7, 1H), 4.96-4.85 (m, 2H).

Example 525

The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 2-(2-bromophenoxy)pyrimidine. MS (ESI): mass calcd. for C₂₃H₁₅FN₄O, 382.12: m/z found, 383.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.24 (s, 1H), 8.51-8.42 (m, 3H), 8.14-8.05 (m, 1H), 7.57-7.28 (m, 8H), 6.99-6.89 (m, 1H), 6.55 (dd, J=3.6, 1.8, 1H).

Intermediate HI

To a 48 mL pressure tube containing a stirbar were added 2-chloropyrimidine (1.69 g, 14.7 mmol), 2-bromophenol (1.63 mL, 14.0 mmol), Cs₂CO₃ (5.49 g, 16.8 mmol) and DMSO (30 mL). The vial was sealed and heated at 120° Celsius for 15 hours. The reaction was then diluted with 100 mL of ethyl acetate and extracted with brine (2×50 mL). The organic layer was isolated, dried and concentrated to dryness to provide the crude product which was subsequently purified FCC to provide the title compound. ¹H NMR (500 MHz, CDCl₃) δ 8.57 (s, 1H), 8.56 (s, 1H), 7.72-7.60 (dd, J=8.0, 1.6, 1H), 7.45-7.34 (m, 1H), 7.32-7.23 (m, 1H), 7.23-7.11 (m, 1H), 7.10-7.01 (t, J=4.8, 1H).

Intermediate HJ

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloropyrimidin-4-amine. ¹H NMR (500 MHz, CDCl₃) δ 8.04-7.94 (d, J=5.7, 1H), 7.66-7.58 (dd, J=8.0, 1.5, 1H), 7.41-7.30 (m, 1H), 7.30-7.20 (m, 1H), 7.18-7.05 (m, 1H), 6.20-6.09 (d, J=5.7, 1H), 5.19 (s, 2H).

Intermediate HK

The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloropyrimidin-2-amine. ¹H NMR (500 MHz, CDCl₃) δ 8.15-8.12 (d, J=5.6, 1H), 7.65-7.61 (dd, J=8.0, 1.6, 1H), 7.37-7.32 (m, 1H), 7.20-7.16 (dd, J=8.1, 1.5, 1H), 7.16-7.09 (m, 1H), 6.19-6.14 (d, J=5.7, 1H), 5.21 (s, 2H).

Intermediate HL

The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloropyrimidin-4-amine. ¹H NMR (500 MHz, DMSO-d) δ 7.95 (d, J=0.8, 1H), 7.67-7.62 (m, 1H), 7.38 (m, 1H), 7.20-7.14 (m, 2H), 6.75 (s, 2H), 5.77 (d, J=0.9, 1H).

Intermediate HM

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-4-methylpyrimidine. ¹H NMR (500 MHz, DMSO-d₆) δ 8.44 (d, J=5.1, 1H), 7.72 (dd, J=8.0, 1.6, 1H), 7.49-7.43 (m, 1H), 7.34 (dd, J=8.0, 1.6, 1H), 7.26-7.20 (m, 1H), 7.17-7.14 (m, 1H), 2.41 (s, 3H).

Intermediate HN

The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloro-2-methylpyrimidine. ¹H NMR (500 MHz, CDCl₃) δ 8.47 (d, J=5.8, 1H), 7.64 (dd, J=8.0, 1.5, 1H), 7.42-7.33 (m, 1H), 7.23-7.10 (m, 2H), 6.64 (d, J=5.7, 1H), 2.55 (s, 3H).

Intermediate HO

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloronicotinonitrile. ¹H NMR (500 MHz, CDCl₃) δ 8.32-8.21 (dd, J=5.0, 1.9, 1H), 8.09-7.95 (dd, J=7.6, 1.9, 1H), 7.68-7.60 (dd, J=8.0, 1.5, 1H), 7.45-7.36 (m, 1H), 7.29-7.23 (dd, J=8.1, 1.5, 1H), 7.21-7.16 (m, 1H), 7.15-7.09 (dd, J=7.6, 5.0, 1H).

Intermediate HP

The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloropicolinonitrile. ¹H NMR (500 MHz, DMSO-d₆) δ 8.60-8.55 (m, 1H), 7.82-7.77 (m, 1H), 7.73-7.66 (m, 1H), 7.51 (m, 1H), 7.42-7.36 (m, 1H), 7.34-7.27 (m, 1H), 7.11-7.06 (m, 1H).

Intermediate HQ

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-5-methoxypyrimidine. ¹H NMR (500 MHz, DMSO-d₆) δ 8.41 (d, J=0.6, 2H), 7.73 (d, J=8.0, 1H), 7.46 (m, 1H), 7.33 (d, J=8.1, 1H), 7.23 (m, 1H), 3.87 (d, J=0.5, 3H).

Intermediate HR

The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloro-2-(trifluoromethyl)pyrimidine. ¹H NMR (500 MHz, DMSO-d) δ 8.92 (d, J=5.8, 1H), 7.76 (dd, J=8.0, 1.5, 1H), 7.53-7.40 (m, 3H), 7.29 (m, 1H).

Intermediate HS

The title compound was prepared in a manner similar to that described for Intermediate HI using 4-(azetidin-1-yl)-6-chloropyrimidine. ¹H NMR (400 MHz, DMSO-d₆) δ 8.10 (d, J=0.8, 1H), 7.70 (dd, J=8.0, 1.5, 1H), 7.43 (m, 1H), 7.30-7.18 (m, 2H), 5.84 (d, J=0.8, 1H), 4.06-3.97 (m, 4H), 2.41-2.30 (m, 2H).

Intermediate HT

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-bromo-5-(trifluoromethyl)phenol. ¹H NMR (500 MHz, CDCl₃) δ 8.62-8.49 (d, J=4.8, 2H), 7.82-7.75 (dd, J=8.4, 0.9, 1H), 7.54-7.51 (d, J=2.0, 1H), 7.44-7.40 (m, 1H), 7.13-7.08 (m, 1H).

Intermediate HU

To a sealable 4 mL vial, containing 6-(chloromethyl)picolinonitrile (100 mg, 0.66 mmol) and 2-bromophenol (113 mg, 0.66 mmol), were added Cs₂CO₃ (320 mg, 0.98 mmol) and acetonitrile (1.7 mL). The vial was then heated at 80° Celsius for 15 hours. The reaction was then diluted with ethyl acetate, filtered through a celite plug and concentrated to dryness. The material was used without further purification. ¹H NMR (500 MHz, CDCl₃) δ 8.02-7.93 (m, 1H), 7.93-7.85 (m, 1H), 7.65-7.59 (dd, J=7.7, 1.1, 1H), 7.58-7.53 (dd, J=7.9, 1.6, 1H), 7.29-7.22 (m, 1H), 6.93-6.90 (dd, J=8.3, 1.3, 1H), 6.90-6.86 (m, 1H), 5.23 (s, 2H).

Intermediate HV

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-(chloromethyl)nicotinonitrile. ¹H NMR (500 MHz, CDCl₃) δ 8.83-8.74 (dd, J=4.9, 1.7, 1H), 8.02-7.97 (dd, J=7.9, 1.7, 1H), 7.57-7.49 (dd, J=7.9, 1.6, 1H), 7.42-7.35 (dd, J=7.9, 4.9, 1H), 7.27-7.20 (m, 1H), 7.08-7.01 (dd. J=8.2, 1.3, 1H), 6.91-6.83 (m, 1H), 5.37 (s, 2H).

Example 526

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidine. MS (ESI): mass calcd. for C₂₀H₁₄FN₅O, 359.12; m/z found, 360.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.56 (d, J=4.8, 2H), 8.35-8.30 (m, 1H), 7.99 (d, J=1.5, 1H), 7.82 (m, 1H), 7.58 (dd, J=7.6, 1.7, 1H), 7.52-7.46 (m, 1H), 7.42-7.28 (m, 4H), 7.17 (t, J=4.8, 1H), 6.70 (s, 2H).

Example 527

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₄FN₅O, 359.12; m/z found, 360.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.58 (d, J=4.8, 2H), 8.43 (d, J=1.4, 2H), 7.58-7.46 (m, 3H), 7.42-7.27 (m, 4H), 7.20 (t, J=4.8, 1H), 6.88 (s, 2H).

Example 528

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O, 374.13; m/z found, 375.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.35-8.28 (dd, J=2.1, 1.5, 1H), 8.08-8.00 (d, J=1.5, 1H), 7.84-7.77 (m, 1H), 7.77-7.71 (d, J=5.9, 1H), 7.52-7.47 (dd, J=7.6, 1.7, 1H), 7.46-7.40 (m, 1H), 7.38-7.32 (m, 2H), 7.32-7.27 (dd, J=12.6, 1.7, 1H), 7.23-7.16 (dd, J=8.1, 1.2, 1H), 6.11-6.09 (d, J=5.9, 1H).

Example 529

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-4-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O, 374.13; m/z found, 375.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.49-8.43 (d, J=1.4, 2H), 7.79-7.72 (d, J=5.9, 1H), 7.51-7.47 (dd, J=7.6, 1.7, 1H), 7.47-7.41 (m, 2H), 7.39-7.28 (m, 3H), 7.22-7.17 (dd, J=8.1, 1.2, 1H), 6.16-6.05 (d, J=5.9, 1H).

Example 530

The title compound was prepared in a manner similar to that described in Example 88 using 6-((2-bromophenoxy)methyl)picolinonitrile. MS (ESI): mass calcd. for C₂₃H₁₆FN₅O, 397.13; m/z found, 398.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.29 (d, J=1.5, 1H), 8.24 (s, 1H), 8.01-7.90 (m, 2H), 7.83-7.73 (m, 1H), 7.72-7.64 (dd, J=8.2, 1.0, 1H), 7.52-7.48 (dd, J=8.1, 1.6, 1H), 7.48-7.44 (m, 1H), 7.44-7.40 (dd, J=7.6, 1.7, 1H), 7.40-7.34 (m, 1H), 7.19-7.15 (dd. J=8.3, 1.1, 1H), 7.14-7.07 (m, 1H), 5.26 (s, 2H).

Example 531

The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenoxy)methyl)nicotinonitrile. MS (ESI): mass calcd. for C₂₃H₁₆FN₅O, 397.13; m/z found, 398.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.80-8.73 (dd, J=5.0, 1.7, 1H), 8.32-8.27 (m, 1H), 8.24-8.22 (d, J=1.4, 1H), 8.22-8.15 (dd, J=7.9, 1.7, 1H), 7.89-7.82 (m, 1H), 7.57-7.49 (dd, J=7.9, 5.0, 1H), 7.45 (s, 1H), 7.44-7.42 (dd, J=4.4, 1.6, 1H), 7.41-7.35 (m, 2H), 7.26-7.22 (dd, J=8.2, 1.0, 1H), 7.14-7.09 (m, 1H), 5.34 (s, 2H).

Example 532

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)nicotinonitrile. MS (ESI): mass calcd. for C₂₂H₁₄FN₅O, 383.12; m/z found, 384.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.28-8.25 (m, 1H), 8.22-8.18 (d, J=1.4, 1H), 8.17-8.13 (dd. J=5.0, 1.9, 1H), 8.10-8.04 (dd, J=7.6, 1.9, 1H), 7.89-7.82 (m, 1H), 7.57-7.53 (dd, J=7.6, 1.7, 1H), 7.53-7.47 (m, 1H), 7.45-7.41 (m, 1H), 7.41-7.37 (dd, J=8.1, 1.7, 1H), 7.34-7.28 (m, 2H), 7.12-7.04 (dd, J=7.6, 5.0, 1H).

Example 533

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O, 374.13; m/z found, 375.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.35-8.29 (m, 1H), 8.12-8.07 (d, J=1.5, 1H), 8.05-8.00 (d, J=7.0, 1H), 7.92-7.85 (m, 1H), 7.59-7.55 (dd, J=7.5, 1.8, 1H), 7.55-7.49 (m, 1H), 7.49-7.43 (m, 1H), 7.36-7.33 (dd, J=8.1, 1.7, 1H), 7.33-7.31 (dd, J=8.0, 1.3, 1H), 7.31-7.27 (dd, J=12.5, 1.7, 1H), 6.72-6.42 (d, J=7.0, 1H).

Example 534

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyrimidin-2-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O, 374.13; m/z found, 375.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.46 (s, 2H), 7.98-7.94 (d, J=5.8, 1H), 7.53-7.49 (d, J=7.6, 1H), 7.49-7.42 (m, 2H), 7.41-7.36 (m, 1H), 7.36-7.32 (d, J=8.2, 1H), 7.32-7.27 (m, 1H), 7.26-7.14 (d, J=8.0, 1H), 6.13-6.04 (d, J=5.8, 1H).

Example 535

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O, 374.13; m/z found, 375.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.24 (s, 1H), 7.97 (d, J=1.4, 1H), 7.90 (s, 1H), 7.74 (m, 1H), 7.50 (dd, J=7.6, 1.7, 1H), 7.42 (m, 1H), 7.36-7.29 (m, 2H), 7.28-7.22 (m, 1H), 7.13 (d, J=8.1, 1H), 6.65 (s, 2H), 6.52 (s, 2H), 5.67 (s, 1H).

Example 536

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)pyrimidin-4-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O, 374.13; m/z found, 375.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.38 (s, 2H), 7.92 (s, 1H), 7.47 (m, 2H), 7.40 (d, J=6.4, 1H), 7.36-7.23 (m, 3H), 7.11 (d, J=7.7, 1H), 6.68 (br, 4H), 5.68 (s, 1H).

Example 537

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)picolinonitrile. MS (ESI): mass calcd. for C₂₂H₁₄FN₅O, 383.12; m/z found, 384.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.47 (d, J=5.1, 1H), 8.29 (s, 1H), 7.96 (s, 1H), 7.81 (s, 1H), 7.66-7.56 (m, 2H), 7.48 (dd, J=20.1, 7.3, 2H), 7.39-7.20 (m, 3H), 7.07 (s, 1H), 6.68 (s, 2H).

Example 538

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)picolinonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₁₄FN₅O, 383.12; m/z found, 384.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.50 (d, J=5.7, 1H), 8.40 (d, J=1.3, 2H), 7.61 (dd, J=7.9, 2.0, 2H), 7.53 (dd, J=11.1, 5.0, 2H), 7.48-7.42 (m, 1H), 7.36 (dd, J=12.1, 1.5, 1H), 7.31 (dd, J=11.5, 5.0, 2H), 7.11 (dd, J=5.7, 2.5, 1H), 6.86 (s, 2H).

Example 539

The title compound was prepared in a manner similar to that described in Example 88 using 4-(azetidin-1-yl)-6-(2-bromophenoxy)pyrimidine. MS (ESI): mass calcd. for C₂₃H₁₉FN₆O, 414.16; m/z found, 415.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39-8.31 (m, 1H), 8.08 (d, J=0.9, 1H), 8.02 (d, J=1.5, 1H), 7.85 (m, 1H), 7.55 (dd, J=7.6, 1.7, 1H), 7.51-7.42 (m, 1H), 7.40-7.29 (m, 3H), 7.18 (dd, J=8.0, 1.2, 1H), 6.71 (s, 2H), 5.71 (d, J=0.9, 1H), 3.96 (t, J=7.5, 4H), 2.39-2.24 (m, 2H).

Example 540

The title compound was prepared in a manner similar to that described in Example 88 using 4-(azetidin-1-yl)-6-(2-bromophenoxy)pyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₃H₁₉FN₆O, 414.16; m/z found, 415.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, J=1.5, 2H), 8.11 (d, J=0.9, 1H), 7.60-7.52 (m, 2H), 7.50-7.41 (m, 1H), 7.41-7.31 (m, 3H), 7.17 (dd, J=8.1, 1.2, 1H), 6.89 (s, 2H), 5.73 (d, J=0.9, 1H), 3.98 (t, J=7.5, 4H), 2.41-2.27 (m, 2H).

Example 541

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-methylpyrimidine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O, 373.13; m/z found, 374.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.53 (s, 1H), 8.35 (d, J=5.8, 1H), 8.08 (d, J=1.3, 1H), 7.87 (m, 1H), 7.51 (dd, J=7.5, 1.9, 1H), 7.45 (m, 1H), 7.38 (dd, J=7.8, 6.9, 1H), 7.33 (dd, J=7.9, 1.6, 1H), 7.26 (m, 1H), 7.21 (d, J=8.1, 1H), 6.49 (d, J=5.8, 1H), 4.73 (s, 2H), 2.51 (s, 3H).

Example 542

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-methylpyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O, 373.13; m/z found, 374.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.50 (s, 2H), 8.38 (d, J=5.8, 1H), 7.53-7.28 (m, 6H), 7.21 (d, J=7.9, 1H), 6.51 (d, J=5.7, 1H), 5.30 (s, 2H), 2.52 (s, 3H).

Example 543

The title compound was prepared in a manner similar to that described in Example 88 using 5-bromo-1H-benzo[d]imidazole and 2-((3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-yl)oxy)pyrimidine. MS (ESI): mass calcd. for C₂₃H₁₅FN₄O, 382.12; m/z found, 383.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 9.31 (s, 1H), 8.52-8.45 (d, J=4.9, 2H), 7.95 (s, 1H), 7.92-7.87 (d, J=8.6, 1H), 7.79-7.70 (d, J=8.6, 1H), 7.59-7.55 (dd, J=7.7, 1.7, 1H), 7.55-7.47 (m, 2H), 7.45-7.39 (m, 2H), 7.38-7.32 (dd, J=12.0, 1.7, 1H), 7.30-7.23 (dd, J=8.1, 1.2, 1H), 7.13-7.08 (t, J=4.8, 1H).

Example 544

The title compound was prepared in a manner similar to that described in Example 88 using 6-bromo-3H-imidazo[4,5-b]pyridine and 2-((3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-yl)oxy)pyrimidine. MS (ESI): mass calcd. for C₂₂H₁₄FN₅O, 383.12; m/z found, 384.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.55-8.52 (m, 1H), 8.51-8.47 (d, J=4.9, 2H), 8.43 (s, 1H), 8.19-8.14 (t, J=1.7, 1H), 7.59-7.55 (dd, J=7.7, 1.8, 1H), 7.55-7.47 (m, 2H), 7.46-7.40 (m, 2H), 7.39-7.33 (dd, J=11.9, 1.7, 1H), 7.30-7.25 (dd, J=8.0, 1.2, 1H).

Example 545

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4-methylpyrimidine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O, 373.13; m/z found, 374.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.37 (d, J=5.1, 1H), 8.32 (d, J=1.6, 1H), 8.00 (d, J=1.6, 1H), 7.82 (m, 1H), 7.56 (dd, J=7.5, 1.7, 1H), 7.51-7.44 (m, 1H), 7.41-7.24 (m, 4H), 7.05 (d, J=5.1, 1H), 6.70 (s, 2H), 2.34 (s, 3H).

Example 546

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4-methylpyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O, 373.13; m/z found, 374.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.44 (s, 2H), 8.39 (d. J=5.1, 1H), 7.57-7.44 (m, 3H), 7.41-7.31 (m, 3H), 7.25 (d, J=7.2, 1H), 7.07 (d, J=4.9, 1H), 6.89 (s, 2H), 2.35 (s, 3H).

Example 547

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-(trifluoromethyl)pyrimidine. MS (ESI): mass calcd. for C₂₁H₁₃F₄N₅O, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.76 (d, J=5.8, 1H), 8.29-8.24 (m, 1H), 7.95 (d, J=1.5, 1H), 7.78 (m, 1H), 7.58 (dd, J=7.5, 1.8, 1H), 7.54-7.48 (m, 1H), 7.45 (m, 1H), 7.39 (dd, J=8.0, 1.3, 1H), 7.27 (m, 3H), 6.66 (s, 2H).

Example 548

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-(trifluoromethyl)pyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₃F₄N₅O, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.78 (d, J=5.7, 1H), 8.37 (m, 2H), 7.57 (dd, J=7.5, 1.8, 1H), 7.48 (m, 3H), 7.39 (dd, J=8.0, 1.3, 1H), 7.33-7.22 (m, 3H), 6.85 (s, 2H).

Example 549

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-5-methoxypyrimidine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O₂, 389.13; m/z found, 390.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.45 (s, 1H), 8.35 (s, 1H), 7.55 (m, 2H), 7.46 (m, 1H), 7.42-7.32 (m, 3H), 7.22 (d, J=8.0, 1H), 6.89 (s, 2H), 3.83 (s, 3H).

Example 550

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-5-methoxypyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O₂, 389.13; m/z found, 390.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.30-8.26 (m, 3H), 7.96 (d, J=1.5, 1H), 7.78 (m, 1H), 7.52 (dd, J=7.6, 1.7, 1H), 7.46-7.39 (m, 1H), 7.37-7.26 (m, 3H), 7.19 (dd, J=8.1, 1.2, 1H), 6.66 (s, 2H), 3.76 (d, J=1.9, 3H).

Example 551

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidine. MS (ESI): mass calcd. for C₂₁H₁₃F₄N₅O, 427.11; m/z found, 428.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.49 (s, 1H), 8.48 (s, 1H), 8.30-8.27 (d, J=1.7, 1H), 8.13-8.10 (d, J=1.4, 1H), 7.89-7.84 (m, 1H), 7.77-7.73 (m, 1H), 7.73-7.68 (m, 1H), 7.63-7.59 (d, J=2.0, 1H), 7.42-7.38 (dd, J=8.1, 1.7, 1H), 7.37-7.33 (dd, J=12.4, 1.7, 1H), 7.14-7.07 (t, J=4.9, 1H).

Example 552

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidine. MS (ESI): mass calcd. for C₂₁H₁₃F₄N₅O, 427.11; m/z found, 428.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.50 (s, 1H), 8.49 (s, 1H), 8.45-8.43 (d, J=1.4, 2H), 7.76-7.73 (m, 1H), 7.73-7.69 (m, 1H), 7.62-7.60 (d, J=1.6, 1H), 7.49-7.44 (m, 1H), 7.41-7.38 (m, 1H), 7.38-7.34 (dd, J=11.9, 1.7, 1H), 7.14-7.11 (t, J=4.8, 1H).

Example 553

The title compound was prepared in a manner similar to that described in Example 88 using 1-bromo-2-methoxy-4-(trifluoromethyl)benzene. MS (ESI): mass calcd. for C₁₈H₁₃F₄N₃O, 363.10; m/z found, 364.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39-8.37 (m, 1H), 8.11-8.08 (d, J=1.5, 1H), 7.93-7.87 (m, 1H), 7.55-7.52 (m, 1H), 7.45-7.37 (m, 2H), 7.36-7.31 (m, 2H), 3.90 (s, 3H).

Example 554

To a stirred solution of 5-[3-fluoro-2′-methoxy-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine (370 mg, 1.02 mmol) in dry dichloromethane (9.8 mL) at −78° Celsius, was added a boron tribromide in dichloromethane (3.1 mL, 1 M). The flask was slowly warmed to rt and stirred overnight. The reaction was poured into sat. NH₄Cl and the pH adjusted to 8 with saturated NaHCO₃. The resultant mixture was extracted with DCM (3×30 mL) and the combined extracts dried over Na₂SO₄, filtered and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C₁₇H₁₁F₄N₃O, 349.08; m/z found, 350.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.35 (m, 1H), 8.17-8.10 (d, J=1.5, 1H), 7.99-7.88 (m, 1H), 7.56-7.46 (m, 3H), 7.22-7.19 (m, 1H), 7.19-7.17 (d, J=1.7, 1H).

Example 555

To a 5 mL vial were added a stir bar, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol (40 mg, 0.12 mmol), 4-chloropyrimidin-2-amine (17.8 mg, 0.14 mmol), DMSO (1 mL) and Cs₂CO₃ (52 mg, 0.16 mmol). The vial was flushed with nitrogen and heated for 15 hours at 120° Celsius. The reaction was diluted with 5 mL of ethyl acetate and 5 mL of brine. The aqueous layer was then extracted with ethyl acetate (3×10 mL), the combined organic extracts dried over Na₂SO₄, and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C₂₁H₁₄F₄N₆O, 442.12; m/z found, 443.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.34 (s, 1H), 8.09-8.07 (d, J=1.4, 1H), 8.07-8.05 (d, J=7.0, 1H), 7.96-7.88 (m, 1H), 7.82-7.74 (d, J=1.6, 2H), 7.71 (s, 1H), 7.41-7.37 (dd, J=8.1, 1.7, 1H), 7.37-7.32 (dd, J=12.4, 1.7, 1H), 6.64-6.56 (d, J=7.0, 1H).

Example 556

The title compound was prepared in a manner similar to that described in Example 555 using 2-chloropyrimidin-4-amine. MS (ESI): mass calcd. for C₂₁H₁₄F₄N₆O, 442.12; m/z found, 443.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.32 (m, 1H), 8.10-8.04 (d, J=1.5, 1H), 7.98-7.90 (m, 1H), 7.89-7.84 (d, J=6.9, 1H), 7.78 (s, 3H), 7.40-7.37 (dd, J=8.1, 1.8, 1H), 7.37-7.33 (dd, J=12.4, 1.7, 1H), 6.36-6.26 (d, J=6.9, 1H).

Example 557

The title compound was prepared in a manner similar to that described in Example 88 using (2-((2-bromo-5-(trifluoromethyl)phenoxy)methoxy)ethyl)trimethylsilane and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₃H₂₅F₄N₃O₂Si, 479.17; m/z found, 480.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.55-8.48 (m, 2H), 7.60-7.51 (m, 3H), 7.48-7.36 (m, 3H), 5.33-5.29 (d, J=1.0, 2H), 3.73-3.66 (m, 2H), 0.93-0.84 (t, J=8.0, 2H), −0.03-−0.07 (m, 9H).

Example 558

To a stirred solution of 5-[3-fluoro-4′-(trifluoromethyl)-2′-{[2-(trimethylsilyl)ethoxy]-methoxy}-biphenyl-4-yl]pyrimidin-2-amine in 14 mL of THF were added water (1.40 mL), acetic acid (1.40 mL) and hydrochloric acid (0.43 mL, 6 N). The reaction was stirred overnight at 65° Celsius, before diluting with ethyl acetate (20 mL) and water (20 mL). The aqueous layer was extracted with ethyl acetate (3×30 mL) and the combined organic extracts dried over Na₂SO₄, and concentrated to dryness. The crude product was purified by FCC to provide the title compound. MS (ESI): mass calcd. for C₁₇H₁₁F₄N₃O, 349.08; m/z found, 350.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.61 (s, 2H), 7.61-7.48 (m, 4H), 7.23-7.19 (dd, J=8.3, 1.8, 1H), 7.19-7.17 (d, J=1.6, 1H).

Example 559

The title compound was prepared in a manner similar to that described in Example 555 using 2-chloropyrimidin-4-amine and 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol. MS (ESI): mass calcd. for C₂₁H₁₄F₄N₆O, 442.12; m/z found, 443.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.46 (s, 2H), 7.80-7.74 (m, 1H), 7.74-7.67 (m, 1H), 7.67-7.62 (m, 1H), 7.52 (s, 1H), 7.51-7.44 (m, 1H), 7.44-7.31 (dd, J=17.9, 10.0, 2H), 6.20-6.08 (dd, J=6.0, 1.4, 1H).

Example 560

The title compound was prepared in a manner similar to that described in Example 555 using 4-chloropyrimidin-2-amine and 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol. MS (ESI): mass calcd. for C₂₁H₁₄F₄N₆O, 442.12; m/z found, 443.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.51-8.43 (d, J=1.3, 2H), 8.06-7.94 (d, J=5.7, 1H), 7.72-7.69 (m, 1H), 7.69-7.66 (m, 1H), 7.55 (s, 1H), 7.52-7.47 (m, 1H), 7.39-7.31 (m, 2H), 6.31-6.03 (d, J=5.7, 1H).

Example 561

The title compound was prepared in a manner similar to that described in Example 555 using 6-chloropyrimidin-4-amine and 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol. MS (ESI): mass calcd. for C₂₁H₁₄F₄N₆O, 442.12; m/z found, 443.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.60-8.54 (d, J=1.3, 2H), 8.11-8.07 (d, J=0.9, 1H), 7.82-7.69 (m, 2H), 7.60 (s, 1H), 7.59-7.52 (m, 1H), 7.47-7.36 (m, 2H), 5.95-5.88 (d, J=0.9, 1H).

Example 562

The title compound was prepared in a manner similar to that described in Example 88 using 1-((2-bromo-5-(trifluoromethyl)phenyl)sulfonyl)-4-methylpiperazine. MS (ESI): mass calcd. for C₁₈H₁₀F₇N₃, 401.08: m/z found, 402.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.43-8.39 (m, 1H), 8.11-8.07 (m, 2H), 8.04-8.00 (d, J=8.2, 1H), 7.99-7.93 (m, 1H), 7.71-7.65 (d, J=8.0, 1H), 7.29-7.25 (d, J=8.2, 1H), 7.25-7.20 (d, J=11.6, 1H).

Example 563

The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-5-(trifluoromethyl)benzonitrile. MS (ESI): mass calcd. for C₁₈H₁₀F₄N₄, 358.08; m/z found, 359.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.45 (s, 1H), 8.23 (s, 1H), 8.11-8.08 (m, 1H), 8.08-8.03 (m, 2H), 7.91-7.84 (d, J=8.2, 1H), 7.58-7.49 (m, 2H).

Intermediate HW

The title compound was prepared using conditions analogous to those described in Example 1 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid and 1-(4-bromo-2-fluorophenyl)ethanone. ¹H NMR (500 MHz, CDCl₃) δ 8.19 (dd, J=7.9, 1.3, 1H), 7.95 (m, 1H), 7.63-7.57 (m, 1H), 7.57-7.52 (m, 1H), 7.38-7.30 (m, 2H), 7.28 (dd, J=7.5, 1.3, 1H), 2.70 (d, J=4.9, 3H), 1.05 (m, 9H).

Intermediate HX

The title compound was prepared using conditions analogous to those described in Example 1 using (4-acetyl-3-fluorophenyl)boronic acid and 2-bromo-N,N-diethylbenzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₂₀FNO₃S, 349.11; m/z found, 350.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.05 (dd, J=7.9, 1.2, 1H), 7.92 (m, 1H), 7.61-7.56 (m, 1H), 7.55-7.49 (m, 1H), 7.29-7.27 (m, 2H), 7.25-7.24 (m, 1H), 2.95 (q, J=7.1, 4H), 2.69 (d, J=4.9, 3H), 1.01 (t, J=7.1, 6H).

Intermediate HY

The title compound was prepared using conditions analogous to those described in Example 1 using (4-acetyl-3-fluorophenyl)boronic acid and 1-(2-bromo-phenylsulfonyl)pyrrolidine. MS (ESI): mass calcd. for C₁₈H₁₈FNO₃S, 347.10; m/z found, 348.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.10 (dd, J=7.9, 1.3, 1H), 7.95-7.89 (m, 1H), 7.63-7.58 (m, 1H), 7.58-7.51 (m, 1H), 7.30-7.27 (m, 2H), 7.26-7.25 (m, 1H), 2.98-2.90 (m, 4H), 2.69 (d, J=4.9, 3H), 1.76-1.67 (m, 4H).

Example 564

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₃F₃N₆O, 410.11; m/z found, 411.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.98 (s, 2H), 8.73 (d, J=2.3, 1H), 8.50 (d, J=4.8, 2H), 8.04 (dd, J=8.3, 2.4, 1H), 7.85 (d, J=8.4, 1H), 7.81-7.72 (m, 2H), 7.66 (d, J=1.7, 1H), 7.13 (t, J=4.8, 1H).

Example 565

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidin-2-amine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₄F₃N₇O, 425.12; m/z found, 426.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.89 (s, 2H), 8.67 (dd, J=2.3, 0.8, 1H), 7.99 (d, J=5.6, 1H), 7.95 (dd, J=8.3, 2.3, 1H), 7.81 (dd. J=8.2, 0.9, 1H), 7.76-7.69 (m, 2H), 7.59 (s, 1H), 6.18 (d. J=5.8, 1H).

Example 566

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₄N₆O, 342.12; m/z found, 343.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.97 (s, 2H), 8.70 (dd, J=2.3, 0.8, 1H), 8.48 (d, J=4.8, 2H), 8.06 (dd, J=8.3, 2.3, 1H), 7.85 (dd, J=8.3, 0.9, 1 H), 7.58 (dd, J=7.6, 1.8, 1H), 7.56-7.50 (m, 1H), 7.48-7.41 (m, 1H), 7.30 (dd. J=8.0, 1.2, 1H), 7.10 (t, J=4.8, 1H).

Example 567

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyrimidin-2-amine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₅N₇O, 357.13; m/z found, 358.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.91 (s, 2H), 8.68-8.59 (m, 1H), 8.03 (dd, J=6.9, 0.9, 1H), 7.97-7.89 (m, 1H), 7.83 (d, J=8.3, 1H), 7.60-7.53 (m, 2H), 7.52-7.44 (m, 1H), 7.35 (d, J=7.9, 1H), 6.53 (dd, J=6.9, 0.9, 1H).

Example 568

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-4-amine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₅N₇O, 357.13; m/z found, 358.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.86 (s, 2H), 8.64 (dd, J=2.3, 0.8, 1H), 7.95 (dd, J=8.3, 2.3, 1H), 7.78-7.72 (m, 2H), 7.53-7.45 (m, 2H), 7.38 (m, 1H), 7.23 (dd, J=8.1, 1.2, 1H), 6.11 (d, J=5.9, 1H).

Example 569

The title compound was prepared in a manner similar to that described in Example 571 using (4-bromo-2-methylphenyl)boronic acid in Step A. MS (ESI): mass calcd. for C₂₁H₂₄N₄O₂S, 396.16; m/z found, 397.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.21-8.17 (dd, J=8.0, 1.3, 1H), 8.13-8.07 (m, 2H), 7.61-7.54 (m, 1H), 7.52-7.47 (m, 1H), 7.47-7.39 (m, 3H), 7.36-7.31 (dd, J=7.5, 1.4, 1H), 4.82 (s, 2H), 4.16-4.09 (m, 1H), 2.41 (s, 3H), 1.05 (s, 9H).

Example 570

The title compound was prepared in a manner similar to that described in Example 571 using (4-bromo-2-methoxyphenyl)boronic acid in Step A. MS (ESI): mass calcd. for C₂₁H₂₄N₄O₃S, 412.16; m/z found, 413.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.51-8.45 (d, J=1.6, 1H), 8.21-8.16 (d, J=1.5, 1H), 8.16-8.11 (dd, J=8.0, 1.3, 1H), 7.84-7.78 (d, J=7.9, 1H), 7.67-7.61 (m, 1H), 7.58-7.54 (m, 1H), 7.45-7.38 (dd, J=7.6, 1.4, 1H), 7.32-7.25 (d, J=1.6, 1H), 7.15-7.09 (dd, J=7.9, 1.6, 1H), 3.92 (s, 3H), 1.04 (s, 9H).

Example 571

Step A: 5-(4-Bromophenyl)pyrazin-2-amine

(4-Bromophenyl)boronic acid (100 mg, 0.498 mmol) and 5-bromopyrazin-2-amine (173 mg, 0.996 mmol) were added to a 5 mL sealable vial equipped with a stir bar. To this vial was added toluene (1.5 mL), ethanol (1.5 mL) and K₂CO₃(0.7 mL, 2 M). The solvent was sparged with argon for 10 min before adding Pd(PPh₃)₄ (17 mg, 0.004 mmol), the vial sealed and the mixture stirred at 50° Celsius for 15 hours. The reaction was cooled to rt and then diluted with ethyl acetate (50 mL) and water (50 mL) and the layers separated. The aqueous layer was further extracted with ethyl acetate (3×50 mL). The combined organic extracts were dried with Na₂SO₄ and concentrated to dryness. The crude material was purified FCC to give 5-(4-bromophenyl)pyrazin-2-amine. ¹H NMR (500 MHz, CDCl₃) δ 8.52-8.31 (d, J=1.5, 1H), 8.08-7.95 (d, J=1.6, 1H), 7.86-7.71 (d, J=8.4, 2H), 7.63-7.49 (d, J=8.6, 2H), 4.70 (s, 2H).

Step B: 4′-(5-Aminopyrazin-2-yl)-N-tert-butylbiphenyl-2-sulfonamide

To a 5 mL sealable vial equipped with a stir bar were added 5-(4-bromophenyl)pyrazin-2-amine (40 mg, 0.16 mmol), (2-(N-(tert-butyl)sulfamoyl)phenyl)-boronic acid (62 mg, 0.24 mmol), K₂CO₃ (66 mg, 0.48 mmol) and Pd(dppf)Cl₂.CH₂Cl₂ (12 mg, 0.016 mmol). The vial was then sealed, evacuated, backfilled with argon and charged with argon sparged DMSO (0.64 mL). The vial was heated at 70° Celsius for 15 hours. The reaction mixture was cooled to rt diluted with ethyl acetate (2 mL) and water (2 mL), the layers separated and the aqueous layer further extracted with ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na₂SO₄ and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C₂₀H₂₂N₄O₂S, 382.15; m/z found, 383.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.48-8.39 (d, J=1.5, 1H), 8.23-8.18 (dd, J=8.0, 1.4, 1H), 8.18-8.15 (d, J=1.4, 1H), 7.99-7.95 (d, J=8.4, 1H), 7.65-7.61 (m, 2H), 7.61-7.55 (m, 1H), 7.55-7.46 (m, 1H), 7.38-7.31 (dd, J=7.5, 1.4, 1H), 3.70 (s, 1H), 1.25 (s, 1H), 1.03 (s, 9H).

Example 572

The title compound was prepared in a manner similar to that described in Example 571 using (2-(N,N-dimethylsulfamoyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₁₈H₁₈N₄O₂S, 354.12; m/z found, 355.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.60-8.32 (d, J=1.5, 1H), 8.09-8.05 (dd, J=8.0, 1.4, 1H), 8.05-8.02 (d, J=1.5, 1H), 7.95-7.86 (m, 2H), 7.72-7.62 (m, 1H), 7.61-7.53 (m, 1H), 7.48-7.41 (m, 2H), 7.41-7.35 (dd, J=7.6, 1.4, 1H), 2.40 (s, 6H).

Example 573

The title compound was prepared in a manner similar to that described in Example 571 using (2-(morpholinosulfonyl)phenyl)boronic acid in in Step B. MS (ESI): mass calcd. for C₂₀H₂₀N₄O₃S, 396.13; m/z found, 397.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.60-8.55 (d, J=1.4, 1H), 8.05-8.00 (dd, J=8.0, 1.3, 1H), 8.00-7.94 (m, 3H), 7.78-7.73 (m, 1H), 7.69-7.62 (m, 1H), 7.49-7.39 (m, 3H), 6.61 (s, 2H), 2.76-2.68 (t. J=4.7, 3H).

Example 574

The title compound was prepared in a manner similar to that described in Example 571 using (4-bromo-3-fluorophenyl)boronic acid in Step A. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.50-8.43 (d, J=1.5, 1H), 8.18-8.12 (dd, J=8.0, 1.4, 1H), 8.05-8.02 (d, J=1.5, 1H), 7.74-7.67 (m, 2H), 7.66-7.61 (m, 1H), 7.60-7.53 (m, 1H), 7.47-7.39 (m, 1H), 7.39-7.32 (dd, J=7.5, 1.5, 1H), 1.11 (s, 9H).

Example 575

The title compound was prepared in a manner similar to that described in Example 571 using (4-bromo-3-fluorophenyl)boronic acid in Step A and using (2-(N,N-dimethylsulfamoyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.11; m/z found, 373.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.51-8.41 (d, J=1.5, 1H), 8.10-8.06 (dd, J=8.0, 1.4, 1H), 8.06-8.02 (d, J=1.5, 1H), 7.75-7.67 (m, 3H), 7.67-7.59 (m, 1H), 7.43-7.39 (m, 1H), 7.39-7.34 (m, 1H), 2.49 (s, 6H).

The title

Example 576

Step A: 4-(4-Bromo-2-fluorophenyl)oxazol-2-amine

A solution of 2-bromo-1-(4-bromo-2-fluorophenyl)ethanone (53 mg, 0.18 mmol) and urea (10.6 mg, 0.18 mmol) in CH₃CN (0.7 mL) was heated at 80° Celsius for 18 hours. The mixture was cooled to rt and made basic with NaOH (2 N). The resulting solution was extracted with EtOAc and the extract was dried (Na₂SO₄), filtered, and concentrated to dryness. The residue was purified using FCC to give 4-(4-bromo-2-fluorophenyl)oxazol-2-amine (37 mg, 82%). MS (ESI): mass calcd. for C₉H₆BrFN₂O, 255.96; m/z found, 257.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 7.78 (m, 1H), 7.58 (d, J=4.3, 1H), 7.36-7.32 (m, 1H), 7.28 (dd, J=10.5, 1.9, 1H), 4.60 (s, 2H).

Step B

The title compound was prepared using methods described in Example 427 using 4-(4-bromo-2-fluorophenyl)oxazol-2-amine and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₁₉H₂₀FN₃O₃S, 389.12; m/z found, 390.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.18 (dd, J=7.9, 1.4, 1H), 7.98 (m, 1H), 7.66 (d, J=4.2, 1H), 7.57 (m, 1H), 7.54-7.48 (m, 1H), 7.38-7.30 (m, 3H), 4.63 (s, 2H), 3.64 (s, 1H), 1.03 (s, 9H).

Example 577

A solution of 4′-acetyl-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide (100 mg, 0.29 mmol), iodine (94.6 mg, 0.37 mmol), thiourea (44.01, 0.57 mmol) in EtOH (1.1 mL) was heated at 100 Celcius for 48 h. The reaction mixture was cooled to rt and the precipitate collected by filtration thus providing the title compound. MS (ESI): mass calcd. for C₁₉H₂₀FN₃O₂S₂, 405.10; m/z found, 406.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.71 (s, 2H), 8.19 (d, J=7.9, 1H), 7.94 (m, 1H), 7.59 (m, 1H), 7.54 (dd, J=11.6, 3.8, 1H), 7.44 (dd, J=12.1, 1.6, 1H), 7.38 (dd, J=8.1, 1.7, 1H), 7.33 (dd, J=7.5, 1.3, 1H), 6.96 (d, J=1.3, 1H), 1.08 (s, 9H).

Example 578

The title compound was prepared using methods analogous to those described in Example 577 using 4′-acetyl-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide. MS (ESI): mass calcd. for C₁₉H₂₀FN₃O₂S₂, 405.10; m/z found, 406.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.64 (s, 2H), 8.06 (dd, J=7.9, 1.2, 1H), 7.93 (m, 1H), 7.59 (td, J=7.5, 1.4, 1H), 7.52 (m, 1H), 7.39-7.28 (m, 3H), 6.95 (d, J=1.1, 1H), 2.97 (q, J=7.2, 4H), 1.02 (t, J=7.1, 6H).

Example 579

The title compound was prepared using methods analogous to those described in Example 577 using 1-[3-fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]ethanone. MS (ESI): mass calcd. for C₁₉H₁₈FN₃O₂S₂, 403.08; m/z found, 404.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.11 (d, J=6.7, 1H), 7.91 (m, 1H), 7.61 (td, J=7.5, 1.4, 1H), 7.54 (m, 1H), 7.41-7.28 (m, 3H), 6.94 (d, J=1.2, 1H), 2.95 (t, J=6.7, 4H), 1.85-1.64 (m, 4H).

Example 580

The title compound was prepared using methods analogous to those described in Example 577 using 3-fluoropyridin-2-amine. MS (ESI): mass calcd. for C₂₃H₂₁F₂N₃O₂S, 441.13; m/z found, 442.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.60-8.51 (m, 1H), 8.51-8.45 (m, 2H), 8.20 (d, J=6.6, 1H), 7.68-7.53 (m, 3H), 7.53-7.48 (m, 2H), 7.38 (d, J=7.6, 2H), 1.16-1.08 (m, 9H).

Example 581

The title compound was prepared using methods analogous to those described in Example 577 using pyridine-2,3-diamine. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O₂S, 438.15; m/z found, 439.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.19-8.11 (m, 2H), 7.99-7.95 (m, 1H), 7.61 (dd, J=8.1, 6.8, 1H), 7.55 (m, 1H), 7.38-7.32 (m, 3H), 7.20-7.12 (m, 2H), 6.36 (d, J=8.5, 1H), 1.13 (s, 9H).

Example 582

The title compound was prepared using methods analogous to those described in Example 577 using 6-aminonicotinamide. MS (ESI): mass calcd. for C₂₄H₂₃FN₄O₃S, 466.15; m/z found, 467.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.91 (s, 1H), 8.24 (d, J=6.5, 1H), 8.14-8.03 (m, 2H), 7.93-7.84 (m, 2H), 7.64-7.52 (m, 3H), 7.49-7.42 (m, 1H), 7.35 (d, J=11.7, 1H), 6.49-6.40 (m, 1H), 1.28-1.20 (m, 9H).

Example 583

The title compound was prepared using methods analogous to those described in Example 577 using 6-aminonicotinamide. MS (ESI): mass calcd. for C₂₄H₂₃FN₄O₃S, 466.15; m/z found, 467.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.91 (s, 1H), 8.24 (d, J=6.5, 1H), 8.14-8.03 (m, 2H), 7.93-7.84 (m, 2H), 7.64-7.52 (m, 3H), 7.49-7.42 (m, 1H), 7.35 (d, J=11.7, 1H), 6.49-6.40 (m, 1H), 1.28-1.20 (m, 9H).

Example 584

The title compound was prepared using methods analogous to those described in Example 577 using 2-amino-4-cyanopyridine. MS (ESI): mass calcd. for C₂₄H₂₁FN₄O₂S, 448.14; m/z found, 449.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.38-8.33 (m, 2H), 8.32-8.25 (m, 2H), 8.20 (dd, J=8.0, 1.2, 1H), 7.61 (m, 1H), 7.54 (td, J=7.8, 1.4, 1H), 7.51-7.45 (m, 1H), 7.42 (dd, J=8.0, 1.7, 1H), 7.35 (dd, J=7.5, 1.3, 1H), 7.16 (dd, J=7.0, 1.6, 1H), 1.07 (s, 9H).

Example 585

The title compound was prepared using methods analogous to those described in Example 577 using 2-amino-5-cyanopyridine. MS (ESI): mass calcd. for C₂₄H₂₁FN₄O₂S, 448.14; m/z found, 449.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.70 (s, 1H), 8.28 (m, 1H), 8.25-8.19 (m, 2H), 8.14 (d, J=9.4, 1H), 7.61 (m, 1H), 7.58-7.52 (m, 2H), 7.51-7.47 (m, 1H), 7.43 (dd, J=8.0, 1.7, 1H), 7.35 (dd, J=7.5, 1.3, 1H), 1.07 (s, 9H).

Example 586

The title compound was prepared using methods analogous to those described in Example 577 using 2-amino-5-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C₂₄H₂₁F₄N₃O₂S, 491.13; m/z found, 492.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.68 (s, 1H), 8.31 (dd, J=16.6, 8.7, 2H), 8.25 (d, J=2.8, 1H), 8.20 (dd, J=8.0, 1.2, 1H), 7.72-7.66 (m, 1H), 7.65-7.59 (m, 1H), 7.59-7.49 (m, 2H), 7.43 (dd, J=8.0, 1.7, 1H), 7.35 (dd, J=7.5, 1.2, 1H), 1.05 (m, 9H).

Example 587

The title compound was prepared using methods analogous to those described in Example 577 using 2-aminonicotinic acid. The ethyl ester was formed as a result of carrying out the reaction in EtOH. MS (ESI): mass calcd. for C₂₆H₂₆FN₃O₄S, 495.16; m/z found, 496.3 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.62-8.55 (m, 1H), 8.36 (d, J=6.5, 1H), 8.23-8.18 (m, 2H), 8.01 (d. J=7.3, 1H), 7.62-7.55 (m, 1H), 7.55-7.49 (m, 1H), 7.44-7.33 (m, 3H), 6.91 (m, 1H), 4.54 (dd, J=14.2, 7.1, 2H), 1.51 (t, J=7.2, 3H), 1.03 (s, 9H).

Example 588

Step A: 2-(4-Bromo-2-fluorophenyl)-5-methoxyimidazo[1,2-a]pyridine

A solution of 2-bromo-1-(4-bromo-2-fluorophenyl)ethanone (100 mg, 0.34 mmol) and 2-amino-3-methoxypyridine (42 mg, 0.34 mmol) in EtOH (0.8 mL) was heated at 90° Celsius for 24 hours. The reaction mixture was cooled to rt and diluted with water. The resultant precipitate was collected by filtration to provide 2-(4-bromo-2-fluorophenyl)-5-methoxyimidazo[1,2-a]pyridine (35 mg, 32%) which was used without further purification.

Step B

The title compound was prepared using methods analogous to those described in Example 88 using 2-(4-bromo-2-fluorophenyl)-5-methoxyimidazo[1,2-a]pyridine and 2-(tert-butylamino)sulfonylphenylboronic acid. MS (ESI): mass calcd. for C₂₄H₂₄FN₃O₃S, 453.15; m/z found, 454.4 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.58 (m, 1H), 8.19 (dd, J=8.0, 1.4, 1H), 8.10 (d, J=3.9, 1H), 7.81 (dd, J=6.7, 0.9, 1H), 7.60-7.55 (m, 1H), 7.54-7.48 (m, 1H), 7.43 (dd, J=12.1, 1.7, 1H), 7.38-7.32 (m, 2H), 6.73 (dd, J=7.6, 6.7, 1H), 6.50 (d, J=7.6, 1H), 4.07 (s, 3H), 3.68 (s, 1H), 1.02 (s, 9H).

Intermediate HZ

5-Bromopyrazin-2-amine (173 mg, 0.99 mmol) and (4-bromophenyl)boronic acid (100 mg, 0.490 mmol) were placed in a sealable vial followed by toluene (1.5 mL), ethanol (1.5 mL), and K₂CO₃ (0.7 mL, 2 M). The resultant mixture was then sparged with argon for 10 minutes before adding tetrakis(triphenylphosphine)palladium(0) (17 mg, 0.15 mmol), and heating at 50° Celsius. Reaction progress was monitored by LCMS. Once the reaction was complete, the reaction mixture was cooled to rt, diluted with EtOAc, filtered through Celite, and the resultant filtrate concentrated to dryness. The crude product was purified by FCC to provide the title compound. ¹H NMR (500 MHz, CDCl₃) δ 8.52-8.31 (d, J=1.5, 1H), 8.08-7.95 (d, J=1.6, 1H), 7.86-7.71 (d, J=8.4, 2H), 7.63-7.49 (d, J=8.6, 2H), 4.81-4.61 (s, 2H).

Intermediate IA

The title compound was prepared in a manner similar to that described for Intermediate HZ using (4-bromo-2-methylphenyl)boronic acid. ¹H NMR (500 MHz, CD₃OD) δ 8.01-7.97 (m, 2H), 7.47 (dd, J=1.9, 0.9, 1H), 7.43-7.38 (m, 1H), 7.23 (d, J=8.2, 1H), 2.31 (s, 3H).

Intermediate IB

The title compound was prepared in a manner similar to that described Intermediate HZ using (4-bromo-2-methoxyphenyl)boronic acid.

Example 589

5-(4-Bromophenyl)pyrazin-2-amine (51 mg, 0.20 mmol), (2-(methylsulfonyl)phenyl) boronic acid (61 mg, 0.31 mmol), K₂CO₃ (85 mg, 0.61 mmol) and Pd(dppf)Cl₂.CH₂Cl₂ (15 mg, 0.020 mmol) were weighed into a sealable vial containing a stir-bar. The vial was sealed and evacuated before backfilling with argon and adding deoxygenated DMSO (0.8 mL). The vial was heated at 70° Celsius for 3 hours by which point the starting material had been consumed. The vial was cooler to rt, diluted with MeOH (1 mL), filtered with a syringe filter, and the filtrate subjected to HPLC purification to provide the title compound. MS (ESI): mass calcd. for C₁₇H₁₅N₃O₂S, 325.39; m/z found, 326.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.32 (dd, J=8.1, 1.4, 2H), 8.26 (dd, J=8.0, 1.4, 1H), 8.00-7.90 (m, 2H), 7.74-7.64 (m, 1H), 7.64-7.56 (m, 3H), 7.41 (dd, J=7.5, 1.4, 1H), 2.70 (s, 3H).

Example 590

The title compound was prepared in a manner similar to that described in Example 589 using 5-(4-bromo-2-methylphenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₇N₃O₂S, 339.42; m/z found, 340.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.25 (dd, J=8.0, 1.4, 1H), 8.20 (d, J=1.5, 1H), 8.11 (d, J=1.6, 1H), 7.70-7.63 (m, 1H), 7.60-7.54 (m, 1H), 7.49-7.45 (m, 1H), 7.43-7.36 (m, 3H), 4.75 (s, 2H), 2.71 (s, 3H), 2.45 (s, 3H).

Example 591

The title compound was prepared in a manner similar to that described in Example 589 using 5-(4-bromo-2-methylphenyl)pyrazin-2-amine and (2-(N,N-dimethylsulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C₁₉H₂₀N₄O₂S, 368.46; m/z found, 369.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.16 (d, J=1.5, 1H), 8.12 (dd, J=8.0, 1.3, 1H), 8.10 (d, J=1.5, 1H), 7.60-7.55 (m, 1H), 7.52-7.47 (m, 1H), 7.43 (d, J=7.8, 1H), 7.35-7.29 (m, 3H), 4.77 (s, 2H), 2.44 (s, 3H), 2.42 (s, 6H).

Example 592

The title compound was prepared in a manner similar to that described in Example 589 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid and 5-(4-bromo-2-methoxyphenyl)pyrazin-2-amine. After the coupling, the tert-butyl group and methyl group were removed by treating a solution consisting of 4′-(5-aminopyrazin-2-yl)-N-(tert-butyl)-3′-methoxy-[1,1′-biphenyl]-2-sulfonamide (48 mg, 0.12 mmol) and DCM (2 mL), with BBr₃ (0.14 mL, 1 M in DCM) at −78° Celsius. The reaction mixture was warmed to room temperature. After the starting material was consumed the reaction mixture was poured into saturated NH₄Cl (10 mL) and extracted with DCM (3×10 mL). The combined organic extracts were dried with sodium sulfate, filtered, and concentrated to dryness. The resultant residue was subjected to HPLC purification to provide the title compound. MS (ESI): mass calcd. for C₁₆H₁₄N₄O₃S, 342.38; m/z found, 343.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.71 (s, 1H), 8.18 (dd, J=7.9, 1.4, 1H), 7.93 (d, J=1.4, 1H), 7.80 (d, J=8.2, 1H), 7.64-7.57 (m, 1H), 7.57-7.48 (m, 1H), 7.39 (dd, J=7.6, 1.3, 1H), 7.12 (dd, J=8.1, 1.9, 1H), 7.09-7.03 (m, 1H), 4.38 (s, 2H).

Example 593

The title compound was prepared in a manner similar to that described in Example 589 using (2-(methylsulfonamido)phenyl)boronic acid. MS (ESI): mass calcd. for C₁₇H₁₆N₄O₂S, 340.41; m/z found, 341.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.38 (d, J=1.4, 1H), 8.26 (d, J=1.5, 1H), 8.03-7.94 (m, 2H), 7.67 (dd, J=8.2, 1.1, 1H), 7.46 (d, J=8.3, 2H), 7.45-7.40 (m, 1H), 7.33-7.29 (m, 1H), 7.26-7.23 (m, 1H), 6.49 (s, 1H), 2.93 (s, 3H).

Example 594

The title compound was prepared in a manner similar to that described in Example 589 using (2-sulfamoylphenyl)boronic acid. MS (ESI): mass calcd. for C₁₆H₁₄N₄O₂S, 326.38; m/z found, 327.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.40 (d. J=1.5, 1H), 8.22 (d, J=1.4, 1H), 8.13 (dd, J=8.0, 1.3, 1H), 7.93 (d, J=8.3, 2H), 7.67-7.59 (m, 1H), 7.59-7.50 (m, 3H), 7.37 (dd, J=7.6, 1.4, 1H).

Example 595

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromoindolin-2-one. MS (ESI): mass calcd. for C₂₄H₂₃FN₂O₃S, 438.52; m/z found, 439.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.20 (dd, J=7.9, 1.4, 1H), 8.09 (s, 1H), 7.63-7.56 (m, 1H), 7.56-7.50 (m, 1H), 7.50-7.41 (m, 3H), 7.39-7.36 (m, 1H), 7.35 (dd, J=7.6, 1.4, 1H), 7.32 (dd, J=11.4, 1.8, 1H), 6.97 (d, J=7.9, 1H), 3.90 (s, 1H), 3.61 (s, 2H), 1.08 (s, 9H).

Example 596

The title compound was prepared in a manner similar to that described in Example 427 using 6-bromoquinazoline-2,4(1H, 3H)-dione. MS (ESI): mass calcd. for C₂₄H₂₂FN₃O₄S, 467.52; m/z found, 468.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.30-8.21 (m, 1H), 8.14 (dd, J=8.1, 1.4, 1H), 7.97-7.88 (m, 1H), 7.68-7.62 (m, 1H), 7.62-7.52 (m, 2H), 7.40 (dd, J=7.6, 1.4, 1H), 7.36 (s, 1H), 7.35-7.32 (m, 1H), 7.29 (d, J=8.5, 1H), 1.08 (s, 9H).

Example 597

The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-1H-indazol-3-amine. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O₂S, 438.53; m/z found, 439.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.15 (dd, J=8.0, 1.3, 1H), 8.11 (s, 1H), 7.80 (d, J=8.6, 1H), 7.69-7.63 (m, 1H), 7.63-7.55 (m, 2H), 7.49 (dd, J=8.8, 0.9, 1H), 7.40 (dd, J=7.6, 1.4, 1 H), 7.37-7.35 (m, 1H), 7.34 (dd, J=6.0, 1.6, 1H), 1.10 (s, 9H).

Example 598

The title compound was prepared in a manner similar to that described in Example 427 using 3-amino-6-bromopyrazine-2-carboxylic acid. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₄S, 444.49; m/z found, 445.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.50 (s, 1H), 8.13 (dd, J=8.0, 1.3, 1H), 7.89 (s, 1H), 7.65 (td, J=7.5, 1.4, 1H), 7.56 (td, J=7.8, 1.4, 1H), 7.43 (d, J=7.4, 1H), 7.37-7.22 (m, 2H), 1.07 (s, 8H).

Intermediate IC

Step A: 2-((2-Bromophenyl)thio)acetamide

To a 20 mL vial were added a stir-bar 2-chloroacetamide (783 mg, 8.37 mmol) 2-bromothiophenol (1.00 mL, 8.32 mmol) N,N-diisopropylethyl amine (1.5 ml, 8.7 mmol), and dry THF (5 mL). The reaction mixture was stirred for 4 days before concentrating and subjecting the crude product to FCC to afford the title compound. ¹H NMR (600 MHz, DMSO-d₆) δ 7.65 (s, 1H), 7.60 (dd, J=7.9, 1.4, 1H), 7.41-7.30 (m, 2H), 7.25 (s, 1H), 7.13-7.06 (m, 1H), 3.69 (s, 2H).

Step B: 2-((2-Bromophenyl)sulfonyl)acetamide

To a 40 mL vial were added 2-((2-bromophenyl)thio)acetamide (1.00 g, 4.06 mmol), Oxone (7.51 g, 12.2 mmol), methanol (12 mL) and water (15 mL). The reaction mixture was stirred for 21 hours at which point it was diluted with ethyl acetate (25 mL) and washed with aqueous Na₂S₂O₃ (25 mL). The organic and water layers were separated and the aqueous phase further extracted with ethyl acetate (3×25 mL). The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated to dryness. The crude product was subjected to FCC to provide the title compound. ¹H NMR (600 MHz, DMSO-d₆) δ 8.04-7.95 (m, 1H), 7.93-7.87 (m, 1H), 7.72 (s, 1H), 7.68-7.60 (m, 2H), 7.39 (s, 1H), 4.41 (s, 2H).

Intermediate ID

The title compound was prepared in a manner similar to that described for 2-((2-bromophenyl)sulfonyl)acetamide using 2-chloro-N,N-diethylacetamide in Step A. ¹H NMR (600 MHz, DMSO-d₆) δ 8.01-7.97 (m, 1H), 7.91-7.87 (m, 1H), 7.66-7.60 (m, 2H), 4.75 (s, 2H), 3.47-3.39 (q, J=7.1, 2H), 3.25-3.14 (q, J=7.0, 2H), 1.18-1.09 (t, J=7.1, 3H), 0.99-0.87 (t, J=7.0, 3H).

Intermediate IE

The title compound was prepared in a manner similar to that described for 2-((2-bromophenyl)sulfonyl)acetamide using 2-chloro-1-morpholinoethanone in Step A. ¹H NMR (600 MHz, DMSO-d₆) δ 8.06-8.01 (m, 1H), 7.93-7.88 (m, 1H), 7.68-7.60 (m, 2H), 4.84 (s, 2H), 3.63-3.55 (m, 4H), 3.53-3.48 (dd, J=5.6, 4.0, 2H), 3.42-3.37 (d, J=5.2, 2H).

Example 599

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)acetamide. MS (ESI): mass calcd. for C₁₈H₁₅FN₄O₃S, 386.41; m/z found, 387.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.55 (d, J=1.4, 2H), 8.15 (dd, J=7.9, 1.2, 1H), 7.80-7.72 (m, 1H), 7.69-7.61 (m, 1H), 7.59-7.53 (m, 1H), 7.43 (dd, J=7.5, 1.3, 1H), 7.39-7.30 (m, 2H).

Example 600

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)-N,N-diethylacetamide. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O₃S, 442.52; m/z found, 443.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.55 (d, J=1.4, 2H), 8.13 (dd, J=8.0, 1.3, 1H), 7.81-7.73 (m, 1H), 7.71-7.63 (m, 1H), 7.62-7.55 (m, 1H), 7.44 (dd, J=7.6, 1.3, 1H), 7.39 (dd, J=4.5, 1.7, 1H), 7.37 (dd, J=8.0, 1.3, 1H), 3.29-3.27 (m, 4H), 1.07 (t, J=7.2, 3H), 1.04 (t, J=7.2, 3H).

Example 601

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)-1-morpholinoethanone. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₄S, 456.5; m/z found, 457.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.55 (d, J=1.4, 2H), 8.15 (dd, J=7.7, 1.3, 1H), 7.83-7.72 (m, 1H), 7.72-7.63 (m, 1H), 7.58 (dd, J=8.5, 7.7, 1H), 7.45 (dd, J=7.2, 1.2, 1H), 7.42-7.31 (m, 2H), 3.67-3.55 (m, 4H), 3.48 (t, J=4.8, 2H), 3.39 (t, J=4.8, 2H).

Example 602

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 1-bromo-2-iodobenzene. MS (ESI): mass calcd. for C₂₆H₁₈F₂N₆, 452.47; m/z found, 453.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.35-8.30 (m, 2H), 8.02 (d, J=1.6, 2H), 7.78-7.70 (m, 2H), 7.49 (s, 4H), 7.07 (dd, J=8.1, 1.7, 2H), 7.04 (dd, J=12.4, 1.7, 2H).

Example 603

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-5-(trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C₁₈H₁₁F₄N₃O₂, 377.3; m/z found, 378.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.39 (s, 1H), 8.13 (s, 1H), 8.10 (s, 1H), 8.00-7.84 (m, 2H), 7.65 (d, J=8.0, 1H), 7.28 (d, J=8.1, 1H), 7.24 (d, J=12.6, 1H).

Example 604

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-5-(trifluoromethyl)benzaldehyde. MS (ESI): mass calcd. for C₁₈H₁₁F₄N₃O, 361.3; m/z found, 362.1 [M+H]⁺. The title compound can exist as either the aldehyde or the hydrate (gem-diol). Hydrate: ¹H NMR (400 MHz, CD₃OD) δ 8.39 (s, 1H), 8.15 (d, J=1.5, 1H), 8.10-8.02 (m, 2H), 7.70 (d, J=7.7, 1H), 7.49 (d, J=8.0, 1H), 7.36-7.27 (m, 2H), 5.47 (s, 1H). Aldehyde: ¹H NMR (400 MHz, CD₃OD) δ 10.04 (s, 1H), 8.43 (s, 1H), 8.39 (s, 1H), 8.26 (s, 1H), 8.02-7.94 (m, 2H), 7.77 (d, J=8.2, 1H), 7.44-7.36 (m, 2H).

Intermediate IF

2-Bromo-5-(trifluoromethyl)benzaldehyde (266 mg, 1.05 mmol) and morpholine (0.10 mL, 1.2 mmol) were dissolved in DCM (2 mL), stirred for 20 minutes, and then treated with NaBH₄ (79 mg, 2.1 mmol). The reaction was stirred overnight at rt, after which time, the reaction was quenched by the slow addition of water (10 mL). The aqueous layer was further extracted with DCM (3×10 mL), dried over sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by FCC to provide the title compound. ¹H NMR (500 MHz, CDCl₃) δ 7.77 (s, 1H), 7.67 (d, J=8.3, 1H), 7.37 (d, J=8.3, 1H), 3.80-3.69 (m, 4H), 3.63 (d, J=1.7, 2H), 2.59-2.49 (m, 4H).

Intermediate IG

The title compound was prepared using analogous conditions to those described in Intermediate IF utilizing tert-butyl piperidin-4-ylcarbamate. ¹H NMR (500 MHz, CDCl₃) δ 7.82 (s, 1H), 7.71-7.59 (m, 1H), 7.41 (d, J=8.3, 1H), 4.80 (s, 2H) 4.44 (s, 1H), 3.52 (s, 1H), 3.14-2.89 (m, 2H), 2.65 (t, J=12.0, 2H), 1.93 (d, J=12.0, 2H), 1.45 (s, 9H), 1.36-1.16 (m, 2H).

Example 605

The title compound was prepared using analogous conditions to those described in Example 6 utilizing 4-(2-bromo-5-(trifluoromethyl)benzyl)morpholine. MS (ESI): mass calcd. for C₂₂H₂₀F₄N₄O, 432.42; m/z found, 433.0 [M+H]⁺. ¹H NMR (400 MHz, MeOD) δ 8.43 (s, 1H), 8.21-8.11 (m, 2H), 8.11-8.04 (m, 1H), 7.90 (dd, J=8.2, 1.8, 1H), 7.67 (d, J=8.1, 1H), 7.40-7.27 (m, 2H), 4.54 (s, 2H), 3.78 (s, 4H), 3.07 (s, 4H).

Example 606

The title compound was prepared using analogous conditions to those described in Example 6 utilizing tert-butyl (1-(2-bromo-5-(trifluoromethyl)benzyl)piperidin-4-yl)carbamate, followed by removal of the Boc group.

Removal of Boc group: To a stirred solution of tert-butyl (1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)methyl)piperidin-4-yl)carbamate (83 mg, 0.15 mmol) in DCM (2.4 mL) was added TFA (0.64 mL, 8.4 mmol) at room temperature. When the reaction had gone to completion, as followed by LCMS, the stir-bar was removed and the reaction mixture concentrated to dryness and the resultant residue subjected to HPLC purification to provide the title compound. MS (ESI): mass calcd. for C₂₃H₂₃F₄N₅, 445.47; m/z found, 446.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.44-8.40 (m, 1H), 8.13 (d, J=1.5, 1H), 8.10-8.08 (m, 1H), 8.08-8.03 (m, 1H), 7.87 (d, J=8.2, 1H), 7.65 (d, J=8.1, 1H), 7.35 (dd, J=11.8, 1.7, 1H), 7.31 (dd, J=8.0, 1.7, 1H), 4.41 (s, 2H), 3.42-3.35 (m, 2H), 3.29-3.26 (m, 1H), 2.82-2.69 (m, 2H), 2.14-2.06 (m, 2H), 1.87-1.72 (m, 2H).

Example 607

The title compound was prepared using analogous conditions to those described in Intermediate IF using 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carboxylic acid and ethanolamine. MS (ESI): mass calcd. for C₂₀H₁₈F₄N₄O, 406.39; m/z found, 407.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.18 (s, 1H), 8.12-8.01 (m, 2H), 7.86 (dd, J=8.1, 1.7, 1H), 7.65 (d, J=8.1, 1H), 7.34 (dd, J=3.5, 1.6, 1H), 7.33-7.31 (m, 1H), 4.38 (s, 2H), 3.78-3.63 (m, 2H), 3.09-3.00 (m, 2H).

Intermediate IH

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-4,6-dimethylpyrimidine. ¹H NMR (400 MHz, DMSO-d₆) δ 7.72 (dd, J=8.0, 1.4, 1H), 7.48-7.41 (m, 1H), 7.31 (dd, J=8.0, 1.6, 1H), 7.25-7.19 (m, 1H), 7.02 (s, 1H), 2.32 (s, 6H).

Intermediate ZZ

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-6-methylpyrimidin-4-amine. ¹H NMR (400 MHz, DMSO-d₆) δ 7.63 (dd, J=8.0, 1.6, 1H), 7.40-7.34 (m, 1H), 7.21 (dd, J=8.0, 1.6, 1H), 7.15-7.09 (m, 1H), 6.83 (s, 2H), 5.99 (s, 1H), 2.07 (s, 3H).

Intermediate II

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-4-(trifluoromethyl)pyrimidine. ¹H NMR (400 MHz, DMSO-d) δ 9.03 (d, J=4.9, 1H), 7.86-7.73 (m, 2H), 7.55-7.42 (m, 2H), 7.32-7.24 (m, 1H).

Intermediate IJ

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloropyrimidin-5-amine. ¹H NMR (400 MHz, DMSO-d₆) δ d 7.98-7.94 (m, 2H), 7.71-7.66 (m, 1H), 7.45-7.37 (m, 1H), 7.24-7.20 (m, 1H), 7.17-7.12 (m, 1H), 5.22 (s, 2H).

Intermediate IK

The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloro-2-methylpyrimidin-4-amine. ¹H NMR (400 MHz, DMSO-d₆) δ 7.64 (dd, J=8.3, 1.5, 1H), 7.47-7.33 (m, 1H), 7.17 (ddd, J=7.2, 3.8, 1.3, 2H), 6.54 (s, 2H), 5.46 (s, 1H), 2.14 (s, 3H).

Intermediate IL

The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloro-6-cyclopropylpyrimidine. ¹H NMR (400 MHz, DMSO-d₆) δ 8.48 (s, 1H), 7.81-7.64 (m, 1H), 7.47-7.41 (m, 1H), 7.36-7.28 (m, 1H), 7.26-7.21 (m, 1H), 7.14-7.09 (m, 1H), 2.16-2.08 (m, 1H), 1.06-0.99 (m, 4H).

Intermediate IM

The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloropicolinonitrile. ¹H NMR (400 MHz, DMSO-d₆) δ 8.13 (dd, J=8.5, 7.3, 1H), 7.82 (dd, J=7.3, 0.7, 1H), 7.77 (dd, J=8.0, 1.5, 1H), 7.53-7.47 (m, 2H), 7.38 (dd, J=8.1, 1.6, 1H), 7.32-7.25 (m, 1H).

Intermediate IN

The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloronicotinonitrile. ¹H NMR (400 MHz, DMSO-d₆) δ 8.71-8.56 (m, 1H), 8.39-8.34 (m, 1H), 7.78-7.74 (m, 1H), 7.51-7.46 (m, 1H), 7.39-7.33 (m, 2H), 7.30-7.24 (m, 1H).

Intermediate IO

The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloro-2-(trifluoromethyl)pyridine. ¹H NMR (400 MHz, DMSO-d₆) δ 8.60 (d, J=5.7, 1H), 7.80 (dd, J=8.0, 1.5, 1H), 7.55-7.48 (m, 1H), 7.43-7.36 (m, 2H), 7.31 (m 1H), 7.03 (dd, J=5.7, 2.4, 1H).

Intermediate IP

The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-6-(trifluoromethyl)pyridine. ¹H NMR (400 MHz, DMSO-d₆) 8.18-8.12 (m, 1H), 7.80-7.74 (m, 1H), 7.65 (d, J=7.4, 1H), 7.51-7.46 (m, 1H), 7.40-7.35 (m, 2H), 7.29-7.24 (m, 1H).

Intermediate IQ

The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloropyridin-2-amine. ¹H NMR (400 MHz, DMSO-d₆) δ 8.14 (s, 1H), 7.82-7.72 (m, 2H), 7.50-7.41 (m, 1H), 7.29-7.18 (m, 2H), 6.11 (dd, J=5.9, 2.3, 1H), 6.02 (s, 2H), 5.73 (d, J=2.3, 1H).

Intermediate IR

The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloropyridin-3-amine. ¹H NMR (400 MHz, DMSO-d) δ 7.63 (dd, J=8.0, 1.6, 1H), 7.40-7.34 (m, 1H), 7.21 (dd, J=8.0, 1.6, 1H), 7.15-7.09 (m, 1H), 6.83 (s, 2H), 5.99 (s, 1H), 2.07 (s, 3H).

Example 608

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4,6-dimethylpyrimidine. MS (ESI): mass calcd. for C₂₂H₁₈FN₅O, 387.15; m/z found, 388.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.28 (s, 1H), 7.96 (s, 1H), 7.78 (m, 1H), 7.50 (d, J=7.6, 1H), 7.42 (m 1H), 7.35-7.23 (m, 3H), 7.19 (d, J=7.8, 1H), 6.88 (s, 1H), 6.66 (s, 2H), 2.22 (s, 6H).

Example 609

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4,6-dimethylpyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₁₈FN₅O, 387.15; m/z found, 388.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ d 8.40 (s, 2H), 7.52-7.46 (m, 2H), 7.44-7.39 (m, 1H), 7.35-7.25 (m, 3H), 7.18 (d, J=8.0, 1H), 6.90 (s, 1H), 6.85 (s, 2H), 2.24 (s, 6H).

Example 610

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C₂₂H₁₄F₄N₄O, 426.11; m/z found, 426.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.51 (d, J=5.7, 1H), 8.30-8.25 (m, 1H), 7.96 (d, J=1.5, 1H), 7.81 (m, 1H), 7.64 (dd, J=7.6, 1.8, 1H), 7.50 (m, 2H), 7.39-7.29 (m, 4H), 7.04 (dd, J=5.7, 2.4, 1H), 6.68 (s, 2H).

Example 611

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-(trifluoromethyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₁₄F₄N₄O, 426.11; m/z found, 426.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.51 (d, J=5.7, 1H), 8.38 (d, J=1.5, 2H), 7.62 (dd, J=7.6, 1.8, 1H), 7.56-7.42 (m, 3H), 7.38-7.30 (m, 4H), 7.04 (dd, J=5.6, 2.4, 1H), 6.84 (s, 2H).

Example 612

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4-(trifluoromethyl)pyrimidine. MS (ESI): mass calcd. for C₂₁H₁₃F₄N₅O, 427.11; m/z found, 428.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO): δ 8.91 (d, J=4.9, 1H), 8.34-8.28 (m, 1H), 8.00 (d, J=1.4, 1H), 7.82 (m, 1H), 7.67 (d, J=4.9, 1H), 7.61-7.58 (m, 1H), 7.55-7.50 (m, 1H), 7.47-7.39 (m, 2H), 7.34-7.29 (m, 2H), 6.70 (s, 2H).

Example 613

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4-(trifluoromethyl)pyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₃F₄N₅O, 427.11; m/z found, 428.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.93 (d, J=4.9, 1H), 8.41 (d, J=1.4, 2H), 7.69 (d, J=4.9, 1H), 7.60-7.57 (m, 1H), 7.55-7.50 (m, 2H), 7.46-7.38 (m, 2H), 7.35-7.29 (m, 2H), 6.88 (s, 2H).

Example 614

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-5-amine. MS (ESI): mass calcd. for C₂H₁₅FN₆O, 374.13; m/z found, 375.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.35-8.31 (m, 1H), 8.01 (m, 1H), 7.92-7.89 (m, 2H), 7.83 (m, 1H), 7.53 (dd, J=7.6, 1.7, 1H), 7.44-7.26 (m, 4H), 7.13 (dd, J=8.1, 1.2, 1H), 6.68 (s, 2H), 5.16 (s, 2H).

Example 615

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-5-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O, 374.13; m/z found, 374.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.45 (d, J=1.5, 2H), 7.95-7.90 (m, 2H), 7.57-7.50 (m, 2H), 7.44-7.39 (m, 1H), 7.38-7.37 (m, 1H), 7.36-7.34 (m, 1H), 7.33-7.28 (m, 1H), 7.11 (dd, J=8.1, 1.2, 1H), 6.86 (s, 2H), 5.19 (s, 2H).

Example 616

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-6-methylpyrimidin-4-amine. MS (ESI): mass calcd. for C₂₁H₁₇FN₆O, 388.15; m/z found, 389.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.31 (s, 1H), 7.98 (s, 1H), 7.82 (m, 1H), 7.47 (d, J=7.6, 1H), 7.42-7.25 (m, 4H), 7.13 (d, J=8.0, 1H), 6.80 (s, 2H), 6.66 (s, 2H), 5.92 (s, 1H), 2.03 (s, 3H).

Example 617

The title compound was prepared in a manner similar to that described in Example 88 2-(2-bromophenoxy)-6-methylpyrimidin-4-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₇FN₆O, 388.15; m/z found, 389.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (d, J=1.2, 2H), 7.53 (t, J=8.2, 1H), 7.49-7.44 (m, 1H), 7.41-7.36 (m, 1H), 7.34 (s, 1H), 7.33-7.30 (m, 1H), 7.29-7.25 (m, 1H), 7.12 (d, J=8.0, 1H), 6.85 (s, 2H), 6.82 (s, 2H), 5.94 (s, 1H), 2.04 (s, 3H).

Example 618

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)picolinonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₁₄FN₅O, 383.12; m/z found, 383.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (d, J=1.4, 2H), 7.99 (dd, J=8.5, 7.4, 1H), 7.71-7.67 (m, 1H), 7.56 (dd, J=7.6, 1.7, 1H), 7.55-7.46 (m, 2H), 7.42-7.37 (m, 1H), 7.35-7.25 (m, 4H), 6.85 (s, 2H).

Example 619

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)picolinonitrile. MS (ESI): mass calcd. for C₂₂H₁₄FN₅O, 383.12; m/z found, 383.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.30-8.27 (m, 1H), 8.00-7.94 (m, 2H), 7.83-7.77 (m, 1H), 7.68-7.64 (m, 1H), 7.57 (dd, J=7.6, 1.7, 1H), 7.52-7.45 (m, 1H), 7.43-7.36 (m, 1H), 7.34-7.32 (m, 1H), 7.32-7.27 (m, 3H), 6.67 (s, 2H).

Example 620

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)pyridin-3-amine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O, 373.14; m/z found, 373.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.31 (s, 1H), 7.98 (d, J=1.2, 1H), 7.83 (m, 1H), 7.51-7.45 (m, 2H), 7.42-7.31 (m, 3H), 7.23-7.18 (m, 1H), 7.03-6.99 (m, 1H), 6.94-6.90 (m, 1H), 6.71 (d, J=8.6, 1H), 6.66 (s, 2H), 5.01 (s, 2H).

Example 621

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)pyridin-3-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O, 373.14; m/z found, 373.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.44 (s, 2H), 7.53 (m, 1H), 7.50-7.45 (m, 2H), 7.44-7.38 (m, 2H), 7.36-7.30 (m, 1H), 7.20 (t, J=7.4, 1H), 7.06-7.00 (m, 1H), 6.91 (d, J=8.0, 1H), 6.85 (s, 2H), 6.72 (d, J=8.6, 1H), 5.03 (s, 2H).

Example 622

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)-2-methylpyrimidin-4-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₇FN₆O, 388.14; m/z found, 389.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.45 (d, J=1.4, 2H), 7.54 (dd, J=7.6, 1.7, 1H), 7.50-7.42 (m, 2H), 7.42-7.29 (m, 3H), 7.20 (dd, J=8.0, 1.2, 1H), 5.43-5.31 (m, 1H), 2.25 (s, 3H).

Example 623

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)-2-methylpyrimidin-4-amine. MS (ESI): mass calcd. for C₂₁H₁₇FN₆O, 388.14; m/z found, 389.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.31 (dd, J=2.1, 1.6, 1H), 8.02 (d, J=1.5, 1H), 7.81 (m, 1H), 7.55 (dd, J=7.5, 1.8, 1 H), 7.49-7.44 (m, 1H), 7.42-7.33 (m, 3H), 7.30 (dd, J=12.6, 1.7, 1H), 7.21 (dd, J=8.0, 1.2, 1H), 5.39 (s, 1H), 2.25 (s, 3H).

Example 624

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-6-(trifluoromethyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₁₄F₄N₄O, 426.11; m/z found, 427.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.42 (s, 2H), 8.04 (m, 1H), 7.59-7.48 (m, 4H), 7.41 (m, 1H), 7.35-7.24 (m, 4H), 6.89 (s, 2H).

Example 625

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C₂₂H₁₄F₄N₄O, 426.11; m/z found, 427.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.33-8.27 (m, 1H), 8.05-7.98 (m, 2H), 7.81 (m, 1H), 7.62-7.56 (m, 1H), 7.54-7.47 (m, 2H), 7.44-7.38 (m, 1H), 7.35-7.23 (m, 4H), 6.70 (s, 2H).

Example 626

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)nicotinonitrile. MS (ESI): mass calcd. for C₂₂H₁₄FN₅O, 383.12; m/z found, 384.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.57 (dd, J=2.3, 0.8, 1H), 8.34-8.31 (m, 1H), 8.24 (dd, J=8.8, 2.3, 1H), 7.99 (d, J=1.4, 1 H), 7.83 (m, 1H), 7.60 (dd, J=7.6, 1.6, 1H), 7.53-7.47 (m, 1H), 7.45-7.40 (m, 1H), 7.35-7.28 (m, 3H), 7.19 (dd, J=8.6, 0.6, 1H), 6.70 (s, 2H).

Example 627

The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)nicotinonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₁₄FN₅O, 383.12; m/z found, 384.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.60 (dd, J=2.3, 0.8, 1H), 8.44 (d, J=1.6, 2H), 8.26 (dd, J=8.6, 2.3, 1H), 7.59 (dd, J=7.6, 1.8, 1H), 7.56-7.48 (m, 2H), 7.45-7.39 (m, 1H), 7.36-7.27 (m, 3H), 7.21 (dd, J=8.7, 0.7, 1H), 6.89 (s, 2H).

Example 628

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)ethanol. MS (ESI): mass calcd. for C₁₈H₁₆FN₃O₂, 325.12; m/z found, 326.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.35 (s, 1H), 8.00 (d, J=1.2, 1H), 7.86 (m, 1H), 7.55-7.45 (m, 2H), 7.40-7.36 (m, 1H), 7.35-7.29 (m, 1H), 7.11 (d, J=8.2, 1H), 7.02 (m, 1H), 6.66 (s, 2H), 4.81 (s, 1H), 4.04 (t, J=5.0, 2H), 3.73-3.63 (m, 2H).

Example 629

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)ethanol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₆FN₃O₂, 325.12; m/z found, 326.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.48 (d, J=1.0, 2H), 7.57-7.51 (m, 2H), 7.48-7.44 (m, 1H), 7.38-7.30 (m, 2H), 7.12 (d. J=8.4, 1H), 7.02 (m, 1H), 6.90 (s, 2H), 4.05 (t, J=5.0, 2H), 3.68 (t, J=5.0, 2H).

Example 630

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)piperidine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O, 364.17; m/z found, 365.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36 (s, 1H), 8.29 (s, 1H), 8.01 (s, 1H), 7.89 (m, 1H), 7.46-7.31 (m, 4H), 7.19 (d, J=8.2, 1H), 7.05 (m, 1H), 6.68 (s, 2H), 4.68-4.59 (m, 1H), 2.97-2.87 (m, 4H), 2.07-1.93 (m, 2H), 1.82-1.54 (m, 2H).

Example 631

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)piperidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O, 364.17; m/z found, 365.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.48 (s, 2H), 8.29 (s, 1H), 7.56 (m, 1H), 7.46-7.31 (m, 4H), 7.20 (d, J=8.4, 1H), 7.05 (m, 1H), 6.86 (s, 2H), 4.62-4.66 (m, 1H), 2.91-2.93 (m, 4H), 2.07-1.96 (m, 2H), 1.77-1.65 (m, 2H).

Example 632

The title compound was prepared in a manner similar to that described in Example 88 using (R)-3-(2-bromophenoxy)piperidine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O, 364.17; m/z found, 365.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (dd, J=2.1, 1.6, 1H), 8.08 (d, J=1.5, 1H), 7.94-7.90 (m, 1H), 7.48-7.37 (m, 4H), 7.23-7.13 (m, 2H), 4.52-4.40 (m, 1H), 3.30-3.24 (m, 2H), 3.20-3.06 (m, 2H), 2.01-1.69 (m, 4H).

Example 633

The title compound was prepared in a manner similar to that described in Example 88 using (R)-3-(2-bromophenoxy)piperidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O, 364.17; m/z found, 365.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.48-8.45 (m, 2H), 7.60-7.48 (m, 2H), 7.46-7.34 (m, 3H), 7.23 (d, J=8.0, 1H), 7.13-7.06 (m, 1H), 6.87 (s, 2H), 4.68-4.56 (m, 1H), 3.35-3.30 (m, 1H), 3.11-2.99 (m, 2H), 2.98-2.89 (m, 1H), 2.03-1.93 (m, 1H), 1.88-1.77 (m, 1H), 1.72-1.58 (m, 2H).

Example 634

The title compound was prepared in a manner similar to that described in Example 88 using (S)-3-(2-bromophenoxy)piperidine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O, 364.17; m/z found, 365.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.02 (s, 1H), 7.91-7.87 (m, 1H), 7.52-7.45 (m, 2H), 7.42 (d, J=7.4, 1H), 7.36 (d, J=7.1, 1H), 7.22 (d, J=8.3, 1H), 7.12-7.08 (m, 1H), 6.69 (s, 2H), 4.57 (br m, 1H), 3.09-3.04 (m, 3H), 2.98-2.92 (m, 1H), 2.02-1.90 (m, 1H), 1.87-1.75 (m, 1H), 1.70-1.58 (m, 2H).

Example 635

The title compound was prepared in a manner similar to that described in Example 88 using (S)-3-(2-bromophenoxy)piperidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O, 364.17; m/z found, 365.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.48 (s, 2H), 7.59-7.48 (m, 2H), 7.44 (d, J=8.1, 1H), 7.40-7.35 (m, 2H), 7.24 (d, J=8.3, 1H), 7.11-7.07 (m, 1H), 6.87 (s, 2H), 4.73-4.53 (m, 1H), 3.38-3.30 (m, 1H), 3.12-2.86 (m, 3H), 2.04-1.94 (m, 1H), 1.80-1.71 (m, 2H), 1.65-1.54 (m, 1H).

Example 636

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-6-cyclopropylpyrimidine. MS (ESI): mass calcd. for C₂₃H₁₈FN₅O, 399.15; m/z found, 399.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (s, 1H), 8.30 (s, 1H), 7.97 (s, 1H), 7.81 (m, 1H), 7.58-7.54 (m, 1H), 7.49-7.43 (m, 1H), 7.41-7.35 (m, 1H), 7.33-7.23 (m, 3H), 6.98 (s, 1H), 6.68 (s, 2H), 2.09-2.01 (m, 1H), 1.02-0.89 (m, 4H).

Example 637

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-6-cyclopropylpyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₃H₁₈FN₅O, 399.15; m/z found, 399.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.45 (s, 1H), 8.42 (s, 2H), 7.56-7.50 (m, 2H), 7.48-7.43 (m, 1H), 7.41-7.36 (m, 1H), 7.33-7.23 (m, 3H), 6.99 (s, 1H), 6.86 (s, 2H), 2.09-2.01 (m, 1H), 1.02-0.92 (m, 4H).

Example 638

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyridin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O, 373.13; m/z found, 374.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36-8.30 (m, 1H), 7.99 (d, J=1.4, 1H), 7.90-7.82 (m, 1H), 7.76 (d. J=6.5, 1H), 7.63 (dd, J=7.7, 1.7, 1H), 7.57-7.48 (m, 1H), 7.46-7.40 (m, 1H), 7.39-7.31 (m, 2H), 7.27 (d, J=8.0, 1H), 6.70 (s, 2H), 6.55 (s, 2H), 6.23 (dd, J=6.4, 2.2, 1H), 5.86 (d, J=2.3, 1H).

Example 639

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyridin-2-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O, 373.13; m/z found, 374.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.44 (s, 2H), 7.77 (d, J=6.3, 1H), 7.65-7.48 (m, 3H), 7.45-7.32 (m, 3H), 7.25 (d, J=8.0, 1H), 6.88 (s, 2H), 6.52 (s, 2H), 6.23 (dd, J=6.3, 2.2, 1H), 5.87 (d, J=2.2, 1H).

Example 640

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)ethanamine. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O, 324.14; m/z found, 325.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36 (s, 1H), 8.31 (s, 1H), 8.01 (d, J=1.3, 1H), 7.90-7.86 (m, 1H), 7.50-7.45 (m, 2H), 7.41-7.33 (m, 2H), 7.14 (d, J=8.1, 1H), 7.08-7.05 (m, 1H), 6.67 (s, 2H), 4.10 (t, J=5.4, 2H), 3.01 (t, J=5.4, 2H).

Example 641

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)ethanamine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O, 324.14; m/z found, 325.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=0.9, 2H), 8.29 (s, 1H), 7.58-7.54 (m, 1H), 7.53-7.49 (m, 1H), 7.45 (dd, J=8.0, 1.4, 1H), 7.39-7.34 (m, 2H), 7.15 (d, J=8.1, 1H), 7.09-7.05 (m, 1H), 6.86 (s, 2H), 4.13 (t J=5.4, 2H), 3.05 (t, J=5.4, 2H).

Example 642

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)acetonitrile. MS (ESI): mass calcd. for C₁₈H₁₃FN₄O, 320.11; m/z found, 320.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.40-8.33 (m, 1H), 8.01 (d, J=1.4, 1H), 7.91-7.87 (m, 1H), 7.45-7.39 (m, 3H), 7.37 (s, 1H), 7.30-7.24 (m, 1H), 7.18-7.15 (m, 1H), 6.68 (s, 2H), 5.18 (s, 2H).

Example 643

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)acetonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₃FN₄O, 320.11; m/z found, 320.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.5, 2H), 7.60-7.56 (m, 1H), 7.46-7.34 (m, 4H), 7.26 (d. J=8.0, 1H), 7.18-7.14 (m, 1H), 6.87 (s, 2H), 5.18 (s, 2H).

Example 644

The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)acetic acid and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₄FN₃O₃, 339.10; m/z found, 339.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, J=1.4, 2H), 7.71 (d, J=13.3, 1H), 7.51 (d, J=5.7, 2H), 7.29 (dd, J=7.5, 1.7, 1H), 7.25-7.17 (m, 1H), 6.92-6.89 (m, 1H), 6.88-6.80 (m, 3H), 4.14 (s, 2H).

Intermediate IS

Step A: tert-Butyl 4-((3-bromopyridin-2-yl)oxy)piperidine-1-carboxylate

A suspension of 2-bromophenol (2.0 g, 10 mmol), tert-butyl 4-hydroxypiperidine-1-carboxylate (2.09 g, 10.4 mmol), and cesium carbonate (6.8 g, 21 mmol) in dimethylsulfoxide (10 mL) was heated at 130° Celsius overnight. The reaction mixture was then cooled to rt, diluted with water (20 mL), and extracted with ethyl acetate (3×20 mL). The combined organic extracts were washed with water (3×10 mL) and dried over anhydrous magnesium sulfate. The solvent was removed in vacuo, and the residue purified by FCC to provide the title compound.

Step B: 3-Bromo-2-(piperidin-4-yloxy)pyridine

To a solution of tert-butyl 4-((3-bromopyridin-2-yl)oxy)piperidine-1-carboxylate in MeOH (10 mL) was added HCl (2 mL, 1 N). The reaction mixture was stirred at rt for 2 h before adjusting the pH to ˜9 with NH₄OH. The mixture was then concentrated to dryness and the crude product purified by FCC to provide the title compound. ¹H NMR (400 MHz, DMSO-d₆) δ 8.17 (dd, J=4.8, 1.7, 1H), 8.06 (dd, J=7.7, 1.7, 1H), 6.98 (dd, J=7.7, 4.9, 1H), 5.31 (m, 1H), 3.18-3.07 (m, 4H), 2.22-2.05 (m, 2H), 1.92 (m, 2H).

Intermediate IT

Step A: 3-Bromo-2-((tetrahydro-2H-thiopyran-4-yl)oxy)pyridine

To a 100 mL reaction tube, equipped with a reflux condenser and under a nitrogen atmosphere, was added a solution consisting of tetrahydro-2H-thiopyran-4-ol (1.04 g, 8.78 mmol) in DMF (2 mL). The mixture was cooled to the 0° Celsius, and then treated with NaH (0.540 g, 60% dispersion in mineral oil, 13.5 mmol). When the addition was complete, the reaction was warmed to rt and stirred 30 min before adding 3-bromo-2-chloropyridine (1.3 g, 6.8 mmol), and heating at 130° Celsius for 10 hours. The reaction mixture was cooled to rt and carefully quenched with H₂O, concentrated to remove the solvent, and extracted with water (20 mL) and EtOAc (3×20 mL). The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated to dryness. The crude material was purified by FCC to provide the title compound.

Step B: 4-((3-Bromopyridin-2-yl)oxy)tetrahydro-2H-thiopyran 1,1-dioxide

To a 100 mL round-bottomed flask, was added a solution, consisting of 3-bromo-2-(tetrahydro-2H-thiopyran-4-yloxy)pyridine (1.6 g, 5.8 mmol) and DCM (25 mL), under a nitrogen atmosphere. The mixture was cooled to the 0° Celsius and m-CPBA (3.63 g, 14.6 mmol, 77%) was added in portions. When the addition was complete, the reaction was warmed to rt and stirred for 3 h. The reaction was quenched by adding H₂O (10 mL) and the organic layer isolated. The aqueous phase was extracted with DCM (3×20 mL) and the combined organic extracts were washed with saturated NaHCO₃, dried over sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by FCC to provide the title compound. ¹H NMR (400 MHz, DMSO-d₆) δ 8.17 (dd, J=4.9, 1.6, 1H), 8.07 (dd, J=7.8, 1.6, 1H), 6.99 (dd, J=7.7, 4.9, 1H), 5.43-5.36 (m, 1H), 3.23-3.19 (m, 2H), 3.15 (dd, J=14.3, 7.3, 2H), 2.31-2.25 (m, 4H).

Intermediate IU

Sodium hydride (1.6 g, 42 mmol) was added to cooled (ice-water bath) ethane-1,2-diol (5 mL) and the resulting mixture stirred at rt for 30 min before adding 3-bromo-2-chloropyridine (2.0 g, 100 mmol). The mixture was then heated at 130° Celsius under a N₂ atmosphere overnight before cooling to rt and subjecting the reaction mixture to FCC purification to afford the title compound. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (dd, J=4.9, 1.7, 1H), 7.82 (dd, J=7.6, 1.7, 1H), 6.80 (dd, J=7.6, 4.9, 1H), 4.54-4.50 (m, 2H), 3.97 (dd, J=8.8, 5.5, 2H), 3.18 (t, J=5.8, 1H).

Intermediate IV

To a cooled (0° C.) 150 mL reaction tube equipped with reflux condenser and under a nitrogen atmosphere, were added trans-4-aminocyclohexanol (2.0 g, 17 mmol), NaH (2.08 g, 60% dispersion in mineral oil, 52.1 mmol), and DMF (25 mL) to give a colorless solution. After stirring for 1 h, 3-bromo-2-chloropyridine (3.34 g, 17.4 mmol) was added to the mixture And the resulting mixture heated at 60° Celsius for 5 h. After the starting material was consumed, the reaction was cooled to room temperature and quenched with H₂O (2 mL). The reaction mixture was concentrated to dryness and the resultant residue purified by FCC to provide the title compound. ¹H NMR (400 MHz, DMSO-d₆) δ 8.11 (dd, J=4.8, 1.6, 1H), 7.98 (dd, J=7.7, 1.6, 1H), 6.89 (dd, J=7.7, 4.8, 1H), 4.92 (dd, J=9.4, 5.2, 1H), 2.98 (s, 1H), 2.05 (m, 2H), 1.95 (m, 2H), 1.53-1.38 (m, 4H)

Intermediate IW

The title compound was prepared in a manner similar to that described in Step A for the synthesis of 4-((3-bromopyridin-2-yl)oxy)tetrahydro-2H-thiopyran1,1-dioxide using tetrahydro-2H-pyran-4-ol. ¹H NMR (400 MHz, DMSO-d) 68.11 (dd, J=4.8, 1.7, 1 H), 7.99 (dd, J=7.7, 1.7, 1H), 6.90 (dd, J=7.7, 4.8, 1H), 5.22 (m, 1H), 3.86-3.77 (m, 2H), 3.49 (m, 2H), 1.95 (m, 2H), 1.61 (m, 2H).

Intermediate IX

Step A: (R)-2-((1-(Benzyloxy)propan-2-yl)oxy)-3-bromopyridine

To a stirred solution of (R)-1-(benzyloxy)propan-2-ol (2.0 g, 12 mmol) in dry DMF (5 mL) was added NaH (1.5 g, 36 mmol) at 0 Celsius. The reaction mixture was then stirred for 30 min before adding 3-bromo-2-chloropyridine (2.3 g, 12 mmol) and stirring continued for another 4 h. The reaction was quenched by slow addition of water (10 mL) and the resultant mixture extracted with ethyl acetate (3×10 mL). The combined organic extracts were dried over Na₂SO₄, filtered, concentrated to dryness, and the crude product purified by FCC to provide the title compound.

Step B: (R)-2-((3-Bromopyridin-2-yl)oxy)propan-1-ol

To a stirred solution of (R)-2-((1-(benzyloxy)propan-2-yl)oxy)-3-bromopyridine (2.4 g, 7.5 mmol) in dry DCM (10 mL) was added BBr₃ (7.5 mL, 22 mmol, 3 M in DCM) at −78 Celsius in a drop-wise manner and stirring continued for 3 h. The reaction mixture was warmed to rt and the pH adjusted to ˜7-8 with sat. NaHCO₃ (30 mL). The mixture was extracted with DCM (2×10 mL), and the combined extracts dried over Na₂SO₄, filtered, concentrated to dryness. The crude product was purified by FCC to provide the title compound. ¹H NMR (400 MHz, CDCl₃) δ 8.05-7.99 (m, 1H), 7.84-7.75 (m, 1H), 6.83-6.71 (m, 1H), 5.25-5.12 (m, 1H), 3.78 (d, J=5.1, 2H), 3.29 (s, 1H), 1.37 (d, J=6.4, 3H).

Intermediate IY

The title compound was prepared in a manner similar to that described for (R)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol using (S)-1-(benzyloxy)propan-2-ol. ¹H NMR (400 MHz, CDCl₃) δ 8.07-7.97 (m, 1H), 7.79 (m, 1H), 6.76 (m, 1H), 5.26-5.12 (m, 1H), 3.77 (t, J=6.1, 2H), 3.35 (s, 1H), 1.36 (d, J=6.3, 3H).

Example 645

The title compound was prepared in a manner similar to that described in Example 88 using 3-bromo-2-(piperidin-4-yloxy)pyridine. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O, 365.17; m/z found, 366.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (dd, J=2.3, 1.5, 1H), 8.20 (dd, J=4.9, 1.9, 1H), 8.04 (d, J=1.5, 1H), 8.00-7.88 (m, 2H), 7.60-7.52 (m, 2H), 7.15 (dd, J=7.4, 4.9, 1H), 6.73 (s, 2H), 5.45-5.32 (m, 1H), 3.11 (t, J=5.9, 4H), 2.23-2.06 (m, 2H), 2.04-1.83 (m, 2H).

Example 646

The title compound was prepared in a manner similar to that described in Example 88 using 3-bromo-2-(piperidin-4-yloxy)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O, 365.17; m/z found, 366.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.51 (d, J=1.5, 2H), 8.20 (dd, J=4.9, 1.9, 1H), 7.89 (dd, J=7.4, 1.9, 1H), 7.68-7.51 (m, 3H), 7.14 (dd, J=7.4, 4.9, 1H), 6.90 (s, 2H), 5.36 (s, 1H), 3.06 (d, J=11.3, 4H), 2.13 (s, 2H), 1.86 (s, 2H).

Example 647

The title compound was prepared in a manner similar to that described in Example 88 using 4-((3-bromopyridin-2-yl)oxy)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (s, 1H), 8.21 (dd, J=4.8, 1.6, 1H), 8.04 (s, 1H), 7.99-7.88 (m, 2H), 7.61-7.51 (m, 2H), 7.16 (dd, J=7.4, 5.0, 1H), 6.71 (s, 2H), 5.49-5.38 (m, 1H), 3.21-3.15 (m, 2H), 3.10-2.99 (m, 2H), 2.30 (d, J=5.1, 4H).

Example 648

The title compound was prepared in a manner similar to that described in Example 88 using 4-((3-bromopyridin-2-yl)oxy)tetrahydro-2H-thiopyran 1,1-dioxide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) b 8.51 (d, J=1.3, 2H), 8.21 (dd, J=4.9, 1.8, 1H), 7.90 (dd, J=7.4, 1.8, 1H), 7.64 (m, 1H), 7.58 (dd, J=12.4, 1.5, 1H), 7.53 (dd, J=8.0, 1.7, 1H), 7.16 (dd, J=7.4, 4.9, 1H), 6.89 (s, 2H), 5.42 (dd, J=6.3, 3.0, 1H), 3.21 (dd, J=14.5, 8.0, 2H), 3.09-3.01 (m, 2H), 2.34-2.24 (m, 4H).

Example 649

The title compound was prepared in a manner similar to that described in Example 88 using 2-((3-bromopyridin-2-yl)oxy)ethanol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₇H₁₅FN₄O₂, 326.12; m/z found, 326.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.3, 2H), 8.15 (dd, J=4.9, 1.8, 1H), 7.84 (dd, J=7.4, 1.8, 1H), 7.65-7.52 (m, 3H), 7.08 (dd. J=7.4, 5.0, 1H), 6.87 (s, 2H), 4.80 (s, 1H), 4.40-4.32 (m, 2H), 3.70 (t, J=5.0, 2H).

Example 650

The title compound was prepared in a manner similar to that described in Example 88 using 2-((3-bromopyridin-2-yl)oxy)ethanol. MS (ESI): mass calcd. for C₁₇H₁₅FN₄O₂, 326.12; m/z found, 327.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36 (d, J=1.6, 1H), 8.15 (dd, J=4.9, 1.8, 1H), 8.00 (d, J=1.4, 1H), 7.93-7.83 (m, 2H), 7.58 (m, 2H), 7.08 (dd, J=7.4, 4.9, 1H), 6.68 (s, 2H), 4.80 (s, 1H), 4.39-4.34 (m, 2H), 3.70 (d, J=4.5, 2H).

Example 651

The title compound was prepared in a manner similar to that described in Example 88 using trans-4-((3-bromopyridin-2-yl)oxy)cyclohexanamine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O, 379.18; m/z found, 380.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.1, 2H), 8.15 (dd, J=4.9, 1.7, 1H), 7.81 (dd. J=7.4, 1.7, 1H), 7.53 (m, 3H), 7.05 (dd, J=7.4, 5.0, 1H), 6.87 (s, 2H), 5.02 (m, 1H), 2.63 (m, 1H), 2.05 (m, 2H), 1.77 (m, 2H), 1.39 (m, 2H), 1.18 (m, 4H).

Example 652

The title compound was prepared in a manner similar to that described in Example 88 using trans-4-((3-bromopyridin-2-yl)oxy)cyclohexanamine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O, 379.18; m/z found, 380.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.42 (s, 1H), 8.36 (d, J=1.9, 1H), 8.15 (dd, J=4.9, 1.8, 1H), 8.00 (d, J=1.4, 1H), 7.88 (m, 1H), 7.83 (dd, J=7.4, 1.9, 1H), 7.53-7.49 (m, 1H), 7.48 (s, 1H), 7.06 (dd, J=7.4, 4.9, 1H), 6.70 (s, 2H), 5.02 (m, 1H), 2.89 (s, 1H), 2.10 (m, 2H), 1.89 (m, 2H), 1.45-1.33 (m, 4H).

Example 653

The title compound was prepared in a manner similar to that described in Example 88 using 3-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridine. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂, 366.15; m/z found, 367.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.38-8.31 (m, 1H), 8.15 (dd. J=4.9, 1.9, 1H), 8.00 (d. J=1.5, 1H), 7.94-7.83 (m, 2H), 7.57-7.48 (m, 2H), 7.07 (dd, J=7.4, 4.9, 1H), 6.68 (s, 2H), 5.38-5.23 (m, 1H), 3.83-3.68 (m, 2H), 3.50 (m, 2H), 1.98 (d, J=7.5, 2H), 1.71-1.54 (m, 2H).

Example 654

The title compound was prepared in a manner similar to that described in Example 88 using 3-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂, 366.15; m/z found, 367.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) b 8.47 (d, J=1.5, 2H), 8.15 (dd, J=4.9, 1.9, 1H), 7.84 (dd, J=7.4, 1.9, 1H), 7.64-7.48 (m, 3H), 7.07 (dd, J=7.4, 4.9, 1H), 6.86 (s, 2H), 5.30 (m, 1H), 3.81-3.72 (m, 2H), 3.49 (m, 2H), 1.98 (m, 2H), 1.70-1.55 (m, 2H).

Example 655

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂, 340.13; m/z found, 341.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.41-8.35 (m, 1H), 8.17 (dd, J=4.9, 1.8, 1H), 8.03 (d, J=1.4, 1H), 7.94-7.84 (m, 2H), 7.66-7.55 (m, 2H), 7.09 (dd, J=7.4, 4.9, 1H), 6.71 (s, 2H), 5.35-5.23 (m, 1H), 4.86 (t, J=5.4, 1H), 3.62-3.51 (m, 2H), 1.25 (d, J=6.3, 3H).

Example 656

The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂, 340.13; m/z found, 340.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) b 8.50 (d, J=1.4, 2H), 8.17 (dd, J=4.9, 1.9, 1H), 7.85 (dd, J=7.4, 1.9, 1H), 7.67-7.54 (m, 3H), 7.09 (dd, J=7.4, 4.9, 1H), 6.89 (s, 2H), 5.35-5.23 (m, 1H), 4.86 (t, J=5.4, 1H), 3.62-3.51 (m, 2H), 1.25 (d, J=6.3, 3H).

Example 657

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂, 340.13; m/z found, 341.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.38-8.32 (m, 1H), 8.14 (dd. J=4.9, 1.9, 1H), 8.00 (d, J=1.5, 1H), 7.91-7.80 (m, 2H), 7.64-7.52 (m, 2H), 7.05 (dd, J=7.4, 4.9, 1H), 6.68 (s, 2H), 5.32-5.22 (m, 1H), 4.82 (t, J=5.3, 1H), 3.58-3.48 (m, 2H), 1.22 (d, J=6.3, 3H).

Example 658

The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂, 340.13; m/z found, 341.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) b 8.47 (d, J=1.2, 2H), 8.14 (dd, J=4.9, 1.8, 1H), 7.82 (dd, J=7.4, 1.8, 1H), 7.64-7.52 (m, 3H), 7.05 (dd, J=7.4, 4.9, 1H), 6.86 (s, 2H), 5.34-5.21 (m, 1H), 4.83 (s, 1H), 3.58-3.47 (m, 2H), 1.22 (d, J=6.3, 3H).

Example 659

The title compound was prepared in a manner similar to that described in Example 341 using (2-(methylsulfonamido)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C₁₈H₁₆FN₃O₂S, 357.09; m/z found, 358.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 14.69-13.78 (m, 1H), 9.21-9.14 (s, 1H), 8.52-8.10 (m, 5H), 7.72-7.63 (m, 1H), 7.52-7.36 (m, 10H), 7.18-7.10 (d, J=9.3, 1H), 2.90-2.80 (s, 3H).

Example 660

The title compound was prepared in a manner similar to that described in Example 341 using (2-(morpholinosulfonyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C₂₁H₂₀FN₃O₃S, 413.12; m/z found, 414.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.20-8.13 (s, 1H), 8.05-7.98 (m, 1H), 7.81-7.73 (m, 1H), 7.70-7.60 (m, 3H), 7.57-7.50 (m, 1H), 7.49-7.45 (dd, J=7.6, 1.2, 1H), 7.36-7.29 (dd, J=12.0, 1.6, 1 H), 7.29-7.24 (m, 1H), 6.59-6.52 (d, J=8.5, 1H), 6.26-6.14 (s, 2H), 3.44-3.36 (m, 5H), 2.82-2.72 (m, 5H).

Example 661

The title compound was prepared in a manner similar to that described in Example 341 using (2-(N-methylsulfamoyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C₁₈H₁₆FN₃O₂S, 357.09; m/z found, 358.0 [M+H]⁺. ¹H NMR (500 MHz, acetone-d₆) δ 8.29-8.20 (s, 1H), 7.73-7.28 (m, 9H), 6.72-6.65 (m, 1H), 5.74-5.53 (d, J=8.2, 2H), 3.01-2.93 (s, 3H).

Example 662

A mixture of 4′-(6-aminopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (55 mg, 0.14 mmol) and TFA (1 mL) was heated to 50° Celsius for 1.5 h. The mixture was cooled to rt and diluted with ether (10 mL. The resulting precipitate was collected via filtration and dried to provide the title compound. MS (Cl): mass calcd. for C₁₇H₁₄FN₃O₂S, 343.08; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.29-7.90 (m, 4H), 7.70-7.58 (m, 4H), 7.46-7.30 (m, 6H), 7.14-7.04 (d, J=9.2, 1 H).

Example 663

The title compound was prepared in a manner similar to that described in Example 347 using (1S,4S)-5-((2-bromophenyl)sulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane. MS (Cl): mass calcd. for C₂₁H₁₉FN₄O₃S, 426.12; m/z found, 427.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d) δ 8.20-8.13 (s, 1H), 8.05-7.98 (m, 1H), 7.81-7.73 (m, 1H), 7.70-7.60 (m, 3H), 7.57-7.50 (m, 1H), 7.49-7.45 (dd, J=7.6, 1.2, 1H), 7.36-7.29 (dd, J=12.0, 1.6, 1H), 7.29-7.24 (m, 1H), 6.59-6.52 (d, J=8.5, 1H), 6.26-6.14 (s, 2H), 3.44-3.36 (m, 5H), 2.82-2.72 (m, 5H).

Example 664

The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-((3-hydroxyazetidin-3-yl)methyl)benzenesulfonamide. MS (Cl): mass calcd. for C₂₀H₂₀FN₅O₃S, 429.13; m/z found, 430.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.79-8.64 (s, 1H), 8.63-8.51 (s, 1H), 8.43-8.37 (m, 1H), 8.06-8.02 (d, J=1.5, 1H), 8.00-7.94 (m, 1H), 7.94-7.87 (m, 1H), 7.84-7.77 (m, 1H), 7.75-7.69 (m, 1H), 7.69-7.63 (m, 1H), 7.49-7.43 (m, 1H), 7.36-7.27 (m, 2H), 6.89-6.55 (s, 2H), 6.36-6.08 (s, 1H), 3.93-3.88 (m, 2H), 3.72-3.70 (m, 2H), 3.04-2.97 (d, J=6.5, 2H).

Example 665

The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide. MS (Cl): mass calcd. for C₂₁H₂₂FN₃O₃S, 415.14; m/z found, 418.0 (off) [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.30-7.97 (m, 5H), 7.71-7.57 (m, 3H), 7.42-7.29 (m, 3H), 7.12-7.06 (d, J=9.2, 1H), 6.70-6.63 (s, 1H), 3.20-3.13 (s, 2H), 1.00-0.92 (s, 6H).

Example 666

The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylbenzenesulfonamide. MS (Cl): mass calcd. for C₂₁H₂₂FN₃O₃S, 494.17; m/z found, 494.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.27-8.21 (d, J=9.5, 1H), 8.17-8.10 (m, 2H), 7.72-7.65 (m, 1H), 7.65-7.54 (m, 2H), 7.41-7.34 (m, 3H), 7.33-7.24 (m, 5H), 7.19-7.12 (d, J=9.3, 1H), 4.57-4.49 (d, J=8.4, 1H), 3.97-3.86 (m, 1H), 2.63-2.52 (s, 3H), 0.94-0.61 (d, J=6.9, 3H).

Example 667

Step A: (4-(6-Amino-5-fluoropyridin-3-yl)-3-fluorophenyl)boronic acid

A mixture of 4-chloro-2-fluorophenylboronic acid (820 mg, 4.70 mmol), 2-amino-3-fluoro-5-bromopyrazine (900 mg, 4.70 mmol), palladium trifluoroacetate (31 mg, 0.094 mmol), triphenylphosphine (49 mg, 0.19 mmol), toluene (15 mL), EtOH (15 mL), and Na₂CO₃ (9 mL, 2 M) was deoxygenated by sparging with nitrogen. The mixture was then heated at 50° Celsius while stirring for 16 h. The mixture was then cooled to rt and diluted with EtOAc. The mixture was filtered and the filtrate transferred to a separatory funnel. The organic phase was isolated, and the aqueous phase extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na₂SO₄, concentrated to dryness, and subjected to FCC to give 5-(4-chloro-2-fluorophenyl)-3-fluoropyridin-2-amine (980 mg). This material was combined with bis(pinacolato)diboron (1.03 g, 4.94 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl)]palladium(II) (62 mg, 0.079 mmol) and anhydrous potassium acetate (1.06 g, 11.8 mmol) in a sealable vessel under nitrogen. Deoxygenated 1,4-dioxane (150 mL) was added, and the reaction vessel sealed and heated at 60° Celsius for 16 h. The mixture was cooled to rt, diluted with EtOAc, and filtered through a pad of silica gel, and concentrated to give a brown residue. This material was taken up in HCl (40 mL, 1 M) and MeOH (ca. 5 mL), and any insoluble material was removed by filtration. The resulting solution was treated with solid NaHCO₃ to achieve pH 7. The precipitate was collected and dried to give 4-(6-amino-5-fluoropyridin-3-yl)-3-fluorophenyl)boronic acid (968 mg, 84%). MS (Cl): mass calcd. for C₁₁H₉BF₂N₂O₂, 250.01; m/z found, 252.0 [M+H]⁺.

Step B: 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, trifluoroacetate salt

A mixture of 4-(6-amino-5-fluoropyridin-3-yl)-3-fluorophenyl)boronic acid (80 mg, 0.32 mmol), 2-bromo-N-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide (118 mg, 0.380 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (12 mg, 0.016 mmol), K₂CO₃ (0.80 mL, 1.6 mmol, 2 M), and 1,4-dioxane (2 mL) was deoxygenated by sparging with nitrogen for 10 min, then heated at 80° Celsius for 16 h. The mixture was filtered using a syringe filter and directly subjected to HPLC purification to provide the title compound (74 mg, 42%). MS (Cl): mass calcd. for C₂₁H₂₁F₂N₃O₃S, 433.13; m/z found, 435.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-do) δ 8.13-8.04 (m, 2H), 7.80-7.73 (d, J=12.3, 1H), 7.69-7.64 (m, 1H), 7.64-7.56 (m, 2H), 7.40-7.36 (m, 1H), 7.36-7.31 (m, 1H), 7.31-7.26 (m, 1H), 6.62-6.55 (s, 1H), 3.19-3.11 (s, 2H), 1.01-0.87 (s, 6H).

Example 668

The title compound was prepared in a manner similar to that described in Example 676 using (racemic)-1-((2-bromophenyl)sulfonyl)piperidin-3-ol in Step B. MS (Cl): mass calcd. for C₂₂H₂₁F₂N₃O₃S, 445.13; m/z found, 448.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.11-8.06 (m, 1H), 8.06-7.98 (m, 2H), 7.74-7.68 (m, 1H), 7.66-7.55 (m, 2H), 7.44-7.39 (m, 1H), 7.36-7.29 (m, 2H), 3.45-3.36 (m, 1H), 1.71-1.62 (m, 1H), 3.30-3.23 (m, 1H), 3.17-3.09 (d, J=12.7, 1H), 2.52-2.42 (m, 1H), 2.30-2.21 (dd, J=12.0, 9.1, 1H), 1.91-1.81 (m, 1H), 1.43-1.31 (m, 1H), 1.28-1.17 (m, 1H).

Example 669

The title compound was prepared in a manner similar to that described in Example 676 using 2-bromo-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylbenzenesulfonamide in Step B. MS (Cl): mass calcd. for C₂₇H₂₅F₂N₃O₃S, 509.16; m/z found, 510.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.15-8.09 (m, 1H), 8.04-7.95 (m, 2H), 7.69-7.63 (m, 1H), 7.62-7.52 (m, 2H), 7.38-7.22 (m, 8H), 4.55-4.45 (d, J=8.4, 1H), 3.95-3.81 (m, 1H), 2.59-2.49 (s, 3H), 0.79-0.70 (d, J=6.9, 3H).

Example 670

The title compound was prepared in a manner similar to that described in Example 676 using N-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)acetamide in Step B. MS (Cl): mass calcd. for C₂₄H₂₄F₂N₄O₃S, 486.15; m/z found, 487.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.11-8.01 (m, 3H), 7.74-7.67 (m, 1H), 7.65-7.57 (m, 2H), 7.43-7.38 (m, 1H), 7.36-7.28 (m, 2H), 3.68-3.57 (m, 1H), 3.38-3.32 (d, J=13.1, 2H), 2.58-2.48 (m, 2H), 1.90-1.86 (s, 3H), 1.78-1.69 (m, 2H), 1.38-1.25 (m, 2H).

Example 671

The title compound was prepared in a manner similar to that described in Example 676 using racemic 2-(1-((2-bromophenyl)sulfonyl)piperidin-3-yl)ethanol in Step B. MS (Cl): mass calcd. for C₂₄H₂₅F₂N₃O₃S, 473.16; m/z found, 474.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.12-7.99 (m, 3H), 7.73-7.67 (m, 1H), 7.65-7.55 (m, 2H), 7.43-7.38 (m, 1H), 7.38-7.30 (m, 2H), 3.51-3.45 (m, 2H), 3.28-3.21 (m, 2H), 2.48-2.40 (m, 1H), 2.18-2.10 (m, 1H), 1.78-1.69 (m, 1H), 1.65-1.55 (m, 1H), 1.54-1.43 (m, 1H), 1.42-1.27 (m, 3H), 1.04-0.89 (m, 1H).

Example 672

The title compound was prepared in a manner similar to that described in Example 676 using racemic 2-(1-((2-bromophenyl)sulfonyl)piperidin-3-yl)methanol in Step B. MS (Cl): mass calcd. for C₂₃H₂₃F₂N₃O₃S, 459.14; m/z found, 460.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.11-8.00 (m, 3H), 7.73-7.68 (m, 1H), 7.66-7.55 (m, 2H), 7.45-7.30 (m, 3H), 3.45-3.39 (m, 1H), 3.38-3.34 (dd, J=11.0, 5.2, 1H), 3.29-3.24 (d, J=11.7, 1H), 3.24-3.18 (dd, J=11.0, 7.7, 1H), 2.47-2.38 (m, 1H), 2.23-2.14 (m, 1H), 1.68-1.56 (m, 2H), 1.55-1.43 (m, 1H), 1.39-1.26 (m, 1H), 1.04-0.92 (m, 1H).

Example 673

The title compound was prepared in a manner similar to that described in Example 427 using (6-(2-aminopyrimidin-5-yl)-5-fluoropyridin-3-yl)boronic acid and (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₈FN₅O₃S, 403.11; m/z found, 404.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 9.02 (d, J=0.8, 2H), 8.52-8.47 (m, 1H), 8.09 (dd, J=7.9, 1.4, 1H), 7.81 (dd, J=11.9, 1.8, 1H), 7.72 (m, 1H), 7.66 (m, 1H), 7.46 (dd, J=7.5, 1.4, 1H), 3.74-3.59 (m, 1H), 2.84-2.66 (m, 2H), 1.06 (d, J=6.3, 3H).

Example 674

The title compound was prepared in a manner similar to that described in Example 427 using (6-(2-aminopyrimidin-5-yl)-5-fluoropyridin-3-yl)boronic acid and 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₅F₄N₅O₂S, 441.09; m/z found, 442.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.94 (d, J=1.1, 2H), 8.51-8.46 (m, 1H), 8.37-8.31 (m, 1H), 8.03 (dd, J=8.1, 1.9, 1H), 7.81 (dd, J=11.9, 1.8, 1H), 7.68 (d, J=7.9, 1H), 2.86 (q, J=7.3, 2H), 1.02 (t, J=7.2, 3H).

Example 675

The title compound was prepared in a manner similar to that described in Example 427 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid and 5-(5-chloro-3-fluoropyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₂₀FN₅O₂S, 401.13; m/z found, 402.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.97 (d, J=1.1, 2H), 8.50-8.44 (m, 1H), 8.17 (dd, J=8.0, 1.3, 1H), 7.79 (dd, J=12.0, 1.8, 1H), 7.70 (m, 1H), 7.63 (m, 1H), 7.43 (dd, J=7.5, 1.5, 1H), 1.09 (s, 9H).

Example 676

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 4-(2-bromo-5-(trifluoromethyl)benzyl)morpholine. MS (ESI): mass calcd. for C₂₁H₂₀F₃N₅O, 415.16; m/z found, 416.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.96 (s, 2H), 8.67 (dd, J=2.3, 0.9, 1H), 7.97 (dd, J=8.2, 2.3, 1H), 7.89 (dd, J=8.2, 0.9, 1H), 7.86-7.84 (m, 1H), 7.72-7.65 (m, 1H), 7.52 (d, J=7.9, 1H), 3.63-3.58 (m, 4H), 3.54-3.48 (m, 2H), 2.41-2.28 (m, 4H).

Example 677

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (2-bromophenyl)(morpholino)methanone. MS (ESI): mass calcd. for C₂₀H₁₉N₅O₂, 361.15; m/z found, 362.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.96 (s, 2H), 8.69-8.64 (m, 1H), 7.95-7.87 (m, 2H), 7.64-7.59 (m, 1H), 7.58-7.51 (m, 2H), 7.49-7.42 (m, 1H), 3.69-3.54 (m, 3H), 3.48-3.33 (m, 2H), 3.20-3.07 (m, 1H), 2.97-2.80 (m, 2H).

Example 678

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-bromo-2-methoxybenzene. MS (ESI): mass calcd. for C₁₆H₁₄N₄O. C₂HF₃O₂, 278.12; m/z found, 279.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.00 (s, 2H), 8.81 (d, J=2.2, 1H), 8.28 (dd, J=8.4, 2.2, 1H), 8.02 (d, J=8.4, 1H), 7.48-7.41 (m, 2H), 7.16 (d, J=8.4, 1H), 7.11 (m, 1H), 3.87 (s, 3H).

Example 679

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoropiperidine. MS (ESI): mass calcd. for C₂₀H₁₉F₂N₅O₂S, 431.12; m/z found, 432.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.06 (s, 2H), 8.62 (dd, J=2.1, 1.1, 1H), 8.12 (dd, J=8.0, 1.3, 1H), 8.00-7.91 (m, 2H), 7.77 (m, 1H), 7.68 (m, 1H), 7.46 (dd, J=7.6, 1.4, 1H), 3.07 (t, J=11.3, 2H), 2.98-2.90 (m, 2H), 1.99-1.80 (m, 2H), 1.70-1.55 (m, 2H).

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoropyrrolidine. MS (ESI): mass calcd. for C₁₉H₁₇F₂N₅O₂S, 417.11; m/z found, 418.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.06 (s, 2H), 8.63 (m, 1H), 8.13 (dd, J=8.0, 1.3, 1H), 7.99-7.92 (m, 2H), 7.78 (m, 1H), 7.69 (m, 1H), 7.48 (dd, J=7.6, 1.4, 1H), 3.30-3.25 (m, 2H), 3.18 (t, J=7.3, 2H), 2.35-2.06 (m, 2H).

Example 681

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)azepane. MS (ESI): mass calcd. for C₂₁H₂₃N₅O₂S, 409.16; m/z found, 410.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.05 (s, 2H), 8.62 (m, 1H), 8.01 (dd. J=7.8, 1.4, 1H), 7.98-7.92 (m, 2H), 7.71 (m, 1H), 7.64 (m, 1H), 7.43 (dd, J=7.5, 1.4, 1H), 3.01-2.91 (m, 4H), 1.65-1.51 (m, 8H).

Example 682

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-4,4-difluoropiperidine. MS (ESI): mass calcd. for C₂₀H₁₉F₂N₅O₂S, 431.12: m/z found, 432.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.08 (s, 2H), 8.63 (m, 1H), 8.13 (dd, J=8.0, 1.3, 1H), 7.96 (d, J=2.0, 2H), 7.77 (m, 1H), 7.68 (m, 1H), 7.47 (dd, J=7.5, 1.4, 1H), 3.09-2.95 (m, 4H), 1.97-1.71 (m, 4H).

Example 683

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-ethylbenzenesulfonamide. MS (ESI): mass calcd. for C₁H₁₇N₅O₂S, 355.11; m/z found, 356.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.06 (s, 2H), 8.66 (dd, J=2.3, 0.9, 1H), 8.08 (dd, J=7.9, 1.4, 1H), 8.05 (dd, J=8.3, 2.3, 1 H), 7.97 (dd, J=8.3, 0.9, 1H), 7.72 (m, 1H), 7.65 (m, 1H), 7.44 (dd, J=7.5, 1.4, 1H), 2.86 (q, J=7.2, 2H), 1.02 (t, J=7.2, 3H).

Example 684

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-(dicyclopropylmethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₃N₅O₂S, 421.16; m/z found, 422.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.99 (s, 2H), 8.65 (dd, J=2.3, 0.8, 1H), 8.16 (dd, J=7.9, 1.3, 1H), 8.03 (dd, J=8.3, 2.3, 1H), 7.93 (dd, J=8.3, 0.8, 1H), 7.70 (td, J=7.5, 1.4, 1H), 7.61 (m, 1H), 7.40 (dd. J=7.5, 1.3, 1H), 2.07 (t, J=8.3, 1H), 0.89-0.75 (m, 2H), 0.49-0.36 (m, 2H), 0.30-0.13 (m, 4H), 0.00-−0.09 (m, 2H).

Example 685

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,55-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (S)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₆F₃N₅O₂S C₁₈H₁₆F₃N₅O₂S, 423.10; m/z found, 424.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 9.06 (s, 2H), 8.64 (dd, J=2.2, 0.9, 1H), 8.15 (dd, J=8.0, 1.3, 1H), 8.04 (dd, J=8.2, 2.2, 1H), 7.99 (dd, J=8.2, 0.9, 1H), 7.73 (m, 1H), 7.66 (m, 1H), 7.43 (dd, J=7.6, 1.3, 1H), 3.96-3.71 (m, 1H), 1.23 (d, J=7.0, 3H).

Example 686

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (R)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₆F₃N₅O₂S C₁₈H₁₆F₃N₅O₂S, 423.10; m/z found, 424.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 9.05 (d, J=0.9, 2H), 8.63 (m, 1H), 8.15 (dd, J=8.0, 1.3, 1H), 8.03-7.99 (m, 1H), 7.97 (m, 1H), 7.73 (m, 1H), 7.65 (m, 1H), 7.42 (dd, J=7.5, 1.3, 1H), 3.91-3.81 (m, 1H), 1.23 (d, J=7.0, 3H).

Example 687

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 4-((2-bromophenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C₁₉H₁₈N₆O₃S, 410.12; m/z found, 411.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.97 (s, 2H), 8.60 (dd, J=2.2, 0.9, 1H), 8.18 (dd, J=8.0, 1.3, 1H), 7.91 (dd, J=8.2, 2.2, 1H), 7.87 (dd, J=8.2, 1.0, 1H), 7.80 (m, 1H), 7.70 (m, 1H), 7.50 (dd, J=7.5, 1.3, 1H), 3.42 (s, 2H), 3.15 (s, 4H).

Example 688

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (S)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₉N₅O₃S, 385.12; m/z found, 386.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.92 (s, 2H), 8.61-8.57 (m, 1H), 8.09 (d, J=8.0, 1H), 7.91 (dd, J=8.2, 2.3, 1H), 7.82 (d, J=8.2, 1H), 7.70 (m, 1H), 7.62 (m, 1H), 7.41 (d, J=6.8, 1H), 3.70-3.61 (m, 1H), 2.79-2.66 (m, 2H), 1.04 (d, J=6.3, 3H).

Example 689

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₉N₅O₃S, 385.12; m/z found, 386.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.92 (s, 2H), 8.60 (dd, J=2.3, 0.8, 1H), 8.09 (dd, J=8.0, 1.3, 1 H), 7.91 (dd, J=8.2, 2.3, 1H), 7.82 (dd, J=8.2, 0.9, 1H), 7.70 (m, 1H), 7.62 (m, 1H), 7.41 (dd, J=7.6, 1.4, 1H), 3.70-3.59 (m, 1H), 2.79-2.67 (m, 2H), 1.04 (d, J=6.3, 3H).

Example 690

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₆F₃N₅O₃S, 439.09; m/z found, 440.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.96 (s, 2H), 8.64 (d, J=1.7, 1H), 8.39 (s, 1H), 8.01 (d, J=8.0, 1H), 7.95 (dd, J=8.2, 2.3, 1H), 7.87 (d, J=8.3, 1H), 7.64 (d, J=8.0, 1H), 3.46 (t, J=5.9, 2H), 2.91 (t, J=5.9, 2H).

Example 691

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C₁₈H₁₆N₄O₂S, 352.10; m/z found, 353.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.80 (s, 2H), 7.41-7.36 (m, 1H), 6.86 (dd, J=8.0, 1.2, 1H), 6.74-6.70 (m, 1H), 6.69-6.64 (m, 1H), 6.50 (m, 1H), 6.42 (m, 1H), 6.20 (dd, J=7.5, 1.2, 1H), 1.08-0.98 (m, 1H), −0.28-−0.39 (m, 4H).

Example 692

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₆F₃N₅O₂S, 423.10; m/z found, 424.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.95 (s, 2H), 8.62 (d, J=2.0, 1H), 8.35 (s, 1H), 8.01 (d, J=9.9, 1H), 7.93 (dd, J=8.2, 2.3, 1H), 7.87 (d, J=8.2, 1H), 7.64 (d, J=7.9, 1H), 2.84 (q, J=7.2, 2H), 1.01 (t, J=7.2, 3H).

Example 693

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-(tert-butyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₂₁N₅O₂S, 383.14; m/z found, 384.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.96 (s, 2H), 8.62 (dd, J=2.3, 0.9, 1H), 8.34 (d, J=1.8, 1H), 8.01 (dd, J=8.0, 1.6, 1 H), 7.94 (dd, J=8.2, 2.3, 1H), 7.87 (dd, J=8.2, 0.9, 1H), 7.65 (d, J=7.9, 1H), 2.84 (q, J=7.2, 2H), 1.01 (t, J=7.2, 3H).

Example 694

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₉N₅O₃S, 385.12; m/z found, 386.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.92 (s, 2H), 8.66-8.56 (m, 1H), 8.19 (dd, J=8.0, 1.4, 1H), 7.95 (dd, J=8.2, 2.3, 1H), 7.83 (dd, J=8.2, 0.9, 1H), 7.72 (m, 1H), 7.64 (m, 1H), 7.43 (dd, J=7.5, 1.4, 1H), 3.43-3.16 (m, 4H), 1.03 (d, J=6.6, 3H).

Example 695

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C₂₁H₁₄FN₇O, 399.12; m/z found, 400.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.73-8.70 (m, 1H), 7.89-7.81 (m, 2H), 7.51-7.43 (m, 2H), 7.41-7.35 (m, 4H), 7.23 (m, 1H).

Example 696

The title compound was prepared in a manner similar to that described for Intermediate D with DME as a solvent, heating at 100° Celsius for 16 hours and using 2-amino-5-bromopyrazine and 4-bromo-2-fluorobenzeneboronic acid. MS (ESI): mass calcd. for C₁₆H₁₀BrF₂N₃, 361.00; m/z found, 362.0, 364.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.47 (s, 1H), 8.30 (d, J=1.4, 1H), 8.12-8.02 (m, 1H), 7.49-7.32 (m, 5H), 6.37-5.94 (m, 1H), 6.15 (s, 2H).

Example 697

The title compound was prepared in a manner similar to that described for Intermediate HF heating at 90° Celsius for 16 hours and using 5-bromo-1H-pyrrolo[2,3-b]pyridine and 4-bromo-2-fluorobenzeneboronic acid. MS (ESI): mass calcd. for C₁₉H₁₁BrF₂N₂, 384.01; m/z found, 385.0, 387.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 12.29 (s, 1H), 8.47 (s, 2H), 7.60-7.50 (m, 2H), 7.50-7.34 (m, 5H), 6.73 (s, 1H).

Example 698

The title compound was prepared in a manner similar to that described for Example 850 using 5-(4-bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine and 4-(trifluoromethyl)phenylboronic acid. MS (ESI): mass calcd. for C₁₈H₁₃F₄N₃O, 363.10; m/z found, 363.9 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.61-8.56 (m, 1H), 8.12 (d, J=1.5, 1H), 7.72-7.66 (m, 4H), 7.22 (dd, J=8.3, 1.4, 1H), 7.28-7.24 (m, 1H), 4.73 (s, 2H), 3.77 (d. J=1.2, 3H).

Example 699

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2,4-difluorophenyl)boronic acid. MS (ESI): mass calcd. for C₁₆H₁₀F₃N₃, 301.08; m/z found, 302.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.43-8.35 (m, 1H), 8.03 (d. J=1.4, 1H), 7.97 (m, 1H), 7.73-7.65 (m, 1H), 7.54-7.35 (m, 3H), 7.26-7.20 (m, 1H), 6.74 (s, 2H).

Example 700

The title compound was prepared using conditions analogous to those used to make Intermediate EB utilizing 5-(3-fluoro-2′-(methylsulfinyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine. MS (ESI): mass calcd. for C₁₇H₁₄FN₃OS, 327.08; m/z found, 328.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.41 (s, 1H), 8.10-7.89 (m, 3H), 7.79-7.58 (m, 2H), 7.51-7.28 (m, 3H), 6.75 (s, 2H), 2.49 (s, 3H).

Example 701

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2-cyanophenyl)boronic acid. MS (ESI): mass calcd. for C₁₇H₁₁FN₄, 290.10; m/z found, 291.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.42 (s, 1H), 8.05-7.98 (m, 3H), 7.83 (m, 1H), 7.71 (d, J=7.6, 1H), 7.66-7.47 (m, 3H), 6.77 (s, 2H).

Intermediate IZ

To a solution of imidazolidin-2-one (86 mg, 1.0 mmol) in 1,4-dioxane (5 mL) was added Cs₂CO₃ (651 mg, 2.00 mmol) and Pd(OAc)₂ (15 mg, 0.050 mmol). The mixture was purged with N₂ several times. XantPhos (43 mg, 0.075 mmol) and 1-bromo-2-iodobenzene 4 (280 mg, 1.00 mmol) were added and the reaction mixture was stirred at 100° Celsius for 14 hours under an N₂ atmosphere. After cooling to rt, the mixture was concentrated to dryness and the residue purified by FCC to give the title compound (60 mg, 25% yield). MS (ESI): mass calcd. for C₉H₉N₂OBr 239.99, m/z found 240.1 [M+H]⁺; ¹H NMR (300 MHz, CDCl₃) 67.65-7.61 (m, 1H), 7.38-7.34 (m, 2H), 7.25-7.19 (m, 1H), 3.94-3.89 (m, 2H), 3.66-3.61 (m, 2H).

Example 702

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluor-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)imidazolidin-2-one. MS (ESI): mass calcd. for C₁₉H₁₆FN₅O, 349.13; m/z found, 350.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.10 (s, 1H), 7.94 (m, 1H), 7.81-7.77 (m, 1H), 7.51-7.46 (m, 5H), 3.51 (t, J=6.2, 2H), 3.37 (t, J=6.2, 2H).

Example 703

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing (2′-(N-(tert-butyl)sulfamoyl)-3-fluoro-[1,1′-biphenyl]-4-yl)boronic acid and 2-amino-5-bromo-4-cyanopyrimidine. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₂S, 327.08; m/z found, 328.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.64-8.59 (m, 1H), 8.07 (dd, J=7.9, 1.4, 1H), 7.71-7.65 (m, 1H), 7.65-7.59 (m, 2H), 7.57 (s, 2H), 7.45-7.39 (m, 2H), 7.36 (dd, J=7.8, 1.7, 1H), 6.89 (s, 1H), 1.02 (s, 9H).

Example 704

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₂₁H₁₈FN₅O₄S₂, 487.08: m/z found, 488.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 8.26 (s, 1H), 8.08 (dd, J=8.0, 1.3, 1H), 7.83-7.77 (m, 1H), 7.73-7.68 (m, 1H), 7.68-7.63 (m, 1H), 7.51 (dd, J=7.6, 1.3, 1H), 7.44 (dd, J=10.9, 1.7, 1H), 7.40 (s, 2H), 7.35 (dd, J=7.9, 1.6, 1H), 3.31-3.23 (m, 4H), 3.11-3.04 (m, 4H).

Example 705

The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-N-methylazetidine-3-carboxamide. MS (ESI): mass calcd. for C₂₁H₂₀FN₅O₃S, 441.13; m/z found, 441.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-δ₆) δ 8.52 (s, 2H), 8.02 (d, J=7.9, 1H), 7.84 (d, J=4.8, 1H), 7.79-7.72 (m, 1H), 7.69-7.63 (m, 1H), 7.61-7.55 (m, 1H), 7.45 (d, J=7.5, 1H), 7.33 (d, J=11.7, 1H), 7.27 (d, J=7.8, 1H), 6.89 (s, 2H), 3.70 (t, J=7.0, 2H), 3.63 (t, J=8.0, 2H), 3.19-3.08 (m, 1H), 2.56 (d, J=4.4, 3H).

Example 706

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₉H₁₆FN₅O₃S, 413.10; m/z found, 414.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-δ₆) δ 8.26 (s, 1H), 7.99 (dd, J=7.9, 1.4, 1H), 7.72-7.59 (m, 3H), 7.47-7.41 (m, 2H), 7.41-7.31 (m, 4H), 4.70-4.64 (t, J=5.5, 1H), 3.45-3.27 (m, 2H), 2.85-2.78 (m, 2H).

Example 707

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and S-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 427.11; m/z found, 428.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-δ₆) δ 8.26 (s, 1H), 7.97 (dd, J=7.9, 1.4, 1H), 7.72-7.59 (m, 3H), 7.49-7.43 (m, 2H), 7.41-7.33 (m, 4H), 4.71 (d, J=4.7, 1H), 3.61-3.53 (m, 1H), 3.17 (d, J=5.3, 1H), 2.73-2.59 (m, 2H), 0.98 (d, J=6.2, 3H).

Example 708

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and R-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. Characterization data were identical to the enantiomer (Example X).

Example 709

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)piperidine-4-carboxamide. MS (ESI): mass calcd. for C₂₂H₂₂FN₅O₃S, 455.14; m/z found, 455.9 [M+H]⁺. ¹H NMR (500 MHz, DMSO-δ₆) δ 8.51 (d, J=1.4, 2H), 8.02 (dd, J=8.0, 1.3, 1H), 7.78-7.71 (m, 1H), 7.69-7.63 (m, 1H), 7.61-7.54 (m, 1H), 7.45 (dd, J=7.6, 1.4, 1H), 7.32 (dd, J=11.8, 1.7, 1H), 7.26 (dd, J=7.9, 1.8, 1H), 7.17 (s, 1H), 6.88 (s, 2H), 6.73 (s, 1H), 3.26-3.19 (m, 2H), 2.47-2.38 (m, 2H), 2.13-2.02 (m, 1H), 1.59 (dd, J=13.9, 3.8, 2H), 1.31-1.17 (m, 2H).

Example 710

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and R-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₃S, 426.11; m/z found, 427.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.22 (s, 1H), 8.15 (dd, J=8.0, 1.4, 1H), 7.72-7.64 (m, 1H), 7.64-7.56 (m, 2H), 7.46-7.33 (m, 3H), 3.46-3.36 (m, 1H), 3.30-3.25 (m, 1H), 3.25-3.14 (m, 1H), 1.02 (d, J=6.6, 3H).

Example 711

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and S-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. Characterization data were identical to the enantiomer (Example X).

Example 712

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-bromo-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₅F₄N₅O₃S, 481.08; m/z found, 482.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 8.35-8.31 (m, 1H), 8.26 (s, 1H), 8.10-8.05 (m, 1H), 7.91-7.86 (m, 1H), 7.71 (d, J=7.9, 1H), 7.68-7.63 (m, 1H), 7.46 (dd, J=10.9, 1.7, 1H), 7.43-7.36 (m, 3H), 4.75 (t, J=5.4, 1H), 3.40-3.33 (m, 2H), 2.88-2.78 (m, 2H).

Example 713

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₀H₁₅F₄N₅O₂S, 465.09; m/z found, 465.8 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 8.26 (s, 2H), 8.11-8.07 (m, 1H), 7.87-7.81 (m, 1H), 7.72 (d, J=7.9, 1H), 7.69-7.63 (m, 1H), 7.45 (dd, J=10.8, 1.7, 1H), 7.43-7.36 (m, 3H), 2.78 (qd, J=7.2, 5.5, 2H), 0.97 (t, J=7.2, 3H).

Example 714

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-bromo-N-(3-hydroxy-2,2-dimethylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₂₂H₂₂FN₅OS, 455.14; m/z found, 456.0 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 8.26 (s, 1H), 7.93 (dd, J=7.8, 1.5, 1H), 7.72-7.60 (m, 3H), 7.47 (dd, J=7.4, 1.5, 1H), 7.43-7.34 (m, 5H), 4.49 (t, J=5.4, 1H), 3.08 (d, J=5.4, 2H), 2.62 (d, J=6.5, 2H), 0.73 (s, 6H).

Example 715

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 4-((2-bromo-5-(trifluoromethyl)phenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C₂₂H₁₆F₄N₆O₃S, 520.09; m/z found, 520.8 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 8.29 (d, J=1.9, 1H), 8.26 (s, 1H), 8.19 (dd, J=8.2, 1.9, 1H), 8.07-8.01 (m, 1H), 7.77 (d, J=7.9, 1H), 7.70-7.64 (m, 1H), 7.49 (dd, J=10.8, 1.7, 1H), 7.44-7.36 (m, 3H), 3.39 (s, 2H), 3.07-2.96 (m, 4H).

Example 716

The title compound was prepared using conditions analogous to those used to make Example 337 utilizing N-(2-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)thio)ethyl)benzamide. MS (ESI): mass calcd. for C₂₅H₂₁FN₄O₃S, 476.13; m/z found, 477.0 [M+H]⁺. ¹H NMR (600 MHz, DMSO) δ 8.52-8.46 (m, 3H), 8.11 (dd. J=7.8, 1.4, 1 H), 7.74-7.68 (m, 1H), 7.68-7.61 (m, 3H), 7.61-7.56 (m, 1H), 7.52-7.47 (m, 1H), 7.43-7.38 (m, 3H), 7.36 (dd, J=11.7, 1.7, 1H), 7.30 (dd, J=7.9, 1.7, 1H), 6.93 (s, 2H), 3.47-3.40 (m, 2H), 3.30-3.24 (t, J=6.7, 2H).

Example 717

The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-dimethylbutan-2-one. MS (ESI): mass calcd. for C₂₂H₂₂FN₃O₃S, 427.14; m/z found, 428.0 [M+H]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.51 (d, J=1.5, 2H), 8.09 (dd, J=8.0, 1.3, 1H), 7.82-7.76 (m, 1H), 7.75-7.69 (m, 1H), 7.68-7.62 (m, 1H), 7.44 (dd, J=7.6, 1.3, 1H), 7.39-7.34 (dd, J=11.6, 1.8, 1H), 7.29 (dd, J=7.9, 1.7, 1H), 6.96 (s, 2H), 4.44 (s, 2H), 0.94 (s, 9H).

Example 718

Step A: Ethyl 3-(4′-(2-aminopyrimidin-5-yl)-5′-fluorobiphenyl-2-ylthio)propanoate

A mixture of ethyl 3-((2-bromophenyl)thio)propanoate (5.8 g, 20 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine (6.95 g, 22.1 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (1.7 g, 2.0 mmol), Na₂CO₃ (4.25 g, 40.1 mmol) and 1,4-dioxane/water (80 mL/10 mL) was stirred at 90° C. overnight under N₂. The reaction mixture was cooled to rt, filtered, and the filtrate concentrated to dryness. The resultant residue was subjected to FCC to give the title compound (6.5 g, 82%). MS (ESI): mass calcd. for C₂₁H₂₀FN₃O₂S, 397.13; m/z found, 397.9 [M+H]⁺.

Step B: 4′-(2-Aminopyrimidin-5-yl)-5′-fluorobiphenyl-2-thiol

To a solution of ethyl 3-(4′-(2-aminopyrimidin-5-yl)-5′-fluorobiphenyl-2-ylthio)propanoate (6.5 g, 16 mmol) in THF (70 mL) was added t-BuOK (3.68 g, 32.8 mmol) under a N₂ atmosphere. After stirring for 10 min, methanol (5 mL) was added and the resulting mixture purified by FCC to give the title compound (4.8 g, 16 mmol, 98%). MS (ESI): mass calcd. for C₁₆H₁₂FN₃S, 297.07; m/z found, 298.1 [M+H]⁺.

Step C: 5-(3-Fluoro-6′-(pyrimidin-2-ylthio)biphenyl-4-yl)pyrimidin-2-amine

A solution of 4′-(2-aminopyrimidin-5-yl)-5′-fluorobiphenyl-2-thiol (300 mg, 1.00 mmol), 2-chloropyrimidine (229 mg, 2.00 mmol), PPh₃ (262 mg, 1.00 mmol) and TEA (0.38 mL) in DMF (10 mL) was stirred at 120° C. under a N₂ atmosphere over-night. The reaction mixture was then cooled to rt, concentrated to dryness, and the residue subjected to FCC purification to give the title compound (170 mg, 45%). MS (ESI): mass calcd. for C₂₀H₁₄FN₅S, 375.10; m/z found, 375.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.66 (s, 2H), 8.56 (d, J=4.9, 2H), 7.79-7.73 (m, 1H), 7.63-7.56 (m, 2H), 7.55-7.48 (m, 2H), 7.33-7.24 (m, 2H), 7.21 (t, J=4.9, 1H), 6.23 (s, 2H).

Step D: 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine

To a rt solution of 5-(3-fluoro-6′-(pyrimidin-2-ylthio)biphenyl-4-yl)pyrimidin-2-amine (100 mg, 0.270 mmol), NalO₄ (170 mg, 0.810 mmol) in CH₃CN/DCM/H₂O (5 mL/5 mL/5 mL) was added RuCl₃ (6 mg, 0.03 mmol). The resultant mixture was stirred for 3 h before diluting with saturated NaHCO₃ (15 mL). The organic solvent was removed in vacuo, and the resultant solid isolated by filtration. The filter cake was washed with water, dried under vacuum and then subjected to HPLC purification to give the title compound (12 mg, 11%). MS (ESI): mass calcd. for C₂₀H₁₄FN₅O₂S, 407.09; m/z found, 408.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.87 (d, J=4.8, 2H), 8.42 (s, 2H), 8.33 (d, J=7.6, 1H), 7.86 (m, 1H), 7.80 (t, J=7.6, 1H), 7.74 (m, 1H), 7.43 (d, J=7.1, 1H), 7.30 (m, 1H), 6.93 (s, 2H), 6.80 (d, J=11.7, 1H), 6.75 (d, J=8.0, 1H).

Example 719

The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C₂₀H₁₄FN₅O₂S, 407.09; m/z found, 408.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.88 (d, J=2.3, 1H), 8.71 (dd, J=2.3, 1.5, 1H), 8.55 (d, J=1.3, 1H), 8.44 (d, J=1.4, 2H), 8.35 (dd, J=7.8, 1.4, 1H), 7.85 (m, 1H), 7.81 (m, 1H), 7.41 (dd, J=7.4, 1.3, 1H), 7.34 (m, 1H), 6.95 (s, 2H), 6.80 (dd, J=7.9, 1.7, 1H), 6.75 (dd. J=11.4, 1.6, 1H).

Example 720

The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C₂₀H₁₄FN₅O₂S, 407.09; m/z found, 408.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.28 (d, J=1.3, 1H), 8.96 (d, J=5.1, 1H), 8.57 (s, 2H), 8.35 (dd, J=7.8, 1.3, 1H), 7.88 (m, 1H), 7.83 (m, 1H), 7.58 (dd, J=5.1, 1.3, 1H), 7.44 (dd, J=7.4, 1.2, 1H), 7.36 (m, 1H), 6.86-6.81 (m, 2H).

Example 721

The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O₂S, 422.10; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₅) δ 8.64 (s, 2H), 8.27-8.25 (m, 2H), 7.83 (m, 1H), 7.78 (m, 1H), 7.56-7.35 (m, 4H), 6.97-6.87 (m, 2H), 6.45 (s, 1H).

Example 722

The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O₂S, 422.10; m/z found, 423.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (s, 2H), 8.22 (d, J=7.7, 1H), 7.98 (d, J=5.8, 1H), 7.80 (m, 1H), 7.74 (m, 1H), 7.53 (s, 2H), 7.41 (d, J=7.3, 1H), 7.36 (m, 1H), 7.01 (s, 2H), 6.89-6.84 (m, 2H), 6.43 (d, J=5.9, 1H).

Example 723

The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O₂S, 422.10; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.88 (s, 2H), 8.34 (dd, J=7.8, 1.5, 1H), 7.88 (d, J=1.2, 1H), 7.79-7.68 (m, 3H), 7.51 (m, 1H), 7.34 (dd, J=7.3, 1.4, 1H), 7.04 (dd, J=7.9, 1.6, 1H), 6.98 (dd, J=11.4, 1.5, 1H).

Example 724

The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O₂S, 422.10; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (s, 2H), 8.28 (d, J=4.8, 1H), 8.24 (d, J=7.6, 1H), 7.86-7.79 (m, 1H), 7.76 (m, 1H), 7.43 (d, J=6.1, 1H), 7.36 (m, 1H), 7.25 (s, 2H), 6.98-6.83 (m, 4H), 6.50 (d, J=4.8, 1H).

Example 725

The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O₂S, 422.10; m/z found, 423.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.84 (s, 2H), 8.36 (dd, J=7.8, 1.3, 1H), 7.96 (s, 1H), 7.80 (m, 1H), 7.75 (m, 1H), 7.61 (s, 1H), 7.47 (m, 1H), 7.38 (dd, J=7.4, 1.2, 1H), 7.03 (dd, J=7.9, 1.6, 1H), 6.96 (dd, J=11.4, 1.5, 1H).

Example 726

The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O₂S, 422.10; m/z found, 423.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.25-8.22 (m, 2H), 8.02 (s, 1H), 7.85-7.71 (m, 2H), 7.65 (m, 1H), 7.42-7.39 (m, 3H), 6.88 (s, 1H), 6.84 (d, J=7.2, 1H), 6.47 (s, 1H).

Example 727

The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C₂₀H₁₅FN₆O₂S, 422.10; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.31 (s, 1H), 8.20 (d, J=7.2, 1H), 8.02 (s, 1H), 7.97 (d, J=5.7, 1H), 7.83-7.61 (m, 3H), 7.51 (s, 2H), 7.41 (d, J=7.5, 1H), 6.89-6.82 (m, 2H), 6.43 (d, J=5.9, 1H).

Example 728

The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-bromo-2-((cyclopropylmethyl)sulfonyl)benzene. MS (ESI): mass calcd. for C₂H₁₈FN₃O₂S, 383.11; m/z found, 384.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.53 (d, J=1.5, 2H), 8.11 (dd, J=7.9, 1.2, 1H), 7.80 (m, 1H), 7.72 (m, 1H), 7.62 (m, 1H), 7.46 (dd, J=7.6, 1.1, 1H), 7.37 (dd, J=11.8, 1.7, 1H), 7.28 (dd, J=7.9, 1.7, 1H), 6.93 (s, 2H), 2.91 (d, J=7.2, 2H), 0.78-0.69 (m, 1H), 0.45-0.37 (m, 2H), 0.13-0.05 (m, 2H).

Example 729

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C₂₀H₁₅FN₄O₂S, 394.09; m/z found, 395.0 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 8.26 (s, 1H), 8.07 (dd, J=8.0, 1.3, 1H), 7.82-7.77 (m, 1H), 7.74-7.69 (m, 1H), 7.66-7.62 (m, 1H), 7.52 (dd, J=7.6, 1.3, 1H), 7.44 (dd, J=10.8, 1.7, 1H), 7.41-7.36 (m, 3H), 2.47-2.41 (m, 1H), 0.99-0.91 (m, 2H), 0.90-0.83 (m, 2H).

Intermediate JA

Step A: 2-(2-Bromophenylthio)acetonitrile

A mixture of 2-bromobenzenethiol (6.3 mL, 53 mmol), K₂CO₃ (13.8 g, 100 mmol) and 2-chloroacetonitrile (3.2 mL, 50 mmol) in DMF (50 mL) was stirred at 25° C. for 6 h, poured into water (700 mL), and extracted with petroleum ether (300 mL) followed by DCM (2×200 mL). The combined DCM extracts were concentrated to dryness, and re-dissolved in petroleum ether/ethyl acetate (10:1, 600 mL). The organic solution was washed with water (250 mL) and brine (250 mL), dried over Na₂SO₄, filtered and concentrated to dryness to give the title compound (11 g, 85%). ¹H NMR (300 MHz, CDCl₃) δ 7.67 (dd, J=7.8, 1.5, 1H), 7.60 (dd, J=7.8, 1.5, 1H), 7.41 (m, 1H), 7.25 (m, 1H), 3.68 (s, 2H).

Step B: 2-(2-Bromophenylsulfonyl)acetonitrile

A mixture of 2-(2-bromophenylthio)acetonitrile (10.8 g, 47.4 mmol), NalO₄ (30.4 g, 142 mmol) and RuCl₃ (4 mg) in DCM/ACN/H₂O (1:1:1, 300 mL) was stirred at rt for 18 h, and then filtered. The filtrate was diluted with water (600 mL), extracted with DCM (3×200 mL). The combined organic extracts were washed with brine (200 mL), dried over Na₂SO₄, filtered through a pad of silica gel, and concentrated to dryness to give the title compound (10.4 g, 84%). ¹HNMR (400 MHz, CDCl₃) δ 8.30-8.24 (m, 1H), 7.88-7.82 (m, 1H), 7.11-7.62 (m, 2H), 4.48 (s, 2H).

Step C: 1-((2-Bromophenyl)sulfonyl)cyclopentanecarbonitrile

A mixture of 2-(2-bromophenylsulfonyl)acetonitrile (4.4 g, 17 mmol), tetrabutylammonium bromide (0.82 g, 2.6 mmol), 1,4-dibromobutane (3.85 g, 17.8 mmol) and NaOH (14 mL, 5 N) in DCM (30 mL) was stirred at rt for 5 h, before diluting with DCM (200 mL), washing with water (2×80 mL) and brine (60 mL), drying over Na₂SO₄, filtering, and concentrating to dryness. The residue was treated with IPA (20 mL) and sonicated before isolating the title compound (2.2 g) via vacuum filtration. The filtrate was concentrated to dryness and the resultant residue subjected to FCC to give additional title compound. MS (ESI): mass calcd. for C₁₂H₁₂BrFN₃O₂S, 312.98; m/z found, 314.0 [M+H]⁺. ¹HNMR (300 MHz, CDCl₃) 68.28 (dd, J=7.5, 1.5, 1H), 7.85 (dd, J=7.5, 1.5, 1H), 7.62-7.51 (m, 2H), 2.80-2.68 (m, 2H), 2.34-2.22 (m, 2H), 2.02-1.81 (m, 4H).

Intermediate JB

The title compound was prepared using conditions analogous to those used to make 1-((2-bromophenyl)sulfonyl)cyclopentanecarbonitrile utilizing Mel in Step A.

Intermediate JC

A 30% H₂O₂ solution (1.6 mL) was added drop-wise at rt to a mixture of 1-(2-bromophenylsulfonyl)cyclopentanecarbonitrile (1.6 g, 5.1 mmol), K₂CO₃ (2.1 g, 15 mmol), and DMSO (5 mL). The mixture was stirred for 30 min before diluting with water (40 mL) and isolating the precipitate via vacuum filtration. The precipitate was washed with water and air-dried to give the title compound (1.5 g, 89%). MS (ESI): mass calcd. for C₁₂H₁₉NO₃S, 330.99; m/z found, 331.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 7.99-7.95 (m, 1H), 7.89-7.84 (m, 1H), 7.64-7.51 (m, 4H), 2.41-2.25 (m, 4H), 1.78-1.66 (m, 2H), 1.58-1.45 (m, 2H).

Intermediate JD

The title compound was prepared using conditions analogous to those used to make 1-(2-bromophenylsulfonyl)cyclopentanecarboxamide starting with 2-((2-bromophenyl)sulfonyl)-2-methylpropanenitrile.

Example 730

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)cyclopentanecarbonitrile. MS (ESI): mass calcd. for C₂₂H₁₉FN₄O₂S, 422.12; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.40 (s, 1H), 8.21 (dd, J=8.0, 1.0, 1H), 8.03 (d, J=1.4, 1H), 7.92 (m, 1H), 7.88-7.80 (m, 2H), 7.53 (d, J=7.6, 1H), 7.35 (dd, J=12.3, 1.5, 1H), 7.29 (dd, J=8.0, 1.6, 1H), 6.74 (s, 2H), 2.21-2.04 (m, 4H), 1.71-1.67 (m, 4H).

Example 731

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenylsulfonyl)cyclopentanecarboxamide. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₃S, 440.13; m/z found, 441.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (s, 1H), 8.05 (s, 1H), 7.98 (d, J=7.8, 1H), 7.86 (m, 1H), 7.76 (m, 1H), 7.65 (m, 1H), 7.46 (s, 1H), 7.37 (d, J=7.4, 2H), 7.26-7.23 (m, 2H), 6.77 (s, 2H), 2.20 (s, 2H), 2.05-1.88 (m, 2H), 1.56 (s, 2H), 1.43 (s, 2H).

Example 732

The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropanenitrile. MS (ESI): mass calcd. for C₂₀H₁₇FN₄O₂S, 396.11; m/z found, 397.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.62 (s, 2H), 8.19 (d, J=7.9, 1H), 7.94 (m, 1H), 7.84 (m, 1H), 7.59 (m, 1H), 7.52 (d, J=7.5, 1H), 7.40 (dd, J=11.8, 1.1, 1H), 7.31 (dd, J=7.9, 1.4, 1H), 1.51 (s, 6H).

Example 733

The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropanamide. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.68 (s, 2H), 7.97 (d, J=7.9, 1H), 7.79 (m, 1H), 7.68 (m, 1H), 7.58 (m, 1H), 7.41 (s, 1H), 7.36 (d, J=7.5, 1H), 7.32-7.29 (m, 2H), 7.26 (d, J=7.9, 1H), 1.32 (s, 6H).

Example 734

Step A: 2-(2-Bromophenylsulfonyl)-2-methylpropan-1-amine

BH₃.THF (4 mL, 1 M in THF) was added drop-wise to a solution of 2-((2-bromophenyl)sulfonyl)-2-methylpropanenitrile (258 mg, 1.00 mmol) in THF (1 mL) at rt. The mixture was refluxed for 4 hours and then cooled to rt. Aqueous HCl (5 mL, 6 N) was added and stirring continued for an additional 1 hour. The mixture was basified to pH=9 by addition of NaOH (6 N), diluted with water (20 mL), and extracted with DCM (3×20 mL). The combined extracts were washed with water (2×30 mL) and brine (60 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give the crude title compound (203 mg, 70%), which was used in the subsequent step without further purification. MS (ESI): mass calcd. for C₁₀H₁₄NO₂S, 290.99; m/z found, 292.1 [M+H]⁺.

Step B: tert-Butyl 2-(2-bromophenylsulfonyl)-2-methylpropylcarbamate

A mixture of 2-(2-bromophenylsulfonyl)-2-methylpropan-1-amine (203 mg, 0.700 mmol) and di-tert-butyl dicarbonate (152 mg, 0.700 mmol) in MeOH (10 mL) was stirred at 50° C. for 6 hours, cooled to rt, and then concentrated to dryness. The resulting residue was subjected to FCC purification to give the title compound (180 mg, 65%). MS (ESI): mass calcd. for C₁₅H₂₂NO₄S, 391.05; m/z found, 291.8 [M-Boc+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (dd, J=7.8, 1.7, 1H), 7.80 (dd, J=7.7, 1.0, 1H), 7.56-7.50 (m, 1H), 7.52-7.42 (m, 1H), 5.51 (s, 1H), 3.52 (d, J=6.4, 2H), 1.45 (s, 9H), 1.37 (s, 6H).

Step C: tert-Butyl 2-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylsulfonyl)-2-methylpropyl carbamate

A mixture of K₂CO (55 mg, 0.40 mmol) and dry DMF (5 mL) was sparged with N₂ for 2 minutes and then treated with tert-butyl 2-(2-bromophenylsulfonyl)-2-methylpropylcarbamate (78 mg, 0.20 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (66 mg, 0.21 mmol), t-BuXphos (14 mg, 0.020 mmol) and Pd₂(dba)₃ (18 mg, 0.020 mmol). The resulting mixture was purged with N₂ several times, and then stirred at 80° C. overnight. The reaction mixture was cooled to rt, diluted with EtOAc (20 mL), and filtered. The filtrate was concentrated to dryness and subjected to FCC to give the title compound (52 mg, 52%). MS (ESI): mass calcd. for C₂₅H₂₉N₄O₄S, 500.19; m/z found, 501.1 [M+H]⁺.

Step D: 5-(6′-(1-Amino-2-methylpropan-2-ylsulfonyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine

To a solution of tert-butyl 2-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylsulfonyl)-2-methylpropyl carbamate (52 mg, 0.10 mmol) in DCM (5 mL) was added TFA (2 mL). The resulting mixture was stirred at rt overnight then concentrated to dryness. The residue was basified to pH˜7-8 by addition of saturated NaHCO₃. The resulting mixture was diluted with water (30 mL), extracted with DCM (3×10 mL), and the combined extracts washed with brine (20 mL), concentrated to dryness, and the resultant crude product purified by HPLC to give the title compound. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.88 (s, 2H), 8.18 (d. J=7.9, 1H), 7.90-7.86 (m, 1H), 7.80-7.76 (m, 1H), 7.68-7.64 (m, 1H), 7.50 (d, J=7.6, 1H), 7.40 (d, J=3.1, 1H), 7.38 (s, 1H), 3.18 (s, 2H), 1.22 (s, 6H).

Example 735

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluor-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropanenitrile. MS (ESI): mass calcd. for C₂₀H₁₇FN₄O₂S, 396.11; m/z found, 397.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.18 (d, J=8.0, 1H), 8.12 (d, J=1.2, 1H), 7.94 (m, 1H), 7.88-7.82 (m, 2H), 7.54 (d, J=7.6, 1H), 7.37 (dd, J=12.4, 1.4, 1H), 7.29 (dd, J=8.1, 1.6, 1H), 1.50 (s, 6H).

Example 736

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropanamide. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (s, 1H), 8.16 (d, J=1.2, 1H), 7.96 (dd, J=8.0, 0.9, 1H), 7.85 (m, 1H), 7.78 (m, 1H), 7.72-7.64 (m, 1H), 7.44 (s, 1H), 7.37 (dd, J=7.6, 0.9, 1H), 7.34 (s, 1H), 7.27 (dd, J=6.4, 1.3, 1H), 7.24 (s, 1H), 1.31 (s, 6H).

Example 737

The title compound was prepared using conditions analogous to those used to make Example 6 using -(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropan-1-amine. MS (ESI): mass calcd. for C₂₀H₂₁FN₄O₂S, 400.14; m/z found, 401.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 8.11 (d, J=6.9, 1H), 8.08 (d, J=1.4, 1H), 7.89-7.85 (m, 1H), 7.82-7.78 (m, 1H), 7.72-7.68 (m, 1H), 7.47 (d, J=6.5, 1H), 7.30-7.26 (m, 2H), 2.77 (s, 2H), 1.12 (s, 6H).

Example 738

The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)cyclopentanecarbonitrile. MS (ESI): mass calcd. for C₂₂H₁₉FN₄O₂S, 422.12; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.52 (s, 2H), 8.21 (d, J=8.0, 1H), 7.91 (m, 1H), 7.86-7.79 (m, 1H), 7.57 (m, 1H), 7.52 (d, J=7.6, 1H), 7.37 (dd, J=11.8, 1.4, 1H), 7.29 (dd, J=8.0, 1.6, 1H), 6.92 (s, 2H), 2.22-2.07 (m, 4H), 1.72-1.68 (m, 4H).

Example 739

The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-(2-bromophenylsulfonyl)cyclopentanecarboxamide. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₃S, 440.13; m/z found, 441.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.52 (s, 2H), 7.98 (d, J=7.7, 1H), 7.75 (m, 1H), 7.65 (m, 1H), 7.54 (m, 1H), 7.42 (s, 1H), 7.36-7.34 (m, 2H), 7.28-7.22 (m, 2H), 6.93 (s, 2H), 2.27-2.16 (m, 2H), 2.04-1.91 (m, 2H), 1.57 (s, 2H), 1.49-1.35 (m, 2H).

Example 740

The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (1-((2-bromophenyl)sulfonyl)cyclopentyl)methanamine. MS (ESI): mass calcd. for C₂₂H₂₃FN₅O₂S, 426.15; m/z found, 427.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.54 (d, J=1.3, 2H), 8.20 (dd, J=7.9, 1.2, 1H), 7.83 (m, 1H), 7.73 (m, 1H), 7.57-7.46 (m, 2H), 7.35-7.32 (m, 2H), 2.92 (s, 2H), 2.13-1.99 (m, 2H), 1.65-1.42 (m, 6H).

Example 741

The title compound was prepared using conditions analogous to those used to make Example 718, Steps A-C using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine in Step A and 2-amino-5-chloropyrazine in Step C. MS (ESI): mass calcd. for C₁₉H₁₆FN₅O₃S, 390.11; m/z found, 391.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.05 (s, 1H), 7.94-7.86 (m, 3H), 7.33-7.28 (m, 5H), 7.12-7.06 (m, 1H).

Example 742

The title compound was prepared using conditions analogous to those used to make Example 718, Steps A-C using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine in Step A and 2-amino-6-chloropyrazine in Step C. MS (ESI): mass calcd. for C₂₀H₁₅FN₆S, 390.11; m/z found, 391.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.28 (s, 1H), 8.21 (s, 1H), 7.84 (m, 1H), 7.73-7.65 (m, 1H), 7.58-7.41 (m, 5H), 7.28-7.21 (m, 2H), 7.20-7.10 (m, 2H).

Example 743

The title compound was prepared using conditions analogous to those used to make Example 718, Steps A-C using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine in Step A and 4-chloropyrimidine in Step C. MS (ESI): mass calcd. for C₂₀H₁₄FN₅S, 375.10; m/z found, 375.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.73 (s, 1H), 8.32 (d, J=5.7, 1H), 8.28 (m, 1H), 8.19 (d, J=1.4, 1H), 7.85 (m, 1H), 7.81-7.74 (m, 1H), 7.72-7.63 (m, 1H), 7.63-7.53 (m, 2H), 7.31-7.18 (m, 2H), 6.90 (dd, J=5.6, 1.3, 1H).

Example 744

The title compound was prepared using conditions analogous to those used to make Example 718, Steps A-C using 2-amino-5-chloropyrazine in Step C. MS (ESI): mass calcd. for C₂H₁₅FN₆S, 390.11; m/z found, 391.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.51 (d, J=1.4, 2H), 7.79 (d, J=1.4, 1H), 7.72 (d, J=1.4, 1H), 7.47 (m, 1H), 7.32-7.17 (m, 6H).

Example 745

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C₂₁H₁₄FN₇OS₂, 399.12; m/z found, 400.2 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 8.22 (s, 1H), 7.79 (d, J=5.8, 1H), 7.62-7.51 (m, 2H), 7.49-7.38 (m, 3H), 7.38-7.30 (m, 3H), 7.20 (dd, J=8.0, 1.2, 1H), 7.01 (s, 2H), 6.10 (d, J=5.8, 1H).

Example 746

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidine. MS (ESI): mass calcd. for C₂₂H₁₂F₄N₆O, 452.10; m/z found, 453.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 8.56 (d, J=4.8, 2H), 8.20 (s, 1H), 7.89-7.81 (m, 2H), 7.81-7.75 (m, 1H), 7.61-7.54 (m, 1H), 7.48 (dd, J=11.1, 1.7, 1H), 7.43 (dd, J=8.1, 1.7, 1H), 7.37 (s, 2H), 7.22-7.17 (m, 1H).

Example 747

The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-(2-bromophenoxy)pyrimidine. MS (ESI): mass calcd. for C₂₁H₁₃FN₆O, 384.11; m/z found, 385.0 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 8.55 (d, J=4.8, 2H), 8.20 (s, 1H), 7.61 (dd, J=7.7, 1.7, 1H), 7.57-7.49 (m, 2H), 7.44-7.37 (m, 3H), 7.35 (s, 2H), 7.32 (dd, J=8.1, 1.2, 1H), 7.19-7.15 (m, 1H).

Example 748

Step A: N-(tert-Butyl)-3′-fluoro-4′-(5-(N-(methylsulfonyl)methylsulfonamido)pyrazin-2-yl)-[1,1′-biphenyl]-2-sulfonamide

To a 20 mL vial were added a stir-bar, 4′-(5-aminopyrazin-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (49 mg, 0.12 mmol), dry DCM (2.0 mL), DIPEA, (0.10 mL, 0.58 mmol), and methanesulfonyl chloride (0.020 mL, 0.25 mmol). The mixture was stirred at rt for 17.25 h before subjecting it to FCC to give impure title compound. The product was used in the next step without further purification.

Step B: N-(tert-Butyl)-3′-fluoro-4′-(5-(methylsulfonamido)pyrazin-2-yl)-[1,1′-biphenyl]-2-sulfonamide

To a 20 mL vial containing N-(tert-butyl)-3′-fluoro-4′-(5-(N-(methylsulfonyl)methylsulfonamido)pyrazin-2-yl)-[1,1′-biphenyl]-2-sulfonamide (38 mg, 0.068 mmol) were added a stir-bar and DMSO (1 mL). The mixture was sonicated until homogeneous, and then treated with NaOH (0.23 mL, 0.23 mmol, 1.0 N). The mixture was stirred at rt for 18.7 h before passing it through a syringe filter and subjecting it to HPLC purification thus yielding the title compound (28 mg, 86%). MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₄S₂, 478.11; m/z found, 479.1 [M+H]⁺. ¹H NMR (600 MHz, DMSO-δ₆) δ 11.29 (s, 1H), 8.82-8.72 (m, 1H), 8.46 (d, J=1.5, 1H), 8.07 (dd, J=7.9, 1.4, 1H), 7.98-7.91 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.43-7.32 (m, 3H), 7.05 (s, 1H), 3.41 (s, 3H), 1.03 (s, 9H).

Example 749

Step A: 5-(6′-(Chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine

A mixture of (4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methanol (1.8 g, 6.1 mmol) and SOCl₂ (6 mL) in DCM (20 mL) was stirred at 70° C. for 4 h. The reaction mixture was cooled to rt and concentrated to dryness to give the title compound (1.86 g, 98%). ¹H NMR (300 MHz, DMSO-d₆) δ 8.40 (s, 1H), 8.04 (s, 1H), 7.96 (m, 1H), 7.66-7.57 (m, 1H), 7.51-7.42 (m, 2H), 7.40-7.30 (m, 3H), 6.89-6.62 (m, 2H), 4.73 (s, 2H).

Step B: S-(4′-(5-Aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate

A mixture of 5-(6′-(chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine (1.86 g, 5.94 mmol) and KSAc (0.81 g, 7.1 mmol) in 1,4-dioxane/H₂O (30 mL/6 mL) was stirred at rt for 2 h. The solvent was then removed in vacuo and the residue purified by FCC to give the title compound (1.42 g, 68%). MS (ESI): mass calcd. for C₁₉H₁₆FN₃OS, 353.10; m/z found, 353.9 [M+H]⁺.

Step C: 5-(2′-(Ethylthiomethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine

To a solution of S-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate (100 mg, 0.280 mmol) in CH₃OH (30 mL) were added Ph₃P (150 mg, 0.560 mmol), K₂CO₃ (78 mg, 0.56 mmol), and bromoethane [drop-wise addition (60 mg, 0.56 mmol)] at rt. The reaction mixture was stirred at rt for 16 h, before removing the solvent in vacuo. The crude product was purified first by preparative-TLC followed by HPLC to give the title compound (70 mg HCOOH salt, 73%).

Step D: 5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine

A mixture of 5-(2′-(ethylthiomethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine (70 mg, 0.21 mmol), m-CPBA (107 mg, 0.618 mmol) and TFA (0.2 mL) in dry DCM (20 mL) was stirred at rt for 5 h, and then the solvent was removed under vacuum. The residue was purified by HPLC to give the title compound (40 mg, 52%). MS (ESI): mass calcd. for C₁₉H₁₈FN₃O₂S, 371.11; m/z found, 371.9 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) 8.68 (d, J=1.2, 1H), 8.26 (d, J=1.3, 1H), 8.15 (m, 1H), 7.70-7.61 (m, 1H), 7.53-7.31 (m, 5H), 4.43 (s, 2H), 2.97 (q, J=7.4, 2H), 1.20 (t, J=7.4, 3H).

Example 750

The title compound was prepared using conditions analogous to those used to make Example 749 utilizing 2-iodomethane in Step C. MS (ESI): mass calcd. for C₁₈H₁₆FN₃O₂S, 357.09; m/z found, 357.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.66 (d, J=1.4, 1H), 8.26 (d, J=1.3, 1H), 8.14 (m, 1H), 7.70-7.61 (m, 1H), 7.54-7.45 (m, 2H), 7.43-7.32 (m, 3H), 4.49 (s, 2H), 2.83 (s, 3H).

Example 751

The title compound was prepared using conditions analogous to those used to make Example 749 utilizing 2-iodopropane in Step C. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₃S, 385.13; m/z found, 386.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.72-8.61 (m, 1H), 8.24 (s, 1H), 8.13 (m, 1H), 7.70-7.59 (m, 1H), 7.54-7.28 (m, 5H), 4.40 (s, 2H), 3.18-3.07 (m, 1H), 1.23 (d, J=6.8, 6H).

Example 752

The title compound was prepared using conditions analogous to those used to make Example 749 utilizing 5-(3-fluoro-2′-((pyrimidin-2-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine in Step D. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O₂S, 421.10; m/z found, 422.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.91 (d, J=4.9, 2H), 8.41 (s, 1H), 8.11 (d, J=1.3, 1H), 7.90 (t, J=8.1, 1H), 7.71 (m, 1H), 7.66-7.59 (m, 1H), 7.52-7.40 (m, 2H), 7.34 (dd, J=7.3, 1.5, 1H), 7.27-7.14 (m, 2H), 5.02 (s, 2H).

Example 753

The title compound was prepared using conditions analogous to those used to make Example 749, Steps A-C utilizing 4-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C₂₁H₁₇FN₆S, 404.12; m/z found, 405.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.63 (d, J=1.1, 1H), 8.25 (d, J=1.2, 1H), 8.10 (m, 1H), 7.86 (d, J=7.2, 1H), 7.68-7.58 (m, 1H), 7.51-7.39 (m, 2H), 7.37-7.23 (m, 3H), 6.40 (d, J=7.2, 1H), 4.62 (s, 2H).

Example 754

The title compound was prepared as described in Step C of Example 504 utilizing racemic 2-(trifluoromethyl)morpholine. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₄O₂, 446.14; m/z found, 447.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.61 (s), 8.18-7.95 (m), 7.59-7.29 (m), 4.88-4.41 (m), 4.11-3.51 (m), 3.32 (m), 3.17-3.00 (m), 3.00-2.84 (m), 2.68-2.41 (m), 2.37-2.16 (m).

Example 755

The title compound was prepared as described in Step C of Example 504 utilizing 3-hydroxyazetidine. MS (ESI): mass calcd. for C₂₀H₁₇FN₄O₂, 364.13; m/z found, 364.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.02 (s, 1H), 7.93-7.89 (m, 1H), 7.55-7.38 (m, 4H), 7.36-7.24 (m, 2H), 6.67 (s, 2H), 5.64 (s, 1H), 4.28 (s, 1H), 4.08-4.01 (m, 1H), 3.79-3.75 (m, 1H), 3.58-3.54 (m, 1H), 3.15 (s, 1H).

Example 756

The title compound was prepared as described in Step C of Example 504 utilizing tetrahydro-2H-pyran-4-amine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 392.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.33 (s, 1H), 8.22 (d, J=7.7, 1H), 8.01 (d, J=1.1, 1H), 7.86-7.82 (m, 1H), 7.54-7.38 (m, 4H), 7.29-7.25 (m, 2H), 6.65 (s, 2H), 3.86-3.77 (m, 1H), 3.73-3.70 (m, 2H), 3.26 (s, 2H), 1.61-1.59 (m, 2H), 1.38-1.28 (m, 2H).

Example 757

The title compound was prepared as described in Step C of Example 504 utilizing thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₄O₃S, 494.10; m/z found, 494.7 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36 (s, 1H), 8.02-7.90 (m, 4H), 7.78-7.76 (m, 1H), 7.36-7.29 (m, 2H), 6.75 (s, 2H), 4.35-4.20 (m, 1H), 3.59-3.46 (m, 2H), 3.31-3.12 (m, 4H), 3.04-2.90 (m, 1H).

Example 758

The title compound was prepared as described in Step C of Example 504 utilizing a diastereomeric mixture of 1-(piperidin-3-yl)ethanolgiving the title compound. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O₃, 422.18; m/z found, 422.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ Complex due to the presence of multiple conformations on the NMR time-scale and diastereoisomers, peaks listed for identification purposes only: 8.30 (s), 8.01-7.80 (m), 7.53-7.14 (m), 4.55-4.49 (m), 4.33-4.25 (m), 3.90-3.66 (m), 3.61-3.31 (m), 3.25 (s), 3.16-2.85 (m), 2.84-2.12 (m), 1.07-0.76 (m).

Example 759

The title compound was prepared as described in Step C of Example 504 utilizing a diastereomeric mixture of 1-(piperidin-3-yl)ethanol. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O₃, 422.18; m/z found, 422.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) Complex due to the presence of multiple conformations on the NMR time-scale and diastereoisomers, peaks listed for identification purposes only: δ 8.43 (s), 7.57-7.17 (m), 4.55-4.49 (m), 4.32-4.26 (m), 3.89-3.70 (m), 3.61-3.33 (m), 3.33-3.23 (m), 3.12-2.86 (m), 2.85-2.12 (m), 1.10-0.77 (m).

Example 760

The title compound was prepared as described in Step C of Example 504 utilizing ethanolamine. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₂, 352.13; m/z found, 352.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.06 (d, J=1.2, 1H), 7.94-7.83 (m, 1H), 7.59-7.39 (m, 4H), 7.38-7.22 (m, 2H), 3.51 (t, J=6.1, 2H), 3.35-3.31 (m, 2H).

Example 761

The title compound was prepared as described in Step C of Example 504 utilizing ethanolamine. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₂, 352.13; m/z found, 352.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.51 (s, 2H), 7.57-7.42 (m, 5H), 7.34-7.27 (m, 5H), 3.52 (t, J=6.0, 2H), 3.35-3.31 (m, 2H).

Example 762

The title compound was prepared as described in Step C of Example 504 utilizing (R)-3-hydroxypiperidine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.37 (s), 8.09 (br s), 8.03-7.87 (m), 7.65-7.45 (m), 7.45-7.23 (m), 4.34-4.20 (m), 4.13-4.09 (m), 3.94-3.80 (m), 3.68-3.31 (m), 3.21-2.84 (m), 2.79-2.48 (m), 1.94-1.65 (m), 1.39-1.08 (m).

Example 763

The title compound was prepared as described in Step C of Example 504 utilizing (cis/trans) 4-aminocyclohexanol. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O₂, 406.18; m/z found, 407.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.36 (s, 1H), 8.07-8.04 (m, 1H), 7.88 (m, 1H), 7.57-7.40 (m, 4H), 7.33-7.24 (m, 2H), 3.69-3.62 (m, 1H), 3.46-3.39 (m, 4H), 3.34 (br s, 1H), 1.87-1.76 (m, 4H), 1.33-1.26 (m, 2H), 1.18-1.08 (m, 2H).

Example 764

The title compound was prepared as described in Step C of Example 504 utilizing (R)-piperidin-3-ol. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.52-8.51 (m), 7.59-7.47 (m), 7.44-7.28 (m), 4.30-4.04 (m), 3.93-3.81 (m), 3.69-3.32 (m), 3.17-2.89 (m), 2.83-2.57 (m), 1.96-1.67 (m), 1.53-1.15 (m).

Example 765

The title compound was prepared as described in Step C of Example 504 utilizing (cis/trans) 4-aminocyclohexanol. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O₂, 406.18; m/z found, 407.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.49 (d, J=1.2, 2H), 7.58-7.40 (m, 5H), 7.33-7.26 (m, 2H), 3.69-3.61 (m, 1H), 3.51-3.38 (m, 1H), 3.33 (br s, 1H), 1.88-1.76 (m, 4H), 1.35-1.27 (m, 2H), 1.14 (m, 2H).

Example 766

The title compound was prepared as described in Step C of Example 504 utilizing racemic 2-(trifluoromethyl)morpholine. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₄O₂, 446.14; m/z found, 447.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.57 (s), 7.62-7.27 (m), 5.21 (s), 4.74 (dd), 4.52 (d), 4.12-3.73 (m), 3.65 (d), 3.48-3.21 (m), 3.21-3.01 (m), 2.94 (m), 2.60 (m), 2.35 (s), 2.16 (s).

Example 767

The title compound was prepared as described in Step C of Example 504 utilizing (S)-piperidin-3-ol. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.51 (d), 7.64-7.45 (m), 7.43-7.29 (m), 4.31-4.03 (m), 3.94-3.80 (m), 3.69-3.58 (m), 3.51-3.35 (m), 3.34 (s), 3.22-2.84 (m), 2.84-2.56 (m), 2.44 (dd), 2.10-1.55 (m), 1.52-1.15 (m).

Example 768

The title compound was prepared as described in Step C of Example 504 utilizing (S)piperidin-3-ol. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.38 (s), 8.07 (s), 7.97-7.87 (m), 7.59-7.45 (m), 7.44-7.25 (m), 4.30-4.27 (m), 4.11 (dd), 4.30-4.27 (m), 3.66-3.56 (m), 3.49-3.32 (m), 3.20-2.83 (m), 2.79-2.50 (m), 2.36 (dd), 2.04-1.58 (m), 1.50-1.13 (m).

Example 769

The title compound was prepared as described in Step C of Example 504 utilizing (R)-pyrrolidin-3-ol. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O₂, 378.15; m/z found, 379.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.39 (s), 8.00 (s), 7.89-7.79 (m), 7.45-7.22 (m), 5.13 (m), 4.30 (m), 4.14 (m), 3.70-3.36 (m), 3.02-2.96 (m), 2.59 (m), 1.90-1.55 (m).

Example 770

The title compound was prepared as described in Step C of Example 504 utilizing (R)-pyrrolidin-3-ol. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O₂, 378.15; m/z found, 379.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.46 (d), 7.46-7.23 (m), 5.47 (m), 4.31 (m), 4.16 (m), 3.65-3.37 (m), 3.13-2.86 (m), 2.81 (m), 1.86-1.60 (m).

Example 771

The title compound was prepared as described in Step C of Example 504 utilizing (S)-pyrrolidin-3-ol. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O₂, 378.15; m/z found, 378.9 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.28 (s), 7.96 (s), 7.87-7.78 (m), 7.51-7.18 (m), 4.25-4.16 (m), 4.05 (m), 3.58-3.29 (m), 3.20 (m), 3.11-2.77 (m), 1.73 (m), 1.60 (m).

Example 772

The title compound was prepared as described in Step C of Example 504 utilizing (S)-pyrrolidin-3-ol. MS (ESI): mass calcd. for C₂₁H₁₉FN₄O₂, 378.15; m/z found, 379.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.45 (d), 7.45-7.23 (m), 5.19 (m), 4.33 (m), 4.17 (m), 3.63-3.56 (m), 3.50 (d), 3.06-2.87 (m), 1.79 (m), 1.67 (m).

Example 773

The title compound was prepared as described in Step C of Example 504 utilizing a diastereoisomeric mixture of 2,6-dimethylmorpholine. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O₂, 406.18; m/z found, 407.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) Complex due to the presence of multiple diastereoisomers and conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.58 (d), 8.11 (s), 8.09-8.00 (m), 7.55-7.29 (m), 4.77 (br s), 4.52 (d), 3.64-3.30 (m), 3.10-3.00 (m), 2.58-2.47 (m), 2.44-2.33 (m), 2.18-2.01 (m), 1.14 (dd), 0.97-0.84 (m).

Example 774

The title compound was prepared as described in Step C of Example 504 utilizing (S)-3-methylmorpholine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (d, J=9.6, 1H), 8.04 (s, 1H), 8.00-7.91 (m, 1H), 7.61-7.45 (m, 3H), 7.45-7.20 (m, 3H), 6.75 (d, J=5.1, 2H), 4.54-4.01 (m, 1H), 3.77-3.39 (m, 2H), 3.25-3.15 (m, 1H), 3.05-2.85 (m, 1H), 2.85-2.63 (m, 1H), 2.22-1.95 (m, 1H), 1.20 (d, J=6.9, 3H).

Example 775

The title compound was prepared as described in Step C of Example 504 utilizing (R)-3-methylmorpholine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (d, J=9.6, 1H), 8.04 (s, 1H), 8.01-7.89 (m, 1H), 7.61-7.46 (m, 3H), 7.45-7.19 (m, 3H), 6.75 (d, J=5.1, 2H), 4.53-4.03 (m, 1H), 3.73-3.58 (m, 1H), 3.54-3.41 (m, 1H), 3.25-3.15 (m, 1H), 3.05-2.86 (m, 1H), 2.84-2.64 (m, 1H), 2.23-1.88 (m, 1H), 1.20 (d, J=6.9, 3H).

Example 776

The title compound was prepared as described in Step C of Example 504 utilizing (S)-2-methylmorpholine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.39 (s, 1H), 8.04 (s, 1H), 7.97-7.95 (m, 1H), 7.65-7.46 (m, 3H), 7.45-7.24 (m, 3H), 6.76 (s, 2H), 4.27 (dd, J=23.7, 13.0, 1H), 3.87-3.38 (m, 2H), 3.13-2.70 (m, 2H), 2.63-2.42 (m, 1H), 2.19-1.90 (m, 1H), 1.04 (d, J=6.0, 3H).

Example 777

The title compound was prepared as described in Step C of Example 504 utilizing (S)-2-methylmorpholine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.50 (d. J=5.2, 2H), 7.76-7.60 (m, 1H), 7.60-7.46 (m, 3H), 7.46-7.22 (m, 3H), 6.76 (s, 2H), 4.27 (dd, J=20.9, 12.6, 1H), 3.88-3.52 (m, 1H), 3.43 (m, 1H), 3.17-2.82 (m, 2H), 2.81-2.52 (m, 1H), 2.31-1.97 (m, 1H), 1.05 (d, J=5.9, 3H).

Example 778

The title compound was prepared as described in Step C of Example 504 utilizing (S)-3-methylmorpholine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆): δ 8.54-8.45 (m, 2H), 7.72-7.60 (m, 1H), 7.57-7.47 (m, 3H), 7.42-7.21 (m, 3H), 6.94 (d, J=6.0, 2H), 4.48 (s, 1H), 3.90 (dd, J=13.9, 11.2, 1H), 3.60 (d, J=11.4, 1H), 3.16 (s, 1H), 3.01-2.68 (m, 2H), 2.27-1.96 (m, 1H), 1.20 (d, J=6.8, 3H)

Example 779

The title compound was prepared as described in Step C of Example 504 utilizing (R)-3-methylmorpholine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 393.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, J=11.5, 2H), 7.69-7.58 (m, 1H), 7.56-7.42 (m, 3H), 7.40-7.18 (m, 3H), 6.91 (d. J=5.8, 2H), 4.41 (d. J=21.0, 1H), 3.87 (dd, J=13.5, 11.0, 1H), 3.56 (d, J=11.2, 1H), 3.15 (dd, J=8.0, 5.6, 1H), 3.00-2.66 (m, 2H), 2.12 (m, 1H), 1.17 (d, J=6.8, 3H).

Example 780

The title compound was prepared as described in Step C of Example 504 utilizing a diastereoisomeric mixture of 2,6-dimethylmorpholine. MS (ESI): mass calcd. for C₂₃H₂₃FN₄O₂, 406.18; m/z found, 407.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=9.3, 2H), 7.68-7.59 (m, 1H), 7.54-7.45 (m, 3H), 7.36-7.26 (m, 3H), 6.91 (d, J=10.5, 2H), 4.29 (d, J=12.6, 2H), 3.00 (dd, J=31.3, 12.7, 1H), 2.59-2.50 (m, 1H), 2.40-2.26 (m, 1H), 2.17-2.07 (m, 1H), 1.12-0.96 (m, 3H), 0.89-0.72 (m, 3H).

Example 781

The title compound was prepared as described in Example 376 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine. MS (ESI): mass calcd. for C₂₃H₁₉FN₄O₂, 402.15; m/z found, 403.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.34 (s, 1H), 8.73-8.64 (m, 1H), 8.55 (s, 1H), 8.18 (m, 1H), 7.88-7.79 (m, 1H), 7.60 (m, 1H), 7.51-7.41 (m, 1H), 7.43-7.32 (m, 3H), 6.65-6.55 (m, 1H), 3.73 (dd, J=5.8, 4.0, 2H), 3.63 (dd, J=5.7, 4.2, 2H), 3.34 (dd, J=5.6, 4.1, 2H), 3.18-3.06 (m, 2H).

Intermediate JE

To a round-bottomed flask that had been purged with nitrogen, were added 3-bromopicolinic acid (500 mg, 2.50 mmol), morpholine (259 mg, 3.00 mmol), EDCl (712 mg, 3.70 mmol), HOBT (501 mg, 3.70 mmol), triethylamine (1.0 mL, 7.4 mmol) and DMF (12 mL). The mixture was stirred at rt for 24 h, before diluting with water (100 mL) and extracting with ethyl acetate (2×100 mL). The combined organic extracts were washed with saturated bicarbonate (1×50 mL), water (2×50 mL), dried with sodium sulfate, and concentrated to dryness. The crude product was purified by FCC to provide the title compound. MS (ESI): mass calcd. for C₁₀H₁₁BrN₂O₂, 270.00; m/z found, 271.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.57 (dd. J=4.7, 1.4, 1H), 7.93 (dd, J=8.2, 1.4, 1H), 7.23 (dd, J=8.2, 4.7, 1H), 3.90-3.77 (m, 4H), 3.74-3.62 (m, 2H), 3.30-3.15 (m, 2H).

Example 782

The title compound was prepared as described in Example 376 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₂, 379.14; m/z found, 380.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.72-8.63 (m, 1H), 8.56 (d, J=1.4, 2H), 7.85-7.75 (m, 1H), 7.53-7.42 (m, 2H), 7.39-7.28 (m, 2H), 5.17 (s, 2H), 3.71 (dd, J=5.6, 3.8, 2H), 3.63 (dd, J=5.6, 3.8, 2H), 3.37 (dd, J=5.6, 4.2, 2H), 3.18-3.06 (m, 2H).

Example 783

The title compound was prepared as described in Example 376 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₂, 379.14; m/z found, 380.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.67 (dd, J=4.8, 1.6, 1H), 8.61 (m, 1H), 8.12 (d, J=1.4, 1H), 8.06 (m, 1H), 7.81 (dd, J=7.9, 1.6, 1H), 7.44 (dd, J=7.9, 4.8, 1H), 7.38 (dd, J=8.1, 1.8, 1H), 7.32 (dd, J=12.1, 1.8, 1H), 4.72 (s, 2H), 3.69 (dd, J=5.6, 3.9, 2H), 3.60 (dd, J=5.7, 4.1, 2H), 3.30 (dd, J=5.6, 4.1, 2H), 3.07 (dd. J=5.5, 4.1, 2H).

Example 784

The title compound was prepared as described in Step C of Example 504 utilizing t-butylamine. MS (ESI): mass calcd. for C₂₂H₂₀F₄N₄O, 432.16; m/z found, 432.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.37-8.32 (m, 1H), 8.06-8.00 (m, 2H), 7.92-7.88 (m, 1H), 7.83 (d, J=8.2, 1H), 7.68-7.65 (m, 2H), 7.38-7.35 (m, 2H), 6.68 (s, 2H), 1.21 (s, 9H).

Example 785

The title compound was prepared as described in Step C of Example 504 utilizing (R)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₄O₂, 434.14; m/z found, 434.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (s, 1H), 8.29 (d, J=7.9, 1 H), 8.05 (s, 1H), 7.97-7.84 (m, 2H), 7.77 (s, 1H), 7.71 (d, J=7.9, 1H), 7.37 (d, J=9.4, 2H), 6.71 (s, 2H), 4.70 (s, 1H), 3.93-3.78 (m, 1H), 3.25-3.15 (m, 2H), 1.00 (d, J=6.2, 3H).

Example 786

The title compound was prepared as described in Step C of Example 504 utilizing (S)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₄O₂, 434.14; m/z found, 434.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.42-8.39 (m, 1H), 8.31 (d, J=8.1, 1H), 8.07 (d, J=1.5, 1H), 7.96-7.89 (m, 2H), 7.79 (s, 1H), 7.74 (d, J=8.0, 1H), 7.41 (s, 1H), 7.38 (dd, J=4.5, 1.6, 1H), 6.74 (s, 2H), 4.72 (t, J=5.7, 1H), 3.92-3.83 (m, 1H), 3.25-3.19 (m, 2H), 1.02 (d, J=6.7, 3H).

The title compound was prepared as described in Step C of Example 504 utilizing (R)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C₂₁H₁₅F₇N₄O, 472.11; m/z found, 472.8 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (d, J=8.8, 1H), 8.41-8.35 (m, 1H), 8.04 (d, J=1.4, 1H), 7.94-7.90 (m, 2H), 7.80-7.72 (m, 2H), 7.36-7.28 (m, 2H), 6.72 (s, 2H), 4.70-4.60 (m, 1H), 1.22 (d, J=7.0, 3H).

Example 788

The title compound was prepared as described in Step C of Example 504 utilizing (S)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C₂₁H₁₅F₇N₄O, 472.11; m/z found, 472.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.10 (d, J=8.8, 1H), 8.48 (s, 2H), 7.94 (d, J=8.1, 1H), 7.80-7.72 (m, 2H), 7.65-7.61 (m, 1H), 7.34-7.30 (m, 2H), 6.90 (s, 2H), 4.69-4.60 (m, 1H), 1.22 (d, J=7.0, 3H).

Example 789

The title compound was prepared as described in Step C of Example 504 utilizing (R)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C₂₁H₁₅F₇N₄O, 472.11; m/z found, 472.8 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.10 (d, J=8.8, 1H), 8.48 (s, 2H), 7.93 (d, J=8.0, 1H), 7.81-7.71 (m, 2H), 7.65-7.61 (m, 1H), 7.37-7.26 (m, 2H), 6.91 (s, 2H), 4.68-4.62 (m, 1H), 1.22 (d, J=7.0, 3H).

Example 790

The title compound was prepared as described in Step C of Example 504 utilizing (S)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C₂₁H₁₅F₇N₄O, 472.11; m/z found, 472.8 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (d. J=8.8, 1H), 8.43-8.35 (m, 1H), 8.06 (d, J=1.4, 1H), 7.96-7.91 (m, 2H), 7.77 (d, J=8.8, 2H), 7.37-7.29 (m, 2H), 6.73 (s, 2H), 4.71-4.61 (m, 1H), 1.23 (d, J=7.0, 3H).

Example 791

The title compound was prepared as described in Step C of Example 504 utilizing azetidin-3-. MS (ESI): mass calcd. for C₂₀H₁₇FN₄O₂, 364.13; m/z found, 364.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.51 (s, 2H), 7.65-7.61 (m, 1H), 7.57-7.40 (m, 4H), 7.35-7.30 (m, 2H), 6.88 (s, 2H), 5.65 (d, J=4.8, 1H), 4.31 (s, 1H), 4.11-4.04 (m, 1H), 3.81 (t, J=7.9, 1H), 3.60 (dd, J=10.2, 4.4, 1H), 3.39 (dd, J=9.1, 4.4, 1 H).

Example 792

The title compound was prepared as described in Step C of Example 504 utilizing N-methylpiperidin-4-amine. MS (ESI): mass calcd. for C₂₃H₂₄FN₅O, 405.20; m/z found, 405.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.61 (d, J=10.6, 2H), 7.71-7.55 (m, 4H), 7.54-7.32 (m, 3H), 4.57 (d, J=12.6, 1H), 3.45-3.43 (m, 1H), 3.05-2.90 (m, 1H), 2.75-2.63 (m, 1H), 2.59-2.54 (m, 1H), 2.35 (m, 3H), 2.02-1.92 (m, 1H), 1.73-1.62 (m, 1H), 1.41-1.16 (m, 1H), 1.08-0.44 (m, 1H).

Example 793

The title compound was prepared as described in Step C of Example 504 utilizing thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₄O₃S, 494.10; m/z found, 494.8 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.49 (s, 2H), 8.03 (s, 1H), 7.94 (d, J=8.2H, 1H), 7.80 (d, J=8.1, 1H), 7.72-7.68 (m, 1H), 7.40 (d, J=11.7, 1H), 7.34 (d, J=7.6, 1H), 6.92 (s, 2H), 4.25-4.10 (m, 1H), 3.68-3.65 (m, 1H), 3.59-3.48 (m, 1H), 3.26-3.11 (m, 3H), 3.03-2.92 (m, 1H), 2.42-2.28 (m, 1H).

Example 794

The title compound was prepared as described in Step C of Example 504 utilizing t-butyl amine. MS (ESI): mass calcd. for C₂₂H₂₀F₄N₄O, 432.16: m/z found, 432.8 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.46 (s, 2H), 8.04 (s, 1H), 7.83 (d, J=8.0, 1H), 7.71-7.58 (m, 3H), 7.41-7.32 (m, 2H), 6.87 (s, 2H), 1.22 (s, 9H).

Example 795

The title compound was prepared as described in Step C of Example 504 utilizing piperidin-4-ol. MS (ESI): mass calcd. for C₂₃H₂₀F₄N₄O₂, 460.15; m/z found, 460.8 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.39-8.33 (m, 1H), 8.03 (s, 1H), 7.98-7.91 (m, 1H), 7.86 (d, J=8.2, 1H), 7.75 (dd, J=8.1, 3.2, 1H), 7.70 (d, J=6.3, 1H), 7.40-7.32 (m, 2H), 6.72 (s, 2H), 4.69-4.61 (m, 1H), 3.99-3.73 (m, 1H), 3.53-3.50 (m, 1H), 3.17-2.59 (m, 3H), 1.66-1.34 (m, 2H), 1.17-0.45 (m, 2H).

Example 796

The title compound was prepared as described in Step C of Example 504 utilizing piperidin-4-ol. MS (ESI): mass calcd. for C₂₃H₂₀F₄N₄O₂, 460.15; m/z found, 460.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.49 (d, J=7.1, 2H), 7.89 (d, J=8.2, 1H), 7.83-7.65 (m, 3H), 7.48-7.33 (m, 2H), 6.91 (s, 2H), 4.05-4.02 (m, 1H), 3.91-3.76 (m, 1H), 3.64-3.48 (m, 1H), 3.23-3.18 (m, 1H), 3.05-2.63 (m, 2H), 1.72-1.40 (m, 2H), 1.20-0.97 (m, 2H).

Example 797

The title compound was prepared as described in Step C of Example 504 utilizing tetrahydro-2H-pyran-4-amine. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₂, 392.16; m/z found, 392.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.1, 2H), 8.24 (d, J=7.8, 1H), 7.61-7.49 (m, 2H), 7.48-7.41 (m, 3H), 7.32-7.29 (m, 2H), 6.87 (s, 2H), 3.89-3.79 (m, 1H), 3.76-3.73 (m, 2H), 3.34 (s, 2H), 1.64-1.61 (m, 2H), 1.41-1.29 (m, 2H).

Example 798

The title compound was prepared as described in Step C of Example 504 utilizing morpholin-2-ylmethanol. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₃, 408.16; m/z found, 408.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.39 (s, 1H), 8.07 (s, 1H), 7.97-7.91 (m, 1H), 7.58-7.25 (m, 6H), 4.51-4.31 (m, 1H), 3.95-3.56 (m, 1H), 3.55-3.43 (m, 2H), 3.40-3.33 (m, 1H), 3.26-2.96 (m, 2H), 2.90-2.63 (m, 1H), 2.60-2.19 (m, 1H).

Example 799

The title compound was prepared as described in Step C of Example 504 utilizing racemic morpholin-2-ylmethanol. MS (ESI): mass calcd. for C₂₂H₂₁FN₄O₃, 408.16; m/z found, 409.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.52 (s, 2H), 7.67-7.25 (m, 7H), 4.49-4.33 (m, 1H), 3.96-3.56 (m, 1H), 3.56-3.43 (m, 2H), 3.41-3.31 (m, 1H), 3.23-2.95 (m, 2H), 2.89-2.53 (m, 1H), 2.52-2.13 (m, 1H).

Intermediate JF

3-Bromopyridin-2-amine (500 mg, 2.89 mmol) and pivaloyl chloride (420 mg, 3.48 mmol) were added to a 50 mL round-bottomed flask. Pyridine (10 mL) was then added and the mixture stirred and heated at 80° C. for 4 h. The reaction was then cooled to rt and stirred overnight. The reaction mixture was then concentrated to dryness and the resultant residue subjected to FCC to provide the title compound. MS (ESI): mass calcd. for C₁₀H₁₃BrN₂O, 256.02; m/z found, 257.1 [M+H]⁺.

Example 800

The title compound was prepared as described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine and N-(3-bromopyridin-2-yl)pivalamide. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O, 365.17; m/z found, 366.15 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.65 (s, 1H), 8.52-8.43 (m, 3H), 7.93-7.83 (m, 1H), 7.56-7.64 (m, 1H), 7.47-7.68 (m, 1H), 7.38-7.26 (m, 2H), 6.93 (s, 2H), 1.05 (s, 9H).

Example 801

The title compound was prepared as described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrazin-2-amine and N-(3-bromopyridin-2-yl)pivalamide. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O, 365.17; m/z found, 366.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 9.66 (s, 1H), 8.52-8.42 (m, 1H), 8.40-8.30 (m, 1H), 8.03 (d, J=1.4, 1H), 7.95-7.82 (m, 2H), 7.47-7.38 (m, 1H), 7.39-7.30 (m, 1H), 6.73 (s, 2H), 1.05 (s, 9H).

Example 802

The title compound was prepared as described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and N-(3-bromopyridin-2-yl)pivalamide. MS (ESI): mass calcd. for C₂₃H₂₁FN₄O, 388.17; m/z found, 389.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 11.81 (s, 1H), 9.67 (s, 1H), 8.54-8.46 (m, 1H), 8.42-8.33 (m, 1H), 8.18-8.09 (m, 1H), 7.96-7.87 (m, 1H), 7.71-7.62 (m, 1H), 7.55 (d, J=3.5, 1H), 7.50-7.40 (m, 1H), 7.41-7.31 (m, 2H), 6.54 (d, J=3.5, 1H), 1.07 (s, 9H).

Example 803

Step A: 3-Bromopyridine-2-thiol

A mixture of 3-bromo-2-chloropyridine (10 g, 0.050 mol) and Na₂S (12 g, 0.15 mol) in DMF (150 mL) was stirred at 120° C. for 16 h. and the reaction mixture was cooled to rt and then concentrated to dryness. The resultant residue was diluted with water (80 mL), acidified to pH=5-6 with conc. HCl, and then extracted with ethyl acetate (3×50 mL). The combined organic extracts were dried over Na₂SO₄ and concentrated to dryness to give the title compound (6.4 g, crude). MS (ESI): mass calcd. For C₅H₄BrNS 188.92; m/z found, 191.9 [M+H]⁺.

Step B: tert-Butyl 3-(3-bromopyridin-2-ylthio)pyrrolidine-1-carboxylate

A mixture of 3-bromopyridine-2-thiol (0.30 g, 1.6 mmol), tert-butyl 3-bromopyrrolidine-1-carboxylate (0.79 g, 3.2 mmol) and K₂CO₃ (438 mg, 3.20 mmol) in DMF (12 mL) was stirred at rt for 4 h. The reaction mixture was concentrated to dryness and the residue subjected to FCC purification to give partially purified title compound (1.05 g, 63% purity).

Step C: tert-Butyl 3-(3-bromopyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate

To a solution of tert-butyl 3-(3-bromopyridin-2-ylthio)pyrrolidine-1-carboxylate (0.9 g, 63% purity, 1.6 mmol) in DCM/CH₃CN (20 mL/20 mL) were added NalO₄ (1.6 g, 7.6 mmol), H₂O (20 mL), and RuCl₃ (10 mg, 0.070 mmol). The mixture was stirred at rt for 10 minutes and then concentrated to dryness. The resultant residue was diluted with water (50 mL) and extracted with DCM (3×40 mL). The combined extracts were dried over MgSO₄, concentrated to dryness to give impure title compound (1.0 g, 60% purity) which was used for next step without any further purification.

Step D: tert-Butyl 3-(3-(4-(5-aminopyrazin-2-yl)-3-fluorophenyl)pyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate

A mixture of tert-butyl 3-(3-bromopyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate (205 mg, 60% purity, 0.320 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (100 mg, 0.320 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (23 mg, 0.030 mmol), and Na₂CO₃ (101 mg, 0.950 mmol) in DMF (6 mL) was stirred at 100° C. for 16 h under N₂ before cooling to rt and concentrating it to dryness. The resultant residue was subjected to FCC followed by HPLC purification to give the title compound (150 mg, 99%). MS (ESI): mass calcd. For C₂₄H₂₆FN₅O₄S 499.17; m/z found, 521.9 [M+Na]⁺.

Step E: 5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrazin-2-amine hydrochloride.

To a solution consisting of tert-butyl 3-(3-(4-(5-aminopyrazin-2-yl)-3-fluorophenyl)pyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate (150 mg, 0.300 mmol) and DCM (10 mL) was added HCl/EtOH (5 N, 10 mL). The mixture was stirred at rt for 2 h, concentrated to dryness, and the resultant residue subjected to HPLC purification to give the title compound (67 mg, 52%). MS (ESI): mass calcd. For C₁₉H₁₈FN₅O₂S.HCl 399.12; m/z found, 400.1 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 9.79 (br s, 1H), 9.42 (br s, 1H), 8.79 (d, J=4.6, 1H), 8.51-8.30 (m, 1H), 8.20-7.78 (m, 3H), 7.51-7.02 (m, 3H), 4.81 (dd, J=14.1, 7.6, 1H), 3.72 (s, 1H), 3.49-3.14 (m, 3H), 2.44-2.20 (m, 2H).

Example 804

The title compound was prepared as described in step E of Example 803 using tert-butyl 3-(3-(4-(5-aminopyrimidin-2-yl)-3-fluorophenyl)pyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate. MS (ESI): mass calcd. for C₁₉H₁₈FN₅O₂S, 399.12; m/z found, 400.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.71 (dd, J=4.7, 1.6, 1H), 8.52 (d, J=1.4, 2H), 8.41 (br s, 1H), 8.03 (dd, J=7.9, 1.5, 1H), 7.78 (dd, J=7.9, 4.7, 1H), 7.58 (m, 1H), 7.49-7.35 (m, 2H), 4.95-4.90 (m, 1H), 3.81 (dd, J=13.3, 8.9, 1H), 3.66 (dd, J=13.3, 5.4, 1H), 3.44-3.33 (m, 2H), 2.52-2.38 (m, 2H).

Example 805

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclobutylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₂S.HCl, 384.11; m/z found, 385.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.80 (d, J=0.8, 2H), 8.70 (dd, J=4.7, 1.6, 1H), 7.99 (dd, J=7.8, 1.6, 1H), 7.74 (dd, J=7.8, 4.7, 1H), 7.69 (m, 1H), 7.53-7.46 (m, 2H), 4.80-4.69 (m, 1H), 2.54-2.41 (m, 2H), 2.41-2.30 (m, 2H), 2.20-2.07 (m, 1H), 2.05-1.94 (m, 1H).

Example 806

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclobutylsulfonyl)pyridine. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₂S.HCl, 384.11; m/z found, 385.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.69 (dd, J=4.7, 1.5, 1H), 8.52 (s, 1H), 8.33 (s, 1H), 8.12 (m, 1H), 7.99 (dd, J=7.8, 1.5, 1H), 7.74 (dd, J=7.8, 4.7, 1H), 7.49 (d, J=2.7, 1H), 7.46 (s, 1H), 4.80-4.70 (m, 1H), 2.54-2.42 (m, 2H), 2.40-2.30 (m, 2H), 2.21-2.07 (m, 1H), 2.04-1.94 (m, 1H).

Example 807

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclohexylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₂S.HCl, 412.14; m/z found, 413.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.74 (dd, J=4.6, 1.6, 1H), 8.56 (s, 2H), 7.96 (dd, J=7.9, 1.6, 1H), 7.74 (dd, J=7.9, 4.7, 1H), 7.57 (m, 1H), 7.37 (dd, J=3.6, 1.3, 1H), 7.34 (s, 1H), 3.97-3.83 (m, 1H), 2.01-1.63 (m, 5H), 1.52-1.13 (m, 5H).

Example 808

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclohexylsulfonyl)pyridine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₂S.HCl, 412.14; m/z found, 413.1 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 8.78 (d, J=4.4, 1H), 8.39 (s, 1H), 8.02 (d, J=6.3, 2H), 7.90 (m, 1H), 7.80 (dd, J=7.8, 4.6, 1H), 7.35 (dd, J=14.8, 10.8, 2H), 6.75 (s, 2H), 3.98-3.80 (m, 1H), 1.80 (d, J=14.9, 4H), 1.62 (d, J=12.3, 1 H), 1.39-1.07 (m, 5H).

Example 809

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclopentylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂S.HCl, 398.12; m/z found, 399.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.88 (s, 2H), 8.73 (dd, J=4.6, 1.5, 1H), 7.96 (dd, J=7.8, 1.5, 1H), 7.80-7.62 (m, 2H), 7.55-7.41 (m, 2H), 4.56-4.40 (m, 1H), 2.09-1.79 (m, 4H), 1.69 (d, J=4.7, 4H).

Example 810

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclopentylsulfonyl)pyridine. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂S.HCl, 398.12; m/z found, 399.10 [M+H]⁺. 1H NMR (300 MHz, CD₃OD) δ 8.80-8.68 (m, 2H), 8.25 (d, J=1.1, 1H), 8.13 (m, 1H), 7.96 (dd, J=7.8, 1.5, 1H), 7.73 (dd, J=7.8, 4.6, 1H), 7.43 (d, J=10.3, 2H), 4.52-4.39 (m, 1H), 2.10-1.80 (m, 4H), 1.68 (d, J=5.4, 4H).

Example 811

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(tert-butylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₂S, 386.12; m/z found, 387.0 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.73 (dd, J=4.6, 1.7, 1H), 8.56 (d, J=1.4, 2H), 7.73 (dd, J=7.8, 1.7, 1H), 7.56 (dd, J=7.8, 4.6, 1H), 7.41 (m, 1H), 7.28 (dd, J=7.9, 1.8, 1H), 7.21 (d, J=1.7, 1H), 5.29 (s, 2H), 1.48 (s, 9H).

Example 812

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(tert-butylsulfonyl)pyridine. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₂S, 386.12; m/z found, 387.0 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.73 (dd, J=4.5, 1.7, 1H), 8.54 (s, 1H), 8.12 (s, 1H), 7.98 (m, 1H), 7.74 (dd, J=7.8, 1.7, 1H), 7.56 (dd, J=7.8, 4.6, 1H), 7.28 (d, J=1.7, 1H), 7.20 (d, J=1.7, 1H), 5.01 (s, 2H), 1.45 (s, 9H).

Example 813

The title compound was prepared as described in step D of Example 803 using racemic 3-bromo-2-(sec-butylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₂S, 386.12; m/z found, 387.0 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.73 (dd, J=4.6, 1.6, 1H), 8.53 (d, J=1.4, 2H), 7.96 (dd, J=7.8, 1.6, 1H), 7.73 (dd, J=7.8, 4.6, 1H), 7.56 (m, 1H), 7.40-7.32 (m, 2H), 4.00-3.89 (m, 1H), 1.95-1.81 (m, 1H), 1.53-1.43 (m, 1H), 1.23 (d, J=8.3, 3H), 1.01 (t, J=7.5, 3H).

Example 814

The title compound was prepared as described in step D of Example 803 using racemic 3-bromo-2-(sec-butylsulfonyl)pyridine. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₂S, 386.12; m/z found, 387.0 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.73 (dd, J=4.6, 1.6, 1H), 8.41-8.35 (m, 1H), 8.20 (d, J=1.4, 1H), 8.03-7.94 (m, 2H), 7.74 (dd, J=7.8, 4.6, 1H), 7.40-7.32 (m, 2H), 3.90 (s, 1H), 1.92-1.82 (m, 1H), 1.53-1.42 (m, 1H), 1.24 (d, J=6.9, 3H), 1.00 (t, J=7.5, 3H).

Example 815

The title compound was prepared as described in step D of Example 803 using 1-(4-((3-bromopyridin-2-yl)sulfonyl)piperidin-1-yl)ethanone and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₂H₂₂FN₅O₃S.HCl, 455.14; m/z found, 456.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.76 (dd, J=4.6, 1.6, 1H), 8.56 (d, J=1.3, 2H), 8.00 (dd, J=7.9, 1.6, 1H), 7.78 (dd, J=7.9, 4.7, 1H), 7.59 (m, 1H), 7.40 (dd, J=4.3, 1.4, 1H), 7.38 (s, 1H), 4.61 (d, J=13.4, 1H), 4.35 (m, 1H), 4.06 (d, J=14.0, 1H), 3.24 (d, J=13.0, 2.8, 1H), 2.76 (m, 1H), 2.11 (s, 3H), 2.09-1.97 (m, 2H), 1.74 (m, 1H), 1.61 (m, 1H).

Example 816

The title compound was prepared as described in step D of Example 803 using 1-(4-((3-bromopyridin-2-yl)sulfonyl)piperidin-1-yl)ethanone. MS (ESI): mass calcd. for C₂₂H₂₂FN₅O₃S.HCl, 455.14; m/z found, 456.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD): δ 8.76 (dd, J=4.6, 1.6, 1 H), 8.46-8.39 (m, 1H), 8.10 (d, J=1.4, 1H), 8.01 (dd, J=7.9, 1.6, 1H), 7.96 (m, 1H), 7.78 (dd, J=7.9, 4.7, 1H), 7.39 (s, 1H), 7.37 (dd, J=4.4, 1.5, 1H), 4.60 (d, J=13.5, 1H), 4.37-4.26 (m, 1H), 4.05 (d, J=14.0, 1H), 3.23 (m, 1H), 2.75 (m, 1H), 2.10 (s, 3H), 2.07-1.97 (m, 2H), 1.74 (m, 1H), 1.61 (m, 1H).

Example 817

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-((3-methoxypropyl)sulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.74 (dd, J=4.6, 1.5, 1H), 8.61 (s, 2H), 7.99 (dd, J=7.8, 1.5, 1H), 7.76 (dd, J=7.8, 4.7, 1H), 7.60 (m, 1H), 7.42 (dd, J=3.9, 1.3, 1H), 7.40 (s, 1H), 3.70-3.62 (m, 2H), 3.48 (m, 2H), 3.32 (s, 3H), 2.03-1.94 (m, 2H).

Example 818

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-((3-methoxypropyl)sulfonyl)pyridine. MS (ESI): mass calcd. for C₁₉H₁₉FN₄O₃S, 402.12; m/z found, 403.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.69 (d, J=3.5, 1H), 8.35 (s, 1H), 8.21 (s, 1H), 8.04-7.90 (m, 2H), 7.72 (dd, J=7.8, 4.7, 1H), 7.39 (s, 1H), 7.35 (d, J=2.0, 1H), 3.68-3.56 (m, 2H), 3.45 (m, 2H), 3.29 (s, 3H), 2.04-1.89 (m, 2H).

Example 819

The title compound was prepared as described in step D of Example 803 using 4-((3-bromopyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine giving the target molecule after purification by HPLC. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₄S₂.HCOOH, 462.08; m/z found, 463.00 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.67 (d, J=4.1, 1H), 8.58 (s, 2H), 7.87 (d, J=7.3, 1H), 7.72-7.59 (m, 1H), 7.56-7.44 (m, 1H), 7.42-7.29 (d, J=14.6, 2H), 5.22 (s, 2H), 4.52-4.48 (m, 1H), 3.43-3.23 (m, 2H), 3.03 (s, 2H), 2.68-2.47 (m, 4H).

Example 820

The title compound was prepared as described in step D of Example 803 using 4-((3-bromopyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide giving the target molecule after purification by HPLC. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₄S₂.HCOOH, 462.08; m/z found, 463.00 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃): δ 8.66 (dd, J=4.6, 1.6, 1H), 8.63-8.59 (m, 1H), 8.11 (d, J=1.5, 1H), 8.06 (m, 1H), 7.86 (dd, J=7.8, 1.6, 1H), 7.63 (dd, J=7.8, 4.6, 1H), 7.37 (dd, J=8.1, 1.8, 1H), 7.31 (dd, J=11.6, 1.7, 1H), 4.77 (s, 2H), 4.42-4.28 (m, 1H), 3.45-3.27 (m, 2H), 3.10-2.94 (m, 2H), 2.67-2.48 (m, 4H).

Example 821

The title compound was prepared as described in step D of Example 803 using 4-(2-((3-bromopyridin-2-yl)sulfonyl)ethyl)morpholine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₃S.HCOOH, 443.14; m/z found, 444.10 [M+H]⁺. ¹H NMR (300 MHz. CDCl₃) δ 8.65 (dd, J=4.7, 1.6, 1 H), 8.56 (s, 2H), 7.82 (dd, J=7.8, 1.6, 1H), 7.61 (dd, J=7.9, 4.7, 1H), 7.47 (m, 1H), 7.39 (dd, J=8.0, 1.7, 1H), 7.33 (dd, J=11.0, 1.7, 1H), 5.52 (s, 2H), 3.85 (t, J=9, 2H), 3.63 (s, 4H), 2.93 (t, J=9, 2H), 2.54 (s, 4H).

Example 822

The title compound was prepared as described in step D of Example 803 using 4-(2-((3-bromopyridin-2-yl)sulfonyl)ethyl)morpholine giving the target molecule after purification by HPLC. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₃S.HCOOH, 443.14; m/z found, 444.10 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃): δ 8.65 (dd, J=4.6, 1.6, 1H), 8.51 (s, 1H), 8.14 (d, J=1.5, 1H), 8.04 (m, 1H), 7.83 (dd, J=7.8, 1.6, 1H), 7.61 (dd, J=7.8, 4.7, 1H), 7.43-7.30 (m, 2H), 5.28 (m, 2H), 3.98-3.84 (m, 2H), 3.80-3.58 (m, 4H), 3.09-2.96 (m, 2H), 2.78-2.54 (m, 4H).

Example 823

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.71 (dd, J=4.6, 1.5, 1H), 8.53 (d, J=1.3, 2 H), 7.97 (dd, J=7.8, 1.6, 1H), 7.74 (dd, J=7.9, 4.6, 1H), 7.57 (m, 1H), 7.44-7.35 (m, 2H), 3.96-3.78 (m, 2H), 3.57 (d, J=6.3, 2H), 3.47-3.37 (m, 2H), 2.25-2.10 (m, 1H), 1.85-1.69 (m, 2H), 1.54-1.36 (m, 2H).

Example 824

The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine. MS (ESI): mass calcd. for C₂₁H₂₁FN₄O₃S, 428.13; m/z found, 429.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.65 (dd, J=4.6, 1.6, 1H), 8.60 (s, 1H), 8.10 (s, 1H), 8.04 (m, 1H), 7.82 (dd, J=7.8, 1.6, 1H), 7.59 (dd, J=7.8, 4.7, 1H), 7.40 (dd, J=8.0, 1.7, 1H), 7.34 (dd, J=11.8, 1.6, 1H), 4.76 (s, 2H), 3.92 (dd, J=10.6, 3.2, 2H), 3.56 (d, J=6.4, 2H), 3.39 (m, 2H), 2.40-2.26 (m, 1H), 1.84 (d, J=11.0, 2H), 1.49 (m, 2H).

Example 825

The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 3-bromo-2-(isopropylsulfonyl)pyridine. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₂S, 372.11; m/z found, 373.0 [M+H]⁺. 1H NMR (400 MHz, CDCl₃) δ 8.69 (dd, J=4.7, 1.7, 1H), 8.57 (d, J=1.4, 2H), 7.80 (dd, J=7.8, 1.6, 1H), 7.59 (dd, J=7.8, 4.6, 1H), 7.46 (m, 1H), 7.39 (dd, J=7.9, 1.8, 1H), 7.32 (dd, J=11.1, 1.7, 1H), 5.17 (s, 2H), 4.26 (hept, J=6.9, 1H), 1.32 (d, J=6.9, 6H).

Example 826

The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 3-bromo-2-(isopropylsulfonyl)pyridine. MS (ESI): mass calcd. for C₂₁H₁₈FN₄O₂S, 395.11; m/z found, 396.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 9.45 (s, 1H), 8.70 (dd, J=4.6, 1.6, 2H), 8.25-8.17 (m, 1H), 7.84 (dd, J=7.8, 1.7, 1H), 7.64-7.54 (m, 2H), 7.46-7.32 (m, 3H), 6.61 (s, 1H), 4.26 (hept, J=6.8, 1H), 1.34 (d, J=6.9, 6H).

Example 827

The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.91 (s, 2H), 8.78 (m, 1H), 8.03 (m, 1H), 7.82 (m, 1H), 7.75-7.71 (m, 1H), 7.50-7.42 (m, 2H), 4.52-4.46 (m, 1H), 3.57-3.54 (m, 2H), 3.24-3.17 (m, 2H), 2.31-2.28 (m, 2H), 2.13-1.96 (m, 2H).

Example 828

Step A: 3-Bromo-2-((3-chloropropyl)thiopyridine

A mixture of 3-bromopyridine-2-thiol (0.04 g, 0.2 mmol), 1-bromo-3-chloropropane in DMF (0.424 mmol/mL, 2.0 mL), and K₂CO₃ (60 mg, 0.424 mmol) in DMF (2.0 mL) was stirred at rt for 10 minutes. The reaction mixture was then concentrated to dryness and the resultant residue diluted with water (10 mL) and extracted with ethyl acetate (3×10 mL). The combined organic extracts were dried over Na₂SO₄ and concentrated to dryness to give the title compound (0.05 g, 89% purity). MS (ESI): mass calcd. for C₈H₉BrClNS, 264.93; m/z found, 265.8 [M+H]⁺.

Step B: 3-Bromo-2-((3-chloropropyl)sulfonyl)pyridine

To a solution of 3-bromo-2-((3-chloropropyl)thio)pyridine (0.05 g, 89% purity, 0.2 mmol) in DCM/CH₃CN (3.0 mL/3.0 mL) were added NalO₄ (0.121 g, 0.567 mmol), H₂O (3.0 mL), and RuCl₃ (2.0 mg, 0.014 mmol). The mixture was stirred at rt. for 10 minutes and concentrated to dryness. The residue was diluted with water (10 mL) and extracted with ethyl acetate (3×10 mL). The combined organic extracts were dried over MgSO₄, and concentrated to dryness to give the title compound (0.05 g, 89% purity), which was used in next step without any further purification. MS (ESI): mass calcd. for C₈H₉BrClNO₂S, 296.92; m/z found, 297.9 [M+H]⁺.

Step C: 3-Bromo-2-(cyclopropylsulfonyl)pyridine

To a solution of 3-bromo-2-((chloropropyl)sulfonyl)pyridine (0.05 g, 89% purity, 0.2 mmol) in THF (20 mL) was added t-BuOK (0.047 g, 0.42 mmol) at −38° C. and the mixture was stirred for an additional 30 minutes. The reaction was quenched by adding saturated NH₄Cl aqueous solution (2.5 mL) and concentrated to dryness. The resultant residue was diluted with water (10 mL) and extracted with DCM (2×10 mL). The combined organic extracts were dried over MgSO₄, and concentrated to dryness to give the title compound (0.08 g, crude), which was used in the next step without further purification. MS (ESI): mass calcd. for C₈H₈BrNO₂S, 260.95; m/z found, 262.0 [M+H]⁺.

Step D: 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine

The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine and 3-bromo-2-(cyclopropylsulfonyl). MS (ESI): mass calcd. for C₁₈H₁₅FN₄O₂S.HCOOH, 370.09; m/z found, 370.9 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.67 (m, 1H), 8.55 (s, 2H), 7.76 (m, 1H), 7.55 (m, 1H), 7.49-7.27 (m, 3H), 5.37 (s, 2H), 3.23-3.08 (m, 1H), 1.25-1.01 (m, 4H).

Example 829

The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrazin-2-amine and 3-bromo-2-(cyclopropylsulfonyl)pyridine. MS (ESI): mass calcd. for C₁₈H₁₅FN₄O₂S, 370.09; m/z found, 370.9 [M+H]⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.66 (m, 1H), 8.55 (s, 1H), 8.06 (d, J=1.4, 1H), 8.02-7.96 (m, 1H), 7.77 (m, 1H), 7.54 (m, 1H), 7.36 (m, 1H), 7.30 (m, 1H), 4.70 (s, 2H), 3.12-3.01 (m, 1H), 1.25-0.97 (m, 4H).

Example 830

The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrazin-2-amine and 3-bromo-2-((tetrahydro-2H-pyran-4-yl)sulfonyl)pyridine. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S.HCl, 414.12; m/z found, 415.1 [M+H]⁺; ¹H NMR (300 MHz, CDCl₃) δ 8.78 (d, J=4.6, 1H), 8.40 (s, 1H), 8.13-7.99 (m, 2H), 7.95-7.89 (m, 1H), 7.87-7.78 (m, 1H), 7.38 (m, 2H), 6.76 (s, 2H), 4.33-4.20 (m, 1H), 3.92 (dd, J=11.1, 3.7, 2H), 3.50-3.35 (m, 2H), 1.85-1.69 (m, 2H), 1.69-1.48 (m, 2H).

Example 831

The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine and 3-bromo-2-((tetrahydro-2H-pyran-4-yl)sulfonyl)pyridine. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₃S, 414.12; m/z found, 415.1 [M+H]⁺; ¹H NMR (300 MHz, CD₃OD) δ 8.78 (m, 1H), 8.52 (d, J=1.4, 2H), 8.04 (m, 1H), 7.82 (m, 1H), 7.67-7.61 (m, 1H), 7.43 (m, 1H), 7.36 (m, 1H), 6.95 (s, 2H), 4.29-4.24 (m, 1H), 3.94-3.89 (m, 2H), 3.45-3.35 (m, 2H), 1.77-1.73 (m, 2H), 1.77-1.52 (m, 2H).

Example 832

The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.81-8.69 (m, 1H), 8.54 (s, 1H), 8.29 (s, 1H), 8.11-8.06 (m, 1H), 8.01 (m, 1H), 7.78 (m, 1H), 7.42 (s, 1H), 7.39 (d, J=2.1, 1H), 4.55-4.38 (m, 1H), 3.54-3.50 (m, 2H), 3.19-3.12 (m, 2H), 2.30-2.26 (m, 2H), 2.09-1.88 (m, 2H).

Example 833

The title compound was prepared by a method analogous to Example 461 using phenylboronic acid. MS (ESI): mass calcd. for C₁₆H₁₁F₂N₃, 283.09; m/z found, 284.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.43-8.40 (m, 1H), 8.04 (d, J=1.5, 1H), 7.78-7.72 (m, 1H), 7.65-7.60 (m, 2H), 7.55-7.50 (m, 2H), 7.50-7.41 (m, 2H), 6.83 (s, 2H).

Intermediate JF

Step A: (4-Bromo-2-fluoro-3-methoxyphenyl)boronic acid

A solution of 2,2′,6,6′-tetramethylpiperidine (0.98 ml, 5.8 mmol) in THF (9.8 ml) was cooled to −78° C. under a N₂ atmosphere. To the solution was then added n-BuLi (2.21 N in hexanes, 2.45 ml, 5.41 mmol) drop-wise over a couple of minutes, and then the mixture warmed to 0° C. for 20-30 min. The mixture was then cooled back to −78° Celsius and treated with triisopropyl borate (1.25 ml, 5.41 mmol). After 5 minutes 1-bromo-3-fluoro-2-methoxybenzene (1.0 g, 4.9 mmol) was slowly added and the reaction stirred at −78° Celsius for 1.5 h before warming to rt The reaction mixture was then treated with AcOH (2.8 ml, 49 mmol), diluted with water, and extracted with EtOAc. The EtOAc extract was dried over MgSO₄, filtered, and concentrated to dryness. The crude product was used without purification.

Step B: 5-(4-Bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine

A mixture of (4-bromo-2-fluoro-3-methoxyphenyl)boronic acid (940 mg, 1.69 mmol) and 5-bromopyrazin-2-amine (1.31 g, 7.56 mmol) was treated with EtOH (12.4 ml), toluene (12.8 ml), and aqueous Na₂CO₃ (2.0 N, 9.44 ml, 18.9 mmol), and the resulting mixture deoxygenated by sparging with for 10 minutes. Pd(PPh₃)₄ (218 mg, 0.189 mmol) was then added, and the mixture heated at 80° Celsius for 17 h. The reaction was cooled to rt and then partitioned between saturated aqueous NH₄Cl and EtOAc. The organic layer was isolated, dried over MgSO₄, and concentrated to dryness. The resultant residue was suspended in DCM and the title compound isolated by filtration (300 mg, 27%), which was used without further purification. Additional product was obtained by concentrating the filtrate to dryness and subjecting the residue to FCC (560 mg, 50%). MS (ESI): mass calcd. for C₁₁H₉BrFN₃O, 296.99; m/z found, 298.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d) δ 8.34 (dd, J=2.6, 1.5, 1H), 8.00 (d, J=1.5, 1H), 7.54-7.49 (m, 2H), 6.78 (s, 2H), 3.90 (d, J=0.6, 3H).

Example 834

The title compound was prepared by a method analogous to Example 461 using phenylboronic acid and 5-(4-bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C₁₇H₁₄FN₃O, 295.11; m/z found, 296.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.58-8.55 (m, 1H), 8.12 (d, J=1.5, 1H), 7.65 (dd, J=8.1, 7.5, 1H), 7.61-7.54 (m, 2H), 7.48-7.42 (m, 2H), 7.41-7.34 (m, 1H), 7.23 (dd, J=8.2, 1.4, 1H), 4.69 (s, 2H), 3.74 (d, J=0.9, 3H).

Example 835

The title compound was prepared by a method analogous to Example 461 using 5-(4-bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₆FN₃O₃S, 373.09; m/z found, 374.1 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.58-8.53 (m, 1H), 8.21 (dd, J=8.0, 1.3, 1H), 8.11 (d, J=1.5, 1H), 7.71-7.58 (m, 3H), 7.35 (dd, J=7.5, 1.2, 1H), 7.13 (dd, J=8.1, 1.3, 1H), 4.74 (s, 2H), 3.82 (d, J=1.9, 3H), 2.96 (s, 3H).

Example 836

The title compound was prepared by a method analogous to Example 461 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid and 5-(4-bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₃FN₄O₃S, 430.15; m/z found, 431.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.53-8.48 (m, 1H), 8.19 (dd, J=7.9, 1.4, 1H), 8.08 (d, J=1.5, 1H), 7.64-7.55 (m, 2H), 7.52 (m, 1H), 7.29 (dd, J=7.4, 1.4, 1H), 7.18 (dd, J=8.2, 1.4, 1H), 4.80 (s, 2H), 4.42 (s, 1H), 3.85 (d, J=1.8, 3H), 1.21 (s, 9H).

Example 837

The title compound was prepared by a method analogous to Example 461 using (2-(methylsulfonamido)phenyl)boronic acid and 5-(4-bromo-2-fluoro-3-methoxyphenyl) pyrazin-2-amine. MS (ESI): mass calcd. for C₁₈H₁₇FN₄O₃S, 388.10; m/z found, 389.1 [M+H]⁴. ¹H NMR (400 MHz, CDCl₃) δ 8.59 (dd, J=2.3, 1.6, 1H), 8.12 (d, J=1.5, 1H), 7.75 (dd, J=8.2, 7.2, 1H), 7.69 (d, J=8.0, 1H), 7.46 (m, 1H), 7.37-7.32 (m, 2H), 7.15 (dd, J=8.2, 1.5, 1H), 7.10 (s, 1H), 4.77 (s, 2H), 3.73 (d, J=1.1, 3H), 2.58 (s, 3H).

Example 838

Step A: 2-(2-Chlorophenyl)pyrazine

2-Bromopyrazine (100 mg, 0.630 mmol) and ((2-chlorophenyl)boronic acid (103 mg, 0.660 mmol) were added to a 5 mL sealable vial equipped with a stir-bar. A solution consisting of 1,4-dioxane (3 mL) and Na₂CO₃ (1.6 mL, 2 M) was added and the mixture sparged with argon for 10 minutes before adding Pd(ddp)Cl₂.CH₂Cl₂ (23 mg, 0.031 mmol) and heating at 80° Celsius for 15 hours. The reaction was then cooled to rt, diluted with 5 mL of ethyl acetate and 5 mL of water, and the mixture extracted with ethyl acetate (3×20 mL). The combined organic extracts were then dried with sodium sulfate and concentrated to dryness. The resultant residue was subjected to FCC to provide the title compound. ¹H NMR (500 MHz, CDCl₃) δ 8.98-8.96 (d, J=1.6, 1H), 8.70-8.68 (dd, J=2.5, 1.6, 1H), 8.58-8.56 (d, J=2.6, 1H), 7.66-7.58 (m, 1H), 7.54-7.50 (m, 1H), 7.43-7.39 (m, 2H).

Step B: 5-(3-Fluoro-2′-pyrazin-2-ylbiphenyl-4-yl)pyrazin-2-amine

2-(2-Chlorophenyl)pyrazine (58 mg, 0.31 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (88 mg, 0.28 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (4.4 mg, 0.0060 mmol) were placed into a sealable 5 mL vial equipped with a stir-bar. The vial was sealed, evacuated and backfilled with argon three times. To this vial was added separately deoxygenated THF (0.56 mL) and K₃PO₄ (1.1 mL, 0.5 M). The vial was then heated at 45° Celsius for 1 hour before cooling to rt diluting with brine (5 mL), and extracting with EtOAc (1×5 mL, 3×10 mL). The combined organic extracts were then dried with sodium sulfate, filtered, and concentrated to dryness. The crude product was purified via FCC to provide the title compound. MS (ESI): mass calcd. for C₂₀H₁₄FN₅, 343.12; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.65-8.59 (dd, J=2.6, 1.6, 1H), 8.47-8.42 (d, J=2.6, 1H), 8.33-8.31 (dd, J=2.2, 1.4, 1H), 8.31-8.29 (d, J=1.5, 1H), 8.04-8.02 (d, J=1.5, 1H), 7.79-7.73 (m, 1H), 7.72-7.69 (m, 1H), 7.64-7.53 (m, 3H), 7.11-6.87 (m, 2H).

Example 839

The title compound was prepared in a manner similar to that described in Example 838 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C₂₀H₁₄FN₅, 343.12; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.61 (s, 1H), 8.56 (s, 2H), 8.47-8.40 (d, J=2.6, 1H), 8.31 (s, 1H), 7.74-7.67 (d, J=7.3, 1H), 7.65-7.57 (m, 1H), 7.57-7.54 (d, J=7.3, 1H), 7.46-7.41 (m, 1H), 7.08-7.04 (d, J=11.8, 1H), 7.04-7.00 (d, J=8.0, 1H).

Example 840

The title compound was prepared in a manner similar to that described in Example 847 using 5-bromopyrazin-2-amine in Step A. MS (ESI): mass calcd. for C₂₀H₁₅FN, 358.13; m/z found, 359.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.37-8.29 (m, 1H), 8.06-8.02 (d, J=1.5, 1H), 7.93-7.90 (d, J=1.5, 1H), 7.82-7.73 (m, 1H), 7.63-7.55 (m, 2H), 7.53-7.44 (m, 3H), 7.05-6.97 (m, 2H).

Example 841

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrazin-2-amine in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C₂₀H₁₅FN₆, 358.13; m/z found, 359.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.50-8.44 (d, J=1.4, 2H), 7.95-7.90 (d, J=1.5, 1H), 7.63-7.55 (m, 2H), 7.52-7.44 (m, 3H), 7.43-7.38 (m, 1H), 7.06-7.03 (m, 1H), 7.03-7.01 (dd, J=6.2, 1.6, 1H).

Example 842

The title compound was prepared in a manner similar to that described in Example 838 using 6-bromopyrazin-2-amine in Step A. MS (ESI): mass calcd. for C₂₀H₁₅FN₆, 358.13: m/z found, 359.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.34-8.25 (m, 1H), 8.15-8.08 (d, J=1.5, 1H), 7.86-7.78 (m, 1H), 7.77 (s, 1H), 7.66-7.59 (m, 1H), 7.59-7.48 (m, 3H), 7.40 (s, 1H), 7.10-7.00 (m, 2H).

Example 843

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrimidin-2-amine in Step A. MS (ESI): mass calcd. for C₂₀H₁₅FN₆, 358.13; m/z found, 359.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.33 (s, 1H), 8.19-8.14 (m, 2H), 8.12-8.08 (d, J=1.9, 1H), 7.90-7.80 (dd, J=8.8, 7.2, 1H), 7.57-7.41 (m, 4H), 7.12 (s, 1H), 7.10 (s, 1H).

Example 844

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrimidin-2-amine in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C₂₀H₁₅FN₆, 358.13; m/z found, 359.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.57 (s, 2H), 8.16 (d, J=2.0, 2H), 7.57-7.45 (m, 5H), 7.14 (t, J=10.3, 2H).

Example 845

The title compound was prepared in a manner similar to that described in Example 838 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromo-1-chloro-4-(trifluoromethyl)benzene in Step A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C₂₁H₁₄F₄N₆, 426.12; m/z found, 427.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.36 (dd, J=2.1, 1.5, 1H), 8.10 (s, 2H), 8.05 (d, J=1.5, 1H), 7.90-7.85 (m, 1H), 7.81-7.77 (m, 1H), 7.74 (d, J=1.8, 1H), 7.66 (d, J=8.0, 1H), 7.13 (dd, J=2.6, 1.7, 1H), 7.11 (dd, J=6.5, 1.6, 1H).

Example 846

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromo-2-methoxypyrimidine in Step A. MS (ESI): mass calcd. for C₂₁H₁₆FN₅O, 373.13; m/z found, 374.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.36 (s, 2H), 8.34 (dd, J=2.1, 1.4, 1H), 8.04 (d, J=1.5, 1H), 7.84-7.74 (m, 1H), 7.56-7.44 (m, 4H), 7.12-6.97 (m, 2H), 3.98 (s, 3H).

Example 847

The title compound was prepared in a manner similar to that described in Example 838 using 4-bromo-1-methyl-1H-pyrazole in Step A. MS (ESI): mass calcd. for C₂₀H₁₆FN₅, 345.14; m/z found, 346.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.38-8.35 (m, 1H), 8.06 (d, J=1.5, 1H), 7.85-7.79 (m, 1H), 7.51-7.46 (m, 1H), 7.42-7.37 (m, 1H), 7.37-7.32 (m, 3H), 7.15-7.11 (m, 2H), 7.05 (dd. J=12.2, 1.7, 1H), 3.80 (s, 3H).

Example 848

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrimidine in Step A. MS (ESI): mass calcd. for C₂₀H₁₄FN₅, 343.12; m/z found, 344.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 9.01 (s, 1H), 8.61 (s, 2H), 8.32-8.27 (m, 1H), 8.17 (d, J=1.4, 1H), 7.88-7.78 (m, 1H), 7.63-7.50 (m, 4H), 7.11-7.00 (m, 2H).

Example 849

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrimidine-2-carbonitrile in Step A. MS (ESI): mass calcd. for C₂₁H₁₃FN₆, 368.12; m/z found, 369.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) 8.73 (s, 2H), 8.37-8.33 (m, 1H), 8.04 (d, J=1.5, 1H), 7.80 (m, J=8.1, 1H), 7.68-7.55 (m, 4H), 7.11 (dd, J=12.1, 1.7, 1H), 7.01 (dd, J=8.1, 1.7, 1H).

Example 850

The title compound was prepared in a manner similar to that described in Example 838 using 4-(5-bromopyrimidin-2-yl)morpholine in Step A. MS (ESI): mass calcd. for C₂₄H₂₁FN₆O, 428.18; m/z found, 429.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.36-8.32 (m, 1H), 8.14 (s, 2H), 8.04 (d, J=1.5, 1H), 7.83-7.77 (m, 1H), 7.54-7.38 (m, 4H), 7.09-7.07 (m, 1H), 7.06 (dd, J=7.1, 1.6, 1H), 3.76-3.66 (m, 8H).

Example 851

The title compound was prepared in a manner similar to that described in Example 838 using 1-(4-bromo-1H-pyrazol-1-yl)-2-methylpropan-2-ol in Step A. MS (ESI): mass calcd. for C₂₃H₂₂FN₅O, 403.18; m/z found, 404.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.37-8.32 (m, 1H), 8.07 (d, J=1.5, 1H), 7.85-7.78 (m, 1H), 7.53-7.48 (m, 1H), 7.44-7.37 (m, 1H), 7.35 (dd, J=5.0, 1.1, 2H), 7.32 (d, J=0.9, 1H), 7.25 (d, J=0.8, 1H), 7.15 (dd, J=8.0, 1.7, 1H), 7.04 (dd, J=12.3, 1.7, 1H), 3.98 (s, 2H), 1.07 (s, 6H).

Example 852

The title compound was prepared in a manner similar to that described in Example 838 using tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate and 2-bromo-1-chloro-4-(trifluoromethyl)benzene in Step A, followed by removal of the Boc group. To a stirred solution of tert-butyl 4-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (68 mg, 0.13 mmol) in DCM (2 mL) was added TFA (0.56 mL, 7.3 mmol) at room temperature. When analysis by LCMS indicated the reaction was complete, the stir-bar was removed, the reaction mixture concentrated to dryness, and the residue subjected to HPLC purification to provide the title compound. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₄, 414.15; m/z found, 415.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.41-8.37 (m, 1H), 8.13 (d, J=1.5, 1H), 8.03-7.96 (m, 1H), 7.78-7.72 (m, 1H), 7.64 (d, J=1.8, 1H), 7.61 (d, J=8.0, 1H), 7.37 (dd, J=8.0, 1.7, 1H), 7.33 (dd, J=12.1, 1.7, 1H), 5.89 (m, 1H), 3.85-3.75 (m, 2H), 3.19 (t, J=6.0, 2H), 2.33-2.22 (m, 2H).

Example 853

The title compound was prepared in a manner similar to that described in Example 838 using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine and 2-bromo-1-chloro-4-(trifluoromethyl)benzene in Step A. MS (ESI): mass calcd. for C₂₁H₁₄F₄N₆, 426.12; m/z found, 427.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.34 (s, 1H), 8.16 (d, J=1.2, 2H), 8.10 (s, 1H), 7.92-7.86 (m, 1H), 7.80 (d, J=8.3, 1H), 7.78 (d, J=1.7, 1H), 7.69 (d, J=8.0, 1H), 7.23-7.08 (m, 2H).

Example 854

The title compound was prepared in a manner similar to that described in Example 427 using (6-(2-aminopyrimidin-5-yl)-5-fluoropyridin-3-yl)boronic acid and 5-(2-chlorophenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₄FN₇, 359.13; m/z found, 360.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.93 (s, 2H), 8.31-8.28 (m, 1H), 8.19 (s, 2H), 7.64 (dd, J=12.0, 1.9, 1H), 7.59-7.51 (m, 4H).

Example 855

The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 5-(2-bromophenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₅N₇, 341.14; m/z found, 342.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 8.97 (s, 2H), 8.47 (dd, J=2.3, 0.9, 1H), 8.16 (s, 2H), 7.86 (dd, J=8.2, 0.9, 1H), 7.80 (dd, J=8.2, 2.3, 1H), 7.59-7.49 (m, 4H).

Example 856

Title compound was prepared using conditions analogous to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-(2-bromophenyl)isothiazolidine 1,1-dioxide. MS (ESI): mass calcd. for C₁₉H₇FN₄O₂S, 384.11; m/z found, 385.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.62-8.58 (m, 1H), 8.12 (d, J=1.5, 1H), 7.99 (m, 1H), 7.76-7.71 (m, 1H), 7.49-7.45 (m, 1H), 7.46-7.38 (m, 4H), 4.69 (s, 2H), 3.30-3.04 (m, 4H), 2.39-2.11 (m, 2H).

Example 857

Title compound was prepared using conditions analogous to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(2-bromophenyl)-1,2-thiazinane 1,1-dioxide. MS (ESI): mass calcd. for C₂₀H₁₉FN₄O₂S, 398.12; m/z found, 399.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.48-8.43 (m, 1H), 8.38-8.33 (m, 1H), 8.08-8.02 (m, 1H), 7.62 (m, 1H), 7.45-7.39 (m, 4H), 7.34 (dd, J=12.5, 1.7, 1H), 3.76-3.65 (m, 2H), 3.24-3.10 (m, 2H), 3.00-2.89 (m, 2H), 2.35-2.23 (m, 2H), 2.22-2.10 (m, 2H).

Example 858

Title compound was prepared using methods analogous to those described in Example 384 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-(2-bromophenyl)isothiazolidine 1,1-dioxide. MS (ESI): mass calcd. for C₁₉H₁₇FN₄O₂S, 384.11; m/z found, 385.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J=1.4, 2H), 7.78-7.71 (m, 1H), 7.69-7.58 (m, 1H), 7.50-7.32 (m, 4H), 7.29-7.20 (m, 1H), 5.21 (s, 2H), 3.77 (t, J=6.8, 1H), 3.43-3.17 (m, 2H), 2.67-2.47 (m, 1H), 2.42-2.17 (m, 2H).

Example 859

Title compound was prepared using methods analogous to those described in Example 377 using (2-(pyrrolidin-1-yl)pyridine-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C₁₉H₁₈FN₅, 335.15; m/z found, 336.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.61-8.56 (m, 1H), 8.22-8.17 (m, 1H), 8.12 (s, 1H), 7.97-7.88 (m, 1H), 7.45-7.38 (m, 1H), 7.29-7.23 (m, 1H), 7.21-7.14 (m, 1H), 6.75-6.67 (m, 1H), 4.67 (s, 2H), 3.28-3.10 (m, 4H), 1.87-1.73 (m, 4H).

Example 860

Title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)pyrrolidin-2-one. MS (ESI): mass calcd. for C₂₀H₁₇FN₄O, 348.14; m/z found, 349.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.03 (s, 1H), 7.91 (m, 1H), 7.54-7.14 (m, 6H), 6.72 (s, 2H), 3.44 (t, J=6.7, 2H), 2.26 (t, J=7.9, 2H), 1.97-1.87 (m, 2H).

Intermediate JF

To a mixture of 2-chlorophenylboronic acid (16.6 g, 106 mmol), tert-butyl 4-bromo-1H-pyrazole-1-carboxylate (17.4 g, 71 mmol) and K₂CO₃ (14.7 g, 142 mmol) in a 1 L round-bottomed flask were added Pd(dppf)Cl₂-DCM (0.58 g, 0.71 mmol), 1,4-dioxane (200 mL) and H₂O (50 mL). The mixture was sparged with N₂ for 15 min then stirred at 80° C. for 16 h. The reaction mixture was cooled to RT, filtered, and concentrated to dryness. The resulting residue was diluted with water (100 mL), and then extracted with EtOAc (3×100 mL). The combined organic extracts were washed with brine (100 mL), dried over Na₂SO₄, concentrated to dryness, and the resulting residue was purified by FCC to give the title compound (9.2 g, 73%). MS (ESI): mass calcd. for C₉H₇ClN₂, 178.03; m/z found 179.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 8.59 (s, 1H), 7.52-7.46 (m, 1H), 7.45-7.39 (m, 1H), 7.36-7.25 (m, 2H).

Intermediate JG

To a 50 mL round-bottomed flask, were added 4-(2-chlorophenyl)-1H-pyrazole (1.0 g, 5.6 mmol), 1-bromo-2-methoxyethane (1.17 g, 8.4 mmol). Cs₂CO₃ (3.64 g, 11.2 mmol) and DMF (10 mL). The mixture was stirred at RT for 16 h and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (3×50 mL), dried over Na₂SO₄, concentrated to dryness and purified by FCC to afford the title compound (890 mg, 67%). MS (ESI): mass calcd. for C₁₂H₁₃ClN₂O, 236.07; m/z found 237.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.93 (s, 1H), 7.87 (s, 1H), 7.47-7.43 (m, 2H), 7.29-7.27 (m, 1H), 7.21-7.17 (m, 1H), 4.39 (t, J=5.2 Hz, 2H), 3.81 (t, J=5.2 Hz, 2H), 3.36 (s, 3H).

Intermediate JH

The title compound was prepared using analogous conditions to those described for 4-(2-chlorophenyl)-1-(2-methoxyethyl)-1H-pyrazole using tert-butyl(2-bromoethyl)carbamate. MS (ESI): mass calcd. for C₁₆H₂₀ClN₃O₂, 321.12; m/z found 322.1 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 7.82 (d, J=2.2 Hz, 2H), 7.46-7.42 (m, 2H), 7.32-7.13 (m, 2H), 4.95 (s, 1H), 4.29 (t, J=5.5 Hz, 2H), 3.61 (d, J=5.2 Hz, 2H), 1.44 (s, 9H).

Intermediate JI

A mixture of tert-Butyl 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)ethylcarbamate (1.0 g, 3.1 mmol) and HCl (20 mL, 30% solution in EtOH) was stirred at RT for 16 h. Precipitated solid was collected by filtration and washed with ethyl ether (10 mL) to give the title compound (670 mg, 84%). MS (ESI): mass calcd. for C₁₁H₁₂ClN₃, 221.07; m/z found 222.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.31 (s, 1H), 8.22 (s, 3H), 7.97 (s, 1H), 7.62 (dd, J=7.7, 1.4 Hz, 1H), 7.52 (d, J=8.0 Hz, 1H), 7.39-7.35 (m, 1H), 7.32-7.24 (m, 1H), 4.46 (t, J=6.2 Hz, 2H), 3.35-3.23 (m, 2H).

Intermediate JJ

A mixture of 4-(2-chlorophenyl)-1H-pyrazole (1.0 g, 5.6 mmol), 2-bromoacetonitrile (1.0 g, 8.4 mmol) and Cs₂CO₃ (3.64 g, 11.2 mmol) and DMF (10 mL) in a 50 mL round-bottomed flask was stirred at 50° C. After 16 h, additional 2-bromoacetonitrile (1 g, 8.4 mmol) was added. The resulting mixture was stirred at 100° C. for 8 h, cooled to RT and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (3×50 mL), dried over Na₂SO₄, concentrated to dryness and the resulting residue was purified by FCC to give the title compound (600 mg, 49%). MS (ESI): mass calcd. for C₁₁H₈ClN₃, 217.04; m/z found 218.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 7.88 (s, 1H), 7.47-7.44 (m, 2H), 7.32-7.28 (m, 1H), 7.26-7.21 (m, 1H), 5.14 (s, 2H).

Intermediate JK

To a 50 mL round-bottomed flask were added 4-(2-chlorophenyl)-1H-pyrazole (1.0 g, 5.6 mmol), 2-bromoethanol (1.05 g, 8.4 mmol), Cs₂CO₃ (3.64 g, 11.2 mmol) and DMF (10 mL). The reaction mixture was stirred at 80° C. for 16 h, then treated with additional of 2-bromoethanol (1.05 g, 8.4 mmol) was added. The resulting mixture was stirred at 100° C. for an additional 8 h, cooled to RT and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (3×50 mL), dried over Na₂SO₄, concentrated to dryness and the resulting residue was purified by FCC to give the title compound (800 mg, 64%). MS (ESI): mass calcd. for C₁₁H₁₁ClN₂O, 222.06; m/z found 223.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.91 (s, 1H), 7.87 (s, 1H), 7.49-7.45 (m, 2H), 7.32-7.29 (m, 1H), 7.24-7.20 (m, 1H), 4.46-4.23 (m, 2H), 4.19-3.99 (m, 2H), 3.31 (s, 1H).

Intermediate JL

Step A: (Z—N-(2-(2-Chlorophenyl)-3-(dimethylamino)allylidene)-N-methyl methanaminium chloride

DMF (27 mL, 0.4 mol) was added drop wise to POCl₃ (28 mL, 0.3 mol) in a 250 mL round-bottomed flask at 0° C. After the addition was complete, the resulting mixture was stirred at 0° C. for 20 min, followed by the addition of 2-(2-chlorophenyl)acetic acid (17 g, 0.1 mol). The reaction mixture was stirred at 85° C. for 2 h, cooled to RT and poured into ice water (400 mL). The resulting mixture was extracted with CH₂Cl₂ (3×150 mL). The combined organic extracts were washed with water (200 mL), dried over Na₂SO₄, concentrated to dryness and the resulting residue was purified by FCC to give the title compound (26.2 g, 96%). MS (ESI): mass calcd. for C₁₃H₁₈ClN₂+, 237.12; m/z found 237.0 [M]⁺. ¹H NMR (300 MHz, CDCl₃) δ 8.94 (s, 2H), 7.43-7.38 (m, 1H), 7.36-7.30 (m, 1H), 7.29-7.22 (m, 2H), 3.39 (s, 6H), 2.44 (s, 6H).

Step B: 2-(2-Chlorophenyl)malonaldehyde

To a solution consisting of (Z)—N-(2-(2-chlorophenyl)-3-(dimethylamino)allylidene)-N-methyl methanaminium chloride (8.0 g, 29 mmol) and EtOH (40 mL) in a 250 mL round-bottomed flask was added aqueous NaOH (25%, 40 mL). The resulting mixture was refluxed for 1 h and then cooled to RT. The EtOH was removed by evaporation under vacuum and the aqueous mixture was diluted with ice water (100 mL), acidified to pH=1 by adding HCl (1 N) and then extracted with EtOAc (3×100 mL). The combined organic extracts were washed with brine (100 mL), dried over Na₂SO₄ and concentrated to dryness to give the title compound (5.37 g, 100%). MS (ESI): mass calcd. for C₉H₇ClO₂, 182.01; m/z found 182.9 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 12.05 (s, 1H), 8.58 (s, 2H), 7.47-7.43 (m, 1H), 7.36-7.25 (m, 2H), 7.18-7.10 (m, 1H).

Step C: (Z-3-Chloro-2-(2-chlorophenyl)acrylaldehyde

To a 0° C. solution consisting of 2-(2-chlorophenyl)malonaldehyde (2.82 g, 15.5 mmol) and CH₂Cl₂ (20 mL) in a 50 mL round-bottomed flask was added SOCl₂ (10 mL, 138 mmol). The resulting mixture was stirred at 0° C. for 30 min, concentrated to dryness and purified by FCC to give the title compound (2.37 g, 76%). ¹H NMR (300 MHz, CDCl₃) δ 9.66 (s, 1H), 7.51 (s, 1H), 7.51-7.46 (m, 1H), 7.40-7.31 (m, 2H), 7.20-7.13 (m, 1H).

Step D: 4-(2-Chlorophenyl)isothiazole

To a 25 mL round-bottomed flask containing a solution consisting of (Z)-3-chloro-2-(2-chlorophenyl)acryl aldehyde (2.37 g, 11.8 mmol) and DMF (8 mL), was added NH₄SCN (3.58 g, 47.2 mmol). The reaction mixture was stirred at 70° C. for 16 h before cooling to RT and diluting with brine (100 mL). The resulting mixture was extracted with ethyl ether (3×100 mL). The combined organic extracts were washed with brine (3×100 mL), dried over Na₂SO₄, concentrated to dryness and the resulting residue was purified by FCC to provide the title compound (980 mg, 43%). MS (ESI): mass calcd. for C₉H₆ClNS, 194.99; m/z found 195.9 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.78 (s, 1H), 8.69 (s, 1H), 7.54-7.46 (m, 1H), 7.46-7.38 (m, 1H), 7.37-7.27 (m, 2H).

Example 861

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyridin-2-amine in Step A. MS (ESI): mass calcd. for C₂₁H₁₆FN₅, 357.14; m/z found, 358.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.34 (s, 1H), 8.06 (s, 1H), 7.80-7.76 (m, 1H), 7.70 (d, J=2.0 Hz, 1H), 7.51-7.39 (m, 4H), 7.28 (dd, J=8.6, 2.2 Hz, 1H), 7.07 (d, J=8.1 Hz, 1H), 7.02 (d. J=12.5 Hz, 1H), 6.51 (d, J=8.6 Hz, 1H).

Example 862

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromo-2-(piperazin-1-yl)pyrimidine in Step A. MS (ESI): mass calcd. for C₂₄H₂₂FN₇, 427.19; m/z found, 427.8 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.34 (s, 1H), 8.22 (s, 2H), 8.06 (d, J=1.3 Hz, 1H), 7.82-7.76 (m, 1H), 7.54-7.47 (m, 4H), 7.17 (d, J=12.6 Hz, 1H), 7.07 (dd, J=8.0, 1.6 Hz, 1H), 4.00-3.83 (m, 4H), 3.21-3.09 (m, 4H).

Example 863

The title compound was prepared in a manner similar to that described in Example 838 using 6-bromopyridazin-3-amine in Step A. MS (ESI): mass calcd. for C₂₀H₁₅FN₆, 358.13; m/z found, 358.8 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.35 (s, 1H), 8.17 (s, 1H), 7.88-7.82 (m, 1H), 7.74-7.57 (m, 4H), 7.51 (d, J=9.6 Hz, 1H), 7.39 (dd, J=9.6, 1.9 Hz, 1H), 7.27 (d, J=12.4 Hz, 1H), 7.05 (d, J=8.0 Hz, 1H).

Example 864

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)ethanamine hydrochloride. MS (ESI): mass calcd. for C₂₁H₁₉FN₆, 374.17; m/z found, 375.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.73 (d, J=1.3 Hz, 1H), 8.23 (d, J=1.3 Hz, 1H), 8.08-8.04 (m, 1H), 7.60 (s, 1H), 7.56-7.51 (m, 1H), 7.47-7.34 (m, 3H), 7.26 (s, 1H), 7.23 (dd, J=8.1, 1.6 Hz, 1H), 7.17 (dd, J=12.7, 1.6 Hz, 1H), 4.41 (t. J=5.8 Hz, 2H), 3.38 (t, J=5.8 Hz, 2H).

Example 865

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyridin-2-amine in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C₂₁H₁₆FN₅, 357.14; m/z found, 358.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, J=1.3 Hz, 2H), 7.71 (d, J=2.0 Hz, 1H), 7.53-7.36 (m, 5H), 7.14 (dd, J=8.5, 2.5 Hz, 1H), 7.09 (dd, J=12.1, 1.5 Hz, 1H), 7.03 (dd, J=8.0, 1.7 Hz, 1H), 6.89 (s, 2H), 6.34 (d, J=8.6 Hz, 1H), 5.94 (s, 2H).

Example 866

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromo-N-methylpyrimidin-2-amine in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C₂₁H₁₇FN₆, 372.15; m/z found, 373.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.1 Hz, 2H), 8.06 (s, 2H), 7.57-7.40 (m, 5H), 7.19-7.13 (m, 2H), 7.06 (dd, J=8.0, 1.5 Hz, 1H), 6.90 (s, 2H), 2.77 (d, J=4.8 Hz, 3H).

Example 867

The title compound was prepared in a manner similar to that described in Example 838 using 4-bromopyrimidin-2-aminein Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C₂₀H₁₅FN₆, 358.13; m/z found, 359.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.46 (d, J=1.1 Hz, 2H), 8.04 (d, J=5.0 Hz, 1H), 7.63-7.45 (m, 5H), 7.16 (dd, J=12.0, 1.4 Hz, 1H), 7.04 (dd, J=8.0, 1.6 Hz, 1H), 6.90 (s, 2H), 6.66 (s, 2H), 6.19 (d, J=5.0 Hz, 1H).

Example 868

The title compound was prepared in a manner similar to that described in Example 838 using 4-bromopyrimidin-2-amine in Step A. MS (ESI): mass calcd. for C₂₀H₁₅FN, 358.13; m/z found, 359.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.35 (s, 1H), 8.03 (d, J=5.0 Hz, 1H), 8.00 (s, 1H), 7.81-7.77 (m, 1H), 7.63-7.46 (m, 4H), 7.13 (d, J=12.5 Hz, 1H), 7.05 (d, J=8.7 Hz, 1H), 6.71 (s, 2H), 6.65 (s, 2H), 6.17 (d. J=5.1 Hz, 1H).

Example 869

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 4-(2-chlorophenyl)-1-(2-methoxyethyl)-1H-pyrazole. MS (ESI): mass calcd. for C₂₂H₂₀FN₅O, 389.17; m/z found, 390.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.32 (s, 1H), 7.98-7.94 (m, 1H), 7.53 (d, J=7.4 Hz, 1H), 7.47-7.34 (m, 4H), 7.25 (s, 1H), 7.19 (d, J=8.1 Hz, 1H), 7.10 (d, J=12.5 Hz, 1H), 4.21 (t, J=4.9 Hz, 2H), 3.65 (t, J=4.8 Hz, 2H), 3.25 (s, 3H).

Example 870

The title compound was prepared in a manner similar to that described in Example 838 using tert-butyl 4-bromo-1H-pyrazole-1-carboxylate in Step A. MS (ESI): mass calcd. for C₁₉H₁₄FN₅, 331.12; m/z found, 332.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) b 12.77 (s, 1H), 8.37 (s, 1H), 8.02 (s, 1H), 7.86-7.82 (m, 1H), 7.54 (d, J=7.6 Hz, 1H), 7.47 (s, 1H), 7.44-7.31 (m, 3H), 7.17 (s, 1H), 7.12 (d, J=5.4 Hz, 1H), 7.10 (s, 1H), 6.71 (s, 2H).

Example 871

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)acetonitrile. MS (ESI): mass calcd. for C₂₁H₁₅FN₆, 370.13; m/z found, 370.8 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.37 (s, 1H), 8.02 (d, J=1.3 Hz, 1H), 7.87-7.82 (m, 1H), 7.62 (s, 1H), 7.52 (d, J=7.1 Hz, 1H), 7.47-7.33 (m, 3H), 7.30 (s, 1H), 7.15-7.09 (m, 2H), 6.72 (s, 2H), 5.42 (s, 2H).

Example 872

The title compound was prepared in a manner similar to that described in Example 838 using 5-bromo-N-methylpyrimidin-2-amine in Step A. MS (ESI): mass calcd. for C₂₁H₁₇FN₆, 372.15; m/z found, 373.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.36 (s, 1H), 8.09-8.06 (m, 3H), 7.85-7.81 (m, 1H), 7.55-7.44 (m, 4H), 7.13-7.05 (m, 2H), 2.90 (s, 3H).

Example 873

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 4-(2-chlorophenyl)isothiazole. MS (ESI): mass calcd. for C₁₉H₁₃FN₄S, 348.08; m/z found, 349.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.53 (s, 1H), 8.30 (s, 1H), 8.23 (s, 1H), 8.10 (d, J=1.4 Hz, 1H), 7.87-7.82 (m, 1H), 7.53-7.39 (m, 4H), 7.03 (dd, J=8.0, 1.7 Hz, 1H), 6.98 (dd, J=12.1, 1.6 Hz, 1H), 4.76 (s, 2H).

Example 874

The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)ethanol. MS (ESI): mass calcd. for C₂₁H₁₈FN₅O, 375.15; m/z found, 376.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.40-8.35 (m, 1H), 8.02 (d, J=1.5 Hz, 1H), 7.86-7.82 (m, 1H), 7.53-7.50 (m, 2H), 7.45-7.38 (m, 1H), 7.34-7.33 (m, 2H), 7.15-7.11 (m, 2H), 7.08 (d, J=0.6 Hz, 1H), 6.72 (s, 2H), 4.84 (t, J=5.3 Hz, 1H), 4.04 (t, J=5.7 Hz, 2H), 3.66-3.62 (m, 2H).

Example 875

The title compound was prepared using analogous conditions to those described in Example 287 using 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)acetonitrile. MS (ESI): mass calcd. for C₂₁H₁₅FN₆, 370.13; m/z found, 371.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.49 (d, J=1.0 Hz, 2H), 7.61-7.50 (m, 3H), 7.48-7.31 (m, 4H), 7.16 (dd, J=11.8, 1.3 Hz, 1H), 7.09 (dd, J=7.9, 1.5 Hz, 1H), 6.92 (s, 2H), 5.43 (s, 2H).

Example 876

The title compound was prepared in a manner similar to that described in Example 838 using tert-butyl 4-bromo-1H-pyrazole-1-carboxylate in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C₁₉H₁₄FN₅, 331.12; m/z found, 332.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 12.79 (s, 1H), 8.49 (s, 2H), 7.60-7.47 (m, 3H), 7.45-7.39 (m, 1H), 7.39-7.30 (m, 2H), 7.26-7.07 (m, 3H), 6.91 (s, 2H).

Intermediate JM

The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-1-aminopropan-2-ol. MS (ESI): mass calcd. for C₉H₁₂BrNO₃S, 292.97; m/z found, 294.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (dd, J=7.7, 1.8 Hz, 1H), 7.75 (dd, J=7.7, 1.4 Hz, 1H), 7.53-7.46 (m, 1H), 7.46-7.40 (m, 1H), 5.62 (s, 1H), 3.98-3.78 (m, 1H), 3.02 (d, J=12.9 Hz, 1H), 2.74 (dd, J=13.0, 8.1 Hz, 1H), 2.01 (d, J=4.1 Hz, 1H), 1.16 (d, J=6.3 Hz, 3H).

Intermediate JN

The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-aminoethanol. MS (ESI): mass calcd. for C₈H₁₀BrNO₃S, 278.96; m/z found, 279.9 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.17-8.11 (dd, J=7.8, 1.8 Hz, 1H), 7.79-7.72 (dd, J=7.8, 1.3 Hz, 1H), 7.52-7.46 (m, 1H), 7.46-7.40 (m, 1H), 5.79-5.66 (t, J=5.7 Hz, 1H), 3.73-3.65 (dd, J=5.6, 4.6 Hz, 2H), 3.13-3.03 (ddd, J=6.0, 5.1, 4.4 Hz, 2H), 2.22-2.10 (s, 1H).

Intermediate JO

Step A: 5-(5-Chloro-3-fluoropyridin-2-yl)pyrimidin-2-amine

A solution consisting of (2-aminopyrimidin-5-yl)boronic acid (3.4 g, 25 mmol), 2-bromo-5-chloro-3-fluoropyridine (5.4 g, 25 mmol), palladium(II)acetate/1,1′-bis(di-t-butylphosphino)ferrocene/potassium phosphate admixture (1.1 g, 1.0 mmol), Na₂CO₃ (122 mL, 245 mmol, 2 M) and THF (122 mL) was stirred at RT. After 1 h, the THF was removed in vacuo and the residue was diluted with CH₂Cl₂ (200 mL). The organic extracts were isolated and the aqueous mixture was further extracted with CH₂Cl₂ (2×200 mL). The combined organic extracts were, concentrated to dryness and triturated with EtOAc to afford the title compound (5.5 g, 44%). MS (ESI): mass calcd. for C₉H₆ClFN₄, 224.03; m/z found, 225.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 8.76 (d, J=1.4 Hz, 2H), 8.57 (m, 1H), 8.18 (dd, J=11.1, 2.0 Hz, 1H), 7.18 (s, 2H).

Step B: 5-(3-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine

To a 200 mL round-bottomed flask were added a stirbar, 5-(5-chloro-3-fluoropyridin-2-yl)pyrimidin-2-amine (2.4 g, 11 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (3.4 g, 13 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (161 mg, 0.214 mmol), KOAc (3.1 g, 32 mmol) and 1,4-dioxane (100 mL). The flask was fitted with a septum, sparged with N₂ for 10 min and heated at 80° C. for 5 h. The resulting reaction mixture was cooled to RT and then filtered through a Büchner funnel. The filter paper was washed with CH₂Cl₂ (50 mL) and the filtrate was concentrated directly onto silica and subjected to FCC to give the title compound (2.4 g, 71%). C₁₅H₁₈BFN₄O₂, 316.15; m/z found, 235.0 [M-pinacol]⁺. ¹H NMR (600 MHz, DMSO-d₆) δ 8.83 (d, J=1.2 Hz, 2H), 8.64-8.59 (m, 1H), 7.80 (dd, J=11.7, 1.3 Hz, 1H), 7.19 (s, 2H), 1.32 (s, 12H).

Example 877

A mixture of 5-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine (420 mg, 1.32 mmol), (S)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide (480 mg, 1.46 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (100 mg, 10%), THF (4 mL) and aqueous K₃PO₄ (0.5 M, 4 mL) in a 25 mL sealed tube was sparged with N₂ for 10 minutes and then stirred at 70° C. for 16 h. The resulting reaction mixture was cooled to RT and concentrated to dryness. The resulting residue was dissolved in CH₂Cl₂ (35 mL) and washed with water (3×10 mL). The organic phase was isolated and dried over Na₂SO₄, concentrated to dryness and the resulting residue was purified by prep-HPLC to give title compound (35 mg hydrochloride, 6%). MS (ESI): mass calcd. for C₁₈H₁₅F₄N₅O₂S, 441.09; m/z found 442.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.24 (s, 2H), 8.50 (s, 1H), 8.13 (d, J=7.7 Hz, 1H), 7.81-7.66 (m, 3H), 7.44 (d, J=6.7 Hz, 1H), 3.94-3.85 (m, 1H), 1.25 (d, J=6.9 Hz, 3H).

Example 878

The title compound was prepared using analogous conditions to those described in Example 877 using 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C₁₈H₁₅FN₄O₂S, 370.09; m/z found, 371.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 10.55 (s, 2H), 9.03 (s, 2H), 8.54 (s, 1H), 8.11 (d, J=7.8 Hz, 1H), 7.98 (d, J=12.0 Hz, 1H), 7.86-7.83 (m, 1H), 7.79-7.75 (m, 1H), 7.55 (d, J=7.4 Hz, 1H), 2.63-2.55 (m, 1H), 1.04-0.95 (m, 2H), 0.95-0.88 (m, 2H).

Example 879

The title compound was prepared using analogous conditions to those described in Example 877 using (S)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₈FN₅O₃S, 403.11; m/z found, 404.0 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 9.24 (s, 2H), 8.61-8.53 (m, 1H), 8.09 (dd, J=7.7, 1.5 Hz, 1H), 7.90 (dd, J=11.8, 1.7 Hz, 1H), 7.80-7.59 (m, 2H), 7.47 (dd, J=7.3, 1.6 Hz, 1H), 3.76-3.61 (m, 1H), 2.87-2.69 (m, 2H), 1.08 (d, J=6.3 Hz, 3H).

Example 880

The title compound was prepared using analogous conditions to those described in Example 877 using (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₈FN₅O₃S, 403.11; m/z found, 404.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD): δ 9.24 (s, 2H), 8.57-8.56 (m, 1H), 8.17 (dd, J=7.7, 1.3 Hz, 1H), 7.90 (dd, J=12.0, 1.6 Hz, 1H), 7.78-7.61 (m, 2H), 7.45 (dd, J=7.3, 1.3 Hz, 1H), 3.42-3.36 (m, 1H), 3.28-3.18 (m, 2H), 1.05 (d, J=6.5 Hz, 3H).

Example 881

The title compound was prepared using analogous conditions to those described in Example 877 using (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₈FN₅O₃S, 403.11; m/z found, 404.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 9.24 (s, 2H), 8.57-8.56 (m, 1H), 8.17 (dd, J=7.7, 1.3 Hz, 1H), 7.90 (dd, J=12.0, 1.6 Hz, 1H), 7.78-7.61 (m, 2H), 7.45 (dd, J=7.3, 1.3 Hz, 1H), 3.42-3.36 (m, 1H), 3.28-3.18 (m, 2H), 1.05 (d, J=6.5 Hz, 3H).

Example 882

The title compound was prepared using analogous conditions to those described in Example 877 using 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₇H₁₆FN₅O₃S, 389.10; m/z found, 390.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) b 9.23 (s, 2H), 8.55 (s, 1H), 8.10 (d, J=7.6 Hz, 1H), 7.87 (d, J=11.9 Hz, 1H), 7.75-7.64 (m, 2H), 7.45 (d, J=7.2 Hz, 1H), 3.49 (t, J=5.8 Hz, 2H), 2.95 (t, J=5.6 Hz, 2H).

Example 883

The title compound was prepared using analogous conditions to those described in Example 877 using (R)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C₁₈H₁₅F₄N₅O₂S, 441.09; m/z found, 442.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.08 (s, 2H), 8.47 (s, 1H), 8.14 (dd, J=7.8, 1.3 Hz, 1H), 7.77-7.63 (m, 3H), 7.44 (dd, J=7.5, 1.3 Hz, 1H), 3.94-3.85 (m, 1H), 1.25 (d, J=7.0 Hz, 3H).

Intermediate JP

Step A: 4-((2-Bromophenoxy)methyl)tetrahydro-2H-thiopyran

To a solution consisting of 1-bromo-2-fluorobenzene (1.3 g, 7.4 mmol) and DMF (10 mL) were added (tetrahydro-2H-thiopyran-4-yl)methanol (1.0 g, 7.4 mmol), NaH (0.6 g, 14.9 mmol) at 0° C. Then the mixture was stirred at 60° C. under N₂ overnight. After which time the reaction mixture was cooled to RT, poured into ice-water, and extracted with ethyl acetate (3×20 mL). The combined organic extracts were washed with brine (20 mL), dried over MgSO₄, filtered and concentrated to dryness to give the title compound, which was used in next step without further purification.

Step B: 4-((2-Bromophenoxy)methyl)tetrahydro-2H-thiopyran 1,1-dioxide

To a 0° C. solution consisting of 4-((2-bromophenoxy)methyl)tetrahydro-2H-thiopyran and CH₂Cl₂ (15 mL) was slowly added meta-chloroperoxybenzoic acid (3.4 g, 14.9 mmol). The resulting reaction mixture was stirred at RT overnight, then diluted with Na₂S₂O₃ (20 mL, 10% aq.) and extracted with CH₂Cl₂ (3×20 mL). The combined organic extracts were washed with brine (20 mL), dried over MgSO₄, filtered and concentrated to dryness. The crude product was recrystallized from ethyl acetate to afford the title compound (1.6 g, 67%). ¹H NMR (400 MHz, CDCl₃) δ 7.54 (dd, J=8.2, 1.6, 1H), 7.28-7.24 (m, 1H), 6.86 (dd, J=7.5, 6.6, 2H), 3.92 (d, J=5.8, 2H), 3.23-3.12 (m, 2H), 3.05 (dd, J=17.5, 8.9, 2H), 2.37 (d, J=11.2, 2H), 2.09 (m, 3H).

Intermediate JQ

Step A: 4-(2-bromophenoxy)tetrahydro-2H-thiopyran

To a 0° C. solution consisting of 1-bromo-2-fluorobenzene (1.3 g, 7.5 mmol) in DMF (10 mL) was added tetrahydro-2H-thiopyran-4-ol (740 mg, 6.3 mmol) and NaH (750 mg, 18.8 mmol). The mixture was stirred at 60° C. under a N₂ atmosphere. After 12 h, the reaction mixture was cooled to RT, poured into ice-water and extracted with ethyl acetate (3×30 mL). The combined organic extracts were washed with brine (30 mL), dried over MgSO₄, filtered and concentrated to dryness to give the title compound, which was used without further purification.

Step B: 4-(2-Bromophenoxy)tetrahydro-2H-thiopyran 1,1-dioxide

To a 0° C. solution consisting of 4-(2-bromophenoxy)tetrahydro-2H-thiopyran and CH₂Cl₂ (20 mL), was slowly added meta-chloroperoxybenzoic acid (3.7 g, 16.5 mmol). The reaction mixture was stirred at RT overnight. After which time the mixture was diluted with Na₂S₂O₃ (20 mL, 10% aq.), basified with NaOH (2 N) to pH=8 and extracted with CH₂Cl₂ (3×15 mL). The combined organic extracts were concentrated to dryness and the resulting residue was purified by FCC to give the title compound (650 mg, 38%). ¹H NMR (400 MHz, CDCl₃) 57.58-7.56 (m, 1H), 7.31-7.25 (m, 1H), 6.98-6.85 (m, 2H), 4.72 (s, 1H), 3.62-3.46 (m, 2H), 2.97-2.87 (m, 2H), 2.52-2.43 (m, 2H), 2.41-2.34 (m, 2H).

Intermediate JR

Step A: Methyl 4-(2-bromophenoxy)benzoate

A mixture of methyl 4-fluorobenzoate (3.0 g, 19.5 mmol), 2-bromophenol (6.7 g, 39 mmol), Cs₂CO₃ (12.7 g, 39 mmol) and DMSO (30 mL) was stirred at RT for 36 h, and then diluted with water (30 mL). The aqueous mixture was extracted with EtOAc (3×50 mL). The combined organic extracts were dried over Na₂SO₄, filtered and concentrated to dryness. The crude residue was purified by FCC to give the title compound (3.6 g, 60%).

Step B: 4-(2-Bromophenoxy)benzoic acid

To a solution consisting of methyl 4-(2-bromophenoxy)benzoate (3.5 g, 11.4 mmol), MeOH (30 mL) and water (10 mL) was added NaOH (910 mg, 22.8 mmol). The reaction mixture was stirred for 10 h at RT. The MeOH was removed by evaporation and the resulting mixture was acidified with HCl (1 N) to pH=7. The resulting solid was isolated by filtration, washed with water, and then dried in a vacuum to provide the title compound (2.9 g, 87%). MS (ESI): mass calcd. for C₁₃H₉BrO₃, 291.97; m/z found, 293.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 7.93 (d, J=8.6 Hz, 2H), 7.76 (d, J=8.2 Hz, 1H), 7.50-7.41 (m, 1H), 7.27-7.17 (m, 2H), 6.98-6.85 (m, 2H).

Intermediate JS

To a 100 mL round-bottomed flask, were added SOCl₂ (20 mL, 276 mmol) followed by 4-(2-bromophenoxy)benzoic acid (1.8 g, 6.1 mmol) and the reaction mixture was refluxed for 2 h. The reaction mixture was cooled to RT and then concentrated to dryness. The resulting residue was dissolved in THF (30 mL) and treated with NH₄OH (10 mL). The reaction mixture was stirred overnight, and then concentrated to dryness to give a solid residue. The resulting residue was collected by filtration washed with water and dried under vacuum to afford the title compound which was used without further purification (1.4 g, 78%). ¹H NMR (400 MHz, DMSO-d₆) δ 7.92-7.84 (m, 3H), 7.78-7.73 (m, 1H), 7.47-7.41 (m, 1H), 7.26 (s, 1H), 7.23-7.15 (m, 2H), 6.91 (d, J=8.8 Hz, 2H).

Intermediate JT

Step A: Methyl 4-((2-bromophenoxy)methyl)benzoate

To a 10 mL reaction tube equipped with reflux condenser, under N₂, were added 2-bromophenol (1.5 g, 8.6 mmol), methyl 4-(bromomethyl)benzoate (2.0 g, 8.6 mmol), K₂CO₃ (2.4 g, 17.3 mmol) and MeCN (5 mL). The resulting mixture was heated at reflux for 3 h before it was cooled to RT and EtOAc (30 mL) was added and the resulting mixture was filtered then washed with EtOAc (2×10 mL). The combined organic extracts were concentrated to dryness and the residue was purified by FCC to provide the title compound (2.5 g, 90%).

Step B: 4-((2-bromophenoxy)methyl)benzoic acid

To a 150 mL round-bottomed flask, under a N₂ atmosphere, were added methyl 4-((2-bromophenoxy)methyl)benzoate (2.5 g, 7.8 mmol), NaOH (0.6 g, 15.6 mmol) and MeOH (50 mL). The resulting mixture was stirred at RT for 10 h. After which time, water (50 mL) was added and the mixture was concentrated in vacuo to remove the MeOH. The aqeuous mixture was adjusted to pH=4 with 1 M HCl, which resulted in formation of a solid that was collected by filtration. The solid was dried under vacuum to obtain the title compound (2.2 g, 92%). MS (ESI): mass calcd. for C₁₄H₁₁BrO₃, 305.99; m/z found, 328.2 [M+Na]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 12.94 (s, 1H), 7.95 (d, J=8.1, 2H), 7.61-7.48 (m, 3H), 7.35-7.28 (m, 1H), 7.16 (d. J=8.3, 1H), 6.89 (m, 1H), 5.28 (s, 2H).

Intermediate JU

To a 150 mL round-bottomed flask equipped with a reflux condenser under a N₂ atmosphere, were added trans-4-aminocyclohexanol (2.3 g, 20 mmol), NaH (2.4 g, 60% purity, 60 mmol) and DMF (25 mL) at 0° C. After 1 h, 1-bromo-2-fluorobenzene (2.051 mL, 19.97 mmol) was added to the solution. The resulting mixture was heated at 60° C. for 5 h. The reaction mixture was cooled to RT, quenched with H₂O (2 mL) and concentrated to dryness. The resulting residue was purified using FCC to provide the title compound (1.8 g, 33.4%). MS (ESI): mass calcd. for C₁₂H₁₆BrNO, 269.04; m/z found, 269.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.41 (s, 1H), 7.53 (dd, J=7.9, 1.6 Hz, 1H), 7.32-7.24 (m, 1H), 7.17 (dd, J=8.4, 1.4 Hz, 1H), 6.88-6.81 (m, 1H), 4.37-4.25 (m, 1H), 3.00-2.90 (m, 1H), 2.09-2.01 (m, 2H), 1.96-1.88 (m, 2H), 1.50-1.34 (m, 4H).

Example 884

The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromophenoxy)methyl)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C₂₂H₂₂FN₃O₃S, 427.14; m/z found, 427.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36 (d, J=1.5 Hz, 1H), 8.01 (d, J=1.3 Hz, 1H), 7.90-7.86 (m, 1H), 7.44-7.32 (m, 4H), 7.13 (d, J=8.3 Hz, 1H), 7.06-7.02 (m, 1H), 6.67 (s, 2H), 3.94 (d, J=5.7 Hz, 2H), 3.17-3.08 (m, 2H), 3.03-3.00 (m, 2H), 2.10-2.00 (m, 3H), 1.79-1.73 (m, 2H).

Example 885

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C₂₁H₂₀FN₃O₃S, 413.12; m/z found, 413.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (s, 1H), 8.04 (s, 1H), 7.95-7.91 (m, 1H), 7.51-7.35 (m, 4H), 7.25 (d, J=8.3 Hz, 1H), 7.13-7.09 (m, 1H), 6.68 (s, 2H), 4.82-4.67 (m, 1H), 3.09-3.06 (m, 2H), 2.92-2.87 (m, 2H), 2.19-2.15 (m, 4H).

Example 886

The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromophenoxy)methyl)benzoic acid. MS (ESI): mass calcd. for C₂₄H₁₈FN₃O₃, 415.13; m/z found, 415.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.35 (s, 1H), 8.02 (d, J=1.4 Hz, 1H), 7.89-7.84 (m, 1H), 7.79 (d, J=8.1 Hz, 2H), 7.49-7.43 (m, 2H), 7.40 (dd, J=7.5, 1.6 Hz, 1H), 7.37-7.31 (m, 1H), 7.26 (d, J=8.1 Hz, 2H), 7.20 (d, J=8.1 Hz, 1H), 7.06-7.03 (m, 1H), 6.68 (s, 2H), 5.13 (s, 2H).

Example 887

The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromophenoxy)methyl)benzoic acid and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₄H₁₈FN₃O₃, 415.13; m/z found, 415.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (d, J=1.2 Hz, 2H), 7.79 (d, J=8.0 Hz, 2H), 7.58-7.54 (m, 1H), 7.50-7.43 (m, 2H), 7.40-7.31 (m, 2H), 7.25 (d, J=8.0 Hz, 2H), 7.19 (d, J=8.3 Hz, 1H), 7.06-7.02 (m, 1H), 6.85 (s, 2H), 5.14 (s, 2H).

Example 888

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)benzoic acid. MS (ESI): mass calcd. for C₂₃H₁₆FN₃O₃, 401.12; m/z found, 402.4 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.31 (s, 1H), 7.97 (s, 1H), 7.89-7.79 (m, 3H), 7.64-7.58 (m, 1H), 7.50-7.44 (m, 1H), 7.43-7.35 (m, 3H), 7.19-7.14 (m, 1H), 6.98-6.89 (m, 2H), 6.67 (s, 2H).

Example 889

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)benzoic acid and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₃H₁₈FN₃O₃, 401.12; m/z found, 401.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.45-8.39 (m, 2H), 7.89-7.85 (m, 2H), 7.61-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.49-7.44 (m, 1H), 7.43-7.34 (m, 3H), 7.16-7.12 (m, 1H), 6.98-6.93 (m, 2H), 6.86 (s, 2H).

Example 890

The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)benzamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₃H₁₇FN₄O₂, 400.13; m/z found, 400.9 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (s, 2H), 7.88-7.79 (m, 3H), 7.62-7.50 (m, 2H), 7.48-7.38 (m, 3H), 7.37-7.31 (m, 1H), 7.23 (s, 1H), 7.09 (d, J=7.8 Hz, 1H), 6.94 (d, J=8.8 Hz, 2H), 6.85 (s, 2H).

Example 891

The title compound was prepared in a manner similar to that described in Example 88 using trans 4-(2-bromophenoxy)cyclohexanamine. MS (ESI): mass calcd. for C₂₂H₂₃FN₄O, 378.19; m/z found, 379.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.42 (s, 1H), 8.35 (s, 1H), 8.01 (d, J=1.4 Hz, 1H), 7.89-7.83 (m, 1H), 7.43-7.35 (m, 3H), 7.34-7.29 (m, 1H), 7.17 (d, J=8.2 Hz, 1H), 7.05-6.98 (m, 1H), 6.67 (s, 2H), 4.34-4.24 (m, 1H), 2.91-2.83 (m, 1H), 2.08-2.01 (m, 2H), 1.89-1.83 (m, 2H), 1.40-1.29 (m, 4H).

Example 892

The title compound was prepared using analogous conditions to those described in Example 1 using 2-bromo-5-(trifluoromethyl)aniline. MS (ESI): mass calcd. for C₁₇H₁₂F₄N₄, 348.10; m/z found, 349.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 8.59-8.57 (m, 1H), 8.12 (d, J=1.5 Hz, 1H), 8.02 (m, 1H), 7.36-7.33 (m, 1H), 7.31-7.22 (m, 3H), 7.08-7.05 (m, 1H), 7.01-6.99 (m, 1H), 4.75 (s, 2H), 4.00 (s, 2H).

Intermediate JV

Step A: tert-Butyl 4-(3-bromopyridin-2-ylthio)piperidine-1-carboxylate

To a 250 mL round-bottomed flask were added, 3-bromopyridine-2-thiol (3.0 g, 16 mmol), tert-butyl 4-bromopiperidine-1-carboxylate (5.0 g, 19 mmol), K₂CO₃ (4.3 g, 31 mmol) and DMF (30 mL). The reaction mixture was stirred at RT for 4 h and then concentrated to dryness. The residue was purified by FCC to give the title compound (3.2 g, 54% purity). MS (ESI): mass calcd. for C₁₅H₂₁BrN₂O₂S, 372.05; m/z found, 373.1 [M+H]⁺.

Step B: tert-Butyl 4-(3-bromopyridin-2-ylsulfonyl)piperidine-1-carboxylate

To a 250 mL round bottom flask was added, tert-butyl 4-(3-bromopyridin-2-ylthio)piperidine-1-carboxylate (3.0 g, 8.0 mmol, 54% purity), NalO₄ (5.0 g, 24.0 mmol), RuCl₃ (10 mg, 0.05 mmol) and H₂O/DCM/CH₃CN (15 mL/15 mL/15 mL). The reaction mixture was stirred at RT for 1 h and then concentrated to dryness. The residue was diluted with water (50 mL) and extracted with DCM (3×50 mL). The combined organic extracts were dried over Na₂SO₄, filtered, concentrated to dryness and the resultant residue was purified by FCC to give the title compound (1.61 g, 50%). MS (ESI): mass calcd. for C₁₅H₂₁BrN₂O₄S, 404.04; m/z found, 405.3 [M+H]⁺.

Step C: 3-Bromo-2-(piperidin-4-ylsulfonyl)pyridine hydrochloride

To a 100 mL round-bottomed flask were added, tert-butyl 4-(3-bromopyridin-2-ylsulfonyl)piperidine-1-carboxylate (242 mg, 0.6 mmol), MeOH (20 mL) and HCl (4 mL, 6 N in EtOH). The mixture was stirred at RT for 3 h and then concentrated to dryness to give the title compound (210 mg) which was used without further purification. MS (ESI): mass calcd. for C₁₀H₁₄BrClN₂O₂S, 303.99; m/z found, 304.4 [M+H]⁺.

Step D: 2-(4-(3-Bromopyridin-2-ylsulfonyl)piperidin-1-yl)ethanol

To a 100 mL round-bottomed flask were added, 3-bromo-2-(piperidin-4-ylsulfonyl)pyridine hydrochloride (500 mg, 1.47 mmol), 1-bromoethan-2-ol (204 mg, 1.5 mmol), K₂CO₃ (304 mg, 2.2 mmol) and CH₃CN (20 mL). The mixture was stirred at 60° C. for 16 h, cooled to RT, concentrated to dryness and the resulting residue was purified by FCC to give the title compound (370 mg, 69%). MS (ESI): mass calcd. for C₁₂H₁₇BrN₂O₃S, 348.01; m/z found, 349.3 [M+H]⁺.

Intermediate JW

To a microwave vial were added phenyl boronic acid (76 mg, 0.62 mmol), 2-bromo-3-chloropyridine (100 mg, 0.52 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (20 mg, 0.025 mmol), acetonitrile (2.0 mL) and sat. aq. NaHCO₃ (1.5 mL). Nitrogen was bubbled through the biphasic mixture for 2 minutes before the vial was sealed. The reaction vessel was then placed in the microwave and heated at 110° C. for 1.5 h. The resulting reaction mixture was cooled to RT, diluted with ethyl acetate (50 mL), washed with water (1×25 mL), brine (1×25 mL), dried with Na₂SO₄ and concentrated to dryness. The resultant residue was subjected to prep-HPLC to afford the title compound (48 mg, 49%). MS (ESI): mass calcd. for C₁₁H₈ClN, 189.03; m/z found, 190.0 [M+H]⁺.

Example 893

The title compound was prepared in a manner similar to that described in Step B of Example 838 using 3-chloro-2-phenylpyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₅FN₄, 342.13; m/z found, 343.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (dd, J=4.8, 1.7 Hz, 1H), 8.45 (d, J=1.5 Hz, 2H), 7.90 (dd, J=7.7, 1.7 Hz, 1H), 7.55-7.44 (m, 2H), 7.41-7.26 (m, 5H), 7.16 (dd, J=11.9, 1.8 Hz, 1H), 7.05 (dd, J=8.0, 1.8 Hz, 1H), 6.92 (s, 2H).

Intermediate JX

To a 50 mL round-bottomed flask under nitrogen were added 2-bromo-3-chloropyridine (250 mg, 1.3 mmol), phenol (145 mg, 1.5 mmol), cesium carbonate (502 mg, 1.5 mmol) and DMSO (5 mL). The mixture was then heated at 60° C. for 24 h. The resulting reaction mixture was then cooled to RT, diluted with ethyl acetate (100 mL), washed with sat. aq. NaHCO₃ (1×75 mL), water (1×75 mL). The organic extracts were dried over Na₂SO₄ and concentrated to dryness. The resultant residue was then purified by FCC to provide the title compound (205 mg, 77%). MS (ESI): mass calcd. for C₁₁H₈ClNO, 189.03; m/z found, 190.0 [M+H]⁺.

Example 894

The title compound was prepared in a manner similar to that described in Step B of Example 838 using 3-chloro-2-phenoxypyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₅FN₄O, 358.12; m/z found, 359.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₈) δ 8.39 (dd, J=2.4, 1.5 Hz, 1H), 8.14 (dd, J=4.9, 1.9 Hz, 1H), 8.07-8.00 (m, 2H), 8.00-7.92 (m, 1H), 7.70-7.60 (m, 2H), 7.46-7.37 (m, 2H), 7.27 (dd, J=7.5, 4.8 Hz, 1H), 7.24-7.13 (m, 3H), 6.74 (s, 2H).

Example 895

The title compound was prepared in a manner similar to that described in Step B of Example 838 using 3-chloro-2-phenoxypyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₅FN₄O, 358.12; m/z found, 359.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.50 (d, J=1.5 Hz, 2H), 8.14 (dd, J=4.8, 1.9 Hz, 1H), 8.02 (dd. J=7.5, 1.9 Hz, 1H), 7.70-7.59 (m, 3H), 7.46-7.38 (m, 2H), 7.30-7.13 (m, 4H), 6.93 (s, 2H).

Intermediate JY

To a screw-capped vial was added 3-bromo-2-chloropyridine (250 mg, 1.3 mmol), 3-hydroxy pyridine (150 mg, 1.6 mmol), cesium carbonate (510 mg, 1.6 mmol) and DMSO (5.0 mL). The vial was capped and the mixture was stirred at 60° C. for 24 h. The resulting reaction mixture was cooled to RT, poured into water (100 mL) and extracted with ethyl acetate (2×50 mL). The combined organic extracts were washed with water (1×50 mL) and brine (1×50 mL). The organic extracts were concentrated to dryness and purified by FCC to provide the title compound (214 mg, 66%). MS (ESI): mass calcd. for C₁₀H₇BrN₂O, 249.97; m/z found, 250.9 [M+H]⁺.

Example 896

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(pyridine-3-yloxy)pyridine. MS (ESI): mass calcd. for C₂₀H₁₄FN₅O, 359.12; m/z found, 360.1 [M+H]^(. 1) H NMR (400 MHz, DMSO-d₆) δ 8.51 (d, J=2.7 Hz, 1H), 8.44 (dd, J=4.6, 1.4 Hz, 1H), 8.45-8.35 (m, 1H), 8.14 (dd, J=4.9, 1.8 Hz, 1H), 8.09-8.01 (m, 2H), 7.81-7.92 (m, 1H), 7.74-7.62 (m, 3H), 7.48 (dd, J=8.3, 4.7 Hz, 1H), 7.31 (dd, J=7.5, 4.9 Hz, 1H).

Example 897

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(phenylsulfonyl)pyridine. MS (ESI): mass calcd. for C₂₁H₁₅FN₄O₂S, 406.09; m/z found, 406.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.63 (dd, J=4.7, 1.6 Hz, 1H), 8.44 (s, 1H), 8.12 (d, J=1.4 Hz, 1H), 7.94-7.88 (m, 2H), 7.74-7.64 (m, 4H), 7.54-7.48 (m, 2H), 7.23 (dd, J=8.0, 1.7 Hz, 1H), 7.17 (dd, J=12.0, 1.6 Hz, 1H).

Example 898

Step A: 3-Bromo-2-(phenylthio)pyridine

The intermediate was prepared in a manner similar to that for Intermediate JZ using thiophenol. MS (ESI): mass calcd. for C₁₁H₈BrNS 264.96, m/z found 265.8 [M+H]⁺.

Step B: 3-Bromo-2-(phenylsulfonyl)pyridine

The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 3-bromo-2-(phenylthio)pyridine. MS (ESI): mass calcd. for C₁₁H₈BrNO₂S 296.95, m/z found 298.1 [M+H]⁺.

Step C: 5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(phenylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₅FN₄O₂S, 406.09; m/z found, 407.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.73 (s, 2H), 8.62 (dd, J=4.6, 1.5 Hz, 1H), 7.92 (dd, J=7.8, 1.5 Hz, 1H), 7.77-7.73 (m, 2H), 7.73-7.67 (m, 2H), 7.64-7.59 (m, 1H), 7.57-7.52 (m, 2H), 7.33-7.25 (m, 2H).

Intermediate JZ

To a 100 mL round-bottomed flask were added 3-bromo-2-chloropyridine (500 mg, 2.6 mmol), pyridine-3-thiol (291 mg, 2.6 mmol), Cs₂CO₃ (2.4 g, 7.8 mmol) and DMSO (15 mL). The reaction mixture was stirred at 100° C. for 5 h. After which time the reaction mixture was cooled to RT, concentrated to dryness and the resultant residue was purified by FCC to give the title compound (400 mg, 58%). MS (ESI): mass calcd. for C₁₀H₇BrN₂S, 265.95; m/z found, 267.1 [M+H]⁺.

Example 899

Step A: 3-Bromo-2-(pyridin-3-ylsulfonyl)pyridine

The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 3-bromo-2-(pyridin-3-ylthio)pyridine. MS (ESI): mass calcd. for C₁₀H₇BrN₂O₂S, 297.94, m/z found 298.6 [M+H]⁺.

Step B: 5-{2-Fluoro-4-[2-(pyridin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(pyridin-3-ylsulfonyl)pyridine. MS (ESI): mass calcd. for C₂₀H₁₄FN₅O₂S, 407.09; m/z found, 408.0 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.90 (dd, J=2.3, 0.6 Hz, 1H), 8.81 (dd, J=4.9, 1.6 Hz, 1H), 8.56 (dd, J=4.6, 1.6 Hz, 1H), 8.48-8.42 (m, 1H), 8.21-8.18 (m, 1H), 8.11 (d, J=1.5 Hz, 1H), 8.01-7.94 (m, 2H), 7.70 (dd, J=7.8, 4.7 Hz, 1H), 7.63-7.59 (m, 1H), 7.38-7.29 (m, 2H).

Example 900

Step A: tert-Butyl 3-(3-bromopyridin-2-ylthio)pyrrolidine-1-carboxylate

The intermediate was prepared in a manner similar to that described in Step A of Intermediate JV using tert-butyl 3-bromopyrrolidine-1-carboxylate. MS (ESI): mass calcd. for C₁₄H₁₉BrN₂O₂S, 358.04, m/z found 381.0 [M+Na]⁺.

Step B: tert-Butyl 3-(3-bromopyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate

The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using tert-butyl 3-(3-bromopyridin-2-ylthio)pyrrolidine-1-carboxylate. MS (ESI): mass calcd. for C₁₄H₁₉BrN₂O₄S, 390.02, m/z found 335.0 [M-Me₃C]⁺.

Step C: 3-Bromo-2-(pyrrolidin-3-ylsulfonyl)pyridine

To a 100 mL round-bottomed flask were added, tert-butyl 3-(3-bromopyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate (1.8 g, 4.2 mmol) and DCM (20 mL). A solution of HCl (20 mL, 6 N in EtOH) was then added and the mixture was stirred at RT for 2 h followed by concentration to dryness. The residue was diluted with sat. aq. NaHCO₃ (50 mL) and extracted with DCM (6×40 mL). The combined organic extracts were dried over MgSO₄ and concentrated to dryness to provide the title compound (1 g, 83%). MS (ESI): mass calcd. for C₉H₁₁BrN₂O₂S, 289.97, m/z found 291.0 [M+H]⁺.

Step D: 3-Bromo-2-(1-methylpyrrolidin-3-ylsulfonyl)pyridine

To a 100 mL round-bottomed flask was added, 3-bromo-2-(pyrrolidin-3-ylsulfonyl)pyridine (1.0 g, 3.4 mmol) and DCM (20 mL). An aqueous solution of formaldehyde (37%, 280 mg, 10.3 mmol), AcOH (0.5 mL) and NaBH(AcO)₃ (2.2 g, 10.3 mmol) were then added. The resulting mixture was stirred at RT for 1 h. then concentrated to dryness. The residue was purified by FCC to give the title compound (240 mg, 23%). MS (ESI): mass calcd. for C₁₀H₁₃BrN₂O₂S, 303.99, m/z found 305.0 [M+H]⁺.

Step E: 5-(2-Fluoro-4-{2-[(1-methylpyrrolidin-3-yl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(1-methylpyrrolidin-3-ylsulfonyl)pyridine. MS (ESI): mass calcd. for C₂₀H₂₀FN₅O₂S, 413.13; m/z found, 414.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.63 (d, J=3.2 Hz, 1H), 8.61 (s, 1H), 8.12 (s, 1H), 8.11-8.07 (m, 1H), 7.89 (d, J=6.7 Hz, 1H), 7.65 (dd, J=7.8, 4.7 Hz, 1H), 7.42-7.35 (m, 2H), 4.89-4.85 (m, 1H), 4.80 (s, 2H), 4.31-4.21 (m, 1H), 3.63-3.59 (m, 1H), 3.29-3.24 (m, 1H), 3.05-2.98 (m, 1H), 2.81 (s, 3H), 2.77-2.58 (m, 2H).

Example 901

Step A: 3-Bromo-6-(trifluoromethyl)pyridine-2-thiol

To a 100 mL round-bottomed flask were added, 3-bromo-2-chloro-6-(trifluoromethyl)pyridine (1.0 g, 3.8 mmol), Na₂S.9H₂O (2.8 g, 11.5 mmol) and DMSO (15 mL). The reaction mixture was stirred at 100° C. for 48 h, then cooled to RT and filtered. The filtrate was used in the next step without purification.

Step B: 3-Bromo-2-(iso-propylthio-6-(trifluoromethyl)pyridine

The intermediate was prepared in a manner similar to that described in Step A of Intermediate JV using 3-bromo-6-(trifluoromethyl)pyridine-2-thiol and 2-bromopropane. MS (ESI): mass calcd. for C₉H₉BrF₃NS, 298.96; m/z found, 300.0 [M+H]⁺.

Step C: 3-Bromo-2-(iso-propylsulfonyl)-6-(trifluoromethyl)pyridine

The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 3-bromo-2-(isopropylthio)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C₉H₉BrF₃NO₂S, 330.95; m/z found, 331.9 [M+H]⁺.

Step D: 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}phenyl)pyrazin-2-amine

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(isopropylsulfonyl)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₂S, 440.09; m/z found, 441.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.71 (d, J=1.3 Hz, 1H), 8.33-8.25 (m, 2H), 8.22-8.18 (m, 2H), 7.57-7.49 (m, 2H), 4.37-4.17 (m, 1H), 1.34 (d, J=6.9 Hz, 6H).

Example 902

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(isopropylsulfonyl)-6-(trifluoromethyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₁₉H₁₆F₄N₄O₂S, 440.09; m/z found, 441.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.90 (s, 2H), 8.26 (d, J=8.1 Hz, 1H), 8.19 (d, J=8.1 Hz, 1H), 7.76-7.72 (m, 1H), 7.58-7.49 (m, 2H), 4.30-4.20 (m, 1H), 1.33 (d, J=6.9 Hz, 6H).

Example 903

Step A: tert-Butyl 3-(3-bromopyridin-2-ylthio)piperidine-1-carboxylate

To a 250 mL round-bottomed flask was added, 3-bromopyridine-2-thiol (1.0 g, 5.3 mmol), tert-butyl 3-(tosyloxy)cyclohexanecarboxylate (1.2 g, 3.7 mmol), K₂CO₃ (720 mg, 5.3 mmol) and DMF (15 mL). The reaction mixture was stirred at 60° C. for 16 h then cooled to RT. The resulting mixture was concentrated to dryness and purified by FCC to give the title compound (300 mg, 21% purity). MS (ESI): mass calcd. for, C₁₅H₂₁BrN₂O₂S, 372.05; m/z found, 373.1 [M+H]⁺.

Step B: tert-Butyl 3-(3-bromopyridin-2-ylsulfonyl)piperidine-1-carboxylate

The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using tert-butyl 3-(3-bromopyridin-2-ylthio)piperidine-1-carboxylate. MS (ESI): mass calcd. for, C₁₅H₂₁BrN₂O₄S, 404.04; m/z found, 405.1 [M+H]⁺.

Step C: 3-Bromo-2-(piperidin-3-ylsulfonyl)pyridine

The intermediate was prepared in a manner similar to that described in Step C of Intermediate JV using tert-butyl 3-(3-bromopyridin-2-ylsulfonyl)piperidine-1-carboxylate. MS (ESI): mass calcd. for C₁₀H₁₃BrN₂O₂S, 303.99; m/z found, 305.0 [M+H]⁺.

Step D: 1-(3-(3-Bromopyridin-2-ylsulfonyl)piperidin-1-yl)ethanone

To a 100 mL round-bottomed flask were added 3-bromo-2-(piperidin-3-ylsulfonyl)pyridine hydrochloride (150 mg, 0.44 mmol), acetyl chloride (52 mg, 0.66 mmol), CH₂Cl₂ (20 mL) and Et₃N (90 mg, 0.88 mmol). The mixture was stirred at RT for 1 h then neutralized to pH=7 by adding sat. aq. NaHCO₃ and extracted with DCM (3×10 mL). The combined organic extracts were dried over Na₂SO₄ and concentrated to dryness to give the title compound (160 mg) which was used in the next step without further purification. MS (ESI): mass calcd. for C₁₂H₁₅BrN₂O₃S, 346.00; m/z found, 346.9 [M+H]⁺.

Step E: 5-(4-{2-[(1-Acetylpiperidin-3-yl)sulfonyl]pyridin-3-yl}-2-fluorphenyl)pyrazin-2-amine

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 1-(3-(3-bromopyridin-2-ylsulfonyl)piperidin-1-yl)ethanone. MS (ESI): mass calcd. for C₂₂H₂₂FN₅O₃S, 455.14; m/z found, 455.9 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.78 (s, 1H), 8.69-8.58 (m, 1H), 8.30 (s, 1H), 8.17-8.11 (m, 1H), 8.03 (dd, J=11.5, 7.9 Hz, 1H), 7.83-7.78 (m, 1H), 7.48-7.43 (m, 2H), 4.67-3.78 (m, 3H), 3.58-3.17 (m, 1H), 3.07-2.92 (m, 1H), 2.19 (s, 1H), 2.13 (m, 3H), 1.99-1.78 (m, 2H), 1.68-1.50 (m, 1H).

Example 904

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 2-(4-(3-bromopyridin-2-ylsulfonyl)piperidin-1-yl)ethanol. MS (ESI): mass calcd. for C₂₂H₂₄FN₅O₃S, 457.16; m/z found, 458.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.80-8.74 (m, 1H), 8.72 (d, J=1.1 Hz, 1H), 8.25 (d, J=1.2 Hz, 1H), 8.20-8.11 (m, 1H), 8.03 (dd, J=7.8, 1.4 Hz, 1H), 7.79 (dd, J=7.9, 4.6 Hz, 1H), 7.50-7.40 (m, 2H), 4.56-4.42 (m, 1H), 3.96-3.72 (m, 4H), 3.54-3.45 (m, 1H), 3.30-3.11 (m, 4H), 2.39-2.28 (m, 2H), 2.20-2.00 (m, 2H).

Example 905

Step A: 1-(4-(3-Bromopyridin-2-ylsulfonyl)piperidin-1-yl)propan-2-ol

To a 100 mL round-bottomed flask were added, 3-bromo-2-(piperidin-4-ylsulfonyl)pyridine hydrochloride (500 mg, 1.47 mmol), 1-bromopropan-2-ol (204 mg, 1.47 mmol), K₂CO₃ (304 mg, 2.2 mmol) and CH₃CN (20 mL). The mixture was stirred at 60° C. for 16 h. The resulting mixture was cooled to RT, concentrated to dryness and the resultant residue was purified by FCC to give the title compound (370 mg, 69%). MS (ESI): mass calcd. for C₁₃H₁₉BrN₂O₃S, 362.03; m/z found, 363.3 [M+H]⁺.

Step B: 1-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}sulfonyl)piperidin-1-yl]propan-2-ol

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 1-(4-(3-bromopyridin-2-ylsulfonyl)piperidin-1-yl)propan-2-ol. MS (ESI): mass calcd. for C₂₃H₂₆FN₅O₃S, 471.17; m/z found, 472.1 [M+H]⁺. ¹H NMR (300 MHz, CD₃OD) δ 8.78-8.73 (m, 1H), 8.72-8.66 (m, 1H), 8.26 (s, 1H), 8.15 (m, 1H), 8.05-8.00 (m, 1H), 7.79 (dd, J=7.9, 4.6 Hz, 1H), 7.48-7.40 (m, 2H), 4.59-4.42 (m, 1H), 4.26-4.11 (m, 1H), 3.79 (t, J=11.4 Hz, 2H), 3.52-3.41 (m, 1H), 3.23-2.94 (m, 4H), 2.39-2.25 (m, 2H), 2.22-2.01 (m, 2H), 1.23 (d, J=6.1 Hz, 3H).

Example 906

Step A: 3-Bromo-2-(tetrahydro-2H-pyran-4-ylthio)-6-(trifluoromethyl)pyridine

The intermediate was prepared in a manner similar to that described in Step A of Intermediate JV using 3-bromo-6-(trifluoromethyl)pyridine-2-thiol and 4-bromotetrahydro-2H-pyran. MS (ESI): mass calcd. for C₁₁H₁₁BrF₃NOS, 340.97; m/z found, 342.0 [M+H]⁺.

Step B: 3-Bromo-2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridine

The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 3-bromo-2-(tetrahydro-2H-pyran-4-ylthio)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C₁₁H₁₁BrF₃NO₃S₂, 372.96; m/z found, 373.6 [M+H]⁺.

Step C: 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}pyrazin-2-amine

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₄O₃S, 482.10; m/z found, 483.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1H), 8.29 (d, J=8.0 Hz, 1H), 8.20 (d, J=8.1 Hz, 1H), 8.15 (s, 1H), 8.05-8.01 (m, 1H), 7.48 (d, J=4.1 Hz, 1H), 7.46 (s, 1H), 4.38-4.32 (m, 1H), 4.08-4.04 (m, 2H), 3.54-3.49 (m, 2H), 1.96-1.93 (m, 2H), 1.89-1.79 (m, 2H).

Example 907

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₄O₃S, 482.10; m/z found, 483.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.74 (d, J=0.8 Hz, 2H), 8.27 (d, J=8.1 Hz, 1H), 8.20 (d, J=8.1 Hz, 1H), 7.70-7.66 (m, 1H), 7.53-7.48 (m, 2H), 4.39-4.34 (m, 1H), 4.07-4.03 (m, 2H), 3.54-3.47 (m, 2H), 1.95-1.92 (m, 2H), 1.87-1.78 (m, 2H).

Example 908

Step A: 3-Bromo-2-(1-(methylsulfonyl)piperidin-4-ylsulfonyl)pyridine

The intermediate was prepared in a manner similar to that described in Step D of Intermediate JV using methanesulfonyl chloride. MS (ESI): mass calcd. for C₁₁H₁₅BrN₂O₄S₂, 381.97; m/z found, 382.7 [M+H]⁺.

Step B: 5-2-Fluoro-4-(2-[1-(methylsulfonyl)piperidin-4-ylsulfonyl)pyridin-3-yl)phenyl]pyrazin-2-amine

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(1-(methylsulfonyl)piperidin-4-ylsulfonyl)pyridine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₄S₂, 491.11; m/z found, 492.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.75 (dd, J=4.7, 1.5 Hz, 1H), 8.65 (d, J=1.2 Hz, 1H), 8.26 (d, J=1.2 Hz, 1H), 8.15-8.11 (m, 1H), 8.00 (dd, J=7.9, 1.5 Hz, 1H), 7.77 (dd, J=7.9, 4.7 Hz, 1H), 7.44-7.42 (m, 2H), 4.26-4.21 (m, 1H), 3.84-3.81 (m, 2H), 2.91-2.83 (m, 5H), 2.11-2.08 (m, 2H), 1.83-1.73 (m, 2H).

Example 909

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(1-(methylsulfonyl)piperidin-4-ylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₂₂FN₅O₄S₂, 491.11; m/z found, 492.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.88 (s, 2H), 8.76 (dd, J=4.6, 1.5 Hz, 1H), 7.99 (dd, J=7.9, 1.5 Hz, 1H), 7.78 (dd, J=7.9, 4.7 Hz, 1H), 7.71-7.67 (m, 1H), 7.46 (dd, J=7.0, 1.4 Hz, 1H), 7.44-7.43 (m, 1H), 4.29-4.23 (m, 1H), 3.84-3.81 (m, 2H), 2.91-2.85 (m, 5H), 2.12-2.09 (m, 2H), 1.83-1.72 (m, 2H).

Example 910

Step A: 1-(4-(3-Bromo-6-(trifluoromethyl)pyridin-2-ylsulfonyl)piperidin-1-yl)ethanone

The intermediate was prepared in a manner similar to that described in Step D of Example 903 using 3-bromo-2-(piperidin-4-ylsulfonyl)-6-(trifluoromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C₁₃H₁₄BrF₃N₂O₃S 413.99; m/z found, 414.6 [M+H]⁺.

Step B: 5-(4-{2-[(1-Acetylpiperidin-4-ylsulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 1-(4-(3-bromo-6-(trifluoromethyl)pyridin-2-ylsulfonyl)piperidin-1-yl)ethanone. MS (ESI): mass calcd. for C₂₃H₂₁F₄N₅O₃S, 523.13; m/z found, 524.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.73 (d, J=1.2 Hz, 1H), 8.32-8.29 (m, 2H), 8.25-8.18 (m, 2H), 7.58-7.50 (m, 2H), 4.64-4.61 (m, 1H), 4.42-4.36 (m, 1H), 4.10-4.07 (m, 1H), 3.29-3.23 (m, 1H), 2.83-2.76 (m, 1H), 2.18-2.15 (m, 1H), 2.12-2.07 (m, 4H), 1.81-1.75 (m, 1H), 1.73-1.59 (m, 1H).

Example 911

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 1-(4-(3-bromo-6-(trifluoromethyl)pyridin-2-ylsulfonyl)piperidin-1-yl) ethanone and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₃H₂₁F₄N₅O₃S, 523.13; m/z found, 524.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD) δ 8.93 (s, 2H), 8.30 (d, J=8.1 Hz, 1H), 8.23 (d. J=8.1 Hz, 1H), 7.79-7.75 (m, 1H), 7.61-7.51 (m, 2H), 4.64-4.61 (m, 1H), 4.45-4.34 (m, 1H), 4.11-4.07 (m, 1H), 3.33-3.26 (m, 1H), 2.84-2.78 (m, 1H), 2.23-2.05 (m, 5H), 1.85-1.76 (m, 1H), 1.71-1.61 (m, 1H).

Example 912

Step A: 4-((3-Bromo-6-(trifluoromethyl)pyridin-2-yl)thio)tetrahydro-2H-thiopyran 1,1-dioxide

The intermediate was prepared in a manner similar to that described in Step A of Intermediate JV using 3-bromo-6-(trifluoromethyl)pyridine-2-thiol and 4-iodotetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C₁₁H₁₁BrF₃NO₂S₂, 388.94; m/z found, 389.5 [M+H]⁺.

Step B: 4-((3-Bromo-6-(trifluoromethyl)pyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide

The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 4-((3-bromo-6-(trifluoromethyl)pyridin-2-yl)thio)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C₁₁H₁₁BrF₃NO₄S₂, 420.93; m/z found, 421.5 [M+H]⁺.

Step C: 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 4-((3-bromo-6-(trifluoromethyl)pyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₄O₄S₂, 530.07; m/z found, 531.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d) δ 8.42-8.37 (m, 3H), 8.06 (s, 1H), 8.00-7.95 (m, 1H), 7.50 (dd, J=12.1, 1.5 Hz, 1H), 7.43 (dd, J=8.1, 1.7 Hz, 1H), 6.83 (s, 2H), 4.33-4.27 (m, 1H), 3.41-3.34 (m, 2H), 3.22-3.19 (m, 2H), 2.38-2.35 (m, 2H), 2.13-2.04 (m, 2H).

Example 913

The title compound was prepared in a manner similar to that described in Step D of Example 803 using 4-((3-bromo-6-(trifluoromethyl)pyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₄O₄S₂, 530.07; m/z found, 531.0 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.65-8.62 (m, 2H), 8.39 (s, 2H), 7.75-7.71 (m, 1H), 7.54 (d, J=11.6 Hz, 1H), 7.44 (d, J=8.0 Hz, 1H), 5.10 (s, 2H), 4.34-4.28 (m, 1H), 3.40-3.34 (m, 2H), 3.22-3.19 (m, 2H), 2.38-2.35 (m, 2H), 2.13-2.04 (m, 2H).

The following Examples 1-13 summarized in Table 4 are prophetic and unless otherwise specified, can be readily synthesized by a person skilled in the art utilizing the above described reaction schemes or by synthesis routes generally known to a person skilled in the art. One skilled in the art based on presently disclosed compounds would conclude the following prophetic compounds to be active against FLAP.

TABLE 4 Prophetic Examples STRUCTURE No. NAME

1 4′-(6-Aminopyridazin-3-yl)-3′- fluorobiphenyl-2-sulfonamide

2 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′- fluoro-5-(trifluoromethyl)biphenyl-2- sulfonamide

4 N-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]methanesulfonamide

5 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′- fluoro-5-methoxybiphenyl-2-sulfonamide

6 (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3- carboxamide

7 (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3- carboxamide

8 5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine

9 5-{2′-[(Cyclopropylmethyl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrazin-2-amine

10 1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-4- (pentafluoroethyl)piperidin-4-ol

11 tert-Butyl (1-{[3′-fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- yl]sulfonyl}piperidin-4-yl)carbamate

12 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4- difluorobiphenyl-2-sulfonamide

13 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′- fluoro-4-(trifluoromethyl)biphenyl-2- sulfonamide

D) General Administration, Formulation, and Dosages

The present invention provides substituted heteroaryl ketone compounds which are useful as FLAP modulators.

The invention features a method for treating a subject in need thereof with an FLAP-mediated disease and/or disorder, said method comprising administering to the subject a therapeutically effective amount of a compound of the invention. In particular, the invention also provides a method for treating or inhibiting the progression of an FLAP-mediated disease and/or disorder, or associated symptoms or complications thereof in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of the invention.

Embodiments of the present invention include a method wherein the compound of Formula (I) is a FLAP modulator.

Embodiments of the present invention include a use of the compound of Formula (I) in the manufacture of a medicament for treating an FLAP-mediated disease and/or disorder.

Embodiments of the present invention include a use of the compound of Formula (I) as a medicine.

The compounds of Formula (I) have an FLAP-modulating effect and are useful as therapeutic agents for various FLAP-mediated disorders and/or disorders, or associated symptoms or complications, for example, respiratory disorders, cardiac and cardiovascular diseases, autoimmune disorders, carcinogenesis, and associated symptoms or complications thereof.

The compounds of Formula (I) may be administered orally or parenterally, and after formulation into preparations suitable for the intended administration route, they can be used as therapeutic agents for treating an FLAP-mediated disease and/or disorder. FLAP-mediated diseases and/or disorders include, but are not limited, diseases and/or disorders that are related to leukotriene synthesis pathway, and therefore may be treated, controlled or in some cases prevented, by treatment with the compounds of this invention.

One aspect of the present invention provides a method for the treatment of diseases and/or disorders, or associated symptoms or complications thereof, responsive to the modulation of FLAP in a subject in need thereof which comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.

Another aspect of the present invention provides a method for the treatment of a disease and/or disorder selected from the group consisting of respiratory diseases and/or disorders, cardiac and cardiovascular diseases and/or disorders, autoimmune diseases and/or disorders, carcinogenesis, and associated symptoms or complications thereof, in a subject in need thereof which comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.

More specifically, this invention is directed to a method of treating exacerbations, non-allergic asthma, aspirin exacerbated resipiratory disease, pulmonary arterial hypertension, fibrotic lung diseases, acute respiratory distress syndrome, obstructive sleep apnea and chronic obstructive pulmonary disease, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.

Furthermore, this invention is directed to a method of treating myocardial infarction, atherosclerosis and coronary artery disease, stroke, aortic aneurisms, atherosclerosis, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.

Yet, this invention is also directed to a method of treating rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis, allergic rhinitis, chronic sinusitis, allergic dermatitis and asthma, wherein the method comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.

Finally, this invention is also directed to a method of treating tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells, wherein the method comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.

Another aspect of the present invention provides a pharmaceutical composition comprising at least one compound of Formula (I) or a form thereof, and a pharmaceutically acceptable carrier.

The invention also features a method for treating a subject in need thereof with an FLAP-mediated disease and/or disorder, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one compound of the invention.

Yet another aspect of the present invention relates to the use of a compound of Formula (I) or a form thereof, for the manufacture of a medicament useful for the treatment of an FLAP-mediated disease and/or disorder in a subject in need thereof.

In a clinical use of the compounds of the invention, pharmaceutically-acceptable additives may be added thereto to formulate various preparations in accordance with the intended administration route thereof, and the preparations may be administered.

Various additives generally used in the field of pharmaceutical compositions may be used herein, including, for example, gelatin, lactose, sucrose, titanium oxide, starch, crystalline cellulose, methyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, corn starch, microcrystalline wax, white petrolatum, magnesium metasilicate aluminate, anhydrous calcium phosphate, citric acid, trisodium citrate, hydroxypropyl cellulose, sorbitol, sorbitan fatty acid ester, polysorbate, sucrose fatty acid ester, polyoxyethylene, hardened castor oil, polyvinylpyrrolidone, magnesium stearate, palmitoleic acid, light silicic acid anhydride, talc, vegetable oil, benzyl alcohol, gum arabic, propylene glycol, polyalkylene glycol, cyclodextrin, and hydroxypropylcyclodextrin.

Combined with such additives, the compound of the invention may be formulated into various forms of preparations, for example, solid preparations such as tablets, capsules, granules, powders and suppositories; and liquid preparations such as syrups, elixirs and injections. These preparations can be produced in any method known in the field of pharmaceutical compositions. The liquid preparations may be in such a form that is dissolved or suspended in water or in any other suitable medium before use. Especially for injections, the preparation may be dissolved or suspended, if desired, in a physiological saline or glucose solution, and a buffer and a preservative may be added thereto.

The compounds of the invention are effective for animals, including humans and other mammals. Any ordinary physician, veterinarian or clinician may readily determine the necessity, if any, of treatment with an instant compound.

Those of skill in the treatment of diseases and/or disorders, or associated symptoms or complications thereof, mediated by FLAP can determine the effective daily amount from the test results presented hereinafter and other information. The exact dosage and frequency of administration depends on the particular compound of invention used, the particular disease and/or disorder, or associated symptoms or complications thereof, being treated, the severity of the disease and/or disorder, or associated symptoms or complications thereof, being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned herein are therefore only guidelines in practicing the present invention.

Preferably, the method for the treatment of the FLAP diseases and/or disorders described in the present invention using any of the compounds as defined herein, the dosage form will contain a pharmaceutically acceptable carrier containing between from about 1 mg to about 1000 mg; particularly from about 0.5 mg to about 500 mg of the compound, and may be constituted into any form suitable for the mode of administration selected. The dosages, however, may be varied depending upon the requirement of the subjects, the severity of the disease and/or disorder, or associated symptoms or complications thereof, being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.

When the compound of the invention is, for example, put into clinical use, then its dose and its administration frequency may vary depending on the sex, the age, the body weight and the condition of the patient and on the type and the range of the necessary treatment with the compound. For oral administration, in general, the dose of the compound may be in a range of from about 0.01 mg/kg/day to about 100 mg/kg of body weight/day or in a range of from about 0.03 mg/kg/day to about 1 mg/kg/day. The oral administration frequency is preferably from one to a few times per day. For parenteral administration, the dose may be in a range of from about 0.001 mg/kg/day to about 10 mg/kg/day, in a range of from about 0.001 mg/kg/day to about 0.1 mg/kg/day or, in a range of from about 0.01 mg/kg/day to about 0.1 mg/kg/day. The parenteral administration frequency is preferably from one to a few times per day. For oral administration, the compositions are preferably provided in the form of tablets containing from about 1.0 mg to about 1000 mg of the active ingredient, particularly 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, 500 mg, 600 mg, 750 mg, 800 mg, 900 mg, and 1000 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

Ordinary physicians, veterinarians and clinicians may readily determine the effective dose of the pharmaceutical compound necessary to treat, prevent, inhibit, retard or stop the intended disease, and may readily treat the diseased patient with the compound.

The pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.001 mg/kg/day to about 10 mg/kg/day (particularly from about 0.01 mg/kg/day to about 1 mg/kg/day; and, more particularly, from about 0.1 mg/kg/day to about 0.5 mg/kg/day) and may be given at a dosage of from about 0.001 mg/kg/day to about 30 mg/kg/day (particularly from about 0.01 mg/kg/day to about 2 mg/kg/day, more particularly from about 0.1 mg/kg/day to about 1 mg/kg/day and even more particularly from about 0.5 mg/kg/day to about 1 mg/kg/day).

Preferably these compositions are in unit dosage forms from such as tablets, pills, capsules, dry powders for reconstitution or inhalation, granules, lozenges, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories for administration by oral, intranasal, sublingual, intraocular, transdermal, parenteral, rectal, vaginal, dry powder inhaler or other inhalation or insufflation means. Alternatively, the composition may be presented in a form suitable for 1 to 4 times per day, preferably once or twice per day administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.

The preparation may contain the compound of the invention in an amount in a range of from about 1.0 to about 100% by weight or, in a range of from about 1.0 to about 60% by weight of the preparation. The preparation may contain any other therapeutically-effective compound.

The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.

Some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are intended to be encompassed within the scope of this invention.

Where the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form or as individual enantiomers or diasteromers by either stereospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers or diastereomers by standard techniques, such as the formation of stereoisomeric pairs by salt formation with an optically active base, followed by fractional crystallization and regeneration of the free acid. The compounds may also be resolved by formation of stereoisomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alliteratively, the compounds may be resolved using a chiral HPLC column. It is to be understood that all stereoisomers, racemic mixtures, diastereomers, cis-trans isomers, and enantiomers thereof are encompassed within the scope of the present invention.

E) Use

Dosages

For preparing pharmaceutical compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as diluents, binders, adhesives, disintegrants, lubricants, antiadherents and gildants. Suitable diluents include, but are not limited to, starch (i.e. corn, wheat, or potato starch, which may be hydrolized), lactose (granulated, spray dried or anhydrous), sucrose, sucrose-based diluents (confectioner's sugar; sucrose plus about 7 to 10 weight percent invert sugar; sucrose plus about 3 weight percent modified dextrins; sucrose plus invert sugar, about 4 weight percent invert sugar, about 0.1 to 0.2 weight percent cornstarch and magnesium stearate), dextrose, inositol, mannitol, sorbitol, microcrystalline cellulose (i.e. AVICEL™ microcrystalline cellulose available from FMC Corp.), dicalcium phosphate, calcium sulfate dihydrate, calcium lactate trihydrate and the like. Suitable binders and adhesives include, but are not limited to acacia gum, guar gum, tragacanth gum, sucrose, gelatin, glucose, starch, and cellulosics (i.e. methylcellulose, sodium carboxymethylcellulose, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, and the like), water soluble or dispersible binders (i.e. alginic acid and salts thereof, magnesium aluminum silicate, hydroxyethylcellulose [i.e. TYLOSE™ available from Hoechst Celanese], polyethylene glycol, polysaccharide acids, bentonites, polyvinylpyrrolidone, polymethacrylates and pregelatinized starch) and the like. Suitable disintegrants include, but are not limited to, starches (corn, potato, etc.), sodium starch glycolates, pregelatinized starches, clays (magnesium aluminum silicate), celluloses (such as crosslinked sodium carboxymethylcellulose and microcrystalline cellulose), alginates, pregelatinized starches (i.e. corn starch, etc.), gums (i.e. agar, guar, locust bean, karaya, pectin, and tragacanth gum), cross-linked polyvinylpyrrolidone and the like. Suitable lubricants and antiadherents include, but are not limited to, stearates (magnesium, calcium and sodium), stearic acid, talc waxes, stearowet, boric acid, sodium chloride, DL-leucine, carbowax 4000, carbowax 6000, sodium oleate, sodium benzoate, sodium acetate, sodium lauryl sulfate, magnesium lauryl sulfate and the like. Suitable gildants include, but are not limited to, talc, comstarch, silica (i.e. CAB-O-SIL™ rusilica available from Cabot, SYLOID™ silica available from W.R. Grace/Davison, and AEROSIL™ silica available from Degussa) and the like. Sweeteners and flavorants may be added to chewable solid dosage forms to improve the palatability of the oral dosage form. Additionally, colorants and coatings may be added or applied to the solid dosage form for ease of identification of the drug or for aesthetic purposes. These carriers are formulated with the pharmaceutical active to provide an accurate, appropriate dose of the pharmaceutical active with a therapeutic release profile.

Generally these carriers are mixed with the pharmaceutical active to form a solid preformulation composition containing a homogeneous mixture of the pharmaceutical active form of the present invention, or a pharmaceutically acceptable salt thereof. Generally the preformulation will be formed by one of three common methods: (a) wet granulation, (b) dry granulation and (c) dry blending. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from about 0.1 mg to about 500 mg of the active ingredient of the present invention. The tablets or pills containing the novel compositions may also be formulated in multilayer tablets or pills to provide a sustained or provide dual-release products. For example, a dual release tablet or pill can comprise an inner dosage and an outer dosage component the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer, which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric materials such as shellac, cellulose acetate (i.e. cellulose acetate phthalate, cellulose acetate trimetllitate), polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, methacrylate and ethylacrylate copolymers, methacrylate and methyl methacrylate copolymers and the like. Sustained release tablets may also be made by film coating or wet granulation using slightly soluble or insoluble substances in solution (which for a wet granulation acts as the binding agents) or low melting solids a molten form (which in a wet granulation may incorporate the active ingredient). These materials include natural and synthetic polymers waxes, hydrogenated oils, fatty acids and alcohols (i.e. beeswax, carnauba wax, cetyl alcohol, cetylstearyl alcohol, and the like), esters of fatty acids metallic soaps, and other acceptable materials that can be used to granulate, coat, entrap or otherwise limit the solubility of an active ingredient to achieve a prolonged or sustained release product.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, but are not limited to aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable suspending agents for aqueous suspensions, include synthetic and natural gums such as, acacia, agar, alginate (i.e. propylene alginate, sodium alginate and the like), guar, karaya, locust bean, pectin, tragacanth, and xanthan gum, cellulosics such as sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and combinations thereof, synthetic polymers such as polyvinyl pyrrolidone, carbomer (i.e. carboxypolymethylene), and polyethylene glycol; clays such as bentonite, hectorite, attapulgite or sepiolite; and other pharmaceutically acceptable suspending agents such as lecithin, gelatin or the like. Suitable surfactants include but are not limited to sodium docusate, sodium lauryl sulfate, polysorbate, octoxynol-9, nonoxynol-10, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxamer 188, polyoxamer 235 and combinations thereof. Suitable deflocculating or dispersing agents include pharmaceutical grade lecithins. Suitable flocculating agents include but are not limited to simple neutral electrolytes (i.e. sodium chloride, potassium, chloride, and the like), highly charged insoluble polymers and polyelectrolyte species, water soluble divalent or trivalent ions (i.e. calcium salts, alums or sulfates, citrates and phosphates (which can be used jointly in formulations as pH buffers and flocculating agents). Suitable preservatives include but are not limited to parabens (i.e. methyl, ethyl, n-propyl and n-butyl), sorbic acid, thimerosal, quaternary ammonium salts, benzyl alcohol, benzoic acid, chlorhexidine gluconate, phenylethanol and the like. There are many liquid vehicles that may be used in liquid pharmaceutical dosage forms; however, the liquid vehicle that is used in a particular dosage form must be compatible with the suspending agent(s). For example, nonpolar liquid vehicles such as fatty esters and oils liquid vehicles are best used with suspending agents such as low HLB (Hydrophile-Lipophile Balance) surfactants, stearalkonium hectorite, water insoluble resins, water insoluble film forming polymers and the like. Conversely, polar liquids such as water, alcohols, polyols and glycols are best used with suspending agents such as higher HLB surfactants, clays silicates, gums, water soluble cellulosics, water soluble polymers and the like. For parenteral administration, sterile suspensions and solutions are desired. Liquid forms useful for parenteral administration include sterile solutions, emulsions and suspensions. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.

Furthermore, compounds of the present invention can be administered in an intranasal dosage form via topical use of suitable intranasal vehicles or via transdermal skin patches, the composition of which are well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the administration of a therapeutic dose will, of course, be continuous rather than intermittent throughout the dosage regimen.

Compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, multilamellar vesicles and the like. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, phosphatidylcholines and the like.

The daily dose of a pharmaceutical composition of the present invention may be varied over a wide range from about 0.1 mg to about 5000 mg; preferably, the dose will be in the range of from about 1 mg to about 100 mg per day for an average human. For oral administration, the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 or 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated. Advantageously, a compound of the present invention may be administered in a single daily dose or the total daily dosage may be administered in divided doses of two, three or four times daily.

It is also apparent to one skilled in the art that the therapeutically effective dose for active compounds of the invention or a pharmaceutical composition thereof will vary according to the desired effect. Therefore, optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level. The above dosages are thus exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Compounds of this invention may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of the compounds of the invention as FLAP modulators is required for a subject in need thereof.

In their use, the compounds of the invention may be combined with any other therapeutic agents that are useful for the treatment of an FLAP-mediated disorder.

The combination includes not only the composition of compounds of the invention and one other active substance but also the composition of compounds of the invention and two or more other active substances or non-drug therapy. The scope of possible combinations of a compound of the invention and one, two or more active substances are within the knowledge of one skilled in the art for the treatment of an FLAP-mediated disorder.

Specifically, the combination of a FLAP modulator with prostaglandin modulators, cyclooxygenase-1 modulators, or cyclooxygenase-2 modulators might be used to treat inflammatory and autoimmune diseases and/or disorders as well as cardiovascular diseases and/or disorders, or vascular injury (Z. Yu et al., “Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice,” Proc. Natl. Acad. Sci. USA, 2012, 109(17), 6727-32; Z. Yu et al., “Myeloid Cell 5-Lipoxygenase Activating Protein Modulates the Response to Vascular Injury,” Circ. Res., 2012, Epub December 18). Due to the synergy of histamine and leukotrienes, the combination of a FLAP modulator and a histamine receptor 1 or 4 antagonist might have utility in treating respiratory, allergic, dermatological and autoimmune disorders (A. Reicin et al., “Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma,” Arch. Intern. Med., 2000, 160(16), 2418-88; S. Sanada et al., “The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria,” Arch. Dermatol. Res., 2005, 297(3), 134-38).

Formulations

To prepare the pharmaceutical compositions of this invention, one or more compounds of Formula (I) or salt thereof as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration (e.g. oral or parenteral). Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers may be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.

The compounds of the present invention may be formulated into various pharmaceutical forms for administration purposes. Methods of formulating pharmaceutical compositions have been described in numerous publications such as Pharmaceutical Dosage Forms: Tablets. Second Edition. Revised and Expanded, Volumes 1-3, edited by Lieberman et al; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1-2, edited by Avis et al; and Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1-2, edited by Lieberman et al; published by Marcel Dekker, Inc.

F) Biological Examples

The ability of the compounds of the present invention to treat a FLAP-mediated disease and/or disorder, or associated symptoms or complications thereof, was determined using the following procedures. Binding assay data represent the average value obtained from two different assay plates, with samples run in duplicate on each plate. Human whole blood assay data represent a single replicate on an assay plate using whole blood from at least one healthy donor. Certain FLAP binding and human whole blood assay data are presented in Table 5.

FLAP Binding Assay

The assay below is used to test the modulatory activity of compounds against FLAP. Human and mouse FLAP-encoding DNA was amplified by polymerase chain reaction and cloned into pFastBac1 (Invitrogen) with a NH2-terminal 6-His tag for expression in Spodoptera frugiperda (Sf-9) cells. FLAP-containing membranes were prepared as was a FITC-labeled FLAP modulator [5-[({[2-(2-{3-[3-(tert-Butylsulfanyl)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropanoyl}hydrazino)-2-oxoethyl]sulfanyl}acetyl)amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid]. The FLAP binding assay is performed in HTRF format (homogeneous time resolved fluorescence). FLAP-containing membranes (1 pg/well final for human) are incubated in the presence of the HTRF ligand. [5-[({[2-(2-{3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropanoyl}hydrazino)-2-oxoethyl]sulfanyl}acetyl)amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid] (25 nM final), a terbium labeled anti-His tag antibody (0.5 ng/well final, from Cisbio) and compounds. The reaction is allowed to proceed for two hours after which the plate is read on an Envision plate reader in HTRF mode. Data are expressed as a HTRF ratio.

For human FLAP binding assays, data are analyzed with 3DX Explorer software. A ratio is calculated with the relative light units at 520 nm over the relative light units at 495 nm. For analysis, data from multiple runs are averaged and each compound may be tested in 2 to 20 runs. Each run comprises two plates and each plate includes duplicates. Data from each plate is averaged and data are imported into 3DX. The data from multiple runs are aggregated as the average of duplicates of the calculated ratios in order to calculate K_(i) and IC₅₀ values. It will be understood that a calculated value of 0.000 in Table 5 indicates that the K_(i) is less than 1 nM. The letters ND and/or the absence of data in any of the boxes in Table 5 and Table 6 indicates that K_(i) or IC₅₀ values were not determined.

Human Whole Blood Assay

An in vitro cellular assay was performed using human whole blood collected in heparin-containing tubes, which was used to test the ability of compounds to modulate the leukotriene pathway in human whole blood. The blood was diluted 1:1 in RPMI medium, pre-incubated for 15 min at 37° Celsius with test compounds at various concentrations, and then stimulated with calcium ionophore, A23187 (7 μg/mL), for 30 min at 37° Celsius. The samples were then centrifuged and plasma was removed. The plasma was diluted in assay buffer and LTB₄ levels were measured using a commercial kit (Enzo Life Sciences). The concentration of each compound that was required for half-maximal inhibition (modulation) of recombinant enzyme activity (IC₅₀) was calculated by a 4-parameter equation using the program GraphPad Prism (GraphPad software).

TABLE 5 FLAP binding and Human Whole Blood assay data Cmp FLAP Binding wild type HTRF Human Whole Blood LTB4 IC₅₀ No. K_(i) (μM) 1:1 (μM) 1 0.217 0.860 2 0.286 0.358 3 >10 4 0.001 0.018 5 0.035 0.370 6 0.001 0.033 7 0.002 0.014 8 0.001 0.012 9 0.003 0.060 10 0.003 0.053 11 0.002 0.015 12 0.002 0.021 13 0.001 0.018 14 0.003 0.032 15 0.010 0.059 16 0.006 0.018 17 0.002 0.025 18 0.002 0.070 19 0.002 0.050 20 0.001 0.009 21 0.002 0.035 22 0.002 0.048 23 0.001 0.013 24 0.002 0.048 25 0.003 0.023 26 0.001 0.026 27 0.029 10.000 28 0.090 0.325 29 0.059 0.030 30 0.095 31 0.004 0.036 32 0.008 0.030 33 0.304 34 0.031 0.334 35 0.036 0.094 36 0.010 0.120 37 0.030 0.676 38 0.033 0.177 39 0.008 0.075 40 0.014 0.112 41 0.014 2.687 42 0.011 0.149 43 0.002 0.111 44 0.007 0.058 45 0.003 0.010 46 0.057 0.194 47 0.001 0.017 48 0.011 0.158 49 0.002 0.021 50 0.001 0.015 51 0.004 0.042 52 0.004 0.155 53 0.003 0.238 54 0.020 0.023 55 0.001 1.232 56 0.011 3.516 57 0.015 0.252 58 0.005 0.991 59 0.020 1.017 60 0.028 0.464 61 0.011 0.117 62 0.142 0.111 63 0.006 0.028 64 0.002 0.006 65 0.049 0.322 66 0.021 0.069 67 0.003 0.012 68 0.001 0.006 69 0.001 0.008 70 0.002 0.010 71 0.002 0.023 72 0.111 0.168 73 0.062 0.077 74 0.006 0.061 75 0.012 0.185 76 0.002 0.027 77 0.003 0.342 78 0.001 0.166 79 0.005 0.150 80 0.004 0.088 81 0.006 0.152 82 0.001 0.018 83 0.001 0.019 84 0.003 0.097 85 0.002 0.020 86 0.003 0.027 87 0.003 0.075 88 0.007 0.036 89 0.006 0.043 90 0.001 0.012 91 0.005 0.028 92 0.325 0.222 93 0.127 0.128 94 0.076 0.235 95 0.010 0.053 96 0.354 >10 97 0.008 0.042 98 0.008 0.039 99 0.002 0.030 100 0.001 0.024 101 0.002 0.014 102 0.000 0.035 103 0.000 0.017 104 0.012 >1 105 0.025 0.481 106 0.019 >1 107 0.016 0.132 108 0.010 0.049 109 0.001 0.018 110 0.003 0.029 111 0.004 0.058 112 0.007 0.154 113 0.010 0.145 114 0.012 0.221 115 0.004 0.108 116 0.001 0.012 117 0.001 0.007 118 0.000 0.006 119 0.003 0.022 120 0.001 0.017 121 0.000 0.010 122 0.001 0.018 123 0.083 1.125 124 0.035 0.217 125 0.050 >10 126 0.141 0.572 127 0.002 0.035 128 0.001 0.038 129 0.004 0.534 130 0.129 0.633 131 0.144 0.695 132 0.002 0.011 133 0.001 0.032 134 0.001 >1 135 0.000 0.016 136 0.001 0.015 137 0.003 0.044 138 0.011 0.174 139 0.133 0.341 140 0.001 0.011 141 0.001 0.003 142 0.015 0.041 143 0.008 0.049 144 0.015 0.097 145 0.017 0.021 146 0.019 0.168 147 0.001 0.102 148 0.002 0.008 149 0.005 0.082 150 0.001 0.011 151 0.001 0.114 152 0.081 0.537 153 0.003 0.007 154 0.029 1.044 155 0.012 0.103 156 0.351 >10 157 0.010 1.841 158 0.001 0.001 159 0.001 0.001 160 0.000 0.005 161 0.000 0.048 162 0.005 0.122 163 0.001 0.595 164 0.001 0.333 165 0.018 0.879 166 0.164 4.463 167 0.047 0.442 168 0.014 0.135 169 0.003 0.023 170 0.001 0.012 171 0.002 0.013 172 0.004 0.020 173 0.001 0.017 174 0.002 0.023 175 0.001 0.017 176 0.000 0.010 177 0.000 0.302 178 1.323 179 0.000 0.002 180 0.002 0.037 181 0.007 0.240 182 0.020 0.217 183 0.034 0.130 184 0.009 0.021 185 0.010 0.051 186 0.019 0.021 187 0.066 0.069 188 0.201 1.185 189 0.173 1.649 190 0.058 0.471 191 0.658 192 0.058 0.171 193 0.026 0.144 194 0.733 195 0.003 0.093 196 0.010 0.104 197 0.010 0.083 198 0.083 0.375 199 0.039 0.250 200 0.035 0.176 201 0.021 0.358 202 0.072 0.172 203 0.005 0.052 204 0.004 0.128 205 0.008 0.066 206 0.002 0.043 207 0.017 0.205 208 0.000 0.014 209 0.001 0.034 210 0.000 0.020 211 0.001 0.006 212 0.001 0.005 213 0.002 0.025 214 0.012 0.138 215 0.002 0.012 216 0.002 0.016 217 0.001 0.009 218 0.003 0.029 219 0.005 0.031 220 0.205 0.219 221 0.300 0.854 222 0.118 0.638 223 0.663 224 0.293 0.516 225 0.856 226 0.211 0.329 227 0.670 228 1.055 229 1.067 230 1.205 5.000 231 0.135 0.564 232 0.358 233 0.637 234 0.025 0.238 235 0.036 0.285 236 0.057 0.443 237 0.008 0.134 238 0.005 0.038 239 0.006 240 0.002 0.021 241 0.015 0.061 242 0.001 0.004 243 0.003 0.120 244 0.029 0.211 245 0.045 0.233 246 0.199 0.302 247 0.089 0.197 248 0.050 0.124 249 0.059 0.094 250 0.038 0.077 251 0.005 0.068 252 0.127 0.206 253 0.134 0.191 254 0.080 0.586 255 0.008 0.076 256 0.035 0.073 257 0.154 1.125 258 0.243 0.202 259 0.005 0.034 260 0.010 0.057 261 0.006 0.075 262 0.018 0.046 263 0.169 0.207 264 0.028 0.144 265 0.045 0.160 266 0.184 0.464 267 0.154 0.350 268 0.011 0.056 269 0.015 0.087 270 0.057 1.065 271 0.051 0.606 272 0.032 0.125 273 0.009 0.105 274 275 0.065 0.192 276 0.023 0.325 277 0.052 >1 278 0.036 0.095 279 0.070 0.149 280 0.003 0.087 281 0.061 0.044 282 0.750 0.280 283 0.009 0.119 284 0.042 1.037 285 0.003 0.111 286 0.142 0.206 287 0.009 0.074 288 0.103 0.420 289 0.022 0.036 290 0.940 291 0.007 0.421 292 0.012 1.029 293 >10 294 0.002 0.248 295 0.025 0.110 296 0.005 0.066 297 0.005 0.045 298 0.081 1.166 299 0.121 300 0.013 0.120 301 0.013 0.204 302 2.500 303 0.612 304 >10 305 0.002 0.078 306 0.397 307 0.004 0.416 308 >10 309 0.214 1.785 310 0.492 311 0.747 312 0.262 0.376 313 0.397 0.574 314 0.089 0.178 315 0.001 0.027 316 0.746 317 0.335 >10 318 0.689 2.001 319 0.204 3.263 320 0.129 1.084 321 0.505 8.486 322 0.032 0.138 323 0.770 6.644 324 0.019 0.101 325 0.004 0.091 326 0.003 0.029 327 0.002 0.039 328 0.015 0.119 329 0.012 0.066 330 0.012 0.088 331 0.014 0.062 332 0.065 0.125 333 0.045 0.671 334 0.012 0.067 335 0.002 0.037 336 0.004 0.065 337 2.500 338 0.199 1.094 339 2.500 340 0.104 0.321 341 >10 342 0.002 0.117 343 0.004 0.057 344 0.081 >10 345 0.028 0.259 346 0.005 0.095 347 0.077 0.161 348 0.005 0.106 349 0.001 0.013 350 0.002 0.026 351 0.017 0.297 352 0.016 0.064 353 0.001 0.020 354 0.037 0.093 355 0.005 0.029 356 0.032 0.107 357 0.114 1.128 358 0.055 >10 359 0.004 0.054 360 0.022 0.067 361 0.005 0.026 362 0.001 0.047 363 0.001 0.184 364 0.003 0.150 365 0.003 0.060 366 0.001 0.040 367 0.001 0.006 368 0.013 0.178 369 0.017 0.375 370 0.002 0.088 371 0.001 0.015 372 0.025 0.031 373 0.001 0.007 374 0.001 0.011 375 0.002 0.031 376 0.000 0.010 377 0.033 0.979 378 0.001 0.016 379 0.001 0.033 380 0.001 0.046 381 0.005 0.141 382 0.000 0.011 383 0.008 1.633 384 0.004 0.082 385 0.042 1.083 386 0.002 0.077 387 0.008 0.253 388 0.002 0.037 389 0.013 0.137 390 0.000 0.010 391 0.002 0.056 392 0.001 0.016 393 0.001 0.012 394 >10 395 0.009 0.032 396 0.008 0.137 397 >10 398 0.034 1.132 399 0.028 0.358 400 0.014 0.729 401 0.158 0.538 402 0.092 0.522 403 0.070 0.389 404 0.155 1.490 405 0.100 2.708 406 0.135 4.314 407 >10 408 0.128 1.142 409 >10 410 0.004 0.088 411 0.036 1.968 412 0.019 0.509 413 0.019 0.448 414 0.065 0.120 415 0.011 0.037 416 1.249 417 0.108 0.726 418 1.250 419 1.369 420 0.086 3.280 421 0.028 >10 422 0.003 0.146 423 0.284 4.795 424 0.010 >10 425 0.002 0.111 426 0.002 0.073 427 0.054 1.599 428 0.004 0.004 429 0.013 0.209 430 0.005 0.059 431 0.001 0.009 432 0.004 0.019 433 0.001 0.025 434 0.001 0.036 435 0.009 0.166 436 0.308 3.277 437 0.023 0.381 438 0.001 0.017 439 0.063 0.300 440 0.031 0.215 441 0.001 0.006 442 0.001 0.009 443 0.343 3.331 444 0.183 >10 445 0.001 0.008 446 0.304 1.371 447 0.003 0.144 448 0.010 0.112 449 0.022 0.079 450 0.074 0.340 451 0.002 0.038 452 0.081 1.954 453 >10 >10 454 0.012 0.345 455 0.001 0.094 456 0.003 0.114 457 0.003 0.140 458 0.004 0.053 459 >10 460 >10 461 0.041 0.209 462 0.002 0.062 463 0.982 464 0.121 >10 465 0.186 0.957 466 0.254 0.990 467 0.250 2.827 468 0.620 469 0.250 2.347 470 0.620 471 0.250 3.395 472 0.145 2.524 473 0.113 1.411 474 0.021 2.653 475 0.750 476 0.032 0.891 477 0.016 0.738 478 0.250 479 0.006 0.571 480 0.354 481 1.912 482 0.120 483 0.354 484 0.078 3.465 485 >10 486 2.500 487 0.054 0.444 488 0.097 1.653 489 0.020 0.307 490 0.354 0.269 491 0.015 0.215 492 0.015 0.155 493 0.007 0.303 494 0.032 0.099 495 0.004 0.509 496 0.019 0.165 497 0.025 0.510 498 0.016 0.111 499 0.433 500 0.048 0.139 501 0.359 502 0.083 0.363 503 0.014 0.092 504 0.768 505 0.018 0.071 506 >10 507 >10 508 0.790 509 0.147 0.093 510 1.939 511 0.213 0.323 512 0.443 0.470 513 >10 514 0.132 0.148 515 >10 516 >10 517 >10 518 >10 519 >10 520 >10 521 0.005 0.013 522 0.348 0.393 523 0.001 0.025 524 0.001 0.018 525 0.003 0.036 526 0.008 0.019 527 0.074 0.183 528 0.005 0.034 529 0.036 0.090 530 0.034 1.112 531 0.008 0.323 532 0.006 0.032 533 0.005 0.023 534 0.012 0.069 535 0.001 0.017 536 0.021 0.068 537 0.003 0.042 538 0.020 0.330 539 0.002 0.052 540 0.016 0.085 541 0.012 0.066 542 0.107 0.311 543 0.444 4.165 544 0.028 1.652 545 0.012 0.050 546 0.148 0.253 547 0.035 0.104 548 0.467 0.741 549 0.009 0.123 550 0.002 0.016 551 0.000 0.021 552 0.005 0.102 553 0.019 0.430 554 0.002 0.039 555 0.002 0.024 556 0.001 0.013 557 0.147 1.066 558 0.012 0.210 559 0.002 0.055 560 0.005 0.095 561 0.004 0.043 562 0.055 0.226 563 0.020 0.328 564 0.200 0.583 565 0.081 0.984 566 >10 567 1.135 568 2.500 569 0.070 0.335 570 0.035 1.183 571 0.002 0.091 572 0.370 573 0.114 574 0.015 0.494 575 0.750 576 0.008 0.116 577 0.010 0.091 578 0.025 0.956 579 0.095 1.544 580 0.055 5.000 581 0.060 2.823 582 >10 583 >10 584 >10 585 >10 586 >10 587 >10 588 0.133 >10 589 >10 590 >10 591 ~2.49 592 >10 593 >10 594 >10 595 ~2.49 596 >10 597 ~2.49 598 >10 599 >10 600 >10 601 >10 602 0.0006 0.0167 603 0.0276 >10 604 0.0050 0.0894 605 0.0019 0.0978 606 0.0463 2.624 607 0.1384 0.1520 608 0.0287 0.0539 609 0.2464 0.7677 610 0.0274 0.1170 611 0.2489 0.5626 612 0.0146 0.0420 613 0.2146 0.5565 614 615 616 617 618 0.0146 0.2109 619 0.0034 0.0451 620 0.0019 0.0132 621 0.0050 0.1006 622 0.0461 0.3401 623 0.0049 0.0935 624 625 0.0078 0.1727 626 0.0062 0.0453 627 0.0437 0.3661 628 0.3362 629 0.8358 630 1.8950 631 >10 632 1.2677 633 >10 634 0.3108 1.470 635 1.0869 636 0.0046 0.1072 637 0.0188 0.3975 638 0.0014 0.0148 639 0.0072 0.0670 640 1.3397 641 >10 642 0.0788 0.9806 643 0.3225 4.2874 644 >10 645 646 647 648 649 >10 650 0.8316 651 0.3062 1.5363 652 0.0627 0.8425 653 0.0173 0.5267 654 0.1303 1.0459 655 0.5034 1.8302 656 1.3957 657 0.0735 2.3415 658 0.5717 659 ~0.7500 660 0.0833 >10 661 ~2.49 662 ~1.22 663 0.0058 0.0347 664 0.0050 >1 665 0.0026 0.0224 666 0.0032 0.0361 667 0.0060 0.0396 668 0.0230 0.1897 669 0.0040 0.1064 670 0.0977 0.5255 671 0.0157 0.1645 672 0.0137 0.1964 673 0.1343 0.1013 674 0.0024 0.0174 675 0.0007 0.0551 676 0.2339 3.7145 677 >10 678 >10 679 0.1316 0.2054 680 0.6097 1.0502 681 0.0522 0.1057 682 0.2239 0.2638 683 0.6021 0.2800 684 0.0463 0.1342 685 0.0523 0.1148 686 0.3343 1.4900 687 0.7399 3.5456 688 0.6955 1.1844 689 0.4846 0.7872 690 0.1771 0.1175 691 >10 692 0.0533 0.1097 693 0.0495 0.1032 694 0.6762 1.0115 695 0.0084 0.3355 696 ~0.2499 3.27492 697 >10 698 0.0087 0.1117 699 700 >10 701 ~1.41 702 ~0.3041 703 >10 704 0.1025 0.1906 705 0.0869 0.2891 706 0.0796 0.3620 707 0.0327 0.1266 708 0.0235 0.1416 709 0.0054 0.2682 710 0.0137 0.05651 711 0.0417 0.1420 712 0.0019 0.05233 713 0.0017 0.05339 714 0.0024 0.03311 715 0.0082 0.1858 716 >10 717 1.0083 718 >10 719 >10 720 >10 721 >10 722 >10 723 >10 724 >10 725 1.2960 726 0.9041 727 0.4838 1.1740 728 0.7813 729 0.0647 0.8609 730 0.0067 0.1359 731 0.0147 0.05132 732 0.5571 733 >10 734 >10 735 0.0320 0.2722 736 0.3303 0.4144 737 0.9842 738 0.2400 2.9546 739 0.3701 1.1132 740 >10 741 0.0046 0.02633 742 0.0029 0.02572 743 0.0016 0.02165 744 0.0155 0.13173 745 0.0117 0.11073 746 0.0020 0.13699 747 0.0271 0.26224 748 >10 749 0.2455 0.46752 750 1.1582 751 0.0809 1.05657 752 0.1352 0.29915 753 0.0044 0.02130 754 0.0699 0.37722 755 0.9395 756 >10 757 0.0052 0.016206 758 0.5569 759 >10 760 1.1559 761 >10 762 0.1589 0.44177 763 1.1148 764 >10 765 >10 766 1.9090 767 >10 768 0.5728 769 1.5449 770 >10 771 >10 772 >10 773 0.2227 0.63899 774 775 776 777 778 >10 779 ~2.49 780 >10 781 0.7295 782 >10 783 >10 784 0.0079 0.1105 785 0.0085 0.0575 786 0.0607 0.10485 787 0.0091 0.0979 788 0.0178 0.2715 789 0.1303 0.9392 790 0.0015 0.02533 791 >10 792 >10 793 0.2795 0.6419 794 0.0328 3.9355 795 0.0085 0.0686 796 0.3912 797 >10 798 0.2573 0.220039 799 >10 800 >10 801 >10 802 >10 0.000993574 803 0.1065 0.241268 804 0.6359 805 0.0297 0.352777 806 0.0018 0.048395 807 0.0058 0.0721606 808 0.0004 0.00637236 809 0.0038 0.0376964 810 0.0006 0.00563897 811 0.3149 0.541252 812 0.0085 0.0120393 813 0.0339 0.0750585 814 0.0028 0.0209218 815 0.2555 0.128115 816 0.0218 0.0460044 817 0.4629 818 0.0272 0.051606 819 0.0405 0.0474898 820 0.0033 0.041639 821 >10 822 0.2804 0.099106 823 0.1923 0.0950605 824 0.0103 0.0180053 825 0.2732 0.122321 826 0.0007 0.0199205 827 >10 828 0.1153 0.259777 829 0.0032 0.00596486 830 0.0029 0.00555393 831 0.1309 0.0791589 832 1.3119 833 ~0.500034 834 0.0489 1.09069 835 ~0.35359 0.417157 836 0.0255 0.595114 837 ~1.74985 838 0.0286 0.350106 839 0.8297 2.78805 840 0.0127 0.0995864 841 0.1458 0.369658 842 0.0053 0.061038 843 0.0156 0.0442792 844 0.5093 0.907193 845 >10 846 0.0105 0.0418215 847 0.0081 0.0991289 848 0.0968 0.321736 849 0.0356 >1 850 0.0377 0.195434 851 0.0326 0.359335 852 0.1179 1.34555 853 0.0047 0.0456037 854 1.2773 855 >10 856 0.0605 0.083888 857 0.0280 0.205494 858 0.2097 0.369743 859 ~1.249 860 ~1.479

Certain compounds were tested in additional runs for the assays described above and the data is provided in Table 6.

TABLE 6 FLAP binding and Human Whole Blood assay data Cmp FLAP Binding wild type HTRF Human Whole Blood LTB4 IC₅₀ No. K_(i) (μM) 1:1 (μM) 1 0.3521 0.8596 2 0.1785 0.3582 3 >10 4 0.0004 0.0184 5 0.0366 0.3698 6 0.0011 0.0328 7 0.0008 0.0136 8 0.0013 0.0120 9 0.0015 0.0603 10 0.0027 0.0531 11 0.0016 0.0154 12 0.0019 0.0213 13 0.0012 0.0178 14 0.0035 0.0324 15 0.0111 0.0590 16 0.0050 0.0184 17 0.0017 0.0251 18 0.0018 0.0703 19 0.0022 0.0498 20 0.0009 0.0085 21 0.0021 0.0347 22 0.0021 0.0481 23 0.0012 0.0129 24 0.0023 0.0482 25 0.0032 0.0263 26 0.0009 0.0258 27 0.0263 ~10 28 0.0822 0.3246 29 0.0632 0.0301 30 0.0950 31 0.0040 0.0358 32 0.0062 0.0299 33 ~0.3041 34 0.0308 0.3340 35 0.0361 0.0944 36 0.0081 0.1366 37 0.0296 0.6761 38 0.0288 0.1773 39 0.0081 0.0751 40 0.0144 0.1118 41 0.0106 2.6866 42 0.0102 0.1493 43 0.0030 0.0381 44 0.0065 0.0582 45 0.0031 0.0102 46 0.0615 0.1774 47 0.0016 0.0166 48 0.0070 0.1583 49 0.0020 0.0211 50 0.0013 0.0154 51 0.0038 0.0424 52 0.0037 0.1551 53 0.0033 0.2377 54 0.0249 0.0413 55 0.0011 1.2317 56 0.0088 3.5164 57 0.0134 0.2517 58 0.0046 0.9911 59 0.0204 1.0170 60 0.0280 0.4638 61 0.0159 0.1173 62 0.1418 0.1111 63 0.0061 0.0284 64 0.0019 0.0131 65 0.0633 0.3224 66 0.0266 0.0689 67 0.0042 0.0168 68 0.0011 0.0109 69 0.0009 0.0081 70 0.0023 0.0100 71 0.0019 0.0227 72 0.1200 0.1682 73 0.0620 0.0769 74 0.0057 0.0610 75 0.0107 0.1851 76 0.0017 0.0267 77 0.0032 0.3416 78 0.0007 0.1663 79 0.0053 0.1498 80 0.0039 0.0881 81 0.0064 0.1518 82 0.0007 0.0181 83 0.0007 0.0191 84 0.0031 0.0975 85 0.0019 0.0199 86 0.0026 0.0266 87 0.0032 0.0752 88 0.0062 0.0364 89 0.0049 0.0432 90 0.0009 0.0125 91 0.0047 0.0383 92 0.2802 0.3092 93 0.0833 0.1275 94 0.0760 0.2347 95 0.0097 0.0515 96 0.3537 >10 97 0.0066 0.0422 98 0.0061 0.0391 99 0.0016 0.0301 100 0.0008 0.0245 101 0.0018 0.0137 102 0.0004 0.0345 103 0.0003 0.0165 104 0.0117 >1 105 0.0247 0.4805 106 0.0191 >1 107 0.0164 0.1316 108 0.0095 0.0486 109 0.0015 0.0181 110 0.0026 0.0294 111 0.0042 0.0576 112 0.0069 0.1543 113 0.0105 0.1451 114 0.0120 0.2215 115 0.0041 0.1080 116 0.0007 0.0122 117 0.0007 0.0066 118 0.0004 0.0063 119 0.0027 0.0217 120 0.0011 0.0171 121 0.0005 0.0096 122 0.0007 0.0179 123 0.0827 1.1249 124 0.0353 0.2172 125 0.0497 >10 126 0.1408 0.5717 127 0.0020 0.0346 128 0.0008 0.0382 129 0.0039 0.5341 130 0.1295 0.6326 131 0.1438 0.6947 132 0.0024 0.0111 133 0.0010 0.0320 134 0.0013 >1 135 0.0004 0.0161 136 0.0005 0.0155 137 0.0029 0.0438 138 0.0114 0.1737 139 0.1330 0.3409 140 0.0014 0.0106 141 0.0007 0.0033 142 0.0151 0.0406 143 0.0085 0.0488 144 0.0148 0.0971 145 0.0167 0.0209 146 0.0191 0.1684 147 0.0006 0.1021 148 0.0025 0.0083 149 0.0052 0.0824 150 0.0015 0.0113 151 0.0013 0.1140 152 0.0807 0.5365 153 0.0025 0.0069 154 0.0293 1.0445 155 0.0116 0.1025 156 0.3513 >10 157 0.0098 1.8408 158 0.0006 0.0014 159 0.0008 0.0013 160 0.0004 0.0053 161 0.0004 0.0478 162 0.0051 0.1223 163 0.0005 0.5953 164 0.0008 0.3332 165 0.0184 0.8790 166 0.1645 4.4627 167 0.0468 0.4416 168 0.0143 0.1348 169 0.0029 0.0229 170 0.0013 0.0118 171 0.0020 0.0135 172 0.0036 0.0201 173 0.0008 0.0165 174 0.0024 0.0231 175 0.0014 0.0170 176 0.0005 0.0100 177 0.0005 0.3016 178 ~1.3228 179 0.0004 0.0021 180 0.0021 0.0369 181 0.0067 0.2397 182 0.0199 0.2171 183 0.0344 0.1300 184 0.0089 0.0206 185 0.0095 0.0507 186 0.0188 0.0207 187 0.0657 0.0689 188 0.2014 1.1849 189 0.0632 1.6493 190 0.0662 0.4710 191 ~0.6579 192 0.0483 0.1708 193 0.0309 0.1439 194 0.1558 195 0.0023 0.0690 196 0.0078 0.0963 197 0.0071 0.0831 198 0.0721 0.8194 199 0.0386 0.2518 200 0.0349 0.1762 201 0.0207 0.3582 202 0.0716 0.1721 203 0.0050 0.0523 204 0.0045 0.1282 205 0.0076 0.0656 206 0.0020 0.0427 207 0.0171 0.2046 208 0.0004 0.0137 209 0.0010 0.0340 210 0.0004 0.0196 211 0.0005 0.0058 212 0.0008 0.0053 213 0.0024 0.0246 214 0.0116 0.1378 215 0.0024 0.0116 216 0.0022 0.0160 217 0.0012 0.0089 218 0.0033 0.0291 219 0.0048 0.0312 220 0.2052 0.2186 221 0.3001 0.8543 222 0.1176 0.6381 223 0.6628 224 0.2926 0.5158 225 0.8561 226 0.2108 0.3289 227 0.6699 228 1.0554 229 1.0673 230 1.2050 ~5.00034 231 0.1354 0.5639 232 0.3575 233 0.6365 234 0.0255 0.2382 235 0.0357 0.2848 236 0.0571 0.4431 237 0.0078 0.1338 238 0.0050 0.0379 239 0.0059 240 0.0024 0.0215 241 0.0146 0.0605 242 0.0007 0.0039 243 0.0033 0.1199 244 0.0294 0.2109 245 0.0453 0.2330 246 0.1990 0.3017 247 0.0894 0.1968 248 0.0568 0.1237 249 0.0595 0.0940 250 0.0382 0.0774 251 0.0045 0.0678 252 0.1267 0.2055 253 0.1344 0.1906 254 0.0800 0.5856 255 0.0081 0.0761 256 0.0350 0.0734 257 0.1537 1.1249 258 0.2430 0.2021 259 0.0078 0.0340 260 0.0089 0.0566 261 0.0056 0.0749 262 0.0183 0.0456 263 0.1272 0.2074 264 0.0276 0.1439 265 0.0355 0.1600 266 0.1330 0.4639 267 0.1854 0.3504 268 0.0114 0.0559 269 0.0149 0.0873 270 0.0573 1.0654 271 0.0505 0.6062 272 0.0269 0.1246 273 0.0093 0.1047 274 275 0.0648 0.1921 276 0.0235 0.3248 277 0.0516 >1 278 0.0356 0.0945 279 0.0700 0.1176 280 0.0033 0.0872 281 0.0608 0.0445 282 ~0.7500 0.2799 283 0.0090 0.1187 284 0.0423 1.0373 285 0.0033 0.1110 286 0.1419 0.2060 287 0.0085 0.0744 288 0.1028 0.4201 289 0.0216 0.0361 290 ~0.9401 291 0.0067 0.4205 292 0.0099 1.0294 293 >10 294 0.0024 0.2477 295 0.0200 0.1097 296 0.0031 0.0660 297 0.0032 0.0446 298 0.0806 1.1657 299 0.1212 300 0.0128 0.1205 301 0.0126 0.2044 302 ~2.4997 303 ~0.612351 304 >10 305 0.0016 0.0776 306 0.3974 307 0.0045 0.4158 308 >10 309 0.2143 1.7848 310 0.4919 311 0.7466 312 0.3226 0.3764 313 0.3877 0.5739 314 0.0888 0.1776 315 0.0013 0.0272 316 0.7456 317 0.3346 >10 318 0.6890 2.0012 319 0.2036 3.2629 320 0.1293 1.0839 321 0.5055 8.4859 322 0.0324 0.1382 323 0.7702 6.6435 324 0.0188 0.1014 325 0.0047 0.0908 326 0.0031 0.0287 327 0.0018 0.0386 328 0.0154 0.1187 329 0.0120 0.0658 330 0.0119 0.0883 331 0.0144 0.0619 332 0.0654 0.1245 333 0.0448 0.6710 334 0.0117 0.0672 335 0.0019 0.0370 336 0.0042 0.0651 337 ~2.49977 338 0.1992 1.0937 339 ~2.49977 340 0.1043 0.3210 341 >10 342 0.0018 0.1167 343 0.0043 0.0568 344 0.0812 >10 345 0.0277 0.2591 346 0.0045 0.0946 347 0.0769 0.1612 348 0.0050 0.1059 349 0.0009 0.0128 350 0.0024 0.0259 351 0.0165 0.2966 352 0.0158 0.0642 353 0.0014 0.0198 354 0.0365 0.0930 355 0.0049 0.0294 356 0.0320 0.1066 357 0.1139 1.1282 358 0.0550 >10 359 0.0043 0.0541 360 0.0216 0.0675 361 0.0052 0.0262 362 0.0012 0.0472 363 0.0006 0.1840 364 0.0025 0.1498 365 0.0029 0.0600 366 0.0010 0.0399 367 0.0009 0.0056 368 0.0132 0.1780 369 0.0173 0.3751 370 0.0019 0.0880 371 0.0007 0.0150 372 ~0.0249977 0.0313 373 0.0008 0.0066 374 0.0012 0.0115 375 0.0021 0.0313 376 0.0005 0.0099 377 0.0330 0.9786 378 0.0006 0.0163 379 0.0013 0.0334 380 0.0011 0.0460 381 0.0048 0.1405 382 0.0005 0.0110 383 0.0079 1.6334 384 0.0039 0.0819 385 0.0419 1.0829 386 0.0018 0.0773 387 0.0080 0.2528 388 0.0017 0.0367 389 0.0131 0.1371 390 0.0004 0.0096 391 0.0020 0.0563 392 0.0009 0.0163 393 0.0010 0.0124 394 >10 395 0.0088 0.0269 396 0.0076 0.1372 397 >10 398 0.0344 1.1316 399 0.0285 0.3583 400 0.0141 0.7291 401 0.1581 0.5379 402 0.0921 0.5223 403 0.0698 0.3889 404 0.1547 1.4904 405 0.0998 2.7077 406 0.1347 4.3142 407 >10 408 0.1284 1.1424 409 >10 410 0.0037 0.0884 411 0.0360 1.9679 412 0.0193 0.5087 413 0.0186 0.4476 414 0.0655 0.1204 415 0.0109 0.0370 416 1.2485 417 0.1082 0.7264 418 ~1.2499 419 ~1.3693 420 0.0856 3.2802 421 0.0283 >10 422 0.0031 0.1460 423 0.2841 4.7951 424 0.0103 >10 425 0.0023 0.1108 426 0.0020 0.0731 427 0.0439 1.5992 428 0.0043 0.0044 429 0.0131 0.2089 430 0.0051 0.0592 431 0.0008 0.0094 432 0.0042 0.0188 433 0.0011 0.0254 434 0.0011 0.0362 435 0.0094 0.1657 436 0.3075 3.2772 437 0.0233 0.3809 438 0.0007 0.0166 439 0.0629 0.3005 440 0.0309 0.2155 441 0.0008 0.0065 442 0.0009 0.0090 443 0.3430 3.3312 444 0.1826 >10 445 0.0005 0.0077 446 0.3044 1.3709 447 0.0031 0.1441 448 0.0101 0.1119 449 0.0216 0.0788 450 ~0.0740 0.3398 451 0.0024 0.0385 452 ~0.0805 1.9543 453 >10 >10 454 0.0115 0.3450 455 0.0007 0.0943 456 0.0026 0.1139 457 0.0027 0.1400 458 0.0042 0.0530 459 >10 460 >10 461 0.0405 0.2088 462 0.0023 0.0616 463 ~0.9819 464 0.1209 >10 465 0.1860 0.9565 466 ~0.2544 0.9901 467 0.0535 2.8275 468 0.3317 469 0.1790 2.3469 470 0.3973 471 0.0558 3.3947 472 0.1360 2.5241 473 0.0730 1.4109 474 0.0215 2.6534 475 0.0896 4.1812 476 0.0241 0.3500 477 0.0147 0.2678 478 ~0.2499 479 0.0077 0.5710 480 ~0.3535 481 1.9116 482 0.0609 0.3203 483 ~0.35359 484 0.0759 3.4650 485 >10 486 ~2.4997 487 0.0543 0.4443 488 0.0975 1.6527 489 0.0196 0.3069 490 ~0.3535 0.2691 491 0.0146 0.2147 492 0.0154 0.1555 493 0.0069 0.3030 494 0.0316 0.0993 495 0.0041 0.5091 496 0.0188 0.1653 497 0.0251 0.5103 498 0.0157 0.1113 499 0.4330 500 0.0485 0.1386 501 0.3591 502 0.0833 0.3626 503 0.0140 0.0923 504 0.7679 505 0.0181 0.0705 506 >10 507 >10 508 0.7905 509 0.1473 0.1598 510 1.9387 511 0.2128 0.3231 512 0.4430 0.4699 513 >10 514 0.1319 0.1477 515 >10 516 >10 517 >10 518 >10 519 >10 520 >10 521 0.0054 0.0133 522 0.2861 0.2639 523 0.0013 0.0251 524 0.0007 0.0182 525 0.0030 0.0365 526 0.0083 0.0188 527 0.0743 0.1829 528 0.0055 0.0340 529 0.0362 0.0796 530 0.0344 1.1117 531 0.0085 0.3234 532 0.0060 0.0318 533 0.0045 0.0227 534 0.0118 0.0689 535 0.0015 0.0155 536 0.0214 0.0678 537 0.0030 0.0421 538 0.0202 0.3298 539 0.0016 0.0521 540 0.0163 0.0850 541 0.0118 0.0660 542 0.1070 0.3112 543 0.4438 4.1649 544 0.0282 1.6516 545 0.0115 0.0504 546 0.1480 0.2531 547 0.0348 0.1042 548 0.4672 0.7408 549 0.0094 0.1228 550 0.0017 0.0160 551 0.0004 0.0209 552 0.0055 0.1020 553 0.0193 0.4304 554 0.0021 0.0390 555 0.0016 0.0245 556 0.0007 0.0131 557 0.1471 1.0659 558 0.0120 0.2100 559 0.0015 0.0547 560 0.0052 0.0951 561 0.0044 0.0429 562 0.0548 0.2259 563 0.0197 0.3276 564 0.2001 0.5828 565 0.0813 0.9836 566 >10 567 1.1347 568 ~2.499 569 ~0.0700 0.3345 570 0.0355 1.1833 571 0.0017 0.0907 572 ~0.3699 573 0.1136 574 0.0139 0.4942 575 ~0.7500 576 0.0079 0.1157 577 0.0102 0.0907 578 0.0252 0.9557 579 0.0951 1.5442 580 0.0548 ~5.00034 581 0.0596 2.8229 582 >10 583 >10 584 >10 585 >10 586 >10 587 >10 588 0.1333 >10 589 >10 590 >10 591 ~2.4997 592 >10 593 >10 594 >10 595 ~2.4997 596 >10 597 ~2.4997 598 >10 599 >10 600 >10 601 >10 602 0.0006 0.0167 603 0.0276 >10 604 0.0050 0.0895 605 0.0019 0.0979 606 0.0463 2.6242 607 0.1384 0.1521 608 0.0287 0.0539 609 0.2464 0.7677 610 0.0274 0.1171 611 0.2489 0.5626 612 0.0146 0.0420 613 0.2146 0.5565 614 0.0098 615 0.0509 616 0.0164 617 0.1615 618 0.0146 0.2109 619 0.0034 0.0451 620 0.0019 0.0132 621 0.0050 0.1007 622 0.0461 0.3402 623 0.0049 0.0935 624 0.0327 625 0.0078 0.1727 626 0.0062 0.0454 627 0.0437 0.3662 628 0.3362 629 0.8358 630 1.8950 631 >10 632 1.2677 633 >10 634 0.3108 1.4706 635 1.0869 636 0.0046 0.1073 637 0.0188 0.3976 638 0.0014 0.0148 639 0.0072 0.0671 640 1.3397 641 >10 642 0.0788 0.9806 643 0.3225 4.2875 644 >10 645 >10 646 >10 647 0.2271 648 0.8339 649 >10 650 0.8316 651 0.3062 1.5364 652 0.0627 0.8426 653 0.0173 0.5267 654 0.1303 1.0459 655 0.5034 1.8302 656 1.3957 657 0.0735 2.3415 658 0.5717 659 ~0.7500 660 0.0833 >10 661 ~2.4997 662 ~1.2246 663 0.0058 0.0347 664 0.0050 >1 665 0.0026 0.0224 666 0.0032 0.0361 667 0.0060 0.0396 668 0.0230 0.1897 669 0.0040 0.1064 670 0.0977 0.5255 671 0.0157 0.1646 672 0.0137 0.1965 673 0.1343 0.1013 674 0.0036 0.0133 675 0.0010 0.0551 676 0.2339 3.7145 677 >10 678 >10 679 0.1316 0.2054 680 0.6097 1.0503 681 0.0522 0.1058 682 0.2239 0.2638 683 0.6021 0.2800 684 0.0463 0.1343 685 0.0592 0.1150 686 0.3343 1.4900 687 0.7399 3.5457 688 0.6955 1.1844 689 0.4846 0.7872 690 0.1771 0.1175 691 >10 692 0.0533 0.1098 693 0.0495 0.1033 694 0.6762 1.0116 695 0.0084 0.3356 696 0.1410 3.2749 697 >10 698 0.0087 0.1117 699 700 >10 701 0.1318 702 ~0.3041 703 >10 704 0.1025 0.1907 705 0.0869 0.2891 706 0.0796 0.3621 707 0.0327 0.1267 708 0.0235 0.1416 709 0.0054 0.2682 710 0.0137 0.0565 711 0.0417 0.1420 712 0.0019 0.0523 713 0.0017 0.0534 714 0.0024 0.0331 715 0.0082 0.1858 716 >10 717 1.0083 718 >10 719 >10 720 >10 721 >10 722 >10 723 >10 724 >10 725 1.2960 726 0.9041 727 0.4838 1.1741 728 0.7813 729 0.0647 0.8610 730 0.0067 0.1359 731 0.0147 0.0513 732 0.5571 733 >10 734 >10 735 0.0320 0.2723 736 0.3303 0.4145 737 0.9842 738 0.2400 2.9546 739 0.3701 1.1133 740 >10 741 0.0046 0.0263 742 0.0029 0.0257 743 0.0016 0.0217 744 0.0155 0.1317 745 0.0117 0.1107 746 0.0020 0.1370 747 0.0271 0.2622 748 >10 749 0.2455 0.4675 750 1.1582 751 0.0809 1.0566 752 0.1352 0.2992 753 0.0044 0.0213 754 0.0699 0.3772 755 0.9395 756 >10 757 0.0052 0.0162 758 0.5569 759 >10 760 1.1558 761 >10 762 0.1589 0.4418 763 1.1148 764 >10 765 >10 766 1.9090 767 >10 768 0.5728 769 1.5449 770 >10 771 >10 772 >10 773 0.2227 0.6390 774 1.2975 775 0.0304 776 0.1497 777 1.6211 778 >10 779 ~2.4997 780 >10 781 0.7295 782 >10 783 >10 784 0.0079 0.1105 785 0.0085 0.0576 786 0.0607 0.1049 787 0.0091 0.0980 788 0.0178 1.8026 789 0.1303 0.9386 790 0.0015 0.0253 791 >10 792 >10 793 0.2795 0.6419 794 0.0328 3.9355 795 0.0085 0.0686 796 0.3912 797 >10 798 0.2573 0.2200 799 >10 800 >10 801 >10 802 >10 >1 803 0.1065 0.2413 804 0.6359 805 0.0297 0.3528 806 0.0018 0.0484 807 0.0058 0.0722 808 0.0004 0.0064 809 0.0038 0.0377 810 0.0006 0.0056 811 0.3149 0.5413 812 0.0085 0.0120 813 0.0339 0.0751 814 0.0028 0.0209 815 0.2555 0.1281 816 0.0370 0.0610 817 0.4629 818 0.0272 0.0516 819 0.0743 0.0475 820 0.0033 0.0416 821 >10 822 0.2804 0.0991 823 0.1923 0.0951 824 0.0103 0.0180 825 0.2732 0.1223 826 0.0007 0.0199 827 >10 828 0.1153 0.2598 829 0.0057 0.0090 830 0.0029 0.0056 831 0.1492 0.0725 832 1.3119 833 ~0.5000 834 0.0489 1.0907 835 ~0.35359 0.4172 836 0.0255 0.5951 837 ~1.74985 838 0.0286 0.3501 839 0.8297 2.7880 840 0.0127 0.0996 841 0.1458 0.3697 842 0.0053 0.0610 843 0.0156 0.0443 844 0.5093 0.9072 845 >10 846 0.0105 0.0418 847 0.0081 0.0991 848 0.0968 0.3217 849 0.0383 3.9030 850 0.0377 0.1954 851 0.0326 0.3593 852 0.1179 1.3456 853 0.0047 0.0456 854 1.2773 855 >10 856 0.0605 0.0839 857 0.0280 0.2055 858 0.2097 0.3697 859 ~1.2499 860 ~1.4791 861 0.0040 0.0449 862 0.1221 0.1210 863 0.0411 0.1401 864 0.2164 0.4128 865 0.0962 0.1924 866 0.1705 0.5388 867 0.2463 0.7930 868 0.0215 0.3446 869 0.1412 0.8437 870 0.0143 0.0867 871 0.0250 0.3714 872 0.0083 0.0530 873 0.0231 0.3355 874 0.0511 0.3588 875 0.1699 0.8511 876 0.0803 1.0770 877 0.0047 0.0105 878 0.2762 0.3202 879 0.1681 0.1064 880 0.0867 0.1796 881 0.0760 0.1282 882 0.1666 0.0688 883 0.0342 0.0695 884 0.2387 0.7055 885 0.0408 1.0573 886 0.0058 >1 887 0.0304 >1 888 0.0007 0.3666 889 0.0039 0.2358 890 0.0037 0.0623 891 0.0315 0.7516 892 0.0774 0.7311 893 0.0303 0.6027 894 0.0038 0.1411 895 0.0132 0.2220 896 0.0221 0.4664 897 0.0070 0.0903 898 0.0797 0.9281 899 0.0770 0.0873 900 0.0351 0.0408 901 0.0018 0.0016 902 0.0184 0.0886 903 0.0387 0.0634 904 0.2547 0.1046 905 0.0579 0.0529 906 0.0003 0.0020 907 0.0060 0.0120 908 0.0266 0.0437 909 0.2528 0.1166 910 0.0029 0.0092 911 0.1663 0.0287 912 0.0005 0.0088 913 0.0063 0.0119

Throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.

While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents. 

1. A compound of Formula (I)

wherein L is a bond, —CH₂—, —SO₂—, —CH₂—SO₂—, —SO₂—CH₂—, —SO₂—NR—, —SO₂—NR—CH₂—, —CH₂—SO₂—NR—, —NR—, —NR—SO₂—, —NR—SO₂—NR—, —S—, S—CH₂—, —CH₂—S—, —C(═O)—, —C(═O)—O—, —O—, —O—CH₂—, —NR—C(═O)—, —NR—C(═O)—NR—, or —C(═O)—NR—, wherein R is H, C₁₋₂alkyl, C₁₋₂alkyl-OH or cyclopropyl; R₁ is H, halo, methyl, CF₃, —O—CF₃, or —O— CH₃; R₂ is H, cyano, halo, —SO₂—CH₃, 2-(trimethylsilyl)ethoxy, phenyl, C₁₋₆-alkyl, heteroaryl, heterocyclyl, C₃₋₉cycloalkyl, provided R₂ is not H if L is a bond, and wherein said phenyl, C₁₋₆alkyl, heteroaryl, heterocyclyl or C₃₋₉cycloalkyl is optionally and independently substituted with 1-4 substituents selected from the group consisting of: methyl, ethyl, oxo, fluoro, hydroxyl, cyano, amino, methoxy, tert-butoxy, acetyl, cyclopropyl, cyclobutyl, cyclohexyl, phenyl, azetidin-1-yl, azetidin-3-yl, pyrrolidin-1-yl, 2,4-dihydro-3H-1,2,4-triazol-3-one-4-yl, 1H-imidazol-4-yl, pyrazin-2-yl, pyrimidin-2-yl, 1,3-oxazolidin-2-one-5-yl, N-benzamide, benzo[d]imidazol-2(3H)-one, 4-methylpiperazin-1-yl, morpholin-4-yl, CF₃, —SO₂—CH₃, —C(═O)-cyclopropyl, —SO₂-cyclohexyl, —NHCH₃, —N(CH₃)₂, —NHAc, —NHCO₂t-Bu, —CH₂—NH₂, —C(═O)—NH₂, —C(═O)—N(ethyl)₂, —NH—C(═O)—NH₂, —NH—C(═O)—CH₃, —C(═O)—(C₁-C₄alkyl), —C(═O)—OH, —C(═O)—NH(C₁-C₄alkyl) —(CH₂)_(n)—OH, and —(CH₂)_(n)—CN, wherein n is 1 or 2; V is CH, CR′, or N, wherein R is methyl or F; W is CR″ or N, wherein R″ is H, F, hydroxyl, amino, CH₃ or —O—CH₃; ring A is selected from the group consisting of:

R₃ is H, F, methyl, or —O—CH₃; R₃′ is H or F; R₄ is H, methyl, cyano, amino, halo, —COOH, or —O—CH₃; R₅ is H, methyl, cyano, or —CF₃; R₆ is H, cyano, amino, halo, or —CF₃; and R₇ is halo, amino, —CONH₂, cyano, —O—CH₃, —CF₃, or —COO-ethyl; or a pharmaceutically acceptable salt thereof.
 2. The compound of claim 1, wherein L is a bond, —O—, —SO₂—NH—, —NH—SO₂—, —SO₂—, —S—, —C(═O)—, fluoro or —C(═O)—NH—; R₁ is H, bromo or CF₃; R₂ is H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclohexyl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, tetrahydro-2H-thiopyran-4-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, pyrazin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl, provided R₂ is not H if L is a bond, and wherein R₂ is optionally substituted with hydroxyl, fluoro, amino, oxo, methyl, or —CH₂—NH₂; V is CH or N; W is CR″ or N, wherein R″ is H or F; ring A is

R₃ is H; R₃′ is H; R₄ is H or cyano; and R₅ is H or cyano; or a pharmaceutically acceptable salt thereof.
 3. The compound of claim 1, wherein L is a bond, —O—, —SO₂—NH—, —NH—SO₂—, —SO₂—, —S—, or —C(═O)—; R₁ is H or CF₃; R₂ is H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclohexyl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, tetrahydro-2H-thiopyran-4-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, pyrazin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl, provided R₂ is not H if L is a bond, and wherein R₂ is optionally substituted with hydroxyl, fluoro, amino, oxo, methyl, or —CH₂—NH₂; V is CH or N; W is CR″ or N, wherein R″ is H or F; ring A is

R₃ is H; and R₃′ is H; or a pharmaceutically acceptable salt thereof.
 4. The compound of claim 1, wherein the compound is selected from: 5-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide, 6-Amino-3-[3-fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazine-2-carbonitrile, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-methylpropyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-methylethyl)biphenyl-2-sulfonamide (racemic), 4′-(5-Aminopyrazin-2-yl)-N-(cyclobutylmethyl)-3′-fluorobiphenyl-2-sulfonamide, (endo)-4′-(5-Aminopyrazin-2-yl)-N-bicyclo[2.2.1]hept-2-yl-3′-fluorobiphenyl-2-sulfonamide (racemic), 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-methylcyclobutyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(1,1-dimethylpropyl)-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1-dimethylethyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-cyclopentyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-phenylethyl)biphenyl-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(2,3-dihydro-1H-inden-2-yl)-3′-fluorobiphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-3′-fluorobiphenyl-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-3′-fluorobiphenyl-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1-phenylethyl]biphenyl-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-N-[(3S)-1-ethyl-2-oxoazepan-3-yl]-3′-fluorobiphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-2-oxoazepan-3-yl]biphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-1-methyl-2-oxoazepan-3-yl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-pyridin-3-ylbiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfamide, N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)propane-2-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]propane-1-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-2-methylpropane-1-sulfonamide, N-(4′-(5-aminopyrazin-2-yl))-3′-fluoro-[1,1′-biphenyl]-2-yl)cyclopropanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]hexane-1-sulfonamide, N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)cyclobutanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-, 1,1-trifluoromethanesulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N,N-dimethylbiphenyl-2-sulfonamide, 5-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-[3-Fluoro-2′-(piperazin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide, 5-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(4,4-Difluoropiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(3,3-Difluoropiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(3,3-Difluoroazetidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-[2′-(Azepan-1-ylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-(trifluoromethyl)piperidin-4-ol, 5-(3-Fluoro-2′-{[4-(methylsulfonyl)piperazin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine, 5-{2′-[(4-Acetylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-(2′-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine, 2-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-1-yl)ethanol, 5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, racemic 5-[3-Fluoro-2′-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(3,5-Dimethylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine-3-carbonitrile, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine-4-carbonitrile, 5-{2′-[(4-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-one, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-ol, (1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)methanol, 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)ethanol, racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-ol, racemic 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)ethanol, 5-(3-Fluoro-2′-{[4-(methylamino)piperidin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine, 5-(2′-{[4-(Dimethylamino)piperidin-1-yl]sutfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine, racemic 5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, N-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)acetamide, racemic (1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)methanol, racemic tert-Butyl (1-{[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)carbamate, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxypropyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2R)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)propyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2S)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2-sulfonamide, (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)pyrrolidin-2-yl)methanol, (R)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, (S)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, (R) 5-(2′-{[2-(Aminomethyl)pyrrolidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine, (S)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)pyrrolidin-2-yl)methanol, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(methylsulfonyl)biphenyl-2-sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′-biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1-hydroxycyclohexyl)methyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-1,1-dimethylethyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-methylpropyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-1,1-dimethylpropyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, (trans)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3,4-diol, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopyrrolidin-3-yl)-[1,1′-biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)-[1,1′-biphenyl]-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1-(hydroxymethyl)-2-methylpropyl]biphenyl-2-sulfonamide, trans 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-sulfonamide, (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)pyrrolidin-3-yl)methanol, (S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-3-yl)methanol, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)biphenyl-2-sulfonamide, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3-ylbiphenyl-2-sulfonamide, (S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3-ylbiphenyl-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-phenylpropan-2-yl)-[1,1-biphenyl]-2-sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-phenylethyl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin-3-ol, racemic (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxycyclohexyl)biphenyl-2-sulfonamide, racemic (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-(hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide, racemic (cis)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-(hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-piperidin-4-ylbiphenyl-2-sulfonamide, 5-(2′-{[3-(Aminomethyl)azetidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-(azetidin-3-ylmethyl)-3′-fluorobiphenyl-2-sulfonamide, (R)-5-(3-Fluoro-2′-{[3-(methylamino)pyrrolidin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine, (R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-methylethyl)biphenyl-2-sulfonamide, 5-[3-Fluoro-2′-(1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, 5-(2′-((1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, 5-(2′-((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-hydroxypentyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(6-hydroxyhexyl)biphenyl-2-sulfonamide, N-(4-Aminocyclohexyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide, (S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2,3-dihydro-1H-indol-2-yl)methanol, 4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide, (S)-5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N,N-bis(2-hydroxyethyl)biphenyl-2-sulfonamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidine-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluoro-N-(tetrahydro-2H-pyran-4-yl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1-methylethyl)biphenyl-2-sulfonamide, racemic (4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}morpholin-2-yl)methanol, (1R,5S)-3-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-azabicyclo[3.1.0]hexan-6-amine, (S)-5-(3-fluoro-2′-((2-methylpiperazin-1-yl)sulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, (R)-5-(3-fluoro-2′-((2-methylpiperazin-1-yl)sulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, (R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperazin-2-yl)methanol, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]biphenyl-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-methylbutan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, tert-Butyl [2-({[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}amino)ethyl]carbamate, N-(2-Aminoethyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxybutan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(pyrrolidin-3-yl)-[1,1′-biphenyl]-2-sulfonamide, N-[2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}amino)ethyl]acetamide, (S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-ylsulfonamido)propanoic acid, 4′-(5-Aminopyrazin-2-yl)-N-[2-(carbamoylamino)ethyl]-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxycyclohexyl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[6-(trifluoromethyl)pyridin-3-yl]biphenyl-2-sulfonamide, 5-(3-Fluoro-2′-{[4-(1H-imidazol-4-yl)piperidin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine, N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(2,6-dimethoxypyrimidin-4-yl)-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-methylpyrazin-2-yl)biphenyl-2-sulfonamide, (S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-ylsulfonamido)-4-methylpentanamide, 4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2-sulfonamide, (R)-4′-(5-aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, (S)-4′-(5-aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-methyloxetan-3-yl)biphenyl-2-sulfonamide, 3-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-1-yl)propanenitrile, (S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-methoxypropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, 5-{3-Fluoro-2′-[(4-pyrazin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(4-pyrimidin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine, 5-(2′-Amino-3-fluorobiphenyl-4-yl)pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1-(hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3-phenylpyrrolidin-3-ol, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,N-dimethylsulfamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]morpholine-4-sulfonamide, (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-3-ol, (3R)-1-{[4′-(5-Aminopyrazin-2-yl-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-3-ol, (3′S,4′S)-1′-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-1,3′-bipyrrolidin-4′-ol, (3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-morpholin-4-ylpyrrolidin-3-ol, (3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-(4-methylpiperazin-1-yl)pyrrolidin-3-ol, 5-{3-Fluoro-2′-[(trifluoromethyl)-sulfanyl]biphenyl-4-yl}pyrazin-2-amine, 5-[2′-(tert-Butylsulfanyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(Ethylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(propylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{3-Fluoro-2′-[(2-methylpropyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine, 5-[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(Cyclopentylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(Cyclobutylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-{3-Fluoro-2′-[(1-methylethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(trifluoromethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}acetamide, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}-N,N-diethylacetamide, 5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfanyl]biphenyl-4-yl}pyrazin-2-amine, (racemic) 5-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}methyl)-1,3-oxazolidin-2-one, N-(2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}ethyl)benzamide, 5-(3-Fluoro-2′-{[4-(methylsulfonyl)benzyl]sulfanyl}biphenyl-4-yl)pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide, 5-[3-Fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-4-(trifluoromethyl)biphenyl-2-sulfonamide, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]sulfonyl}piperazin-2-one, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide, 5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine hydrochloride, 5-[3-Fluoro-2′-(pyrimidin-4-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine formate salt, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4-amine hydrochloride, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4-amine hydrochloride, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5-amine hydrochloride, 5-[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine hydrochloride, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5-amine hydrochloride, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylmethanesulfonamide formic acid salt, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-(2-hydroxyethyl)methanesulfonamide formic acid salt, 1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)azetidin-3-ol formic acid salt, 4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)piperazin-2-one formic acid salt, (S)-1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1-hydroxypropan-2-yl)methanesulfonamide, (R)-1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1-hydroxypropan-2-yl)methanesulfonamide hydrochloride, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-Nrans-4-hydroxycyclohexyl)methanesulfonamide, (S)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2-hydroxypropyl]methanesulfonamide hydrochloride, (R)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2-hydroxypropyl]methanesulfonamide, 5-(2′-{[(4-Aminopiperidin-1-yl)sulfonyl]methyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine hydrochloride, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide hydrochloride, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-ethylmethanesulfonamide formate salt, 1-[1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)piperidin-4-yl]urea hydrochloride, N-[1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)piperidin-4-yl]acetamide formate salt, 5-{2′-[(Ethylsulfanyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine formate salt, 5-{3-Fluoro-2′-[(methylsulfanyl)methyl]biphenyl-4-yl}pyrazin-2-amine hydrochloride, 5-(3-Fluoro-2′-{[(1-methylethyl)sulfanyl]methyl}biphenyl-4-yl)pyrazin-2-amine hydrochloride, 2-(((4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methyl)thio)pyrimidin-4-amine hydrochloride, 6-(((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methyl)thio)pyrimidin-4-amine hydrochloride, 5-(3-fluoro-2′-((pyridazin-3-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine hydrochloride, 6-(((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methyl)thio)pyridazin-3-amine hydrochloride, 5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2-amine hydrochloride, 5-(3-fluoro-2′-((pyrimidin-4-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine hydrochloride, 5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfonyl)biphenyl-4-yl]pyrazin-2-amine hydrochloride, 5-(3-Fluoro-2′-{[3-(methylsulfonyl)propyl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine hydrochloride, 5-(3-Fluoro-2′-{[(2R)-2-methylpiperazin-1-yl]sulfonyl}biphenyl-4-yl)pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)propyl]biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide, racemic (4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}morpholin-2-yl)methanol, 5-(3-Fluoro-2′-{[(2S)-2-methylpiperazin-1-yl]sulfonyl}biphenyl-4-yl)pyrimidin-2-amine, 5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]biphenyl-2-sulfonamide, 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3S)-piperidin-3-yl]biphenyl-2-sulfonamide, 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3R)-piperidin-3-yl]biphenyl-2-sulfonamide, [(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-yl]methanol, racemic cis 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(cis)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide, racemis trans 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(trans)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1-methylethyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(trans-4-hydroxycyclohexyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]biphenyl-2-sulfonamide, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin-3-ol trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3R)-2-oxopiperidin-3-yl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopiperidin-3-yl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)-2,2-dimethylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-2-methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-[(2S)-2,3-dihydroxypropyl]-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, [(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt, [(2S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-1,1-dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, 5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine trifluoroacetic acid salt, 2-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-1-yl)ethanol trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid, 4′-(2-Aminopyrimidin-5-yl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-tert-butyl-3′-fluoro-3-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[3-Fluoro-2′-(piperazin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1-dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N,N-dimethylbiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 5-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt, 4′-(2-aminopyrimidin-5-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide trifluoroacetic acid salt, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-one trifluoroacetic acid salt, tert-Butyl N-{[4′-(2-aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L-alaninate, N-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L-alanine, N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1-sulfonamide, N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]morpholine-4-sulfonamide, N′-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N,N-dimethylsulfamide, 5-(2′-(2-oxa-6-azaspiro[3.3]heptan-6-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrimidin-2-amine, 6-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide, 1-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)azetidine-3-carbonitrile, 1-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-(trifluoromethyl)azetidin-3-ol, 5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine hydrochloride, 2-(((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)methyl)quinazolin-4(3H)-one, 1-(3-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)propyl)-1H-benzo[d]imidazol-2(3H)-one, 5-(2′-{[3-(Cyclohexylsulfonyl)propyl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrimidin-2-amine, 5-{3-Fluoro-2′-[(1-methyl-1H-benzimidazol-2-yl)sulfonyl]biphenyl-4-yl}pyrimidin-2-amine, 5-(2′-{[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrimidin-2-amine, 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide, 5-[3-fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrimidin-2-amine, 4-{[4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]sulfonyl}piperazin-2-one, 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-4-(trifluoromethyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide, 5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(5-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt, 5-{2′-[(4-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt, 5-{2′-[(5-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt, 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine hydrochloride, 5-[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine hydrochloride, 5-{2′-[(6-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2-amine formate salt, 5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt, 5-{2′-[(5-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine hydrochloride, 5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfonyl)biphenyl-4-yl]pyrimidin-2-amine formate salt, 5-{2′-[(5-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine hydrochloride, 5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl)biphenyl-4-yl]pyrimidin-2-amine, 5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine, 4′-(6-aminopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, 4′-(6-aminopyridin-3-yl)-N,N-diethyl-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, 5-(3-fluoro-2′-(pyrrolidin-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine, 5-(3-fluoro-2′-(piperidin-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine, 4′-(6-aminopyridin-3-yl)-N-cyclohexyl-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, (S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-isobutyl-[1,1′-biphenyl]-2-sulfonamide, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(tert-pentyl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1,1,1-trifluoro-2-methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, (S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-phenylethyl)-[1,1′-biphenyl]-2-sulfonamide, (R)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-methylcyclobutyl)-[1,1′-biphenyl]-2-sulfonamide, 4-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)thiomorpholine 1,1-dioxide, (S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1,1,1-trifluoropropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, 5-(2′-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2-amine, tert-butyl 3-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-ylsulfonamido)methyl)-3-hydroxyazetidine-1-carboxylate, 4′-(6-aminopyridin-3-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)-[(1,1′-biphenyl]-2-sulfonamide, 2-(1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-yl)ethanol, 1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-ol, (1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-yl)methanol, 3′-Fluoro-N-[(1S)-2-hydroxy-1-methylethyl]-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide, 3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide, 3′-Fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide, 5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]-1H-pyrrolo[2,3-b]pyridine, 3′-Fluoro-N-(2-hydroxyethyl)-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide, 3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide, N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]methanesulfonamide, 3′-Fluoro-N,N-dimethyl-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide, 2-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, N, N-Diethyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide, 2-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, 2-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, 3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-N-(2,2,2-trifluoro-1-methylethyl)biphenyl-2-sulfonamide, 2-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, 3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide, 3′-Fluoro-N-methyl-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide, 3′-Fluoro-N-[(1S)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide, 1-{[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]sulfonyl}piperidin-4-amine, 2-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-5H-pyrrolo[2,3-b]pyrazine, 2-[3,5′-Difluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, 2-[2′-(Ethylsulfanyl)-3-fluorobiphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, 7-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine, 7-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine, 4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-2-sulfonamide, 4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 1-{[4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-amine, 4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide, 7-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine, N-tert-Butyl-4′-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-2-sulfonamide, 2-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]-5-(trifluoromethyl)pyridin-3-yl}phenyl)-5H-pyrrolo[2,3-b]pyrazine, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]pyridin-3-yl}phenyl)pyrazin-2-amine, 2-{2-Fluoro-4-[2-(2,2,2-trifluoroethoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-b]pyrazine, 2-{2-Fluoro-4-[2-(2-methylpropoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-b]pyrazine, 2-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-b]pyrazine, 2-{4-[2-(Cyclopropylmethoxy)pyridin-3-yl]-2-fluorophenyl}-5H-pyrrolo[2,3-b]pyrazine, 5-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-{4-[2-(Cyclopentyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, 5-{4-[2-(Cyclohexyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, 5-[2-Fluoro-4-(2-methoxypyridin-3-yl)phenyl]pyrazin-2-amine, 5-{4-[2-(Cyclobutyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, tert-Butyl 3-[({3-[4-(5-aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)methyl]pyrrolidine-1-carboxylate, 5-{2-Fluoro-4-[2-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrimidin-2-amine, 5-[4-(2-Aminopyridin-3-yl)-2-fluorophenyl]pyrimidin-2-amine, 4′-(5-amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 3-Amino-6-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carbonitrile, 4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide, 3-Amino-6-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazine-2-carbonitrile, 4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide, 3-Amino-6-[3-fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazine-2-carbonitrile, 4′-(6-Aminopyridazin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(7H-pyrrolo[2,3-d]pyrimidin-2-yl)biphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1,8-naphthyridin-3-yl)biphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-quinoxalin-6-ylbiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1H-indol-5-yl)biphenyl-2-sulfonamide, 4′-(1H-Benzimidazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(1H-Benzimidazol-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide, 4′-(1,3-Benzothiazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1H-pyrrolo[3,2-b]pyridin-6-yl)biphenyl-2-sulfonamide, 3′-Fluoro-N-methyl-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide, 4′-(5-Aminopyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-4′-(5,6-diaminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)biphenyl-2-sulfonamide, 4′-(6-Amino-5-fluoropyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-4′-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(3H-imidazo[4,5-b]pyridin-6-yl)biphenyl-2-sulfonamide, 4′-(5-Amino-6-methoxypyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Amino-6-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(6-Amino-4-cyanopyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(6-amino-2-cyanopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-amino-1,3,4-thiadiazol-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, (R)-4′-(5-amino-1,3,4-thiadiazol-2-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, 4-((4′-(5-amino-1,3,4-thiadiazol-2-yl-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)thiomorpholine 1,1-dioxide, 4′-(5-Amino-6-chloropyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Amino-6-bromopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 6-amino-3-(2′-(cyclopropylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)picolinonitrile, N-tert-Butyl-3′-fluoro-4′-[1,2,4]triazolo[4,3-a]pyridin-7-ylbiphenyl-2-sulfonamide, 4′-(5-Amino-6-methylpyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(1H-imidazo[4,5-b]pyrazin-5-yl)biphenyl-2-sulfonamide, N-tert-Butyl-4′-(5,6-diaminopyridin-3-yl)-3′-fluorobiphenyl-2-sulfonamide, 4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide, 4′-(6-Amino-5-cyanopyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(6-Amino-5-chloropyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-[6-Amino-5-(trifluoromethyl)pyridin-3-yl]-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-[2-Amino-4-(trifluoromethyl)pyrimidin-5-yl]-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Amino-4-methylpyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, N-tert-Butyl-3′-fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]biphenyl-2-sulfonamide, 4′-(7-Amino-1H-indol-5-yl)-3′-fluoro-N-[1-(hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide, 3′-Fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methylbiphenyl-2-sulfonamide, 4′-(7-Amino-1H-indol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]acetamide, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]urea, 5-[2,3-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methylbiphenyl-2-yl]methanesulfonamide, 4′-(5-Aminopyrazin-2-yl)-2′,3′-difluorobiphenyl-2-sulfonamide, 4′-(2-Aminopyrimidin-5-yl)-2′,3′-difluoro-N-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt, 4′-(2-Aminopyrimidin-5-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2-sulfonamide trifluoroacetic acid salt, 5-[2′,3-Difluoro-4′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine, 5-(2′,3-Difluorobiphenyl-4-yl)pyrazin-2-amine, 5-(2′-Chloro-3-fluorobiphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2′-methylbiphenyl-4-biphenyl)pyrazin-2-amine, 5-[2′,3-Difluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-(3-Fluoro-2′-methoxybiphenyl-4-yl)pyrazin-2-amine, 5-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-ol, 5-[3-Fluoro-2′-(phenylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-(2′,3,6′-Trifluorobiphenyl-4-yl)pyrazin-2-amine, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]benzenesulfonamide, 5-(2′-Ethyl-3-fluorobiphenyl-4-yl)pyrazin-2-amine, {[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid, 5-[3-Fluoro-2′-(1-methylethyl)biphenyl-4-yl]pyrazin-2-amine, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanone, 5-[3-Fluoro-2′-(2,2,2-trifluoroethoxy)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxylic acid, 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxamide, 5-[3-Fluoro-2′-(1-methylethoxy)biphenyl-4-yl]pyrazin-2-amine, 5-{4-[2-(Cyclopropylmethoxy)pyridin-3-yl)-2-fluorophenyl}pyrazin-2-amine, 2-[3,4′-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylmethanesulfonmide, N-(3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]ethanesulfonamide, N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-N-methylmethanesulfonamide, N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-N-methylethanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylethanesulfonamide, N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-2-methylpropane-1-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-ethylmethanesulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,2-dimethylpropane-1-sulfonamide, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-1H-pyrrolo[2,3-b]pyridine, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrimidin-2-amine, 2-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-N,N-diethyl-3′-fluorobiphenyl-2-carboxamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide, 5-[3-Fluoro-2′-(piperazin-1-ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(4-Acetylpiperazin-1-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2-carboxamide, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-carboxamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-4-ol, 5-{2′-[(4-Aminopiperidin-1-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-2′[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-carboxamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperazin-2-one, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperazin-2-one, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrimidin-2-amine, 4-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-yl]oxy}pyrimidin-2-amine, 2-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-yl]oxy}pyrimidin-4-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1H-pyrrolo[2,3-b]pyridine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrimidin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4-amine, 5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 6-({[4′-(5-Aminopyrazin-2-yl-3′-fluorobiphenyl-2-yl]oxy}methyl)pyridine-2-carbonitrile, 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}methyl)pyridine-3-carbonitrile, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2-amine, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2-amine, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4-amine, 5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile, 5-{2′-[(6-Azetidin-1-ylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(6-Azetidin-1-ylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrimidin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1H-benzimidazole, 6-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-3H-imidazo[4,5-b]pyridine, 5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2-amine, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}biphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine, 5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrimidin-2-amine, 5-[3-Fluoro-2′-methoxy-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]oxy}pyrimidin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]oxy}pyrimidin-4-amine, 5-[3-Fluoro-4′-(trifluoromethyl)-2′-{[2-(trimethylsilyl)ethoxy]methoxy}biphenyl-4-yl]pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol, 5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]oxy}pyrimidin-2-amine, 5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine, 5-[3-Fluoro-2′,4′-bis(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carbonitrile, 5-{5-[2-(Pyrimidin-2-yloxy)-4-(trifluoromethyl)phenyl]pyridin-2-yl}pyrimidin-2-amine, 4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-5-(trifluoromethyl)phenoxy}pyrimidin-2-amine, 5-{5-[2-(Pyrimidin-2-yloxy)phenyl]pyridin-2-yl}pyrimidin-2-amine, 4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenoxy}pyrimidin-2-amine, 5-(5-{2-[(4-Aminopyrimidin-2-yl)oxy]phenyl}pyridin-2-yl)pyrimidin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methylbiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methoxybiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N-tert-butylbiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-N,N-dimethylbiphenyl-2-sulfonamide, 5-[2′-(Morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′-fluorobiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-2′-fluoro-N,N-dimethylbiphenyl-2-sulfonamide, 4′-(2-Amino-1,3-oxazol-4-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(2-Amino-1,3-thiazol-4-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 4′-(2-Amino-1,3-thiazol-4-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide, 4-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]-1,3-thiazol-2-amine, N-tert-Butyl-3′-fluoro-4′-(8-fluoroimidazo[1,2-a]pyridin-2-yl)biphenyl-2-sulfonamide, 4′-(5-Aminoimidazo[1,2-a]pyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-6-carboxamide, 2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-6-carboxamide, N-tert-Butyl-4′-(5-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-4′-(6-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-[6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]biphenyl-2-sulfonamide, Ethyl 2-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-5-carboxylate, N-tert-Butyl-3′-fluoro-4′-(5-methoxyimidazo[1,2-a]pyridin-2-yl)biphenyl-2-sulfonamide, 5-[2′-(Methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Methyl-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N,N,3′-trimethylbiphenyl-2-sulfonamide, 4′-(5-Aminopyrazin-2-yl)-3′-hydroxybiphenyl-2-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)biphenyl-2-yl]methanesulfonamide, 4′-(5-Aminopyrazin-2-yl)biphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-indol-5-yl)biphenyl-2-sulfonamide, N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)-3′-fluorobiphenyl-2-sulfonamide, 4′-(3-Amino-1H-indazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 3-Amino-6-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carboxylic acid, 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}acetamide, 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N,N-diethylacetamide, 5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfonyl]biphenyl-4-yl}pyrimidin-2-amine, 5,5′-(3,3″-Difluoro-1,1′:2′,1″-terphenyl-4,4″-diyl)dipyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carboxylic acid, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carbaldehyde, 5-[3-Fluoro-2′-(morpholin-4-ylmethyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(4-Aminopiperidin-1-yl)methyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine, 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)ethanol, 5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine, 5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluor-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-5-amine, 5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-6-methylpyrimidin-4-amine, 5-{2′-[(4-Amino-6-methylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile, 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(6-Amino-2-methylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-2-methylpyrimidin-4-amine, 5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine, 5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrazin-2-amine, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile, 6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol, 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol, 5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrimidin-2-amine, 5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine, 5-{3-Fluoro-2′-[(3S)piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine, {[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile, {[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile, {[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid, 5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine, 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine, 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine, 2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol, 2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol, 5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine, 5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine formic acid salt, 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine, (2R)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol, (2R)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol, (2S)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol, (21)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol, N-(4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methanesulfonamide, 5-(3-Fluoro-2′-(morpholinosulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine, 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-sulfonamide, 4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide trifluoroacetate, 5-(2′-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2-amine, 4′-(6-Aminopyrazin-2-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)-[1,1-biphenyl]-2-sulfonamide, 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide, 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, (racemic)-1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-3-ol, 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide, N-(1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-yl)acetamide, racemic 2-(1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-3-yl)ethanol, racemic 1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-3-yl)methanol, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-ethyl-5-(trifluoromethyl)benzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-tert-butylbenzenesulfonamide, 5-{5-[2-(Morpholin-4-ylmethyl)-4-(trifluoromethyl)phenyl]pyridin-2-yl}pyrimidin-2-amine, 5-{5-[2-(Morpholin-4-ylcarbonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine, 5-[5-(2-Methoxyphenyl)pyridin-2-yl]pyrimidin-2-amine, 5-(5-{2-[(3,3-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine trifluoroacetic acid salt, 5-(5-{2-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine trifluoroacetic acid salt, 5-{5-[2-(Azepan-1-ylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine trifluoroacetic acid salt, 5-(5-{2-[(4,4-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine trifluoroacetic acid salt, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethylbenzenesulfonamide trifluoroacetic acid salt, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-Nicyclopropylmethyl)benzenesulfonamide trifluoroacetic acid salt, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide trifluoroacetic acid salt, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide trifluoroacetic acid salt, 4-({2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenyl}sulfonyl)piperazin-2-one, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2S)-2-hydroxypropyl]benzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide, 5-{5-[2-(Cyclopropylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine trifluoroacetic acid salt, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethyl-5-(trifluoromethyl)benzenesulfonamide trifluoroacetic acid salt, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-tert-butylbenzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide, 3-Amino-6-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile trifluoroacetic acid salt, 5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)pyrazin-2-amine, 5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)-1H-pyrrolo[2,3-b]pyridine, 5-(3-fluoro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, 5-(2′,3,4′-Trifluorobiphenyl-4-yl)pyrazin-2-amine, racemic 5-[3-Fluoro-2′-(methylsulfinyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carbonitrile, 1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)imidazolidin-2-one, 4′-(2-Amino-4-cyanopyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 6-Amino-3-{2′-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N-methylazetidine-3-carboxamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-2-sulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide, 1-((4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidine-4-carboxamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)-[1,1′-biphenyl]-2-sulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide, 6-Amino-3-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrazine-2-carbonitrile, N-(2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}ethyl)benzamide, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3,3-dimethylbutan-2-one, 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine, 5-[3-Fluoro-2′-(pyrazin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine, 5-[3-Fluoro-2′-(pyrimidin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine, 5-{2′-[(6-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(4-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-2-amine, 5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine, 5-{2′-[(Cyclopropylmethyl sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 6-Amino-3-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carbonitrile, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide, 2-{[4′-(2-Aminopyrimidin-5-yl)-3-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanenitrile, 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide, 5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanenitrile, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide, 5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide, 5-(2′-{[1-(Aminomethyl)cyclopentyl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrimidin-2-amine, 5-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrazin-2-amine, 5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-(3-Fluoro-2-(pyrimidin-4-ylthio)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, 5-{2′-[(5-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine 6-Amino-3-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile, 6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazine-2-carbonitrile, 6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazine-2-carbonitrile, N-(tert-Butyl)-3′-fluoro-4′-(5-(methylsulfonamido)pyrazin-2-yl)-[1,1′-biphenyl]-2-sulfonamide, 5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine hydrogen chloride salt, 5-{3-Fluoro-2′-[(methylsulfonyl)meth yl]biphenyl-4-yl}pyrazin-2-amine, 5-(3-Fluoro-2′-{[(1-methylethyl)sulfonyl]methyl}biphenyl-4-yl)pyrazin-2-amine, 5-{3-Fluoro-2′-[(pyrimidin-2-ylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine, 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfanyl)pyrimidin-4-amine, racemic 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}azetidin-3-ol, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(tetrahydro-2H-pyran-4-yl)biphenyl-2-carboxamide, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine, 1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture), 1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture), 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide, (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol, (cis/trans) 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-carboxamide, (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol, (cis/trans) 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-carboxamide, racemic 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine, (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol, (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol, (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol, (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol, (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol, (3S-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol, 5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine (diastereoisomeric mixture), 5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine, 5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine, 5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine, 5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine (diastereoisomeric mixture), 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}-1H-pyrrolo[2,3-b]pyridine, 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine, 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrazin-2-amine, 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-tert-butyl-5-(trifluoromethyl)benzamide, 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1R)-2-hydroxy-1-methyl-ethyl]-5-(trifluoromethyl)benzamide, 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1S)-2-hydroxy-1-methyl-ethyl]-5-(trifluoromethyl)benzamide, 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1R)-2,2,2-trifluoro-1-methyl-ethyl]benzamide, 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1S)-2,2,2-trifluoro-1-methyl-ethyl]benzamide, 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1R)-2,2,2-trifluoro-1-methyl-ethyl]benzamide, 2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1S)-2,2,2-trifluoro-1-methyl-ethyl]benzamide, [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-(3-hydroxyazetidin-1-yl)methanone, [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-[4-(methylamino)-1-piperidyl]methanone, [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)phenyl]-(1,1-dioxo-1,4-thiazinan-4-yl)methanone, 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tert-butyl-5-(trifluoromethyl)benzamide, [2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)phenyl]-(4-hydroxy-1-piperidyl)methanone, [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)phenyl]-(4-hydroxy-1-piperidyl)methanone, 2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tetrahydropyran-4-yl-benzamide, [2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]phenyl]-[2-(hydroxymethyl)morpholin-4-yl]methanone, racemic [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-[2-(hydroxymethyl)morpholin-4-yl]methanone, N-{3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-dimethylpropanamide, N-{3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-dimethylpropanamide, N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]pyridin-2-yl}-2,2-dimethylpropanamide, racemic 5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrazin-2-amine hydrochloride, 5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrimidin-2-amine formic acid salt, 5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine hydrochloride, 5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine hydrochloride, 5-(4-(2-(Cyclohexlsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine hydrochloride, 5-(4-(2-(Cyclohexylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine hydrochloride, 5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidine-2-amine hydrochloride, 5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine hydrochloride, 5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine formic acid salt, 5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine formic acid salt, racemic 5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine formate, racemic 5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine formate, 1-((3-(4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)piperidin-1-yl)ethanone, 1-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)piperidin-1-yl)ethanone hydrogen chloride salt, 5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3-yl)phenyl)pyrimidin-2-amine hydrogen chloride salt, 5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3-yl)phenyl)pyrazin-2-amine hydrogen chloride salt, 4-((3-(4-(2-aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide, 4-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide, 5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3-yl)phenyl)pyrimidin-2-amine formic acid salt, 5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3-yl)phenyl)pyrazin-2-amine, 5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3-yl)pyrimidin-2-amine formic acid salt, 5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3-yl)pyrazin-2-amine formic acid salt, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine, 5-(2-Fluoro-4-(2-(isopropylsulfonyl)pyridine-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine, 5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine formic acid salt, 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine formic acid salt, 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine formic acid salt, 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine hydrochloride 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine formic acid salt, 5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine hydrochloride, 5-(2,3-Difluorobiphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2-methoxybiphenyl-4-yl)pyrazin-2-amine, 5-[3-Fluoro-2-methoxy-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-2′-methoxybiphenyl-2-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methoxybiphenyl-2-yl]methanesulfonamide, 5-(3-Fluoro-2′-(pyrazin-2-yl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2′-pyrazin-2-ylbiphenyl-4-yl)pyrimidin-2-amine, 5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrazin-2-amine, 5-[2′-(5-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine, 5-[2′-(6-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine, 5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrimidin-2-amine, 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-5-(trifluoromethyl)biphenyl-2-yl]pyrimidin-2-amine, 5-[3-Fluoro-2′-(2-methoxypyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Fluoro-2′-(1-methyl-1H-pyrazol-4-yl)biphenyl-4-yl]pyrazin-2-amine, 5-(3-Fluoro-2′-pyrimidin-5-ylbiphenyl-4-yl)pyrazin-2-amine, 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidine-2-carbonitrile, 5-[3-Fluoro-2′-(2-morpholin-4-ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine, 1-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-yl}-2-methylpropan-2-ol, 5-[3-Fluoro-2′-(1,2,3,6-tetrahydropyridin-4-yl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]pyrimidin-2-amine, 5-{2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]phenyl}pyrimidin-2-amine, 5-{5-[2-(2-Aminopyrimidin-5-yl)phenyl]pyridin-2-yl}pyrimidin-2-amine, 5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(1,1-Dioxido-1,2-thiazinan-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine, 5-[2-Fluoro-4-(2-pyrrolidin-1-ylpyridin-3-yl)phenyl]pyrazin-2-amine, 1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidin-2-one, 5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)-1H-pyrrolo[2,3-b]pyridine, 5-(2′,3,4′-Trifluorobiphenyl-4-yl)pyrazin-2-amine, 5-[3-Fluoro-2′-(methylsulfinyl)biphenyl-4-yl]pyrazin-2-amine, 5-[2′-(Methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 5-[3-Methyl-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-hydroxybiphenyl-2-sulfonamide, N-[4′-(5-Aminopyrazin-2-yl)biphenyl-2-yl]methanesulfonamide, 4′-(5-Aminopyrazin-2-yl)biphenyl-2-sulfonamide, 4′-(6-Aminopyridazin-3-yl)-3′-fluorobiphenyl-2-sulfonamide, N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)-3′-fluorobiphenyl-2-sulfonamide, 3-Amino-6-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carboxylic acid, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5-(trifluoromethyl)biphenyl-2-sulfonamide, 5-{5-[2-(Cyclopropylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine, 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}acetamide, 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N,N-diethylacetamide, 5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfonyl]biphenyl-4-yl}pyrimidin-2-amine, 5-[5-(2-Methoxyphenyl)pyridin-2-yl]pyrimidin-2-amine, 5-{5-[2-(Morpholin-4-ylcarbonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine, 4′-(2-Amino-4-cyanopyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine, 5-[3-Fluoro-2′-(pyrazin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine, N-(2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}ethyl)benzamide, 5-[3-Fluoro-2′-(pyrimidin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine, 5-{2′-[(6-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(4-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-(2-Fluoro-4-{2-[(2-morpholin-4-ylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine, 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-5-(trifluoromethyl)biphenyl-2-yl]pyrimidin-2-amine, 5-{5-[2-(2-Aminopyrimidin-5-yl)phenyl]pyridin-2-yl}pyrimidin-2-amine, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-2-amine, 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine, 5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine, 5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine, (3S-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol, (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol, (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol, 2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol, 5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol, 5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrimidin-2-amine, 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide, 5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine, 5-(2′-{[1-(Aminomethyl)cyclopentyl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrimidin-2-amine, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-carboxamide, (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol, {[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid, 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(tetrahydro-2H-pyran-4-yl)biphenyl-2-carboxamide, 5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine, 2-[3,5′-Difluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide, 4′-(5-Aminopyrazin-2-yl)-N,N,3′-trimethylbiphenyl-2-sulfonamide, 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide, N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-indol-5-yl)biphenyl-2-sulfonamide, 4′-(3-Amino-1H-indazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine, 5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrazin-2-amine, N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methoxybiphenyl-2-yl]methanesulfonamide, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}azetidin-3-ol, (3R)-1-{[4-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol, 4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carbonitrile, (2R)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol, 5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 4′-(6-Aminopyrazin-3-yl)-3′-fluorobiphenyl-2-sulfonamide, 5-{3-Fluoro-2′-[(methylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine, 5-{3-Fluoro-2′-[(3S)piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-carboxamide, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3,3-dimethylbutan-2-one, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine, 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol, 2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl)oxy}ethanol, 5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, N-[4′-(6-Aminopyridin-3-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide, 4-({2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenyl}sulfonyl)piperazin-2-one, 5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}-1H-pyrrolo[2,3-b]pyridine, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2S)-2-hydroxypropyl]benzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide, 5-{2-Fluoro-4-[2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine, 5-(5-{2-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethylbenzenesulfonamide, (3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol, (2S)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol, 2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanenitrile, (2R)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5-methoxybiphenyl-2-sulfonamide, 5-(2-Fluoro-4-{2-[(3-methoxypropyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide, 5-[3-Fluoro-2-methoxy-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide, {[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile, 5-{4-[2-(tert-Butylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine, 5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine, 5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine, 5-(2-Fluoro-4-{2-[(2-morpholin-4-ylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine, 5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine, 5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)pyrazin-2-amine, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine, 5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile, (3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3-carboxamide, 5-{5-[2-(Morpholin-4-ylmethyl)-4-(trifluoromethyl)phenyl]pyridin-2-yl}pyrimidin-2-amine, 5-(5-{2-[(4,4-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine, 5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine, (3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3-carboxamide, 5-(2-Fluoro-4-{2-[(tetrahydro-2H-pyran-4-ylmethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide, (3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol, 5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine, 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)ethanol, 5-{3-Fluoro-2′-[(pyrimidin-2-ylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide, 5-(5-{2-[(3,3-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine, 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine, 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine, 5-[3-Fluoro-2′-(1,2,3,6-tetrahydropyridin-4-yl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine, 5-{2-Fluoro-4-[2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine, 6-Amino-3-{2′-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile, N-(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)acetamide, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N-methylazetidine-3-carboxamide, 5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyridin-2-amine, 5-(3-Fluoro-2′-{[(1-methylethyl)sulfonyl]methyl}biphenyl-4-yl)pyrazin-2-amine, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide, {[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile, (2S)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol, 6-Amino-3-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carbonitrile, 5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethyl-5-(trifluoromethyl)benzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide, 5-{5-[2-(Azepan-1-ylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-tert-butylbenzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-Nicyclopropylmethyl)benzenesulfonamide, 5-{2′-[(4-Aminopiperidin-1-yl)methyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(6-Amino-2-methylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine, 5-(2-Fluoro-4-{2-[(1-methylpropyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-2-sulfonamide, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanenitrile, 5-{4-[2-(Cyclobutylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine, 5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carboxylic acid, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-yl)pyrazin-2-amine, 5-(2-Fluoro-4-{2-[(3-methoxypropyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine, 6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazine-2-carbonitrile, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-2′-methoxybiphenyl-2-sulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide, 1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-ol, 5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine, 5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine, 2-(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)ethanol, 5-{2′-[(5-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide, 6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile, 5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-yl)pyrazin-2-amine, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide, (1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)methanol, 6-Amino-3-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile, 5-[3-Fluoro-2′-(2-methoxypyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine 5-(2-Fluoro-4-{2-[(tetrahydro-2H-pyran-4-ylmethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine, 5-{4-[2-(tert-Butylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine 3-Amino-6-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile, 6-Amino-3-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrazine-2-carbonitrile, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carboxamide, 5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrazin-2-amine, 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile, 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(2-hydroxy-1,1-dimethylethyl)biphenyl-2-sulfonamide, 5-{4-[2-(Cyclohexylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine, 5-{3-Fluoro-2′-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylsulfonyl]biphenyl-4-yl}pyrazin-2-amine, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine-4-carboxamide, 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carbaldehyde, 4′-(5-Aminopyrazin-2-yl-3′-fluoro-N-[(3-hydroxyazetidin-3-yl)methyl]biphenyl-2-sulfonamide, 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrazin-2-amine, 5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfanyl)pyrimidin-4-amine, 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylbiphenyl-2-sulfonamide, 5-{4-[2-(Cyclopentylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine, 2-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine, 6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile, 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine, 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylbiphenyl-2-sulfonamide, 5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine, N, N-Diethyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide, 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-(2-Fluoro-4-{2-[(1-methylpropyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine, 4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(2-hydroxy-1,1-dimethylethyl)biphenyl-2-sulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-ethyl-5-(trifluoromethyl)benzenesulfonamide, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide, 6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazine-2-carbonitrile, 5-[3-Fluoro-2′-(morpholin-4-ylmethyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide, 5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{4-[2-(Cyclobutylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, 4′-(5-Amino-3-cyanopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide, 5-[3-Fluoro-2′-(pyrimidin-4-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine, 1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-(pentafluoroethyl)piperidin-4-ol, 5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)-1H-pyrrolo[2,3-b]pyridine, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-tert-butylbenzenesulfonamide, tert-Butyl (1-{[3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]sulfonyl}piperidin-4-yl)carbamate, 5-{4-[2-(Cyclopentylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3,3′-difluorobiphenyl-2-sulfonamide, 5-{4-[2-(Cyclohexylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2-sulfonamide, 5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine, 5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-5-amine, 5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-(2-fluoro-4-(2-(piperidin-4-yloxy)pyridin-3-yl)phenyl)pyrazin-2-amine, 5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine, 2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-6-methylpyrimidin-4-amine, 5-{2′-[(4-Amino-6-methylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, 5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine, 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine, 5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine, 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine, 5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine, 5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine, 1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-yl)ethanol, 1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-yl)ethanol, 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine, N-{3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-dimethylpropanamide, N-{3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-dimethylpropanamide, 5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine, N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]pyridin-2-yl}-2,2-dimethylpropanamide, 4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide, 5-[2′-Amino-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)methoxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}methyl)benzoic acid, 4-({[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}methyl)benzoic acid, 4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic acid, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic acid, 2-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}sulfonyl)piperidin-1-yl]ethanol, 4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine, 1-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}sulfonyl)piperidin-1-yl]propan-2-ol, 5-[3-Fluoro-2′-(1H-pyrazol-4-yl)biphenyl-4-yl]pyrazin-2-amine, 5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine, 5-{3-Fluoro-2′-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]biphenyl-4-yl}pyrazin-2-amine, 5-{5-[2-(Cyclopropylsulfonyl)phenyl]-3-fluoropyridin-2-yl}pyrimidin-2-amine, 4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}benzamide, 5-{2′-[(trans-4-Aminocyclohexyl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine, 6-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyridazin-3-amine, {4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-yl}acetonitrile, 5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylpyrimidin-2-amine, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide, 5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine, 5-[3-Fluoro-2′-(2-piperazin-1-ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine, 5-{2′-[1-(2-Aminoethyl)-1H-pyrazol-4-yl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2S)-2-hydroxypropyl]benzenesulfonamide, 5-(3-Fluoro-2′-isothiazol-4-ylbiphenyl-4-yl)pyrazin-2-amine, 5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrazin-2-amine, 5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrimidin-2-amine, 2-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-yl}ethanol, 5-(4-{2-[(1-Acetylpiperidin-3-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine, 5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2-hydroxy-1-methylethyl]benzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide, 5-[2-Fluoro-4-(2-phenylpyridin-3-yl)phenyl]pyrazin-2-amine, 5-(2-Fluoro-4-{2-[(1-methylpyrrolidin-3-yl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine, 5-{2-Fluoro-4-[2-(pyridin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}phenyl)pyrazin-2-amine, 5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine, 5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine, 5-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N-methylpyrimidin-2-amine, 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}phenyl)pyrimidin-2-amine, {4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-yl}acetonitrile 5-[3-Fluoro-2′-(1H-pyrazol-4-yl)biphenyl-4-yl]pyrimidin-2-amine, 4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine, 5-{2-Fluoro-4-[2-(pyridin-3-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine, 5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4-yl]sulfonyl}pyridin-3-yl)phenyl]pyrazin-2-amine, 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine, 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}pyrazin-2-amine, 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}pyrimidin-2-amine, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-(2-hydroxyethyl)benzenesulfonamide, 2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide, and 5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4-yl]sulfonyl}pyridin-3-yl)phenyl]pyrimidin-2-amine.
 5. A pharmaceutical composition comprising at least one compound of claim 1 and at least one pharmaceutically acceptable carrier.
 6. The pharmaceutical composition of claim 5 comprising at least one compound of claim
 4. 7. A method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by FLAP activity, comprising administering to the subject a therapeutically effective amount of at least one compound of claim
 1. 8. A method according to claim 7, wherein the disease, disorder, or medical condition is selected from the group consisting of respiratory disorders, cardiac and cardiovascular diseases, autoimmune and allergic disorders, carcinogenesis disorder, and associated symptoms or complications thereof.
 9. A method according to claim 8, wherein respiratory disorder is selected from the group consisting of non-allergic asthma, fibrotic lung diseases, acute respiratory distress syndrome and chronic obstructive pulmonary disease, or associated symptoms or complications thereof.
 10. A method according to claim 8, wherein the cardiac and cardiovascular disease is selected from the group consisting of myocardial infarction, atherosclerosis and stroke aortic aneurisms, atherosclerosis, or associated symptoms or complications thereof.
 11. A method according to claim 8, wherein the autoimmune and allergic disease is selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis, allergic rhinitis, allergic dermatitis and asthma, or associated symptoms or complications thereof.
 12. A method according to claim 8, wherein the carcinogenesis disorder is selected from the group consisting of tumor cell proliferation, differentiation, apoptosis, tumor-associated angiogenesis, and the migration or invasion of carcinoma cells.
 13. The method of claim 7, wherein the therapeutically effective amount of the compound of Formula (I) is from about 0.1 mg/dose to about 5 g/dose.
 14. A process for making a pharmaceutical composition comprising admixing any of the compounds according to claim 1 and a pharmaceutically acceptable carrier. 